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During the past three decades, the world scientific community has witnessed major achieve‐
ments understanding the pathogenesis of Human immunodeficiency virus (HIV) which
leads to a deadly catastrophic disease acquired immune deficiency syndrome (AIDS). As per
recent UNAIDS reports currently ~34 million adults and children are estimated to be living
with HIV. Ever since the discovery of HIV, it has been an ultimate challenge to the health
and scientific authorities. There is a constant research being done by scientists worldwide to
find ways to combat with HIV. HIV has occupied place as a topmost health and social disas‐
ter. It is affecting several developing economies. Thus it becomes an urgency to find ways of
management against HIV infection. To device a way, basic and thorough knowledge about
HIV, stands as a priority. We need to understand viral morphology, functions, and mecha‐
nisms of viral replication, budding, cell signaling, pathogenesis, interaction with host fac‐
tors, and various other important aspects. However many aspects of HIV infection are still
poorly understood.
HIV-1, a retrovirus, attacks the T-lymphocytes of the hosts, and causes several multifaceted
altered immune responses and finally leads to fatality. HIV-1 displays extraordinary genetic
variation, leading to the classification of the viral strains into phylogenetically distinct
groups and subtypes. Amongst the various subtype/clade (A to K) of HIV-1, subtype C is
linked to ~48% of the infections globally and is associated with rapidly growing epidemics
in Sub-Saharan Africa and parts of Asia, including India and China. In addition to genetic
and demographic factors, biological properties unique to the subtype of HIV may also play
a role in their exponential proliferation.
HIV is capable of being latent and hidden in various reservoirs in the body where drug tar‐
geting becomes impossible. HIV can enter brain and attack neuronal cells and deregulate
there functioning which leads to neuropathogenesis. Hence drug targeting to viral reser‐
voirs like brain stands as a big issue. Drugs capable of travelling across the Blood Brain Bar‐
rier (BBB) are an urgent need. Along with these genes specific targeting drugs are also
important. These drugs can focus on one particular gene or a part of gene that is motif,
which is conserved and is most stable. This stable part can be very well targeted by the de‐
signed drugs.
Henceforth, keeping in mind all the issues, this book gives a comprehensive overview of
HIV and AIDS including NeuroAIDS. The book is divided into several parts which cover
various topics deeply, explaining HIV and related pathology, immunity and immunopathol‐
ogy, altered immune responses, screening, diagnosis, manifestations, prevention, treatment,
epidemiology and etiology to current clinical recommendations in management of HIV/
Preface
During the past three decades, the world scientific community has witnessed major achieve‐
ments understanding the pathogenesis of Human immunodeficiency virus (HIV) which
leads to a deadly catastrophic disease acquired immune deficiency syndrome (AIDS). As per
recent UNAIDS reports currently ~34 million adults and children are estimated to be living
with HIV. Ever since the discovery of HIV, it has been an ultimate challenge to the health
and scientific authorities. There is a constant research being done by scientists worldwide to
find ways to combat with HIV. HIV has occupied place as a topmost health and social disas‐
ter. It is affecting several developing economies. Thus it becomes an urgency to find ways of
management against HIV infection. To device a way, basic and thorough knowledge about
HIV, stands as a priority. We need to understand viral morphology, functions, and mecha‐
nisms of viral replication, budding, cell signaling, pathogenesis, interaction with host fac‐
tors, and various other important aspects. However many aspects of HIV infection are still
poorly understood.
HIV-1, a retrovirus, attacks the T-lymphocytes of the hosts, and causes several multifaceted
altered immune responses and finally leads to fatality. HIV-1 displays extraordinary genetic
variation, leading to the classification of the viral strains into phylogenetically distinct
groups and subtypes. Amongst the various subtype/clade (A to K) of HIV-1, subtype C is
linked to ~48% of the infections globally and is associated with rapidly growing epidemics
in Sub-Saharan Africa and parts of Asia, including India and China. In addition to genetic
and demographic factors, biological properties unique to the subtype of HIV may also play
a role in their exponential proliferation.
HIV is capable of being latent and hidden in various reservoirs in the body where drug tar‐
geting becomes impossible. HIV can enter brain and attack neuronal cells and deregulate
there functioning which leads to neuropathogenesis. Hence drug targeting to viral reser‐
voirs like brain stands as a big issue. Drugs capable of travelling across the Blood Brain Bar‐
rier (BBB) are an urgent need. Along with these genes specific targeting drugs are also
important. These drugs can focus on one particular gene or a part of gene that is motif,
which is conserved and is most stable. This stable part can be very well targeted by the de‐
signed drugs.
Henceforth, keeping in mind all the issues, this book gives a comprehensive overview of
HIV and AIDS including NeuroAIDS. The book is divided into several parts which cover
various topics deeply, explaining HIV and related pathology, immunity and immunopathol‐
ogy, altered immune responses, screening, diagnosis, manifestations, prevention, treatment,
epidemiology and etiology to current clinical recommendations in management of HIV/
AIDS including NeuroAIDS, It also highlights the ongoing issues, recent advances and fu‐
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Chapter 1
Immune Responses and
Cell Signaling During Chronic HIV Infection
Abdulkarim Alhetheel, Mahmoud Aly and
Marko Kryworuchko
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53010
1. Introduction
The immune response can be defined by the reaction of the immune system to a particular
antigen to which it is exposed. In order to understand immune responses against an infectious
agent such as human immunodeficiency virus (HIV) and their regulation during the course of
chronic HIV infection, we will provide a brief overview of HIV and its proteins and attempt
to shed light on this disease process. We will also review the immune system, its components
and describe how these components interact at the molecular levels to fight an invading
pathogen such as HIV.
2. Human immunodeficiency virus (HIV)
AIDS (Acquired Immuno-Deficiency Syndrome) in patients was discovered in 1981 and
characterized by the appearance symptoms including persistent lymphadenopathy and
opportunistic infections such as Kaposi sarcoma, Pneumocystis carinii pneumonia. In addition,
it was found that all of these patients shared a common defect in cell-mediated immunity
characterized by a significant decrease in CD4+T lymphocytes, later revealed to be a principal
target of infection [1-3]. Three years later, the causative agent of AIDS was identified as HIV
[4, 5]. HIV was classified under the lentivirus genus and the Retroviridae family. It is an
enveloped virus with a size of about 100 nm in diameter. Its genome consists of two identical
copies of positive-sense single stranded RNA (ssRNA) that are reverse transcribed into cDNA
in infected cells [2, 5]. Each ssRNA is about 9,500 nucleotides in length, and encodes three
structural genes called gag, pol, env, and a complex of several other nonstructural regulatory
© 2013 Alhetheel et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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genes known as tat, rev, nef, vif, vpr, and vpu [2, 5]. The gag gene encodes the viral structural
proteins including p24 (capsid), p17 (matrix), p7 (nucleocapsid). The pol gene, on the other
hand, encodes viral enzymes including p32 (integrase), p66 and p51 (reverse transcriptase),
and p10 (protease). The env gene encodes the coat glycoproteins gp120 (surface) and gp41
(transmembrane), which play a major role in viral attachment and fusion with host target cell
membranes. The nonstructural genes including transactivator of transcription (Tat), regulator
of virion protein expression (Rev), negative regulatory factor (Nef), viral infectivity factor (Vif),
viral protein R (Vpr), and viral protein U (Vpu) proteins, respectively, are also essential for
viral replication and pathogenesis [2, 5].
3. The immune system and its cellular components
The immune system is a very complex and dynamic network, which can be broadly divided
into innate and adaptive components [4,6,7]. The cellular components of innate immunity
include dendritic cells, natural killer (NK) cells, NK T cells, macrophages, and granulocytes,
whereas, the adaptive immunity is mediated by B and T lymphocytes [4,6-8]. The components
of both branches act in conjunction and are regulated by soluble mediator proteins known as
cytokines and chemokines in order to fight, clear, and protect the host from a wide variety of
pathogens [4,6-8].
3.1. The innate immune system
The innate immune system is the first line of defense against invading pathogens. Viral
infections including HIV induce the interferon (IFN) response that is characterized by the
production and secretion of pro-inflammatory cytokines including type-I IFN (IFN-α/β). These
cytokines have antimicrobial and anti-proliferative properties and serve to propagate the
adaptive immune responses [9]. In humans, cellular RNA molecules are short stem secondary
structures. In contrast, RNA viruses produce long dsRNA molecules in the infected cells as a
part of their life cycle. Thus, the long dsRNA can be recognized as a foreign molecule and
triggers both cellular and humoral innate immune responses [10]. There are two well charac‐
terized ways in which a cell can recognize pathogens. Distinct extracellular pathogen compo‐
nents are recognized by different Toll- like receptors (TLR) expressed on the cell surface or in
the endosome such as TLR2, TLR3, TLR4, TLR7, TLR8, and TLR9 [11]. Intracellular replicating
pathogens however, are recognized by RNA helicases, which are encoded by the retinoic acid-
inducible gene I (RIG-I) and/or melanoma differentiation-associated gene 5 (MDA5) [12].
Following viral recognition, the activation and translocation of the transcription factor nuclear
factor κB (NFκB) and interferon-regulatory factor (IRF)-3 to the nucleus occurs and promotes
the transcription of IFN type I [13]. Production of type-I IFN stimulates the surrounding cells
to produce a wide range of antiviral proteins including protein kinase R (PKR), myxovirus
resistance factor, 2'-5' oligoadenylate synthase/RNaseL and dsRNA adenosine deaminase 1,
which subsequently leads to the activation of eukaryotic initiation factor (eIF)-2, and transla‐
tion inhibition of both host and viral mRNAs [14].
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Monocytes, which are the precursors of macrophages, as a part of the innate immune system,
play a major role in controlling and clearing pathogens. They exhibit antimicrobial, antifungal,
and antiparasitic properties [4,6-8]. They possess phagocytic and endocytic activity. In
addition, they act as antigen presenting cells by uptaking, processing, and presenting antigen
in the context of major histocompatibility complex (MHC) class II to CD4+ T cells. Moreover,
they secrete inflammatory cytokines such as IFN type-I (IFN-α/β), interleukin (IL)-1, IL-6,
IL-12, and chemokines such as IL-8 [4,6-8]. This stimulates the adaptive immune system and
leads to the activation and differentiation of B and T lymphocyte populations. These important
monocyte/macrophage (M/M) functions are largely driven and regulated by the responsive‐
ness of these cells to numerous cytokines such as IFN-γ, IL-10, and Tumor Necrosis Factor
(TNF)-α, and signals delivered to them via the TLR family through recognition of different
microbial products such as bacterial lipopolysaccharide (LPS) and viral proteins and nucleic
acids including those of HIV [4,6-8].
3.2. The adaptive immune system
B and T lymphocytes form the arm of the adaptive and antigen-specific immune response. B
lymphocytes are antigen presenting cells, upon antigenic and cytokine stimulation they
differentiate into plasma cells which produce antigen-specific antibodies. While T lympho‐
cytes are divided into two distinct populations: helper and cytotoxic cells which are differ in
their function T helper lymphocytes express the CD4 surface receptor, recognize antigens
presented as peptide epitopes bound to MHC class II molecules expressed on the surface of
antigen presenting cells, and function mainly as cytokine producing cells to ‘help’ the devel‐
opment of the immune response. Activated CD4+ T cells differentiate into T helper (Th)-1 and
Th-2 effectors, and memory cell sub-populations. The Th-1 and Th-2 subsets of CD4+ T cells
were originally defined by their polarized cytokine production patterns [15,16]. Th-1 cells
produce IFN-γ, IL-2, IL-12 and lymphotoxin-α, which enhance antigen presentation, phago‐
cytosis, and cell-mediated cytotoxicity. On the other hand, Th-2 cells secrete IL-4, IL-5, IL-9,
IL-10, and IL-13, promoting more of an antibody response [16-18]. Cytotoxic T lymphocytes
however, express the CD8 surface receptor, and recognize antigenic peptide epitopes present‐
ed on cell surface MHC class I molecules. Antigen-activated CD8+ T cells also proliferate and
differentiate into effectors and memory cell populations, largely in response to cytokines that
share the common γc receptor, such as IL-2, IL-15, and IL-7. Cytotoxic T cells secrete IFN-γ,
which inhibits virus replication, as well as perforin, and granzymes in order to kill virus-
infected cells.
3.3. HIV and the cellular immune response
HIV is commonly transmitted by sexual contact, and thus it initially interacts with and activates
the innate immune system and antigen presenting cells including macrophages and dendritic
cells at the mucosal surfaces [5,19,20]. Importantly, these cells then migrate to the lymphoid
tissues and thereby also deliver the virus to other susceptible cells located at these sites. In the
lymphoid tissues, HIV interacts and infects other cells such as CD4+ T cells and is able to
disseminate to other areas such as the brain and gut [5,21]. Subsequently, inflammatory cells
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cells at the mucosal surfaces [5,19,20]. Importantly, these cells then migrate to the lymphoid
tissues and thereby also deliver the virus to other susceptible cells located at these sites. In the
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and cytokines accumulate during chronic infection and immune activation causing severe
reactions and tissue pathology. This includes destruction of regulatory immune cells, mainly
CD4+ T cells, and overall impairment of immune functions, which are the hallmarks of chronic
HIV infection [5,22-24]. Studies have shown that M/M and T lymphocyte functions are
impaired over the course of HIV infection, thus contributing to the overall immune dysfunction
and appearance of the opportunistic infections observed in HIV-infected patients. Several ex
vivo and in vitro studies have reported that many M/M defects arise during chronic HIV
infection including poor phagocytic activity [25-27], altered cytokine and chemokine secretion
[24,28-31], impaired antigen uptake and MHC class II molecule expression [32,33]. Other
studies have shown defects in T lymphocyte effector functions including impairment of CD4
T lymphocytes to produce IL-2 and to proliferate in response to recall antigens (influenza,
tetanus toxoid), alloantigens (mixed lymphocytes reaction), or exogenous mitogens (phyto‐
hemagglutinin) [34,35]. Also, CD8 T lymphocytes exhibit an altered differentiation and
proliferative phenotype and impaired capacity to kill virus-infected cells and clear the virus
[36]. However, the molecular mechanism by which HIV impairs these cellular functions
remains unclear. One possible mechanism by which chronic HIV infection may adversely
affect immune cell function is through the modulation of cell signaling molecules, as observed
in several cell types including M/M, CD4+ and CD8+ T cells, and neuronal cells [37-42]. This
may occur by the direct action of HIV and its different immunomodulatory proteins such as
Gp120, Nef, Tat, and Vpr, or indirectly via its effects on the cytokine secretion profile induced
during the course of the disease as discussed in more detail below [43-46].
4. Cytokines
As mentioned above, cytokines are small secreted proteins with molecular weights of about
10-40 kDa [18,47,48]. These proteins function as mediators to regulate both the innate and
adaptive immune responses [4,6,7]. They transmit the biochemical message from the extrac‐
ellular environment to the nucleus of the targeted cell via cytokine-cytokine receptor interac‐
tion and subsequent triggering of complex intracellular signal transduction [49,50]. They can
affect cell function in a paracrine as well as an autocrine manner. There are many cytokines
produced by the immune system. Certain cytokines are associated with the initial response to
an infection or inflammation and are referred to as inflammatory cytokines. Other cytokines
are induced according to the nature of the infectious agent and the type of immune responses
produced against them. For instance, infection with Influenza virus, Vaccinia virus, or Listeria
monocytogenes is known to induce a Th-1 immune response [51]. This type of immune response
is associated with the production of cytokines such as IL-2, IFN-γ, and IL-12, which regulate
cell-mediated immunity including delayed hypersensitivity reactions, activation of macro‐
phages and leukocyte cytolytic processes, and result in the protection and elimination of
intracellular pathogens [16,50,52]. On the other hand, infection with Nippostrongylus barsilien‐
sis or Leishmania major is known to induce a Th-2 response [51]. This immune response is
characterized by secretion of cytokines such as IL-4, IL-5, IL-9, IL-10, and IL-13 that predom‐
inantly regulate antibody-mediated immunity and generally lead to the protection and
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clearance of extracellular antigens/pathogens [16,50,52]. During chronic HIV infection, both
types of immune response and their associated cytokines are dysregulated, which may result
in altered M/M and lymphocyte functions and increased susceptibility to programmed cell
death (PCD) [53-56].
The following section will focus on cytokines that play an important role in regulating M/M
as well as T lymphocytes effector functions and cell survival. These cytokines include IFN-γ,
granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-10, IL-4, IL-2, IL-7, and IL-15
(summarized in Table 1).
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Table 1. Cytokines and their effects on monocyte/macrophage and T lymphocyte functions
4.1. Cytokines that affect monocytes
Cytokines such as IFN-γ and GM-CSF affect mainly M/M, while, IL-10 and IL-4 act on both
M/M and lymphocytes. IFN-γ is an 18-kDa potent pleiotropic cytokine produced by NK cells,
NK T cells, Th-1, and CD8+ T cells. It has a critical role in the regulation of both innate and
adaptive immunity [57,58]. It inhibits Th-2 and promotes Th-1 cell polarization and differen‐
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tiation. Also, it inhibits viral replication and regulates cell death [57,58]. Moreover, it activates
monocytes and macrophages, increases MHC class II expression, promotes antigen processing
and presentation, and enhances their phagocytic, antimicrobial, and tumoricidal activities
[59-64]. For instance, it has been shown that treatment of M/M with IFN-γ enhanced phagocytic
activity against many pathogens including Aspergillus fumigatus, Cryptococcus neoformans,
Listeria monocytogenes, Mycobacterium avium, Toxoplama cruzi and gondii [26,61,65]. Other studies
have revealed that the lack of IFN-γ responses, such as in IFN- γ, IFN-γ receptor (IFN-γR), or
STAT1-deficient mice, or in patients with mutations in the IFN-γ-R gene, lead to impaired
immunity and increased susceptibility to infection [66-70]. GM-CSF is a 22-kDa protein
secreted by macrophages and T cells. It facilitates growth and differentiation of monocyte and
granulocyte lineages. It also enhances M/M effector functions including phagocytic, antimi‐
crobial and antiparasitic activities [71,72].
IL-10 is a potent immunosuppressive and anti-inflammatory cytokine produced by macro‐
phages and T cells. It downregulates MHC class II molecule expression and antigen presen‐
tation to CD4+ T cells [73,74]. It also inhibits the expression of co-stimulatory molecules, B7.1/
B7.2, on monocytes and macrophages as well as the production of various cytokines such as
TNF-α, IL-1, IL-2, IFN-γ, IL-3, and GM-CSF [73,75,76]. In addition, it suppresses macrophage
nitric oxide production, and anti-fungal activity [77]. Moreover, it stimulates proliferation and
differentiation of B cells, and polarizes T cells towards a Th-2 type response [17,78].
IL-4 is a 20-kDa cytokine secreted by Th-2 lymphocytes that promotes a Th-2 immune response.
It has dual immunoregulatory functions [18]. It activates B cell differentiation and antibody
production. Also, it enhances macrophage cytotoxicity and their expression of MHC class II
and mannose receptor [79-84]. On the other hand, it inhibits cytokine secretion such as TNF-
α, IL-1, IL-6, IL-18, GM-CSF and granulocyte colony-stimulating factor (G-CSF) [85-94]. It also
suppresses cytokine-induced macrophage activation, oxidative burst, and intracellular killing
[62,95]. Moreover, it downregulates monocyte adhesion and CD14 expression [96,97], mono‐
cyte-mediated cytotoxicity, nitric oxide production, and anti-fungal activity [77,98].
4.2. Cytokines that affect lymphocytes
Cytokines that share the γ-chain receptor, such as IL-2, IL-7, and IL-15, play a critical role in
lymphocyte growth and differentiation [36,99]. IL-2 is a protein produced mainly by activated
CD4 but also CD8 T lymphocytes and dendritic cells. It is a T cell growth factor and plays a
critical role in regulating the immune response. It plays a major role in activating the immune
system in the presence of antigenic stimulation, but also in downregulating this response
following pathogen clearance. IL-2 stimulates T cell proliferation and is essential for develop‐
ing regulatory T cells. In addition, IL-2 has been shown to upregulate expression of Tumor
Necrosis Family death receptor ligand, FasL, in activated T cells thereby enhancing their
susceptibility to activation-induced cell death [100,101].
IL-7 is a pleiotropic cytokine secreted by bone marrow and stromal cells of lymphoid organs.
It stimulates the growth and maintains the survival of thymocytes (B and T lymphocyte
progenitor cells) by increasing the expression of the anti-apoptotic molecule Bcl-2 and down-
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regulating the expression of the pro-apoptotic molecule Bax [102-105]. Thus, it is an essential
element for T cell survival, proliferation, and optimal effector function.
IL-15 is a cytokine that is produced by different cell types including M/M, dendritic cells, mast
cells, epithelial cells, and fibroblasts. It plays an important role in growth and homeostasis. It
provokes adaptive and innate immune responses. For example, it shares several biological
effects with IL-2 such as mediating survival and proliferation of naïve and memory CD8 T
cells. It also stimulates NK T cell expansion and regulates the development of NK cells and its
cytotoxicity [36,99,106].
It has been reported that during the course of chronic HIV infection, many inflammatory and
anti-inflammatory cytokines such as TNF-α, IFN-β, IFN-γ, IL-18, IL-2, IL-10, and IL-4 are
increased in patients serum [77,107-115], and thus may play a role in the alteration of M/M and
T lymphocyte functions and signaling pathways (Table 1) [38-42]. Several studies have also
proposed and used cytokines such as IFN-γ, GM-CSF, IL-4, IL-2, IL-7 and IL-15 as therapeutics
in clinical trials for diseases including HIV and myeloma in an attempt to compensate for
impairments in the cytokine network [36,99,116-118].
4.3. Cytokine signaling pathways
Cytokine  signaling  pathways  can  be  defined as  biochemical  signaling  cascades  that  are
triggered within minutes to relay the information required to mediate various cytokine-
dependent cellular functions [119-123].  Most cytokines share general  mechanisms of sig‐
nal transduction in which cytokine-cytokine receptor binding causes the assembly of the
specific  receptor subunits.  Subsequently,  a  number of  tyrosine kinases from the Src and
Syk families are activated leading to signal transduction through mainly three major sig‐
naling pathways: (i) Janus Kinase (JAK)/Signal Transducer and Activator of Transcription
(STAT),  (ii)  Phosphoinositide  3-kinase  (PI3K),  and (iii)  Mitogen-activated  protein  kinase
(MAPK)  [124-126].  These  signaling  pathways  form  a  very  complex  and  evolutionarily
conserved network.
A general overview of these cascades is illustrated in Figure 1. Briefly, when the ligand-
receptor interaction occurs, subsequent events are activated based on the nature of these
ligands and receptors. For example, a receptor with intrinsic kinase activity (e.g. epidermal
growth factor receptor) is usually autophosphorylated directly leading to the creation of a
docking site for an adapter protein complex called Grb2/SOS (son of sevenless) [36]. As a result,
SOS is recruited to the plasma membrane where it encounters and activates a small G protein
named Ras [36,127,128]. Activated Ras induces the activation of several downstream signaling
molecules, including a serine/threonine kinase called Raf, which in turn activates the MAPK
and PI3K signaling pathways [36,127,129]. PI3K signaling molecules can also be activated
directly via the p110α catalytic subunit of the PI3K [127]. A receptor with no intrinsic kinase
activity (e.g. cytokine receptors) generally requires activation of receptor-associated kinases
such as JAKs for its phosphorylation. Subsequently, activated JAKs can activate the STAT
signaling pathway directly and also interact with and activate Grb2/SOS, which in turn
activates PI3K and MAPK signaling [36,122,130,131].
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Figure 1. Overview of the major intracellular signaling pathways Upon ligand-receptor binding, signal transduc‐
tion triggers takes place based on the type and nature of the receptor. If the receptor has intrinsic tyrosine kinase ac‐
tivity, autophosphorylation of the tyrosine residues of the receptor will occur and thus creates docking sites for a
variety of different signaling molecules that have SH2 and PTB domains. Grb2/SOS complexes bind to docking sites
and lead to recruitment of SOS (son of sevenless) to the plasma membrane where they interact with Ras. Subsequent‐
ly, activated Ras molecules activate several downstream molecules including Raf, MAPKK, and MAPK. The PI3K signal‐
ing pathway can be activated directly via the p110α catalytic subunit of the PI3K. Phosphorylated receptors also
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activate phospholipase Cγ (PLCγ), which activate Protein Kinase C (PKC) and calcium-dependent signaling pathways. If
the receptor has no intrinsic kinase activity, activation of the Janus Kinase (Jak) or other receptor-associated kinase
occurs. Subsequently, activated Jaks phosphorylate the receptor and thus create docking sites for various signaling
molecules including members of the Signal Transducers and Activators of Transcription (STAT) family. Signal transduc‐
tion culminates in the transcriptional activation of STAT responsive genes that influence cellular proliferation, differen‐
tiation, cytokine production, mobility, phagocytosis, and survival [modified from [187]].
Evidence has also demonstrated the presence of a complex crosstalk between these pathways.
For instance, it has been shown that Jak2 is responsible for the activation of STAT, Erk MAPK,
and Akt signaling pathways in response to growth hormone in hepatoma and preadipocyte
cells [132]. Another report has demonstrated a role for Akt in serine phosphorylation of the
STAT1 transcription factor and upregulation of gene expression in response to IFN-γ [133].
HIV-induced perturbation of the JAK/STAT, PI3K, and MAPK signaling pathways in immune
cells including M/M and T lymphocytes has been documented (summarized in Table 1, 4)
[41,134-146]. These effects appear to be to the advantage of the virus. On one hand, it may help
the virus to replicate and establish infection. On the other hand, it may also help the virus to
escape the immune system. In the following subsections, we will provide a brief overview of
cytokine signaling and where HIV infection appears to target these cascades.
4.3.1. JAK/STAT signaling pathway
The JAK/STAT pathway is one of the major signaling pathways involved in cytokine responses.
Studies have shown that many ligands such as epidermal growth factor (EGF), receptor
tyrosine kinases (RTK), G protein-coupled receptors (GPCR) and several cytokine families
including interferons and interleukins are the main triggers of the JAK/STAT signaling cascade
[147-149]. An overview of the JAK/STAT signal transduction pathway is illustrated in Figure
1. Initially, cytokine-receptor interaction triggers tyrosine transphosphorylation of receptor-
associated JAKs. This is followed by phosphorylation of receptor cytoplasmic domains by JAKs
and recruitment of latent STAT proteins via their Src homology 2 (SH2) domains to the
activated (tyrosine phosphorylated) receptor. This is followed by STAT tyrosine phosphory‐
lation. Activated STATs form dimers via their SH2 domains and are translocated into the
nucleus where they bind STAT responsive elements [119,120,123], and thus promote tran‐
scription of STAT responsive genes such as cytokine-inducible SH2-containing protein (CIS),
members of the IRF family, and numerous other genes [150-153].
In  mammalian  cells,  four  JAKs  (Jak1,  Jak2,  Jak3  and  Tyk2)  and  seven  STAT  proteins
(STAT1,  2,  3,  4,  5a,  5b,  and  6)  with  their  different  isoforms  have  been  identified.
[147,154]. Through IL-6-induced signaling, Jak1 is the principal kinase in the downstream
signaling  cascade.  It  has  been  shown  in  many  cell  lines  that  down  regulation  of  Jak1
would lead to  impaired signal  transduction.  Activated JAKs lead to  phosphorylation of
STAT proteins. However, JAK kinases do not appear to show specificity for a particular
STAT protein  [147,154].  STAT proteins  play  an  important  role  in  regulating  and  main‐
taining  both  innate  and  adaptive  immune  responses  (summarized  in  Table  2)
[119-121,123].  For instance, studies have suggested that impairment of JAK/STAT signal‐
ing may increase susceptibility to many infections including HIV [65,67,70,155].
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the receptor has no intrinsic kinase activity, activation of the Janus Kinase (Jak) or other receptor-associated kinase
occurs. Subsequently, activated Jaks phosphorylate the receptor and thus create docking sites for various signaling
molecules including members of the Signal Transducers and Activators of Transcription (STAT) family. Signal transduc‐
tion culminates in the transcriptional activation of STAT responsive genes that influence cellular proliferation, differen‐
tiation, cytokine production, mobility, phagocytosis, and survival [modified from [187]].
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cytokine signaling and where HIV infection appears to target these cascades.
4.3.1. JAK/STAT signaling pathway
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including interferons and interleukins are the main triggers of the JAK/STAT signaling cascade
[147-149]. An overview of the JAK/STAT signal transduction pathway is illustrated in Figure
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associated JAKs. This is followed by phosphorylation of receptor cytoplasmic domains by JAKs
and recruitment of latent STAT proteins via their Src homology 2 (SH2) domains to the
activated (tyrosine phosphorylated) receptor. This is followed by STAT tyrosine phosphory‐
lation. Activated STATs form dimers via their SH2 domains and are translocated into the
nucleus where they bind STAT responsive elements [119,120,123], and thus promote tran‐
scription of STAT responsive genes such as cytokine-inducible SH2-containing protein (CIS),
members of the IRF family, and numerous other genes [150-153].
In  mammalian  cells,  four  JAKs  (Jak1,  Jak2,  Jak3  and  Tyk2)  and  seven  STAT  proteins
(STAT1,  2,  3,  4,  5a,  5b,  and  6)  with  their  different  isoforms  have  been  identified.
[147,154]. Through IL-6-induced signaling, Jak1 is the principal kinase in the downstream
signaling  cascade.  It  has  been  shown  in  many  cell  lines  that  down  regulation  of  Jak1
would lead to  impaired signal  transduction.  Activated JAKs lead to  phosphorylation of
STAT proteins. However, JAK kinases do not appear to show specificity for a particular
STAT protein  [147,154].  STAT proteins  play  an  important  role  in  regulating  and  main‐
taining  both  innate  and  adaptive  immune  responses  (summarized  in  Table  2)
[119-121,123].  For instance, studies have suggested that impairment of JAK/STAT signal‐
ing may increase susceptibility to many infections including HIV [65,67,70,155].
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STAT1 IFNs,IL-6,IL-10
IRF-1, ISG54, MIG, GBP,
CIITA
Impaired IFN and innate immune
responses, increase susceptibility to
tumors, opportunistic and viral
infections
STAT2 IFNs IRF-1, ISG54 Impaired Type-1 IFN responses
STAT3 IL-2,IL-6,IL-10




IFN-γ, IRF-1, MHC class
II, CD23, Fc-γRI
Defect in IL-4 and IL-12 responses, and
impaired Th1 differentiation.
STAT5 a, b




Impaired proliferation, growth and
survival, defect in IL-2 responses,
impaired growth.
STAT6 IL-4,IL-13 IL-4R-α, C-γ-1, C-γ-4
Defect in IL-4 responses, and impaired
Th1 differentiation.
Table 2. STATs proteins and their role in the immune system
A number of reports have suggested that defects in cytokine responsiveness arise in different
cell types during chronic HIV infection and these defects could be due to the direct effects of
HIV and/or its proteins, or due to indirect effects associated with alterations of the host cytokine
profile [38-42,139,141-143,156]. In M/M, it has been revealed that GM-CSF-induced STAT5
activation in monocyte-derived macrophages (MDM) is inhibited by in vitro HIV-1 infection
[156]. Other in vitro reports have suggested that HIV and its Gp120 and Nef proteins are capable
of activating STAT1 and STAT3 in monocytic cell lines and MDM [141-143]. Recently, the HIV
matrix protein p17 has been shown to induce STAT1 and pro-inflammatory cytokines in
macrophages [139]. Moreover, in ex vivo studies, we found that among the responses to
cytokines tested (IFN-γ, IFN-α, IL-10, IL-4, and GM-CSF) in terms of STAT induction in
monocytes, only IFN-γ showed a significant upregulation of STAT1 activation in HIV+ patients
that were off antiretroviral therapy (ART) compared to HIV- controls and patients on ART [39].
Furthermore, this potentiation of IFN-γ-induced STAT1 activation was associated with
increased total STAT1 expression levels and monocyte cell death [39]. Another ex vivo study
has shown a defect in IFN-α induced STAT1 activation in monocytes obtained from a similar
set of HIV patients, and this defect was due to the decreased IFN-α receptor expression levels
on these cells [42].
In lymphocytes, we and others have shown that both IL-7Rα expression and IL-7-induced
STAT5 activation was impaired in CD8 T cells from HIV+ patients [36,40,41]. STAT activation in
response to IL-4 and IL-10 did not appear to be similarly impaired [40]. We also found that IL-2-
induced STAT5 activation was inhibited in CD8+ T cells from a subset of HIV-infected patients
naive to therapy, but was restored, at least in part, after ART [38]. Somewhat similar results have
been observed in other in vitro studies in which activation of STAT5 in response to IL-2 was in‐
hibited by HIV-1 infection through prior Gp120-CD4 interactions in CD4+ T cells [37,144].
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4.3.2. PI3K signaling pathway
Phosphoinositide 3-kinases or phosphatidylinositol-3-kinases (PI3Ks) belong to a family of
enzymes that have serine/threonine kinase activity. These enzymes can be activated by various
stimuli including growth factors, antigens, cytokines [157,158], and are capable of phosphor‐
ylating the third position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns)
[157,159]. This family is composed of four classes, which differ in their structure and functions
(known as Ia, Ib, II, and III). However, all of them contain at least one catalytic domain and
one regulatory domain [157,159]. Many PI3K cellular functions rely on the ability of PI3Ks to
activate protein kinase B (PKB, also known as Akt) (Figure 1). In humans, three Akt genes have
been identified named akt1, akt2, and akt3.
PI3-kinases have been shown to play a major role in diverse cellular functions, including cell
growth, proliferation, differentiation, survival, and migration [160-163]. Thus, dysregulation
of this pathway may influence different cellular responses that are associated with immunity
as well as carcinogenesis (Table 3) [157,164]. It has also been reported that there is a basal
activation of the PI3K/Akt pathways in macrophages that is required for their survival [165].
Certain reports have suggested a critical role for PI3K signaling in chronic immune activation
by promoting cell survival [166]. For instance, an in vitro study has revealed that HIV infection
and its protein Tat was sufficient to activate the PI3K/Akt pathway in macrophages [166].
Interestingly, PI3K/Akt inhibitors including Miltefosine, an antiprotozoal drug known to
inhibit PI3K/Akt pathway, significantly reduced HIV-1 production from infected macrophages
and increased susceptibility to cell death in response to extracellular stress, as compared to
uninfected cells [166]. Another study has shown that inhibition of Akt phosphorylation is
required for TNF related apoptosis inducing ligand (TRAIL)-induced cell death in HIV
infected macrophages [167].
Target Gene Phenotype
p85α Decreased B cell development and activation, increased antiviral responses
p85β Increased insulin sensitivity
p110α Embryonic lethal and defective proliferation
P110β Embryonic lethal
P110γ
Decreased T cell development and activation, decreased inflammation, chemotaxis,
and oxidative burst
PTEN
Embryonic lethal, autoimmune disease, decreased T cell development, increased T cell
activation, and chemotaxis
SHIP1
Increased myeloid cell proliferation and survival, increased B cell activation,
chemotaxis, and mast cell degranulation
SHIP2 Perinatal lethal
Table 3. Characteristics of PI3K knockout mice
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Viral protein Effects on M/M Effects on lymphocytes
gp120 Stimulates STAT1 activation Stimulates STAT1 activation
p17 Stimulates STAT1 activation No report
Tat Stimulates MAPK, Akt activation Stimulates Akt, MAPK activation
Nef Stimulates STAT1 & 3, MAPK activation Stimulates Erk & p38 MAPK activation
Vpr Stimulates MAPK activation No report
HIV infection
Inhibits STAT5 activation, Stimulates STAT1, Akt
activation
Inhibits STAT5 activation, Stimulates STAT1,
MAPK activation
Table 4. HIV viral proteins and their effects on monocytes/macrophages and lymphocytes
4.3.3. MAPK signaling pathway
Mitogen-activated protein kinases (MAPKs) are also a family of enzymes that have serine/
threonine kinase activity [168]. This family of kinases is generally activated in response to vari‐
ous extracellular stimuli such as growth factors and inflammatory signals, as well as cellular
stress. They regulate different cellular processes including mitosis, proliferation, differentia‐
tion, and cell death [168]. The MAPK family is composed of three major subfamilies of kinases
known as the extracellular receptor kinases (ERKs), the c-Jun N-terminal kinases/stress-activat‐
ed protein kinases (JNK/SAPK) and the p38 MAP kinases [169]. Activation of a specific MAP
kinase requires activation of a small GTP binding protein (e.g. Ras) which results in the phos‐
phorylation of a series of downstream kinases (Figure 1) [128]. Activation of the MAPK kinase
kinase (MAPKKK) (e.g. Raf) leads to the activation of downstream MAPK kinase (MAPKK),
and finally, specific MAPK (p38, Erk or JNK) [170,171]. The Erk MAPK family is found in two
isoforms called Erk1 and Erk2. Both isoforms are phosphorylated by members of the MEK fami‐
ly, which are often activated by extracellular stimuli such as growth factors, LPS and chemo‐
therapeutic agents [129,172,173]. The JNK family is found in three isoforms named JNK1, JNK2,
and JNK3 [174], while the P38 family is found in five different isoforms called p38 (SAPK2),
p38β, p38β2, p38γ (SAPK3), and p38δ [175,176]. Both JNK and p38 MAPKs are phosphorylated
by SAPK/Erk kinases (SEKs) and mitogen-activated protein kinase kinases (MKKs), which are
usually induced by inflammatory cytokines as well as other stressors such as endotoxins, reac‐
tive oxygen species, protein synthesis inhibitors, and ultraviolet (UV) irradiation [174,177-179].
MAPKs have been shown to activate various downstream transcription factors such as activa‐
tor transcription factor (ATF)-2, SP-1 (a member of Specificity Protein/Krüppel-like Factor fami‐
ly) and activator protein (AP)-1, and even STAT3 [178,180-182].
Several reports have shown that activation of the MAPKs resulted in phosphorylation of HIV
Rev, Tat, Nef, and p17 proteins and enhanced viral replication [140,183]. Other studies have
demonstrated a role for MAPK in regulating monocyte and lymphocyte functions and cell
death during HIV infection. For example, in monocytes, it has been shown that the HIV Tat
protein stimulates IL-10 production via activation of calcium/MAPK signaling pathways in
human monocytes [134,135,184]. Another report has suggested that HIV Vpr is capable of
inducing programmed cell death in primary monocytes and the monocytic cell line THP-1 cells
[185]. Further, it has been shown that HIV and its protein nef induced FasL, Programmed
Death-1 expression and apoptosis in peripheral blood mononuclear cells (PBMCs) and the
Jurkat T cell line through activation of the p38 MAPK signaling pathway [138,186].
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Figure 2. A model for the effect of chronic HIV infection on cellular signal transduction Cell signaling molecules
may be regulated directly or indirectly during chronic HIV infection. In the direct setting, HIV and its proteins (Gp120,
Nef, Tat, Vpr), through the binding of cellular receptors or internalization by endocytosis, alter signaling pathways in‐
cluding JAK/STAT, PI3K, and MAPK. In the indirect scenario, HIV infection may adversely affects the host cytokine net‐
work, which may in turn affect signal transduction. Both scenarios may thus promote viral replication and defective
host immune effector functions and reduce immune cell survival [modified from [187].
5. Conclusion
It is well established that HIV targets the immune system and mainly immune cells that express
the CD4 surface receptor, but the virus is not exclusive to these cells. Thus, through the course
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of chronic HIV infection the immune system becomes progressively impaired and unable to
protect the body from opportunistic pathogens. This impairment not only includes CD4 T cell
depletion, but also the dysregulation of immune cell effector functions, and a skewed cytokine/
chemokine expression profile. These effects may be due to the disruption of the described
signaling pathways as a result of direct HIV infection, through the action of numerous viral
proteins and/or the chronic, but defective state of host immune activation, as summarized in
Figure 2. Understanding the molecular mechanisms and identifying the key molecules
involved in this impairment may provide important insight towards developing new thera‐
peutic strategies aimed at prolonging the life span of HIV infected individuals and clearing
HIV from the host.
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depletion, but also the dysregulation of immune cell effector functions, and a skewed cytokine/
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proteins and/or the chronic, but defective state of host immune activation, as summarized in
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1. Introduction
DC are key regulators of immunity in view of the fact that they are involved in immune re‐
sponses against infectious diseases, allergy and cancer [1, 2]. Ralph Steinman was awarded
the Nobel Prize for Medicine 2011 for DC discovery in 1973 [3]. Steinman and Cohn [3] de‐
scribed a novel cell type in mouse spleen, which they named ´dendritic cell´ due to their
tree-like shape. The major function of DC is the induction of adaptive immunity in the
LN.Yet, DC can also interact with innate immune cells, for instance natural killer (NK) and
NKT cells [1, 4].
Upon entry of HIV into the host, the virus has to be transported from mucosal surfaces to
lymphatic tissues, where it is transmitted to its primary targets, CD4+ T lymphocytes. This
process is thought to be contrived by DC.
DC thereby play critical roles during HIV and SIV (simian immunodeficiency virus) infection.
The skin and mucosa are composed of two compartments, the epidermis and the dermis
(skin) or stratified squamous epithelium and lamina propria (mucosa), each containing a
major subset of DC - Langerhans cells (LC) reside in the suprabasal layers of the epidermis
and epithelia [5], while dermal/interstitial DC are distributed throughout the connective tis‐
sue of the dermis [6, 7].
Both subsets represent immature DC that are very efficient in Ag uptake and processing. As
immature DC (iDC), they reside in peripheral tissue, which they survey for invading patho‐
gens. Upon encounter with antigen (Ag), DC mature (mDC) and migrate to the draining
lymph nodes (LN). They pass through different maturation stages, which enable them to
fulfill specific tasks such as the uptake, the processing and the presentation of Ag on major
histocompatiblity complex (MHC) molecules to naïve T cells. In the T cell area of lymphatic
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tissue the mature DC stimulate Ag-specific CD4+ and CD8+ T cells to proliferate and develop
effector function, such as cytokine production and cytotoxic activity. Effector T cells are re‐
cruited to inflamed peripheral tissue and participate in the elimination of pathogens and in‐
fected cells. This very particular life cycle illustrates why DC are called the ´sentinels of the
immune system´ [8].
In humans, different DC subsets have been identified in blood, spleen and skin, but little is
known respecting resident and migratory DC in human LN. This book chapter will review
the major DC subsets found in humans and their role in HIV-pathogenesis. If data are avail‐
able, also the role of the viral opsonization pattern and its impact on DC interaction will be
discussed.
2. DC subsets and their role in HIV infection
DC are divided into two main groups: conventional myeloid DC (cDC) and non-convention‐
al plasmacytoid DC (pDC) (Figure 1). As recently described byDoulatov et al. (2010) [9], hu‐
man multi-lymphoid progenitors can bring forth all lymphoid cell types, including
monocytes, macrophages and DC. Nonetheless, most DC in steady-state emerge from a
common myeloid progenitor [10]. DC areheterogenous subtypes with distinct functions,
properties and localization [11]. DC progenitors migrate from the bone-marrow through the
blood to lymphoid organs and peripheral tissues. There, they give rise to different cDC sub‐
sets (Figure 1). LC display an exception within the cDC group since they maintain in the epi‐
dermis independent on circulating precursors [12]. Within cDC, migratory and lymphoid-
resident DC are distinguished: migratory DC travel from peripheral tissues to lymphoid
organs, whereas lymphoid-resident DC populate lymphoid organs during their whole life-
span and lack the migratory function. In humans cDC comprise Langerhans Cells (LC), der‐
mal DC (CD103+ and CD103-), BDCA1+ (CD1c)- and BDCA3+ (CD141) DC, and the recently
described CD56+ DC (Figure 1). They are localized in the skin, secondary lymphoid organs
(spleen, tonsils) and blood. pDC develop in the bone-marrow and then they reside in lym‐
phoid organs [13]. HLA-DR+CD123+pDC express BDCA2 and this cell subset is found in
blood, secondary lymphoid organs as well as peripheral tissues, e.g. skin or lungs (Figure 1).
The cDC subtypes and pDC express a different receptor repertoir and comprise distinct
functions with respect to HIV spread, antiviral activity and transmission, which is reviewed
below and shown in Figure 1 (Table adapted from Altfeld et al., [14]). Both cell types are
resident in lymphoid tissues in the steady state, but during an inflammatory response, pDC
and cDC are actively recruited to these tissues [15-17].
2.1. cDC
2.1.1. LC and HIV
LC survey the basal  and suprabasal  layers  of  the stratified squamous epithelium of  the
skin and oral and ano-genital mucosa for invading pathogens [18-21].  Due to their ideal
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localization  in  mucosal  tissues  and  their  long  dendrites  to  efficiently  capture  Ag,  they
comprise the first  line defense against mucosal infections.  After Ag acquisition, LC start
to  mature,  as  represented  by  up-regulation  of  co-stimulatory  molecules  (CD80,  CD86,
CD40), MHC class I and II molecules, CD83 and CCR7 and down-regulation of Langerin
and E-cadherin [22].
Due to CCR7 up-regulation, the mature LC migrate to the LN along a CCL19 and CCL21-leu
(leucine isoform of CCL21) gradient to efficiently prime T cells there [23]. Beside initiating
an effective adaptive immune response, LC were illustrated by DeWitte et al. [24, 25] to also
have important functions with respect to innate immune responses. Beside a specific set of
TLRs (TLR2, 3, 5) and high expression of CD1a, LC express Langerin and contain Birbeck
granules that might be crucial to their innate function [21, 26-29] (Figure 1). The C-type lec‐
tin Langerin interacts with non-opsonized HIV-1 (Figure 2) and other pathogens such as
fungi and bacteria, via fucose or mannose residues. Thereby degradation of HIV-1 in Bir‐
beck granules is promoted and HIV-1 dissemination is limited [24].
Figure 1. DC-subsets and functions during HIV-infection (Table adapted from Altfeld et al., 2011; CD56+ DC added).
HIV co-localizes with Langerin in LC to high extend as shown by confocal microscopic analyses (co-localization: yel‐
low). CD1a+ LC were isolated from human skin, incubated with HIV for 2 hrs, fixed and permeabilized with Cytofix/-
perm (BD Biosciences). The cells were then stained using an anti-human Langerin-PE mAb (red, Dendritics) and the
anti-HIV-Ab KC57-FITC ((green, Beckman Coulter). The nucleus was stained using DRAQ5TM (blue, Invitrogen) (Posch et
al., unpublished).
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tissue the mature DC stimulate Ag-specific CD4+ and CD8+ T cells to proliferate and develop
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Figure 2. Co-localization of HIV and Langerin on CD1a+ Langerhans Cells isolated from human skin
Early investigations of HIV-LC interactions illustrated that LC are productively infected by
HIV and that they efficiently transmit the virus to T cells [30-32]. These results suggested
that HIV take advantage of the antigen-capturing properties of LC to reach the T cell zone in
the lymphatic tissues and via this route, HIV can establish a productive infection of the host.
However, in vivo only low percentages of LC are infected and despite abundant expression
of the primary HIV-receptor CD4 and the chemokine co-receptor CCR5, high HIV-1 concen‐
trations are required to infect LC in vitro [31, 32]. As shown by Wu and KewalRemani [33]
the percentages to acquire HIV-1 after heterosexual contact with an HIV-positive individual
are between 0.01 to 0.1%, which might be due to a restriction by LC.
Engagement of Langerin trimers on the surface of LC induces formation of Birbeck granules,
which are part of the endosomal recycling system and uniquely found in LC (Figure 3, low‐
er right panel) [34]. Upon capture of mycobacterial lipoproteins by Langerin, these were ex‐
posed to CD1a molecules in Birbeck granules [35], which suggests that Birbeck granule
formation displays a non-classical antigen processing pathway [20]. Also HIV-1 attaches to
Langerin on LC and is subsequently routed to Birbeck granules, which points to a role of the
granules with respect to degradation of viruses.
Studies by Gejitenbeek´s laboratory [24] showed that under homeostatic conditions, Lan‐
gerin expressed on LC and acts as restriction factor for HIV infection. They demonstrated
that, if HIV-gp120 attaches to Langerin, the viral particle is internalized and subsequently
degraded in Birbeck granules. Thus, LC are protected from infection with incoming, non-
opsonized HIV particles and HIV-1 is not disseminated throughout the host [24]. The rap‐
id  internalization  of  HIV-1  into  LC  by  Langerin  impedes  interactions  and  subsequent
fusion with CD4 and CCR5 and also prevents transmission to the main target cells of the
virus,  CD4+  T  cells.  Thereby,  Langerin  acts  as  a  protective  anti-HIV  barrier  during  the
first  steps  of  HIV-1  infection,  if  the  virus  is  non-opsonized  and  if  sexually  transmitted
pathogens are lacking.
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As demonstrated, if the host system is facing other sexually transmitted infections, the anti-
HIV-1-barrier of LC is abrogated and HIV-1 transfer to susceptible CD4+ T cells is promoted
[20, 36, 37]. Pathogens, such as Candida or Neisseria, directly interact with Langerin and
compete with HIV-1-binding. Additional factors explaining the by-passing of the anti-
HIV-1-barrier function of Langerin are that:
• by high viral loads the receptor becomes saturated,
• infections, e.g. Herpes simplex virus infection, down-regulate Langerin surface expres‐
sion [20],
• the HIV-1 entry receptors CD4 and CCR5 are up-regulated during additional sexually
transmitted infections [37],
• or the antiviral function of Langerin is reverted by inflammation-induced TNF-α (tumor-
necrosis-factor α) production due to Candida albicans or Neisseria gonorrhoea [36].
These observations allow to conclude that during acute co-infection the anti-viral function of
LC is significantly decreased.
Not only acute co-infection, but also opsonization of HIV with either complement fragments
or specific Abs might result in reduction or abolishment of the anti-viral function mediated
by Langerin (Wilflingseder and Posch, unpublished data). Upon entry of viruses into the body,
immediate non-specific immune responses are triggered and within a short time the innate
immune system is completely activated. During acute infection multiple humoral and cellu‐
lar players, including cytokines, complement, acute-phase proteins, DC, macrophages, and
natural killer (NK) cells, that co-operate to generate an efficient defense against infection, are
activated. HIV-1 spontaneously triggers the complement system also in absence of specific
Abs by interactions of gp41 with C1q [38-41]. Due to regulators of complement activation
(RCAs) in the viral surface, HIV-1 is very efficiently protected against virolysis, which nor‐
mally occurs due to MAC (membrane attack complex) formation and destruction of patho‐
gens or infected cells. The incorporation of RCAs in the viral surface acts as protection
mechanism and results in opsonization of HIV-1 with complement C3 fragments at the very
initial steps following viral entry. After seroconversion, when HIV-1-specific Abs are estab‐
lished, the virus additionally is opsonized with specific IgGs. The different coating patterns
of the virus change the receptor used on DC due to the density of complement fragments or
Abs on the viral surface [42]. The C-type lectin-virus interaction becomes rather unimpor‐
tant if the virus is opsonized and is substituted by complement or Fc receptor-virus interac‐
tions as already demonstrated using dermal DC [42]. After LC incubation using
complement-opsonized HIV-1, we found that not only sexually transmitted diseases abro‐
gate the antiviral barrier mediated via Langerin but also opsonization of HIV-1 (Wilflingseder
and Posch, unpublished data).
In summary, during acute co-infection or by opsonization with complement fragments or
Abs, the anti-viral function of LC is significantly reduced due to competition for Langerin or
different receptor utilization. This facilitates HIV-1 infection of LC via CD4 and CCR5, intra‐
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cellular uptake of the virus (Figure 3) and promotion of HIV-1 transfer to its targets, CD4+ T
cells.
On the other hand LC were implicated in establishment of infection due to their location in
the foreskin and due to compelling evidence that male circumcision efficiently reduces the
risk to become infected with HIV-1 [43]. It was furthermore shown in vivo in highly HIV-1-
exposed but (IgG) seronegative individuals, that gp41-specific IgA Abs efficiently blocked
transfer of sexually transmitted HIV-1 [44-46]. A very recent study by Tudor et al. [46] illus‐
trated that monomeric 2F5 IgA2 bound to gp41 MPER (membrane proximal external region)
and free virus with greater efficiency than IgG1 and interferred with the initial HIV-1 trans‐
mission via Langerhans Cells. 2F5 IgA2 and IgG1 monomers blocked HIV-1 transcytosis in
monostratified or multilayered epithelia as well as in rectal tissue [46, 47]. These Abs de‐
creased infection of CD4+ T cells and transfer from LC to autologous CD4+ T cells [46]. The
2F5 IgA2 monomer inhibited virus transcytosis and CD4+ T cell infection more efficiently,
while the 2F5 IgG1 monomer was superior in blocking the LC-CD4+ T cell transmission. A
synergistic effect of both, 2F5 IgA2 and IgG1, was observed with respect to LC-CD4+ T cell
transmission and decrease of CD4+ T cell infection [46].
2.1.2. Dermal DC and HIV
Along with LC, HIV-1 firstly attaches to dermal (interstitial) DC upon entry at mucosal sur‐
faces (Figure 1). Dermal DC are underlying the epithelium, do not contain Birbeck granules
and express heterogenous amounts of CD1a [48].
Interstitial DC are localized in the dermis and oral, vaginal and colonic lamina propria [6,
49-52]. They are characterized by the expression of CD11c, high expression of various C-
type lectin receptors (Langerin on CD103+ DC, DC-SIGN on CD103- DC, DEC-205 on both
subsets), TLR2, 3, 4 and 5 and they secrete various cytokines upon pathogenic stimulation
(Figure 1). Since there are only 2 studies available on human CD103+ DC and SIV [53, 54],
the following chapter refers to CD103-, DC-SIGN+ dermal DC.
In vitro experiments showed that DC efficiently capture HIV-1 or SIV, independent on the
maturation status of the cells (Figure 3 and [55]) and subsequently transfer the virus to CD4+
T cells, which initiates a vigorous infection [41, 42, 56, 57]. These experiments imply that in
vivo HIV exploits DC at mucosal sites as shuttles to CD4+ T cells in the LN, but the exact
events with respect to virus spread from mucosal sites to LN have not been enlightened yet.
Thereby, DC seem to play a significant role in the spread of infection as well as in the induc‐
tion of antiviral immunity.
As shown in Figure 3, dermal DC (left panel) and LC (right panel), which emigrated from
whole skin explants, take up variable amounts of HIV-1 particles. As demonstrated by
Frank et al. [55], human and macaque DC interacted similarly with SIV and ample amounts
of virus were captured by DC. Transmission electron microscopic analyses revealed that
iDC, which are endocytically highly active, captured few viral particles near the periphery
of the membrane, while mDC, which down-regulate the endocytic capacity, retained high
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amounts of virions in large vesicular compartments deeper within DC [55]. This points to a
diverse entry and handling of virions within iDC and mDC.
Figure 3. Uptake of HIV into dendritic cells from human skin. Dendritic cells emigrated from whole skin explants were
incubated with HIV for 2h and then fixed and embedded for transmission electron microscopy. Variable amounts of
viral particles are taken up by dermal dendritic cells (left panels) and epidermal Langerhans cells (right panels). Lower
panels show higher magnifications of membrane-enclosed virus particles in a dermal dendritic cell (left panel; some
viruses marked with red/black). In a Langerhans cell (lower right panel) viruses can be seen docking onto the surface
membrane (right asterisk) and already taken up into vesicular structures (left asterisk). A Birbeck granule is depicted in
the inset as the identifying structure for Langerhans cells. N, nucleus.(Photos courtesy of Hella Stössel and Nikolaus
Romani).
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cellular uptake of the virus (Figure 3) and promotion of HIV-1 transfer to its targets, CD4+ T
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Beside the different handling of HIV-1 or SIV within iDC and mDC, opsonization of the vi‐
rus with either complement fragments and/or Abs significantly affects the binding mecha‐
nism, internalization and infection of DC as well as their T cell stimulatory capacity [41, 42,
58]. As shown by Pruenster et al. [42], the complement cloud around the virus significantly
blocked the accessibility of gp120 and therefore interfered with C-type lectin interaction.
Similar amounts of HIV-1 bound to the surface of DC independent on the opsonization pat‐
tern of the virus (Pruenster et al., 2005). The attachment of the differentially opsonized
HIV-1-preparations was found to be specific (Figure 4 [Wilflingseder and Posch, unpublished
data]), since pre-incubation of the DC with blocking Abs against human DC-SIGN, CD11b
(CR3-α chain) or CD32 (FcγRII) particularly blocked the interactions with the corresponding
virus preparations:
• blocking α-DC-SIGN mAb inhibited interaction with non-opsonized HIV-1 (Figure 4,
HIV),
• blocking α-CR3mAb (TMG6.5) significantly interferred with binding of complement-
opsonized HIV (HIV-C) to DC (Fig.4, HIV-C) and
• blocking α-CD32mAb (AT10) inhibited binding of Ab-opsonized HIV-1 (Figure 4, HIV-
Ig).
Additionally, we found variations respecting infection of DC with differentially opsonized
HIV-1 preparations [41]. Productive infection of DC and LC with HIV-1 was described to be
relatively inefficient compared to HIV-infection of CD4+ T cells and HIV- or SIV-infected DC
are rarely detected in vivo (rev. in Piguet and Steinman[59]). Our study using non-, comple‐
ment-, complement-Ig- or Ig-opsonized HIV-1 uncovered that complement-opsonization of
HIV-1 significantly enhanced DC-infection compared to non-opsonized HIV [41] and further‐
more acted as an endogenous adjuvans for DC-mediated induction of HIV-specific CTLs [58].
In contrast, HIV-1 coated with specific, non-neutralizing Abs significantly impaired infec‐
tion of and integration in DC and also ´trans´-infection of CD4+ T cells after delayed addition
of T cells [41].
Despite the low-level productive infection of DC, non-opsonized HIV-1 is very efficiently
transmitted to T cells either via de novo (´cis´-transfer) or without (´trans´-)infection [60].
This is also true for Ab-opsonized HIV-1, if CD4+ T cells are added immediately to HIV-ex‐
posed DC [41]. Especially C-type lectins, such as DC-SIGN on dermal DC, were connected
to transmitting HIV-1 to T cells in the LN [60, 61]. Similar to Langerin, DC-SIGN has high
affinity for mannose and fucose structures, but despite sharing this feature these receptors
exert completely different effects and functions regarding pathogen processing. Dermal
CD103- DC express DC-SIGN, which captures low titres of HIV-1 by interaction with the en‐
velope glycoprotein gp120 [62]. By complexing DC-SIGN via gp120, HIV-1 is protected from
degradation within the DC in contrast to Langerin, which promotes degradation of the virus
through Birbeck granules as described above [24, 62]. DC-SIGN-complexed HIV-1 remains
stable and infectious over prolonged periods of time within non-lysosomal acidic organelles
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of DC [62, 63]. Thereby, DC-SIGN efficiently transfers HIV-1 to CD4+ T cells, enhances infec‐
tion in DC-CD4+ T cell co-cultures and facilitates ‘trans’-infection of the T cells [62].
Figure 4. Binding of differentially opsonized HIV (non-opsonized HIV, HIV-C, HIV-Ig) in absence and presence of a
blocking anti-human DC-SIGN, CR3 [CD11b] (TMG6.5) or CD32 (AT-10) antibodies. Binding of non-opsonized HIV was
signficantly decreased in the presence of a blocking anti-DC-SIGN Ab, but not affected by pre-incubation of the cells
with a blocking anti-CR3- or CD32-Ab (white bars). HIV-C-interaction with DC was inhibited using a blocking anti-
CD11b (CR3)-Ab TMG6.5, but not by anti-DC-SIGN or CD32 (grey bars). Binding of IgG-opsonized HIV was inhibited by
using a blocking anti-human CD32, but not DC-SIGN or CD11b-Ab (black bars).
Lastly, the antigen-presenting capacity of DC was also shown to be modulated by the opso‐
nization pattern of the virus [58]. Earlier studies illustrated the role of complement opsoni‐
zation respecting induction of effective CTL responses against viral infections, but the exact
mechanism was not determined [64-66]. The exclusive role of DC in priming naïve CD8+ T
cells in response to exogenous cell-associated as well as endogenously synthesized Ags has
been shown [67, 68]. Endogenously synthesized antigens from DC infected with LCMV
(choriomeningitis virus) mediated strong CTL responses, while macrophages and B cells in‐
fected with LCMV did not induce CTLs [68].
We recently  found that  opsonization  of  retroviral  particles  with  complement  fragments
enhanced the ability of DC to induce CTL responses both in vitro and in vivo [58]. HIV-C-
loaded DC mediated significantly higher CD8+ T cell expansion and signficantly better an‐
tiviral activity than DC exposed to non-opsonized HIV in vitro.  This was further verified
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Beside the different handling of HIV-1 or SIV within iDC and mDC, opsonization of the vi‐
rus with either complement fragments and/or Abs significantly affects the binding mecha‐
nism, internalization and infection of DC as well as their T cell stimulatory capacity [41, 42,
58]. As shown by Pruenster et al. [42], the complement cloud around the virus significantly
blocked the accessibility of gp120 and therefore interfered with C-type lectin interaction.
Similar amounts of HIV-1 bound to the surface of DC independent on the opsonization pat‐
tern of the virus (Pruenster et al., 2005). The attachment of the differentially opsonized
HIV-1-preparations was found to be specific (Figure 4 [Wilflingseder and Posch, unpublished
data]), since pre-incubation of the DC with blocking Abs against human DC-SIGN, CD11b
(CR3-α chain) or CD32 (FcγRII) particularly blocked the interactions with the corresponding
virus preparations:
• blocking α-DC-SIGN mAb inhibited interaction with non-opsonized HIV-1 (Figure 4,
HIV),
• blocking α-CR3mAb (TMG6.5) significantly interferred with binding of complement-
opsonized HIV (HIV-C) to DC (Fig.4, HIV-C) and
• blocking α-CD32mAb (AT10) inhibited binding of Ab-opsonized HIV-1 (Figure 4, HIV-
Ig).
Additionally, we found variations respecting infection of DC with differentially opsonized
HIV-1 preparations [41]. Productive infection of DC and LC with HIV-1 was described to be
relatively inefficient compared to HIV-infection of CD4+ T cells and HIV- or SIV-infected DC
are rarely detected in vivo (rev. in Piguet and Steinman[59]). Our study using non-, comple‐
ment-, complement-Ig- or Ig-opsonized HIV-1 uncovered that complement-opsonization of
HIV-1 significantly enhanced DC-infection compared to non-opsonized HIV [41] and further‐
more acted as an endogenous adjuvans for DC-mediated induction of HIV-specific CTLs [58].
In contrast, HIV-1 coated with specific, non-neutralizing Abs significantly impaired infec‐
tion of and integration in DC and also ´trans´-infection of CD4+ T cells after delayed addition
of T cells [41].
Despite the low-level productive infection of DC, non-opsonized HIV-1 is very efficiently
transmitted to T cells either via de novo (´cis´-transfer) or without (´trans´-)infection [60].
This is also true for Ab-opsonized HIV-1, if CD4+ T cells are added immediately to HIV-ex‐
posed DC [41]. Especially C-type lectins, such as DC-SIGN on dermal DC, were connected
to transmitting HIV-1 to T cells in the LN [60, 61]. Similar to Langerin, DC-SIGN has high
affinity for mannose and fucose structures, but despite sharing this feature these receptors
exert completely different effects and functions regarding pathogen processing. Dermal
CD103- DC express DC-SIGN, which captures low titres of HIV-1 by interaction with the en‐
velope glycoprotein gp120 [62]. By complexing DC-SIGN via gp120, HIV-1 is protected from
degradation within the DC in contrast to Langerin, which promotes degradation of the virus
through Birbeck granules as described above [24, 62]. DC-SIGN-complexed HIV-1 remains
stable and infectious over prolonged periods of time within non-lysosomal acidic organelles
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of DC [62, 63]. Thereby, DC-SIGN efficiently transfers HIV-1 to CD4+ T cells, enhances infec‐
tion in DC-CD4+ T cell co-cultures and facilitates ‘trans’-infection of the T cells [62].
Figure 4. Binding of differentially opsonized HIV (non-opsonized HIV, HIV-C, HIV-Ig) in absence and presence of a
blocking anti-human DC-SIGN, CR3 [CD11b] (TMG6.5) or CD32 (AT-10) antibodies. Binding of non-opsonized HIV was
signficantly decreased in the presence of a blocking anti-DC-SIGN Ab, but not affected by pre-incubation of the cells
with a blocking anti-CR3- or CD32-Ab (white bars). HIV-C-interaction with DC was inhibited using a blocking anti-
CD11b (CR3)-Ab TMG6.5, but not by anti-DC-SIGN or CD32 (grey bars). Binding of IgG-opsonized HIV was inhibited by
using a blocking anti-human CD32, but not DC-SIGN or CD11b-Ab (black bars).
Lastly, the antigen-presenting capacity of DC was also shown to be modulated by the opso‐
nization pattern of the virus [58]. Earlier studies illustrated the role of complement opsoni‐
zation respecting induction of effective CTL responses against viral infections, but the exact
mechanism was not determined [64-66]. The exclusive role of DC in priming naïve CD8+ T
cells in response to exogenous cell-associated as well as endogenously synthesized Ags has
been shown [67, 68]. Endogenously synthesized antigens from DC infected with LCMV
(choriomeningitis virus) mediated strong CTL responses, while macrophages and B cells in‐
fected with LCMV did not induce CTLs [68].
We recently  found that  opsonization  of  retroviral  particles  with  complement  fragments
enhanced the ability of DC to induce CTL responses both in vitro and in vivo [58]. HIV-C-
loaded DC mediated significantly higher CD8+ T cell expansion and signficantly better an‐
tiviral activity than DC exposed to non-opsonized HIV in vitro.  This was further verified
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in  vivo  using  the  murine  Friend virus  model.  These  results  indicated  that  ´complement
acts  as  natural  adjuvant  for  DC-induced expansion  and differentiation  of  specific  CTLs
against retroviruses´ [58].
Additionally, we demonstrated that in contrast to complement opsonization, antibody-coat‐
ing of the viral surface attenuated the CTL-stimulatory capacity of HIV-exposed DC [69]. In
some HIV-1-positive individuals, high levels of antibodies and low levels of complement
fragments coat the HIV-1 surface and therefore we investigated the effects of the non-neu‐
tralizing Abs bound to the surface of HIV-1 on the CTL-stimulatory capacity of DC. We ob‐
served ex vivo and in vitro that DC loaded with IgG-opsonized HIV significantly impaired
the HIV-1-specific CD8+ T cell response compared to the earlier described efficient CD8+ T
cell activation induced by DC exposed to complement-opsonized HIV. These novel modula‐
tory effects of the HIV-1-opsonization pattern on the CTL-activating capacity of DC might
influence future vaccination strategies, since strong transient Ab responses subsequent to
vaccination might weaken the CTL-induction by DC, which has to be considered [69].
Preferential expression of CCR5 on immature LC and DC restricts the transmission of X4-
tropic isolates at the site of infection. Additionally, ex vivo analyses revealed that X4-tropic
HIV replicate worse in DC and LC compared to R5-tropic viruses [31, 70, 71]. The relatively
low susceptibility of DC to HIV-1-infection but efficient transfer of virus to CD4+ T cells was
lately ascribed to an HIV-1 escape mechanism from innate recognition by DC [72, 73]. Manel
et al. [72] showed that if DC by-pass resistance to HIV-1 infection [74, 75], they mature, exert
a type I IFN response as well as adaptive immune responses. More recently, Laguette et al.
[73] described the restriction factor SAMHD1 (SAM domain and HD domain-containing
protein 1) to be responsible for inhibiting HIV-1 replication in DC and other cells of the mye‐
loid lineage by degrading or preventing accumulation of HIV-1 DNA due to a putative nu‐
cleotidase activity. As shown by Lahouassa et al. [76], SAMHD1 depletes the pool of
intracellular dNTPs and thus restricts HIV-1 infection in DC by blocking reverse transcrip‐
tion. These recent important findings respecting a formerly unknown cryptic innate sensor
in DC, SAMHD1, and the induction of an efficient type I IFN and adaptive immune re‐
sponse due to DC infection might pave the way for novel therapeutical approaches to treat
retroviral infections.
2.1.3. Blood DC and HIV
2.1.3.1. BDCA1+ DC, BDCA3+ DC, CD56+ DC and HIV
BDCA1+ myeloid DC can be directly isolated from human blood. This population was de‐
scribed to be reduced in the blood of HIV-infected individuals [76-78]. We found that
BDCA1+ DC exerted a decreased transmission of HIV-1 to autologous CD4+ T cells, when the
virus was opsonized with specific IgGs in contrast to non- or complement-opsonized HIV-1
and when the T cells were added delayed [41]. When CD4+ T cells were immediately added
after washing the differentially loaded DC, the same infection efficiency was observed using
HIV, HIV-C or HIV-Ig [41]. The two-phase transfer of HIV to DC as described above (trans-
infection: by-passing of the virus from endolysosomal compartments, first 24 hrs; cis-infec‐
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tion: ´de novo´ HIV-1-infection of DC before transfer to T cells) was also observable in
BDCA1+ DC, because non- and complement-opsonized HIV-1, which cause productive in‐
fection of DC, efficiently infected autologous CD4+ T cells in short- and long-term co-cul‐
tures. BDCA1+ DC exposed to IgG-opsonized HIV-1, which were not productively infected
by the virus, were not able to promote long-term transfer of HIV-1 to susceptible T cells [41].
BDCA3+ DC represent the human equivalent to mouse CD8α+ DC and they are the major
producers of IFN-λ in response to dsRNA poly I:C [80].As recently described by Dutertre et
al. [81] using an 11-color flow cytometric strategy, circulating BDCA1+ DC and BDCA3+ DC
counts were reduced in 15 viremic, untreated patients compared to 8 HIV-1-positive indi‐
viduals under treatment and 13 healthy donors. By using this method, they illustrated that
both blood DC subsets expressed characteristic lineage markers: BDCA1+ DC expressed
CD14, while particularly BDCA3+ DC displayed CD56 on their surface. BDCA3+ DC were
shown to be more significantly down-modulated in viremic patients compared to controls
[82] and it remains to be investigated by longitudinal studies, if combined antiretroviral
therapy can restore the pool of circulating myeloid BDCA1+ and BDCA3+ DC.
Blood CD56+ DC were recently described by Gruenbacher et al. [83] and comprise inter‐
mediate-sized lymphocytes with an HLA-DRhigh, CD80+ and CD86+ expression profile. Upon
cultivation they acquire DC-like morphology with increased levels of above mentioned sur‐
face markers. Upon stimulation, they are able to efficiently stimulate CD56+γδ T cells, which
results in secretion of IFNγ, TNF-α, and IL-1β [84]. The role of CD56+ DC respecting HIV-1
infection and pathogenesis needs to be further investigated.
2.2. pDC and HIV
Plasmacytoid DC (pDC) (Figure 1) or type 1 IFN-producing dendritic cells are innate im‐
mune cells in blood, which are specialized in releasing massive amounts of IFNα and IFNβ
upon viral challenge, including HIV-1 [83]. They constitute <0.2-0.5% of peripheral blood
mononuclear cells (PBMC) [85] and in humans, pDC express the characteristic surface mark‐
ers BDCA-2 (CD303, CLEC4C) and CD123 along with BDCA4 (CD304, NRP1), but they do
not express CD11c, a marker of myeloid DC, or CD14 [86].
pDCs are key players of the innate immune response in vivo and they can prime adaptive
immunity due to the afore mentioned production of high type I interferon levels, especially
upon exposure to viral products [15, 83]. Upon stimulation with DNA or RNA viruses, they
produce up to 1000-fold higher amounts of type I interferons than other cells [84, 87, 88].
The IFNα production in pDC by viruses represents a two-step process – uptake of viruses
occurs due to recognition of envelope glycoproteins by C-type lectin receptors, e.g. mannose
receptor or BDCA2, but induction of IFNα in fact starts in endosomal compartments by liga‐
tion of TLR9 or TLR7 [89-91]. Pathogenic single-stranded RNA or unmethylated DNA are
mainly recognized by TLR7 and TLR9 expressed inside pDC [92]. Thus, the viruses have to
be ingested by pDC into endosomes and NFkB- and MAPK signals through MyD88 must be
stimulated [93]. Not only viruses, but also virus-infected cells can potently activate IFNα
production from pDC [94]. Once activated, pDCs mature and produce large quantities of
pro-inflammatory and antiviral cytokines [95-97]. pDC respond with high amounts of differ‐
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in  vivo  using  the  murine  Friend virus  model.  These  results  indicated  that  ´complement
acts  as  natural  adjuvant  for  DC-induced expansion  and differentiation  of  specific  CTLs
against retroviruses´ [58].
Additionally, we demonstrated that in contrast to complement opsonization, antibody-coat‐
ing of the viral surface attenuated the CTL-stimulatory capacity of HIV-exposed DC [69]. In
some HIV-1-positive individuals, high levels of antibodies and low levels of complement
fragments coat the HIV-1 surface and therefore we investigated the effects of the non-neu‐
tralizing Abs bound to the surface of HIV-1 on the CTL-stimulatory capacity of DC. We ob‐
served ex vivo and in vitro that DC loaded with IgG-opsonized HIV significantly impaired
the HIV-1-specific CD8+ T cell response compared to the earlier described efficient CD8+ T
cell activation induced by DC exposed to complement-opsonized HIV. These novel modula‐
tory effects of the HIV-1-opsonization pattern on the CTL-activating capacity of DC might
influence future vaccination strategies, since strong transient Ab responses subsequent to
vaccination might weaken the CTL-induction by DC, which has to be considered [69].
Preferential expression of CCR5 on immature LC and DC restricts the transmission of X4-
tropic isolates at the site of infection. Additionally, ex vivo analyses revealed that X4-tropic
HIV replicate worse in DC and LC compared to R5-tropic viruses [31, 70, 71]. The relatively
low susceptibility of DC to HIV-1-infection but efficient transfer of virus to CD4+ T cells was
lately ascribed to an HIV-1 escape mechanism from innate recognition by DC [72, 73]. Manel
et al. [72] showed that if DC by-pass resistance to HIV-1 infection [74, 75], they mature, exert
a type I IFN response as well as adaptive immune responses. More recently, Laguette et al.
[73] described the restriction factor SAMHD1 (SAM domain and HD domain-containing
protein 1) to be responsible for inhibiting HIV-1 replication in DC and other cells of the mye‐
loid lineage by degrading or preventing accumulation of HIV-1 DNA due to a putative nu‐
cleotidase activity. As shown by Lahouassa et al. [76], SAMHD1 depletes the pool of
intracellular dNTPs and thus restricts HIV-1 infection in DC by blocking reverse transcrip‐
tion. These recent important findings respecting a formerly unknown cryptic innate sensor
in DC, SAMHD1, and the induction of an efficient type I IFN and adaptive immune re‐
sponse due to DC infection might pave the way for novel therapeutical approaches to treat
retroviral infections.
2.1.3. Blood DC and HIV
2.1.3.1. BDCA1+ DC, BDCA3+ DC, CD56+ DC and HIV
BDCA1+ myeloid DC can be directly isolated from human blood. This population was de‐
scribed to be reduced in the blood of HIV-infected individuals [76-78]. We found that
BDCA1+ DC exerted a decreased transmission of HIV-1 to autologous CD4+ T cells, when the
virus was opsonized with specific IgGs in contrast to non- or complement-opsonized HIV-1
and when the T cells were added delayed [41]. When CD4+ T cells were immediately added
after washing the differentially loaded DC, the same infection efficiency was observed using
HIV, HIV-C or HIV-Ig [41]. The two-phase transfer of HIV to DC as described above (trans-
infection: by-passing of the virus from endolysosomal compartments, first 24 hrs; cis-infec‐
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tion: ´de novo´ HIV-1-infection of DC before transfer to T cells) was also observable in
BDCA1+ DC, because non- and complement-opsonized HIV-1, which cause productive in‐
fection of DC, efficiently infected autologous CD4+ T cells in short- and long-term co-cul‐
tures. BDCA1+ DC exposed to IgG-opsonized HIV-1, which were not productively infected
by the virus, were not able to promote long-term transfer of HIV-1 to susceptible T cells [41].
BDCA3+ DC represent the human equivalent to mouse CD8α+ DC and they are the major
producers of IFN-λ in response to dsRNA poly I:C [80].As recently described by Dutertre et
al. [81] using an 11-color flow cytometric strategy, circulating BDCA1+ DC and BDCA3+ DC
counts were reduced in 15 viremic, untreated patients compared to 8 HIV-1-positive indi‐
viduals under treatment and 13 healthy donors. By using this method, they illustrated that
both blood DC subsets expressed characteristic lineage markers: BDCA1+ DC expressed
CD14, while particularly BDCA3+ DC displayed CD56 on their surface. BDCA3+ DC were
shown to be more significantly down-modulated in viremic patients compared to controls
[82] and it remains to be investigated by longitudinal studies, if combined antiretroviral
therapy can restore the pool of circulating myeloid BDCA1+ and BDCA3+ DC.
Blood CD56+ DC were recently described by Gruenbacher et al. [83] and comprise inter‐
mediate-sized lymphocytes with an HLA-DRhigh, CD80+ and CD86+ expression profile. Upon
cultivation they acquire DC-like morphology with increased levels of above mentioned sur‐
face markers. Upon stimulation, they are able to efficiently stimulate CD56+γδ T cells, which
results in secretion of IFNγ, TNF-α, and IL-1β [84]. The role of CD56+ DC respecting HIV-1
infection and pathogenesis needs to be further investigated.
2.2. pDC and HIV
Plasmacytoid DC (pDC) (Figure 1) or type 1 IFN-producing dendritic cells are innate im‐
mune cells in blood, which are specialized in releasing massive amounts of IFNα and IFNβ
upon viral challenge, including HIV-1 [83]. They constitute <0.2-0.5% of peripheral blood
mononuclear cells (PBMC) [85] and in humans, pDC express the characteristic surface mark‐
ers BDCA-2 (CD303, CLEC4C) and CD123 along with BDCA4 (CD304, NRP1), but they do
not express CD11c, a marker of myeloid DC, or CD14 [86].
pDCs are key players of the innate immune response in vivo and they can prime adaptive
immunity due to the afore mentioned production of high type I interferon levels, especially
upon exposure to viral products [15, 83]. Upon stimulation with DNA or RNA viruses, they
produce up to 1000-fold higher amounts of type I interferons than other cells [84, 87, 88].
The IFNα production in pDC by viruses represents a two-step process – uptake of viruses
occurs due to recognition of envelope glycoproteins by C-type lectin receptors, e.g. mannose
receptor or BDCA2, but induction of IFNα in fact starts in endosomal compartments by liga‐
tion of TLR9 or TLR7 [89-91]. Pathogenic single-stranded RNA or unmethylated DNA are
mainly recognized by TLR7 and TLR9 expressed inside pDC [92]. Thus, the viruses have to
be ingested by pDC into endosomes and NFkB- and MAPK signals through MyD88 must be
stimulated [93]. Not only viruses, but also virus-infected cells can potently activate IFNα
production from pDC [94]. Once activated, pDCs mature and produce large quantities of
pro-inflammatory and antiviral cytokines [95-97]. pDC respond with high amounts of differ‐
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ent IFNα subsets, IFNβ, IFNκ, IFNλ and IFNω on a wide range of enveloped viruses includ‐
ing HIV-1. They additionally produce pro-inflammatory cytokines TNFα, IFNγ and IL-6 as
well as chemokines CXCL-10, CCL-5 and CCL-4 among others [98]. Thereby, pDC also act
as a linker between innate and adaptive immunity.
Data by Zhou et al. [99] indicate that subsequent to HIV-1 challenge, signaling via TLR7 trig‐
gers autophagy and increased IFNα production from human pDC. The IFNα secretion
mediated by an autophagy-dependent pathway may play an important role for T cell trig‐
gering during HIV-1 pathogenesis.
Beside acting as pro-inflammatory cells, pDC also provide negative regulatory signals and
thus induce tolerance. pDC express IDO (indoleamine 2,3-dioxygenase) and PDL-1 (pro‐
grammed death ligand; 1) which are associated with the negative modulation of T cell re‐
sponses and regulatory T cell induction [100-102].
During acute HIV-1 infection, NK cells are recruited and activated by pDC to the sites of in‐
fection and to LN due to IFNα secretion [103, 104]. IFNα was demonstrated to increase the
perforin levels in NK and CD8+ T cells. At the sites of infection ´DC-editing´ occurs by NK
cells, since activated NK cells delete immature pDC to select for the more immunogenic ma‐
ture pDC [105-108].Beside NK cell recruitment and activation, pDC-secreted IFNα promotes
maturation and migration of other DC subsets. Due to their localization, it is unlikely that
pDC are involved in HIV-1 capture, transport and transmission, but they are supposed to
control HIV-1 in the acute phase of infection due to their immediate antiviral and NK pri‐
ming activity.
Chronic exposure to HIV-1 leads to hyperactivation of pDC resulting in simultaneous type I
IFN secretion and IDO expression. Thus, pDC concurrently exert cytotoxic and suppressive
effects on T cells during chronic HIV-1 infection [109].
HIV-1 infection not only disrupts DC homeostasis within myeloid DC subsets, but also pDC
homeostasis is defective during chronic HIV-1 infection. cDC and pDC are lost from blood,
which correlates with high viral loads and low CD4+ T cell counts [76, 110-113]. Deficiencies
in pDC function were among the earliest observations of immune dysfunction in HIV-1 in‐
fection and some of the earliest studies of the ´natural IFN-α-producing cells´ (i.e. pDC) il‐
lustrated that PBMC from AIDS patients were severely compromised in their ability to
produce IFN-α in vitro after stimulation with the virus.
Cell death and/or a failure of bone marrow progenitors to differentiate into pDC might con‐
tribute to the loss of pDC from blood of chronically infected individuals. In non-pathogenic
models of SIV infection, no depletion of blood pDC was observed [114, 115] and HIV-1-posi‐
tive individuals, who are able to control infection (= long-term non-progressors) were also
shown to have increased numbers of blood pDC [111].In contrast, it was described that dur‐
ing HIV-2 infection, which is highly attenuated compared to HIV-1 infection in humans, al‐
so the numbers of blood pDC is found reduced [116]. Thereby, the exact role of pDC
depletion during HIV infection is not clear yet.
The depletion of cDC from the sites of infection was ascribed to a higher expression of CCR7
on the surface of cDC and a signficantly increased CCL19 expression in LN of SIV-infected
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animals, thus suggesting that inflamed LN lure cDC away from the sites of infection early
during progressive SIV infection [117]. A similar mechanism can be imagined for pDC,
which are recruited to inflamed LN via CXCL9 and E-selectin [16, 118], but the pDC loss
could also be due to direct infection, enhanced apoptosis or CD95 up-regulation [119-123].
Not only pDC numbers are decreased during on-going HIV-1 infection, but also the quality
of the cells is suffering. They exert a reduced ability to migrate towards the CXCR4 ligand
CXCL12 [124], they stimulate Treg cells to dampen HIV-1 immunity and they furthermore
shift the Treg-Th17 balance [125, 126]. So far, interactions of differentially opsonized HIV-1
preparations with pDC has not been investigated.
3. Outlook: Impact of the HIV-1 opsonization pattern on DC function
As follows of investigations on HIV-1 in the last 30 years, antibody responses against the vi‐
rus are not effective and cellular immune responses not powerful enough to suppress or
even control HIV-1. DC, the prime inducers and regulators of immunity and tolerance, are
crucial in designing modern vaccines [127-130]. Therefore, nowadays vaccine science shall
combine established classical vaccine approaches with new attempts based on the expanded
immunological knowledge.
Innate and adaptive immune responses are needed to generate efficient, long-lasting protec‐
tion. Immediate innate responses involve activation of the complement system, ligation of
pattern recognition receptors e.g. TLRs, C-type lectins, activation of NK cells, cDC and pDC,
and type I, II, as well as III interferons. For viral clearance, the optimal balance between
CD4+ and CD8+ T cells is required during the adaptive immune responses. Current HIV-1
vaccination strategies include the use of peptides or monocyte-derived DC exposed to
chemically inactivated HIV-1 and aim in designing a vaccine efficiently inducing both, cellu‐
lar and humoral immune responses [131-133]. So far, disappointing results have been ach‐
ieved in clinical trials targeting either cellular [134, 135] or humoral immunity [136, 137]. The
most prominent AIDS vaccine trial so far was the RV144 in Thailand [138], which evoked
strong, but transient Env-specific CD4+ T cell and Ab responses, but only weak HIV-specific
CD8+ T cell responses [131, 138].
HIV-1 induces immediate responses of the immune system upon entering mucosal surfaces.
There, the complement system constitutes a first line of defense against the virus. Recently,
we illustrated an important role for complement opsonization of retroviruses as an endoge‐
nous adjuvant for DC-mediated CTL-induction [58].
Efficient early CD8+ T cell responses are crucial in controlling HIV-1 replication and their
key role in HIV-1 control is additionally substantiated by association of certain HLA class I
alleles and an improved disease progression [139-141]. In view of our very recent observa‐
tions ([58], [69]), we propose that CD8+ T cells are efficiently primed by DC during acute vi‐
ral infection, particularly by enhanced infection of DC with HIV-C [41]. Thus, more efficient
presentation of endogenously synthesized viral Ags via HLA-ABC [41], and ore efficient
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ent IFNα subsets, IFNβ, IFNκ, IFNλ and IFNω on a wide range of enveloped viruses includ‐
ing HIV-1. They additionally produce pro-inflammatory cytokines TNFα, IFNγ and IL-6 as
well as chemokines CXCL-10, CCL-5 and CCL-4 among others [98]. Thereby, pDC also act
as a linker between innate and adaptive immunity.
Data by Zhou et al. [99] indicate that subsequent to HIV-1 challenge, signaling via TLR7 trig‐
gers autophagy and increased IFNα production from human pDC. The IFNα secretion
mediated by an autophagy-dependent pathway may play an important role for T cell trig‐
gering during HIV-1 pathogenesis.
Beside acting as pro-inflammatory cells, pDC also provide negative regulatory signals and
thus induce tolerance. pDC express IDO (indoleamine 2,3-dioxygenase) and PDL-1 (pro‐
grammed death ligand; 1) which are associated with the negative modulation of T cell re‐
sponses and regulatory T cell induction [100-102].
During acute HIV-1 infection, NK cells are recruited and activated by pDC to the sites of in‐
fection and to LN due to IFNα secretion [103, 104]. IFNα was demonstrated to increase the
perforin levels in NK and CD8+ T cells. At the sites of infection ´DC-editing´ occurs by NK
cells, since activated NK cells delete immature pDC to select for the more immunogenic ma‐
ture pDC [105-108].Beside NK cell recruitment and activation, pDC-secreted IFNα promotes
maturation and migration of other DC subsets. Due to their localization, it is unlikely that
pDC are involved in HIV-1 capture, transport and transmission, but they are supposed to
control HIV-1 in the acute phase of infection due to their immediate antiviral and NK pri‐
ming activity.
Chronic exposure to HIV-1 leads to hyperactivation of pDC resulting in simultaneous type I
IFN secretion and IDO expression. Thus, pDC concurrently exert cytotoxic and suppressive
effects on T cells during chronic HIV-1 infection [109].
HIV-1 infection not only disrupts DC homeostasis within myeloid DC subsets, but also pDC
homeostasis is defective during chronic HIV-1 infection. cDC and pDC are lost from blood,
which correlates with high viral loads and low CD4+ T cell counts [76, 110-113]. Deficiencies
in pDC function were among the earliest observations of immune dysfunction in HIV-1 in‐
fection and some of the earliest studies of the ´natural IFN-α-producing cells´ (i.e. pDC) il‐
lustrated that PBMC from AIDS patients were severely compromised in their ability to
produce IFN-α in vitro after stimulation with the virus.
Cell death and/or a failure of bone marrow progenitors to differentiate into pDC might con‐
tribute to the loss of pDC from blood of chronically infected individuals. In non-pathogenic
models of SIV infection, no depletion of blood pDC was observed [114, 115] and HIV-1-posi‐
tive individuals, who are able to control infection (= long-term non-progressors) were also
shown to have increased numbers of blood pDC [111].In contrast, it was described that dur‐
ing HIV-2 infection, which is highly attenuated compared to HIV-1 infection in humans, al‐
so the numbers of blood pDC is found reduced [116]. Thereby, the exact role of pDC
depletion during HIV infection is not clear yet.
The depletion of cDC from the sites of infection was ascribed to a higher expression of CCR7
on the surface of cDC and a signficantly increased CCL19 expression in LN of SIV-infected
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animals, thus suggesting that inflamed LN lure cDC away from the sites of infection early
during progressive SIV infection [117]. A similar mechanism can be imagined for pDC,
which are recruited to inflamed LN via CXCL9 and E-selectin [16, 118], but the pDC loss
could also be due to direct infection, enhanced apoptosis or CD95 up-regulation [119-123].
Not only pDC numbers are decreased during on-going HIV-1 infection, but also the quality
of the cells is suffering. They exert a reduced ability to migrate towards the CXCR4 ligand
CXCL12 [124], they stimulate Treg cells to dampen HIV-1 immunity and they furthermore
shift the Treg-Th17 balance [125, 126]. So far, interactions of differentially opsonized HIV-1
preparations with pDC has not been investigated.
3. Outlook: Impact of the HIV-1 opsonization pattern on DC function
As follows of investigations on HIV-1 in the last 30 years, antibody responses against the vi‐
rus are not effective and cellular immune responses not powerful enough to suppress or
even control HIV-1. DC, the prime inducers and regulators of immunity and tolerance, are
crucial in designing modern vaccines [127-130]. Therefore, nowadays vaccine science shall
combine established classical vaccine approaches with new attempts based on the expanded
immunological knowledge.
Innate and adaptive immune responses are needed to generate efficient, long-lasting protec‐
tion. Immediate innate responses involve activation of the complement system, ligation of
pattern recognition receptors e.g. TLRs, C-type lectins, activation of NK cells, cDC and pDC,
and type I, II, as well as III interferons. For viral clearance, the optimal balance between
CD4+ and CD8+ T cells is required during the adaptive immune responses. Current HIV-1
vaccination strategies include the use of peptides or monocyte-derived DC exposed to
chemically inactivated HIV-1 and aim in designing a vaccine efficiently inducing both, cellu‐
lar and humoral immune responses [131-133]. So far, disappointing results have been ach‐
ieved in clinical trials targeting either cellular [134, 135] or humoral immunity [136, 137]. The
most prominent AIDS vaccine trial so far was the RV144 in Thailand [138], which evoked
strong, but transient Env-specific CD4+ T cell and Ab responses, but only weak HIV-specific
CD8+ T cell responses [131, 138].
HIV-1 induces immediate responses of the immune system upon entering mucosal surfaces.
There, the complement system constitutes a first line of defense against the virus. Recently,
we illustrated an important role for complement opsonization of retroviruses as an endoge‐
nous adjuvant for DC-mediated CTL-induction [58].
Efficient early CD8+ T cell responses are crucial in controlling HIV-1 replication and their
key role in HIV-1 control is additionally substantiated by association of certain HLA class I
alleles and an improved disease progression [139-141]. In view of our very recent observa‐
tions ([58], [69]), we propose that CD8+ T cells are efficiently primed by DC during acute vi‐
ral infection, particularly by enhanced infection of DC with HIV-C [41]. Thus, more efficient
presentation of endogenously synthesized viral Ags via HLA-ABC [41], and ore efficient
Role of Dendritic Cell Subsets on HIV-Specific Immunity
http://dx.doi.org/10.5772/52744
43
cross-presentation from incoming complement-opsonized HIV-1 are mediated. In contrast,
Ab-opsonization of HIV-1 weakens the CTL-induction by modulation of DC function and
might influence future vaccination strategies [69].
As shown by Lu et al. [142-144] in vitro and in vivo, DC exposed to chemically (aldrithiol-2,
AT-2)-inactivated HIV or SIV induced a virus-specific CTL response. This response was
strong enough to kill HIV-1-infected CD4+ T cells [142], to control the viral load in SIV-in‐
fected monkeys [143] and HIV-infected individuals [144].. The decrease of the viral load in
the HIV-1-infected patients was associated with a higher amount of HIV-1-gag-specific CD8+
T cells and HIV-1-specific CD4+ T cells.
LC were described to allow more cross-priming of CD8+ T cells, while dermal DC are more
specialized in primingnaive CD4+ T cells [145]. The finding that complement-opsonization of
HIV prior loading of DC significantly enhanced the CD8+ T cell-stimulatory capacity of the
cells in combination with using specific DC subtypes might efficiently improve future vacci‐
nation strategies and there is good reason to address DC of the skin, especially Langerhans
cells, for purposes of vaccination.
A greater understanding of the innate and adaptive processes and the different functions of
DC subsets to HIV-1 infection will lead to development of an effective vaccine.
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1. Introduction
In the highly active antiretroviral therapy (HAART) era, the survival of HIV infected pa‐
tients has improved. Opportunistic infections and AIDS related syndromes in these individ‐
uals have declined (Palella et al, 1998). HIV infected individuals have an increased tendency
to develop malignancy. These include a number of non-AIDS defining malignancies, as well
as the AIDS defining malignancies which are Kaposi sarcoma, invasive cervical cancer and
non-Hodgkin Lymphoma (NHL). Among the NHL group, the incidence of systemic NHL,
CNS Lymphoma and primary effusion lymphoma are increased in this population. Malig‐
nancies continue to be an important cause of mortality in these individuals.
The incidence of NHL increases with progressive immunosuppression in HIV-infected pa‐
tients. The majority of these cases are intermediate or high-grade and almost all are diffuse
large B cell (immunoblastic variant) or Burkitt-like lymphomas. The incidence of Hodgkin
lymphoma (HL) is also increased in the HIV positive population (Bigar R et al, 2006) though
it is not an AIDS defining illness. Acute myeloid leukemia may also occur with higher fre‐
quency in the setting of HIV infection (Grulich A et al, 2007). NHL and HL occurring in HIV
infected individuals are characterized by an aggressive clinical course with an advanced
stage at presentation (Levine AM, 2000).
In the pre-HAART era, the standard treatment for AIDS associated NHL was low dose che‐
motherapy. It was thought that they would be unable to tolerate intensive chemotherapy be‐
cause of the underlying immunodeficiency. Randomized trials of standard doses of
combination chemotherapy versus reduced doses revealed inferior results in the standard
dose arm due to increased hematologic toxicity and infections (Kaplan LD et al, 1997). In the
post-HAART era, patients were treated more aggressively due to improved hematologic re‐
serve in patients on HAART. Patients are now treated similar to non HIV NHL patients.
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infected individuals are characterized by an aggressive clinical course with an advanced
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motherapy. It was thought that they would be unable to tolerate intensive chemotherapy be‐
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Their remission rates and median survival with aggressive combination chemotherapy and
HAART is similar to their HIV negative counterparts (Boue, F et al, 2006).
Consequently, more aggressive therapies such as high dose chemotherapy and stem cell
transplantation have been explored in the HAART era with encouraging results. This chap‐
ter will go through autologous and allogeneic stem cell transplantation in HIV infected indi‐
viduals and also highlight some of the recent developments in the field.
2. Autologous Stem Cell Transplantation (ASCT)
Autologous stem cell transplantation means transplantation with a person’s own hemato‐
poietic stem cells which are harvested ahead of time and cryopreserved for later use. Pluri‐
potent hematopoietic stem cells are those which are capable of self renewal and of
differentiation. These are the cells targeted for collection. The main advantage of this proce‐
dure is to enable the patient to receive myeloablative dose intense chemotherapy for a ma‐
lignancy that has demonstrated a dose response to chemotherapy. Stem cells collected from
the peripheral blood after priming with G-CSF (Granulocyte Colony Stimulating Factor) are
generally preferred to stem cells from the bone marrow due to shorter engraftment times,
thereby reducing morbidity and mortality. Stem cell apheresis is an outpatient procedure
where cells are collected through large volume apheresis over approximately 4-6 hours.
These stem cells are either cryopreserved with DMSO directly or can be manipulated by
methods such as CD34 positive selection and transduction prior to cryopreservation.
There are various preparative regimens used for stem cell transplantation in patients with
hematologic malignancy. The ideal regimen should be able to eradicate the malignancy,
have no mortality and manageable side effects or toxicity. Alas, no such treatments exist.
There are several treatment regimens in use. Selection of high dose chemotherapy regimens
is based upon the use of chemotherapeutic agents that have a dose response in the hemato‐
logic malignancy. In addition, drugs are chosen that have nonoverlapping toxicities save for
the hematologic toxicity. For example in NHL, typical agents include Cyclophosphamide,
Etoposide, Carmustine (BCNU) and melphalan. In Hodgkin lymphoma, frequently utilized
preparative regimens include the CBV regimen with Cyclophosphamide, Carmustine
(BCNU), and Etoposide (VP-16) and the BEAM regimen with Carmustine (BCNU), Etopo‐
side (VP-16), Cytarabine (Ara-C) and Melphalan.
Patients typically receive the conditioning regimen followed by infusion of thawed autolo‐
gous stem cells approximately 24- 48 hours post completion of chemotherapy. Thereafter en‐
sues a period of profound neutropenia, also often mucositis and GI toxicity such as nausea
and diarrhea. During this period of neutropenia, the risk of infection is significantly in‐
creased. Hence patients are housed in hepa filtered rooms, and placed on low bacteria diets
in addition to other infectious precautions. Nonetheless, fever and infection can be common.
Mucositis is a risk factor for infection as it increases the likelihood of intermittent bacteremia
from the GI tract. The use of peripheral blood progenitor cells harvested from apheresis in‐
stead of bone marrow stem cells led to a shortening of engraftment of white blood cell times.
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This thereby reduced the period of neutropenia and mucositis, which improved survival in
patients.
This procedure has been the standard treatment for HIV negative patients with relapsed
NHL since the landmark PARMA trial published by Philip et al in the New England Journal
of Medicine (1995). In this trial, patients with relapsed chemosensitive aggressive NHL were
treated with 2 cycles of DHAP (Dexamethasone, Cisplatin and Cytarabine) and if respon‐
sive, randomly assigned to receive either DHAP for 4 additional cycles or high dose chemo‐
therapy with BEAC (BCNU/Carmustine, Etoposide, Cytarabine and Cyclophosphamide)
followed by ASCT, The results of this study revealed an overall survival (OS) benefit of 53
versus 32 percent (p= 0.038) in favor of the high dose chemotherapy arm. This approach has
also been used in high risk patients who are in first remission (Haioun, C et al, 1997). Non-
randomized trials of this high risk group have demonstrated high rates of progression free
survival (FPS). Similarly, trials of HIV negative patients with Hodgkin Lymphoma have
shown that ASCT can provide long term PFS for patients with relapsed disease (Linch,
1993). All these studies were done in the HIV negative population.
2.1. ASCT in HIV positive patients
ASCT in HIV positive patients was pioneered by the French in the pre-HAART era (Ga‐
barre, J et al, 1996). The first patient was reported as a case study. He was a 40 year old male
with HIV related NHL, receiving Zidovudine and Zalcitabine as antiretroviral treatment. He
was treated with BEAM (BCNU, Etoposide, Cytarabine and Melphalan) chemotherapy for
relapsed lymphoma followed by ASCT. His post-transplant course was complicated by sev‐
eral opportunistic infections including cytomegalovirus viremia, mycobacterium pneumo‐
nia and cryptosporidiosis. This report corroborated the fear that the immune impairment
due to HIV augmented the infection risk. However, it also demonstrated that mobilizing
stem cells and successful engraftment were feasible in this setting. In the post-HAART era,
French investigators performed a study with fourteen patients with relapsed or refractory
NHL. Eight patients died of which six deaths were from lymphoma. This study established
that the mortality due to infection was substantially reduced, but that control of the underly‐
ing lymphoma remained the challenge (Gabarre et al, 2001). It set the stage for ASCT to be
considered a feasible task in HIV patients, and revealed that infectious issues were manage‐
able without apparent adverse consequences on the HIV infection.
Other centers have described similar findings. The larger City of Hope study had patients
with less advanced lymphoma and disqualified chemotherapy refractory patients (Krishnan
A, et al, 2005). The initial series consisted of 20 patients with HL or NHL. All patients were
on HAART. The majority of patients underwent CBV (cyclophosphamide, BCNU, Etopo‐
side) chemotherapy as conditioning. Engraftment times were comparable to HIV negative
patients, median was 11 days. Despite efforts to continue HAART throughout the transplant
period, only nine out of twenty were able to tolerate it. The remainder resumed it at a me‐
dian of two months following ASCT. The poor tolerance of HAART was due to either nau‐
sea or mucositis. Transplant related mortality was low, as was the incidence of opportunistic
infections. No patient died of an opportunistic infection. Although the CD4 count did nadir
Hematopoietic Stem Cell Transplantation in HIV Infected Patients
http://dx.doi.org/10.5772/52686
59
Their remission rates and median survival with aggressive combination chemotherapy and
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transplantation have been explored in the HAART era with encouraging results. This chap‐
ter will go through autologous and allogeneic stem cell transplantation in HIV infected indi‐
viduals and also highlight some of the recent developments in the field.
2. Autologous Stem Cell Transplantation (ASCT)
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poietic stem cells which are harvested ahead of time and cryopreserved for later use. Pluri‐
potent hematopoietic stem cells are those which are capable of self renewal and of
differentiation. These are the cells targeted for collection. The main advantage of this proce‐
dure is to enable the patient to receive myeloablative dose intense chemotherapy for a ma‐
lignancy that has demonstrated a dose response to chemotherapy. Stem cells collected from
the peripheral blood after priming with G-CSF (Granulocyte Colony Stimulating Factor) are
generally preferred to stem cells from the bone marrow due to shorter engraftment times,
thereby reducing morbidity and mortality. Stem cell apheresis is an outpatient procedure
where cells are collected through large volume apheresis over approximately 4-6 hours.
These stem cells are either cryopreserved with DMSO directly or can be manipulated by
methods such as CD34 positive selection and transduction prior to cryopreservation.
There are various preparative regimens used for stem cell transplantation in patients with
hematologic malignancy. The ideal regimen should be able to eradicate the malignancy,
have no mortality and manageable side effects or toxicity. Alas, no such treatments exist.
There are several treatment regimens in use. Selection of high dose chemotherapy regimens
is based upon the use of chemotherapeutic agents that have a dose response in the hemato‐
logic malignancy. In addition, drugs are chosen that have nonoverlapping toxicities save for
the hematologic toxicity. For example in NHL, typical agents include Cyclophosphamide,
Etoposide, Carmustine (BCNU) and melphalan. In Hodgkin lymphoma, frequently utilized
preparative regimens include the CBV regimen with Cyclophosphamide, Carmustine
(BCNU), and Etoposide (VP-16) and the BEAM regimen with Carmustine (BCNU), Etopo‐
side (VP-16), Cytarabine (Ara-C) and Melphalan.
Patients typically receive the conditioning regimen followed by infusion of thawed autolo‐
gous stem cells approximately 24- 48 hours post completion of chemotherapy. Thereafter en‐
sues a period of profound neutropenia, also often mucositis and GI toxicity such as nausea
and diarrhea. During this period of neutropenia, the risk of infection is significantly in‐
creased. Hence patients are housed in hepa filtered rooms, and placed on low bacteria diets
in addition to other infectious precautions. Nonetheless, fever and infection can be common.
Mucositis is a risk factor for infection as it increases the likelihood of intermittent bacteremia
from the GI tract. The use of peripheral blood progenitor cells harvested from apheresis in‐
stead of bone marrow stem cells led to a shortening of engraftment of white blood cell times.
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This thereby reduced the period of neutropenia and mucositis, which improved survival in
patients.
This procedure has been the standard treatment for HIV negative patients with relapsed
NHL since the landmark PARMA trial published by Philip et al in the New England Journal
of Medicine (1995). In this trial, patients with relapsed chemosensitive aggressive NHL were
treated with 2 cycles of DHAP (Dexamethasone, Cisplatin and Cytarabine) and if respon‐
sive, randomly assigned to receive either DHAP for 4 additional cycles or high dose chemo‐
therapy with BEAC (BCNU/Carmustine, Etoposide, Cytarabine and Cyclophosphamide)
followed by ASCT, The results of this study revealed an overall survival (OS) benefit of 53
versus 32 percent (p= 0.038) in favor of the high dose chemotherapy arm. This approach has
also been used in high risk patients who are in first remission (Haioun, C et al, 1997). Non-
randomized trials of this high risk group have demonstrated high rates of progression free
survival (FPS). Similarly, trials of HIV negative patients with Hodgkin Lymphoma have
shown that ASCT can provide long term PFS for patients with relapsed disease (Linch,
1993). All these studies were done in the HIV negative population.
2.1. ASCT in HIV positive patients
ASCT in HIV positive patients was pioneered by the French in the pre-HAART era (Ga‐
barre, J et al, 1996). The first patient was reported as a case study. He was a 40 year old male
with HIV related NHL, receiving Zidovudine and Zalcitabine as antiretroviral treatment. He
was treated with BEAM (BCNU, Etoposide, Cytarabine and Melphalan) chemotherapy for
relapsed lymphoma followed by ASCT. His post-transplant course was complicated by sev‐
eral opportunistic infections including cytomegalovirus viremia, mycobacterium pneumo‐
nia and cryptosporidiosis. This report corroborated the fear that the immune impairment
due to HIV augmented the infection risk. However, it also demonstrated that mobilizing
stem cells and successful engraftment were feasible in this setting. In the post-HAART era,
French investigators performed a study with fourteen patients with relapsed or refractory
NHL. Eight patients died of which six deaths were from lymphoma. This study established
that the mortality due to infection was substantially reduced, but that control of the underly‐
ing lymphoma remained the challenge (Gabarre et al, 2001). It set the stage for ASCT to be
considered a feasible task in HIV patients, and revealed that infectious issues were manage‐
able without apparent adverse consequences on the HIV infection.
Other centers have described similar findings. The larger City of Hope study had patients
with less advanced lymphoma and disqualified chemotherapy refractory patients (Krishnan
A, et al, 2005). The initial series consisted of 20 patients with HL or NHL. All patients were
on HAART. The majority of patients underwent CBV (cyclophosphamide, BCNU, Etopo‐
side) chemotherapy as conditioning. Engraftment times were comparable to HIV negative
patients, median was 11 days. Despite efforts to continue HAART throughout the transplant
period, only nine out of twenty were able to tolerate it. The remainder resumed it at a me‐
dian of two months following ASCT. The poor tolerance of HAART was due to either nau‐
sea or mucositis. Transplant related mortality was low, as was the incidence of opportunistic
infections. No patient died of an opportunistic infection. Although the CD4 count did nadir
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at 6 months, post-transplant follow up demonstrated that the underlying HIV disease did
not deteriorate as a result of the transplant and the CD4 counts recovered to pre-transplant
levels by one year in all patients. PFS and OS were 85%. The improved result compared to
the French experience may be from selecting patients with less advanced disease and che‐
motherapy sensitive disease.
Figure 1. Median CD4 count trends during apheresis and after ASCT. Krishnan A et al. Blood 2005; 105:874-878
Blood: Journal of the American Society of Hematology by American Society of Hematology. Copyright 2009 Repro‐
duced with permission of AMERICAN SOCIETY OF HEMATOLOGY (ASH) in the format Journal via Copyright Clearance
Center.
The Italian cooperative group on AIDS and tumors (GIGAT) reported the long term results
on 50 patients with HIV and relapsed or refractory lymphoma (Re A, et al, 2009). Similar to
the City of Hope study, only patients with chemotherapy sensitive disease were selected to
proceed with peripheral stem cell collection. Forty-six patients were already on HAART,
two started at the time of study enrollment, and two at the time of stem cell mobilization. A
minimum CD4 count of 100 cells/micro liter prior to initiating chemotherapy was a pre-
requisite. There were no eligibility criteria for viral load and therefore the viral loads at
study entry ranged considerably. Thirteen patients withdrew before stem cell collection.
Among these, two withdrawals were from early toxic deaths, one patient refusal, and the
remaining ten patients had chemotherapy refractory disease. Eventually, twenty seven pa‐
tients underwent ASCT. Of these, seven temporarily suspended HAART, some for similar
reasons to the City of Hope experience with mucositis, and others for hepatotoxicity. All pa‐
tients received BEAM (Carmustine/BCNU, Etoposide, Cytarabine and Melphalan) as the
conditioning regimen. Three year progression free survival for the patients who proceeded
to transplant was also similar to the City of Hope experience at 76.3%. Multivariate analysis
of prognostic factors for survival showed that bone marrow involvement, performance sta‐
tus less than 2, and CD4 count below 100 cells/micro liter were significant. No significant
HIV-associated infections were noted. In those patients on effective HAART therapy, the in‐
fectious risk was similar to patients without HIV who underwent ASCT. The high patient
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withdrawal rate before transplantation displays the obstacles in treating these aggressive
lymphomas.
The European Group for Blood and Marrow Transplantation conducted a retrospective,
multicentre registry-based analysis of sixty eight patients from twenty institutions since
1999 (Balsalobre P et al, 2009). There were fifty patients with NHL and eighteen patients
with HL. At the time of ASCT, sixteen patients were in first complete remission (CR1); forty
four patients were in CR more than 1, partial remission, or chemotherapy-sensitive relapse;
and eight patients had chemotherapy resistant disease. Most patients were treated with a
chemotherapy based conditioning regimen (BEAM and variants). The median CD4 count at
transplantation was 162 cells/micro litter, and eighty percent of patients had an HIV viral
load under 200/mL. All patients engrafted at a median of eleven days, save one. The inci‐
dence of non relapse mortality (NRM) was 4.4% and 7.5% at 3 and 12 months, respectively.
Three patients died from bacterial infection, two died of HIV related complications, and one
patient died of an unknown cause while in CR. At a median follow-up of 32 months, pro‐
gression free survival and overall survival were 56.5% and 61% at three years, respectively.
On multivariate analysis, chemotherapy resistant disease and not attaining complete remis‐
sion predicted poorer progression free survival and overall survival. This data indicates
again similar to the HIV negative transplant setting, disease control with chemotherapy at
the time of ASCT predicts a more favorable result.
Two case control studies also demonstrated that HIV status does not impact ASCT out‐
comes for lymphoma. The European Group for Blood and Marrow Transplantation under‐
took a retrospective study of 106 patients (Diez-Martin et al, 2009) which included 53 HIV-
positive lymphoma patients who underwent transplant with controls matched for histology,
non-age adjusted IPI (International Prognostic Index), and disease status at transplant. There
were 66 percent NHL and 34 percent HL patients. Both groups were similar, other than the
higher percentage of males, mixed cellularity Hodgkin lymphoma and patients receiving
granulocyte colony stimulating factor before engraftment, and a smaller fraction receiving
total body irradiation based conditioning within the HIV lymphoma cohort. With median
follow-up of 30 months, progression free survival was 61 percent for the HIV-lymphoma
group and 56 percent for the control lymphoma group. Overall survival was 61.5 percent for
HIV-positive patients and 70 percent for controls (p = NS). There was a trend towards delay
in platelet engraftment after transplant in the HIV group. It is uncertain whether this result‐
ed from the more frequent granulocyte colony stimulating factor use in that cohort or to
HAART therapy or to chronic HIV infection of the bone marrow. Incidence of relapse, over‐
all survival and progression free survival were comparable in both groups. In the first year
following ASCT, there was an elevated, but statistically insignificant non relapse mortality
in the HIV lymphoma group, primarily from early bacterial infections. This data suggested
that in the HAART era, HIV infection should not preclude lymphoma patients from under‐
going ASCT. The authors recommended conscientious infection prophylaxis and vigilant
immune recovery surveillance shortly following ASCT.
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Figure 1. Median CD4 count trends during apheresis and after ASCT. Krishnan A et al. Blood 2005; 105:874-878
Blood: Journal of the American Society of Hematology by American Society of Hematology. Copyright 2009 Repro‐
duced with permission of AMERICAN SOCIETY OF HEMATOLOGY (ASH) in the format Journal via Copyright Clearance
Center.
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Figure 2. Survival according to HIV infection status: positive versus negative. Diez-Martin JL et al. Blood 2009;
113:6011-6014 Blood: Journal of the American Society of Hematology by American Society of Hematology. Copyright
2009 Reproduced with permission of AMERICAN SOCIETY OF HEMATOLOGY (ASH) in the format Journal via Copyright
Clearance Center
City of Hope undertook a retrospective matched case-control study (Krishnan, et al, 2010) to
study long-term outcome in HIV positive NHL patients (cases) and HIV negative NHL pa‐
tients (controls). Twenty nine patients with HIV positive NHL were matched with HIV neg‐
ative NHL controls with respect to sex, time to ASCT, year of transplant, histology, age,
disease status, number of prior regimens, and conditioning regimen. A higher ratio of HIV
positive NHL patients had high grade disease versus the HIV negative NHL controls. There
were mostly male patients in both groups. The median CD4 count at study entry was 153.5,
and the viral load was 6500. All patients in the HIV cohort were on HAART at the time of
transplant; however thirteen patients had to interrupt treatment. The median follow-up for
HIV-positive NHL patients was 62.4 months, and 48.4 months for the HIV-negative NHL
controls. The median time to neutrophil engraftment was comparable for both groups. Non
relapse mortality was also comparable for the two groups. Infectious complications did dif‐
fer between the two groups, with more opportunistic infections occurring in the HIV-posi‐
tive cohort, however this did not affect survival. There were more opportunistic viral
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infections in the HIV-positive group, with three cases of cytomegalovirus viremia, one case
of adenovirus viremia, and one case of varicella infection. Disease free survival and overall
survival were not significantly different between the two groups. The two year disease free
survival for the HIV-positive NHL group was 76 percent and 56 percent for the HIV-nega‐
tive group. The overall survival for both groups was also similar at 75 percent notwithstand‐
ing a higher proportion of poor risk HIV positive NHL patients.
Figure 3. Probability of overall survival by HIV status. Krishnan A, Palmer J, Zaia J, et al. Vol. 16, (September 2010), pp.
1302-08. “Reprinted From: HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT)
for Non-Hodgkin Lymphoma (NHL) Biology of Blood and Marrow Transplantation 16:1302-1308 (2010), with permis‐
sion from Elsevier”
Causes of death in the HIV-positive cohort were mostly from relapsed lymphoma, and not
infection. Disease status at the time of transplant was the only clear predictor of outcome.
This single-institution series corroborates the European data.
This data from the European Group for Blood and Marrow Transplantation (Balsalobre et
al, 2009) and the City of Hope experience (Krishnan, et al, 2010) revealed better progres‐
sion free survival rates in the HIV-positive lymphoma patients compared to their HIV-neg‐
ative  counterparts.  This  improved  early  outcome  is  interesting.  Perhaps  incorporating
HAART in the regimen improves the result. Maybe transplant with high dose chemothera‐
py resets the clock on the immunologic effects of HIV, either by depleting the HIV reser‐
voir or by its alterations on the T cell reconstitution. Inherent genetic variability may also
play a part. Homozygosity for the 32-bp CCR5 allele CCR-∆ 32 has been shown to confer
resistance to HIV infection (Liu R et al, 1996). This same deletion may also offer defense
against lymphoma development in HIV patients (Dean M et al, 1999). A trial in the Unit‐
ed States of ASCT for HIV lymphoma via the Bone Marrow Transplant Clinical Trials Net‐
work  will  prospectively  analyze  the  genotypes  and  the  CCR5  mutation  to  find  its
association with disease free survival. Correlative studies will also assess the pre and post-
transplant HIV viral reservoir.
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2.2. Immune recovery post transplant
An Italian study (Simonelli et al, 2010) prospectively evaluated 33 lymphoma patients of
whom 24 were HIV positive and nine were HIV-negative. All patients had relapsed or re‐
fractory disease and both groups were given similar high dose chemotherapy and ASCT
protocols. The study compared the immunological baseline features in the two groups. The
study showed that front line chemotherapy resulted in immunodepression in the general
population, which qualitatively differs from that observed in HIV-infected patients. HIV-
positive patients had higher CD8+ T cell counts and inverted ratios of CD4+ cells to CD8+
cells than HIV-negative patients. There were no significant differences in the CD4+ cell com‐
partment and thymic reservoir, between the groups. The authors attributed this finding to
good control of HIV-RNA levels from ongoing HAART therapy. The initial differences in
the dynamics of immune recovery between the populations also diminished with longer fol‐
low-up. Specifically, the CD8+ subpopulation, together with CD56+ NK cells quickly recov‐
ered in both groups of patients, leading, to a reversal of the ratio of CD4+ cells to CD8+ cells
in the HIV-negative patients for up to two years following transplantation. In the HIV-in‐
fected population, high dose chemotherapy produced a different immune incompetence
compared with conventional chemotherapy, which primarily impacted the CD4+ T cell sub‐
set without significantly affecting the CD4/CD8 ratio. In the first three months post ASCT,
significantly more infectious episodes occurred in the HIV-positive group. The authors dem‐
onstrated that HIV-positive patients with early post-transplant infections had significantly
lower CD4+ T cell counts during the third month post ASCT, compared with HIV-negative
patients without infections. There was no difference in the frequency of infection or the dy‐
namics of CD4+ T cell reconstitution beyond three months post ASCT. Overall, the study
showed that high dose chemotherapy and ASCT in HIV-infected lymphoma patients does
not worsen initial immune impairment or enhance viral replication or peripheral HIV reser‐
voir in the long term. The temporary elevation in the incidence of early infectious events in
the HIV-positive group may be related to an arrest in the CD4+ T cell count increment dur‐
ing the first three months post ASCT. There were no significant changes in the HIV DNA
levels during the follow-up period, with values at 24 months significantly lower than those
at baseline.
It is well-recognized that HIV persists at low levels in peripheral blood mononuclear cells,
mostly in infected resting CD4+ T cells which constitute a stable reservoir for HIV, even
when viral replication is well controlled with antiretroviral therapy. Analysis of HIV-1 DNA
(HIV DNA) (Koelsch, KK et al, 2008) in peripheral blood mononuclear cells is therefore an
accessible virological marker for estimating HIV infection. Bortolin’s study of 22 patients
with HIV associated relapsed or refractory lymphomas treated with salvage high dose che‐
motherapy followed by ASCT looked at the kinetics of the predictive value of HIV DNA.
HIV DNA was measured by real-time PCR in the peripheral blood mononuclear cells. At
baseline, HIV DNA was found to be associated with HIV-1 RNA (HIV RNA), but not with
CD4 counts. HIV RNA load was under control throughout follow-up, while HIV DNA lev‐
els were nearly always detectable. The overall survival analysis demonstrated that patients
with higher HIV DNA levels at baseline had a higher and nearly significant risk of death
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when compared with patients with lower levels (HR, 8.33, 95% CI 0.99 - 70.06, p=0.05). At
the time of publication, of the 22 patients, 14 (63.6%) were still alive, of which 13 were in
remission and one relapsed; 8 (36.5%) died, of which 6 deaths were from relapsed lympho‐
ma and 2 were from opportunistic infections. Of note, baseline HIV DNA levels were signifi‐
cantly different between alive and deceased patients. Results from this study established
HIV DNA as an valuable additional tool to optimize and tailor therapy, and also predict
treatment outcome in these patients.
Figure 4. Kaplan–Meier curve showing survival according to baseline HIV DNA levels (n = 19) Bortolin MT, Zanussi S,
Talamini R, et al. AIDS Research and Human Retroviruses. Vol. 26, No. 2, (2010), pp. 245-251. " The publisher for this
copyrighted material is Mary Ann Liebert, Inc. publishers."
3. Allogeneic transplantation
Allogeneic transplantation refers to hematopoietic stem cells which come from an HLA
matched donor. Allogeneic transplants typically have a higher morbidity and mortality than
autologous transplants mostly due to infection or graft versus host disease. The ‘graft’ refers
to the transplanted hematopoietic stem cells transplanted from the donor (sibling or match‐
ed unrelated donor) and the ‘host’ refers to the patient. In graft versus host disease, the do‐
nor’s immune cells attack the recipient’s organs. Virtually any organ can be affected, but
frequently affected organs include the skin, liver and gut. Graft versus host disease (GVHD)
is a major impediment to the success of bone marrow transplantation. Treatment and pre‐
vention of GVHD includes immunosuppressive medications and sometimes steroids. The
incidence of chronic graft versus host disease (that occurring after 100 days post transplant)
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is up to 80% in recipients of allogeneic peripheral blood stem cells. On the other hand, allo‐
geneic transplant has the advantage of lower rates of relapse due to the ‘clean graft’ as well
as the immunologic effects of the donor graft, the so called graft versus tumor effect. These
immunologic effects could be potentially even more beneficial in the treatment of HIV infec‐
tion if the attendant risks of the procedure in the HIV infected patient could be overcome.
Allogeneic stem cell transplantation (alloSCT) is more difficult than ASCT in HIV infected
individuals due to the need for chronic immunosuppression in an already immunosup‐
pressed individual. Solid organ transplantation set the stage for allogeneic stem cell trans‐
plantation in that solid organ transplant patients also need chronic immunosuppression.
There have been several published reports of solid-organ transplantation in HIV positive pa‐
tients who are receiving HAART, which demonstrated that, in most cases, HIV infection
does not affect the outcome of transplantation. Drug interactions were handled by requisite
dose adjustments. The underlying HIV infection was controlled provided patients remained
on antiretroviral therapy. (Ragni MV et al, 1999; Prachalias AA et al, 2001; Kuo PC, 2001;
Gow PJ & Mutimer D, 2001 as cited in Halpern et al, 2002). Some solid organ transplant cen‐
ters regard HIV patients akin to other high risk patients, for example, diabetics, or the elder‐
ly (Persad G et al, 2008).
The literature on allogeneic transplantation in HIV positive patients is considerably more
limited than ASCT. Experience with ASCT in HIV-positive patients has shown that HIV in‐
fection did not impede engraftment provided myelosuppressive medications like azidothy‐
midine were avoided. Therefore, in the allogeneic field, comparable engraftment times were
expected. Allogeneic transplantation data indicates the rate of immune reconstitution after
transplant is related to the type of conditioning regimen, HLA compatibility of the donor
and host, and the occurrence of GVHD. In an allogeneic transplant with an HIV negative
recipient, T lymphocyte recovery occurs by thirty days following transplant, although ini‐
tially with primarily CD8+ T cells (Keever, CA et al, 1989). CD4+ cell recovery often takes up
to six months.
Early reports of allogeneic transplant were in the pre-HAART period. Holland et al (1989) at
Johns Hopkins published a case of a forty one year old male with HIV lymphoma who re‐
ceived a conditioning regimen consisting of total body irradiation and Cyclophosphamide
followed by allogeneic bone marrow transplantation. Prior to the transplant, he was given
high dose azidothymidine and following the transplant, he was given a lower dose. There
was no significant regimen-related toxicity, and he engrafted at day seventeen, but there‐
after died of lymphoma at day forty seven. At autopsy, no evidence of HIV, either by cul‐
ture, or PCR was found in tissue specimens. Although the result was poor, this early report
demonstrated the achievability of the procedure and raised the intriguing question, could
allogeneic transplant be a route to treat HIV infection.
Woolfrey et al (2008) published a series of two HIV-positive patients who received nonmye‐
loablative transplants at the Fred Hutchinson Research Center. They received conditioning
with Fludarabine and 200 cGy total body irradiation. They got HLA-matched peripheral
blood stem cells, one from a sibling and the other from an unrelated donor. Post-transplan‐
tation cyclosporine and mycophenolatemofetil were given for graft versus host disease pro‐
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phylaxis. HAART was continued with adjustments to prevent drug interactions. The HIV
RNA remained undetectable and no HIV associated infections were noted. The first patient
died of GVHD. The second patient remained alive at the time of publication, more than 180
days following transplant. It is notable that both patients’ donor cells expressed wild-type
CCR5 co receptor, and not the CCR∆32 allele which is linked with resistance to HIV infec‐
tion. Reconstitution of CD4+ and CD8+ subsets was in accordance with other nonmyeloabla‐
tive transplants. New HIV-1 specific CD8+ T cell responses were produced after transplant.
The gradual loss of detectable proviral DNA in the patient who achieved full donor chimer‐
ism suggests that the reservoir of latently infected lymphocytes died out after transplanta‐
tion. This study alluded to the dual benefits of allogeneic transplantation.
Larger studies are needed to determine if the benefits of allogeneic transplant can be pre‐
served in the myeloablative setting with its accompanying elevated morbidity and mortali‐
ty. The largest series was a retrospective study of thirty patients with various hematologic
malignancies transplanted between 1987 and 2003 from the European Group for Blood and
Marrow Transplantation (Gupta V, et al, 2007). Treatment related mortality at 100 days was
46 percent. There was a striking difference in survival in patients transplanted after 1996 af‐
ter availability of HAART. Prior to 1996, only two out of twenty two patients survived, but
after 1996, four out of eight patients survived. This study revealed that reduction of trans‐
plant related mortality and control of HIV infection together are imperative in carrying out
successful allogeneic transplants in this population.
4. Allogeneic transplantation for HIV infection
Allogeneic hematopoietic stem cell transplantation has the exciting prospect of controlling
the HIV infection. HIV-1 enters host cells by binding to a CD4 receptor and then interacting
with either CCR5 or the CXC chemokine receptor (CXCR4). Homozygosity for a 32-bp dele‐
tion (delta 32) in the CCR5 allele confers natural resistance to infection with CCR5 tropic
HIV strains (R5 HIV) because of the lack of CCR5 cell-surface expression. (Dean M et al,
1996 as cited in Allers et al, 2011)
A case report from Germany by Hutter et al (2009) published in the New England Journal of
Medicine described a 40 year old patient with a ten year history of HIV who underwent allo‐
geneic stem cell transplantation (SCT) in February 2007 for relapsed acute myelogenous leu‐
kemia from an HLA-matched unrelated donor who was homozygous for the CCR5 delta 32
allele. HAART was given until the day prior to transplantation. The patient relapsed at day
332 and was treated with a second transplant from the same donor after reinduction therapy
with cytarabine and gemtuzumab along with single dose total body irradiation. There was
no viral rebound twenty months after transplantation and discontinuation of antiretroviral
therapy. Tissue sites, such as the intestines, serve as reservoirs, and were looked at to detect
the HIV virus despite the absence of viremia. In this patient, the rectal biopsy performed at
159 days after transplant did reveal that CCR5-producing macrophages were still present in
the intestinal mucosa, which demonstrated they had not yet been replaced by the new im‐
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is up to 80% in recipients of allogeneic peripheral blood stem cells. On the other hand, allo‐
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phylaxis. HAART was continued with adjustments to prevent drug interactions. The HIV
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mune system. Although these long-lasting cells from the host can be viral reservoirs even
after transplantation, HIV-1 DNA was not found in his rectal mucosa. Immunologic studies
showed a loss of anti-HIV virus specific interferon gamma producing T cells. This indicated
that HIV antigenic stimulation was not present post transplant. His viral load continued to
be undetectable despite the presence of non-CCR5 tropic X4 virus variants. After nearly two
years of follow-up, the patient’s CD4 cell count normalized with all cells exhibiting the ho‐
mozygous CCR5-deleted gene. This observation is notable because homozygosity for CCR5
delta 32 deletion is related to high but not complete resistance to HIV-1.
Figure 5. Clinical Course and HIV-1 Viremia. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5
Delta32/Delta32 stem-cell transplantation. The New England Journal of Medicine, Vol. 360, No. 7, (February 2009) pp.
692-8. Permission granted. Copyright MMS
Allers et al (2011) published an article involving the same patient with extended follow-up,
which reveals that he had remained off HAART and had no evidence of HIV disease for 45
months after the transplant. During his treatment course, he underwent multiple colonos‐
copies with biopsies to rule out GVHD, in addition to a liver biopsy and brain biopsy for
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evaluation of leukoencephalopathy. This study also looked at 10 HIV negative stem cell
transplant controls and 15 HIV negative healthy controls, 5 of whom underwent colonosco‐
py as a cancer preventive examination. It was found that CD4+ T cell reconstitution in‐
creased continuously and, after two years reached levels within the normal range of age
matched healthy patients. There was 100 percent donor chimerism, which was shown by ab‐
sent CCR5 expression. Among the CD4+ T cells, there were more activated effector memory
cells and less naïve cells when compared with healthy controls. CD4+ T cell reconstitution
also occurred in the gut mucosa of the reported patient, similar to the stem cell transplant
control patients, with cells exclusively derived from the donor hematopoietic system. There
was more than a twofold increase in mucosal CD4+ T cells in the transplant patients com‐
pared to healthy controls, which demonstrates that conditioning and transplant elicits the
enrichment of HIV target cells in the gut mucosal immune system.
Figure 6. The mucosal immune system has been efficiently repopulated with donor-derived CD4+ T cells. (A) Immuno‐
histochemical quantification of CD4+ T cells in colon tissue of the CR5Δ32/Δ32 SCT patient, SCT control patients (27 ±
9 months after transplantation), and healthy control patients. The horizontal lines denote the median values of each
group. Allers K, Hütter G, Hofmann J, et al. Blood. Vol. 117, No. 10, (March 2011), pp. 2790-2799. Blood: journal of the
American Society of Hematology by American Society of Hematology. Copyright 2009 Reproduced with permission of
AMERICAN SOCIETY OF HEMATOLOGY (ASH) in the format Journal via Copyright Clearance Center
HIV RNA and DNA were not detected in the peripheral blood or biopsy specimens ob‐
tained from various tissues. These biopsies revealed that tissue macrophages were ultimate‐
ly replaced by donor-derived macrophages without CCR5 expression (Parker and Sereti,
2011). The T cells of the reported patient do not express normal levels of CXCR4 and appear
vulnerable to X4-tropic HIV. HIV specific antibodies declined over time, with only envelope
antibodies being detectable at the time of publication.
The study suggests that CCR5∆32/∆32 SCT has probably led to a cure of HIV infection in
this patient. However it remains difficult to conclusively demonstrate eradication of HIV
and its latent reservoirs, and the chance of resurgence of lingering X4 strains which survived
the chemotherapy and radiation, leading to X4 HIV rebound still exists. Host-originating
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CD4+ T cells appear to be totally removed from the immune system; however tissue macro‐
phages are practically resistant to conditioning and less susceptible to the cytopathic effects
of HIV infection, making them resilient viral reservoirs (Swingler S et al, 2007). One of the
most promising findings of this report was the demonstration that later in the course of im‐
mune reconstitution, host-originating macrophages became undetectable in the GI mucosa
by both phenotypic and genotypic analysis. These findings suggest that the replacement of
host tissue cells with donor derived cells has reduced the size of the viral reservoir during
the course of the immune reconstitution, which consequently had reduced the risk of HIV
rebound over time.
5. Gene therapy and the future
Gooley et al (2010) reported impressive decreases in allogeneic transplantation-related mor‐
tality. Nevertheless, the risk of allogeneic SCT is inappropriately high to recommend it in
the absence of an underlying malignancy that requires it as therapy. It cannot be proposed
as a treatment strategy for the bulk of HIV-infected patients who can live long healthy lives
with the use of HAART. Homozygosity for the delta 32 mutation is only found in a minority
of the population, so it is not feasible to find such HLA-matched donors for the majority of
patients. Preferably, one would aspire to integrate the benefits of transplantation of cells
with the CCR5 mutation without the hazards of allogeneic SCT. One potential way to ach‐
ieve this would be to transplant autologous stem cells that were genetically modified to be
CCR5 negative. We have performed two trials at the City of Hope using this approach. The
most recent employed a lentivirus-based system to transduce stem cells with a combination
of three forms of anti-HIV RNA. This incorporated RNA1 in the form of a short-hairpin
RNA targeted to an exon in HIV-1 tat/rev, a decoy for the HIV tat reactive element and a
ribozyme that targets the host cell CCR5 chemokine receptor. Krishnan et al (2008) reported
four patients with AIDS-related lymphoma transplanted with autologous lentiviral-trans‐
duced modified stem cells and unmanipulated stem cells following high-dose chemothera‐
py. All patients engrafted and exhibited low levels of genetically modified cells. Future trials
will address how to augment engraftment of the genetically modified stem cells. Further
plans are for planned interruption of HAART which would further demonstrate the func‐
tionality of these genetically modified cells. It is likely that an amalgamation of approaches
with an aim to limit CD4 T cell targets and target viral reservoirs may be necessary to ach‐
ieve a cure.
6. Conclusion
In the HAART era, the barrier of HIV infection as an obstacle to transplant has been broken.
The role of ASCT has been well established in the HIV negative population for the treatment
of relapsed or high-risk lymphoma. Numerous studies have now shown that ASCT can be
safely performed in HIV-positive patients, and that it may lead to durable remissions in pa‐
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tients with HIV-related lymphomas. Similar to well controlled diabetes, well controlled HIV
infection does not significantly increase the risk of infections following ASCT if a program
of adequate surveillance and prophylaxis is used. Allogeneic stem cell transplantation re‐
mains a more difficult task, is still in its infancy, and lacks larger studies. The Hutter and
Allers experience of allogeneic SCT with a CCR5 negative donor has given a name and face
to the cure of HIV. The task of finding more feasible options for the enormousglobal popula‐
tion living with HIV remains.
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1. Introduction
Approximately 100 to 200 infants annually in the United States are infected with HIV (CDC,
2007). Most were born to mothers who were unaware of their infected HIV status or who
did not receive preventative services during their pregnancy to reduce transmission rates.
Therefore, in 2006, the CDC updated its guidelines for screening of various populations for
HIV, including pregnant women. Obstetricians and gynecologists are ideally suited to such
screening of their patients during annual exams and prenatal visits.
1.1. Screening for HIV infection during prenatal care
Screening only patients who reported risk factors for the HIV infection will miss many in‐
fected women. Therefore, the current recommendation is for implementation of universal
opt-out screening for HIV as early in pregnancy as possible (Branson et al., 2006). In this uni‐
versal opt-out screening method, a patient is informed that HIV testing will be performed as
a routine part of her prenatal care, unless she declines testing. She should be given written
or oral information about HIV, including an explanation of the infection, the meaning of
positive or negative test results, and measures that can be used to reduce perinatal transmis‐
sion. She should also be given the opportunity to ask further questions. However, no in‐
formed consent is required. If a patient declines screening, this should be documented in the
medical record, and screening should be offered at subsequent prenatal visits (Branson et
al., 2006; ACOG, 2008). Retesting is recommended with each new pregnancy. Although
these are the recommendations endorsed by the CDC and ACOG, healthcare providers must
be aware of the laws regarding screening in their own states, which may differ from the
above guidelines. Further information on state HIV testing laws can be obtained from state
and local health departments.
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Chou et al, estimated that the number needed to screen (NNS) in an area with 0.15% preva‐
lence would be between 3,500 to 12,170 to prevent 1 case of perinatally-acquired HIV infec‐
tion. In a high risk area with a prevalence of 5%, the NNS would be from 105 to 365 to
prevent 1 case of perinatally-acquired infection (Chou et, 2005).
At this time, both conventional and rapid screening tests for HIV are available to the health‐
care provider. Conventional testing consists of a screening test with an enzyme immunoas‐
say (ELISA), followed by confirmatory testing of a positive result with Western blot or
immunofluorescent antibody (IFA) testing. The sensitivity and specificity of this method of
testing is greater than 99%. False positive results are rare even in the setting with low preva‐
lence. Final results may not be available for several days to weeks. With rapid testing, a
blood or saliva test for HIV antibodies is performed, and the results are often available with‐
in an hour. Confirmatory testing of a preliminary positive result is still required before a di‐
agnosis of HIV can be made. A negative result with either the conventional or rapid
screening test indicates a woman does not have HIV, and no further testing is needed, un‐
less one suspects the patient was recently infected with HIV but has not produced an anti‐
body response to the virus (ACOG, 2008; Rahangdale & Cohan, 2008). If the initial screening
test is positive, but the confirmatory test is negative, the patient should be considered not
infected, and no further testing is necessary.
1.2. Rescreening in the third trimester
Studies from several countries have demonstrated that pregnant women seem to be at in‐
creased risk for acquisition of HIV over their non-pregnant counterparts (Moodley et al.,
2009; Gray et al., 2005; Sansom et al., 2003). Theories for this range from behavioral actions
of the woman or her partner that put her at increased risk, to physiologic changes associated
with pregnancy, including changes to the genital tract mucosa to changes in cellular immun‐
ity that may lead to increased susceptibility to HIV with pregnancy. Evidence has demon‐
strated that the rate of seroconversion during pregnancy may be as high as 2 to 3 percent in
some areas (Moodley et al., 2009; Gray et al., 2005; Sansom et al., 2003). A study by Sansom,
et al demonstrated that in a population with an HIV incidence of approximately 1 in 1000
person-years, the cost of repeat testing was offset by the savings in medical costs for preven‐
tion of an infected infant (Sansom et al., 2003). For the above reasons, repeat HIV testing is
recommended in certain populations in the third trimester, preferably before 36 weeks ges‐
tation (Branson et al., 2006; ACOG, 2008). These populations include:
• Women living in areas with a high incidence of HIV/AIDs, including the 20 states with
the highest incidence among women of child-bearing age
• Women who receive their healthcare in facilities where at least 1 in 1000 women screened
for HIV are found to be infected
• Women who engage in high-risk behavior that puts them at risk for HIV acquisition (in‐
jection drug use, exchange of sex for drugs or money, diagnosis of another sexually trans‐
mitted infection in the past year, a sex partner who engages in injection drug use or high-
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risk behaviors or is infected with HIV, or women who have had a new or more than one
sexual partner during their pregnancy)
• Women with signs or symptoms of acute HIV infection
1.3. Screening of women with undocumented HIV status
Studies indicate that between 40 and 85 percent of infants infected with HIV are born to
mothers whose HIV infection status is unknown prior to delivery (ACOG, 2008). If a woman
without documentation of HIV status presents to labor and delivery, opt-out rapid HIV test‐
ing should be performed at time of her initial presentation. A positive result should prompt
immediate treatment with antiretroviral prophylaxis without awaiting the result of confir‐
matory testing. If subsequent confirmatory testing shows the woman to be HIV negative,
treatment may be discontinued. Similarly, if a woman has an unknown HIV status in the
postpartum period, her infant should be tested by rapid screening. Antiretroviral treatment
should be initiated with a positive result, as the benefits of such treatment are maximized
when started within 48 hours of delivery (ACOG, 2008; Rahangdale & Cohan, 2008). Again,
treatment may be stopped if confirmatory testing is negative.
The  above  recommendation  for  prenatal  screening  for  HIV  infection  is  summarized  in
table  1.
Timing Screening test Confirmatory Test
Initial prenatal care visit Enzyme immunoassay (ELISA) Western blot or immunofluorescent
antibody (IFA) testing
Third trimester of pregnancy Repeat ELISA in women at high risk
for acquisition of HIV infection
Western blot or IFA testing
At time of labor and delivery for
women with undocumented HIV
status
Rapid HIV antibody screening test. Western blot or IFA testing
Table 1. CDC and ACOG recommendation for screening for HIV infection during pregnancy.
2. Evidences supporting the effectiveness of current interventions to
decrease mother-to-child transmission of HIV infection
Research in HIV infection reported several key factors in the transmission of the virus from
the mother to the infant. The risk factors for transmission can be divided into: virologic/
immunologic, maternal health status/behavior, and obstetrical factors (McGowan et al,
2000). High maternal plasma HIV-1 viral load, low maternal CD4 T-lymphocyte count, mul‐
tidrug-resistant HIV genotype will increase the transmission rate. Certain maternal behavior
(illicit drug use, cigarette smoking, breast feeding) or maternal health status (increased base‐
Screening for HIV Infection in Pregnancy
http://dx.doi.org/10.5772/54551
79
Chou et al, estimated that the number needed to screen (NNS) in an area with 0.15% preva‐
lence would be between 3,500 to 12,170 to prevent 1 case of perinatally-acquired HIV infec‐
tion. In a high risk area with a prevalence of 5%, the NNS would be from 105 to 365 to
prevent 1 case of perinatally-acquired infection (Chou et, 2005).
At this time, both conventional and rapid screening tests for HIV are available to the health‐
care provider. Conventional testing consists of a screening test with an enzyme immunoas‐
say (ELISA), followed by confirmatory testing of a positive result with Western blot or
immunofluorescent antibody (IFA) testing. The sensitivity and specificity of this method of
testing is greater than 99%. False positive results are rare even in the setting with low preva‐
lence. Final results may not be available for several days to weeks. With rapid testing, a
blood or saliva test for HIV antibodies is performed, and the results are often available with‐
in an hour. Confirmatory testing of a preliminary positive result is still required before a di‐
agnosis of HIV can be made. A negative result with either the conventional or rapid
screening test indicates a woman does not have HIV, and no further testing is needed, un‐
less one suspects the patient was recently infected with HIV but has not produced an anti‐
body response to the virus (ACOG, 2008; Rahangdale & Cohan, 2008). If the initial screening
test is positive, but the confirmatory test is negative, the patient should be considered not
infected, and no further testing is necessary.
1.2. Rescreening in the third trimester
Studies from several countries have demonstrated that pregnant women seem to be at in‐
creased risk for acquisition of HIV over their non-pregnant counterparts (Moodley et al.,
2009; Gray et al., 2005; Sansom et al., 2003). Theories for this range from behavioral actions
of the woman or her partner that put her at increased risk, to physiologic changes associated
with pregnancy, including changes to the genital tract mucosa to changes in cellular immun‐
ity that may lead to increased susceptibility to HIV with pregnancy. Evidence has demon‐
strated that the rate of seroconversion during pregnancy may be as high as 2 to 3 percent in
some areas (Moodley et al., 2009; Gray et al., 2005; Sansom et al., 2003). A study by Sansom,
et al demonstrated that in a population with an HIV incidence of approximately 1 in 1000
person-years, the cost of repeat testing was offset by the savings in medical costs for preven‐
tion of an infected infant (Sansom et al., 2003). For the above reasons, repeat HIV testing is
recommended in certain populations in the third trimester, preferably before 36 weeks ges‐
tation (Branson et al., 2006; ACOG, 2008). These populations include:
• Women living in areas with a high incidence of HIV/AIDs, including the 20 states with
the highest incidence among women of child-bearing age
• Women who receive their healthcare in facilities where at least 1 in 1000 women screened
for HIV are found to be infected
• Women who engage in high-risk behavior that puts them at risk for HIV acquisition (in‐
jection drug use, exchange of sex for drugs or money, diagnosis of another sexually trans‐
mitted infection in the past year, a sex partner who engages in injection drug use or high-
Current Perspectives in HIV Infection78
risk behaviors or is infected with HIV, or women who have had a new or more than one
sexual partner during their pregnancy)
• Women with signs or symptoms of acute HIV infection
1.3. Screening of women with undocumented HIV status
Studies indicate that between 40 and 85 percent of infants infected with HIV are born to
mothers whose HIV infection status is unknown prior to delivery (ACOG, 2008). If a woman
without documentation of HIV status presents to labor and delivery, opt-out rapid HIV test‐
ing should be performed at time of her initial presentation. A positive result should prompt
immediate treatment with antiretroviral prophylaxis without awaiting the result of confir‐
matory testing. If subsequent confirmatory testing shows the woman to be HIV negative,
treatment may be discontinued. Similarly, if a woman has an unknown HIV status in the
postpartum period, her infant should be tested by rapid screening. Antiretroviral treatment
should be initiated with a positive result, as the benefits of such treatment are maximized
when started within 48 hours of delivery (ACOG, 2008; Rahangdale & Cohan, 2008). Again,
treatment may be stopped if confirmatory testing is negative.
The  above  recommendation  for  prenatal  screening  for  HIV  infection  is  summarized  in
table  1.
Timing Screening test Confirmatory Test
Initial prenatal care visit Enzyme immunoassay (ELISA) Western blot or immunofluorescent
antibody (IFA) testing
Third trimester of pregnancy Repeat ELISA in women at high risk
for acquisition of HIV infection
Western blot or IFA testing
At time of labor and delivery for
women with undocumented HIV
status
Rapid HIV antibody screening test. Western blot or IFA testing
Table 1. CDC and ACOG recommendation for screening for HIV infection during pregnancy.
2. Evidences supporting the effectiveness of current interventions to
decrease mother-to-child transmission of HIV infection
Research in HIV infection reported several key factors in the transmission of the virus from
the mother to the infant. The risk factors for transmission can be divided into: virologic/
immunologic, maternal health status/behavior, and obstetrical factors (McGowan et al,
2000). High maternal plasma HIV-1 viral load, low maternal CD4 T-lymphocyte count, mul‐
tidrug-resistant HIV genotype will increase the transmission rate. Certain maternal behavior
(illicit drug use, cigarette smoking, breast feeding) or maternal health status (increased base‐
Screening for HIV Infection in Pregnancy
http://dx.doi.org/10.5772/54551
79
line weight or malnutrition or vitamin A deficiency) can increase the rate of mother-to-child
transmission. Some obstetrical factors (vaginal delivery, prolonged rupture of membrane,
fetal scalp electrode placement, chorioamnionitis, perineal lacerations, prematurity) can in‐
crease the vertical transmission rate (McGowan et al, 2000).
Other reports on perinatal transmission of HIV infection suggested that approximately 70%
of the infections transmitted to the infant during the labor and delivery process; only 30% of
the cases occurred during the antepartum period (Kourtis et al, 2006). Current interventions
to prevent perinatal transmission of HIV infection included: prophylaxis therapy with anti‐
retroviral medication, scheduled cesarean delivery and avoidance of breast feeding. These
interventions resulted in decreasing transmission rate to 2% (Cooper et al, 2002). We will ex‐
amine the evidence supporting these interventions.
2.1. Prophylaxis with antiretroviral agents
The Pediatric AIDS Clinical Trials Group (PACTG) 076 conducted a randomized controlled
study and in 1994 published its landmark results demonstrating a reduction in perinatal
HIV transmission by two-third with the antiretroviral medication Zidovudine (ZDV). HIV-
infected mothers in the study group received a three-part regimen of antiretroviral medica‐
tion. They received ZDV during pregnancy, intravenous ZDV during labor, and their infant
received ZDV orally for 6 weeks (Conner et al, 1994). This trial reported a decrease in trans‐
mission rate from 26% in the placebo group to 8% in those patients who received ZDV. Later
in the year of 1994, FDA approved the use of ZDV for reducing perinatal HIV transmission
and the U.S. Public Health Service Task Force (USPHSTF) and CDC published their recom‐
mendations for the administration of this regimen in an effort to reduce mother-to-child
transmission of the HIV infection (CDC, 2006).
In the late 1990s, additional antiretroviral medications were developed and the combined
use of three or more of these drugs was found to greatly inhibit viral replication and allow
improvement of the immune system. The combination of these medications was known as
highly active antiretroviral therapy (HAART). In 1998, USPHSTF and CDC issued recom‐
mendation regarding HAART: pregnant women should receive HAART if they required the
treatment for their disease status and all HIV-infected pregnant women should be offered
HAART. USPHSTF and CDC at that time acknowledged that the benefits and risks to the
fetus are uncertain (CDC, 1998). Four large U.S. and European cohort studies all concluded
that regimens with two or more antiretroviral drugs were more effective than the one-drug
regimen for reducing vertical transmission of the HIV infection (Cooper et al, 2002, Arch Pe‐
diatr Adolesc Med 2002, Clin Infect Dis 2005, Mandelbrot et al, 2001).
For women diagnosed late in pregnancy and were not able to receive a full course of antire‐
troviral treatment, a short course of antenatal treatment, although less effective, also was
proven to decrease perinatal transmission (Lallemant et al, 2000, Shaffer et al, 1999, Petra
study 2002, Wiktor et al, 1999, Dabis et al, 1999, Chou et al, 2005). There was some reduction
in the HIV infection transmission even when treatment was abbreviated to only antiretrovi‐
ral regimen during labor (Moodley et al, 2003, Taha et al, 2003, Guay et al, 1999). However,
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neonatal prophylaxis alone in a mother who did not receive antiretroviral prophylaxis thera‐
py was less effective in preventing HIV infection (Taha et al, 2003).
2.2. Scheduled cesarean delivery
A  meta-analysis  of  15  prospective  cohort  studies  by  the  International  Perinatal  HIV
Group  (The  International  Perinatal  HIV  Group,  1999)  included  8,533  mother-neonate
pairs.  Vertical  HIV transmission  was  reduced  by  50% when  the  mode  of  delivery  was
elective  cesarean  delivery.  The  effect  of  both  antiretroviral  therapy prophylaxis  and ce‐
sarean  delivery  further  reduced  HIV  transmission  by  87  percent  when  compared  with
other  modes  of  delivery  (either  vaginal  delivery  or  non-elective  cesarean  delivery)  and
no  antiretroviral  therapy.  However,  in  women  who  received  HAART  and  achieved
low  HIV  viral  load  levels  (defined  as  less  than  1,000  copies/  mL),  current  data  is  in‐
sufficient  to  determine  whether  elective  cesarean  delivery  would  offer  further  risk  re‐
duction.  ACOG  concluded  that  scheduled  cesarean  delivery  should  be  discussed  and
recommended  for  HIV-infected  women  whose  HIV-1  RNA  viral  load  exceeds  1,000
copies/mL.  Scheduled  cesarean  delivery  was  recommended as  early  as  38  weeks  gesta‐
tion to  reduce the risk of  labor or  of  prematurely ruptured membranes (ACOG, 1999).
2.3. Avoidance of breastfeeding
Breastfeeding was associated with an HIV transmission rate of 14% to 16% based on the re‐
sults of two meta-analyses of observational studies (Dunn et al, 1992, John et al, 2001). A re‐
view of the literature did not reveal any randomized, controlled trials evaluating the HIV
transmission rate associated with breastfeeding in the United States. A large, prospective co‐
hort study in Italy included 3,770 babies and concluded that HIV infection rates were signifi‐
cantly higher in babies who were breastfed after the authors adjusted for other factors,
including antiretroviral use (adjusted odds ratio, 10.20 [CI, 2.73 to 38.11]) (Arch Pediatr Ado‐
lesc Med., 2002, Chou et al, 2005).
In a study in Africa, women who breastfed and did not receive antiretroviral therapy had a
probability of transmitting the HIV infection of 36.7% (CI, 29.4% to 44.0%) at 24 months and
an infant mortality rate of 24.4% (CI, 18.2% to 30.7%). Those who formula fed their babies
had a transmission probability of 20.5% (CI, 14.0% to 27.0%) and an infant mortality rate of
20.0% (CI, 14.4% to 25.6%) (Nduati et al, 2000).
As a result, in many countries, including the United States where formula feeding is readily
available and inexpensive, breastfeeding is not recommended for infants of HIV-infected
women (WHO, 2000).
3. Potential harms/risks as the result of prenatal HIV screening
We will next explore the potential risks as the results of prenatal HIV screening and the po‐
tential harms of the recommended interventions to reduce perinatal transmission of HIV in‐
fection (Table 2).
Screening for HIV Infection in Pregnancy
http://dx.doi.org/10.5772/54551
81
line weight or malnutrition or vitamin A deficiency) can increase the rate of mother-to-child
transmission. Some obstetrical factors (vaginal delivery, prolonged rupture of membrane,
fetal scalp electrode placement, chorioamnionitis, perineal lacerations, prematurity) can in‐
crease the vertical transmission rate (McGowan et al, 2000).
Other reports on perinatal transmission of HIV infection suggested that approximately 70%
of the infections transmitted to the infant during the labor and delivery process; only 30% of
the cases occurred during the antepartum period (Kourtis et al, 2006). Current interventions
to prevent perinatal transmission of HIV infection included: prophylaxis therapy with anti‐
retroviral medication, scheduled cesarean delivery and avoidance of breast feeding. These
interventions resulted in decreasing transmission rate to 2% (Cooper et al, 2002). We will ex‐
amine the evidence supporting these interventions.
2.1. Prophylaxis with antiretroviral agents
The Pediatric AIDS Clinical Trials Group (PACTG) 076 conducted a randomized controlled
study and in 1994 published its landmark results demonstrating a reduction in perinatal
HIV transmission by two-third with the antiretroviral medication Zidovudine (ZDV). HIV-
infected mothers in the study group received a three-part regimen of antiretroviral medica‐
tion. They received ZDV during pregnancy, intravenous ZDV during labor, and their infant
received ZDV orally for 6 weeks (Conner et al, 1994). This trial reported a decrease in trans‐
mission rate from 26% in the placebo group to 8% in those patients who received ZDV. Later
in the year of 1994, FDA approved the use of ZDV for reducing perinatal HIV transmission
and the U.S. Public Health Service Task Force (USPHSTF) and CDC published their recom‐
mendations for the administration of this regimen in an effort to reduce mother-to-child
transmission of the HIV infection (CDC, 2006).
In the late 1990s, additional antiretroviral medications were developed and the combined
use of three or more of these drugs was found to greatly inhibit viral replication and allow
improvement of the immune system. The combination of these medications was known as
highly active antiretroviral therapy (HAART). In 1998, USPHSTF and CDC issued recom‐
mendation regarding HAART: pregnant women should receive HAART if they required the
treatment for their disease status and all HIV-infected pregnant women should be offered
HAART. USPHSTF and CDC at that time acknowledged that the benefits and risks to the
fetus are uncertain (CDC, 1998). Four large U.S. and European cohort studies all concluded
that regimens with two or more antiretroviral drugs were more effective than the one-drug
regimen for reducing vertical transmission of the HIV infection (Cooper et al, 2002, Arch Pe‐
diatr Adolesc Med 2002, Clin Infect Dis 2005, Mandelbrot et al, 2001).
For women diagnosed late in pregnancy and were not able to receive a full course of antire‐
troviral treatment, a short course of antenatal treatment, although less effective, also was
proven to decrease perinatal transmission (Lallemant et al, 2000, Shaffer et al, 1999, Petra
study 2002, Wiktor et al, 1999, Dabis et al, 1999, Chou et al, 2005). There was some reduction
in the HIV infection transmission even when treatment was abbreviated to only antiretrovi‐
ral regimen during labor (Moodley et al, 2003, Taha et al, 2003, Guay et al, 1999). However,
Current Perspectives in HIV Infection80
neonatal prophylaxis alone in a mother who did not receive antiretroviral prophylaxis thera‐
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Maternal risks Fetal risks
Prenatal screening
Screened positive Discrimination from their partner
Social ostracization from family and
friends
Anxiety and depression
Abandonment and abuse from family
and friend





Potential risk for elective termination
of pregnancy
Interventions to decrease perinatal
transmission
ART prophylaxis Hepatic toxicity and hypersensitivity
reaction (with Nevirapine)




Risks of neural tube defects with
Sustive (Efavirenz) with first trimester
exposure.
? Potential risk of mitochondrial
toxicity and disorder
Inconsistent data regarding increasing
risk for preterm birth and low-birth
weight




endometritis, urinary tract infection.
A trend toward higher risk of
respiratory distress syndrome among
neonates born by cesarean section
(when compared to those born via
vaginal delivery)
Table 2. Potential harms / risks from prenatal screening and strategic interventions to decrease perinatal transmission
of HIV infection:
According to Katz, prenatal screening for HIV in pregnancy aims to test a presumably
healthy population to discover asymptomatic women who are actually infected with HIV
infection. These pregnant women might not have or perceive that they have risk factors for
the HIV infection. This is different than the usual situation when a woman acknowledges
her risk for the infection and requests the screening test. Most women would agree to be
screened as they believe that they are doing everything they can for the health for their baby
but they might not realize the full implication of a positive HIV test result on their lives. In
some instances, they do not perceive that they are at risk for the infection and thus could be
quite unprepared to receive the positive diagnosis. This could result in adverse effect on
their emotional health, their pregnancy, and the family. Thus health care provider should
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always be well prepared to provide the appropriate emotional support for a possibility of
abnormal result (Katz, 2000).
Women tested positive for HIV infection can experience significant problems with discrimi‐
nation from their partner, social ostracization from their family and members of the com‐
munity (Provisional Committee on Pediatric AIDS, 1995, Samson et al, 1998). They were
found to have higher anxiety and depression scores and many women fear abandonment or
abuse, therefore, did not disclose their HIV status to their friend or families. (Lester, 1995)
although no increased risk for intimate partner violence was noted according to one cohort
study (Koenig et al, 2002, Chou et al, 2005)
Data on consequences of false-positive HIV infection diagnoses in pregnant women are
mainly anecdotal as reported by Sheon et al. The potential risks from false-positive results
included: elective termination of pregnancy, anxiety, social discrimination and relationship
problems with their partner (Sheon et al, 1994, Chou et al, 2005).
False positive results from rapid HIV testing during labor result in 4 women receiving un‐
necessary antiretroviral prophylaxis out of 4,849 women tested (Bulterys et al, 2004).
4. Risks of Antiretroviral Therapy (ART) to fetus
4.1. Potential teratogenic effects of ART
Efforts continue to increase our knowledge of the potential teratogenic effects of the antiretrovi‐
ral agents administered in pregnancy. The Antiretroviral Pregnancy Registry Steering Commit‐
tee published their recent report of antiretroviral exposures during pregnancy from January
1989 through July 2007. They did not identify an increased risk of birth defects in those exposed
to any of the antiretroviral therapy in the first trimester. The risk of birth defects among women
exposed to antiretroviral therapy in first trimester was 2.8 per 100 live births, which is not differ‐
ent from the risk of birth defects in women exposed to these agents in the second or third trimes‐
ter (2.6 per 100 live births), nor the CDC’s reported background rate of birth defects of 2.72 per
100 live births (www.APRegistry.com, 2007, Bardeguez, 2009).
Four retrospective reports associated Sustiva (Efavirenz) with neural tube defects in infants
born of mothers exposed to this medication in the first trimester (Bardeguez, 2009). There
are discrepant results with regard to mitochondrial toxicity and disorders in children ex‐
posed in utero to antiretroviral therapy. Two deaths believed to be due to mitochondrial dis‐
order were reported in children exposed in utero to nucleoside analogues (in specific, a
combination of Zidovudine and Lamivudine regimen) (Blanche et al, 1999). However, Euro‐
pean Collaborative report and systematic review of U.S. cohorts reports did not find evi‐
dence of clinical symptoms, or deaths due to mitochondrial dysfunction among HIV-
negative infants exposed to antiretroviral agents in utero (Bardeguez, 2009).
Of infants exposed in utero to Zidovudine who were followed at 4 years to 6 years of life. The re‐
ports were reassuring. Normal growth, cognitive, and developmental function were noted in
these infants at 4 years old. They did not sustain any tumors or deaths from cancer at 6 years old.
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4.2. Association between ART and preterm birth and low-birth weight
Inconsistent results were noted among the reports studying the effects of combination antire‐
troviral therapy on two obsterics outcomes: preterm birth and low birth-weight. Lorenzi et al in
1998 first reported the association between combination antiretroviral therapy with preterm
birth in a retrospective Swiss study of 30 women (Lorenzi et al, 1998). Subsequently, other Euro‐
pean studies reported a similar association between combination antiretroviral therapy and
preterm birth (The European Collaborative Study (ECS) andSwiss Mother + Child HIV Cohort
Study (Mo-CHiV), 2000, Grosch-Woerner et al, 2008). However, this association was not found
in U.S. studies until a recent study by Cotter et al. The authors prospectively collected the data
from 1990 through 2002 on 999 women receiving antiretroviral regimen during pregnancy.
They concluded that women who received combination therapy that included a protease inhib‐
itor had an increased risk of preterm delivery (Cotter et al, 2006).
In a largest analysis to date, Tuomola et al did not find an increased rate of premature birth
or low birth-weight infants among 2,123 HIV infected pregnant women from seven clinical
studies who received combination ART and gave birth from 1990 through 1998.
5. Risks of ART to mothers
A large prospective study evaluating the rates of maternal toxicity, pregnancy complica‐
tions, and peripartum morbidity among HIV-infected pregnant women receiving prenatal
care and ART concluded that adverse events were rare. Gestational diabetes was noted to be
highest among women who received combination therapy including protease inhibitors ei‐
ther before or during first trimester (Watts et al, 2004). Reports of potential risks of hepatic
toxicity and hypersensitivity reaction were noted in pregnant women receiving the drug Ne‐
virapine (Bardeguez, 2009).
Another valid concern is the potential development of drug resistance when ART was ad‐
ministered to the mother for a short period during pregnancy. Drug resistance was noted in
20 – 69% of women who received only intrapartum prophylaxis with single-dose nevira‐
pine. This could decrease the choice of medications for these women should they later need
treatment for their disease. Although, there are reports that this observed resistance dis‐
solved over time. (Bardeguez, 2009). Limited exposure to zidovudine alone did not alter ma‐
ternal disease progression, time until development of AIDS or death, or development of
genotypic zidovudine resistance (Bardeguez et al, 2003).
6. Potential maternal risks from scheduled cesarean delivery
Cesarean deliveries could result in significant complications when compared to vaginal de‐
livery even for HIV-negative women (Allen et al., 2003; Makoha et al., 2004). HIV-infected
women with an immunodeficient state could potentially at risk for post-operative infectious
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morbidities. Most studies report that HIV-infected women are at higher risk for post-opera‐
tive complications, mostly infectious, than the uninfected women (Coll et al., 2002; Grubert
el al., 1999; Vimercati et al., 2000). The rate of complications is higher in those with severe
immunodeficiency (Jamieson et al., 2007).
Read  et  al  conducted  a  largest  prospective  observational  study  which  included  1,186
HIV-infected  women  from  The  Women  and  Infants  Transmission  Study.  The  authors
evaluated  the  postpartum  morbidity  among  these  infected  women  according  to  their
mode of delivery. When compared to women who delivered vaginally, women who un‐
derwent scheduled cesarean delivery had an increased rate of postpartum fever (14.3%),
hemorrhage (7.1%),  endometritis  (5.4%),  urinary tract  infection (5.4%),  and any postpar‐
tum morbidity (26.7%) (Read et al, 2001).
7. Potential neonatal risks from scheduled cesarean delivery at 38 weeks
gestation
In  the  absence  of  medical  or  obstetrical  indications,  ACOG recommends  against  sched‐
uled  cesarean  delivery  at  less  than  39  weeks  of  gestation,  due  to  the  increased  risk  of
respiratory  morbidity  in  the  neonate  born  prior  to  this  gestational  age  (ACOG,  2001).
Neonatal  morbidity  is  high  even  among  those  neonates  born  via  cesarean  delivery  a
few  days  younger  than  39  weeks  (Tita  et  al,  2011).  However,  both  ACOG  and  U.S.
Public  Health  Service  recommend scheduled  cesarean  delivery  at  38  weeks  for  HIV-in‐
fected women with viral  load greater  than 1,000 copies/ml  (ACOG, 2001;  Public  Health
Service Task Force,  2010).  The scheduled cesarean delivery date is  set  at  one week ear‐
lier  than  the  usually  required  gestational  age  of  39  weeks  to  avoid  onset  of  spontane‐
ous  labor  and  rupture  of  membranes  which  could  increase  perinatal  transmission  of
HIV.  Livingston  et  al  and  the  IMPACT  Protocol  1025  Study  Group  evaluated  the  risk
of  neonatal  respiratory distress  syndrome according to the mode of  delivery and gesta‐
tional  age  at  delivery.  They  reported  that  the  mode  of  delivery  was  not  associated
with  respiratory  distress  syndrome.  However,  there  was  a  trend  toward  a  higher  risk
of  respiratory  distress  syndrome  among  neonates  delivered  by  either  elective  or  non-
elective  cesarean  section  when  compared  to  those  delivered  vaginally.  Two  out  of  227
neonates  born  via  scheduled  cesarean  delivery  at  38  weeks  gestation  had  respiratory
distress  syndrome (Livingston et  al.,  2010).
8. Conclusion
Current evidence supports prenatal HIV screening. The benefits from screening appear to
outweight the small risks / harms to the fetus and mothers from the treatment interventions
which significantly reduce perinatal-acquired HIV infection. We concluded the chapter by
discussing the obstacles to the HIV prenatal screening and prevention interventions. Prena‐
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tal screening for HIV infection and implementation of Protocol 076 were lauded as a major
public health success story and resulted in a significant decline in the number of children
infected with HIV from their mother. However, in the United States, there are still about
100–200 infants born every year with perinatally acquired HIV infection (CDC, 2007). Lack
of prenatal care remains one of the obstacles to prevention of perinatal transmission of HIV.
In the United States about 5 to 10% of women do not pursue prenatal care or receive insuffi‐
cient care (Kogan et al., 1998). HIV infected women, in particular, often do not receive pre‐
natal care. In New York City, 50% of women infected with HIV who delivered in at a
municipal hospital did not receive prenatal care (Minkoff et al., 1990). Of the HIV-infected
women surveyed in Philadelphia, only one third reported adequate prenatal care, and 20%
did not receive any care (Turner et al., 1996).
Even more worrisome, at the Medical Center of Louisiana in New Orleans, LA, 50% of the
HIV-infected parturients who did not have prenatal care but presented to the hospital for
labor and delivery did not disclose their HIV status to their physicians (CDC, 2004). Could it
be because the HIV-infected women did not know of the available interventions that they
put their infants at risk for the infection?
Several authors attempt to understand why HIV-infected women opted out of prenatal care
and available interventions to decrease vertical transmission. Rothpletz-Puglia et al solicited
opinions from a group of HIV-negative women about the process of prenatal HIV screening.
The authors reported that fear was a big factor for declining testing. The women are afraid
to find out they are HIV-infected. They are frightened to discover a partner’s infidelity. They
are fearful of being judged by their health care provider or of being denied medical care if
they tested positive (Rothpletz-Puglia et al, 2001).
Lancioni et al. reported that HIV-infected women did not participate in prenatal care be‐
cause they fear disclosing their status to their caretakers and being judged by them for con‐
tinuing the pregnancy (Lancioni et al., 1999). In a recent report by Lindau et al, HIV-infected
women who were interviewed were aware of the benefits of prophylaxis treatment yet most
received insufficient or no prenatal care. They knew of their HIV infection diagnosis but
most did not disclose their status to their caretaker when they presented for delivery at hos‐
pitals capable of providing prophylaxis treatment. They attributed health care providers’
lack of sensitivity, violations of confidentiality, disdain for HIV infection and substance
abuse as reasons for their non-participation in prenatal care, avoidance of treatment for HIV
infection, and non-disclosure of their HIV status. Denial and fear were other barriers to HIV
prophylaxis treatment (Lindau, 2006).
We agreed with Lindau et al that may be what is needed to further reduce perinatal trans‐
mission beyond the conventional models for prevention is to understand the HIV-infected
women’s point of view, their fears and concerns and to eliminate the disrespect treatment as
perceived by them from the health care providers. It is hope that we can create a medical
environment where these women will be confident of our compassion and care to disclose
their status and to want to seek prenatal care and HIV prophylaxis treatment (Lindau, 2006).
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1. Introduction
Testing and counseling for human immunodeficiency virus (HIV) is now recognized as a
priority in national HIV programs because it is the gateway to HIV/AIDS prevention, care,
treatment, and support interventions. In order to ensure access to HIV testing for large pop‐
ulations and to facilitate access to antiretroviral treatment in the context of the World Health
Organization’s universal access strategy, radical scaling up of HIV testing and counseling
services is being advocated globally.
The use of HIV rapid tests will facilitate this in many settings, particularly in services in
which the people most likely to benefit from knowing their HIV status can be reached.
These Settings include diagnostic and treatment services for tuberculosis and sexually trans‐
mitted infections; services linked to the prevention of mother-to-child transmission of HIV;
the management of occupational and non-occupational exposures to HIV; at voluntary
counseling and testing (VCT) sites; in remote areas where the creation and maintenance of a
laboratory infrastructure is not possible; and where hard-to-reach populations have access
to HIV testing (PAHO, 2008).
To date, HIV testing strategies has clear objective for diagnosis, surveillance and transfusion
safety. The need for appropriate selection of testing platforms and protocol had also varied
from setting to setting. In general, four criteria had underpinned the choice of most appro‐
priate test or combination of tests for any given setting and depend on: General goal for test‐
ing, Diagnostic indices of sensitivity and specificity, Prevalence of HIV infection in the
general population and Cost of testing (WHO, 2004).
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HIV testing is the entry point for both care and prevention. In resource limiting settings, this
declaration seems more valid than ever given the increase prevalence and incidence of HIV
infection in these settings and current efforts at universal access for care and prevention. The
aim of this chapter is to provide trend in HIV testing Algorithm- a combination and se‐
quence of specific testing employed in given strategy for the confirmation of HIV status of
an individual or sample.
In the evolving Chapter, we shall transit with set-out for HIV testing algorithms (with ap‐
propriate sub-themes) from HIV testing evolution and forms of testing to HIV testing strat‐
egies and algorithm platforms.
2. HIV testing
2.1. Evolution of HIV testing
HIV screening and diagnostic tests have been developed, and a variety of testing algorithms
have come into use. HIV antibody tests have evolved from first generation HIV-1(clade B)
viral lysate-based, indirect antibody enzyme immunoassays (EIAs) to third generation anti‐
gen-sandwich immunoassays that use synthetic peptide and recombinant DNA derived an‐
tigens that represent the immunodominant epitopes from diverse HIV-1 and HIV-2 strains.
These third generation enzyme immunoassays have substantially enhanced sensitivity to di‐
vergent viral variants and have shortened the infection-to-seroconversion window period
by more than 3 weeks compared with first generation tests. Assays have also been devel‐
oped that detect and quantitate viral antigen (p24) and nucleic acids (HIV RNA or DNA) in
blood, and in body fluids and tissues (Branson, 2010; WHO, 2009a).
These assays have seen increasing application in blood and organ donor screening, as well
as in clinical diagnosis, prognosis, and therapeutic monitoring; and clinicians now have ac‐
cess to a broad and potentially confusing array of test options, each with its own advantages
and limitations. Developing testing algorithms and interpretive criteria appropriate to a par‐
ticular group of patients—high-risk adults; blood, plasma and organ donors; recently ex‐
posed healthcare workers; paediatric patients, and especially in resource limiting settings—
poses a challenge, especially as new tests appear with tantalizing claims of enhanced per‐
formance (WHO, 2009a/b).
The laboratory diagnosis of the HIV infection is based on a two-stage strategy: a screening
analysis followed by a confirmation analysis. A positive screening analysis must always be
supplemented by a confirmation analysis on the same sample. An HIV infection can only be
confirmed when the result of the confirmation analysis is positive and consistent results are
obtained for two separate samples (PAHO, 2008).
Screening tests provide presumptive identification of specimens that contain antibody to
HIV. These enzyme immunosorbent assays (EIAs) or simple/rapid immuno-diagnostics are
selected for their high sensitivity of detecting antibodies to HIV. Supplemental or confirma‐
tory tests, such as Western blot (WB), can be used to confirm infection in samples that are
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initially reactive on conventional EIAs. Alternatively, repetitive testing incorporating EIAs
or rapid tests selected for their specificity may be used to confirm whether specimens found
to be reactive for HIV antibodies with a particular screening test are specific to HIV. For
practical purposes, resource-poor settings depend heavily on EIA and rapid tests for screen‐
ing and confirmation (WHO, 2004).
2.2. Enzyme immunsorbent assays
EIAs are the most widely used screening tests because of their suitability for analyzing large
numbers of specimens, particularly in blood screening centers. Since 1985, EIAs have pro‐
gressed considerably from first to fourth generation assays: first generation assays were
based on purified HIV whole viral lysates, however, sensitivity and specificity of these as‐
says were poor; second generation assays used HIV-recombinant proteins and/or synthetic
peptides, which enabled the production of assays capable of detecting HIV-1 and HIV-2.
The assays had improved specificity, although their overall sensitivity was similar to that of
first-generation assays. Third-generation assays used the solid phase coated with recombi‐
nant antigens and /or peptides and similar recombinant antigens and peptides conjugated to
a detection enzyme or hapten that could detect HIV-specific antibodies bound to a solid
phase. These assays could detect immunoglobulin M, early antibodies to HIV, in addition to
IgG, thus resulting in a reduction of the seroconversion window. Fourth generation assays
are very similar to third-generations tests but have the ability to detect simultaneously HIV
antibodies and antigens. Typical fourth-generation EIAs incorporate cocktails of HIV-1
group M (HIV-1 p24, HIV-1 gp160), HIV-1 group O, and HIV-2 antigens (HIV-2 env pep‐
tide) (WHO, 2009a/b and 2004).
Furthermore, third and fourth-generation assays are able to detect IgM and IgG antibodies
to both HIV-1 and HIV-2. These assays may reduce the 2-4 week time period, “window peri‐
od” of detecting HIV antibodies (WHO, 2009b).
2.3. Rapid/simple assays
Simple, instrument-free assays are also available and are now widely used in Africa. They
include agglutination, immunofiltration, and immunochromatographic assays. The appear‐
ance of a colored dot or line, or an agglutination pattern indicates a positive result. Most of
these tests can be performed in less than 20 minutes, and are therefore called simple/rapid
assays. Some simple tests, such as agglutination assays, are less rapid and may require
about 30 minutes to 2 hours to be completed. In general, these rapid/simple tests are most
suitable for use in settings that have limited facilities and process fewer than 100 samples
per day (WHO, 2009b and 2004).
2.3.1. Importance of rapid/simple assays
Although EIA–based serodiagnostic algorithms are highly cost effective, their application in
resource-poor settings is limited by several factors. They require well-trained personnel,
need a consistent supply of electricity, and maintenance and cost of most equipment. Rapid
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about 30 minutes to 2 hours to be completed. In general, these rapid/simple tests are most
suitable for use in settings that have limited facilities and process fewer than 100 samples
per day (WHO, 2009b and 2004).
2.3.1. Importance of rapid/simple assays
Although EIA–based serodiagnostic algorithms are highly cost effective, their application in
resource-poor settings is limited by several factors. They require well-trained personnel,
need a consistent supply of electricity, and maintenance and cost of most equipment. Rapid
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assays have high sensitivity and specificity and perform as well as EIAs on specimens from
persons seroconverting for non-B HIV-1 subtypes (Koblavi-Dème et al, 2001). Rapid enzyme
assays circumvent the issue of low rates of return for serologic results associated with EIA-
based testing algorithms because results can be delivered on the same day (Puro et al, 2004).
In addition, their performance has improved considerably, and some do not require recon‐
stitution of reagents or refrigeration; thus, making them very suitable for use in resource
limited settings and hard to reach populations (Koblavi-Dème et al, 2001). Practical applica‐
tions for the use of simple/rapid assays are in settings such as Voluntary Counseling and
Testing (VCT) and Prevention of Mother to Child Transmission (PMTCT) programs. Studies
have shown that using rapid assay testing algorithms result in remarkable increase in the
number of HIV-positive women identified as eligible to receive the short-course therapy
that reduces mother-to-child transmission of HIV (Sibailly et al, 2000).
3. HIV testing strategies and algorithm
3.1. Nature of algorithm/testing strategy
A testing algorithm for serologic diagnosis of HIV-infection is the sequence in which assays
are performed to detect HIV antibody in a body fluid. The most common referenced testing
algorithm employs an EIA to screen specimens with those found to be positive then con‐
firmed by WB testing. This so-called conventional algorithm has several limitations (PAHO,
2008):
• WB is expensive and requires technical expertise.
• WB often yields indeterminate results with certain types of specimens with uncertain di‐
agnostic significance, e.g., hyperimmunoglobulinemia specimens.
• Both ELISA and WB are time consuming and require a well-equipped laboratory infra‐
structure.
Various combinations of tests can be used: combinations of HIV EIAs; combinations of rapid
tests; or an EIA in conjunction with rapid tests. The choice of strategy and of HIV tests
should be determined by the quality of the tests and by the practicality of their implementa‐
tion, logistics, and the cost-benefit analysis. Figure 1, depicts the WHO/UNAIDS testing
strategies which can be adopted in diverse settings
In the WHO/UNAIDS testing strategies I – III, as applicable relative to testing objective (sur‐
veillance, blood screening, or diagnosis) or diagnostic indices (sero-prevalence in a given
population and the duo of sensitivity and specificity of the test being used. The three HIV
testing strategies recommended by WHO and UNAIDS are described below (Figure 1)
(WHO, 2009a; UNAID/WHO, 1998).
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Figure 1. Schematic Representation of the WHO/UNAIDS HIV Testing Strategy(Adapted from WHO, 2009a/b and UN‐
AID/WHO,1998)
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• Requires one test.
• For use in diagnostic testing in populations with an HIV prevalence >30% among persons
with clinical signs or symptoms of HIV infection.
• For use in blood screening, for all prevalence rates.
• For use in surveillance testing in populations with an HIV prevalence >10% (example: un‐
linked anonymous testing for surveillance among pregnant women at antenatal clinics).
No results are provided.
Strategy II:
• Requires up to two tests.
• For use in diagnostic testing in populations with an HIV prevalence ≤30% among persons
with clinical signs or symptoms of HIV infection or >10% among asymptomatic persons.
• For use in surveillance testing in populations with an HIV prevalence ≤10% (example: un‐
linked anonymous testing for surveillance among patients at antenatal clinics or sexually
transmitted infection clinics). No results are provided.
Strategy III:
• Requires up to three tests.
• For use in diagnostic testing in populations with an HIV prevalence ≤10% among asymp‐
tomatic persons.
Sensitivity and specificity are two important factors that determine a test’s accuracy in dis‐
tinguishing between HIV-infected and uninfected individuals. It is crucial that the HIV tests
used in the algorithms all have a sensitivity of at least 99% and a specificity of at least 98%
(WHO, 2009a and 1997). There are commercially available HIV EIAs and HIV rapid tests
that meet these criteria. When selecting HIV tests to be used in combination, it is important
to select tests that do not share the same false positive and same false negative results. This
information can be obtained from comparative evaluation studies of HIV test kits, such as
those published in international scientific publications and in WHO reports (WHO,
2009a/b). It is recommended that such comparative evaluations of a select number of HIV
test kits be conducted at the national and/or regional level prior to the establishment of the
national HIV test algorithms. These principles apply to both conventional HIV EIA and HIV
rapid tests. The national reference laboratory should validate a select number of test kits for
use in the national HIV testing algorithms.
Specific implementation requirements must be considered when selecting tests kits and al‐
gorithms. For example, will testing be performed in a laboratory setting, or in a VCT or clini‐
cal setting without extensive laboratory facilities? In settings without extensive laboratory
facilities or where clients do not return for follow-up visits, algorithms using only rapid tests
are preferred. In situations in which patients return at regular intervals (e.g., TB clinics) or in
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prenatal clinics where blood specimens are taken for other testing purposes, the set-up may
allow for HIV EIA-based algorithms or algorithms combining EIA and rapid tests (Owusu-
Ofori et al, 2005; Routet et al, 2004).
Another factor determining the most cost-efficient approach is the volume of specimens to
be processed daily or weekly. An EIA test is half the price of a rapid test, so if a particular
setting processes 40 specimens a day and the laboratory has the required equipment, it is
more cost effective to use EIAs than rapid tests. It is important that the HIV tests and algo‐
rithms be chosen carefully and with the aim of optimal integration into the existing health
care facilities, minimizing the potential to disrupt their operations or unnecessarily overbur‐
den staff.
There are many strategies for HIV testing (Parekh et al, 2010; WHO, 2009a/b; Paul et al, 2004).
WHO, CDC, and the Association of Public Health Laboratories have jointly developed one
of the most useful references for HIV testing algorithms. These strategies can be divided into
two approaches: serial (or sequential) testing and parallel testing.
3.2. Algorithm platforms
3.2.1. Serial/sequential testing strategy
In a Serial or sequential testing strategy, samples are initially tested with only one, highly
sensitive assay. Samples that are reactive in the first assay are then re-tested using a second,
highly specific assay. A third test may be performed, depending on the result of the second
assay and the objective of the testing. Both the selection of and the order in which the assays
are used are of the utmost importance for the final outcome of the tests. If test combinations
are not carefully selected, individuals may be incorrectly diagnosed. WHO recommends se‐
quential testing (Figure 2) in most settings because it is more economical, as the second test
is required only when the initial test result is positive (Gershy=Damet et al, 2010; WHO,
2009a/b; Ferreira et al, 2005).
3.2.2. Parallel testing strategy
In a parallel testing strategy (Figure 3), samples are tested using two different assays simul‐
taneously. This approach is rather expensive, as it virtually doubles the cost of testing in
low- prevalence settings by requiring two tests at the outset. As with sequential testing, a
third test may be performed preferably at the secondary level, where laboratory facilities
and experienced staff are available, depending on the result of the assays and the objective
of the testing (WHO, 2009a/b).
Therefore, the parallel testing strategy is recommended only in situations in which it can
add value. Prenatal clinics provide one such example: A woman’s first visit to the clinic may
be to deliver her child, thus requiring a rapid decision whether an intervention to prevent
mother-to-child transmission of HIV is needed. Other emergency situations, such as work
accidents, sexual violence, and discordant couples also would benefit from this strategy. In
these cases, two rapid tests using whole-blood finger-stick specimens in parallel will pro‐
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setting processes 40 specimens a day and the laboratory has the required equipment, it is
more cost effective to use EIAs than rapid tests. It is important that the HIV tests and algo‐
rithms be chosen carefully and with the aim of optimal integration into the existing health
care facilities, minimizing the potential to disrupt their operations or unnecessarily overbur‐
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There are many strategies for HIV testing (Parekh et al, 2010; WHO, 2009a/b; Paul et al, 2004).
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sensitive assay. Samples that are reactive in the first assay are then re-tested using a second,
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accidents, sexual violence, and discordant couples also would benefit from this strategy. In
these cases, two rapid tests using whole-blood finger-stick specimens in parallel will pro‐
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vide the answer in just 10–15 minutes. HIV rapid tests using wholeblood finger-stick speci‐
mens have great potential in situations where results need to be known quickly, or where
taking a conventional venous sample is difficult (Gershy-Damet et al, 2010; WHO, 2009a/b;
Ferreira et al, 2005).
Figure 2. Serial/ Sequential Testing Algorithm (Adapted from WHO, 2009a/b)
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Figure 3. Parallel Testing Algorithm (Adapted from WHO, 2009a/b)
4. Conclusion
HIV testing is the essential entry point for both treatment and prevention. As in all societies,
especially in Africa, high degree of genetic diversity exist. One implication for this is the
need for each country to have an in-house evaluation of its country –specific testing strat‐
egy. The selection of a national algorithm is the responsibility of the country’s Ministry of
Health. The choice of sequential or parallel testing should be made after a thorough analysis
of the scientific evidence, logistics, test performance requirements, and cost/affordability of
the various algorithms.
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1. Introduction
Human immunodeficiency virus-1 (HIV-1) engulfs 33 millions of life as per the latest UN
AIDS  report  [Saxena,  Tiwari.,  et  al.,  2012]  and  the  effect  worsens  up  when  it  causes
dementia  with  alarming  occurrence  worldwide  but  the  mechanism  through  which  it
happens is still not well understood, and is in the embryonic stages. The estimated overall
prevalence of nervous system disorders among patients receiving highly active antiretrovi‐
ral  therapy but also requiring neurological care is over 25% (Singh et  al.,  2011).  Accord‐
ing to WHO there are ~ 34 million people in the world infected with HIV. Out of that 95
percent  of  these  cases  as  well  as  deaths  from  AIDS  occur  in  the  developing  world.
Dementia (HIV-associated dementia) is becoming common in HIV infected adults having
prevalence up to 40% in western countries  where clade B prevails  (Sacktor et  al.,  2007).
Dementia cannot be considered as a disease by itself but it is the term used to describe a
set of symptoms resulting from damages and disorders affecting the brain. These symp‐
toms can be caused by a multitude of diseases and depend upon the specific brain regions
affected. These symptoms appear as a variety of cognitive, behavioural,  affective, motor,
and  psychiatric  disorders.  Dementia  can  be  caused  by  a  variety  of  diseases,  known  as
neurodegenerative diseases resulting from protein aggregation in the brain. Many studies
related to this area are been carried out in respect to this, to provide new insights (Saxena
et al., 2012). HIV-1 infects macrophages and microglia, and there is an indirect pathway to
neuronal  injury which happens due to release of  macrophage,  microglial  and astrocytes
toxins and viral proteins. The toxins which are released over stimulate neurons, form free
radicals, finally leading to neurodegenerative diseases. The cognitive and motor dysfunc‐
tion which is observed in HIV patients is termed as HIV associated dementia (HAD). The
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prevalence of the dementia is  eventually increasing as AIDS patients are now surviving
more.  HIV-1 replicates  in monocyte and macrophage but  not  as  severe as  in infected T
cells  and blood mononuclear cells  (Sundaravaradan et  al.,  2006).  These cells  differentiate
and travel to several organs, henceforth acting as a source of infectious virus and secret‐
ed viral proteins to cause pathological issues and alternating several signalling pathways
and distorting many cellular transcription factors, ultimately resulting in HIV-1 pathogen‐
esis.  Increased  transcription  leads  to  the  upregulation  of  virus  production,  and  hence
increased  production  of  viral  proteins  (gp120,  Tat,  Nef,  and  Vpr)  (Gandhi  et  al.,  2020;
Samikkannu et al.,  2010; Saiyed et al.,  2011; Saxena et al.,  2012; Saxena et al.,  2012).  The
high  concentration  of  these  toxic  proteins  lead  to  distorted  cellular  functions,  and  in‐
creased production of toxic metabolites, finally leading to organ-specific like neuroAIDS,
in case  of  viral  entry inside the brain (Kilareski  et  al.,  2009).  Antiretroviral  therapy has
increased  the  lifespan  of  HIV  patients,  but  CNS  function  often  remains  diminished
sometimes developing into HIV-associated dementia and the severity and progression of
dementia is studied to be increased with the effect of drug abuse [Reddy et al., 2012; Ferris
et al., 2008].
2. Prevalence
The prevalence of HAD is estimated to be more than 30% of HIV infected patients, and it is
still reported to be increasing (Dean et al., 2012). Improvements in control of peripheral viral
replication and the treatment of opportunistic infections, helps in extending life expectancy,
resulting in an increase in neuropathogenesis. We are seeing a linear increase in prevalence in
rich countries, but an exponential increase in low-income countries. Just under half of people
with dementia live in high-income countries, 39% live in middle-income countries, and only
14% live in low-income countries. Increasing living standards, in low income countries such
as India (Shankar et al., 2005), may lead to increased life expectancy, which may increase the
frequency of dementia cases. As biggest risk factor for dementia is age, a longer-living global
population means there will be more people with dementia. The report predicts that the
numbers of people with dementia will double every 20 years, to 65.7 million in 2030 and 115.4
million in 2050. Most of this increase will be in developing countries (Prince et al., 2012). A
more complete understanding of the pathogenesis of HAD will help in identifying therapeutic
targets for its prevention and treatment. The global age standardized death rate for dementia
is ~ 6.7 per 100,000 for males and 7.7 per 100,000 for females. According to the World Health
Organization, dementia mortality rate for India is 13.5 per 100,000 males and 11.1 for 100,000
females, which is quite alarming (Prince et al., 2012).
3. HIV- Mechanism of neuronal injury
Presently, neuropathogenesis is winning, because there is an incomplete knowledge about the
mechanism of HIV infection causing neuronal injury and apoptosis in the host (Fig. 1). HIV
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enters the central nervous system through infected monocytes and leads to pathogenesis
involving activation of macrophages and microglia and further toxin release, that activates
several pathways leading to neuronal dysfunction. There are several extracellular and
intracellular signalling pathways, which when activated lead to macrophage or microglial
activation, and induction in neurons and astrocytes. These pathways are of potential thera‐
peutic importance as targets for the prevention or treatment of neuropathogenesis.
Figure 1. HIV virus can enter the CNS by altering the integrity of blood brain barrier.
4. Neuropathology of AIDS
HIV-1 is capable of causing a multi-system disorder including the CNS. HIV-1 enters the CNS
at the early phase of infection, it persists and induces several motor and cognitive disorders
leading to behavioural changes. Major clinical symptoms include impaired short term-
memory, reduced mental concentration, weakness, slowness of hand and leg movement and
depression accompanied by behavioural issues like personality disorders, lethargy and social
withdrawal. These neurological and psychiatric symptoms caused by HIV-1 infection,
constitute together as neuropathogenesis. A more subtle form of CNS dysfunction, known as
minor cognitive motor disorder (MCMD), is also seen common in HIV patients. HAD cannot
be controlled by HAART, HIV-1 infection becomes chronic and even rise in disease has been
reported. The HIV-1 associated neuropathology is characterized by the infiltration of macro‐
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phages into the CNS, the formation of microglial nodules and multinucleated giant cells,
astrocyte activation and damage; neuronal loss in ganglions and hippocampus, myelin
damage, axonal damage and presence of HIV-1 in the CSF. MRI reports say that HIV infection
is associated with progressive cortical atrophy which might be caused by neuronal loss and
demyelination worsening in certain cognitive functions (Ghafouri et al., 2006).
5. HIV entry into the brain and initiation of HAD
HIV-1 infects cells having major HIV-1 receptors,  CD4 and CD8, and several chemokine
receptors which are known to be as HIV-1 co-receptors which help in the attachment of
the virus to the cell and membrane fusion leading to viral entry. Infected CD4+ T cells and
monocytes circulating in the blood are the potential source of CNS infection. HIV-1 infected
cells can be either highly active producers or low/non producers of viruses. Both types of
infections  occur  in  the  CNS.  Studies  of  different  astrocytes  cell  lines,  demonstrated  the
presence of large quantities of Rev in the cytoplasm. Changes in cell environment, like the
elevation  in  the  level  of  cytokines  such  as  TNF-α  and  IL-1β,  might  reactivate  virus
production (Ghafouri et al., 2006). During early infection, HIV enters the CNS (Bertin et al.,
2012) and attacks cells macrophages and microglial cells (Foley et al., 2008). But along with
this infection, periphery factors (non-CNS) are also important for initiating neurodegener‐
ation and triggering dementia, which are like for example; increased number of circulat‐
ing monocytes that express CD16 and CD69. The cells which get activated by viral entry,
progressively  adhere  to  the  endothelium membrane  of  the  brain  microvasculature,  and
further  transmigrate,  triggering  a  spontaneous  array  of  harmful  processes  which  might
finally lead to the loss of Blood Brain Barrier (BBB) integrity making it easy for virus to
enter and replicate inside the brain. The BBB is crucial in HIV infection of the CNS. BBB
is composed of specialized Human brain microvascular endothelial cells (HBMECs), which
do not have any opening and are connected by intercellular junctions in an impermeable
single  layer.  BBB  plays  a  central  role  in  neuropathogenesis  as  it  serves  as  the  channel
through which  free  virus  and infected  immune cells  enter  the  brain.  The  BBB loses  its
integrity  and  permeability  due  to  progressive  HIV  infection  and  immune  compromisa‐
tion, which leads to easy entry of toxins, free virus, infected and activated monocytes into
the brain. It has been reported that HIV-1 gp120 protein and also Tat protein are behind
BBB  disregulation.  PKC  signaling  pathways  and  receptor-mediated  Ca2+  release  are  the
involved pathways resulting into cytotoxicity of the brain endothelial cells (Kanmogne et
al.,  2005)  leading  to  downregulation  and  rupture  of  tight  junction  proteins  (TJPs)  of
HBMECs, by the induction of proteasome by HIV-1. It  has been studied that circulating
virus or envelope proteins may also cause BBB dysfunction during primary infection. CNS
infection of HIV is detected by viral RNA load in CSF (Woods et al., 2009; Morgan et al.,
2011).  Chemokines  like  monocyte  chemoattractant  protein  (MCP)-1  control  PBMCs
relocation through BBB.  Cellular  migration engages  adhesion molecules  and differential
regulation of  inflammatory cytokines,  leading to BBB disintegration and finally immune
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dysregulation by letting sufficient entry of infected or activated immune cells into the brain
causing neuronal injury.
6. Types of CNS cells invaded by HIV-1
BBB is selectively permeable, made up of firmly concurrent brain microvascular endothelial
cells, and its major role is to separate the CNS from the periphery. It manages the trafficking
of cells and molecules across it into the brain parenchyma. For the purpose of brain entry,
HIV-1 has to cross the BBB using several mechanisms which are still poorly understood and
are unclear. Numerous in vitro experimentations have been done to understand the mecha‐
nisms of HIV-1 introduction into the CNS via BBB. It is reported that the severity of HIV-1
associated neuropathogenesis is dependent on amount of HIV DNA circulating in PBMCs
(Shiramizu et al., 2009). It is hypothesized that HIV-1 enters the CNS, in disguise as a commuter
in cells trafficking till the brain (Verma et al., 2010). CD4+ cells, like T cells and monocytes are
infected by HIV-1, which circulate in blood and have the ability to cross the BBB and introduce
the infection into CNS. Though presence of CD4 receptors in human brain microvascular
endothelial cells is still a matter of debate whereas its presence is studied along with expression
of HIV-1 co-receptors have also being reported on primary human brain's microvascular
endothelial cells. Other proposed hypothesis for the entry of HIV-1 is the migration between/
transcytosis of endothelial cells. All types of the CNS cells like astrocytes (Wang et al., 2009),
oligodendrocytes, neurons, macrophage and microglia, are easily infected by HIV-1 as they
have receptors and co-receptors for HIV-1 entry, but only macrophage and microglia get
infected most commonly which are the resident immunocompetent cells of the brain (Gen‐
dleman et al., 1985). Expression of CCL2/MCP-1 in astrocytes is enhanced by nef via calmodulin
dependent pathway. Consequently, increased CCL2/MCP-1 functions as a chemoattractant for
monocytes, thereby facilitating entry of monocytes into the brain (Lehmann et al., 2006).
Peripheral macrophage population is necessary to be refilled, which is compensated by the
migration of monocytes into the CNS, resulting in major drawback of facilitating the entry of
intracellular virus. Microglia and monocyte-derived macrophages are the main culprits of
HIV-1 CNS infection. Immunostaining experiments have shown HIV-1 infection in parenchy‐
mal microglia, but it is still unclear that whether the HIV-1 immunopositive microglia receives
influx of infected cells from blood or directly results from prolonged infection in the CNS. In-
vitro experiments demonstrate that HIV-1 replication takes place in primary microglia isolated
from adults and infants leading to cytopathology. Microglial cells are the major targets as they
express CD4/CCR5 major receptors/co-receptors which is a necessity for HIV-1 infection. On
the other hand astrocytes express CXCR4 and other HIV-1 coreceptors like CCR5, but do not
express CD4 receptors and are still reported to be infected by HIV-1 mechanisms to which are
still unclear. Also in vivo, oligodendrocytes infection by HIV-1 remains unclear and less
understood as they do not have CD4 receptors. Mostly there is absence of in vivo infection in
neurons, however sometimes presence of HIV-1 DNA and proteins in neurons have been
reported too, leading to need of further studies. Various pathways for the entry of virus into
the brain have been studied like (i) direct entry, (ii) transcytosis, (iii) Trojan horse hypothesis
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for entry, which states that HIV enters the CNS via infected CD4 + AND T-cells which are
capable of crossing BBB and they reach CNS and are also capable of transferring infection to
other CNS cells too (Fig. 2).
Figure 2. HIV-1 neuroinvasion. 1) "Trojan Horse hypothesis" for entry of HIV-1 into the brain via migration of infected
monocytes which differentiate into perivascular macrophage. 2) The passage of infected CD4+ T cells into the brain.
Other probable causes of CNS infection might be: 3) the direct entrance of the virus via tight junctions across the
membrane and 4) entrance of HIV-1 by transcytosis phenomenon.
7. Crosstalk between the peripheral and CNS immunity
The way by which HIV-1-infected monocytes escape immune surveillance can be explained
by “Trojan horse cell” model. The “support” needed for the viral entry is through CNS-
produced chemokines like MCP-1 and IFN-γ-inducible peptide, CXCL10, whereas the
“opposition” is through peripheral immune activation (Yadav et al., 2009). Upon entry in the
brain, HIV-1-infected blood-borne macrophages secrete proinflammatory cytokines like
tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and viral proteins which affect
neuronal function (Brabers and Nottet, 2006). Within the brain, astrocytes serve as principal
regulators for neural homeostasis. They bring out a neurotoxic secretory response in macro‐
phages, resulting to upregulation of certain acids and metabolites, chemokines, and cytokine
secretions. They can also alter macrophage phenotype, which may help in neuroprotection.
But on the contrary astrocytes can also influence autocrine and paracrine inflammatory
cascades, which may lead to immune activation, increased viral infection, and allowance of
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cellular entry via BBB (Kraft-Terry et al., 2010). Also CD16+ monocytes are linked to infection
of the brain as they can be easily infected by the virus, they carry virus into the brain and help
in viral dissemination and serve as viral reservoirs as they are apoptosis resistant. HIV proteins
like nef require adaptive selection in brain for efficient replication in macrophages or when it
is exposed to brain specific immune selection (Olivieri et al., 2010). Neuropsychiatric disorders
associated with HIV infection result in substantial morbidity and fatality. HIV injures the CNS
and PNS, leading to neuropsychiatric disorders, which together constitute for neuroAIDS
(McCombe et al.,2009), which includes neurocognitive disorders like HAD, minor neurocog‐
nitive disorder (HAND), mania, anxiety, depression, seizures, myelopathy and neuropathy,
and also involves display of several symptoms like neurocognitive impairment, mood
disorders, neuropathic pain, epilepsy, addiction, physical disability, loss of memory, mood
swings etc (Fig.3).
Figure 3. Associated disorders and symptoms which are commonly seen in patients suffering from neuroAIDS.
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8. Forms of dementia
One form of dementia is Alzheimer’s disease caused by amyloid pathology, during which
peptides of amyloid-β generate and clump together into plaques which release toxic fragments
of amyloid-β leading to neuropathogenesis. Another form of dementia is caused by vascular
pathology in which blood vessels leak and hence deprives small areas of the brain of blood
and oxygen, which damage brain tissue resulting in cognitive defects. Both forms exist equally,
even though Alzheimer pathology is more common, but it coexists with vascular pathology.
(Abott et al., 2011).
TYPES OF DEMENTIA






leading to confusion, disinterest
depression and bad judgement
skills.
Formation of amyloid plaques
and also neurofibrillary tangles.
50–80%
Vascular dementia
Memory is weakened, but not as
intense as in the case of
Alzheimer’s patients.
Causing microstrokes due to





swings and difficulty in
understanding different
languages.






leading to confusion, disinterest
depression and bad judgement
skills, hallucinations and tremors.




Table 1. Displaying the types of dementia and their prevelance. (Source: Abbott A. Dementia: a problem for our age.
Nature. 2011; 475(7355): S2-4)
9. Knowing dementia and its diagnosis
Dementia is considered as loss of memory and other cognitive abilities which reduces the
lifespan of patients. Dementia is often associated with physical, mental and financial burden.
37% of the dementic population in developing countries have vulnerable living environ‐
ment and they require specialised care. Diagnosis of dementia involves investigations for
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decline  in  memory  and  disturbance  in  several  cognitive  abilities  like  coherent  speech,
understanding  spoken  or  written  language,  recognizing  objects,  executing  motor  activi‐
ties, sensory function, thinking abstractly, making sound judgments, planning and carrying
out  complex  tasks.  Dementia  reduces  the  lifespan  of  affected  people.  In  the  developed
countries life span after dementia diagnosis can be expected to be ~7 years, but in low and
middle income countries survival may be shorter. Dementia symptoms and linked issues
can  be  understood  in  three  stages  of  early  stage  (1-2  years)  which  is  often  overlooked
because the onset  of  dementia  is  gradual,  making it  difficult  to  predict  when it  begins,
leading to problems in talking, memory loss. Secondly, the middle stage (2-5 years) which
makes patients life more difficult and restricted, giving them difficulty in day-to-day living
and forgetting  recent  events  and people’s  names,  etc.  Thirdly,  the  late  stage  (>5  years)
leading  to  total  dependence  and  inactivity,  serious  memory  disturbances  difficulty  in
physical works like walking, eating, incapability of communicating, not recognizing familiar
objects, displaying inappropriate behavior in public etc.
HIV associated dementia, referred as the syndrome of cognitive and motor dysfunction
resulting in progressive neurodegeneration observed after infection with human HIV-1, also
known as HIV encephalopathy (HIV-E) and AIDS dementia complex (ADC) (Kaul et al.,
2001). In the last stage of HIV, HAD a severe neurological complication affects 15–20% of the
patients (Van de Bovenkamp et al., 2002). The relationship between spreading of HIV in brain
tissue and pathology has not been thoroughly assessed in HAART era (Lamers et al., 2010).
Inspite of preventing former end stage complications of AIDS by HAART however, with
increased survival times, the prevalence of minor HIV-1 associated cognitive impairment
appears to be rising among AIDS patients. Further, HIV-1 associated dementia (HAD) is still
prevalent in treated patients as well as attenuated forms of HAD and CNS opportunistic
disorders (Ghafouri et al., 2006). Infected macrophages with HIV have an ability to cross BBB
infect inhabitant brain macrophages initiating the development of HAD. Cytokines are
released from infected resident brain macrophages which further attract more macrophages
to sites of infection and a series of self-inflammatory process emerges (Williams et al., 2002).
Studies have suggested that the process of entering in the CNS causing HAD mostly depends
on the HIV variants as some HIV variants have capability of entering in the CNS and develops
HAD but in contrast other variants don’t have capability to develop HAD even after entering
in the CNS (Fischer-Smith et al., 2008; Fischer-Smith et al., 2005).
10. Underlying mechanisms and issues
Some studies suggest that neurological involvement of infected patients occurs at differ‐
ent frequencies, depending on the HIV subtype involved in the infection (Liner 2nd et al.,
2007). HIV-1 Subtype D has more prominent chance for developing dementia (89%) than
subtype A (24%) in the patients localized in a region of Uganda, Africa suggesting genetic
determinants  exist  within  HIV that  influence  the  ability  of  the  virus  to  replicate  in  the
central nervous system. HIV-1 proteins have been shown to be released from HIV infected
cell  and/  or  they  have  found  to  be  present  in  the  extracellular  milieu  in  the  HIV-1-
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8. Forms of dementia
One form of dementia is Alzheimer’s disease caused by amyloid pathology, during which
peptides of amyloid-β generate and clump together into plaques which release toxic fragments
of amyloid-β leading to neuropathogenesis. Another form of dementia is caused by vascular
pathology in which blood vessels leak and hence deprives small areas of the brain of blood
and oxygen, which damage brain tissue resulting in cognitive defects. Both forms exist equally,
even though Alzheimer pathology is more common, but it coexists with vascular pathology.
(Abott et al., 2011).
TYPES OF DEMENTIA






leading to confusion, disinterest
depression and bad judgement
skills.
Formation of amyloid plaques
and also neurofibrillary tangles.
50–80%
Vascular dementia
Memory is weakened, but not as
intense as in the case of
Alzheimer’s patients.
Causing microstrokes due to





swings and difficulty in
understanding different
languages.






leading to confusion, disinterest
depression and bad judgement
skills, hallucinations and tremors.




Table 1. Displaying the types of dementia and their prevelance. (Source: Abbott A. Dementia: a problem for our age.
Nature. 2011; 475(7355): S2-4)
9. Knowing dementia and its diagnosis
Dementia is considered as loss of memory and other cognitive abilities which reduces the
lifespan of patients. Dementia is often associated with physical, mental and financial burden.
37% of the dementic population in developing countries have vulnerable living environ‐
ment and they require specialised care. Diagnosis of dementia involves investigations for
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makes patients life more difficult and restricted, giving them difficulty in day-to-day living
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objects, displaying inappropriate behavior in public etc.
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appears to be rising among AIDS patients. Further, HIV-1 associated dementia (HAD) is still
prevalent in treated patients as well as attenuated forms of HAD and CNS opportunistic
disorders (Ghafouri et al., 2006). Infected macrophages with HIV have an ability to cross BBB
infect inhabitant brain macrophages initiating the development of HAD. Cytokines are
released from infected resident brain macrophages which further attract more macrophages
to sites of infection and a series of self-inflammatory process emerges (Williams et al., 2002).
Studies have suggested that the process of entering in the CNS causing HAD mostly depends
on the HIV variants as some HIV variants have capability of entering in the CNS and develops
HAD but in contrast other variants don’t have capability to develop HAD even after entering
in the CNS (Fischer-Smith et al., 2008; Fischer-Smith et al., 2005).
10. Underlying mechanisms and issues
Some studies suggest that neurological involvement of infected patients occurs at differ‐
ent frequencies, depending on the HIV subtype involved in the infection (Liner 2nd et al.,
2007). HIV-1 Subtype D has more prominent chance for developing dementia (89%) than
subtype A (24%) in the patients localized in a region of Uganda, Africa suggesting genetic
determinants  exist  within  HIV that  influence  the  ability  of  the  virus  to  replicate  in  the
central nervous system. HIV-1 proteins have been shown to be released from HIV infected
cell  and/  or  they  have  found  to  be  present  in  the  extracellular  milieu  in  the  HIV-1-
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infected brain.  In vitro,  neurotoxic and/or neuromodulatory effects have been shown by
HIV proteins: nef, env, tat, rev, vpr and vpu that might play a role in the development of
HIV-1-associated dementia in vivo (Sactor et al., 2009).
11. Fight against dementia
Dementia is engulfing bigger proportion of HIV patients and is expected to worsen more. It is
expected that a significant proportion of dementia is driven by amyloid-β. But so far none of
the amyloid-based strategies has been successful, but still drug developers are strategising on
the concept which can combat against it. More reliable biomarkers are being developed
potentially making it possible to carry out trials on patients before symptoms. Some scientists
are also wondering to target vascular pathology as well, which is equally responsible for
causing dementia. So cholesterol level lowering drugs and blood pressure reducing drugs are
also given long term to patients, who are at higher risk of heart attack which may also help
protect from dementias as well (Abott et al., 2011). There are several extracellular and intra‐
cellular signalling pathways, which when activated lead to macrophage or microglial activa‐
tion, and induction in neurons and astrocytes. These pathways may act as a potential
therapeutic importance as drug targets against neuropathogenesis. NeuroAIDS is challenge
to patients, their families, society and our country, thus development of preclinical models
appropriate for new compounds testing with neurotrophic and neuroprotective potential is
necessary (Crews et al., 2008; Williams et al., 2008).
12. Therapeutic developments
The biggest issue which comes in front of drug developers is the incapability of the drugs to
cross the BBB, which leads to low bioavailability of the drugs into the CNS. HIV-1 protease
inhibitors are totally incapable in entering the CNS, while other HIV-1 therapies such as
zidovudine (AZT) are reported to have efficient BBB penetration. Recently, a broad range of
nanomedicines are being developed to improve drug delivery across BBB, development of
nanoparticulate– antiretroviral therapy (nanoART), against CNS disorders as the structure of
the BBB, efflux pumps and the expression of metabolic enzymes make it difficult for the regular
drug to reach brain. Nanoformulations can evade the BBB and can boost CNS-directed drug
delivery (Fig. 4) (Saxena et al., 2012; Nowacek et al., 2010; Nowacek et al., 2009). Efforts are been
done in finding long-lasting injectable antiretrovirals to avoid the challenges of therapy
adherence (Baert et al., 2009). To specifically target the CNS, NPs are synthesized with various
combinations of ART therapies to be taken up by monocytes and carried into the CNS for
release at sites of HIV-1 infection, for example Indinavir nanoART and p24 loaded and coated
NP, which are providing new avenues for treating or even preventing the spread of HIV-1 in
the brain. Adjunctive therapeutics ART is engaged in making combinatory drugs against virus
mutation. Efforts are being made to improve penetrability of ART across the BBB, but impor‐
tance of considering drug toxicity and elicited cellular response for various ART regiments is
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always a necessity. Adjunctive therapy like platelet-activating factor (PAF) antagonist,
PMS-601, are demonstrated to reduce HAND symptoms and even combination of ART and
PAF antagonists, are also studied to have role in reducing neurodegeneration. All of these are
also being developed as therapies for neurodegenerative disorders which may prove to be a
boon in the combat against NeuroAIDS. Need of the hour is to device an exact combination of
CNS-penetrating nanoART and adjunctive therapies, which might be able to help us against
neurocognitive symptoms (Kraft-Terry et al., 2010).
Figure 4. Comparative display of nanocarrier mediated method of drug delivery (A) versus the classical method of drug de‐
livery across the Blood Brain Barrier (BBB), which is less efficient than the former in the process of drug delivery.
13. Future implications and need of the hour
Since dementia is quite prevalent in HIV patients, in developed countries and has also been
reported to extend its grip towards developing countries as well due to increase in patient
survival rates and life expectancy due to HAART treatment and increased living standards.
Low prevalence of HAD in underdeveloped and developing countries have been attributed
to under diagnosis, short life expectancy and short survival following HIV infection associated
with opportunistic infections and also low prevalence of HIV related neuroinfections and
pathology is not available due to inadequate medical facilities, social stigma and ignorance
that lead to under diagnosis (Vivithanaporn et al., 2010). So a need of collaboratory studies is
there which can be used, for learning the cause, prevalence and diagnosis of neuropathogen‐
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infected brain.  In vitro,  neurotoxic and/or neuromodulatory effects have been shown by
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Dementia is engulfing bigger proportion of HIV patients and is expected to worsen more. It is
expected that a significant proportion of dementia is driven by amyloid-β. But so far none of
the amyloid-based strategies has been successful, but still drug developers are strategising on
the concept which can combat against it. More reliable biomarkers are being developed
potentially making it possible to carry out trials on patients before symptoms. Some scientists
are also wondering to target vascular pathology as well, which is equally responsible for
causing dementia. So cholesterol level lowering drugs and blood pressure reducing drugs are
also given long term to patients, who are at higher risk of heart attack which may also help
protect from dementias as well (Abott et al., 2011). There are several extracellular and intra‐
cellular signalling pathways, which when activated lead to macrophage or microglial activa‐
tion, and induction in neurons and astrocytes. These pathways may act as a potential
therapeutic importance as drug targets against neuropathogenesis. NeuroAIDS is challenge
to patients, their families, society and our country, thus development of preclinical models
appropriate for new compounds testing with neurotrophic and neuroprotective potential is
necessary (Crews et al., 2008; Williams et al., 2008).
12. Therapeutic developments
The biggest issue which comes in front of drug developers is the incapability of the drugs to
cross the BBB, which leads to low bioavailability of the drugs into the CNS. HIV-1 protease
inhibitors are totally incapable in entering the CNS, while other HIV-1 therapies such as
zidovudine (AZT) are reported to have efficient BBB penetration. Recently, a broad range of
nanomedicines are being developed to improve drug delivery across BBB, development of
nanoparticulate– antiretroviral therapy (nanoART), against CNS disorders as the structure of
the BBB, efflux pumps and the expression of metabolic enzymes make it difficult for the regular
drug to reach brain. Nanoformulations can evade the BBB and can boost CNS-directed drug
delivery (Fig. 4) (Saxena et al., 2012; Nowacek et al., 2010; Nowacek et al., 2009). Efforts are been
done in finding long-lasting injectable antiretrovirals to avoid the challenges of therapy
adherence (Baert et al., 2009). To specifically target the CNS, NPs are synthesized with various
combinations of ART therapies to be taken up by monocytes and carried into the CNS for
release at sites of HIV-1 infection, for example Indinavir nanoART and p24 loaded and coated
NP, which are providing new avenues for treating or even preventing the spread of HIV-1 in
the brain. Adjunctive therapeutics ART is engaged in making combinatory drugs against virus
mutation. Efforts are being made to improve penetrability of ART across the BBB, but impor‐
tance of considering drug toxicity and elicited cellular response for various ART regiments is
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always a necessity. Adjunctive therapy like platelet-activating factor (PAF) antagonist,
PMS-601, are demonstrated to reduce HAND symptoms and even combination of ART and
PAF antagonists, are also studied to have role in reducing neurodegeneration. All of these are
also being developed as therapies for neurodegenerative disorders which may prove to be a
boon in the combat against NeuroAIDS. Need of the hour is to device an exact combination of
CNS-penetrating nanoART and adjunctive therapies, which might be able to help us against
neurocognitive symptoms (Kraft-Terry et al., 2010).
Figure 4. Comparative display of nanocarrier mediated method of drug delivery (A) versus the classical method of drug de‐
livery across the Blood Brain Barrier (BBB), which is less efficient than the former in the process of drug delivery.
13. Future implications and need of the hour
Since dementia is quite prevalent in HIV patients, in developed countries and has also been
reported to extend its grip towards developing countries as well due to increase in patient
survival rates and life expectancy due to HAART treatment and increased living standards.
Low prevalence of HAD in underdeveloped and developing countries have been attributed
to under diagnosis, short life expectancy and short survival following HIV infection associated
with opportunistic infections and also low prevalence of HIV related neuroinfections and
pathology is not available due to inadequate medical facilities, social stigma and ignorance
that lead to under diagnosis (Vivithanaporn et al., 2010). So a need of collaboratory studies is
there which can be used, for learning the cause, prevalence and diagnosis of neuropathogen‐
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esis. A synchronised effort is needed by researchers, drug makers, physicians, policy makers,
government bodies nationally as well as globally. A proper and deep understanding about the
entry of the virus into the CNS and the various mechanisms it employs to undertake the host
machinery would be of great help in understanding the issue and combating against the virus.
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1. Introduction
HIV/AIDS is  probably the most challenging and pressing health issue of  our time.  Cur‐
rent  estimates  show  that  over  40million  people  are  now  living  with  HIV.  Despite  the
availability of  antiretroviral  therapy,  the provision of  this  treatment continues to pose a
big challenge for  various reasons.  Globally,  of  the 6  million people requiring treatment,
only  8% receive  it  –  with  considerable  geographical  inequity  ie.  High income countries
vs.  low income countries.  Despite  understanding  the  risk  factors  for  HIV infection,  the
incidence  of  new  HIV  cases  has  not  reduced  at  an  acceptable  rate.  An  unprecedented
number of people still have no access to treatment and continue to die from HIV related
problems. This has brought about devastating social and economic consequences at coun‐
try level, family level and at personal level. A considerable number of individuals suffer
from mental  disorders  resulting  from being  HIV infected.  Independently,  mental  disor‐
ders  make  a  substantial  independent  contribution  to  the  burden  of  disease  worldwide.
The recognition of  mental  disorders as  a  major contributor to the global  burden of  dis‐
ease has led to an increase in the demand for the inclusion of mental health services in
primary health care as  well  as  in  community-based health surveys in order  to  improve
screening, diagnosis and treatment of mental distress. It is estimated that, neuropsychiat‐
ric  conditions account for  up to 15% of  all  disability-adjusted life-years,  and up to 30%
of  those  attributable  to  non-communicable  diseases.  Neuropsychiatric  disorders  also  ac‐
count for 1.2 million deaths every year.  These figures are most likely underestimated as
official  statistics  especially  in  low and middle  income countries  are  scanty  and unrelia‐
ble. In sub-Saharan Africa, it  has been reported that 20–30% of primary health care cen‐
tre  attendees  present  with  depressive  symptoms  as  the  first  or  secondary  reason  for
seeking medical care. A study conducted in Tanzania revealed a 41.6% prevalence of de‐
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pressive symptoms among primary health care patients while a similar study in Uganda
reported  a  20–30% prevalence  of  psychological  disorders  and  depression  among  health
care seekers. These research findings have also shown heightened risk for common men‐
tal disorders among the women i.e. a female to male ratio of 1.5–2.0. Other determinants
have been found to include low socioeconomic position indicated by poor access  to  re‐
sources,  unemployment  and  low  educational  attainment.  It  has  also  been  shown  to  be
higher among those with poor socio-support networks such as the unmarried, widowed
and divorced. Mental disorders interact with many other health conditions,  communica‐
ble  and  non-communicable.  They  commonly  affect  individuals  with  medical  conditions
and  have  been  associated  with  adverse  impacts  on  several  measures  of  morbidity  and
mortality. Depressed patients have been shown to have worse physical,  social and over‐
all  health than other patients.  Of particular interest  to this chapter is  the interaction be‐
tween HIV and mental distress
2. HIV and mental distress
Early stages of HIV epidemic
In the early stages of the HIV epidemic, the individuals who were affected did not know
that their behaviour predisposed them to a potentially fatal disease. The epidemic also
mushroomed at the time of a liberal and tolerant culture and dis-inhibited sexual restraint.
Hence multiple sexual partners spread the epidemic in communities where these behaviours
were more rampant. Intravenous drug use also contributed to the early spread of the epi‐
demic. In the low and middle income countries, factors surrounding poor socio-economic
position (poor education and low income) and inability to negotiate for condom use due to
the disparity between the male and female gender have emerged as stronger predictors.
Several early and recent epidemiologic studies elucidated these risk factors and more con‐
certed effort was placed on public education directed at prevention. Other more recent inno‐
vations directed at rolling-back HIV infection have included massive male circumcision
campaigns, innovation directed at the girl child to reduce early teenage pregnancies and ear‐
ly marriages and the introduction of Highly Active Anti-Retroviral Therapy (HAART). Re‐
cently efforts have been directed at the role mental distress plays in determining acquisition
of HIV infection, initial individual’s reaction and post-infection adaptation. Further poor
mental health has been associated with subsequent development of AIDS.
Mental distress
Mental distress in the context of this book chapter refers to a term used by users of mental
health services as well as some mental health practitioners in describing a wide array of ex‐
periences of a patient's life that commonly manifest as somatic symptoms and held to be out
of the ordinary, distressing, troubling or confusing for the patient, without actually being ill
in the medical sense. Chipimo and Fylkesnes identified some of the common causes of men‐
tal distress in a study conducted among primary health care centers in Zambia. (Table 1)
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Category of factor Frequency Symptoms/comments
Worries about money 51 Concerns about rent, day-to-day living, school fees
Problems of the mind 47 Recurrent headaches, sleeplessness, unhappiness, trouble thinking,
loss of appetite, night mares
Unknown cause of symptoms 32 Most common among informants not acknowledging symptoms as
an illness or as mental distress, suggested witchcraft
Relationship with spouse and
family members
26 Commonest among women, included crying more than usual,
unhappiness, headaches, sleeplessness.
Ill health 24 Sleeplessness, daily life suffering, inability to play useful role in life,
tiredness
Low self-esteem 16 Worthlessness, loss of interest, unhappiness, crying more than usual,
difficulty enjoying daily activities, experience of stigma
Recent life events 6 Bereavement, divorces, newly diagnosed with chronic disease
including HIV. Included symptoms of restlessness, sleeplessness,
trouble thinking, headache, unhappiness
Table 1. Factors associated with Mental Distress as identified by the informants (Chipimo & Fylkesnes, 2011)
The term mental distress is seen by users of mental health services as less stigmatizing as it
fits better with the social model of disability, since everyone experiences mental distress at
one time or the other. The other synonym is psychological distress. The term is also often
preferred as they feel it better captures the uniqueness and personal nature of their experi‐
ences. Mental distress is often thought of as being a concept with a wider scope than the reg‐
ularly used traditional term, mental illness. The later being a specific set of symptoms
medically defined in psychiatry, for example: Mania, schizophrenia, anxiety disorders, de‐
pression etc. Difficult life situations such as: poor social-support structures, bereavement,
stress, poor sleep, drug and alcohol abuse can induce mental distress. These inducers could
be temporary and resolve without further medical intervention. However individuals who
have protracted episodes and endure such symptoms longer are more likely to be diagnosed
with mental illness. This definition is not without controversy and often these terms are
used interchangeably.
Double tragedy
Mental distress has been recognised as a crucial factor to some individual’s ability to modify
their behaviour to prevent HIV infection. With effective treatment options now available,
care for HIV has become more dynamic and has transformed the HIV squeal from terminal
care to chronic care. This further complicates the scenario as mental disorders have further
been recognised as severely complicating treatment. These factors work in tandem with HIV
causing direct damage on the brain, creating turmoil in the lives of the infected and further
exacerbates mental disorders. Further the mental disorders reduce the individual’s ability to
effectively change behaviour thus increasing the risk of infection and morbidity. Published
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Worries about money 51 Concerns about rent, day-to-day living, school fees
Problems of the mind 47 Recurrent headaches, sleeplessness, unhappiness, trouble thinking,
loss of appetite, night mares
Unknown cause of symptoms 32 Most common among informants not acknowledging symptoms as
an illness or as mental distress, suggested witchcraft
Relationship with spouse and
family members
26 Commonest among women, included crying more than usual,
unhappiness, headaches, sleeplessness.
Ill health 24 Sleeplessness, daily life suffering, inability to play useful role in life,
tiredness
Low self-esteem 16 Worthlessness, loss of interest, unhappiness, crying more than usual,
difficulty enjoying daily activities, experience of stigma
Recent life events 6 Bereavement, divorces, newly diagnosed with chronic disease
including HIV. Included symptoms of restlessness, sleeplessness,
trouble thinking, headache, unhappiness
Table 1. Factors associated with Mental Distress as identified by the informants (Chipimo & Fylkesnes, 2011)
The term mental distress is seen by users of mental health services as less stigmatizing as it
fits better with the social model of disability, since everyone experiences mental distress at
one time or the other. The other synonym is psychological distress. The term is also often
preferred as they feel it better captures the uniqueness and personal nature of their experi‐
ences. Mental distress is often thought of as being a concept with a wider scope than the reg‐
ularly used traditional term, mental illness. The later being a specific set of symptoms
medically defined in psychiatry, for example: Mania, schizophrenia, anxiety disorders, de‐
pression etc. Difficult life situations such as: poor social-support structures, bereavement,
stress, poor sleep, drug and alcohol abuse can induce mental distress. These inducers could
be temporary and resolve without further medical intervention. However individuals who
have protracted episodes and endure such symptoms longer are more likely to be diagnosed
with mental illness. This definition is not without controversy and often these terms are
used interchangeably.
Double tragedy
Mental distress has been recognised as a crucial factor to some individual’s ability to modify
their behaviour to prevent HIV infection. With effective treatment options now available,
care for HIV has become more dynamic and has transformed the HIV squeal from terminal
care to chronic care. This further complicates the scenario as mental disorders have further
been recognised as severely complicating treatment. These factors work in tandem with HIV
causing direct damage on the brain, creating turmoil in the lives of the infected and further
exacerbates mental disorders. Further the mental disorders reduce the individual’s ability to
effectively change behaviour thus increasing the risk of infection and morbidity. Published
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literature showing that individuals with pre-existing mental disorders are at increased risk
for contracting HIV/AIDS has been largely indirect. However consistent reports from sever‐
al countries have suggested that individuals with mental disorders have a higher sero-prev‐
alence for HIV/AIDS and that mental distress generally precedes HIV infection. This is valid
given that significant risk of HIV transmission exists within an individual’s network. Fre‐
quencies of 30-60% behavioural risk factors that have been identified among individuals
with mental distress include: high rates of unprotected sexual contact, poor adherence to
condom use and injection-drug abuse. In a study conducted among gay men with depres‐
sive symptoms, use of alcohol and drugs before sex were identified as independent predic‐
tors for sero-conversion. In a systematic review comparing an HIV sero-positive group and
HIV sero-negative control group, the prevalence of depression in the sero-positive group
was two times higher than in the sero-negative (OR 2.0, 95% CI 1.3-3.0).
3. Aetiology of HIV related mental distress
HIV related mental distress can occur in multiple phases in which premorbid psychological
and social adjustment issues play a vital role. Additionally other social factors such as
household income, culture, religion and family circumstances also influence and can alter an
individual’s reaction to a diagnosis of HIV and subsequent adaptation to living with the di‐
agnosis. The same factors have also been shown to influence and pose high risk of being in‐
fected With HIV. Put together all these factors singly or severally affect the clinical
presentation and management of HIV patients. It is as such imperative that these factors are
addressed and assessed in both the Voluntary-Counselling-and-Testing (VCT) and in the
pre-HAART assessment. A self-perpetuating cycle (figure 1) of increasing morbidity ap‐
pears to occur between HIV and mental distress; HIV infection leads to development of
mental distress and/or pre-existing mental distress predispose to HIV infection. In their
study, Chipimo and Fylkesnes (2009) showed that HIV infection has both a direct and indi‐
rect effects on genesis of mental distress.
Direct effect
HIV infection has been known to affect all other organ systems in the human body and is
said to have replaced syphilis as the “great imitator” in the central nervous system (CNS)
and almost any psychiatric or neurological presentation is possible. The CNS is the second
most commonly affected organ in patients with AIDS. HIV can cause direct organic brain
tissue damage thus leading to the development of mental disorders (Psychotic and non-psy‐
chotic). Virtually any mental disorder is possible. Among the most notable are depression
and anxiety, personality disorders and dementia. The mechanisms explaining the develop‐
ment of these mental disorders are largely poorly understood but the presence of HIV-1-
binding sites in the brain (chemokine receptors) allows HIV-1 to infect macrophages and
microglia. It is however thought that it does not affect neurons, although neurons are in‐
jured and die by apoptosis. The pathway to neuronal injury is thought to be through release
of macrophage, microglial and astrocyte toxins alongside the contribution of direct injury on
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the neurons by viral proteins. These toxins overstimulate neurons, resulting in the formation
of free radicals and excitotoxicity, similar to other neurodegenerative diseases.
Figure 1. Self-perpetuating cycle of increasing morbidity: HIV/AIDS and Mental Distress (Chipimo, 2011)
Many HIV related opportunistic infections may involve the brain and lead to mental disor‐
ders. The four most frequent conditions are toxoplasmosis, progressive multifocal leukoen‐
cephalopathy (PML), cryptococcosis and cytomegalovirus infection. Although the incidence
of these infections among patients with AIDS has decreased in the past years as a conse‐
quence of the introduction of highly active antiretroviral therapy (HAART), they remain a
major cause of morbidity and mortality in this patient group. However, highly active antire‐
troviral drugs themselves such as, Zidovudine, Didanosine and Effervirenz have been asso‐
ciated with development of manic episodes
Indirect effect
Chipimo and Fylkesnes (2009) studied the relationship between HIV and mental distress
in a  population with high prevalence of  HIV infection and low awareness  of  own HIV
sero-status.  In  this  study structural  equation modeling (SEM) was used to  establish  the
relationship between HIV infection and mental  distress using maximum likelihood ratio
as  the  method of  estimation.  The  model  indicated that  underlying  factors  such as  resi‐
dence (rural or urban), level of education, marital status and age were inter-correlated as
determinants for mental distress.  Further Mental distress was found to be directly relat‐
ed to  self-perceived risk  and worry  about  being  HIV infected,  HIVsero-status  and self-
rated  health.  Further  indirect  inter-relationships  were  also  found  between  self-rated
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health,  self-perceived risk and worry about being HIV infected,  and the underlying fac‐
tors,  namely  age,  residence,  socio-economic  position and education.  Therefore  self-rated
health and self-perceived risk and worry about being HIV infected appear to be impor‐
tant mediators between underlying factors and mental  distress.  They are also important
mediators  between HIV status  and mental  distress.  The  results  suggest  that  HIV infec‐
tion  has  a  substantial  effect  on  mental  distress  both  directly  and  indirectly.  This  effect
was  mediated  through  self-perceptions  of  health  status,  found  to  capture  changes  in
health  perceptions  related  to  HIV,  and  self-perceived  risk  and  worry  of  actually  being
HIV infected.
4. Prevalence of HIV related mental distress
Prevalence studies conducted world over have shown that when compared to the gener‐
al population, mental disorders where considerably higher among the HIV infected indi‐
viduals.  However  most  of  these  studies  have  been  conducted  in  the  high  income
countries  were the disease burden is  relatively low and confined to selected groups for
example  Injection  drug  users  and  Homosexuals.  Similar  data  in  sub-Saharan  Africa,
where  the  HIV  epidemic  has  its  worse  impact  is  limited.  Therefore,  given  that  mental
disorders manifest in the majority of HIV infected individuals over the course of the ill‐
ness, a simple assumption would then be that the prevalence reported in published stud‐
ies represent an underestimate of the actual prevalence. A meta-analytic study identified
13 studies  on mental  disorders  and HIV infection in low and middle income countries.
The prevalence of mental disorders varied widely among these studies. Most of the stud‐
ies done in Africa with HIV positive participants have shown differing but high percen‐
tages of mental distress, for example, Orange free state, South Africa 40%, rural Ethiopia
14%  and  Botswana  28%.  In  a  study  done  in  Zambia,  Chipimo  and  Fylkesnes  (2009)
found a 13% prevalence of mental distress within the general population with a 2.0 high‐
er  odds  ratio  among the  HIV infected.  In  Uganda,  Musisi  et.  al.  (2006)  showed a  42%
prevalence of depression among HIV infected individuals while in another study, Musisi
& Kinyanda reported a prevalence of 41% among HIV infected adolenscents.
5. Presentation of HIV related mental distress
Diagnosis of mental disorders in HIV infection is a relatively rarely made diagnosis in sub-
Saharan Africa. Studies have reported that physicians tend to be oblivious to psychological
problems in HIV in the presence of a physical ailment. Further, the clinical presentation of
mental distress in HIV infection presents a diagnostic challenge. This is often because the
clinical Indictors of mental disorders are often masked by the symptoms of HIV infection. It
is also a challenge for health care providers to distinguish between mental distress and grief.
This calls for careful history taking that probes for previous history of mental disorders in
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the patient, suicide attempts, family history of mental illness, poor social support structures
and a history of recent adverse events (deaths in family, physical violence, divorce, stigma).
Symptoms
Several studies have shown that mental distress often presents as somatisation. In a popula‐
tion based survey, Chipimo and Fylkesnes (2009) reported that the most frequently reported
symptoms among the HIV infected were:
1. difficulty enjoying life,
2. feeling that their daily life was suffering,
3. poor sleep
4. low energy levels.
Among patients attending Primary Health Care, the most commonly reported symptoms
observed by Chipimo and Fylkesnes (2010) were:
1. feelings of unhappiness,
2. loss of interest,
3. inability to enjoy daily life,
4. poor sleep
5. frequent headaches
Women reported these symptoms more than men in both studies. Musisi and Akena (2009)
reported similar battery of symptoms and further added that, an otherwise asymptomatic
HIV infected individual presenting with symptoms of fatigue and insomnia should be as‐
sessed for severe depression. These and other more pathognomonic symptoms put together
allow clinicians to make a diagnosis of a full blown psychiatric disorder. The recognised
HIV related psychiatric disorders are:
1. Anxiety disorders and depression




6. Drug abuse ie. Substance and Alcohol abuse
6. Impact of HIV related mental distress on course and prognosis
There is a general lack of reported/ published follow-up studies on HIV related mental dis‐
tress. However left untreated mental distress has an effect on the cell mediated immunity,
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allow clinicians to make a diagnosis of a full blown psychiatric disorder. The recognised
HIV related psychiatric disorders are:
1. Anxiety disorders and depression




6. Drug abuse ie. Substance and Alcohol abuse
6. Impact of HIV related mental distress on course and prognosis
There is a general lack of reported/ published follow-up studies on HIV related mental dis‐
tress. However left untreated mental distress has an effect on the cell mediated immunity,
Human Immunodeficiency Virus Infection and Co-Morbid Mental Distress
http://dx.doi.org/10.5772/53696
131
where it causes impairments in T-cell mediated functions, reduced natural-killer cell counts
and cytotoxicity. Depression in particular, has reproducibly been associated with decreased
numbers and altered functioning of natural killer lymphocytes. It can also lead to an in‐
crease in activated CD8 T lymphocytes and viral load. By so doing mental distress can pre‐
dict the onset and progression of both physical and social disability in HIV infection.
Further, Co-morbid mental distress can delay health seeking hence reducing the likelihood
of diagnosis and so can affect treatment and outcome in HIV infection. They may also ad‐
versely affect adherence to medication and activities to prevent disease and promote health.
7. Management
Mental disorders episodes are known to cluster around specific times in the course of the
illness, such as, the period of diagnosis of HIV, period when the infected individual starts
declining in health or the period in the early stages of HIV dementia. However, an episode
of mental distress can occur at any point in the course of the illness. In the early stages social
support alone can suffice alongside psychotherapy. However, in the later stages anti-depres‐
sants such as Imipramine or Amitriptyline can be used. Selective serotonin re-uptake inhibi‐
tors such as Fluoxetine may also be prescribed.
However the mainstay of management should fall around the time of diagnosis with ade‐
quate pre and post testing counseling surrounding the HIV test. The HIV counseling process
should also be optimized to conditions that allow for higher acceptability of the counseling
process. A Clinical trial study conducted in Zambia showed higher acceptability for Home-
based-Voluntary-Counseling and testing as opposed to facility based counseling. Such inno‐
vative means of facilitating the counseling process will by induction lead to better
acceptance of the HIV sero-status thus preventing subsequent maladjustment disorders.
This has been shown in literature to reduce the risk of suicide at the initial diagnosis. Addi‐
tionally follow-up counseling at every stage in the disease process emphasizing safer sex
should be promoted alongside care giver support. This support should especially be extend‐
ed to the most vulnerable; the women, children, orphans and those of low socio-economic
position in society.
8. Conclusion
Mental disorders are common place in HIV infection and potentiate the course, progression
and prognosis of the HIV disease process. The direct and indirect impact of HIV on the in‐
fected individual has conversely also been associated with mental distress episodes. Mental
disorder and HIV/AIDS also have a lot of socio-demographic factors in common that have
been attributed to each of their development. Therefore, a combination of these two disease
entities leads to devastating morbidity and mortality, especially in the most affected com‐
munities. This thus emphasizes the need for prompt screening, diagnosis and treatment of
mental distress in HIV infection.
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1. Introduction
Human immunodeficiency virus, or HIV, is the virus that causes acquired immune deficiency
syndrome (AIDS). The acquired immunodeficiency syndrome (AIDS) was first described in
1981 in USA. In 1983, human immunodeficiency virus type-1 (HIV-1) was isolated, and in the
following year it was demonstrated clearly that it was the causative agent of AIDS. The disease
is a major health problem in many parts of the world. The high prevalence and striking diversi‐
ty of neurological disorders complicating AIDS were recognized in 1983 (Snider et al., 1983).
AIDS was associated with distinct neurological syndromes, such as dementia, myelopathy and
painful neuropathy that appeared to result from the HIV itself. Over the last 30 years, there has
been increasing recognition of the role that auto antibodies play in neurological disorders. Dur‐
ing the past decade, AIDS has become a global health problem with 182,000 000 cases reported
from 152 countries. It is estimated that nearly five to ten million people are infected worldwide
with HIV-1. With a mean incubation period from time of infection to the development of AIDS
of eight to 10 years, it is projected that nearly all HIV-1-infected individual will develop AIDS
within the next 15 years (Quinn, 1990). It has become increasingly evident that the vast majori‐
ty of HIV-1 infected people will eventually develop AIDS or an AIDS-related condition (De
Wolf and Lange, 1991) with a median time of progression to AIDS of 7-10 years from infection
in adults (Lui et al., 1988; Bacchetti and Moss, 1989) and shorter periods in infants and elderly
patients (Medley et al., 1987; Auger et al., 1988; Lagakos & DeGruttola, 1989). In the United
States alone, 104, 210 cases of AIDS and more than 61,000 deaths have been reported. Sexual,
parenteral as well as perinatal transmission routes have remained the major modes of trans‐
mission, although the proportion of cases within each risk behaviour category has changed.
Recently, there has been a dramatic increase in the proportion of AIDS patients who have ac‐
knowledged as IV drug user or have heterosexual contact with other individuals at high risk
for HIV infection (Quinn, 1990).
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In Sub-Saharan Africa, 22.5 million people living with HIV (68% of the global infections) and
1.6 million AIDS death in 2007 (76% of the AIDS deaths worldwide). In recent years, global ef‐
forts have increased substantially. The most encouraging improvements have been in Sub-Sa‐
haran Africa where the number of people being treated with anti-retrovirals has increased
tenfold from 2003 to 2006 (Peters et al., 2008). The decline of HIV infection in some regions was
partially offset by a rise in new infections in other parts of the globe, particularly in Asia and
Eastern Europe (Delpech & Gahagan, 2009). It was estimated that over 5 million people in
South Asia living with HIV/AIDS. Almost 90% of those infected live in India. Other countries in
the region such as Bangladesh, Pakistan and Nepal have a low HIV prevalence in general pop‐
ulation (Abeysena & De Silva, 2005).
2. Back ground of immune defence mechanisms
Humoral immunity and complement system: immunity that is mediated by secreted antibod‐
ies produced in the cells of the B lymphocyte. Cell mediated immunity : is an immune response
that does not involve antibodies but rather involves the activation of macrophages, natural
(NK), antigen-specific cytotoxic T-lymphocytes.
2.1. Causes of immunosuppression primary: Antibody deficiency, combined antibody
Antibody deficiency, combined antibody and cellular deficiency, Complement deficiency. Ac‐
quired: Extremes of age, Diabetes, Chronic alcoholism, HIV infection, Connective tissue dis‐
eases, Organ failure (renal, hepatic), Malignancy, Iatrogenic (chemotherapy, radiotherapy,
Transplantation). HIV is a retrovirus that primarily infects vital organs of the human immune
system such as CD4+ T cells (a subset of T cells), macrophages and dendritic cells. It directly
and indirectly destroys CD4+ T cells (Alimonti et al 2003).
2.2. Cells affected
The virus entering through which ever route and acts primarily on the following cells: Lym‐
phoreticular system: CD4+ T-Helper cells, Macrophages, Monocytes, B-lymphocytes, Certain
endothelial cells and Central nervous system: Microglia, Astrocytes, Oligodendrocytes, and
Neurones.
2.3. Relation of CD4 T cell count
Neurologic Complications increase with decline in CD4 T cell count. CD4 T cell count > 500/µl –
Earlystage – Demyelinating Neuropathies, CD4 T cell count 200 to 500 – Mid stage – Dementia -
VZV radiculities and CD4 T cell count <200 –advance stage → Dementia, Myelopathy, Painful‐
neuropathy.
2.4. Immune deficiency & clinical disease
Clinical manifestations, Susceptibility to infections, Lymphoreticular malignancies, autoim‐
mune disease.
Current Perspectives in HIV Infection138
3. Neurological menifestations of HIV-1 infections
HIV is neuroinvasive, it does not directly infect neurons. The major brain reservoirs for HIV
infection and replication are microglia and macrophages. Astrocytes can be infected but are
not a site of active HIV replication. HIV-associated neurologic complications are indirect effects
of viral neurotoxins (viral proteins gp120 and tat) and neurotoxins released by infected or
activated microglia, macrophages and astrocytes. Neurologic manifestations occur over the
entire spectrum of HIV disease. Fifty to 70% of patients experienced acute clinical syndrome
1 to 6 wks after infection, Neuro Manifestations occur in 10% involves Multiple Parts of nervous
system. Some Monophonic illness Meningitis, Meningioencephalitis, Seizures, Myelopathy,
Cranial and Peripheral Neuropathy linked to primary HIV and recover within 1 week.
Neurological opportunistic infections and malignancies predominated in early reports, but it
became also clear that AIDS was associated with distinct neurological syndromes, such as
Acute/subacute diffuse encephalopathy Progressive dementia, Focal mass lesions, Acute
stroke like presentation, Meningitis, Multiple cranial neuropathies and Acute/subacute
myelopathy.
3.1. HIV encephalopathy
(AIDS Dementia Complex or HIV associated Dementia) is a late complication of HIV infection
and progresses slowly over months seen in pts with CD4 T cell Count >350cells/µl. Dementia is a
major feature but aphasia, apraxia and afnofia uncommon, motor abnormality like unsteady
gait, poor balance, tremor and in late stage develop apathy & lack of initiative – leads to vegeta‐
tive state mania (table 1). Neuro imaging: MRI & CT demonstrate cerebral atrophy, Basal gan‐
glia calcification in children. CSF: MonoNucleatz cells increase, Protein increase, RNA can be
detected and HIV can be cultured. Infective: CMV ventriculoencephalitis, Varicella encephali‐
tis, Herpes encephalitis, Toxoplasma encephalitis (rare).
Table 1. Clinical staging of HIV Encephalopathy
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Combination anti retro viral therapy is beneficial and rapid improvement in cognitive function.
3.2. HIV-associated dementia
The major direct effect of HIV infection on the immune system is the profound and progressive
loss of CD4 lymphocytes. This leads to impaired cellular immunity, and a dysregulation of mac‐
rophages, with the overproduction of a variety of proinflammatory cytokines and chemokines
(Griffin, 1997). HIV can enter the nervous system early after infection, but productive infection
is rarely detectable before immunosuppression has developed. Based upon phylogenetic anal‐
ysis of HIV gp160, the route of central nervous system (CNS) infection appears to primarily in‐
volve infected monocytes (Liu et al., 2000) as well as free viral particles and HIV proteins
crossing a disrupted blood–brain barrier. The presentation of HIV-D includes cognitive, behav‐
ioral, and motor dysfunction, and suggests a predominant subcortical involvement (Navia et
al., 1986). In the early stages, memory loss, mental slowing, reading and comprehension diffi‐
culties, and apathy are frequent com plaints (Fig. 1) (Mc Arthur et al., 2003).
Figure 1. Frequency of symptoms in HIV dementia among 300 subjects personally examined at JHU HIV Neurology
program (McArthur et al., 2003).
The cognitive deficits of HIV- D are characterized primarily by (1) memory loss that is selective
for impaired retrieval; (2) impaired ability to manipulate acquired knowledge; (3) personality
changes including apathy, inertia, and irritability; and (4) general slowing of all thought
processes. Gait disturbance and impairment of fine manual dexterity are common early
manifestations. Examination findings include impaired rapid movements of eyes and limbs,
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diffuse hyperreflexia, frontal release signs, and sometimes Parkinsonism (Mirsattari et al.,
1998). A recent study suggests that antiretroviral drug combinations with drugs that have
better CSF penetration are associated with greater CSF viral load suppression and may be
associated with greater improvement in neuropsychological test deficits compared to antire‐
troviral drug combinations with drugs that have poor CSF penetration (Letendre et al., 2004).
Antiretroviral drugs with the highest CSF:plasma ratios or with profound effects on viral
replication in the periphery with a resulting decrease in virus entry into the CNS (e.g.,
zidovudine, stavudine, abacavir, nevirapine, efavirenz, and indinavir) are likely to be the most
efficacious for the treatment of HIV-D. Affective: Apathy (depression-like features), Irritability,
Mania, new onset psychosis. Behavioral: Psychomotor retardation (slowed speech or response
time), Personality changes, Social withdrawal. Cognitive: Lack of visuospatial memory
(misplacing things), Lack of vasomotor coordination, Difficulty with complex sequencing
(difficulty in performing previously learned complex tasks), Impaired concentration and
attention-Impaired verbal memory (word-finding ability), Mental slowing. Motor: Unsteady
gait, loss of balance, Leg weakness, dropping things, Tremors, poor handwriting and decline
in fine motor skills.
3.3. HIV associated neuropathy
Symptomatic neuropathies occur in approximately 10% to 15%. Pathologic evidence of
peripheral nerve involvement is present in virtually all end-stage AIDS patients. The most
common complaints are numbness, parethesias and painful dysestesias. Zanetti et al., (2004)
reported mild distal dysestesia that neither interfered with the activities of daily living nor
required specific therapy. The main neurological sign was distal symmetric sensory alteration
(in 97.1% of the patients) in the four limbs but mainly in the feet. The etiology and pathogenesis
of peripheral neuropathy associated with HIV infection is uncertain. It can be caused by the
direct or indirect action of HIV and antibody production, or secondary to infections (CMV,
MAC), toxic effects of certain drugs (isoniazid, vincristine, d4T, ddi, ddC), or nutritional
deficiencies (vitamin B12) (Rizzuto et al., 1995; Dalakas et al., 1988; Figg, 1991; Browne et al.,
1993; Pike, 1993; Abrams et al., 1994; Kieburtz et al., 1991; Norton et al., 1996; Gill et al., 1990;
Simpson et al.,1995). Almost all patients with HIV that had diagnosis of peripheral neuropathy
were taking drugs probably neurotoxic (ddi, d4t,ddC isoniazid) (Zanetti et al., 2004) to
determine the effect of 5 weeks of individualized acupuncture treatment, delivered in a group
setting, on pain and symptoms of peripheral neuropathy associated with HIV infection. In
addition, the acupuncture regimen reduced pain/aching/burning and pins/needles/numbness
in the upper and lower limbs (Phillips et al., 2004).
3.4. HIV related to myelopathy with polyradiculopathy
The most common cause of spinal cord disease in AIDS patients is AIDS-associated myelop‐
athy, with a reported prevalence of 20% to 55% in different series (Gray et al., 1990; Henin et
al., 1992; Petito et al., 1985; Goldstick, 1985; Dal et al., 1994; Artigas et al., 1990). Clinical
symptoms and signs of myelopathy included spastic paraparesis, gait disturbance, urinary
problems, and impotence in males, hyperreflexia, and a variable degree of sensory loss. A
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addition, the acupuncture regimen reduced pain/aching/burning and pins/needles/numbness
in the upper and lower limbs (Phillips et al., 2004).
3.4. HIV related to myelopathy with polyradiculopathy
The most common cause of spinal cord disease in AIDS patients is AIDS-associated myelop‐
athy, with a reported prevalence of 20% to 55% in different series (Gray et al., 1990; Henin et
al., 1992; Petito et al., 1985; Goldstick, 1985; Dal et al., 1994; Artigas et al., 1990). Clinical
symptoms and signs of myelopathy included spastic paraparesis, gait disturbance, urinary
problems, and impotence in males, hyperreflexia, and a variable degree of sensory loss. A
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clinical rating of the severity of the myelopathy was established by a neurologist blinded to
the MR findings. The myelopathy was rated as mild, moderate, or severe: mild if there were
only subjective complaints of leg stiffness, heaviness, cramps, or subjective bladder dysfunc‐
tion (not incontinence), together with objective findings of increased tone, hyperreflexia, or
extensor plantar responses; moderate if there was objectively demonstrable weakness of the
lower extremities or incontinence; and severe if the patient was not independently ambulatory.
The MR findings of the spinal cord were subsequently correlated with the clinical rating of the
severity of the myelopathy. June et al, 1999, reported spinal cord MR features were abnormal
in 18 (86%) of the 21 patients (table 2). The most common finding was spinal cord atrophy,
seen in 15 patients (71%) (Fig 2).
Table 2. American Journal of Neuroradiology 20:1412-1416 (9 1999)
Figure 2. American Journal of Neuroradiology 20:1412-1416 (9 1999)
AIDS-associated myelopathy is characterized pathologically by discrete or coalescent intra‐
myelin and periaxonal vacuolation, with cellular debris and lipid-laden macrophages, in the
white matter of the spinal cord. The axons are usually intact, but in severe vacuolization, they
may become disrupted. It typically involves the lateral and posterior columns of the cervical
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and thoracic cord (Henin et al., 1992; Petito et al., 1985; Dal et al., 1994; Tan et al., 1995). The
effect of HAART on improving the symptoms or slowing the progression of HIV-associated
myelopathy is not known. A pilot study using high doses of oral L-methionine led to im‐
provement in clinical and electrophysiologic features of the disease in an open-label clinical
trial (Dorfman et al., 1997). Uncontrolled clinical experience no benefit from corticosteroids
and intravenous immunoglobulin (IVIG).
3.5. HIV-Associated Neuromuscular Weakness Syndrome (HANWS)
Toxic events secondary to use of HAART can be observed globally. Recently, Simpson et al.
2004, reported a heterogeneous syndrome termed the HIV-associated neuromuscular weak‐
ness syndrome (HANWS) which seems to be related to hyperlactatemia and stavudine
and/or didanosine exposure. Rapidly ascending neuromuscular weakness syndrome,"
associated with lactic acidosis syndrome in HIV-infected patients. Majority dramatic motor
weakness developed over days to weeks (resembling GBSrespiratory failure and death in
several patients. Systemic symptoms included nausea, vomiting, weight loss, abdominal
distention, hepatomegaly, and lipoatrophy. Stavudine, Lamivudine and Efavirenz are most
commonly used ARV agent. Muscle weakness worsened even after discontinuation of ARV
therapy. Rapidly progressive sensorimotor polyneuropathy and myopathy observed. In recent
years, a spectrum of metabolic and morphologic alterations has emerged among HIV-infected
patients receiving HAART. Additionally, neurological syndromes, such as antiretroviral toxic
neuropathy, have been clinically well characterized (Höke & Cornblath, 2004; Keswani et al.,
2002). Diagnostic information find out by severe axonal neuropathy, increase Serum lactate
level twice times than normal, decrease Serum bicarbonate and arterial pH level, increase
serum CPK level. Electrophysiology; EMG-NCV: severe axonal neuropathy in most of the
cases, demyelinating features may be seen admixed or in isolation and myopathic features
may be noted. Nerve and Muscle Biopsy: Important in evaluating patients with HANWS.
Mitochondrial studies with morphology assessment and mitochondrial DNA (mtDNA)
quantification may be needed to further elucidate the role of mitochondrial toxicity in this
syndrome Treatment: As was observed in this report, the antiretroviral most often associated
with HANWS was stavudine. Avoiding stavudine or didanosine, the nucleosides with the
highest association with mitochondrial toxicity, may be a satisfactory alternative in the long
run. The treatment of HANWS is controversial and important since this is potentially a fatal
syndrome. Our experience reinforces the recommendation that early interruption of HAART
and clinical support is beneficial. Initiate systemic treatment for lactic acidosis syndrome and
supportive treatment for the neurologic component in a monitored setting. Neuromuscular
weakness - corticosteroids, intravenous immunoglobulins, vitamins (B1, B12), and plasma‐
pheresis have been used (Luciano et al., 2003).
3.6. Toxoplasmosis
Toxoplasmosis is the leading cause of focal central nervous system (CNS) disease in AIDS.
CNS toxoplasmosis in HIV-infected patients is usually a complication of the late phase of the
disease. Toxoplasmosis has been an indicator disease for AIDS since the early days of the
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provement in clinical and electrophysiologic features of the disease in an open-label clinical
trial (Dorfman et al., 1997). Uncontrolled clinical experience no benefit from corticosteroids
and intravenous immunoglobulin (IVIG).
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Toxic events secondary to use of HAART can be observed globally. Recently, Simpson et al.
2004, reported a heterogeneous syndrome termed the HIV-associated neuromuscular weak‐
ness syndrome (HANWS) which seems to be related to hyperlactatemia and stavudine
and/or didanosine exposure. Rapidly ascending neuromuscular weakness syndrome,"
associated with lactic acidosis syndrome in HIV-infected patients. Majority dramatic motor
weakness developed over days to weeks (resembling GBSrespiratory failure and death in
several patients. Systemic symptoms included nausea, vomiting, weight loss, abdominal
distention, hepatomegaly, and lipoatrophy. Stavudine, Lamivudine and Efavirenz are most
commonly used ARV agent. Muscle weakness worsened even after discontinuation of ARV
therapy. Rapidly progressive sensorimotor polyneuropathy and myopathy observed. In recent
years, a spectrum of metabolic and morphologic alterations has emerged among HIV-infected
patients receiving HAART. Additionally, neurological syndromes, such as antiretroviral toxic
neuropathy, have been clinically well characterized (Höke & Cornblath, 2004; Keswani et al.,
2002). Diagnostic information find out by severe axonal neuropathy, increase Serum lactate
level twice times than normal, decrease Serum bicarbonate and arterial pH level, increase
serum CPK level. Electrophysiology; EMG-NCV: severe axonal neuropathy in most of the
cases, demyelinating features may be seen admixed or in isolation and myopathic features
may be noted. Nerve and Muscle Biopsy: Important in evaluating patients with HANWS.
Mitochondrial studies with morphology assessment and mitochondrial DNA (mtDNA)
quantification may be needed to further elucidate the role of mitochondrial toxicity in this
syndrome Treatment: As was observed in this report, the antiretroviral most often associated
with HANWS was stavudine. Avoiding stavudine or didanosine, the nucleosides with the
highest association with mitochondrial toxicity, may be a satisfactory alternative in the long
run. The treatment of HANWS is controversial and important since this is potentially a fatal
syndrome. Our experience reinforces the recommendation that early interruption of HAART
and clinical support is beneficial. Initiate systemic treatment for lactic acidosis syndrome and
supportive treatment for the neurologic component in a monitored setting. Neuromuscular
weakness - corticosteroids, intravenous immunoglobulins, vitamins (B1, B12), and plasma‐
pheresis have been used (Luciano et al., 2003).
3.6. Toxoplasmosis
Toxoplasmosis is the leading cause of focal central nervous system (CNS) disease in AIDS.
CNS toxoplasmosis in HIV-infected patients is usually a complication of the late phase of the
disease. Toxoplasmosis has been an indicator disease for AIDS since the early days of the
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human immunodeficiency virus (HIV) epidemic (Horowitz et al., 1983; Luft et al., 1984). CNS
toxoplasmosis begins with constitutional symptoms and headache. Later, confusion and
drowsiness, seizures, focal weakness, and language disturbance develop. Without treatment,
patients progress to coma in days to weeks. On physical examination, personality and mental
status changes may be observed. Seizures, hemiparesis, hemianopia, aphasia, ataxia, and
cranial nerve palsies may be evident. Occasionally, symptoms and signs of a radiculomyel‐
opathy predominate. Serologic studies in patients with CNS toxoplasmosis may demonstrate
rising titers of anti-toxoplasma immunoglobulin G (IgG) antibodies, CD4 counts < 100 cells
mm-3 and CSF findings are non-specific. Detection of T.gondii DNA by PCR has only moderate
sensitivity. MRI typically reveals multiple enhancing lesions with perifocal oedema and mass
effect in the basal ganglia and gray white matter interface of the cerebral hemispheres. Any
part of the brain can be affected, mostly solitary in appearance. Standard therapy consists of
pyrimethamine, sulfadiazine, and folinic acid in combination. Trimethoprim-sulfamethoxa‐
zole (TMP-SMZ) can be used as an alternative regimen (Dedicoat et al., 2006). A Cochrane data
base review failed to find a significant difference between standard therapy and TMP-SMZ.
Clindamycin can be used in patients allergic to sulfa drugs. Effective antiretroviral therapy is
equally important (Dedicoat et al., 2006; Fung et al., 1996; Bertschy et al., 2006; Behbahani et
al., 1995). Most common cause of cerebral mass lesion, Sub acute course with fever, headache,
confusion or cognitive disturbances with focal deficits, Seizures 24 – 29 %, rarely psychotic
features. Imaging – Multiple mass lesions at grey – white junction & basal ganglia, CSF – Non
specific, Antibody to T. Gondi, PCR recently developed.
3.7. AIDS related primary CNS lymphoma
A relationship between congenital or acquired immune deficiency (AIDS) and lymphoma was
first recognised more than 30 years ago. An association between non-Hodgkin’s lymphoma
(NHL) and the acquired immune deficiency syndrome became evident in the early 1980s.
Lymphoma occurring in the HIV-infected individual may be systemic, may primarily involve
the central nervous system, or may be localised in the body cavities. Systemic lymphoma is
the most common presentation, accounting for approximately 80% of all cases. The histology
usually is diffuse large cell, immunoblastic, or small non-cleaved cell lymphoma. Primary CNS
lymphoma accounts for approximately 20% of all cases. Most patients are profoundly immu‐
nosuppressed and typically have a CD4 lymphocyte count below 50/ml. Approximately two-
thirds or more of them have AIDS-defining conditions prior to the development of primary
CNS lymphoma (Gill et al., 1985; Goldstein, 1991). The lesions are typically few in number (1–
3), large (2–4 cm), and contrast enhances approximately 50% of the time (Fine & Mayer 1993).
Lesions are most common in the cerebrum, but also occur frequently in the cerebellum, basal
ganglia and brain stem, and are nearly always found to be multifocal at autopsy (Loureiro et
al., 1988; MacMahon et al., 1991). The lymphoma cells tend to be distributed along vascular
channels as perivascular cuffs, are of B cell origin, display large cell and immunoblastic
histologies. Subacute presentation with headache, impaired cognition, focal cerebral dysfunc‐
tion. D/D – Toxoplasmosis, PML. Imaging – Multiple enhancing periventricular or subepen‐
dymal lesions, CSF – EBV nucleic acid in CSF being studied. NHL are of higher grade and
advanced stage. Response and tolerance to chemotherapy is poor. Systemic lymphoma in
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patients with HIV infection is a potentially curable disease, although the potential for cure is
less than in immunocompetent individuals. Appropriate use of supportive care is an important
component of therapy (Table 3) (Sparano, 2001).
QD. Daily; TID, three times daily; BID, two times daily; QID, four times daily; s.c., subcutaneous; G CSF, granulocyte colony
stimulating factor; GM,CSF, granulocyte-macrophage colony stimulating factor, NIH, national institute of health; RTIs,
reserve transcript inhibitors.
Table 3. Suggested supportive care for the patient with HIV infection and lymphoma or other malignancies. European
Journal of Cancer 37 (2001) 1296–1305
Appropriate supportive care and CNS prophylaxis might improve outcome. In patients with
HIV infection, the differential diagnosis of a patient with focal brain lesions includes PCNSL,
cerebral toxoplasmosis, and other infections. Focal brain lesions have also been described in
conjunction with relapsed systemic lymphoma (Desai et al., 1999). A proposed algorithm for the
diagnostic approach to a patient with HIV infection and focal brain lesions is shown in Fig. 3.
3.8. HIV related progressive multifocal leukoencephalopathy
Progressive Multifocal Leukoencephalopathy (PML) is a rare demyelinating disease (focal
neurological disease & cognitive impairment) of the CNS caused by reactivation of JC virus
(JCV) 1. Radiographic evidence of white matter disease with subcortical involvement –
‘scalloped’ appearance. CSF – Non specific. Primary infection occurs in childhood and the
virus remains latent in the kidney or lymphoid organs thereafter. In the setting of cellular
immunosuppression, the virus may spread to the central nervous system, leading to a lytic
infection of oligodendrocytes and subsequent demyelination. Classically, PML was observed
in patients with advanced HIV infection, lymphoproliferative disorders and transplant
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human immunodeficiency virus (HIV) epidemic (Horowitz et al., 1983; Luft et al., 1984). CNS
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zole (TMP-SMZ) can be used as an alternative regimen (Dedicoat et al., 2006). A Cochrane data
base review failed to find a significant difference between standard therapy and TMP-SMZ.
Clindamycin can be used in patients allergic to sulfa drugs. Effective antiretroviral therapy is
equally important (Dedicoat et al., 2006; Fung et al., 1996; Bertschy et al., 2006; Behbahani et
al., 1995). Most common cause of cerebral mass lesion, Sub acute course with fever, headache,
confusion or cognitive disturbances with focal deficits, Seizures 24 – 29 %, rarely psychotic
features. Imaging – Multiple mass lesions at grey – white junction & basal ganglia, CSF – Non
specific, Antibody to T. Gondi, PCR recently developed.
3.7. AIDS related primary CNS lymphoma
A relationship between congenital or acquired immune deficiency (AIDS) and lymphoma was
first recognised more than 30 years ago. An association between non-Hodgkin’s lymphoma
(NHL) and the acquired immune deficiency syndrome became evident in the early 1980s.
Lymphoma occurring in the HIV-infected individual may be systemic, may primarily involve
the central nervous system, or may be localised in the body cavities. Systemic lymphoma is
the most common presentation, accounting for approximately 80% of all cases. The histology
usually is diffuse large cell, immunoblastic, or small non-cleaved cell lymphoma. Primary CNS
lymphoma accounts for approximately 20% of all cases. Most patients are profoundly immu‐
nosuppressed and typically have a CD4 lymphocyte count below 50/ml. Approximately two-
thirds or more of them have AIDS-defining conditions prior to the development of primary
CNS lymphoma (Gill et al., 1985; Goldstein, 1991). The lesions are typically few in number (1–
3), large (2–4 cm), and contrast enhances approximately 50% of the time (Fine & Mayer 1993).
Lesions are most common in the cerebrum, but also occur frequently in the cerebellum, basal
ganglia and brain stem, and are nearly always found to be multifocal at autopsy (Loureiro et
al., 1988; MacMahon et al., 1991). The lymphoma cells tend to be distributed along vascular
channels as perivascular cuffs, are of B cell origin, display large cell and immunoblastic
histologies. Subacute presentation with headache, impaired cognition, focal cerebral dysfunc‐
tion. D/D – Toxoplasmosis, PML. Imaging – Multiple enhancing periventricular or subepen‐
dymal lesions, CSF – EBV nucleic acid in CSF being studied. NHL are of higher grade and
advanced stage. Response and tolerance to chemotherapy is poor. Systemic lymphoma in
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patients with HIV infection is a potentially curable disease, although the potential for cure is
less than in immunocompetent individuals. Appropriate use of supportive care is an important
component of therapy (Table 3) (Sparano, 2001).
QD. Daily; TID, three times daily; BID, two times daily; QID, four times daily; s.c., subcutaneous; G CSF, granulocyte colony
stimulating factor; GM,CSF, granulocyte-macrophage colony stimulating factor, NIH, national institute of health; RTIs,
reserve transcript inhibitors.
Table 3. Suggested supportive care for the patient with HIV infection and lymphoma or other malignancies. European
Journal of Cancer 37 (2001) 1296–1305
Appropriate supportive care and CNS prophylaxis might improve outcome. In patients with
HIV infection, the differential diagnosis of a patient with focal brain lesions includes PCNSL,
cerebral toxoplasmosis, and other infections. Focal brain lesions have also been described in
conjunction with relapsed systemic lymphoma (Desai et al., 1999). A proposed algorithm for the
diagnostic approach to a patient with HIV infection and focal brain lesions is shown in Fig. 3.
3.8. HIV related progressive multifocal leukoencephalopathy
Progressive Multifocal Leukoencephalopathy (PML) is a rare demyelinating disease (focal
neurological disease & cognitive impairment) of the CNS caused by reactivation of JC virus
(JCV) 1. Radiographic evidence of white matter disease with subcortical involvement –
‘scalloped’ appearance. CSF – Non specific. Primary infection occurs in childhood and the
virus remains latent in the kidney or lymphoid organs thereafter. In the setting of cellular
immunosuppression, the virus may spread to the central nervous system, leading to a lytic
infection of oligodendrocytes and subsequent demyelination. Classically, PML was observed
in patients with advanced HIV infection, lymphoproliferative disorders and transplant
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recipients. There is no specific treatment for PML, but the survival in HIV-infected PML
patients has increased substantially during the last decade. Before the introduction of highly
active antiretroviral therapy (HAART), only 10% patients with PML lived for more than a year.
In contrast, recent studies have shown at least 50% one-year survival of HIV- infected PML
patients (Falco et al., 2008; De Luca et al., 2008). However, the prognosis of PML associated
with other immunosuppressive conditions remains poor. Immune recovery associated with
HAART has resulted in a better prognosis for HIV-infected PML patients. The prompt
institution of HAART in HIV infected PML patients is the most effective therapeutic approach
in increasing survival in this group. Several studies have shown that PML survival increased
from 10 to 50% in the last decade (Falco et al., 2008; De Luca et al., 2008; Cinque et al., 2003;
Bamford et al., 1989; Du Pasquier et al., 2004; Koralnik et al., 2004; Gasnault et al., 2003; Antinori
et al., 2003). In a recent study, JCV-peptide loaded dendritic cells from PML patients, HIV-
infected individuals and healthy control subjects could elicit a strong cellular immune response
mediated by CD8+ cytotoxic T lymphocytes cell response in vitro (Marzocchetti et al, 2009),
which suggests that autologous dendritic cell-based immunotherapy could be a potential
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3.9. Neurological approach to immunocompromized patients due to HIV-1
Central nervous system pathogens in specific immunocompromised-host (HIV-1) categories
based upon presentation like Meningitis, Meningoencephalitis, and Encephalitis. Cryptococ‐
cal meningitis is seen in populations but cryptococcomas are much more frequent in the latter.
Encephalitis and cerebral abscesses usually do not produce cerebrospinal fluid (CSF) changes
unless the lesion communicates with the ventricular or subarachnoid spaces. Discrete white
matter lesions have a narrower differential including calcineurin-induced demyelination
usually in the posterior territory and progressive multifocal leukoencephalopathy (JC papova
virus) which is characteristically nonenhancing and without mass effect. Meningoencephalitis
due to Toxoplasma gondii continues to be the predominant pathogen in HIV-1 disease even
with highly active antiretroviral therapy (HAART) exposure (Peter K. Linden, 2009).
3.10. Neurogenic manifestation of HIV infection in children
Twenty percent of children present with severe symptoms or die in infancy, Prognosis is
related to: a) Greater inoculation of HIV b) Earlier infection with immature immune system c)
Immune escape from mother. Asceptic Meningitis or Meningoencephalitis does not occur in
infants. Acquired Microcephali, cerebral vasculopathy and basal ganglia, Calcification are
unique in children. OIS are rare in children, here absolute CD4T cell count less helpful. HIV-
DNA PCR on peripheral blood lymphocytes can help to diagnosis. Avoid vaginal delivery,
plan caesarean section and avoid breast feeding.
4. Markers for HIV progression
A combination of different markers is required to predict plasma human immunodeficiency
virus type 1 (HIV-1) disease progression (Fahey et al., 1990; Saves et al., 2001). Levels of plasma
HIV-1 RNA and CD4 + cell count are highly predictive of progression to AIDS or death
(Hughes et al., 1997; Mellors et al., 1997; Saves et al., 2001). However, variations of these
markers do not explain all variations of disease progression and the relative prognostic value
of laboratory markers of HIV disease are not the same at different stages of the disease.
Therefore the use of markers of immune activation has been suggested (Graham, 1996; Saves
et al., 2001). CD4+ cell count (CD4) and RNA viral loads (RNA) are the two most commonly
used prognostic markers of the clinical progression of HIV infection for HIV infection
(Hammer et al., 2006; Gilks et al., 2006). Besides, there are various additional markers for HIV
progression such as CD8+ cell count, anti-HIV antibodies, p24 antigen, hemoglobin concen‐
tration, platelet concentration as well as erythrocyte sedimentation rate (ESR). Various
predictors for progression to AIDS among HIV-positive homosexual men have beed identified.
These include low absolute number and/or percentage of CD4+ lymphocytes, low CD8+ cell
count, low concentration of anti-HIV antibodies, p24 antigenaemia, decreased concentration
of haemoglobin, increased titre of IgG antibody to cytomegalovirus, raised serum IgA and IgM
values, raised concentrations in the serum of interleukin-2 receptor, neopterin and beta2-
microglobulin (Gafa et al., 1993). Among these markers, the percentage of CD4+ cells was
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due to Toxoplasma gondii continues to be the predominant pathogen in HIV-1 disease even
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Immune escape from mother. Asceptic Meningitis or Meningoencephalitis does not occur in
infants. Acquired Microcephali, cerebral vasculopathy and basal ganglia, Calcification are
unique in children. OIS are rare in children, here absolute CD4T cell count less helpful. HIV-
DNA PCR on peripheral blood lymphocytes can help to diagnosis. Avoid vaginal delivery,
plan caesarean section and avoid breast feeding.
4. Markers for HIV progression
A combination of different markers is required to predict plasma human immunodeficiency
virus type 1 (HIV-1) disease progression (Fahey et al., 1990; Saves et al., 2001). Levels of plasma
HIV-1 RNA and CD4 + cell count are highly predictive of progression to AIDS or death
(Hughes et al., 1997; Mellors et al., 1997; Saves et al., 2001). However, variations of these
markers do not explain all variations of disease progression and the relative prognostic value
of laboratory markers of HIV disease are not the same at different stages of the disease.
Therefore the use of markers of immune activation has been suggested (Graham, 1996; Saves
et al., 2001). CD4+ cell count (CD4) and RNA viral loads (RNA) are the two most commonly
used prognostic markers of the clinical progression of HIV infection for HIV infection
(Hammer et al., 2006; Gilks et al., 2006). Besides, there are various additional markers for HIV
progression such as CD8+ cell count, anti-HIV antibodies, p24 antigen, hemoglobin concen‐
tration, platelet concentration as well as erythrocyte sedimentation rate (ESR). Various
predictors for progression to AIDS among HIV-positive homosexual men have beed identified.
These include low absolute number and/or percentage of CD4+ lymphocytes, low CD8+ cell
count, low concentration of anti-HIV antibodies, p24 antigenaemia, decreased concentration
of haemoglobin, increased titre of IgG antibody to cytomegalovirus, raised serum IgA and IgM
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found to be the best predictor of HIV progression (Fahey et al., 1990), followed by serum
concentrations of neopterin and beta2-microglobulin, IgA, interleukin-2 receptors and p24
antigen. Only a few studies have the predictive values of these serological markers which have
been evaluated in cohorts of IVDUs (Gafa et al., 1993). De Wolf & Lange, (1993) observed that
several laboratory markers become most noticeably established as predictors of progression
from asymptomatic HIV-1 infection to AIDS: (1) Decline in antibody reactivity to HIV core
proteins p24 and p17; (2) Appearance of persistent HIV-1 p24 antigenemia; (3) Declining
numbers and percentages of peripheral blood CD4-positive lymphocytes; (4) Elevated serum
beta2-microglobulin concentration and (4) Elevated serum and urine neopterin concentrations.
4.1. Immunological and virological markers
Based upon scientific literature, immunological and virological markers have been proven as
prognostic indicators for progression of HIV disease. The most widely studied marker, the
CD4 + lymphocyte count was found to be the best single indicator of the stage of the illness
(Zeller et al., 1996). HIV infects CD4+ T lymphocytes selectively and causes the destruction of
CD4+ T cells directly as well as indirectly leading to gradual loss of the CD4 T cell numbers in
peripheral circulation. Hence, the CD4+ T cell counts are being used to monitor the disease
progression in HIV infection, to decide the threshold for initiation of anti-retro viral therapy,
to monitor the efficacy of Anti Retrroviral treatment and to initiate prophylactic treatment for
opportunistic infections (OIs) (Atlh Nicholson, 1997; Pattanapanyasat & Thakat, 2005).
Measuring the CD4+ lymphocytes count remains the most effective means of evaluating of the
clinical prognosis of patients infected with Human Immunodeficiency Virus (HIV) (Stein et
al., 1992). This measurement has been universally accepted as a uniform means for the clinical
staging of patients infected with HIV and those progressing to AIDS (Levine et al., 2000) and
for the determination of the commencement of antiretroviral therapy and for monitoring the
response to antiretroviral therapy (Evans-Gilbert et al., 2004).
4.2. CD4+ cell count
CD4+ T lymphocyte play a central regulatory role in the immune response. The decrease in
CD4+ T cell numbers can compromise the normal immune functions of the body. Hence, the
number of CD4+ T cells in the circulation provides important information regarding the
immune competence of an individual (Thakar et al., 2011). HIV primarily targets CD4 cells.
As HIV disease progresses, CD4 cell counts decline, typically by about 30-100 cells/µl per year
(depending on viral load), leaving a person increasingly vulnerable to infections and cancers.
People with CD4 cell counts above 500 cells/µl generally have relatively normal immune
function and are at low risk for opportunistic infections (Hammer et al., 2006). The clinical
staging of HIV disease and the relative risk of developing opportunistic infections have
historically relied on the CD4 cell count as the principle laboratory marker of immune status
(Kleinman et al., 1998; Patton et al., 2003). HIV disease is commonly categorized on the basis
of three levels of immunodeficiency: relative immune competence (CD4 cell count > 500/µl;
≥ 29%), early immune suppression (CD4 cell count between 200/µl and 500/ µl); 4%-28%) and
severe immune suppression (CD4 cell count <200/µl and 500/ µl); <14%) (CDC, 1993).
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Figure 4. Schematic natural history model of HIV-1 replication driving rates of CD4 decline and clinical progression
(Korenromp et al., 2009)
4.3. CD8+ cell count
There are two types of T cells carry the CD8 surface molecule: T-suppressor cells, which inhibit
immune responses, and killer T cells (also known as cytotoxic T lymphocytes, or CTLs), which
target and kill infected or cancerous cells. As with CD4 cells, a variety of factors can cause CD8
cell counts to fluctuate. CD8 cell counts typically rise over time in people with HIV, but (unlike
CD4 cells) CD8 cell numbers do not independently predict disease progression, and their
relation to immune status is not well understood (Vajpayee & Mohan 2011).
4.4. CD4 and CD8 cell percentage
Because absolute CD4 and CD8 cell counts are so variable, some physicians prefer to look at
CD4 or CD8 cell percentages, the proportion of all lymphocytes that are CD4 or CD8 cells.
Percentages are usually more stable over time than absolute counts. A normal CD4 cell
percentage in a healthy person is about 30-60 per cent, while a normal CD8 cell percentage is
15-40 per cent (Taylor et al., 1989).
4.5. CD4/CD8 cell ratio
The CD4/CD8 cell ratio is calculated by dividing the CD4 cell count by the CD8 cell count. A
normal CD4/CD8 cell ratio is about 0.9-3.0 or higher, there are at least 1-3 CD4 cells for every
CD8 cell. In people with HIV this ratio may be much lower, with many more CD8 cells than
CD4 cells (Giorgi, 1993).
4.6. HIV viral load
Viral load tests measure the amount of HIV RNA in the blood. The presence of RNA indicates
that the virus is actively replicating or multiplying. Along with the CD4 cell count, viral load
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found to be the best predictor of HIV progression (Fahey et al., 1990), followed by serum
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is one of the most valuable measures for predicting HIV disease progression and gauging when
anti-HIV treatment is indicated and how well it is working. Viral load is expressed either as
copies of RNA per milliliter of blood (copies/ml) or in terms of logs. A log change is an
exponential or 10-fold change. For example, a change from 100 to 1,000 is a 1 log (10-fold)
increase, while a change from 1,000,000 to 10,000 is a 2 log (100-fold) decrease. If the level of
HIV is too low to be measured, viral load is said to be undetectable, or below the limit of
quantification. However, undetectable viral load does not mean that HIV has been eradicated;
people with undetectable viral load maintain a very low level of virus. Even when HIV is not
detectable in the blood, it may be detectable in the semen, female genital secretions, cerebro‐
spinal fluid, tissues, and lymph nodes (Calmy et al., 2004; Petti et al., 2006; WHO, 2006). In
primary HIV infection, patients may present with flu-like symptoms which usually occur
during the first weeks of HIV-1 infection. It is associated with peak levels of HIV-1 RNA
viremia, which subsequently declines until reaching a set point, where levels remain for
months to years. Initial studies suggested that those with more symptomatic acute infection
and longer duration of illness have faster rates of progression to AIDS (Koenig et al., 2006). A
viral load of 100,000 copies/ml or more is considered high, while levels below 10,000
copies/ml are considered low. Research has consistently shown that higher viral loads are
associated with more rapid HIV disease progression and an increased risk of death. Current
U.S. HIV treatment guidelines (Koenig et al., 2006) recommend that people should consider
starting treatment if their viral load is above 55,000 copies/ml (revised upward from 10,000
copies/ml in the previous guidelines). Importantly, most studies that have correlated viral load
and HIV disease progression have been done in men; more recent research indicates that
women may progress to AIDS at lower viral load levels, suggesting that the treatment
threshold should perhaps be revised downward for women (Monica et al., 2002).
4.7. Beta2-microglobulin (β2-microglobulin)
β2-microglobulin is a low molecular weight protein that forms light chain of the class I major
histocompatibility complex (MHC) which present on the surface of most somatic cells
including T and B lymphocytes as well as macrophages (Cresswell et al., 1974; Lawlor et al.,
1990; De Wolf and Lange 1991). It exhibits amino acid homology with the constant region of
immunoglobins ( Dar & Singh, 1999; Fauci & Lane, 1998; Quin & Benson, 1994). Circulating
β2-MG is generated during normal MHC I turnover (Lawlor et al., 1990) and thus is not specific
to HIV-related cell death. Stimulation of lymphoid cells increases β2-microglobulinproduc‐
tion. Elevated serum concentration are seen in renal failure, hepatitis, rheumatoid arthritis,
myeloproliferative disorders, lymphoproliferative disorders, infectious mononucleosis,
influenza A and cytomegalovirus infection (De wolf and Lange, 1991). Free β2-microglobin
can be measured in both serum and urine and levels of urine β2-microglobin correlate with
the degree of progression of HIV disease. It spikes in acute infection, declines and then rises
during the infection. Levels of β2-microglobin are elevated in a variety of conditions charac‐
terized by lymphocyte activation and/ or lymphocyte destruction; e.g. lymphoproliferative
syndromes, autoimmune diseases, viral infection and in patients with renal diseases. It can be
measured in serum or plasma by using radio immunoassay radio immunoassay (RIA) or
competivive ELISA based tests. Β2-microglobin measurement has several advantages as a
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laboratory assay to help determine prognosis. By contrast with CD4 cell count which requires
special procedures for specimen handling and processing, β2-microglobin can be measured
with a serological assay and equipment available in many laboratories (Vajpayee & Mohan,
2011). Increased concentrations of this molecule are predictive of progression of HIV infection
to AIDS (Moss et al., 1988).
4.8. Neopterin
Neopterin (6-D- erythrohydroxy-propylpterin) is a low molecular weight compound derived
from an intermediate product of the de novo biosynthesis of tetrahydrobiopterin from guano‐
sine triphosphate (GTP) (Dar & Singh, 1999; Fauci & Lane, 1998; Quin & Benson, 1994). It is an
early marker of HIV infection. The levels rise further on progression from pre AIDS to clinical
AIDS (Vajpayee & Mohan 2011). It is produced by macrophages after stimulation with gamma
interferon. The levels have also been found to be associated with progression of HIV-1-related
disease (Fuchs et al., 1988; Melmed et al., 1989; Kramer et al., 1989; De Wolf and Lange 1991)
but the predictive value is slightly inferior to that of β2-microglobulin levels. Since neopterin
levels are stimulated by HIV infection, measurement of neopterin levels can be useful in
monitoring progression and evaluating antiviral therapy (Vajpayee & Mohan 2011).
4.9. Additional markers
Haematological manifestations of HIV infection are common and more frequently occur with
progression of the disease. Therefore the complete blood count (CBC) is one of the important
haematological parameters which need to checked for HIV patients. They may have low blood
cell counts (cytopenias) due to chronic HIV infection or as a side effect of medications,
particularly drugs that damage the bone marrow, where all blood cells are produced. Blood
cell counts are typically reported as the number of cells per µl of blood (cells/µl) or as a
percentage of all blood cells. HIV patients should be checked for CBC for every six months,
and more often if they are experiencing symptoms or taking drugs associated with low blood
cell counts ( De Santis et al., 2011; Olayemi et al, 2008).
4.9.1. Red and white blood cells
Anemia is common in HIV positives. HIV itself and various OIs such as Mycobacterium avium
complex (MAC) can affect red blood cells and their oxygen-carrying capacity (Volberding et al.,
2003; Owiredu et al., 2011). People with HIV infection should be especially concerned with neu‐
trophil and lymphocyte levels, in particular CD4 and CD8 cell counts. Neutrophils normally
make up about 50-70 per cent of all white blood cells. Various anti-HIV drugs, OI medications
[including ganciclovir (Cytovene), used to treat cytomegalovirus, or CMV], and cancer chemo‐
therapies that suppress the bone marrow may lead to neutropenia (Firnhaber, 2010).
4.9.2. Platelets
Platelets are necessary for blood clotting. A normal platelet count is about 130,000-440,000 cells/
µl. Low platelet counts (thrombocytopenia) - which can lead to easy bruising and excessive
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during the first weeks of HIV-1 infection. It is associated with peak levels of HIV-1 RNA
viremia, which subsequently declines until reaching a set point, where levels remain for
months to years. Initial studies suggested that those with more symptomatic acute infection
and longer duration of illness have faster rates of progression to AIDS (Koenig et al., 2006). A
viral load of 100,000 copies/ml or more is considered high, while levels below 10,000
copies/ml are considered low. Research has consistently shown that higher viral loads are
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women may progress to AIDS at lower viral load levels, suggesting that the treatment
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syndromes, autoimmune diseases, viral infection and in patients with renal diseases. It can be
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haematological parameters which need to checked for HIV patients. They may have low blood
cell counts (cytopenias) due to chronic HIV infection or as a side effect of medications,
particularly drugs that damage the bone marrow, where all blood cells are produced. Blood
cell counts are typically reported as the number of cells per µl of blood (cells/µl) or as a
percentage of all blood cells. HIV patients should be checked for CBC for every six months,
and more often if they are experiencing symptoms or taking drugs associated with low blood
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[including ganciclovir (Cytovene), used to treat cytomegalovirus, or CMV], and cancer chemo‐
therapies that suppress the bone marrow may lead to neutropenia (Firnhaber, 2010).
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bleeding may be caused by certain drugs, autoimmune reactions, accelerated destruction by
the spleen, or HIV disease itself (Torre & Pugliese, 2008). In 2012, Parinitha & Kulkarni study
the haematological changes in HIV infection with correlation to CD4+ cell count. In their study,
they found that among 250 patients studied, anaemia was seen in 210 (84%) of cases. Throm‐
bocytopenia occurs in 45 (18%) cases. Majority of cases (70%) had CD4+ cell counts below 200
cells/mm3. Fifty-four cases (21.6%) had CD4 cell counts between 200 to 499 cells/mm3 and 21
(8.4%) cases had CD4 count more than 500 cells/mm3. In patients with CD4 counts less than
200 cells/mm3, anaemia was seen in 91.4% cases, leucopenia in 26.8% cases, lymphopenia in
80% cases and thrombocytopenia in 21.7% cases.
5. Summary
The prevalence of neurological associated with HIV-1 is estimated at 15 to 50% of patients
(Dalakas et al., 1988; Cornblath et al., 1988; So et al., 1988; Monte et al., 1988; Gabbai et al.,
1990). But it may be almost 100% when a pathological study is performed (Rizzuto et al.,
1995; Gabbai et al., 1990). The etiology and pathogenesis of neurological disease associated
with HIV infection is uncertain. It can be caused by the direct or indirect action of HIV and
antibody production, or secondary to infections (CMV, MAC), toxic effects of certain drugs
(isoniazid, vincristine, d4T, ddi, ddC), or nutritional deficiencies (vitamin B12) (Rizzuto et al.,
1995; Dalakas et al., 1988; Figg et al., 1991; Browone et al., 1993; Pike et al., 1993; Abram et al.,
1994; Kieburtz et al., 1991). HIV seropositive patients may be overlooked or misdiagnosed. A
discerning clinical analysis may be helpful in the diagnosis of this common disease and several
laboratory markers become most noticeably established as predictors of HIV-1 infection.
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1. Introduction
HIV-Associated Neurocognitive Disorders (HAND) is a serious menifestation of HIV in‐
fection in the central nervous system (CNS), and encompassess a wide spectrum of cog‐
nitive,  behavioral,  and  motor  deficits  [1-3].  While  the  implementation  of  combination
antiretroviral  therapy  (ART)  has  dramatically  increased  the  life  expectancy  and  led  to
significant improvements in the clinical presentation and progression of HAND, an esti‐
mated 50% of HIV-infected patientscontinue to suffer from implications of HAND in the
ART era, with as much as 20% of these exhibiting symptoms of HIV-associated dementia
(HAD), the most severe form of HAND [3-6]. The brain regions affected in patients with
HAND has  changed in  the  ART era  in  parallel  to  the  changes  observed in  the  clinical
picture; a more subtle and insidious cortical damage mainly in the hippocampus and the
temporal cortex is observed, in contrast to the overt subcortical damage seen before ART
[7-10]. The underlying causes of these changes are not fully elucidated; however, exami‐
nation of  the post-mortem tissue reveals  the persistence of  synaptic  and dendritic  dam‐
age  in  the  affected  brain  regions  [3,  11].  Emerging  evidence  suggests  that  controlling
viral replication in the periphery or in the CNS may not be sufficient to control the un‐
derlying neuropathological  processes  that  culminate  in  the development  of  HAND. The
impact of HAND on the quality of life,  adherence to drug regimens, and co-morbidities
especially in an aging HIV population with decreased cognitive reserves, is of major con‐
cern. In this chapter, we will examine the major factors that continue to impact the CNS
of HIV-infected individuals, and introduce new challenges in the successful treatment of
HAND.
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2. Clinical presentation and neuropathology of HAND
According to the diagnostic criteria established for the assessment of neurocognitive impair‐
ment in HIV-infected individuals, the neurological deficits in HAND patients are divided
into three diagnostic groups. This classification is based on the neuropsychological evalua‐
tion of multiple cognitive domains, including simple motor skills or sensory perceptual abil‐
ity, complex perceptual motor skills, attention and working memory, learning and memory
recall, verbal and language, abstraction and executive function. Asymptomatic neurocogni‐
tive impairment (ANI) is defined as acquired impairment in at least two cognitive domains
without a decline in activities of daily living (ADL), while mild to moderate neurocognitive
impairment that affects ADL is termed minor neurocognitive disorder (MND). Moderate to
severe impairment in two or more domains with marked impact on ADL is defined as HAD.
Additionally, behavioral and emotional problems such as depression, psychosis and anxiety
are commonly observed in HAND patients. Since the multi-drug regimens that form the ba‐
sis of ART have become the mainstay of HIV, the clinical presentation and the course of
HAND have become more unpredictable. The severity of deficits appears to fluctuate over
time during the course of infection: some patients may experience continuing decline in cog‐
nitive abilities, while others may recover from HAD and exhibit only minor deficits for the
remainder of the disease. While clinical studies clearly establish that suppression of viral
replication below the level of detection is paramount to a more favorable outcome, the clini‐
cal course of HAND, once diagnosed, cannot be predicted successfully in most patients.
While microglial nodules, multinucleated giant cells and astrogliosis, all of which are associ‐
ated with HIV-induced inflammatory changes, are not as frequently found in post-mortem
HAND brain tissue after ART, dendritic and synaptic damage still persist [12-16]. For exam‐
ple, several studies have reported the presence of deoxynucleotidyltransferase-mediated
dUTP nick-end labeling (TUNEL)-positive cells, DNA laddering and structural changes
with electron microscopy [17, 18]. Importantly, these markers of neuronal death correlate
with activation of immune cell populations suggesting that the inflammatory mediators se‐
creted by these cells may play a role in initiating the death cascades [1, 19]. Given the chron‐
ic nature of the HIV infection in the ART era, co-existing conditions which can activate
immune responses and precipitate a neuroinflammatory environment independent of infec‐
tion are likely to contribute to the development of persistent neuropathology, and need to be
addressed for a more efficient clinical approach and more favorable outcomes. Foremost, it
is necessary to examine the mechanisms of neuronal injury in order to successfully expound
on the contribution of confounding factors on the persistence of HAND.
The two major cell types targeted by HIV are CD4+ T cells and the cells of monocyte/macro‐
phage lineage. HIV infection of the CD4+ T cells ends in the selective loss of this cell popula‐
tion, leading to severe immunodeficiency [20]. More relevant to HAND, HIV also targets
monocytes early during infection [20]. In the healthy brain, the BBB and the blood-cerebro‐
spinal fluid barriers are the first lines of defense against invading pathogens; however, HIV
can circumvent these barriers and enter the CNS within infected monocytes [21, 22]. Accord‐
ing to this model, supported by a multitude of in vitro and in vivo studies, the infected mon‐
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ocytes differentiate into macrophages, and constitute the viral reservoirs in the CNS [23-26].
Moreover, these cells release a variety of molecules, some of them known neurotoxins, lead‐
ing to the eventual neuronal damage and dysfunction observed in HAND. Importantly, un‐
like other cell types that readily undergo replication, neurons in their post-mitotic state are
more vulnerable to immune cell damage which can disrupt critical neuronal functions. Ad‐
ditionally, recent focus in efforts towards a cure in HIV is purging the virus from its reser‐
voirs, by reactivating pro-viral DNA [27-31]. Thus, it is crucial to examine the impact of HIV
infection on immune cells for a better understanding of the neuropathology of HAND, and
for the development of successful paradigms for HIV reactivation and purging.
3. The immunology of HAND
3.1. Initiation of immune response in the CNS
HIV initially enters helper T lymphocytes and monocytes in the periphery via viral glyco‐
proteins, gp120 and gp41, which are part of the HIV envelope [32]. These glycoproteins en‐
gage with the CD4 on the host cell membrane; however, this fusion step requires the
presence of a chemokine co-receptor, C-X-C chemokine receptor type 4 (CXCR4) in lympho‐
cytes,orC-C chemokine type 5 (CCR5) / C-C chemokine type 3 (CCR3) in macrophages [32,
33]. Of all the cell types in the brain, only macrophages and microglia express CD4 antigen,
are commonly infected by HIV, and are capable of productive infection. There is very limit‐
ed evidence for HIV infection of the glial cells, which if present, has not been conclusively
shown as being productive [34]. More importantly, HIV cannot infect neurons as these cells
lack CD4 co-receptors.
The CNS of a healthy adult human has a relatively low presence of cellular components
of the immune system [35, 36]. The CNS presents the immune system with unique prob‐
lems  with  trafficking  of  immune  cells  and  the  recognition  of  foreign  antigen  when
present. First, the BBB constitutes a physical barrier for the entry of cells and macromole‐
cules from the periphery into the CNS. Additionally, there is minimal expression of major
histocompatibility class II  (MHC class II)  molecules and an absence of professional anti‐
gen presenting cells such as dendritic cells, all of which are required for antigen presenta‐
tion and adaptive immune response activation. However,  it  has been extensively shown
that brain derived factors act to suppress or counter-regulate the actions of pro-inflamma‐
tory  mediators  in  the  CNS  where  immune  surveillance  is  not  sufficient.  For  example,
transforming growth factor-β  (TGF-β)  has  the  ability  to  inhibit  the  activation of  macro‐
phages, T lymphocytes, and natural killer (NK) cells, and has been shown to possess neu‐
roprotective capabilities [37-41]. Interestingly, increased TGF-β protein levels are reported
in the frontal cortex of HAD patients, and elevated TGF-βimmunoreactivity has been de‐
tected in  reactive  astrocytes  and mononuclear  cells  of  the  white  matter  in  HIV-infected
CNS [42, 43]. Similar roles have been proposed for BDNF, NT-3, and NGF, among others,
during HIV infection in the CNS [44, 45].
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According to the diagnostic criteria established for the assessment of neurocognitive impair‐
ment in HIV-infected individuals, the neurological deficits in HAND patients are divided
into three diagnostic groups. This classification is based on the neuropsychological evalua‐
tion of multiple cognitive domains, including simple motor skills or sensory perceptual abil‐
ity, complex perceptual motor skills, attention and working memory, learning and memory
recall, verbal and language, abstraction and executive function. Asymptomatic neurocogni‐
tive impairment (ANI) is defined as acquired impairment in at least two cognitive domains
without a decline in activities of daily living (ADL), while mild to moderate neurocognitive
impairment that affects ADL is termed minor neurocognitive disorder (MND). Moderate to
severe impairment in two or more domains with marked impact on ADL is defined as HAD.
Additionally, behavioral and emotional problems such as depression, psychosis and anxiety
are commonly observed in HAND patients. Since the multi-drug regimens that form the ba‐
sis of ART have become the mainstay of HIV, the clinical presentation and the course of
HAND have become more unpredictable. The severity of deficits appears to fluctuate over
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remainder of the disease. While clinical studies clearly establish that suppression of viral
replication below the level of detection is paramount to a more favorable outcome, the clini‐
cal course of HAND, once diagnosed, cannot be predicted successfully in most patients.
While microglial nodules, multinucleated giant cells and astrogliosis, all of which are associ‐
ated with HIV-induced inflammatory changes, are not as frequently found in post-mortem
HAND brain tissue after ART, dendritic and synaptic damage still persist [12-16]. For exam‐
ple, several studies have reported the presence of deoxynucleotidyltransferase-mediated
dUTP nick-end labeling (TUNEL)-positive cells, DNA laddering and structural changes
with electron microscopy [17, 18]. Importantly, these markers of neuronal death correlate
with activation of immune cell populations suggesting that the inflammatory mediators se‐
creted by these cells may play a role in initiating the death cascades [1, 19]. Given the chron‐
ic nature of the HIV infection in the ART era, co-existing conditions which can activate
immune responses and precipitate a neuroinflammatory environment independent of infec‐
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addressed for a more efficient clinical approach and more favorable outcomes. Foremost, it
is necessary to examine the mechanisms of neuronal injury in order to successfully expound
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The two major cell types targeted by HIV are CD4+ T cells and the cells of monocyte/macro‐
phage lineage. HIV infection of the CD4+ T cells ends in the selective loss of this cell popula‐
tion, leading to severe immunodeficiency [20]. More relevant to HAND, HIV also targets
monocytes early during infection [20]. In the healthy brain, the BBB and the blood-cerebro‐
spinal fluid barriers are the first lines of defense against invading pathogens; however, HIV
can circumvent these barriers and enter the CNS within infected monocytes [21, 22]. Accord‐
ing to this model, supported by a multitude of in vitro and in vivo studies, the infected mon‐
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ocytes differentiate into macrophages, and constitute the viral reservoirs in the CNS [23-26].
Moreover, these cells release a variety of molecules, some of them known neurotoxins, lead‐
ing to the eventual neuronal damage and dysfunction observed in HAND. Importantly, un‐
like other cell types that readily undergo replication, neurons in their post-mitotic state are
more vulnerable to immune cell damage which can disrupt critical neuronal functions. Ad‐
ditionally, recent focus in efforts towards a cure in HIV is purging the virus from its reser‐
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3.1. Initiation of immune response in the CNS
HIV initially enters helper T lymphocytes and monocytes in the periphery via viral glyco‐
proteins, gp120 and gp41, which are part of the HIV envelope [32]. These glycoproteins en‐
gage with the CD4 on the host cell membrane; however, this fusion step requires the
presence of a chemokine co-receptor, C-X-C chemokine receptor type 4 (CXCR4) in lympho‐
cytes,orC-C chemokine type 5 (CCR5) / C-C chemokine type 3 (CCR3) in macrophages [32,
33]. Of all the cell types in the brain, only macrophages and microglia express CD4 antigen,
are commonly infected by HIV, and are capable of productive infection. There is very limit‐
ed evidence for HIV infection of the glial cells, which if present, has not been conclusively
shown as being productive [34]. More importantly, HIV cannot infect neurons as these cells
lack CD4 co-receptors.
The CNS of a healthy adult human has a relatively low presence of cellular components
of the immune system [35, 36]. The CNS presents the immune system with unique prob‐
lems  with  trafficking  of  immune  cells  and  the  recognition  of  foreign  antigen  when
present. First, the BBB constitutes a physical barrier for the entry of cells and macromole‐
cules from the periphery into the CNS. Additionally, there is minimal expression of major
histocompatibility class II  (MHC class II)  molecules and an absence of professional anti‐
gen presenting cells such as dendritic cells, all of which are required for antigen presenta‐
tion and adaptive immune response activation. However,  it  has been extensively shown
that brain derived factors act to suppress or counter-regulate the actions of pro-inflamma‐
tory  mediators  in  the  CNS  where  immune  surveillance  is  not  sufficient.  For  example,
transforming growth factor-β  (TGF-β)  has  the  ability  to  inhibit  the  activation of  macro‐
phages, T lymphocytes, and natural killer (NK) cells, and has been shown to possess neu‐
roprotective capabilities [37-41]. Interestingly, increased TGF-β protein levels are reported
in the frontal cortex of HAD patients, and elevated TGF-βimmunoreactivity has been de‐
tected in  reactive  astrocytes  and mononuclear  cells  of  the  white  matter  in  HIV-infected
CNS [42, 43]. Similar roles have been proposed for BDNF, NT-3, and NGF, among others,
during HIV infection in the CNS [44, 45].
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In the initial stages of HIV infection, the number of CD4+T cells decreases as a consequence
of uncontrolled viral replication. While the impact of primary HIV infection on specific CD8+
T cell subpopulations is not clear, there is an overall expansion of this cell population [46]. In
this environment, infected monocytes can enter the CNS, establish and maintain productive
infection, and HAND becomes clinically manifest. Perivascular macrophages are replenish‐
ed throughout life by the migration of circulating monocytes to the brain, a process en‐
hanced in an inflammatory environment [47]. Several studies have shown that the number
of activated macrophages, rather than the viral load,correlates best with the axonal damage
and synaptic loss observed in the HAND brain [11, 14, 48, 49]. In addition, indirect markers
of macrophage activation, such as neopterin and β2-microglobulin, are elevated in the CSF
of HAND patients [50-52]. Further, soluble factors that are known to be released by macro‐
phages and glia, such as quinolinic acid, tumor necrosis factor-α (TNF-α), reactive oxygen
species (ROS), and cytokines such as CXCL12 (stromal cell-derived factor-1, SDF-1), CCL2
(monocyte chemotactic protein-1, MCP-1), and interleukin-6 (IL-6), are also elevated in the
CSF of HAND patients [53-57]. These findings reinforce the model which proposes mono‐
cyte-derived macrophages and microglia as major instigators of the neuropathological proc‐
esses in the course of disease development in HAND.
It should be noted that viral proteins such as gp120 and transactivator of transcription (Tat)
can directly activate uninfected macrophages [58-62]. Additionally, one mechanism of injury
that is proposed to account for neuronal damage in the absence of neuronal infection by
HIV involves direct neurotoxicity by these viral proteins. Several in vitro studies have shown
that these viral proteins that are released and/or shed by the infected macrophages/micro‐
glia can induce direct synaptic and neuronal damage [63-65]. However, the indicators of
neuroinflammation continue to persist despite successful suppression of replication in the
CSF to levels below the limit of detection with ART, suggesting that other, less direct mecha‐
nisms of injury might be major contributors to the underlying neuropathology.
3.2. The role of cytokines and chemokines in HAND neuropathology
A number of indirect mechanisms for the pathogenesis of HAND have been proposed [1, 25,
66]. These mechanisms are not mutually exclusive, and may be synergistic based on the
common background of macrophage activation and release of cytokines and chemokines.As
a protective measure to suppress viral production, macrophages are responsible for the pro‐
duction of inflammatory mediators including TNF-α, IL (interleukin)-1, interferon-α (IFN-α)
and nitric oxide synthase (NOS) [33, 59]. However, the release of these pro-inflammatory cy‐
tokines can activate the uninfected macrophages, and can induce the migration of leuko‐
cytes into the CNS [62]. For example, in HIV-1 transgenic (Tg) rats, elevated levels of IL-1β
and TNF-α and increased expression of arachidonic acid cascade enzymes have been impli‐
cated in neuronal damage and cognitive and behavioral impairment [67]. A recent study in‐
dicates that similar changes could contribute to cognitive impairment in HIV-infected
patients despite an effective ART [68]. In vivo studies suggest that the progression of HAND
may be predicted by high concentrations of TNF-α in plasma, and polymorphisms in the
TNF-α promoter are associated with HAND to a degree [69, 70]. Interestingly, functional ex-
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vivo studies have shown that the macrophages and B-lymphocytes isolated from HIV-infect‐
ed patients are activated despite viral suppression by ART [71]. Further, in vitro experiments
show that HIV reactivation can be achieved by cytokine and chemokine stimulation [30, 33].
These findings are especially important in light of recent concerns regarding viral latency
and its contribution to the persistence of HAND [29].
In the CNS,chemoattractant cytokines, or chemokines have been demonstrated as essential
factors in neuroinflammation and related neuronal injury and loss through their regulation
of inflammatory responses. Post-mortem studies have revealed up-regulation of chemokines
and chemokine receptors in the brains of patients with HAND [25, 26, 56, 72-75]. The best-
characterized chemokines up-regulated in HAND are the β-chemokines CCL2, CCL5, and
CX3CL1, and the alpha chemokine CXCL12. For example, the levels of one of the more po‐
tent chemokines, CCL2 correlate with the likelihood and severity of HAND [76, 77]. In addi‐
tion, an intriguing regulatory role for the chemokine CCR5 was demonstrated that its
activation led to cell death via caspase-3 mediated apoptosis in a neuroblastoma cell line
[78]. Further, induction of apoptosis has also been reported with CXCL12 in primary neuro‐
glial cultures in the absence of the HIV viral protein gp120. However, results from several
recent studies suggest that the changes in the expression of these chemokines may indicate
neuroprotective efforts in response to the neuroinflammatory environment [79]. Further
studies are needed to dissect the roles of chemokines in HAND pathogenesis, as they take
part in a crucial phase in immune responses, and provide attractive targets for modulation
in resolving HAND persistence.
The mechanisms by which the neuroinflammatory environment eventually ends in damage
to the neurons are not precisely known; however, several mechanisms are likely candidates.
Studies suggest that the neuronal damageis a result of indirect effects of viral proteins as
well as inflammatory mediators [1, 66]. Gp120 and Tat are reported to induce neuronal
apoptosis by activating death-associated proteases, caspases, specifically caspase-3 in in vitro
and in vivo disease models [80]. Another mechanism proposes a role for excitotoxicity secon‐
dary to impaired glutamate reuptake by astrocytes which are overwhelmed by pro-inflam‐
matory factors [81]. The well-defined cascade of excitotoxic injury includes excess Ca2+
influx into the neuronal cytoplasm. Several downstream events secondary to such increases
in Ca2+ such as excess free radical production and oxidative stress, and the activation of Ca2+-
dependent death proteases, calpains and caspases, will be detrimental to neurons, especially
in an environment with inadequate glial support and ongoing inflammation due to immune
cell activation [1, 66].
3.3. Neuroinflammation in HAND
The persistence of immune activation in the CNS and the peripheral nervous system (PNS)
of HIV-infected individuals in the ART era is supported by several lines of evidence. The
relatively low levels of HIV RNA in the presence of widespread neuropathological changes
in the CNS and PNS of HAND patients, and the lack of evidence of HIV infection of neuro‐
nal cells in vivo and in vitro hint at the possibility of chronic immune activation as a factor in
the persistence of HAND. Recent clinical evidence shows that ART reduces intrathecal im‐
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that these viral proteins that are released and/or shed by the infected macrophages/micro‐
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nisms of injury might be major contributors to the underlying neuropathology.
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A number of indirect mechanisms for the pathogenesis of HAND have been proposed [1, 25,
66]. These mechanisms are not mutually exclusive, and may be synergistic based on the
common background of macrophage activation and release of cytokines and chemokines.As
a protective measure to suppress viral production, macrophages are responsible for the pro‐
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and nitric oxide synthase (NOS) [33, 59]. However, the release of these pro-inflammatory cy‐
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cytes into the CNS [62]. For example, in HIV-1 transgenic (Tg) rats, elevated levels of IL-1β
and TNF-α and increased expression of arachidonic acid cascade enzymes have been impli‐
cated in neuronal damage and cognitive and behavioral impairment [67]. A recent study in‐
dicates that similar changes could contribute to cognitive impairment in HIV-infected
patients despite an effective ART [68]. In vivo studies suggest that the progression of HAND
may be predicted by high concentrations of TNF-α in plasma, and polymorphisms in the
TNF-α promoter are associated with HAND to a degree [69, 70]. Interestingly, functional ex-
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vivo studies have shown that the macrophages and B-lymphocytes isolated from HIV-infect‐
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These findings are especially important in light of recent concerns regarding viral latency
and its contribution to the persistence of HAND [29].
In the CNS,chemoattractant cytokines, or chemokines have been demonstrated as essential
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and chemokine receptors in the brains of patients with HAND [25, 26, 56, 72-75]. The best-
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CX3CL1, and the alpha chemokine CXCL12. For example, the levels of one of the more po‐
tent chemokines, CCL2 correlate with the likelihood and severity of HAND [76, 77]. In addi‐
tion, an intriguing regulatory role for the chemokine CCR5 was demonstrated that its
activation led to cell death via caspase-3 mediated apoptosis in a neuroblastoma cell line
[78]. Further, induction of apoptosis has also been reported with CXCL12 in primary neuro‐
glial cultures in the absence of the HIV viral protein gp120. However, results from several
recent studies suggest that the changes in the expression of these chemokines may indicate
neuroprotective efforts in response to the neuroinflammatory environment [79]. Further
studies are needed to dissect the roles of chemokines in HAND pathogenesis, as they take
part in a crucial phase in immune responses, and provide attractive targets for modulation
in resolving HAND persistence.
The mechanisms by which the neuroinflammatory environment eventually ends in damage
to the neurons are not precisely known; however, several mechanisms are likely candidates.
Studies suggest that the neuronal damageis a result of indirect effects of viral proteins as
well as inflammatory mediators [1, 66]. Gp120 and Tat are reported to induce neuronal
apoptosis by activating death-associated proteases, caspases, specifically caspase-3 in in vitro
and in vivo disease models [80]. Another mechanism proposes a role for excitotoxicity secon‐
dary to impaired glutamate reuptake by astrocytes which are overwhelmed by pro-inflam‐
matory factors [81]. The well-defined cascade of excitotoxic injury includes excess Ca2+
influx into the neuronal cytoplasm. Several downstream events secondary to such increases
in Ca2+ such as excess free radical production and oxidative stress, and the activation of Ca2+-
dependent death proteases, calpains and caspases, will be detrimental to neurons, especially
in an environment with inadequate glial support and ongoing inflammation due to immune
cell activation [1, 66].
3.3. Neuroinflammation in HAND
The persistence of immune activation in the CNS and the peripheral nervous system (PNS)
of HIV-infected individuals in the ART era is supported by several lines of evidence. The
relatively low levels of HIV RNA in the presence of widespread neuropathological changes
in the CNS and PNS of HAND patients, and the lack of evidence of HIV infection of neuro‐
nal cells in vivo and in vitro hint at the possibility of chronic immune activation as a factor in
the persistence of HAND. Recent clinical evidence shows that ART reduces intrathecal im‐
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munoactivation in treated patients; however, a significant percentage of patients continue to
exhibit signs of ongoing inflammation [49, 50, 82, 83]. Further, even after successful reduc‐
tion of HIV RNA levels below the limit of detection for several years, patients present with
increased levels of inflammatory markers such as CSF neopterin and intrathecal IgG [52]. It
is thus apparent that ART is not sufficient to prevent or control HAND. One major factor to
consider in addressing this failure is that ART may not be efficient and/or sufficient in con‐
trolling the inflammatory cascade triggered by HIV infection.
Once HIV replication is established in the CNS, the initial chemotactic and inflammatory
factor production leads to further recruitment and activation of monocytes/macrophages,
creating a perpetual neuroinflammatory environment. The phenomenon of monocyte/
macrophage recruitment can be explained by a “push and pull” mechanism [47]. Two key
chemokines that play a role in the recruitment, or “pull”, of monocytes are CCL2 and frac‐
talkine (CXCL1).CCL2 is considered to be the more critical factor involved in the infiltration
of monocytes and lymphocytes across the BBB in the HAND brain [79]. Multiple cell types
of the CNS have been shown to produce CCL2 in models of inflammation, in which CCL2 is
a part of a signaling mechanism for recruitment of monocytes/macrophages from the pe‐
riphery. For example, leukocyte infiltration into the brain parenchyma has been demonstrat‐
ed upon pertussis toxin challenge in CCL2 transgenic mice [84]. More importantly, HIV-
infected leukocyte transmigration across BBB is dependent on CCL2 in an in vitro model of
disease [85]. Further, CCL2 has been shown to directly damage the endothelial cell junctions
of the BBB [86]. These findings clearly indicate a significant role for CCL2 in the “pull” of
monocyte/macrophages across the BBB in HAND. Interestingly, CCL2 levels remain elevat‐
ed in the CSF of HAND patients on ART, implicating that ongoing trafficking might be oc‐
curring despite viral suppression, and warrants further investigations into the persistence of
HAND in the era of ART [83].
The “push” aspect of the monocyte/macrophage recruitment involves the expansion in pe‐
ripheral blood neuroinvasive monocyte population. It has been shown that individuals with
HAND exhibit an expanded population of CD14+ peripheral blood monocytes that co-ex‐
press CD16, which is considered a more mature population [21]. These CD14+/CD16+ mono‐
cytes are preferentially susceptible to infection, and can serve as a reservoir harboring pro-
viral DNA. The entry of monocytes into the brain plays a key role in initiating the series of
events that lead to HAND, and although antiretrovirals hinder viral replication, they may
have minimal effects on the continued transmigration of monocytes into the brain. One
study showed that a single exposure of the CNS to the neurotoxic viral protein Tat led to the
infiltration of peripheral blood monocytes and resulted in prolonged disruption of CNS
function [87]. Thus, continuous and efficient viral suppression in the periphery is critical in
achieving suppressed inflammation in the CNS, and is of prime importance in the fight
against HAND.
While macrophages and microglia play primary roles in HIV infection in the CNS, other
glial cells also contribute to the neuroinflammation and neurotoxicity in the HAND brain.
One important cell type that needs to be mentioned in the neuroinflamatory processes in
HAND is the astrocytic cell population. As the most abundant cells in the CNS, astrocytes
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provide neurotrophic support, and are involved in repair processes for neurons. Further, as‐
trocytes are physiological regulators of microglial and macrophage inflammatory responses,
and indirectly modulate neuronal survival through reduction of the macrophage inflamma‐
tory response. However, their dysfunction, as a result of HIV infection, will lead to the dys‐
regulation of the local cytokine/chemokine balance. Evidence has shown that astrocytes are
key mediators in the regulation of microglial function and its influence on the onset and the
progression of HAND [55, 88]. Viral proteins gp120, and Tat both activate astrocytes to pro‐
duce pro-inflammatory cytokines TNF-α, IL-6, and IL-1β as well as the pro-inflammatory
chemokines CCL2 and CXCL10 [34, 55, 89-91]. The contribution of these pro-inflammatory
mediators by astrocytes as well as the release of pro-inflammatory cytokines IL-1β and TNF-
α by microglia and macrophage will only exacerbate the inflammatory environment in the
HIV-infected CNS.
Although the pathogenic mechanisms of HAND are likely to be multifactorial (Table 1), cel‐
lular activation with the initiation and persistence of the immune system in the CNS play a
pivotal role in this disease progression. Continued CNS inflammation is an essential factor
in many neurodegenerative diseases and HIV infection induces a cascade of inappropriate
immune responses in the CNS. The initial immunological response has protective intentions
through macrophage activation, but with persistent infection, the inflammatory response be‐
comes toxic to the neurons through the production of pro-inflammatory cytokines and che‐
mokines. Further, the decreased viral load in the CNS is accompanied by persistent
microglial activation and inflammation. Ineffective drug penetrance into the CNS, which
continues to be a challenge, can initiate the development of resistance to ART via permitting
mutations to the virus which allows the CNS to become a reservoir for the infection. As
HIV-infected macrophages are shown to be resistant to apoptosis,this will end in exacerbat‐
ing the virus reservoir in the CNS.
Inflammatory Responses During HIV-1 Brain Infection
Macrophage Activation (M1 phenotype)
Micogial nodules
Multinucleated Giant Cells in Central White Matter and Deep Gray Matter
Astrogliosis
Cytokines





Monocyte Chemotactic Protein-1 (MCP-1)
Interferon Gamma Induced Protein-10 (IP-10)
MHC class II presentation
Table 1. Pathological and laboratory evidence for immune activation in the CNS after HIV infection.
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ed in the CSF of HAND patients on ART, implicating that ongoing trafficking might be oc‐
curring despite viral suppression, and warrants further investigations into the persistence of
HAND in the era of ART [83].
The “push” aspect of the monocyte/macrophage recruitment involves the expansion in pe‐
ripheral blood neuroinvasive monocyte population. It has been shown that individuals with
HAND exhibit an expanded population of CD14+ peripheral blood monocytes that co-ex‐
press CD16, which is considered a more mature population [21]. These CD14+/CD16+ mono‐
cytes are preferentially susceptible to infection, and can serve as a reservoir harboring pro-
viral DNA. The entry of monocytes into the brain plays a key role in initiating the series of
events that lead to HAND, and although antiretrovirals hinder viral replication, they may
have minimal effects on the continued transmigration of monocytes into the brain. One
study showed that a single exposure of the CNS to the neurotoxic viral protein Tat led to the
infiltration of peripheral blood monocytes and resulted in prolonged disruption of CNS
function [87]. Thus, continuous and efficient viral suppression in the periphery is critical in
achieving suppressed inflammation in the CNS, and is of prime importance in the fight
against HAND.
While macrophages and microglia play primary roles in HIV infection in the CNS, other
glial cells also contribute to the neuroinflammation and neurotoxicity in the HAND brain.
One important cell type that needs to be mentioned in the neuroinflamatory processes in
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provide neurotrophic support, and are involved in repair processes for neurons. Further, as‐
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through macrophage activation, but with persistent infection, the inflammatory response be‐
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microglial activation and inflammation. Ineffective drug penetrance into the CNS, which
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It should also be noted that the impact of HIV infection in the peripheral tissue will ulti‐
mately impact the immune responses in the CNS. Thus, co-morbidities such as co-infections,
substance abuse, malignancies and antiretroviral drug toxicities, as well as general inflam‐
matory processes in the periphery, such as oxidative stress should be taken into account
when assessing the relationships between immune responses and the neuropathological
processes occurring in the HAND brain. This approach will provide more efficient tools,
and will have a greater impact on resolving the persistence of HAND.
4. Oxidative stress in neurodegenerative diseases
Oxidative stress is a shared pathological finding in a myriad of neurodegenerative diseases
including Alzheimer Disease, Parkinson Disease, Multiple Sclerosis (MS), Amyotrophic Lat‐
eral Sclerosis (ALS), and HAND [92, 93]. While it is clear that chronic oxidative stress which
will overwhelm the protective capacities of the cellular endogenous antioxidant responses
may be responsible in part for the neuronal death occurring in these conditions, in many
neurodegenerative diseases it is difficult to ascertain whether oxidative stress is the causa‐
tive factor for disease pathology and progression, or rather a resultant downstream event of
other cellular dysfunctions [92-95]. Nonetheless, in HAND, several lines of evidence suggest
that both HIV and antiretroviral compounds may result in oxidative and nitrosative stress in
the periphery and in the CNS [96-102]. Deficits in total antioxidant levels and increases in
the markers for oxidative stress are still observed in individuals on stable ART regimens
with undetectable viral titers, necessitating the need for adjunctive therapies to ameliorate
this imbalance [103, 104]. As has been suggested in a variety of neurodegenerative condi‐
tions, antioxidant supplementation or upregulation of the endogenous antioxidant response
in cells of the CNS may ameliorate the neuronal damage and death in HAND [1, 93, 94, 105].
4.1. Oxidative stress in the era of ART
The evidence of disrupted antioxidant balance and oxidative stress represent a continued
concern for HIV-infected individuals even when virus is successfully controlled by ART
[102]. To understand the magnitude and implications of this problem, it is important to un‐
derstand the initial disruptions to the antioxidant system that were observed in infected in‐
dividuals, and determine whether ART contributed to the resolution or the exacerbation of
these problems.
Oxidative stress prior to ART:As early as 1988, while researchers were just beginning to un‐
derstand the HIV virus, Sönnerborg and colleagues determined that plasma levels of malon‐
dialdehyde in adults with HIV infection were elevated up to 30% when compared with
controls [106]. Malondialdehyde is the breakdown product of polyunsaturated lipids by re‐
active oxygen species, and is a mainstay in terms of a biological marker for measuring the
relative levels of lipid peroxidation and oxidative stress in individuals [107]. A multitude of
studies followed, showing significant increases in the levels of free radicals, hydroperoxides,
hydroxynoneal, and oxidation of thiols in infected individuals, and confirming that malon‐
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dialdehyde is increased significantly in infected adults, as well as children [108-118]. The
metabolic synthesis of lipids is closely tied to the oxidative state of the cell and the lipids
residing in the cell membrane, as certain enzymes such as sphingomyelinase, are sensitive to
the oxidative status of the cell and regulate their activity based on cellular need [119]. Stud‐
ies looking into the production of sphingolipids illustrated an overproduction of both sphin‐
gomyelin and ceramides with HIV-infection, suggesting a lipid imbalance caused by the
virus [115, 116, 119]. Additionally, studies showed remarkable deficiencies in antioxidant
micronutrients including zinc, selenium, Vitamin C, Vitamin D, Vitamin E and beta-carotene
(Vitamin A) [109, 110, 118, 120-126]. Conflicting reports exist on perturbation of total antioxi‐
dant status prior to ART, with severalclinical studies reporting decreased total antioxidant
capacity [108, 113, 118], while Repetto et al. described an increase in the overall antioxidant
capacity as individuals progressed to AIDS [114]. The discrepancies between these findings
are likely based on the assays utilized to determine “total antioxidant capacity”, as different
enzymatic approaches target different portions of the antioxidant system.
Activity levels of superoxide dismutase (SOD), which catalyzes the detoxification of the oxi‐
dant superoxide into hydrogen peroxide and water, were assessed by a variety of laborato‐
ries. Elevated SOD activity was observed in all evaluated HIV-infected individuals, with
further increases occuringwith disease progression to AIDS. In addition, increases in SOD
mRNA levels were reported in individuals with HAD, as compared to those who were neu‐
rocognitively normal [114, 127, 128]. These changes in SOD were observed in microglial
cells, as well as in HIV-infected macrophages, suggesting a virus-triggered induction [128].
An essential antioxidant found in the brain which buffers many reactive oxygen species is
glutathione. In HIV-infected patients, overall glutathione levels were found to be reduced,
and the remaining glutathione was greatly skewed to the oxidized versus reduced form.
[114, 127, 129, 130]. The enzyme glutathione peroxidase, which promotes the conversion of
hydrogen peroxide to water through the use of glutathione, was also decreased, illustrating
a severe imbalance in this system whose goal is to maintain cellular redox homeostasis [121].
Another deleterioius consequence of rampant pro-oxidants within cells is oxidative modifi‐
cation of DNA bases. Increased levels of 5-hydroxyuracil, 5-hydroxycytosine, 8-hydroxyade‐
nine and 8-hydroxyguanine were found when comparing DNA isolated from lymphocytes
of HIV-infected individuals versus uninfected controls [131]. One other common product of
an imbalanced oxidative state which is beginning to gain more interest and research focus is
peroxynitrite. This compound, which is formed when superoxide reacts with nitric oxide, is
detectable through its nitrotyrosine moiety, and is found at higher levels and with more fre‐
quency in the brains of patients with HAD, compared with those who are neurocognitively
normal [128]. In addition to the generation of superoxide as a direct result of HIV infection,
the virus also increases mRNA expression of inducible nitric oxide synthase (iNOS), which
enables a precipitous accumulation of this deleterious oxidation product [128].Further re‐
search in the Nath laboratory has illustrated that thirteen proteins with nitrotyrosine modifi‐
cations are present in the CSF of individuals with HIV-infection. Individuals with dementia
had the highest levels of these nitrites and nitrates. Importantly, three of these proteins were
significantly elevated in individuals who showed declines in neurocognitive assessment
over a period of 6 months [101].
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It should also be noted that the impact of HIV infection in the peripheral tissue will ulti‐
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and will have a greater impact on resolving the persistence of HAND.
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derstand the initial disruptions to the antioxidant system that were observed in infected in‐
dividuals, and determine whether ART contributed to the resolution or the exacerbation of
these problems.
Oxidative stress prior to ART:As early as 1988, while researchers were just beginning to un‐
derstand the HIV virus, Sönnerborg and colleagues determined that plasma levels of malon‐
dialdehyde in adults with HIV infection were elevated up to 30% when compared with
controls [106]. Malondialdehyde is the breakdown product of polyunsaturated lipids by re‐
active oxygen species, and is a mainstay in terms of a biological marker for measuring the
relative levels of lipid peroxidation and oxidative stress in individuals [107]. A multitude of
studies followed, showing significant increases in the levels of free radicals, hydroperoxides,
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(Vitamin A) [109, 110, 118, 120-126]. Conflicting reports exist on perturbation of total antioxi‐
dant status prior to ART, with severalclinical studies reporting decreased total antioxidant
capacity [108, 113, 118], while Repetto et al. described an increase in the overall antioxidant
capacity as individuals progressed to AIDS [114]. The discrepancies between these findings
are likely based on the assays utilized to determine “total antioxidant capacity”, as different
enzymatic approaches target different portions of the antioxidant system.
Activity levels of superoxide dismutase (SOD), which catalyzes the detoxification of the oxi‐
dant superoxide into hydrogen peroxide and water, were assessed by a variety of laborato‐
ries. Elevated SOD activity was observed in all evaluated HIV-infected individuals, with
further increases occuringwith disease progression to AIDS. In addition, increases in SOD
mRNA levels were reported in individuals with HAD, as compared to those who were neu‐
rocognitively normal [114, 127, 128]. These changes in SOD were observed in microglial
cells, as well as in HIV-infected macrophages, suggesting a virus-triggered induction [128].
An essential antioxidant found in the brain which buffers many reactive oxygen species is
glutathione. In HIV-infected patients, overall glutathione levels were found to be reduced,
and the remaining glutathione was greatly skewed to the oxidized versus reduced form.
[114, 127, 129, 130]. The enzyme glutathione peroxidase, which promotes the conversion of
hydrogen peroxide to water through the use of glutathione, was also decreased, illustrating
a severe imbalance in this system whose goal is to maintain cellular redox homeostasis [121].
Another deleterioius consequence of rampant pro-oxidants within cells is oxidative modifi‐
cation of DNA bases. Increased levels of 5-hydroxyuracil, 5-hydroxycytosine, 8-hydroxyade‐
nine and 8-hydroxyguanine were found when comparing DNA isolated from lymphocytes
of HIV-infected individuals versus uninfected controls [131]. One other common product of
an imbalanced oxidative state which is beginning to gain more interest and research focus is
peroxynitrite. This compound, which is formed when superoxide reacts with nitric oxide, is
detectable through its nitrotyrosine moiety, and is found at higher levels and with more fre‐
quency in the brains of patients with HAD, compared with those who are neurocognitively
normal [128]. In addition to the generation of superoxide as a direct result of HIV infection,
the virus also increases mRNA expression of inducible nitric oxide synthase (iNOS), which
enables a precipitous accumulation of this deleterious oxidation product [128].Further re‐
search in the Nath laboratory has illustrated that thirteen proteins with nitrotyrosine modifi‐
cations are present in the CSF of individuals with HIV-infection. Individuals with dementia
had the highest levels of these nitrites and nitrates. Importantly, three of these proteins were
significantly elevated in individuals who showed declines in neurocognitive assessment
over a period of 6 months [101].
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While it appears that there is not an all-or-nothing increase or decrease in antioxidant ca‐
pacity, the evidence is clear that the components of the antioxidant defense system prior
to ART were greatly affected by HIV-infection, and that the capabilities of endogenous an‐
tioxidant  response were  not  able  to  alleviate  damaging oxidative  alterations  to  proteins
and DNA.
Persistence of oxidative stress in the era of ART: In the ART era, oxidative stress is still per‐
vasive in individuals living with well controlled HIV-infection [102]. In 2007, a group at the
University of Pennsylvania sought to ascertain whether ART had an effect on inflammation
and oxidative stress in the brains of HIV-infected individuals through utilization of chemi‐
cal-shift magnetic resonance spectroscopy. Through careful analysis of lipid, lactate, and
creatine levels, they determined that the inflammation and oxidative stress initiated by the
HIV infection was not ameliorated in ART-treated individuals, compared to seronegative
controls [132]. While these effects were observed in all HAND patients, the levels of oxida‐
tive stress markers were higher in those with more severe cognitive deficits [132].
Lipid peroxidation is still rampant despite effective viral control. While a couple of studies
report decreased levels in markers of lipid peroxidation in ART-medicated patients, as com‐
pared with those not receiving ART, multiple studies have shown persistent statistically sig‐
nificant increases in hydroperoxides, isoprostanes, and malondialdehyde in ART-treated
HIV-infected individuals, compared to seronegative controls [103, 113, 133-139]. Interesting‐
ly, two independent groups have determined in patient blood samples that the levels of per‐
oxide species and oxidative stress are higher in patients on protease inhibitor (PI) based
regimens, as compared with those in individuals on non-nucleoside reverse transcriptase in‐
hibitor (NNRTI) based regimens, implicating a role for the protease inhibitor class in induc‐
tion or exacerbation of oxidative stress [138, 140].
Micronutrient deficiencies are still problematic with ART, and while most patients have ade‐
quate plasma concentrations of vitamins C, D, and E, reported levels are still considered
sub-optimal and lower than seronegative patients [123, 141]. While subsequent reports have
indicated that zinc and selenium deficits are no longer observed in individuals on ART, fur‐
ther definitive confirmation of these findings is necessary [142, 143]. Additionally, in studies
which evaluated the serum of adults and the saliva of children, the total antioxidant status
was found to be decreased in ART treated HIV-patients when compared to HIV-negative
controls, mirroring findings in studies conducted in the pre-ART era [104, 144].
While several studies have indicated that introduction of ART has been accompanied by an
improvement in overall glutathione status, this effect is not totally rectified and imbalances
still occur [129]. In particular, numerous groups have shown that circulating glutathione lev‐
els are still markedly reduced in HIV-infected individuals, when compared with age-match‐
ed controls, with the ratio of oxidized to reduced glutathione remaining out of balance [112,
133-135, 145]. Unfortunately, studies investigating nitrosative stress and nitrosylated pro‐
teins in HIV-infected individuals on ART are still lacking; however, the Nath, Hammond,
and Sutliff laboratories have been investigating nitrosative stress in HIV, and it is likely that
such reports are forthcoming.
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It has been reported that HIV-positive individuals do not have altered levels of 8-hy‐
droxy-2’-deoxyguanosine [8-oxoG) in their urine regardless of ART or lipodystrophy status
[146]. While these findings appear to be promising, in a very recent study, autopsy tissue
from frontal cortex was stained for both nuclear and mitochondrial 8-oxoG. The levels of
this oxidized DNA product were significantly increased in cases of HAND, suggesting that
ART, or ART in combination with ongoing infection may promote DNA oxidative modifica‐
tion, cellular dysfunction damage and death [147]. Additionally, the presence of clastogenic
factors, which cause chromosomal breaks and DNA damage and which may be released
from cells under conditions of oxidative stress, was observed in the plasma of all HIV-pa‐
tients tested by Edeas et al. [148]. This was true ofpatients that were both asymptomatic and
symptomatic for AIDS-defining pathologies, and was independent of ART status [148]. The
effects of these clastogenic factors appear to persist in multiple cell populations implicated
in HAND pathogenesis. For example, in leukocytes obtained from HIV-infected individuals,
the percentage of cells exhibiting DNA fragmentation was increased in individuals on ART,
as compared with those who were ART- naïve [135]. However, the results of this study have
not addressed the possible contribution of latent or low level of infection to the findings.
Due to pervasive oxidative damage and antioxidant imbalance despite effective long-term
viral control in patients, it is now imperative to recognize the direct effect that viral enclaves
and antiretroviral drugs themselves may have on perpetuating these effects. Further studies
are needed to investigate the independent effects of ART and the virus on oxidative damage
in the CNS, as well as in the periphery in order to better determine therapeutic interventions
to resolve these dysfunctions.
4.2. Oxidative stress induction by HIV
Exhaustive research has been conducted in order to determine the effects of the HIV on in‐
fected cells and the cytotoxic factors released from these cells. As addressed earlier, it is now
clear that HIV-infected macrophages secrete a variety of neurotoxic substances including
glutamate, nitric oxide, and superoxide [96]. Within actively infected human myeloid-mono‐
cytic cell lines or monocyte-derived macrophages, HIV induces an increase in superoxide
anions, with a concomitant increase in superoxide to combat these factors [128, 149]. Mollace
and colleagues have demonstrated that the supernatants from HIV-infected human primary
macrophages induced oxidative stress in astrocytes, as indicated by increases in malondial‐
deyde levels [150]. They further showed that these supernatants, which contained excess su‐
peroxide, induced astrocytic apoptosis, confirming HIV-mediated toxicity of this secreted
product [150]. In a similar fashion, in HIV-infected monocytes, an induction of nitric oxide
synthase and subsequent increase nitric oxide was observed [151]. It is also interesting to
note that elevated oxidative stress in the form of intracellular singlet oxygen is capable of
reactivating latent HIV through long terminal repeat (LTR) transactivation in infected mon‐
ocytes or lymphocytes, suggesting that the virus may rely on oxidative stress signaling cas‐
cades for continuation of long-term infection or viral rebound [152].
The amino acid and neurotransmitter glutamate is normally secreted from neurons into the
synaptic cleft, and is quickly removed and recycled through the actions of astrocytes. This
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els are still markedly reduced in HIV-infected individuals, when compared with age-match‐
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factors, which cause chromosomal breaks and DNA damage and which may be released
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as compared with those who were ART- naïve [135]. However, the results of this study have
not addressed the possible contribution of latent or low level of infection to the findings.
Due to pervasive oxidative damage and antioxidant imbalance despite effective long-term
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are needed to investigate the independent effects of ART and the virus on oxidative damage
in the CNS, as well as in the periphery in order to better determine therapeutic interventions
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Exhaustive research has been conducted in order to determine the effects of the HIV on in‐
fected cells and the cytotoxic factors released from these cells. As addressed earlier, it is now
clear that HIV-infected macrophages secrete a variety of neurotoxic substances including
glutamate, nitric oxide, and superoxide [96]. Within actively infected human myeloid-mono‐
cytic cell lines or monocyte-derived macrophages, HIV induces an increase in superoxide
anions, with a concomitant increase in superoxide to combat these factors [128, 149]. Mollace
and colleagues have demonstrated that the supernatants from HIV-infected human primary
macrophages induced oxidative stress in astrocytes, as indicated by increases in malondial‐
deyde levels [150]. They further showed that these supernatants, which contained excess su‐
peroxide, induced astrocytic apoptosis, confirming HIV-mediated toxicity of this secreted
product [150]. In a similar fashion, in HIV-infected monocytes, an induction of nitric oxide
synthase and subsequent increase nitric oxide was observed [151]. It is also interesting to
note that elevated oxidative stress in the form of intracellular singlet oxygen is capable of
reactivating latent HIV through long terminal repeat (LTR) transactivation in infected mon‐
ocytes or lymphocytes, suggesting that the virus may rely on oxidative stress signaling cas‐
cades for continuation of long-term infection or viral rebound [152].
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molecule normally activates the N-methyl D-aspartate (NMDA) receptor on neurons, and
allows for Ca2+ entry into the cell. However, it has been clearly demonstrated that excessive
extracellular levels of glutamate resulting from overstimulation of neurons, impaired reup‐
take by astrocytes, or release from other cell populations within the brain can lead to hyper‐
activation of NMDA channels, subsequent increases in Ca2+ levels in the neuronal
cytoplasm, resulting in excitotoxic neuronal death [153]. In 2001, Jiang et al. demonstrated
through a series of elegant experiments that the molecule responsible for the neurotoxicity
observed on neuronal cultures was a molecule of less than 3,000 kilodaltons, was not sensi‐
tive to trypsin digestion, and that its neurotoxic effect was blocked by a selective NMDA re‐
ceptor antagonist, MK-801. It was through this study, as well as a subsequent study by
O’Donnell et al. that the increased levels of extracellular glutamate secreted by HIV-infected
macrophages may be a major factor in HIV-infected macrophage mediated indirect neuronal
death [154]. The increases in extracellular glutamate appears to be an effect of dysregulation
of the glutamate synthesis pathway, as inhibition of the mitochondrial glutaminase enzyme
blocks the production and the secretion of glutamate from HIV-infected macrophages
[155-157]. As was distinctly noted in human patient samples, a marked deficiency of gluta‐
thione and an imbalance between the oxidized and the reduced glutathione was observed.
Within cells, glutaminase is the enzyme which converts glutamine to glutamate. It is tempt‐
ing to consider that the oxidative stress resulting from the lack of the antioxidant properties
of glutamine may be very tightly coupled to a depletion of glutamine from cells by hyperac‐
tivation of glutaminase enzymes, precipitating an overproduction of glutamate and trigger‐
ing an excitotoxic neuronal death pathway.
Similar to effects of whole virus in vivo, when gp120 and Tat were injected into the brains of
rats, both of these viral proteins induced lipid peroxidation and glutathione depletion [158].
Additionally, both of these proteins significantly reduced intracellular glutathione, and in‐
creased malondialdehyde in immortalized brain endothelial cells, showing that the oxida‐
tive status of these cells would also be directly affected by the presence of virus. This is of
particular importance as the altered oxidative status of these endothelial cells comprising
the BBB will have potential impact on not only the integrity of the BBB, but also on the mon‐
ocyte/macrophage transmigration to the CNS, an important factor in the persistence of
HAND [159]. Further, when applied to neurons in culture, gp120 and Tat induce disrup‐
tions in the lipid metabolism, leading to increased levels of sphingomyelin, ceramide, and
hydroxynoneal,paralleling disruptions in these pathways observed in the neurons of HAND
patients [116].
Studies that investigated gp120 separately have revealed that it is capable of inducing ROS
formation, and activating the antioxidant response in astrocytes [91, 160]. Studies looking in‐
to the production of oxidant species by gp120 have shown that superoxide ions as well as
nitric oxide are involved in neuronal toxicity [100, 161]. Mechanistically, gp120-induced ni‐
tric oxide formation is dependent on a mannose-specific endocytic lectin in macrophages,
while gp120-induced expression and upregulation of iNOS selectively occurs in astrocytes
in human fetal neuroglial cultures [100, 162]. Multiple studies have shown that in neurons
undergoing gp120-induced toxicity, a significant increase in intracellular Ca2+, likely re‐
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leased from intracellular stores,preceeded death, suggesting at a mechanism of activation of
calpains or other pro-death cellular machinery [63, 160].
Studies investigating Tat-induced neuronal death have revealed that this viral protein trig‐
gered the accumulation of ROS when exogenously applied to a variety of cell  types,  in‐
cluding  lymphocytes,  microglia,  brain  microvascular  endothelial  cells  (BMECs)  and
neurons,  as  well  as  in  HeLa  cells  expressing  Tat  [163-166].  When  directly  injected  into
striatum of rats,  Tat produced dramatic increases in protein oxidative modifications and
protein carbonyls [167]. Protein carbonyls were also markedly increased in HeLa cells ex‐
pressing  Tat,  supporting  in  vivo  data  [166].  In  addition,  decreased levels  of  glutathione
were observed in cardiac myocytes and BMECs exposed to recombinant Tat protein, Tat-
expressing transgenic mice, and in Tat-expressing HeLa cells [164, 168-170].  Two studies
pinpointed the involvement of manganese-dependent superoxide dismutase (Mn-SOD) as
a key player in Tat- induced cellular changes. By expressing Tat in HeLa cells, the labora‐
tories  of  Lehman and McCord convincingly showed that  Tat  suppressed the RNA, pro‐
tein, and activity levels of Mn-SOD, while inducing no changes in the Cu,Zn SOD enzyme
levels  [166,  170].  In  HIV-infected  individuals,  plasma  levels  of  SOD  were  increased  in
plasma, and these changes were in parallel  with disease progression to AIDS. If  the re‐
sults from these HeLa cell studies can be expanded to other cell populations, it is tempt‐
ing  to  speculate  that  perhaps  this  overall  increase  in  SOD  activity  is  a  compensatory
mechanism resulting from the Tat-induced alterations in Mn-SOD activity and the subse‐
quent increases in superoxide ions that cannot be eliminated. The overexpression of Tat in
HeLa cells  also  led  to  decreases  in  overall  glutathione  levels,  with  a  lower  ratio  of  re‐
duced to oxidized glutathione in the remaining supply, mimicking the effect seen in HIV-
infected individuals in vivo and in HIV-infected macrophages in vitro [166, 170].
Finally, studies focusing on microglia have shown that the expression of HIV viral protein R
(Vpr) can induce oxidative stress pathways, and can activate HIV latent gene expression
[171]. When exogenously applied to human fetal astrocytes, the oxidative stress caused by
Vpr causes decreases in intracellular ATP and glutathione, and skews remaining glutathione
in favor of the oxidized versus reduced form [172].
In summary, exhaustive in vivo and in vitro studies indicate that HIV viral proteins them‐
selves can induce, precipitate and augment oxidative stress in multiple cell types, of both
peripheral and CNS tissue. These findings further emphasize the importance of complete in‐
hibition of viral replication in alleviating oxidative stress via antiretroviral therapy. Howev‐
er, emerging evidence suggests that antiretroviral drugs themselves might inadvertently
lead to oxidative stress.
4.3. Oxidative stress and ART
Due to the requirement for lifelong adherence to antiretroviral regimens to prevent viremia
and immune system compromise, it is necessary to investigate the effects of these com‐
pounds in a cellular context. Many of these drugs are associated with negative side effects,
and have been linked to the metabolic syndrome, atherosclerosis, lipodystrophy, protea‐
some inhibition and the unfolded protein response [173-175]. Additionally, it has become
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molecule normally activates the N-methyl D-aspartate (NMDA) receptor on neurons, and
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macrophages may be a major factor in HIV-infected macrophage mediated indirect neuronal
death [154]. The increases in extracellular glutamate appears to be an effect of dysregulation
of the glutamate synthesis pathway, as inhibition of the mitochondrial glutaminase enzyme
blocks the production and the secretion of glutamate from HIV-infected macrophages
[155-157]. As was distinctly noted in human patient samples, a marked deficiency of gluta‐
thione and an imbalance between the oxidized and the reduced glutathione was observed.
Within cells, glutaminase is the enzyme which converts glutamine to glutamate. It is tempt‐
ing to consider that the oxidative stress resulting from the lack of the antioxidant properties
of glutamine may be very tightly coupled to a depletion of glutamine from cells by hyperac‐
tivation of glutaminase enzymes, precipitating an overproduction of glutamate and trigger‐
ing an excitotoxic neuronal death pathway.
Similar to effects of whole virus in vivo, when gp120 and Tat were injected into the brains of
rats, both of these viral proteins induced lipid peroxidation and glutathione depletion [158].
Additionally, both of these proteins significantly reduced intracellular glutathione, and in‐
creased malondialdehyde in immortalized brain endothelial cells, showing that the oxida‐
tive status of these cells would also be directly affected by the presence of virus. This is of
particular importance as the altered oxidative status of these endothelial cells comprising
the BBB will have potential impact on not only the integrity of the BBB, but also on the mon‐
ocyte/macrophage transmigration to the CNS, an important factor in the persistence of
HAND [159]. Further, when applied to neurons in culture, gp120 and Tat induce disrup‐
tions in the lipid metabolism, leading to increased levels of sphingomyelin, ceramide, and
hydroxynoneal,paralleling disruptions in these pathways observed in the neurons of HAND
patients [116].
Studies that investigated gp120 separately have revealed that it is capable of inducing ROS
formation, and activating the antioxidant response in astrocytes [91, 160]. Studies looking in‐
to the production of oxidant species by gp120 have shown that superoxide ions as well as
nitric oxide are involved in neuronal toxicity [100, 161]. Mechanistically, gp120-induced ni‐
tric oxide formation is dependent on a mannose-specific endocytic lectin in macrophages,
while gp120-induced expression and upregulation of iNOS selectively occurs in astrocytes
in human fetal neuroglial cultures [100, 162]. Multiple studies have shown that in neurons
undergoing gp120-induced toxicity, a significant increase in intracellular Ca2+, likely re‐
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leased from intracellular stores,preceeded death, suggesting at a mechanism of activation of
calpains or other pro-death cellular machinery [63, 160].
Studies investigating Tat-induced neuronal death have revealed that this viral protein trig‐
gered the accumulation of ROS when exogenously applied to a variety of cell  types,  in‐
cluding  lymphocytes,  microglia,  brain  microvascular  endothelial  cells  (BMECs)  and
neurons,  as  well  as  in  HeLa  cells  expressing  Tat  [163-166].  When  directly  injected  into
striatum of rats,  Tat produced dramatic increases in protein oxidative modifications and
protein carbonyls [167]. Protein carbonyls were also markedly increased in HeLa cells ex‐
pressing  Tat,  supporting  in  vivo  data  [166].  In  addition,  decreased levels  of  glutathione
were observed in cardiac myocytes and BMECs exposed to recombinant Tat protein, Tat-
expressing transgenic mice, and in Tat-expressing HeLa cells [164, 168-170].  Two studies
pinpointed the involvement of manganese-dependent superoxide dismutase (Mn-SOD) as
a key player in Tat- induced cellular changes. By expressing Tat in HeLa cells, the labora‐
tories  of  Lehman and McCord convincingly showed that  Tat  suppressed the RNA, pro‐
tein, and activity levels of Mn-SOD, while inducing no changes in the Cu,Zn SOD enzyme
levels  [166,  170].  In  HIV-infected  individuals,  plasma  levels  of  SOD  were  increased  in
plasma, and these changes were in parallel  with disease progression to AIDS. If  the re‐
sults from these HeLa cell studies can be expanded to other cell populations, it is tempt‐
ing  to  speculate  that  perhaps  this  overall  increase  in  SOD  activity  is  a  compensatory
mechanism resulting from the Tat-induced alterations in Mn-SOD activity and the subse‐
quent increases in superoxide ions that cannot be eliminated. The overexpression of Tat in
HeLa cells  also  led  to  decreases  in  overall  glutathione  levels,  with  a  lower  ratio  of  re‐
duced to oxidized glutathione in the remaining supply, mimicking the effect seen in HIV-
infected individuals in vivo and in HIV-infected macrophages in vitro [166, 170].
Finally, studies focusing on microglia have shown that the expression of HIV viral protein R
(Vpr) can induce oxidative stress pathways, and can activate HIV latent gene expression
[171]. When exogenously applied to human fetal astrocytes, the oxidative stress caused by
Vpr causes decreases in intracellular ATP and glutathione, and skews remaining glutathione
in favor of the oxidized versus reduced form [172].
In summary, exhaustive in vivo and in vitro studies indicate that HIV viral proteins them‐
selves can induce, precipitate and augment oxidative stress in multiple cell types, of both
peripheral and CNS tissue. These findings further emphasize the importance of complete in‐
hibition of viral replication in alleviating oxidative stress via antiretroviral therapy. Howev‐
er, emerging evidence suggests that antiretroviral drugs themselves might inadvertently
lead to oxidative stress.
4.3. Oxidative stress and ART
Due to the requirement for lifelong adherence to antiretroviral regimens to prevent viremia
and immune system compromise, it is necessary to investigate the effects of these com‐
pounds in a cellular context. Many of these drugs are associated with negative side effects,
and have been linked to the metabolic syndrome, atherosclerosis, lipodystrophy, protea‐
some inhibition and the unfolded protein response [173-175]. Additionally, it has become
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apparent that these compounds themselves produce oxidative stress, even in the absence of
virus, and may in fact be contributing to the persistence of oxidative stress in patients with
well controlled viral load [97, 102].
HIV is highly susceptible to mutations, mostly due to the error-prone reverse transcription
step during replication, and underlies the emergence of drug resistant mutations over time
in patients treated with single antiretroviral drugs in the early 1990s. Additionally, the de‐
velopment of more sensitive methods for HIV RNA detection revealed the presence of viral
reservoirs in multiple tissues, including the CNS. These findings led to the revision of antire‐
troviral therapy, which, until that time included mostly single antiretroviral drug regimens.
A multiple drug treatment approach, termed ART, was implemented to aim at different
steps in the HIV replication. Currently recommended ART regimens include a cocktail of
nucleoside/nucleotide reverse-transcriptaseinhibitors (NRTIs/NtRTIs), non-nucleoside re‐
verse-transcriptase inhibitors (nNRTIs), protease inhibitors (PIs), and to a lesser extent, entry
inhibitors and integrase inhibitors(Panel on Antiretroviral Guidelines for Adults and Ado‐
lescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adoles‐
cents.Department of Health and Human Services.Available at http://aidsinfo.nih.gov/
contentfiles/lvguidelines/AdultandAdolescentGL.pdf). This approach has led to improved
immune function, long-term viral suppression; and underlies the reductions in HIV-associ‐
ated morbidity and mortality in the era of ART. The recently updated guidelines recom‐
mend ART initiation to all HIV- infected, ART-naive individuals irrespective of CD4+ counts
and the impact of early initiation of ART on HIV-associated neurological complications re‐
main to be seen. While a concensus has been reached regarding the time to initiate ART
based on CD4 cell counts, AIDS-defining illnesses, and certain co-morbidity factors; the pan‐
el did not clearly outline strategies to best eradicate the viral reservoirs in the CNS, and to
decrease the risk of developing HAND among infected patients.
In  the  meantime,  one  major  approach  to  better  control  HAND  has  been  to  implement
therapies that include drugs which achieve therapeutic concentrations in the CNS. While
HIV can circumvent the BBB barrier,  complex drug transport  and efflux mechanisms at
this junction hampers effective antiretroviral concentrations in the brain parenchyma. Re‐
cent efforts to address this hurdle have led to the establishment of CNS penetrance effec‐
tiveness  (CPE)  score,  an  algorithm  based  on  the  chemical  structure,  pharmacodynamic
and pharmacokinetic data of antiretroviral drugs [176-178]. In summary, an antiretroviral
drug with high CPE score is small in size (molecular mass below 400-500 kDa), has high
lipid solubility and low protein binding, and it is not a substrate for drug transport or ef‐
flux proteins. Unfortunately, results of several clinical studies which incorporated CPE in‐
to  the  design  and  the  analysis  of  outcomes  are  not  conclusive  [176,  178-183].  While  a
positive correlation between CPE scores and neurological outcomes are observed in sever‐
al studies, one study revealed that ART regimens with higher CPE scores might be associ‐
ated with worse neurocognitive performance [184].
These studies investigating the effect of CPE scores on neurological outcomes have inherent
caveats. First, due to the limited methodologies, the clinical studies cannot assess the drug
concentrations in the brain parenchyma, and instead depend on the CSF levels, which are
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usually based on measurements after a single-dose administration of the drug. Several fac‐
tors, such as poor drug adherence and the impact of co-prescribed drugs on the pharmaco‐
kinetics of antiretroviral drugs can impact the CNS concentrations and can confound the
measured outcomes.Additionally, the escape of drug-resistant viral species into the CNS
and their establishment in viral reservoirs early during infection can lead to the rise of drug-
resistant HIV species in the CNS, and can hinder the efforts to assess the impact of CPE
scores on neurological outcomes. Further, co-morbidity factors impacting the integrity of the
BBB should also be considered in assessing drug availability in the CNS. Among these fac‐
tors are cancer, infections, and drug and alcohol abuse, all of which are shown to alter BBB
integrity independent of HIV infection, and should be considered when CPE scores are es‐
tablished and evaluated [185-187]. One final factor to consider in evaluating the long-term
effectiveness of ART is the potential direct toxicities of antiretroviral drugs in the CNS, espe‐
cially given the interest in implementation of ART regimens with better CNS penetrance
and possibly developing nanoART as part of treatment plans. Antiretroviral drugs have
known side-effects in the periphery, including dyslipidemia, and lipohypertrophy. Further,
antiretroviral drug-associated toxicity is well documented in the peripheral nervous system,
and potential CNS toxicities secondary to ART exist. Oxidative damage elicited by antiretro‐
viral drugs is of particular interest, given ample evidence of ongoing oxidative stress in the
HAND brain, as described above.
In several cavalier studies, researchers eloquently demonstrated in several cell populations
(human adipocytes, monocytes, myeloid cell lines, and human aortic endothelial cells) that a
variety of drugs from the PI and NRTI families, alone or in combinations, induced the pro‐
duction of ROS, hydrogen peroxide, and factors promoting monocyte recruitment. The com‐
pounds reported to induce these changes included PIs: indinavir, nelfinavir, lopinavir,
ritonavir, saquinavir, atazanavir and NRTIs: stavudine (d4T), zidovudine (AZT), and dida‐
nosine [97-99, 188-191]. The compounds amprenavir (PI) and abacavir (NRTI) were consis‐
tently reported as lacking these effects, making these drugs good candidates for inclusion in
regimens to be prescribed to patients with HAND [98].
As the first available antiretroviral drug, AZT has been extensively studied. While AZT may
not be a mainstay drug of choice for customized optimal regimens, as the primary ART
compound available in resource-limited developing countries, it is still of importance to un‐
derstand its cellular effects. AZT was approved for treatment in 1987, and as early as 1992
the Papoian laboratory reported deficits in mitochondrial enzymes and uncoupling of the
electron transport chain (ETC) [192]. The disruption of the ETC is a primary cause of mito‐
chondrial based intracellular ROS accumulation and mitochondrial DNA oxidation, an ef‐
fect since expounded upon in multiple laboratories after acute AZT exposure in isolated
heart mitochondria and primary human cardiomyocytes, and after chronic gestational AZT
exposure in mouse liver and kidney and in the lung and brain of fetal patas monkeys
[193-196]. This compound has also been shown to increase mitochondrial lipid peroxidation,
deplete intracellular glutathione, and lead to oxidation of remaining glutathione, ultimately
inducing a caspase-3- and caspase-7- dependent apoptotic death [193, 195, 197]. When an‐
other NRTI, d4T was investigated, it also was shown to produce ROS, mitochondrial oxida‐
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apparent that these compounds themselves produce oxidative stress, even in the absence of
virus, and may in fact be contributing to the persistence of oxidative stress in patients with
well controlled viral load [97, 102].
HIV is highly susceptible to mutations, mostly due to the error-prone reverse transcription
step during replication, and underlies the emergence of drug resistant mutations over time
in patients treated with single antiretroviral drugs in the early 1990s. Additionally, the de‐
velopment of more sensitive methods for HIV RNA detection revealed the presence of viral
reservoirs in multiple tissues, including the CNS. These findings led to the revision of antire‐
troviral therapy, which, until that time included mostly single antiretroviral drug regimens.
A multiple drug treatment approach, termed ART, was implemented to aim at different
steps in the HIV replication. Currently recommended ART regimens include a cocktail of
nucleoside/nucleotide reverse-transcriptaseinhibitors (NRTIs/NtRTIs), non-nucleoside re‐
verse-transcriptase inhibitors (nNRTIs), protease inhibitors (PIs), and to a lesser extent, entry
inhibitors and integrase inhibitors(Panel on Antiretroviral Guidelines for Adults and Ado‐
lescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adoles‐
cents.Department of Health and Human Services.Available at http://aidsinfo.nih.gov/
contentfiles/lvguidelines/AdultandAdolescentGL.pdf). This approach has led to improved
immune function, long-term viral suppression; and underlies the reductions in HIV-associ‐
ated morbidity and mortality in the era of ART. The recently updated guidelines recom‐
mend ART initiation to all HIV- infected, ART-naive individuals irrespective of CD4+ counts
and the impact of early initiation of ART on HIV-associated neurological complications re‐
main to be seen. While a concensus has been reached regarding the time to initiate ART
based on CD4 cell counts, AIDS-defining illnesses, and certain co-morbidity factors; the pan‐
el did not clearly outline strategies to best eradicate the viral reservoirs in the CNS, and to
decrease the risk of developing HAND among infected patients.
In  the  meantime,  one  major  approach  to  better  control  HAND  has  been  to  implement
therapies that include drugs which achieve therapeutic concentrations in the CNS. While
HIV can circumvent the BBB barrier,  complex drug transport  and efflux mechanisms at
this junction hampers effective antiretroviral concentrations in the brain parenchyma. Re‐
cent efforts to address this hurdle have led to the establishment of CNS penetrance effec‐
tiveness  (CPE)  score,  an  algorithm  based  on  the  chemical  structure,  pharmacodynamic
and pharmacokinetic data of antiretroviral drugs [176-178]. In summary, an antiretroviral
drug with high CPE score is small in size (molecular mass below 400-500 kDa), has high
lipid solubility and low protein binding, and it is not a substrate for drug transport or ef‐
flux proteins. Unfortunately, results of several clinical studies which incorporated CPE in‐
to  the  design  and  the  analysis  of  outcomes  are  not  conclusive  [176,  178-183].  While  a
positive correlation between CPE scores and neurological outcomes are observed in sever‐
al studies, one study revealed that ART regimens with higher CPE scores might be associ‐
ated with worse neurocognitive performance [184].
These studies investigating the effect of CPE scores on neurological outcomes have inherent
caveats. First, due to the limited methodologies, the clinical studies cannot assess the drug
concentrations in the brain parenchyma, and instead depend on the CSF levels, which are
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usually based on measurements after a single-dose administration of the drug. Several fac‐
tors, such as poor drug adherence and the impact of co-prescribed drugs on the pharmaco‐
kinetics of antiretroviral drugs can impact the CNS concentrations and can confound the
measured outcomes.Additionally, the escape of drug-resistant viral species into the CNS
and their establishment in viral reservoirs early during infection can lead to the rise of drug-
resistant HIV species in the CNS, and can hinder the efforts to assess the impact of CPE
scores on neurological outcomes. Further, co-morbidity factors impacting the integrity of the
BBB should also be considered in assessing drug availability in the CNS. Among these fac‐
tors are cancer, infections, and drug and alcohol abuse, all of which are shown to alter BBB
integrity independent of HIV infection, and should be considered when CPE scores are es‐
tablished and evaluated [185-187]. One final factor to consider in evaluating the long-term
effectiveness of ART is the potential direct toxicities of antiretroviral drugs in the CNS, espe‐
cially given the interest in implementation of ART regimens with better CNS penetrance
and possibly developing nanoART as part of treatment plans. Antiretroviral drugs have
known side-effects in the periphery, including dyslipidemia, and lipohypertrophy. Further,
antiretroviral drug-associated toxicity is well documented in the peripheral nervous system,
and potential CNS toxicities secondary to ART exist. Oxidative damage elicited by antiretro‐
viral drugs is of particular interest, given ample evidence of ongoing oxidative stress in the
HAND brain, as described above.
In several cavalier studies, researchers eloquently demonstrated in several cell populations
(human adipocytes, monocytes, myeloid cell lines, and human aortic endothelial cells) that a
variety of drugs from the PI and NRTI families, alone or in combinations, induced the pro‐
duction of ROS, hydrogen peroxide, and factors promoting monocyte recruitment. The com‐
pounds reported to induce these changes included PIs: indinavir, nelfinavir, lopinavir,
ritonavir, saquinavir, atazanavir and NRTIs: stavudine (d4T), zidovudine (AZT), and dida‐
nosine [97-99, 188-191]. The compounds amprenavir (PI) and abacavir (NRTI) were consis‐
tently reported as lacking these effects, making these drugs good candidates for inclusion in
regimens to be prescribed to patients with HAND [98].
As the first available antiretroviral drug, AZT has been extensively studied. While AZT may
not be a mainstay drug of choice for customized optimal regimens, as the primary ART
compound available in resource-limited developing countries, it is still of importance to un‐
derstand its cellular effects. AZT was approved for treatment in 1987, and as early as 1992
the Papoian laboratory reported deficits in mitochondrial enzymes and uncoupling of the
electron transport chain (ETC) [192]. The disruption of the ETC is a primary cause of mito‐
chondrial based intracellular ROS accumulation and mitochondrial DNA oxidation, an ef‐
fect since expounded upon in multiple laboratories after acute AZT exposure in isolated
heart mitochondria and primary human cardiomyocytes, and after chronic gestational AZT
exposure in mouse liver and kidney and in the lung and brain of fetal patas monkeys
[193-196]. This compound has also been shown to increase mitochondrial lipid peroxidation,
deplete intracellular glutathione, and lead to oxidation of remaining glutathione, ultimately
inducing a caspase-3- and caspase-7- dependent apoptotic death [193, 195, 197]. When an‐
other NRTI, d4T was investigated, it also was shown to produce ROS, mitochondrial oxida‐
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tive stress, oxidized mitochondrial DNA, and altered activity of mitochondrial oxidative
phosphorylation enzymes [198, 199]. Similarly, NRTI zalcitabine (ddC) also induces oxida‐
tive stress, as evidenced by the accumulation of protein carbonyls and nitrotyrosine modifi‐
cations. Interestingly, this study also reported that the better-tolerated cytidine analog
lamivudine (3TC) did not produce these effects, suggesting that 3TC may be considered as
an alternative to reduce oxidative stress, and that future compounds generated from this
structural base may behave similarly [200]. Interestingly, in contrast to studies in human
lymphoid cells, Brandmann and collegues have recently reported that in astrocytes AZT,
lamivudine, efavirenz, and nevirapine do not appear to reduce intracellular levels of gluta‐
thione [190]. Whether or not these compounds behave similarly in neurons and other cell
populations in the CNS remains to be elucidated.
In the non-nucleoside reverse transcriptase inhibitor (nNRTI) drug class, efavirenz applied
to a human hepatoblastoma cell line resulted in superoxide generation, depletion of intracel‐
lular glutathione, and decrease in mitochondrial function and membrane potential that was
independent of mitochondrial DNA replication [201]. In addition, efavirenz has also been
linked to neuropsychological side effects in HIV-infected patients, and it is probable that the
specific oxidative stress effects on mitochondria and glutathione may play a role in the neu‐
rotoxicity of this compound, as neurons are particularly sensitive to perturbations in the an‐
tioxidant system [201, 202].
Within the protease inhibitor class, both ritonavir and amprenavir have been associated
with increased superoxide anion production, while ritonavir has been shown to cause in‐
creases in nitrotyrosine levels in porcine coronary arteries [203]. On the other hand, both in‐
dinavir and nelfinavir have been shown to induce a time and concentration dependent
depletion of intracellular glutathione in astrocytes as well as in pancreatic beta cells [99,
190]. Nelfinavir is of particular interest, as it suppresses cytosolic, rather than mitochondrial
superoxide dismutase levels, and induces a necrotic rather than apoptotic cell death cascade
in an adipocyte cell line [99, 204]. Future studies of this compound will undoubtedly prove
interesting and may have important implications in patients with regard to their neurocog‐
nitive outcomes associated with this compund. Finally, it is interesting to note that multiple
studies investigating the oxidative effects of the thymidine analogs in the NRTI class have
reported increased ROS, hydrogen peroxide, and nitric oxide intermediates but no superox‐
ide anions [188, 205].
Currently, there is no information on possible oxidative effects of the entry inhibitor, inte‐
grase inhibitor, and mutation inhibitor drug classes. Similarly, the lack of published studies
for the neuroglial cell populations in the brains of HAND patients is surprising. Several
posters at national and international meetings over recent years have addressed this impor‐
tant issue, and hopefully these reports will be forthcoming [206, 207]. In order to design cus‐
tom drug regimens which will not precipitate, or can ameloirate oxidative stress, cellular
dysfunction and death, it is critical to have an understanding of the cellular effects of each
currently approved antiretroviral compound, and to design future compounds with mini‐
mal oxidative effects. Further, it is possible that the continued dysfunction in superoxide
production and superoxide dismutase levels in patients may be due to the effects of more
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than one drug in a multi-drug regimen. Thus, designing future combinations which do not
precipiateoxidative stressis of utmost importance in efforts to resolve the persistence of
HAND observed in the ART era.
4.4. Potential therapeutic avenues for oxidative stress in ART era
Since the manifestations of oxidative stress induced by HIV and ART have emerged, it has
also become evident to scientists that boosting the endogenous antioxidant response may be
a valid and encouraging adjunctive therapeutic option. Within the cell, the antioxidant re‐
sponse is mediated through the activation of transcription factor NF-E2 (nuclear factor (er‐
ythroid-derived 2)-related factor-2 (Nrf2)and its myriad of effector phase II and III
detoxifying enzymes. Relevant to the previously discussed aberrations in oxidant detoxifica‐
tion, this pathway upregulates superoxide dismutase, peroxiredoxins, thioredoxins, and
multiple glutathione biosynthesis enzymes [208, 209].
In vitro, multiple compounds which act upon the Nrf2 pathway have proven effective in
ameliorating the oxidative effects of viral infection, viral proteins or antiretroviral drugs.
Among these compounds are resveratrol, dimethyl fumarate, N-acetylcysteine, and curcur‐
min [189, 191, 193, 203, 210]. Antioxidants which have not yet been shown to act through the
Nrf2 pathway, but which have similar effects in vitro include dihydroxybenzyl alcohol, wa‐
ter soluble vitamin E (trolox), glutathione mimetic tricyclodecan-9-yl-xanthogenat, and ace‐
tyl-l-carnitine [188, 200, 201, 211]. An alternative approach to specifically inhibit the actions
of NADPH oxidase through the compound diphenyleneiodonium, was able to specifically
prevent the effects of PIs, but not NRTIs in human adipocytes [98]. This interesting finding
suggests that the different antiretroviral classes may lead to ROS production through differ‐
ent mechanisms, and that specific therapeutics targeting individual oxidant-producing en‐
zymes or pathways may need to be considered for specific ART regimens.
An alternative approach to activating Nrf2 pathway is supplementation with the antioxi‐
dant vitamin C (ascorbate), which is capable of directly scavenging reactive oxygen and ni‐
trogen species. This method has been shown to be effective in counteracting the deleterious
effects of gp120, as well as nelfinavir in vitro, and has been shown to have beneficial out‐
comes in patients, when supplemented to ART regimens [100, 195, 204]. Along these same
lines, supplementation with a variety of other antioxidants and micronutrients including
minocycline, glutathione replenishing peptide alpha-lipoic acid, selenium, vitamin A, Vita‐
min E, and a multivitamin regimen including vitamins A, C, E selenium and coenzyme Q10
have demonstrated partial protection from the deleterious oxidative effects of HIV/SIV and
ART in vivo, with particular emphasis on restoration of the total blood glutathione levels
[127, 195, 212-214]. Finally, the NMDA-receptor blocker memantine, and monoamide oxi‐
dase type B inhibitor selegiline, approved for treatment in Alzheimer and Parkinson Diseas‐
es, respectively, have also been proposed as potential therapeutics for HAND [1, 214].
Memantine might exert therapeutic effects through reduction of residual virus-mediated
glutamate excitotoxicity, and selegiline has been reported to be capable of reducing oxygen-
based free radicals [215, 216]. The use of these compounds and their efficacy in reducing oxi‐
dative damage in HAND are still in early stages. Initial studies were confounded by the fact
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tive stress, oxidized mitochondrial DNA, and altered activity of mitochondrial oxidative
phosphorylation enzymes [198, 199]. Similarly, NRTI zalcitabine (ddC) also induces oxida‐
tive stress, as evidenced by the accumulation of protein carbonyls and nitrotyrosine modifi‐
cations. Interestingly, this study also reported that the better-tolerated cytidine analog
lamivudine (3TC) did not produce these effects, suggesting that 3TC may be considered as
an alternative to reduce oxidative stress, and that future compounds generated from this
structural base may behave similarly [200]. Interestingly, in contrast to studies in human
lymphoid cells, Brandmann and collegues have recently reported that in astrocytes AZT,
lamivudine, efavirenz, and nevirapine do not appear to reduce intracellular levels of gluta‐
thione [190]. Whether or not these compounds behave similarly in neurons and other cell
populations in the CNS remains to be elucidated.
In the non-nucleoside reverse transcriptase inhibitor (nNRTI) drug class, efavirenz applied
to a human hepatoblastoma cell line resulted in superoxide generation, depletion of intracel‐
lular glutathione, and decrease in mitochondrial function and membrane potential that was
independent of mitochondrial DNA replication [201]. In addition, efavirenz has also been
linked to neuropsychological side effects in HIV-infected patients, and it is probable that the
specific oxidative stress effects on mitochondria and glutathione may play a role in the neu‐
rotoxicity of this compound, as neurons are particularly sensitive to perturbations in the an‐
tioxidant system [201, 202].
Within the protease inhibitor class, both ritonavir and amprenavir have been associated
with increased superoxide anion production, while ritonavir has been shown to cause in‐
creases in nitrotyrosine levels in porcine coronary arteries [203]. On the other hand, both in‐
dinavir and nelfinavir have been shown to induce a time and concentration dependent
depletion of intracellular glutathione in astrocytes as well as in pancreatic beta cells [99,
190]. Nelfinavir is of particular interest, as it suppresses cytosolic, rather than mitochondrial
superoxide dismutase levels, and induces a necrotic rather than apoptotic cell death cascade
in an adipocyte cell line [99, 204]. Future studies of this compound will undoubtedly prove
interesting and may have important implications in patients with regard to their neurocog‐
nitive outcomes associated with this compund. Finally, it is interesting to note that multiple
studies investigating the oxidative effects of the thymidine analogs in the NRTI class have
reported increased ROS, hydrogen peroxide, and nitric oxide intermediates but no superox‐
ide anions [188, 205].
Currently, there is no information on possible oxidative effects of the entry inhibitor, inte‐
grase inhibitor, and mutation inhibitor drug classes. Similarly, the lack of published studies
for the neuroglial cell populations in the brains of HAND patients is surprising. Several
posters at national and international meetings over recent years have addressed this impor‐
tant issue, and hopefully these reports will be forthcoming [206, 207]. In order to design cus‐
tom drug regimens which will not precipitate, or can ameloirate oxidative stress, cellular
dysfunction and death, it is critical to have an understanding of the cellular effects of each
currently approved antiretroviral compound, and to design future compounds with mini‐
mal oxidative effects. Further, it is possible that the continued dysfunction in superoxide
production and superoxide dismutase levels in patients may be due to the effects of more
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than one drug in a multi-drug regimen. Thus, designing future combinations which do not
precipiateoxidative stressis of utmost importance in efforts to resolve the persistence of
HAND observed in the ART era.
4.4. Potential therapeutic avenues for oxidative stress in ART era
Since the manifestations of oxidative stress induced by HIV and ART have emerged, it has
also become evident to scientists that boosting the endogenous antioxidant response may be
a valid and encouraging adjunctive therapeutic option. Within the cell, the antioxidant re‐
sponse is mediated through the activation of transcription factor NF-E2 (nuclear factor (er‐
ythroid-derived 2)-related factor-2 (Nrf2)and its myriad of effector phase II and III
detoxifying enzymes. Relevant to the previously discussed aberrations in oxidant detoxifica‐
tion, this pathway upregulates superoxide dismutase, peroxiredoxins, thioredoxins, and
multiple glutathione biosynthesis enzymes [208, 209].
In vitro, multiple compounds which act upon the Nrf2 pathway have proven effective in
ameliorating the oxidative effects of viral infection, viral proteins or antiretroviral drugs.
Among these compounds are resveratrol, dimethyl fumarate, N-acetylcysteine, and curcur‐
min [189, 191, 193, 203, 210]. Antioxidants which have not yet been shown to act through the
Nrf2 pathway, but which have similar effects in vitro include dihydroxybenzyl alcohol, wa‐
ter soluble vitamin E (trolox), glutathione mimetic tricyclodecan-9-yl-xanthogenat, and ace‐
tyl-l-carnitine [188, 200, 201, 211]. An alternative approach to specifically inhibit the actions
of NADPH oxidase through the compound diphenyleneiodonium, was able to specifically
prevent the effects of PIs, but not NRTIs in human adipocytes [98]. This interesting finding
suggests that the different antiretroviral classes may lead to ROS production through differ‐
ent mechanisms, and that specific therapeutics targeting individual oxidant-producing en‐
zymes or pathways may need to be considered for specific ART regimens.
An alternative approach to activating Nrf2 pathway is supplementation with the antioxi‐
dant vitamin C (ascorbate), which is capable of directly scavenging reactive oxygen and ni‐
trogen species. This method has been shown to be effective in counteracting the deleterious
effects of gp120, as well as nelfinavir in vitro, and has been shown to have beneficial out‐
comes in patients, when supplemented to ART regimens [100, 195, 204]. Along these same
lines, supplementation with a variety of other antioxidants and micronutrients including
minocycline, glutathione replenishing peptide alpha-lipoic acid, selenium, vitamin A, Vita‐
min E, and a multivitamin regimen including vitamins A, C, E selenium and coenzyme Q10
have demonstrated partial protection from the deleterious oxidative effects of HIV/SIV and
ART in vivo, with particular emphasis on restoration of the total blood glutathione levels
[127, 195, 212-214]. Finally, the NMDA-receptor blocker memantine, and monoamide oxi‐
dase type B inhibitor selegiline, approved for treatment in Alzheimer and Parkinson Diseas‐
es, respectively, have also been proposed as potential therapeutics for HAND [1, 214].
Memantine might exert therapeutic effects through reduction of residual virus-mediated
glutamate excitotoxicity, and selegiline has been reported to be capable of reducing oxygen-
based free radicals [215, 216]. The use of these compounds and their efficacy in reducing oxi‐
dative damage in HAND are still in early stages. Initial studies were confounded by the fact
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that much damage was already present in late stage HAD patients and a protective effect at
this stage was not evident [217]. Further work with these compounds will require identify‐
ing patients with ANI or MND to enroll in longitudinal studies to determine whether these
compounds will have long-term benefit.
Going forward, it is imperative that the oxidative stress imposed by HIV and ART are tar‐
geted by adjunctive therapies. As research progresses with the quest for eliminating viral
reservoirs and designing more effective, less toxic antiretroviral compounds, it is important
to keep in mind that oxidative stress is and will continue to be a persistent burden, especial‐
ly in a patient population with a significantly enhanced life expectancy.
5. The impact of co-morbidities on HAND
HIV, once an acute and catastrophic infection, has now become a chronic and manageable
disease, with advances made in diagnosis and treatment. These changes are reflected in the
increases in life expectancy from 5 years to up to the projected 50 years from the time of di‐
agnosis. However, with the increased lifespan, co-morbidities, such as chronic co-infections,
substance abuse, and aging have become major contributors to HAND persistence, and need
to be addressed for successful evaluation and treatment of HAND.
The compromised immune system in an HIV-infected individual increases the risk of op‐
portunistic infections in the CNS, much like that observed in the peripheral tissue. Most
commonly observed infections, CNS toxoplasmosis, cryptococcosis, CNS tuberculosis, and
cytomegalovirus encephalitis can be treated successfully by a combination of antimicrobi‐
als,  antiviral and antiretroviral drugs. However,  there are several other viral agents that
can either directly target or indirectly compromise CNS, and cannot be readily managed
by antiretroviral drugs or chemotherapeutics. One important virus with serious complica‐
tions in HAND patients is JC virus, the causative agent of progressive multifocal leukoen‐
cephelopathy (PML). While approximately 60-80% of adults globally are seropositive for
JC virus, it leads to the development of PML mostly in individuals who are immuno-com‐
promised,  either  due to an underlying cancer or  immunosuppressive treatment,  or  who
are  HIV-positive.  The  current  incidence  of  PML  in  HIV  patients  is  3%.  Studies  have
shown that JC virus can traffic across the BBB within the B cells, can enter the CNS as a
free virus, or can infect brain vascular endothelial cells. Once in the CNS, JC virus causes
the lytic infection of oligodendrocytes, and results in multifocal demyelination in multiple
regions  of  the  white  matter.  Thus,  PML may exacerbate  white  matter  loss  that  may al‐
ready be occurring in HAND patients. Further, the most efficient, however limited, treat‐
ment  for  PML,  which is  immune restoration with  aggressive  antiretroviral  therapy,  can
potentiate immune reconstitution inflammatory syndrome (IRIS).  IRIS,  a  T-cell  mediated
encephalitis,  can  precipitate  further  injury  and  worsening  of  neurological  symptoms.
While fatality due to PML in HIV-infected individuals can be as high as 50%, the number
of cases with non-lethal  PML is  increasing and PML may be contributing to the persis‐
tence of HIV-associated neurological complications.
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Hepatitis B and C (HBV and HCV) are also commonly found in HIV-infected individuals
due to the shared risk factors of contracting the virus. While these viruses are not thought to
target the primary cells of the CNS, a recent study has reported the presence of HCV anti‐
gens in astrocytes and the cells of the macrophage/microglial lineage in the human brain.
Additionally, there is limited evidence suggesting that HCV core protein might be detrimen‐
tal to neurons in vitro and in vivo. Further, several studies have suggested that HCV and HIV
can potentiate each other’s replication. Currently, there is no conclusive data regarding a
possible correlation between HCV presence in the CNS and the neurocognitive deficits in
HAND patients. However, the potential implications of HCV infection in the CNS are at
least three-fold. First, HCV co-infection can hinder the efforts to suppress HIV replication in
the CNS. Second, weakened immune system function secondary to HCV will negatively im‐
pact subsequent alleviation of neurocognitive functions. Finally, compromised functioning
of CNS support cells, mainly astrocytes, secondary to concomitant HCV infection will aug‐
ment the neuroinflammatory environment with a negative impact on neuronal health. These
implications may underlie the evidence that suggests that viral suppression and CD4+ cell
recovery is not as successful in the presence of HCV, and might partially explain the spora‐
dic data suggesting that worse neurocognitive impairment is observed in HIV-HCV co-in‐
fected patients [184].
Illicit drug use, as well as alcohol abuse, put HIV-positive patients at a greater risk for
HAND [6, 218-224]. The prevalence of HIV infection is 11-17% among illicit drug users, and
methamphetamine (METH) is among the most frequently abused drug with well-known
toxic effects on the BBB and in the CNS [220]. HIV-infected patients using METH exhibit
more neurocognitive deficits, compared to those not using METH. These findings are likely
due to the effects of METH on several fronts in the CNS. First, extensive studies have con‐
clusively shown that METH alters the BBB permeability through direct damage to the
BMECs, which in turn can augment HIV access to the CNS. Additionally, METH can exert
neurotoxic effects in the CNS through oxidative stress and mitochondrial dysfunction [184],
and precipitate further synaptic and neuronal damage. METH may also interfere with the
expected benefits of ART in several ways. Most importantly, studies have shown that al‐
tered patient behavior due to METH use can interfere with drug adherence. Secondly, al‐
tered BBB function in a patient using METH can potentially alter antiretroviral access to the
CNS, hindering efforts to establish an efficient regimen with limited side effects.
6. Aging and HAND
The widespread use of ART has drastically decreased the incidence of AIDS-related compli‐
cations and improved the long-term prognosis of HIV-positive individuals. Currently, 30%
of the HIV-positive population in the United States is over the age of 50,and by 2015 it is
estimated that more than 50% will be over the age of 50 [225, 226]. Despite this remarkable
development, the life expectancy for ART-treated HIV-positive individuals remains 10-30
years less than that of uninfected individuals [227]. Given the rapid global expansion of this
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that much damage was already present in late stage HAD patients and a protective effect at
this stage was not evident [217]. Further work with these compounds will require identify‐
ing patients with ANI or MND to enroll in longitudinal studies to determine whether these
compounds will have long-term benefit.
Going forward, it is imperative that the oxidative stress imposed by HIV and ART are tar‐
geted by adjunctive therapies. As research progresses with the quest for eliminating viral
reservoirs and designing more effective, less toxic antiretroviral compounds, it is important
to keep in mind that oxidative stress is and will continue to be a persistent burden, especial‐
ly in a patient population with a significantly enhanced life expectancy.
5. The impact of co-morbidities on HAND
HIV, once an acute and catastrophic infection, has now become a chronic and manageable
disease, with advances made in diagnosis and treatment. These changes are reflected in the
increases in life expectancy from 5 years to up to the projected 50 years from the time of di‐
agnosis. However, with the increased lifespan, co-morbidities, such as chronic co-infections,
substance abuse, and aging have become major contributors to HAND persistence, and need
to be addressed for successful evaluation and treatment of HAND.
The compromised immune system in an HIV-infected individual increases the risk of op‐
portunistic infections in the CNS, much like that observed in the peripheral tissue. Most
commonly observed infections, CNS toxoplasmosis, cryptococcosis, CNS tuberculosis, and
cytomegalovirus encephalitis can be treated successfully by a combination of antimicrobi‐
als,  antiviral and antiretroviral drugs. However,  there are several other viral agents that
can either directly target or indirectly compromise CNS, and cannot be readily managed
by antiretroviral drugs or chemotherapeutics. One important virus with serious complica‐
tions in HAND patients is JC virus, the causative agent of progressive multifocal leukoen‐
cephelopathy (PML). While approximately 60-80% of adults globally are seropositive for
JC virus, it leads to the development of PML mostly in individuals who are immuno-com‐
promised,  either  due to an underlying cancer or  immunosuppressive treatment,  or  who
are  HIV-positive.  The  current  incidence  of  PML  in  HIV  patients  is  3%.  Studies  have
shown that JC virus can traffic across the BBB within the B cells, can enter the CNS as a
free virus, or can infect brain vascular endothelial cells. Once in the CNS, JC virus causes
the lytic infection of oligodendrocytes, and results in multifocal demyelination in multiple
regions  of  the  white  matter.  Thus,  PML may exacerbate  white  matter  loss  that  may al‐
ready be occurring in HAND patients. Further, the most efficient, however limited, treat‐
ment  for  PML,  which is  immune restoration with  aggressive  antiretroviral  therapy,  can
potentiate immune reconstitution inflammatory syndrome (IRIS).  IRIS,  a  T-cell  mediated
encephalitis,  can  precipitate  further  injury  and  worsening  of  neurological  symptoms.
While fatality due to PML in HIV-infected individuals can be as high as 50%, the number
of cases with non-lethal  PML is  increasing and PML may be contributing to the persis‐
tence of HIV-associated neurological complications.
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Hepatitis B and C (HBV and HCV) are also commonly found in HIV-infected individuals
due to the shared risk factors of contracting the virus. While these viruses are not thought to
target the primary cells of the CNS, a recent study has reported the presence of HCV anti‐
gens in astrocytes and the cells of the macrophage/microglial lineage in the human brain.
Additionally, there is limited evidence suggesting that HCV core protein might be detrimen‐
tal to neurons in vitro and in vivo. Further, several studies have suggested that HCV and HIV
can potentiate each other’s replication. Currently, there is no conclusive data regarding a
possible correlation between HCV presence in the CNS and the neurocognitive deficits in
HAND patients. However, the potential implications of HCV infection in the CNS are at
least three-fold. First, HCV co-infection can hinder the efforts to suppress HIV replication in
the CNS. Second, weakened immune system function secondary to HCV will negatively im‐
pact subsequent alleviation of neurocognitive functions. Finally, compromised functioning
of CNS support cells, mainly astrocytes, secondary to concomitant HCV infection will aug‐
ment the neuroinflammatory environment with a negative impact on neuronal health. These
implications may underlie the evidence that suggests that viral suppression and CD4+ cell
recovery is not as successful in the presence of HCV, and might partially explain the spora‐
dic data suggesting that worse neurocognitive impairment is observed in HIV-HCV co-in‐
fected patients [184].
Illicit drug use, as well as alcohol abuse, put HIV-positive patients at a greater risk for
HAND [6, 218-224]. The prevalence of HIV infection is 11-17% among illicit drug users, and
methamphetamine (METH) is among the most frequently abused drug with well-known
toxic effects on the BBB and in the CNS [220]. HIV-infected patients using METH exhibit
more neurocognitive deficits, compared to those not using METH. These findings are likely
due to the effects of METH on several fronts in the CNS. First, extensive studies have con‐
clusively shown that METH alters the BBB permeability through direct damage to the
BMECs, which in turn can augment HIV access to the CNS. Additionally, METH can exert
neurotoxic effects in the CNS through oxidative stress and mitochondrial dysfunction [184],
and precipitate further synaptic and neuronal damage. METH may also interfere with the
expected benefits of ART in several ways. Most importantly, studies have shown that al‐
tered patient behavior due to METH use can interfere with drug adherence. Secondly, al‐
tered BBB function in a patient using METH can potentially alter antiretroviral access to the
CNS, hindering efforts to establish an efficient regimen with limited side effects.
6. Aging and HAND
The widespread use of ART has drastically decreased the incidence of AIDS-related compli‐
cations and improved the long-term prognosis of HIV-positive individuals. Currently, 30%
of the HIV-positive population in the United States is over the age of 50,and by 2015 it is
estimated that more than 50% will be over the age of 50 [225, 226]. Despite this remarkable
development, the life expectancy for ART-treated HIV-positive individuals remains 10-30
years less than that of uninfected individuals [227]. Given the rapid global expansion of this
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population, it has become increasingly important to understand the risk factors that lie at
the intersection of HIV, ART, and aging.
Older HIV-positive patients,  including those treated with ART, are at  increased risk for
systemic diseases including atherosclerosis, liver and kidney failure, cancer, and osteopo‐
rosis [227, 228]. The aging brain may also be more vulnerable to the effects of HIV as old‐
er adults display an increased susceptibility to HAND, and emerging evidence suggests
an increased prevalence of neurodegenerative diseases, including Alzheimer and Parkin‐
son, in this patient population [229, 230]. It remains unclear if the increased prevalence of
HAND is a result of HIV and related comorbidities, including hypertension, insulin resist‐
ance,  and  lipodystrophy,  or  other  confounding  factors  such  as  immunosenescence  and
ART toxicities,  all  of  which are likely to impact  CNS disease progression in older HIV-
positive individuals [231, 232].
Antiretroviral therapy effectively limits HIV disease progression, maintains patients in a
state of partial immune competence, and arrests subjects in a pre-symptomatic state [233].
However, despite the ability of ART to reduce plasma HIV RNA to undetectable levels,
HIV-positive individuals remain at higher risk for opportunistic illnesses and premature
death [234, 235]. Thus, ART may reduce, but does not appear to eliminate, premature and/or
accelerated aging in HIV-infected individuals. This may be attributed to many factors in‐
cluding drug toxicity and slower immune recovery following ART initiation in older pa‐
tients, compared to younger adults [236]. Furthermore, advanced age has been linked to
decreased production of T cells, B cells, and cytokines as well as to chronic immune activa‐
tion, the latter of which may be linked to the breakdown of gut-associated lymphoid tissue
(GALT) and to the elevated levels of systemic lipopolysaccharide (LPS) [237, 238].
Older patients also display a dampened recovery of CD4 cells following treatment with
ART, which may increase their risk for systemic diseases ranging from heart disease to can‐
cer [238]. Thus, it is not surprising that advanced age at seroconversion and/or onset of ART
treatment is considered a major risk factor for severe HIV disease [239, 240]. Goetz, et al.
performed a retrospective study on HIV-positive patients receiving ART treatment at the
Veteran’s Administration Greater Los Angeles Medical center between 1996 and 1999, and
found that for every 10 years of additional age at the onset of ART treatment, the rate of
CD4 cell replenishment decreased by 35 cells per microliter of blood [241]. Yet, despite the
obvious benefits of beginning ART treatment in asymptomatic HIV-positive individuals,
there remain significant concerns for initiating drug therapy sooner than necessary and how
this may negatively impact drug toxicity, long-term patient outcome, and the evolution of
drug resistant strains of HIV [240, 242]. Based on the updated recommendations for treat‐
ment initiation, as mentioned previously, all HIV-infected individuals will be put on ART
regimen upon diagnosis, and the impact of this approach on older patients will be revealing.
Lower CD4 count, in addition to advanced age, also places older patients at a nearly four-
fold higher risk for liver-related mortality compared to younger patients [243]. This risk is
exacerbated by other factors commonly afflicting ART-treated, HIV-positive individuals in‐
cluding diabetes, alcohol abuse, as well as antiretroviral and cholesterol drug toxicity [243].
Among all non-AIDS-related complications, liver disease is the primary cause of death in
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HIV-positive patients [243]. In addition, older HIV-positive individuals are at increased risk
for frailty, bone loss and non-AIDS related cancers [244, 245]. It remains unclear if HIV itself
places older individuals at higher risk for heart disease compared to older, HIV-negative in‐
dividuals, though specific classes of antiretrovirals, especially protease inhibitors, have been
linked to atherosclerosis [237, 246, 247].
The CNS is particularly susceptible to the synergistic neurodegenerative effects of HIV and
aging. Several studies have demonstrated that, compared to younger (age 20 to 39 years) co‐
horts, older HIV-positive individuals (age > 50 years) display decreased neurocognitive
functioning in several areas including memory, psychomotor speed, and executive functions
[225, 248, 249]. The persistence of HAND in individuals with an undetectable viral load and
CD4 cell counts greater than 200/µL is not well understood and may be a result of aging-
associated processes rendering the cells of the CNS more vulnerable.
Several recent neuroimaging studies have begun to address the structural, physiological,
and functional changes in the CNS in the context of HIV and aging. Six MRI investigations
that assessed the structural changes in the brains of older HIV-positive individuals between
1998 and 2012 found evidence of premature or accelerated aging characterized by significant
brain atrophy in the basal ganglia, cerebellum, and frontal and temporal brain regions,
when compared to seronegative controls [231]. However, several diffusion tensor imaging
(DTI) studies found only normal, age-dependent changes in mean diffusion and fractional
anisotropy, which reflects the directionality of water diffusion in the brain, and is greater
along organized white matter tracts but decreased in pathologically damaged, disorganized
tracts [231, 250-252].
Other studies have employed proton magnetic resonance spectroscopy (MRS) to assess the
changes in brain metabolite levels that are indicative of neuronal damage and death or glial
activation. Ernst and Chang demonstrated a five-fold acceleration of aging effects in a rela‐
tively young (mean age 36 years) ART-naïve, HIV-positive cohort, as compared to HIV-neg‐
ative controls, as reflected by increased levels of glial activation markers, myoinositol (MI)
and choline compounds (CHO), and a decrease in the neuronal marker, N-acetylaspartate
(NAA) [253]. A recent multicenter MRS study of slightly older (ages 30-70], ART-treated
HIV-positive individuals demonstrated elevated MI and CHO in all brain regions of pa‐
tients with asymptomatic or mild neurocognitive impairment, but decreased levels of MI in
those with dementia, which the authors interpreted as premature microglial senescence
[231, 254]. In addition, this study found an age-dependent decrease in NAA in frontal white
matter, but only in patients with HAD [254]. Thus, while ART-naïve HIV-positive patients
show evidence of increased, age-dependent glial activation and neuronal damage leading to
accelerated aging, ART-treated individuals show only signs of premature aging [231].
As mentioned previously, the clinical and pathological hallmarks of post-ART HAND differ
from those in the pre-ART era. While HAD presented as a subcortical dementia afflicting the
basal ganglia and white matter, some post-ART studies suggest the focus of neuroinflamma‐
tion has shifted primarily to the hippocampus, even in effectively treated patients [255-257].
Furthermore, there is emerging evidence that pathologic similarities exist between HAND
and some common neurodegenerative disorders such as Alzheimer Disease, which is char‐
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population, it has become increasingly important to understand the risk factors that lie at
the intersection of HIV, ART, and aging.
Older HIV-positive patients,  including those treated with ART, are at  increased risk for
systemic diseases including atherosclerosis, liver and kidney failure, cancer, and osteopo‐
rosis [227, 228]. The aging brain may also be more vulnerable to the effects of HIV as old‐
er adults display an increased susceptibility to HAND, and emerging evidence suggests
an increased prevalence of neurodegenerative diseases, including Alzheimer and Parkin‐
son, in this patient population [229, 230]. It remains unclear if the increased prevalence of
HAND is a result of HIV and related comorbidities, including hypertension, insulin resist‐
ance,  and  lipodystrophy,  or  other  confounding  factors  such  as  immunosenescence  and
ART toxicities,  all  of  which are likely to impact  CNS disease progression in older HIV-
positive individuals [231, 232].
Antiretroviral therapy effectively limits HIV disease progression, maintains patients in a
state of partial immune competence, and arrests subjects in a pre-symptomatic state [233].
However, despite the ability of ART to reduce plasma HIV RNA to undetectable levels,
HIV-positive individuals remain at higher risk for opportunistic illnesses and premature
death [234, 235]. Thus, ART may reduce, but does not appear to eliminate, premature and/or
accelerated aging in HIV-infected individuals. This may be attributed to many factors in‐
cluding drug toxicity and slower immune recovery following ART initiation in older pa‐
tients, compared to younger adults [236]. Furthermore, advanced age has been linked to
decreased production of T cells, B cells, and cytokines as well as to chronic immune activa‐
tion, the latter of which may be linked to the breakdown of gut-associated lymphoid tissue
(GALT) and to the elevated levels of systemic lipopolysaccharide (LPS) [237, 238].
Older patients also display a dampened recovery of CD4 cells following treatment with
ART, which may increase their risk for systemic diseases ranging from heart disease to can‐
cer [238]. Thus, it is not surprising that advanced age at seroconversion and/or onset of ART
treatment is considered a major risk factor for severe HIV disease [239, 240]. Goetz, et al.
performed a retrospective study on HIV-positive patients receiving ART treatment at the
Veteran’s Administration Greater Los Angeles Medical center between 1996 and 1999, and
found that for every 10 years of additional age at the onset of ART treatment, the rate of
CD4 cell replenishment decreased by 35 cells per microliter of blood [241]. Yet, despite the
obvious benefits of beginning ART treatment in asymptomatic HIV-positive individuals,
there remain significant concerns for initiating drug therapy sooner than necessary and how
this may negatively impact drug toxicity, long-term patient outcome, and the evolution of
drug resistant strains of HIV [240, 242]. Based on the updated recommendations for treat‐
ment initiation, as mentioned previously, all HIV-infected individuals will be put on ART
regimen upon diagnosis, and the impact of this approach on older patients will be revealing.
Lower CD4 count, in addition to advanced age, also places older patients at a nearly four-
fold higher risk for liver-related mortality compared to younger patients [243]. This risk is
exacerbated by other factors commonly afflicting ART-treated, HIV-positive individuals in‐
cluding diabetes, alcohol abuse, as well as antiretroviral and cholesterol drug toxicity [243].
Among all non-AIDS-related complications, liver disease is the primary cause of death in
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HIV-positive patients [243]. In addition, older HIV-positive individuals are at increased risk
for frailty, bone loss and non-AIDS related cancers [244, 245]. It remains unclear if HIV itself
places older individuals at higher risk for heart disease compared to older, HIV-negative in‐
dividuals, though specific classes of antiretrovirals, especially protease inhibitors, have been
linked to atherosclerosis [237, 246, 247].
The CNS is particularly susceptible to the synergistic neurodegenerative effects of HIV and
aging. Several studies have demonstrated that, compared to younger (age 20 to 39 years) co‐
horts, older HIV-positive individuals (age > 50 years) display decreased neurocognitive
functioning in several areas including memory, psychomotor speed, and executive functions
[225, 248, 249]. The persistence of HAND in individuals with an undetectable viral load and
CD4 cell counts greater than 200/µL is not well understood and may be a result of aging-
associated processes rendering the cells of the CNS more vulnerable.
Several recent neuroimaging studies have begun to address the structural, physiological,
and functional changes in the CNS in the context of HIV and aging. Six MRI investigations
that assessed the structural changes in the brains of older HIV-positive individuals between
1998 and 2012 found evidence of premature or accelerated aging characterized by significant
brain atrophy in the basal ganglia, cerebellum, and frontal and temporal brain regions,
when compared to seronegative controls [231]. However, several diffusion tensor imaging
(DTI) studies found only normal, age-dependent changes in mean diffusion and fractional
anisotropy, which reflects the directionality of water diffusion in the brain, and is greater
along organized white matter tracts but decreased in pathologically damaged, disorganized
tracts [231, 250-252].
Other studies have employed proton magnetic resonance spectroscopy (MRS) to assess the
changes in brain metabolite levels that are indicative of neuronal damage and death or glial
activation. Ernst and Chang demonstrated a five-fold acceleration of aging effects in a rela‐
tively young (mean age 36 years) ART-naïve, HIV-positive cohort, as compared to HIV-neg‐
ative controls, as reflected by increased levels of glial activation markers, myoinositol (MI)
and choline compounds (CHO), and a decrease in the neuronal marker, N-acetylaspartate
(NAA) [253]. A recent multicenter MRS study of slightly older (ages 30-70], ART-treated
HIV-positive individuals demonstrated elevated MI and CHO in all brain regions of pa‐
tients with asymptomatic or mild neurocognitive impairment, but decreased levels of MI in
those with dementia, which the authors interpreted as premature microglial senescence
[231, 254]. In addition, this study found an age-dependent decrease in NAA in frontal white
matter, but only in patients with HAD [254]. Thus, while ART-naïve HIV-positive patients
show evidence of increased, age-dependent glial activation and neuronal damage leading to
accelerated aging, ART-treated individuals show only signs of premature aging [231].
As mentioned previously, the clinical and pathological hallmarks of post-ART HAND differ
from those in the pre-ART era. While HAD presented as a subcortical dementia afflicting the
basal ganglia and white matter, some post-ART studies suggest the focus of neuroinflamma‐
tion has shifted primarily to the hippocampus, even in effectively treated patients [255-257].
Furthermore, there is emerging evidence that pathologic similarities exist between HAND
and some common neurodegenerative disorders such as Alzheimer Disease, which is char‐
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acterized by the presence of extracellular beta amyloid (Aβ) plaque deposits, and intracellu‐
lar neurofibrillary tangles composed of hyperphosphorylated Tau [228, 233, 258, 259]. In
vitro work involving the viral protein Tat has demonstrated the ability of this viral protein to
inhibit the activity of the Aβ-degrading enzyme, Neprilysin, and the ability to bind to the
receptor for advanced glycation end products, all of which may promote Aβ accumulation
in the CNS. Indeed, some individuals with HAND display CSF levels of Aβ42 comparable
to those observed in AD patients [228, 260, 261]. However, a recent report utilizing the amy‐
loid-binding, carbon 11-labeled Pittsburgh compound B (11C-PiB) and PET imaging found
that irrespective of neurocognitive impairment, HIV-positive individuals showed no in‐
crease in 11C-PiB levels, highlighting a potential key difference between Aβ metabolism in
HAND vs. AD despite some overlapping pathological features [258].
Among the studies underlining the similarities between HAND and AD, Esiri et al. were the
first to report a predisposition to plaque formation in the brains of pre-ART HIV-positive
individuals [262]. Such pathological changes have been observed in HIV-positive patients
despite successful virologic control with ART, suggesting that antiretrovirals either cannot
achieve therapeutic concentrations within the brain parenchyma, allowing for ongoing viral
replication and neuroinflammation, or may have toxic effects that could facilitate neurode‐
generation [263, 264]. To address the latter concern, several reports investigated differences
in either phospho-tau or beta amyloid levels in ART-naïve vs. ART-treated individuals. Two
groups independently reported elevated Aβ deposition in the hippocampus of ART-treated
individuals compared to pre-ART patients, yet Anthony et al. reported only increased hy‐
perphosphorylated tau, but no Aβ deposition in the hippocampus and entorhinal cortex of
HIV-positive individuals [257, 259, 265]. To date, no group has reported concomitant phos‐
pho-tau and Aβ plaque depositions in the same brain samples from HIV-positive cohorts.
Differences in patient age and ART-regimens, as well as the antibodies used to detect Aβ
may account for the varied outcomes of these reports.
Importantly, the aforementioned studies highlight the potentially under-appreciated con‐
cern of antiretroviral-associated toxicity and its effect on neuropsychological outcomes in
long-term  ART-treated  patients.  As  described  earlier,  ART  drugs  have  been  linked  to
wide-ranging,  peripheral  metabolic and neural  disturbances that could themselves influ‐
ence the progression of HAND and foretell potential mechanisms of toxicity in the CNS
[246, 266-276]. While CNS effects of ART are poorly understood, Schweinsburg et al. dem‐
onstrated  an  association  between  NRTIs  and  decreased  levels  of  frontal  white  matter
NAA, which they attributed to NRTI-mediated mitochondrial dysfunction and depletion
of cellular respiration [268]. Confounding the issue of direct CNS toxicity of antiretroviral
medications is the variability in BBB permeability amongst different drug classes as deter‐
mined by various physicochemical properties such as plasma protein binding, lipophilici‐
ty, and molecular size.
Although it  is  a  widely held that  ART regimens with higher  CNS penetrance generally
confer greater neuropsychological outcomes in HIV-positive individuals,  numerous clini‐
cal  studies  have  suggested  these  regimens  may  negatively  impact  cognition.  In  a  pro‐
spective  study,  Marra  et  al.  found  a  significant  association  between  highly  CNS-
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penetrant  ART  regimens  and  worse  neurocognitive  and  motor  performance,  despite
decreased CSF HIV RNA in a small HIV-positive cohort [181].  In addition, Robertson et
al. reported an improvement in neuropsychological outcome in a cohort of patients with
interrupted  drug  treatment  [277].  Studies  using  SCID  mice,  which  display  neuropatho‐
logical  hallmarks  similar  to  those  associated  with  HIV,  showed reduced viral  load and
astrogliosis  following administration of  ART, but no improvement in cognitive dysfunc‐
tion [278].  Altogether,  these  studies  reinforce  an emerging hypothesis  that  antiretroviral
drugs may be contributing to the rising prevalence of HAND in the aging HIV-positive
population.
However,  many  clinical  studies  have  demonstrated  beneficial  effects  on  neurocognitive
functioning by ART regimens with high CPE scores [279, 280]. A cross-sectional study of
2636 adults  from the  AIDS Clinical  Trials  Group Longitudinal  Linked Randomized Tri‐
als (ALLRT cohort),  on effective ART for at  least 6 weeks showed better neurocognitive
performance in individuals  receiving ART medications with higher CPE scores [281].  In
some  cases,  participants  required  more  than  3  antiretrovirals  to  treat  HIV  in  the  CNS.
Letendre  et  al.  demonstrated  improvements  in  cognition  over  a  15-week  period  in  pa‐
tients beginning ART with higher CPE ART regimens [282]. Another recent investigation
utilized MRS imaging to investigate the effect  of  different  CPE ART regimens with dif‐
ferent CPE scores on changes in brain NAA metabolite levels. Over 48 weeks, HIV-posi‐
tive,  ART-naïve  individuals  receiving  the  regimens  with  highest  CPE  scores  displayed
the highest increases in NAA levels,  and showed the greatest improvement in a battery
of neuropsychological tests [283]. These studies suggest that ART medications with high‐
er  CNS penetrance  may have  a  neuroprotective  effect  in  successfully  treated  HIV-posi‐
tive  adults.  However,  given  the  well-characterized  toxicities  of  ART medications  in  the
periphery,  and the potential  impact of  related co-morbidities on CNS pathology,  it  may
be necessary to consider adjunctive therapies to minimize the synergistic  effects of  ART
and aging in HIV-positive individuals.
7. Summary
The advent of ART has profoundly changed the landscape of disease; however, neurocogni‐
tive impairments continue to be debilitating to patients with the expected life expectancy
closer to that of the uninfected population. A better understanding and appreciation of the
confounding factors has become more acute as the recent focus in the race to cure AIDS has
shifted towards the eradication of latent viral reservoirs, including those in the CNS. It is im‐
perative to anticipate and control the immune responses due to viral reactivation, the poten‐
tial neurotoxicities of viral proteins in the brain parenchyma when latent viral progeny is
activated, and the oxidative damage that may be precipitated by viral particles and the acti‐
vated immune cells. These factors will be even more crucial to control in the aging brain
with limited cognitive reserves.
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acterized by the presence of extracellular beta amyloid (Aβ) plaque deposits, and intracellu‐
lar neurofibrillary tangles composed of hyperphosphorylated Tau [228, 233, 258, 259]. In
vitro work involving the viral protein Tat has demonstrated the ability of this viral protein to
inhibit the activity of the Aβ-degrading enzyme, Neprilysin, and the ability to bind to the
receptor for advanced glycation end products, all of which may promote Aβ accumulation
in the CNS. Indeed, some individuals with HAND display CSF levels of Aβ42 comparable
to those observed in AD patients [228, 260, 261]. However, a recent report utilizing the amy‐
loid-binding, carbon 11-labeled Pittsburgh compound B (11C-PiB) and PET imaging found
that irrespective of neurocognitive impairment, HIV-positive individuals showed no in‐
crease in 11C-PiB levels, highlighting a potential key difference between Aβ metabolism in
HAND vs. AD despite some overlapping pathological features [258].
Among the studies underlining the similarities between HAND and AD, Esiri et al. were the
first to report a predisposition to plaque formation in the brains of pre-ART HIV-positive
individuals [262]. Such pathological changes have been observed in HIV-positive patients
despite successful virologic control with ART, suggesting that antiretrovirals either cannot
achieve therapeutic concentrations within the brain parenchyma, allowing for ongoing viral
replication and neuroinflammation, or may have toxic effects that could facilitate neurode‐
generation [263, 264]. To address the latter concern, several reports investigated differences
in either phospho-tau or beta amyloid levels in ART-naïve vs. ART-treated individuals. Two
groups independently reported elevated Aβ deposition in the hippocampus of ART-treated
individuals compared to pre-ART patients, yet Anthony et al. reported only increased hy‐
perphosphorylated tau, but no Aβ deposition in the hippocampus and entorhinal cortex of
HIV-positive individuals [257, 259, 265]. To date, no group has reported concomitant phos‐
pho-tau and Aβ plaque depositions in the same brain samples from HIV-positive cohorts.
Differences in patient age and ART-regimens, as well as the antibodies used to detect Aβ
may account for the varied outcomes of these reports.
Importantly, the aforementioned studies highlight the potentially under-appreciated con‐
cern of antiretroviral-associated toxicity and its effect on neuropsychological outcomes in
long-term  ART-treated  patients.  As  described  earlier,  ART  drugs  have  been  linked  to
wide-ranging,  peripheral  metabolic and neural  disturbances that could themselves influ‐
ence the progression of HAND and foretell potential mechanisms of toxicity in the CNS
[246, 266-276]. While CNS effects of ART are poorly understood, Schweinsburg et al. dem‐
onstrated  an  association  between  NRTIs  and  decreased  levels  of  frontal  white  matter
NAA, which they attributed to NRTI-mediated mitochondrial dysfunction and depletion
of cellular respiration [268]. Confounding the issue of direct CNS toxicity of antiretroviral
medications is the variability in BBB permeability amongst different drug classes as deter‐
mined by various physicochemical properties such as plasma protein binding, lipophilici‐
ty, and molecular size.
Although it  is  a  widely held that  ART regimens with higher  CNS penetrance generally
confer greater neuropsychological outcomes in HIV-positive individuals,  numerous clini‐
cal  studies  have  suggested  these  regimens  may  negatively  impact  cognition.  In  a  pro‐
spective  study,  Marra  et  al.  found  a  significant  association  between  highly  CNS-
Current Perspectives in HIV Infection182
penetrant  ART  regimens  and  worse  neurocognitive  and  motor  performance,  despite
decreased CSF HIV RNA in a small HIV-positive cohort [181].  In addition, Robertson et
al. reported an improvement in neuropsychological outcome in a cohort of patients with
interrupted  drug  treatment  [277].  Studies  using  SCID  mice,  which  display  neuropatho‐
logical  hallmarks  similar  to  those  associated  with  HIV,  showed reduced viral  load and
astrogliosis  following administration of  ART, but no improvement in cognitive dysfunc‐
tion [278].  Altogether,  these  studies  reinforce  an emerging hypothesis  that  antiretroviral
drugs may be contributing to the rising prevalence of HAND in the aging HIV-positive
population.
However,  many  clinical  studies  have  demonstrated  beneficial  effects  on  neurocognitive
functioning by ART regimens with high CPE scores [279, 280]. A cross-sectional study of
2636 adults  from the  AIDS Clinical  Trials  Group Longitudinal  Linked Randomized Tri‐
als (ALLRT cohort),  on effective ART for at  least 6 weeks showed better neurocognitive
performance in individuals  receiving ART medications with higher CPE scores [281].  In
some  cases,  participants  required  more  than  3  antiretrovirals  to  treat  HIV  in  the  CNS.
Letendre  et  al.  demonstrated  improvements  in  cognition  over  a  15-week  period  in  pa‐
tients beginning ART with higher CPE ART regimens [282]. Another recent investigation
utilized MRS imaging to investigate the effect  of  different  CPE ART regimens with dif‐
ferent CPE scores on changes in brain NAA metabolite levels. Over 48 weeks, HIV-posi‐
tive,  ART-naïve  individuals  receiving  the  regimens  with  highest  CPE  scores  displayed
the highest increases in NAA levels,  and showed the greatest improvement in a battery
of neuropsychological tests [283]. These studies suggest that ART medications with high‐
er  CNS penetrance  may have  a  neuroprotective  effect  in  successfully  treated  HIV-posi‐
tive  adults.  However,  given  the  well-characterized  toxicities  of  ART medications  in  the
periphery,  and the potential  impact of  related co-morbidities on CNS pathology,  it  may
be necessary to consider adjunctive therapies to minimize the synergistic  effects of  ART
and aging in HIV-positive individuals.
7. Summary
The advent of ART has profoundly changed the landscape of disease; however, neurocogni‐
tive impairments continue to be debilitating to patients with the expected life expectancy
closer to that of the uninfected population. A better understanding and appreciation of the
confounding factors has become more acute as the recent focus in the race to cure AIDS has
shifted towards the eradication of latent viral reservoirs, including those in the CNS. It is im‐
perative to anticipate and control the immune responses due to viral reactivation, the poten‐
tial neurotoxicities of viral proteins in the brain parenchyma when latent viral progeny is
activated, and the oxidative damage that may be precipitated by viral particles and the acti‐
vated immune cells. These factors will be even more crucial to control in the aging brain
with limited cognitive reserves.
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1. Introduction
Human Immunodeficiency Virus (HIV) was first reported in USA. In June and July of 1981,
the CDC published two reports on clusters of young homosexual men who developed op‐
portunistic infections that were chiefly detected in several immunodeficient individuals
(CDC, 1993).
Acquired Immunodeficiency Syndrome (AIDS) is a complex of symptoms and infections
caused by the HIV virus as it impacts the immune system. It is an acquired infection, not
hereditary. AIDS since its appearance in 1981 has spread to become a major cause of prema‐
ture death and so far a cure has not yet been found. The diagnosis of HIV/AIDS requires a
positive HIV antibody test or evidence of HIV infection and the appearance of some very
specific conditions/diseases (CDC, 1993).
AIDS is a global pandemic, 33.4 million people are currently living with the disease world‐
wide, and it has killed an estimated 2.4 million people, including 330,000 children (UNAIDS,
2010). Over three-quarters of these deaths occurred in Sub- Saharan Africa, retarding eco‐
nomic growth and destroying human capital. South Africa has the largest population of HIV
patients in the world, followed by Nigeria and India (McNeil, 2007).
Oral lesions have been reported to be early clinical features of HIV infection (Greenspan et
al., 1992). These lesions are often indicators of immune suppression and can be used for ear‐
ly testing, diagnosis and management of patients with HIV/AIDS. Oral lesions contribute to
patients’ morbidity, affecting the psychological and economic functioning of the individual
and community (Kaminu et al., 2002).
The overall prevalence of oral manifestations of HIV infection has changed since the advent
of Highly Active Anti-Retroviral Therapy (HAART). Several Studies have shown reduction
in prevalence of herpes labialis and periodontal diseases along with other lesions to more
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than 30% after the institution of HAART (Ceballos-Salobrena et al., 1997), and in HIV-associ‐
ated opportunistic infections (Septowitz, 1998).
2. Literature review
HIV has two primary strains: HIV-1 and HIV-2. HIV-1 is found throughout the world.
HIV-2 is found primarily in West Africa, where the virus may have been in circulation since
the 1960s–1970s (Beaupre et al., 2006).
Both HIV-1 and HIV-2 have several subtypes. The strains of HIV-1 can be classified into four
groups: the "major" group M, the "outlier" group O and two new groups, N and P. These four
groups may represent four separate introductions of simian immunodeficiency virus into hu‐
mans. Within group M there are known to be at least nine genetically distinct subtypes (or
clades) of HIV-1. These are subtypes A, B, C, D, F, G, H, J and K (Lihana et al., 2009).
Scheme 1.
2.1. Pathophysiology
Human Immunodeficiency Virus (HIV) mainly affects white blood cells called T-lympho‐
cytes (T-cells) by attaching to a protein on the cell surface called CD4 (Cluster of differentia‐
tion 4), it is also expressed on the surface of monocytes, macrophages, and dendritic cells
(Miceli, 1993).
HIV gains entry into the body through the blood or mucosal surfaces. The virus establishes
itself within the lymphoid tissue, where it replicates and makes itself available to the cells of
the immune system (such as T-Lymphocytes, monocytes and macrophages).
The hallmark of HIV disease is the progressive loss of CD4+ lymphocytes. Without interven‐
tion, an average of 60 to 80 cells/mm3 is lost every year; this loss is highly variable and oc‐
curs in periods of stability and rapid decline. The level of metabolic and mitotic activity of
the host CD4 cell is believed to be a factor in the rate at which the disease progresses in indi‐
vidual patients.
With progressive CD4 lymphocyte depletion, immunosuppression becomes increasingly
more severe with the emergence of pre-AIDS opportunistic infections. Once the CD4 lym‐
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phocyte count falls below 200 cells per ml and the ratio of helper and suppressor cells is re‐
versed, a diagnosis of AIDS is made.
3. Oral manifestations of HIV
3.1. Significance of oral lesions of HIV
Oral lesions have been reported to be early clinical features of HIV infection (Greenspan et
al., 1992). They are multiple and varied, and are occasionally the first sign that patients har‐
bour the virus. Studies have estimated that more than 90% of persons with HIV infection
will have at least one oral manifestation during the course of their disease (Weinert et al.,
1996). These lesions may be present in up to 50% of people with HIV infection and in up to
80% of those with a diagnosis of AIDS (Palmer et al., 1996). In cases where a person’s HIV
status is unknown the lesions provide a strong indication of the presence of HIV infection
(Maeve et al., 2005).
Some of these lesions may have a predictive value, warning of a progression from HIV sero‐
positivity to clinically manifest as AIDS. They are often indicators of immune suppression
and can be used for early testing, diagnosis and management of patients with HIV/AIDS
(Scully et al., 1991; Arendorf et al., 1998; Agbelusi and Wright, 2005). Oral lesions in HIV
may serve as markers for immune deterioration and disease progression and may also indi‐
cate poor prognosis (Adurogbangba et al., 2004).
They can therefore be used as an entry or end-point in therapy and vaccine trials and can be de‐
terminants of opportunistic infection and anti- HIV therapy, staging and classification systems
Oral lesions contribute to patients’ morbidity, affecting the psychological and economic
functioning of the individual and community (Kaminu et al., 2002). The pain of oral lesions
can lead to increased morbidity. In cases like herpes zoster of the trigeminal nerve or facial
nerve palsy facial aesthetics may be compromised. Some of the oral lesions have a fatal out‐
come e.g. Kaposi’s sarcoma. Therefore, it is important to perform oral examinations routine‐
ly in the dental and medical settings (Patel et al., 2003), in those affected with HIV and
patients at risk of the disease (Maeve et al., 2005).
Predisposing factors to expression of oral lesions of AIDS include CD4 counts less than 200
cells/mm3, viral load greater than 3000 copies/ml, xerostomia, poor oral hygiene and smok‐
ing (Greenspan et al., 2001).
3.2. Epidemiology of oral lesions of HIV
Several studies done worldwide showed varying reports of oral lesions from 40% to 93% (Mir‐
owsky et al., 1998; Ramirez – Amardor et al., 1998; Ranganathan et al., 2000; Matee et al., 2000;
Campisi et al., 2002). The prevalence of oral lesions seen in a German study showed 39%
(Schmidt- Westhaunsen et al., 1997), in South Africa, 73% was reported by Kaminu and Nai‐
doo (2002). Nigerian reports also showed a prevalence of 36.4% - 84% in various studies done in
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the different geopolitical zones. (Onunu et al., 2002, Anteyi et al., 2003, Wright et al., 2005; Tai‐
wo et al., 2005; Taiwo et al., 2006; Arotiba et al., 2006; Adedigba et al., 2008).
All studies carried out showed presence of oral lesions as a manifestation of HIV/AIDS infec‐
tion.
3.3. Importance of oral lesions of HIV for the dental profession
The overall growth of the global AIDS epidemic appears to have stabilized, the annual number
of new HIV infections has been steadily declining since the late 1990s and there are fewer AIDS-
related deaths due to the significant scale up of antiretroviral therapy over the past few years.
Although the number of new infections has been falling, levels of new infections overall are still
high, and with significant reductions in mortality, the number of people living with HIV
(PLWA) worldwide has increased (UNAIDS, 2010). This increase in the number of PLWA trans‐
lates to the fact that the likelihood of an oral health care worker particularly the dentist treating
a PLWA in high incidence areas is almost certain, therefore the dental team needs to be more in‐
volved in the prevention of spread and care of infected persons.
It is also important to note that the clinical problem of HIV infection poses one of the great‐
est challenges to Health Care Workers all over the world.
Some oral lesions of HIV/AIDS are ulcerative and painful, and so compromise the patients’
ability to eat and swallow, subsequently leading to malnutrition and emaciation which wor‐
sens the already immunocompromized state. Hence prompt and early treatment of lesions is
required.
The mode of spread of HIV also poses special danger to HCW particularly the dentist who
works in an environment contaminated with blood, saliva and other body fluids and has
close contact with his patients.
The dentist may possibly be the first health care provider to diagnose the condition from a high
index of suspicion and results of diagnostic investigations prompted by the head/neck and or‐
al manifestations (Agbelusi and Wright, 2005). Dentists should have a good knowledge of oral
lesions in HIV /AIDS and be able to recognize and accurately diagnose such lesions. Early treat‐
ment of oral lesions is also necessary to reduce morbidity and mortality in HIV-infected pa‐
tients. The need to maintain oral health to prevent complications like microbial infections which
may be fatal in these patients cannot be over-emphasized.
Currently, viral load and CD4 status determination are used to initiate and monitor a patient’s
treatment. Diagnostic tests such as these place a greater responsibility on the dental practice
team as they need to be aware of drug changes, new drugs and appropriate management of such
patients. Some of the antiviral drugs may also have oral lesions as side effects.
3.4. Classification of oral lesions of HIV
Oral mucosal lesions are part of the clinical criteria in a number of HIV/AIDS classification
systems currently in use. This classification can be based on the etiological factors or the
strength of association. EC-Clearinghouse on Oral Problems Related to HIV Infection and
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WHO Collaboration centre on oral manifestations of the Human Immunodeficiency Virus
uses strength of association of Oral lesions with HIV infection as basis for classification
(ECC/WHO, 1993)









Linear gingival erythema (LGE)
Necrotizing (ulcerative) gingivitis (NUG)
Necrotizing (ulcerative) Periodontitis (NUP)







Xerostomia due to decreased salivary flow rate
Unilateral or Bilateral swelling of major salivary glands
Thrombocytopaenic purpura
Ulceration NOS ( Not-otherwise specified)
Viral infections:
Herpes simplex virus






3.5. Clinical characteristics and diagnosis of oral lesions of HIV
3.5.1. Oral candidiasis
This is the most common intra-oral lesion seen among HIV infected individuals. In African
studies, the prevalence ranged from 15% to more than 80% in HIV+ adults. The most com‐
mon organism involved with the presentation of candidiasis is Candida albicans. The pres‐
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ence of oral Candida was associated with a CD4 count of <200 cells/microl, cigarette smoking
and heroine/methadone use (Greenspan et al., 2000). The most common organism involved
with the presentation of candidiasis is Candida albicans, but other non- albicans species, such
as C. glabrata, C. tropicalis, C. krusei and C. dublinieusis can also cause the disease.





It appears as creamy white curd-like plaques on the buccal mucosa, tongue and other oral mu‐
cosal surfaces (palate, lips etc.) that can be wiped away, leaving a red or bleeding underlying
surface. The plaques consist of a mixture of fungal hyphae, desquamated epithelium, and in‐
flammatory cells. These plaques can appear anywhere on the oral and pharyngeal mucosa.
Diagnosis: In most clinical conditions, the presumptive diagnosis of oral candidiasis is
made based on the typical clinical appearance. In this situation, the presumptive diagnosis is
strengthened if the patient responds to an empirical trial of anti-fungal therapy.
When the clinical diagnosis of oral candidiasis is not clear, the diagnosis can be confirmed
by obtaining a direct smear and performing either a Potassium Hydroxide (KOH) wet mount
or a Gram’s stain (Greenspan et al., 1992). The KOH wet mount typically shows presence of
yeasts or pseudo-hyphae, and the gram stain shows gram- positive staining organisms that
are much larger than bacteria. Obtaining oral fungal cultures is generally reserved for situa‐
tions when patients do not respond to therapy and anti-fungal resistance is suspected.
The pseudomembraneous variant was associated with severe immune suppression in sever‐
al studies where these clinical parameters were available (Schoidt et al., 1990; Tukutuku et
al., 1990; Hodgson, 1997; Ranganathan et al., 2000). As with other causes of oral candidiasis,
recurrences are common if the underlying problem persists.
Figure 1. Pseudomembranous and erythematous candidiasis on the dorsum of the tongue
Current Perspectives in HIV Infection214
Figure 2. Pseudomembranous candidiasis on the palate
3.5.1.2. Erythematous candidiasis
This appears as a red lesion commonly located on the palate, dorsum of the tongue (as areas
of depapillation) and buccal mucosa. The lesions tend to be symptomatic with patients com‐
plaining of burning mouth and change of taste, most frequently while eating salty or spicy
foods or drinking acidic beverages.
Figure 3. Erythematous candidiasis on the palate
Figure 4. Erythematous candidiasis on the tongue and angular cheilitis on the lips.
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with the presentation of candidiasis is Candida albicans, but other non- albicans species, such
as C. glabrata, C. tropicalis, C. krusei and C. dublinieusis can also cause the disease.





It appears as creamy white curd-like plaques on the buccal mucosa, tongue and other oral mu‐
cosal surfaces (palate, lips etc.) that can be wiped away, leaving a red or bleeding underlying
surface. The plaques consist of a mixture of fungal hyphae, desquamated epithelium, and in‐
flammatory cells. These plaques can appear anywhere on the oral and pharyngeal mucosa.
Diagnosis: In most clinical conditions, the presumptive diagnosis of oral candidiasis is
made based on the typical clinical appearance. In this situation, the presumptive diagnosis is
strengthened if the patient responds to an empirical trial of anti-fungal therapy.
When the clinical diagnosis of oral candidiasis is not clear, the diagnosis can be confirmed
by obtaining a direct smear and performing either a Potassium Hydroxide (KOH) wet mount
or a Gram’s stain (Greenspan et al., 1992). The KOH wet mount typically shows presence of
yeasts or pseudo-hyphae, and the gram stain shows gram- positive staining organisms that
are much larger than bacteria. Obtaining oral fungal cultures is generally reserved for situa‐
tions when patients do not respond to therapy and anti-fungal resistance is suspected.
The pseudomembraneous variant was associated with severe immune suppression in sever‐
al studies where these clinical parameters were available (Schoidt et al., 1990; Tukutuku et
al., 1990; Hodgson, 1997; Ranganathan et al., 2000). As with other causes of oral candidiasis,
recurrences are common if the underlying problem persists.
Figure 1. Pseudomembranous and erythematous candidiasis on the dorsum of the tongue
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Figure 2. Pseudomembranous candidiasis on the palate
3.5.1.2. Erythematous candidiasis
This appears as a red lesion commonly located on the palate, dorsum of the tongue (as areas
of depapillation) and buccal mucosa. The lesions tend to be symptomatic with patients com‐
plaining of burning mouth and change of taste, most frequently while eating salty or spicy
foods or drinking acidic beverages.
Figure 3. Erythematous candidiasis on the palate
Figure 4. Erythematous candidiasis on the tongue and angular cheilitis on the lips.




Presents as fissures or linear ulcers at the corners (commissures) of the mouth and often as‐
sociated with small white plaques, could be unilateral or bilateral. It can occur with or with‐
out the presence of erythematous candidiasis or pseudomembranous candidiasis. Angular
cheilitis can also exist for an extensive period of time if left untreated.
Figure 5. Angular cheilits
3.5.2. Periodontal diseases
Since the first descriptions of the HIV in 1981, a considerable number of researches have fo‐
cused on the periodontal changes specifically associated with HIV infection. Earlier reports in‐
cluded  unusual  and  severe  forms  of  periodontal  disease  in  HIV-infected  individuals,
particularly among homosexual males. These lesions ranged from severe gingivitis to ad‐
vanced, painful periodontitis characterized by spontaneous bleeding, bone exposure and fre‐
quently bone sequestration followed by the exfoliation of several teeth (Silverman et al., 1986;
Winkler et al., 1988). An increased incidence of acute necrotizing ulcerative gingivitis (ANUG)
was also reported in HIV-seropositive patients (Schiodt & Pindborg, 1987; Gornitsky & Peko‐
vie, 1987).
HIV-associated periodontal diseases were initially classified into four broad categories: HIV-
associated gingivitis (HIV-G) (Winkler et al., 1988), HIV-associated periodontitis (HIV-P),
ANUG and necrotizing stomatitis (NS) (Greenspan et al., 1990). Later classifications pro‐
posed that the term ‘HIV-associated’ be dropped in relation to periodontal disease because
the conditions were also seen in non-HIV infected populations (Smith et al., 1993).
HIV-G is now known as linear gingival erythema (LGE), while HIV-P is referred to as ne‐
crotizing ulcerative periodontitis (NUP). Currently, the spectrum of periodontal diseases as‐
sociated with HIV includes linear gingival erythema, necrotizing diseases (NUG and NUP),
and exarcabated chronic periodontitis. LGE, necrotizing ulcerative gingivitis (NUG) and
NUP are classified under lesions strongly associated with HIV infection ((ECC/WHO, 1993;
Armitage, 1999; Winkler et al., 1988). The exacerbated periodontitis described in HIV infect‐
ed patients is however not clinically distinguishable from that occurring in non-HIV-infect‐
ed populations (Robinson et al., 2002).
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Periodontal  diseases  associated  with  HIV  infection  along  with  some  other  oral  lesions
have important diagnostic values as they may alert the dentist to the presence of HIV in‐
fection  (ECC/WHO,1993;  Robinson  et  al.,  2002).  Their  prognostic  significance  is  due  to
their ability to predict a deteriorating immune status and progression from HIV to AIDS
(Robinson et al.,  1998; Soubry et al.,  1995; Glick et al.,  1994a; Glick et al.,  1994b). Soubry
et al (1995) evaluated 224 people with necrotizing periodontal disease. Overall, 81% were
found to be HIV positive. When compared with the general population in their environ‐
ment, the HIV prevalence was only 30% which was much lower.
3.5.2.1. Linear gingival erythema
This periodontal lesion presents as a persistent, distinct, intense, fiery red band extending
2-3mm apically from the free gingival margin. The erythema may be limited to the mar‐
ginal tissue, the attached gingiva in a punctate or diffuse form, or could extend into the
alveolar  mucosa.  These  erythematous  changes  are  usually  generalized  but  may be  con‐
fined to  few teeth.  Unlike  conventional  marginal  gingivitis,  the  associated teeth usually
have little or no plaque formation (Narani & Epstein, 2001) thus regarded as a non-pla‐
que  induced  gingivitis,  particularly  as  the  degree  of  erythema is  disproportionately  in‐
tense to the amount of plaque seen (Holmstrup & Westergaard, 1998). The gingiva bleeds
easily on tooth brushing or gentle probing or even spontaneously in some cases (Robin‐
son et al., 2002). No ulceration is however present. LGE is commonly first seen earlier in
the course of HIV infection and may or may not serve as a precursor to necrotizing ulcer‐
ative periodontitis (Glick & Holmstrup, 2000).
Studies have revealed a microbiota comprising Candida albicans,  Porphyromonas  gingivalis,
Prevotella  intermedia,  Actinobacillus  actinomycetemcomitans,  Fusobucterium  nucleatum  and
Campylobacter  rectus  (Murray et  al.,  1989;  Murray et  al.,  1991).  This  microflora is  consis‐
tent with that of conventional periodontitis. The Candida species isolated from some LGE
lesions,  suggests  its  possible  aetiologic  role  (Lamster  et  al.,  1994;  Velegraki  et  al.,  1999;
Grbic et  al.,  1995).  LGE has been classified under ‘Gingival  diseases of  fungal  origin’,  a
separate periodontal disease entity at the 1999 International workshop for a Classification
of Periodontal diseases and conditions (Armitage, 1999).
The use  of  tobacco has  been reported to  affect  the  extent  of  gingival  banding which is
measured by the number of affected sites (Swango et al.,  1991). The relationship of LGE
to  severe  immune  suppression  is  variable.  This  condition  may  (Ceballos  et  al.,  1996;
Holmes et al., 2002) or may not be associated with CD4 counts < 200 cells/mm3 (Grbic et
al., 1995; Davoodi et al., 2010).
A major  clinical  hallmark of  LGE is  its  non-responsiveness  to  conventional  scaling  and
root  planing.  The  differential  diagnosis  is  conventional  chronic  gingivitis,  a  plaque-in‐
duced gingival condition which responds to conventional periodontal therapy.
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Figure 6. Linear gingival erythema
The use of tobacco has been reported to affect the extent of gingival banding which is measured by the number of affected sites 
(Swango et al, 1991). The relationship of LGE to severe immune suppression is variable. This condition may (Ceballos et al, 1996; 
Holmes et al, 2002) or may not be associated with CD4 counts < 200 cells/mm3 (Grbic et al, 1995; Davoodi et al, 2010).  
A major clinical hallmark of LGE is its non-responsiveness to conventional scaling and root planing. The differential diagnosis is 
conventional chronic gingivitis, a plaque-induced gingival condition which responds to conventional periodontal therapy. 
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Necrotizing ulcerative gingivitis (NUG) is defined using the presumptive diagnostic criteri‐
on (ECC/WHO, 1993) as the des ruction of ne or m r  i terde tal papillae. In the acute
stage of the disease, ulceration, necrosis and sloughing may be accompanied by hemorrhage
and a characteristic fetor. The affected gingiva may be extremely painful or a ymptomatic
(Robinson et al., 1998). The anterior and lower teeth are often affected (Robinson et al., 1998).
The gingival ulceration may be limited to single tooth or extend to several areas of the jaws.
The clinical description of NUG is only limited to lesions involving the gingiva without any
loss of periodontal attachment. NUG in HIV-associated lesions represents the same spec‐
trum of acute necrotizing ulcerative gingivitis (ANUG) seen in patients without HIV infec‐
tion but in HIV-infected individuals it progresses more rapidly (Winkler and Murray, 1987).
Some of the organisms isolated from NUG lesions include Borrelia, gram-positive cocci, β-
hemolytic streptococci and Candida albicans (Reichart et al., 1987). NUG has been associated
with depleted CD4 lymphocyte counts in some studies (Ceballos et al., 1996). However, oth‐
ers have failed to establish this association (Barr et al., 1992).
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Figure 8. Necrotizing ulcerative gingivitis
Figure 9. Necrotizing ulcerative gingivitis
3.5.2.3. Necrotizing ulcerative periodontitis
Necrotizing ulcerative periodontitis (NUP) may be an extension of NUG in HIV infected in‐
dividuals. It is characterized by soft tissue loss resulting from ulceration or necrosis with
rapid destruction of the periodontal attachment and interproximal bone (EC-WHO 93, Win‐
kler & Robertson, 1992). Initially, the lesion manifests with severe, deep-seated jaw pain, in‐
terproximal necrosis and cratering. This severe pain is however not a consistent feature
(Robinson et al., 1998; Masouredis et al., 1992). The bone may then be exposed, with subse‐
quent necrosis and sequestration, resulting in loosening of the teeth (Umeizudike et al.,
2011a). There is thus radiographic evidence of bone loss. Few teeth are affected in most cases
in either the premolar or molar region, but the lesion may be more generalized in severe
NUP cases. A characteristic fetor oris is usually present. Deep pockets are not a characteris‐
tic feature of NUP because of the extensive gingival necrosis which often coincides with loss
of alveolar bone. The lesion may bleed on probing with 50% of sites bleeding spontaneously
(Winkler & Robertson, 1992). Most studies report a similar microbial component in both
NUP lesions associated with HIV and conventional chronic periodontitis (Glick et al., 1994b;
Murray et al., 1989; Murray et al., 1991). Human herpes-viruses such as cytomegalovirus
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have however been identified in some NUP lesions (Slot, 2004). Homosexuals and bisexual
men appear to have a higher incidence of NUP compared to other cohorts of HIV positive
individuals (Glick et al., 1994b). Several studies reveal an association between NUP and HIV
progression (Masouredis et al., 1992; Winkler et al., 1988). NUP has also been reported to be
one of the strongest predictors of severe immune suppression, characterized by low CD4
lymphocyte counts (Glick et al., 1994a; Glick et al., 1994b). Patients with NUP may however,
have CD4 counts above 200 cells/mm3, indicating that other factors such as high viral loads
may be associated (Umeizudike et al., 2011a).
Figure 10. Necrotizing ulcerative periodontitis with sequestrum,
Figure 11. Radiograph of NUP showing extensive bone loss around 22.
3.5.2.4. Necrotizing ulcerative stomatitis
This is a rare condition in HIV positive patients. It is characterized by a localized, acutely
painful rapidly destructive lesion which is ulcerative and necrotic. The lesion may extend
from the gingiva into the adjacent oral mucosa, resulting in extensive destruction of the un‐
derlying soft tissues and osseous tissues. It may occur as a separate condition or be an exten‐
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sion of NUP. The condition may lead to extensive denudation and eventual sequestration of
bone (Williams et al., 1990). The condition is often associated with severe immune suppres‐
sion with low CD4 lymphocyte counts. This condition is similar to the cancrum oris (noma)
a rare destructive condition described in nutritionally deprived individuals particularly chil‐
dren in Africa which progresses from ANUG (Osuji, 1990). Studies carried out by various
individuals all around Nigeria did not show the presence of the disease, though the condi‐
tion was seen in Lagos University Teaching Hospital in a previously undiagnosed HIV sero‐
positive patient (Agbelusi and Eweka, 2011).
Figure 12. Necrotizing ulcerative stomatitis
Figure 13. Necrotizing ulcerative stomatitis
3.5.2.5. Chronic periodontitis with an increased rate of attachment loss
Rapid periodontal pocket formation has been reported in HIV infection in some controlled
studies (Barr et al., 1992; Yeung et al., 1993; Robinson et al., 1996; Ndiaye et al., 1997; Ranga‐
nathan et al., 2007; Umeizudike et al., 2011b). Although, this is not a consistent finding
(Scheutz et al., 1997).This accelerated periodontal attachment loss reported in HIV infected
individuals could be the result of severe episodes of NUP. The clinical presentation of gingi‐
vitis and chronic periodontitis in HIV-positive individuals is the same as that occurring in
non HIV infected populations. It is characterized by the rapid destruction of the periodontal
tissues characterized by rapid pocket formation and attachment loss. Radiographic features
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with evidence of alveolar bone loss are evident. The risk factors for periodontitis in HIV pos‐
itive patients include age, smoking pack-years, high viral load, Fusobacterium nucleatum, Pre‐
votella intermedia, Actinobacillus actinomycetemcomitans, neutrophil elastase and β-
glucuronidase (Alpagot et al., 2004).
Figure 14. Deep periodontal pocket around tooth 16.
3.5.3. Oral Hairy Leukoplakia: (OHL)
This lesion usually presents as asymptomatic, white, vertical, corrugated, hair-like projec‐
tions on the lateral borders of the tongue (bilaterally or unilaterally). It can spread to the
dorsum of the tongue and on the ventral aspect to the floor of the mouth and occasional‐
ly on the adjacent buccal mucosa, when seen in these areas it is smooth and velvety not
hair-like.  Unlike  candidiasis  the  lesion  cannot  be  wiped  off  the  mucosal  surface  (ECC/
WHO, 1993).
OHL was seen and investigated in 1981 by Greenspan et al., who published the initial report
of its existence among homosexual men in San Francisco in 1984 (Greenspan et al.,1984).
It is slightly less common in women than in men, and it is also rare in children. In HIV posi‐
tive persons OHL heralds more rapid progressions of AIDS (Greenspan et al., 1984; Glick et
al., 1994; Lifson et al., 1994).
The incidence of OHL is reported to be 20% in CDC II individuals, increasing as CD4 count
falls and patient’s clinical condition deteriorates (Glick et al., 1994; Lifson et al., 1994). It also
appears during the late latency stages of HIV infection. Although the studies carried out by
Greenspan et al in 2000, showed that the presence of OHL was not related to CD4 count but
was associated with high viral load.
OHL prevalence rates ranged from 0% amongst Tanzanians (Schiodt et al., 1990) to 20% in
Cape Town (Arendorf et al., 1998).
Although originally postulated to be pathognomonic for HIV infection, this lesion has sub‐
sequently been reported in other immune deficiency states as well as in immunocompetent
individuals (Sirois, 1998) e.g. among organ or bone marrow recipients and those receiving
long-term steroid therapy (King et al., 1994).
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The frequency of OHL is about 20% in those with otherwise symptom- free HIV infection
and increases as the CD4 count falls and the clinical condition deteriorates (Aragues et al.,
1990; Feigel et al., 1991; Glick et al., 1994; Lifson et al., 1994).
Considerable research have provided a body of evidence that the Epstein Barr virus (EBV) is
the likely cause of this lesion, which should probably now be renamed according to its aeti‐
ology as “EBV Leukoplakia” (Greenspan et al., 1984; Iain et al., 2000).
Histologic features of OHL shows surface corrugation, thickening of the prickle- cell layer
(acanthosis) with groups or layers of ballooning cells similar to koilocytes, absence of atypia
and other features of dysplasia, lack of inflammatory cells infilteration in the epithelium or
adjoining connective tissues (Greenspan et al., 1984). These features are not pathognomic of
OHL. Evidence of presence of EBV is required for definitive diagnosis of OHL, although
presumptive diagnosis can be made on clinical appearance alone and non-response to anti‐
fungal drugs. (ECC/WHO, 1993).
Figure 15. Hairy leukoplakia
3.5.4. Kaposi’s sarcoma
This is the most common malignancy encountered in HIV/AIDS patients (Iain et al., 2000).
Kaposi's sarcoma-associated herpes virus (KSHV)/Human Herpes Virus-8 (HHV-8) is the
causative agent of the endothelial cell-derived tumour Kaposi's sarcoma (Sturzl et al., 2009).
The lesions are commonly seen in homosexual men. The lesions are characterized by red‐
dish, bluish or purple, single or multiple macules or nodules. These are seen on the palate or
gingivae and may ulcerate, gingival involvement may lead to underlying bone destruction
and tooth mobility (Iain et al., 1992). Twenty two percent of the lesions are present intraoral‐
ly, with 45% of patients presenting with both skin and oral lesions (Tappero et al., 1993).
Biopsy is essential for a definitive diagnosis. It is considered pathognomonic of HIV infec‐
tions.
There is evidence that oral Kaposi’s sarcoma lesions are associated with patients who have
lower CD4 counts than those with the skin lesions alone. (Iain et al., 2000)
Oral Manifestations of HIV
http://dx.doi.org/10.5772/52941
223
with evidence of alveolar bone loss are evident. The risk factors for periodontitis in HIV pos‐
itive patients include age, smoking pack-years, high viral load, Fusobacterium nucleatum, Pre‐
votella intermedia, Actinobacillus actinomycetemcomitans, neutrophil elastase and β-
glucuronidase (Alpagot et al., 2004).
Figure 14. Deep periodontal pocket around tooth 16.
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Figure 16. Kaposi’s sarcoma on the palate and gingiva
3.5.5. Non- Hogdkin’s Lymphoma (NHL)
This is an uncommon feature of HIV disease. It is however, the second most common malig‐
nancy in this condition, with 4% of patients developing NHL during the course of their dis‐
ease (Iain et al., 2000).
NHL of the oral cavity accounts for 3% of all malignant lymphomas, which tends to occur
extranodally (Epstein et al., 1992).
Characteristically, oral tumours involve the fauces and gingivae but atypically may involve
other sites such as the tongue (Borring et al., 1985).
It often clinically presents as a rapidly enlarging mass with associated bony destruction.
Though the presentation varies, the pathogenesis of NHL remains obscure, but there has
been much interest in the role of the Epstein Barr virus, with 50% of AIDS related tumours
demonstrating EBV genomes and also aetiologic role of Human Herpes Virus-8 (HHV-8)
(Boshoff et al., 1997). Survival rates are low and biopsy is essential for definitive diagnosis.
3.5.6. Oral ulcers
Around 50% of AIDS patients present with oral ulcerations during the course of their dis‐
ease. Recurrent aphthous ulcers (RAU) can be classified as Minor aphthous Ulcers (MiAU)
and Major Aphthous ulcers (MjAU).
MiAU: Occur in non- keratinized mucosa and their frequency in AIDS patients is not any
different from that in the general population. RAU have a prolonged course in AIDS pa‐
tients as well as being more painful and difficult to treat. These ulcers are shallow in appear‐
ance, about 2-5mm in diameter, are generally covered with a whitish pseudomembrane and
surrounded by an erythematous halo.
MjAU: Are generally seen in AIDS patients with severe immunodepression (median CD4 T-
lymphocyte count 100 cells/mm3or below) (Ramos-Gomez, 1997). These larger ulcers devel‐
op generally on the lateral border of the tongue, soft palate, floor of the mouth, buccal
mucosa and oropharynx (occurring on both keratinized and non-keratinized surfaces). They
are crater-like in appearance with elevated borders and covered with a white-yellowish
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pseudomembrane, measuring over 1cm in diameter. These lesions are very painful and may
persist for months causing difficulty in swallowing and impairment of speech and mastica‐
tion. Generally, an erythematous halo can be seen surrounding the ulcer and may be accom‐
panied by regional lymphadenopathy.
Figure 17. Minor apthous ulcers.
Figure 18. Major apthous ulcer.
3.5.7. Salivary gland diseases
Salivary gland diseases such as enlargement of the major salivary glands and xerostomia,
was reported to be high in Northern Africa and Thailand (Nittayananta and Chungpanich,
1997). Malnutrition, especially in Northern Africa may play a role.
Enlargement of the salivary glands due to infilteration by CD8 lymphocytes is seen in both
adult and paediatric HIV infection (Schoidt et al., 1989). Some of these glands undergo cystic
change, and such benign lymphoepithelial cysts occasionally cause pain. The cause of HIV-
related salivary gland diseases is unclear, for no etiological agents have been identified. It
can represent a relatively beneficial host CD8 response - Diffuse Infilterative Lymphocytosis
Syndrome (DILS) (Itescu et al., 1990), the lymphocytes may be anti- HIV CD8 cells. No evi‐
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dence of Epstein-Barr virus or cytomegalovirus has been found in biopsies of salivary gland
(Soberman et al., 1991) One report describes an association between HIV-SGD and HLA-
DR5 and HLA-B35 cell-surface antigen (Schiodt et al.,1989).
Adults and children with salivary glands enlargement seem to experience slower progres‐
sion of HIV disease (Katz et al., 1993).
Oral Mucoceles and ranulas are recently discovered to be oral manifestations of HIV infec‐
tion. Several reports are considering it as initial symptoms and early manifestations of HIV
infection (Syebele et al., 2010; Kamulegeya et al., 2012).
Figure 19. Salivary gland swelling
3.5.7.1. Xerostomia
This may be associated with the salivary gland enlargement but is also a common conse‐
quence of medications used by this population. Cytomegalovirus (CMV) has been demon‐
strated in the salivary gland of xerostomic patients (Greenspan et al., 1992). Symptomatic
relief may be provided by salivary stimulants such as sugarless chewing gums or saliva sub‐
stitutes. Prevention of dental caries in people with xerostomia is extremely important, and
the use of topical fluoride gels and rinses should be encouraged (Greenspan et al., 1996). In
addition, management of xerostomia will improve oral comfort, the quality of speech and
use of any prostheses (Narani et al., 2001).
3.5.7.2. Herpes virus infections
Varicella zoster (VZV) is a herpesvirus, and, like other herpesviruses, it causes both primary
and recurrent infection and remains latent in neurons present in sensory ganglia. VZV is re‐
sponsible for two major clinical infections of humans: chickenpox (varicella) and shingles
(herpes zoster [HZ]) (Greenburg et al., 2003 ).
Herpes zoster may indicate a poor prognosis of HIV infection (Scully et al., 1991). This can
be an early complication of AIDS, where it is five times more common than HIV-negative
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persons, and potentially lethal (Cawson et al., 2002). Varicella-zoster may present with a
prodrome of dental pain, preceding oral and unilateral vesicles on an erythematous base
then appear in clusters, chiefly along the course of the nerve, giving the characteristic clini‐
cal picture of single dermatome involvement. Some lesions spread by viremia occur outside
the dermatome. The vesicles turn to scabs in 1 week, and healing takes place in 2 to 3 weeks
and condition can be life threatening in HIV disease.
 
Figure 20.Herpes zoster of the left maxillary branch and the right occipital branch of the trigeminal nerve 
 
Figure 21.Herpes zoster of the left maxillary branch and the right occipital branch of the trigeminal nerve. 
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dence of Epstein-Barr virus or cytomegalovirus has been found in biopsies of salivary gland
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DR5 and HLA-B35 cell-surface antigen (Schiodt et al.,1989).
Adults and children with salivary glands enlargement seem to experience slower progres‐
sion of HIV disease (Katz et al., 1993).
Oral Mucoceles and ranulas are recently discovered to be oral manifestations of HIV infec‐
tion. Several reports are considering it as initial symptoms and early manifestations of HIV
infection (Syebele et al., 2010; Kamulegeya et al., 2012).
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Figure 22. Melanotic hyperpigmentation
3.6. Management of oral lesions of HIV
3.6.1. Candidiasis
Treatment may be topical (using lozenges or mouth rinses) or systemic depending on the
severity of the disease and other associated underlying conditions e.g. Diabetes, liver dis‐
ease, xerostomia etc.
Topical:
1. Chlorhexidine (0.2%) mouth wash
2. Lozenges: e.g. Nystatin (Mycostatin) 100,000 i.u; Clotrimazole (Mycelex) 1%
3. Adhesive tablets: Miconazole 10mg
4. Miconazole oral gel- X2% daily
5. Suspension: e.g. Amphotericin B (0.5-1mg), Nystatin (100,000 i.u)
Topical treatments are preferred because they limit systemic absorption, but the effective‐
ness depends entirely on patient compliance. Topical medications require that the patient
hold medications in the mouth for 20 to 30 minutes.
Clotrimazole is an effective topical treatment (one oral troche [10-mg tablet]) when dis‐
solved in the mouth five times daily. Used less frequently, one vaginal troche can be dis‐
solved in the mouth daily.
Nystatin preparations include a suspension, a vaginal tablet, and an oral pastille. Regimens
are nystatin tablets (one tablet, 100,000 units, dissolved in the mouth three times a day), or
nystatin oral pastille (available as a 200,000 unit oral pastille, one or two pastilles dissolved
slowly in the mouth five times a day). Nystatin suspension has a high sugar content and
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cannot be held in the mouth long enough to be effective. Topical creams and ointments con‐
taining nystatin, ketoconazole, or clotrimazole may be useful in treating angular cheilitis.
For patients with initial and recurring oropharyngeal candidiasis, a topical agent is general‐
ly recommended, provided the patient has a CD4 count greater than 50 cells/mm3 and no
oesophageal involvement.
Another therapeutic choice is Amphotericin B (0.1 mg/ml). Five to 10 ml of oral solution is
used as a rinse and then expectorated three to four times daily (Greenspan, 1998).
Systemic: Fluconazole 150mg daily (Diflucan) for 2 weeks or more
• Miconazole 250mg daily for 2 weeks or more
• Ketoconazole 200mg daily (Sporanox), for 2 weeks or more
• Itraconazole 100mg daily, for 2 weeks or more
Ketoconazole (Nizoral) is a 200 mg tablet taken with food once daily. Patient compliance is
usually good. Careful monitoring of liver function is necessary for long-term use because of
reported side effects, including hepatotoxicity. Lack of efficacy of ketoconazole may occur
because of poor absorption in those with an abnormally high gastric pH.
Fluconazole (Diflucan) is a triazole antifungal agent effective in treating candidiasis (100-mg
tablet taken once daily for 2 weeks (Just-Nubling et al., 1991).
Itraconazole (100 mg capsules) may be used for the treatment of oral candidiasis (200 mg
daily orally for 14 days. Salivary levels of itraconazole are maintained for several hours after
administration (Smith et al., 1991).
The recommendation to avoid systemic anti-fungal therapies in this setting is based on evi‐
dence that widespread use of systemic azoles is strongly linked with the development of
drug-resistant candidiasis. Patients with concurrent oesophageal involvement or a CD4
count less than 50 cells/mm3 should receive a systemic oral azole.
Ketoconazole, fluconazole, and itraconazole may interact with other medications including
rifampicin, phenytoin, cyclosporin A, terfenadine, digoxin, coumarin-like medications, and
oral hypoglycemic medications.
3.6.2. Linear gingival erythema
The treatment protocol for LGE is similar to that of conventional marginal gingivitis and
consists of scaling and polishing of the affected sites and thorough root planing using chlo‐
rhexidine solution as an irrigant (Murray, 1994). Povidone-iodine (10%) solution may be
beneficial for the irrigation because of its anaesthetic and antiseptic effects. According to
Murray (1994), the rationale for scaling is to prevent the lesion from progressing to NUP, the
more severe form. Typically, the patients are given oral hygiene instructions to achieve good
home care, placed on chlorhexidine mouthrinses twice daily, re-assessed 2 to 3 weeks after
the initial therapeutic phase, and further recalled every 3 months.
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nystatin oral pastille (available as a 200,000 unit oral pastille, one or two pastilles dissolved
slowly in the mouth five times a day). Nystatin suspension has a high sugar content and
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cannot be held in the mouth long enough to be effective. Topical creams and ointments con‐
taining nystatin, ketoconazole, or clotrimazole may be useful in treating angular cheilitis.
For patients with initial and recurring oropharyngeal candidiasis, a topical agent is general‐
ly recommended, provided the patient has a CD4 count greater than 50 cells/mm3 and no
oesophageal involvement.
Another therapeutic choice is Amphotericin B (0.1 mg/ml). Five to 10 ml of oral solution is
used as a rinse and then expectorated three to four times daily (Greenspan, 1998).
Systemic: Fluconazole 150mg daily (Diflucan) for 2 weeks or more
• Miconazole 250mg daily for 2 weeks or more
• Ketoconazole 200mg daily (Sporanox), for 2 weeks or more
• Itraconazole 100mg daily, for 2 weeks or more
Ketoconazole (Nizoral) is a 200 mg tablet taken with food once daily. Patient compliance is
usually good. Careful monitoring of liver function is necessary for long-term use because of
reported side effects, including hepatotoxicity. Lack of efficacy of ketoconazole may occur
because of poor absorption in those with an abnormally high gastric pH.
Fluconazole (Diflucan) is a triazole antifungal agent effective in treating candidiasis (100-mg
tablet taken once daily for 2 weeks (Just-Nubling et al., 1991).
Itraconazole (100 mg capsules) may be used for the treatment of oral candidiasis (200 mg
daily orally for 14 days. Salivary levels of itraconazole are maintained for several hours after
administration (Smith et al., 1991).
The recommendation to avoid systemic anti-fungal therapies in this setting is based on evi‐
dence that widespread use of systemic azoles is strongly linked with the development of
drug-resistant candidiasis. Patients with concurrent oesophageal involvement or a CD4
count less than 50 cells/mm3 should receive a systemic oral azole.
Ketoconazole, fluconazole, and itraconazole may interact with other medications including
rifampicin, phenytoin, cyclosporin A, terfenadine, digoxin, coumarin-like medications, and
oral hypoglycemic medications.
3.6.2. Linear gingival erythema
The treatment protocol for LGE is similar to that of conventional marginal gingivitis and
consists of scaling and polishing of the affected sites and thorough root planing using chlo‐
rhexidine solution as an irrigant (Murray, 1994). Povidone-iodine (10%) solution may be
beneficial for the irrigation because of its anaesthetic and antiseptic effects. According to
Murray (1994), the rationale for scaling is to prevent the lesion from progressing to NUP, the
more severe form. Typically, the patients are given oral hygiene instructions to achieve good
home care, placed on chlorhexidine mouthrinses twice daily, re-assessed 2 to 3 weeks after
the initial therapeutic phase, and further recalled every 3 months.
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Non-responsive lesions could signal a possible candidal co-infection which may need to be
treated concomitantly with topical antifungal rinses or systemic antifungal tablets such as
fluconazole for 7 to 10 days (Murray, 1994). This has been shown to reduce the erythema
associated with LGE. It must be borne in mind that LGE may still be refractory to treatment,
hence, patient should be monitored closely for any signs of severe necrotizing periodontal
conditions. The lesion has sometimes been known to undergo spontaneous remission for
reasons yet unknown.
3.6.3. Necrotizing ulcerative gingivitis
The NUG lesion should be debrided thoroughly under topical anaesthesia to remove tissue
slough, plaque and necrotic soft tissue in the initial phase of treatment. Irrigation should be
done frequently with hydrogen peroxide or povidone iodine which is particularly advanta‐
geous because of its topical anaesthetic effect (Grassi et al., 1988). This should be accompa‐
nied by daily or alternate day visits for further debridement of affected areas for the first
week with the gradual introduction of home plaque control measures to reinforce good oral
hygiene. This initial phase of treatment is followed by scaling and thorough root planing if
indicated. Systemic antibiotics such as metronidazole may be prescribed in severe cases of
tissue loss or associated systemic effects. Topical chlorhexidine gluconate 0.12% mouthwash
is prescribed. Patients are reassessed 1 month after resolution of the acute phase to deter‐
mine if further therapy is needed. Most of the lesions may resolve within a week (Robinson
et al., 1998).
3.6.4. Necrotizing ulcerative periodontitis
The treatment of NUP involves the gentle debridement of the affected lesions, followed by
sub-gingival scaling and root planing, irrigation with chlorhexidine gluconate (Grassi et al.,
1988; Umeizudike et al., 2011a) or povidone-iodine. Oral hygiene instructions should be em‐
phasized alongside the home use of twice daily antimicrobial mouth-rinses such as 0.12% or
0.2% chlorhexidine gluconate. In severe NUP cases, systemic metronidazole 500mg loading
dose and 250 mg four times daily for 5-7 days is the drug of choice. It has been shown to
reduce acute pain and promote rapid healing. Metronidazole should be prescribed with cau‐
tion in patients with liver alteration or history of hepatitis (Winkler & Robertson, 1992). Al‐
ternatively, penicillin may be prescribed. However, it should be used with caution to avoid
the proliferation of opportunistic infections such as candidiasis. Appropriate topical or sys‐
temic antifungal treatment may be used for patients who have concurrent oral candidiasis
(Holmstrup & Samaranayake, 1990). There is a need to follow up these patients after the ini‐
tial phase of therapy to ensure adequate plaque control and reduce the incidence of delayed
healing and continued rapid destruction (Winkler & Robertson, 1992). Oral hygiene aids
such as interproximal brushes may be necessary to achieve better plaque control. Sequestra
should be removed if present to facilitate wound healing (Umeizudike et al., 2011a) and may
not always require antibiotic coverage (Robinson, 1991).
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3.6.5. Necrotizing ulcerative stomatitis
The principles of the treatment are similar to that of necrotizing ulcerative periodontitis. It
should begin with gross scaling to remove visible plaque and debridement of necrotic soft
tissue. Povidone-iodine may be used for irrigation. Systemic metronidazole and chlorhexi‐
dine mouthrinses should be prescribed. Necrotic bone should be removed if present to pro‐
mote wound healing (Williams et al., 1990).
3.6.6. Chronic periodontitis with an increased rate of attachment loss
This should include conservative, non-surgical periodontal therapy which basically consists
of scaling and polishing of all teeth, sub-gingival scaling and root planing of affected teeth.
Detailed oral hygiene instructions should be given to the patient in order to achieve effective
plaque control. This should include the use of 0.2% chlorhexidine mouthwashes twice daily
at home. The overall health status of the patient, the degree of immune suppression, extent
of periodontal attachment loss and patient’s ability to perform effective oral hygiene are all
the factors that should be taken into consideration when planning for elective periodontal
surgical procedures and implant placement. The hematological profile of patients may be re‐
quired prior to these surgical procedures to monitor their overall health status. Periodontal
maintenance recalls should be instituted at 2-3 monthly intervals initially, and later to 6
monthly intervals. Dentists should be ready to advise patients and provide dental treat‐
ments in a relaxed and calm atmosphere to minimize the patients stress and anxiety, as
these HIV positive patients are prone to psychological problems (Asher et al. 1993).
In summary, it should be noted that the treatment of periodontal diseases associated with
HIV should have some basic components (Winkler & Robertson, 1992).
1. Extensive debridement of necrotic tissues.
2. Antimicrobial therapy (local and systemic)
3. Immediate follow up phase
4. Regular long-term maintenance
3.6.7. Oral Hairy Leukoplakia (OHL)
OHL is usually symptomless; complaints about the discomfort and appearance sometimes
justify treatment (Barr, 1995). The lesions respond to high doses of acyclovir, ganciclovir,
and also podophyllin and retinoin. Treatment is usually not indicated, but improved with
antiretroviral therapy e.g. AZT, Ganciclovir, acyclovir or descyclovir. Hairy leukoplakia re‐
curs after discontinuation of therapy (Scully et al., 1992).
3.6.8. Kaposi’s sarcoma
Treatment of oral kaposi’s sarcoma is directed towards control of spread and palliation, for
aesthetic reasons, pain or functional impairment. It is by radiotherapy or chemotherapy
such as Vinblastin. Radiation therapy may be indicated for large, multiple lesions (Green‐
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tial phase of therapy to ensure adequate plaque control and reduce the incidence of delayed
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monthly intervals. Dentists should be ready to advise patients and provide dental treat‐
ments in a relaxed and calm atmosphere to minimize the patients stress and anxiety, as
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3.6.7. Oral Hairy Leukoplakia (OHL)
OHL is usually symptomless; complaints about the discomfort and appearance sometimes
justify treatment (Barr, 1995). The lesions respond to high doses of acyclovir, ganciclovir,
and also podophyllin and retinoin. Treatment is usually not indicated, but improved with
antiretroviral therapy e.g. AZT, Ganciclovir, acyclovir or descyclovir. Hairy leukoplakia re‐
curs after discontinuation of therapy (Scully et al., 1992).
3.6.8. Kaposi’s sarcoma
Treatment of oral kaposi’s sarcoma is directed towards control of spread and palliation, for
aesthetic reasons, pain or functional impairment. It is by radiotherapy or chemotherapy
such as Vinblastin. Radiation therapy may be indicated for large, multiple lesions (Green‐
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span et al., 1984). A single dose of 800 cGy or an equivalent fractionated dose is frequently
used and produces a good response. Other local therapy may involve excision of exophytic
lesions or intra- lesional injection of vinblastin (Iain et al., 2000).
3.6.9. Oral ulcers
Topical steroids can be effective in the treatment of MiAUand MjAU:
i. Fluocinonide gel 0.05% with Orabase - apply to ulcers four times daily.
ii. Clobestasol 0.05% in Orabase – apply 3-4 times daily.
iii. Dexamethasone elixir 0.5mg/ml – rinse with 20ml four times daily
iv. Triamcinolone in Orabase – apply 3-4 times daily.
Ulcers are reevaluated after one week. If there is no improvement, alternative treatment
should be considered, including systemic steroids e.g. Prednisolone.
Alternative forms of treatment have included intralesional injection with Triamcinolone
acetonide.
Supportive therapy is necessary to aid healing of the ulcers, this includes:
• Vitamin B complex i tds
• Tabs Folic acid i daily
• Tabs Vitamin C 300mg tds
• Xylocaine gel to relieve pain and Chlorhexidine mouth wash.
3.6.10. Salivary gland diseases
No treatment is indicated for the salivary gland enlargement, although large cystic glands
are sometimes removed surgically for cosmetic purposes. Radiation therapy has also been
used to reduce the swelling.
3.6.11. Xerostomia
The management of xerostomia involves the use of both saliva substitutes and saliva stimu‐
lants. Patients with little or no responsive salivary gland tissue will need saliva substitutes.
A properly balanced artificial saliva should be of neutral pH and contain electrolytes, in‐
cluding fluoride, to correspond to the composition of saliva.
Gustatory stimuli such as sugarless sweets containing citric and malic acid, chemically in‐
duce saliva production. Care must be taken that the acidic content does not result in the dis‐
solution of tooth enamel. Controlled studies have shown that pilocarpine is an effective
stimulus to saliva production (Greenspan et al., 1987; Rieke et al., 1995), side effects, mainly
the result of generalised parasympathetic stimulation, are the most common reason to dis‐
continue treatment.
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There have been a number of studies that have shown that chewing gum increases salivary
flow from patients with xerostomia of varying aetiology (Risheim et al., 1993). In some xe‐
rostomic patients, the initial stimulated salivary flow rate while chewing sugar free gum is
seven times greater than the unstimulated flow rate. Chewing sugar free gum has been
shown to be one of the most preferred treatments for xerostomia (Bjornstrom et al., 1990).
3.6.12. Herpes zoster
Management should be directed toward shortening the course of the disease, preventing post‐
herpetic neuralgia in patients over 50 years of age, and preventing dissemination in immuno‐
compromised patients. Acyclovir or the newer antiherpes drugs valacyclovir or famciclovir
accelerate healing and reduce acute pain, but they do not reduce the incidence of postherpetic
neuralgia. The newer drugs have greater bioavailability and are more effective in the treat‐
ment of HZ. Supportive therapy, antibiotics and analgesics are also recommended.
• Tabs Acyclovir200-400mg 5x daily for 1 week
3.7. Oral lesions and relationship with CD4 count and viral load
The hallmark of HIV disease is the progressive loss of CD4+ lymphocytes. Without interven‐
tion, an average of 60 to 80 cells/mm3 is lost every year; this loss is highly variable and oc‐
curs in periods of stability and rapid decline. High viral load is also considered to be one of
the main indicators of the progression of HIV- induced immunosuppression. Several studies
have shown that the higher the viral load, the quicker the progression to AIDS.
The CD4 count and viral load measure the progression of the HIV disease. Several studies
have shown high prevalence of oral lesions in patients with low CD4 count, <200 cells/mm3
and high viral load: >55,000 copies/ml. CD4 count < 200 cells/mm3 is used as criterion for ini‐
tiating HAART, which is consistent with the guidelines for initiating HAART treatment by
WHO (2003).
Presence of multiple lesions in infected HIV patients is also associated with severe immuno‐
suppression and AIDS.
3.8. Oral lesions and response to HAART
The goals of HAART should be maximal and durable viral suppression. The aim is preser‐
vation and restoration of the immune system at minimal cost to the patient. This should im‐
prove the quality of life through ease of use of their regimen with minimal side-effects to
enhance optimum adherence. This should translate into a reduction of HIV- related morbid‐
ity including oral manifestations. Reduction of viral burden will prevent progressive immu‐
nodeficiency, decrease the risk of the emergence of resistant viruses and possibly decrease
the risk of viral transmission (Fauci et al., 2000).
It has been shown in various studies that the prevalence of HIV-related oral lesions reduces
significantly with HAART. The reported percentage decrease varied from 10% in a USA
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duce saliva production. Care must be taken that the acidic content does not result in the dis‐
solution of tooth enamel. Controlled studies have shown that pilocarpine is an effective
stimulus to saliva production (Greenspan et al., 1987; Rieke et al., 1995), side effects, mainly
the result of generalised parasympathetic stimulation, are the most common reason to dis‐
continue treatment.
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accelerate healing and reduce acute pain, but they do not reduce the incidence of postherpetic
neuralgia. The newer drugs have greater bioavailability and are more effective in the treat‐
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curs in periods of stability and rapid decline. High viral load is also considered to be one of
the main indicators of the progression of HIV- induced immunosuppression. Several studies
have shown that the higher the viral load, the quicker the progression to AIDS.
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have shown high prevalence of oral lesions in patients with low CD4 count, <200 cells/mm3
and high viral load: >55,000 copies/ml. CD4 count < 200 cells/mm3 is used as criterion for ini‐
tiating HAART, which is consistent with the guidelines for initiating HAART treatment by
WHO (2003).
Presence of multiple lesions in infected HIV patients is also associated with severe immuno‐
suppression and AIDS.
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The goals of HAART should be maximal and durable viral suppression. The aim is preser‐
vation and restoration of the immune system at minimal cost to the patient. This should im‐
prove the quality of life through ease of use of their regimen with minimal side-effects to
enhance optimum adherence. This should translate into a reduction of HIV- related morbid‐
ity including oral manifestations. Reduction of viral burden will prevent progressive immu‐
nodeficiency, decrease the risk of the emergence of resistant viruses and possibly decrease
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It has been shown in various studies that the prevalence of HIV-related oral lesions reduces
significantly with HAART. The reported percentage decrease varied from 10% in a USA
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study on 570 patients (Patton et al., 2000) to 50% in a Mexican study on selected 1000 HIV
patients over a period of 12 years (Ramírez-Amador et al., 2003).
In a Spanish study on 154 subjects, Ceballos-Salobrena et al (2000) showed a 30% reduction
of oral lesions, while Tappuni and Fleming (2001) reported a reduction of 24% in a study on
284 patients in the United Kingdom. Some looked at a particular oral manifestation (Cauda
et al., 1999) as opposed to a range of oral lesions (Ceballos-Salobrena et al., 2000; Tappuni
and Fleming, 2001; Eyeson et al., 2002; Ramírez-Amador et al., 2003).
Studies examining the effect of HAART on the prevalence of individual oral manifestations
mainly reported on oral candidiasis, oral hairy leukoplakia, HIV-related periodontal diseas‐
es, Kaposi’s sarcoma (KS), oral papilloma, and HIV-related salivary gland disease showed
reduction in the prevalence (Patton et al., 2000; Schmidt-Westhausen et al., 2000; Tappuni et
al., 2001).
Oral candidiasis (OC) has been shown to be one of the most common oral lesions in HIV
patients. With the advent of HAART, most studies reported a decrease in the prevalence of
Oral Candidiasis. In a study on 93 patients, 7% of patients on protease inhibitors (PI) had
Oral Candidiasis, compared with 36% in non-PI-treated patients (Cauda et al., 1999).
Schmidt-Westhausen et al (2000) detected Oral Candidiasis in 10/103 (9.7%) of their study
subjects who had been on HAART for 4 weeks and in none after 6 months’ therapy (n = 61).
Tappuni and Fleming (2000) reported that the prevalence of Oral Candidiasis was about
50% less in patients on therapy (n = 89) compared with drug-naïve patients (n = 195). Con‐
versely, Patton et al (2000) found no significant difference in the prevalence of Oral Candi‐
diasis with the use of Protease Inhibitors (n = 507). In the same study, the prevalence of oral
hairy leukoplakia (OHL) was found to decrease with therapy (Patton et al., 2000), in agree‐
ment with reports from other studies (Tappuni and Fleming, 2001).
The prevalence of HIV-associated periodontal diseases was reported to decrease significantly
in an American cohort, from 4.8% to 1.7% with HAART (Patton et al., 2000), in concordance with
findings in other studies (Ceballos-Salobrena et al., 2000; Tappuni and Fleming, 2001).
Kaposi’s Sarcoma (KS) is one of the oral manifestations that is strongly associated with HIV,
although its prevalence is quite low in this group (Ceballos-Salobrena et al., 2000), Studies
from the USA (Patton et al., 2000) and Mexico (Ramírez-Amador et al., 2003) found no sig‐
nificant change in the occurrence of Kaposi Sarcoma with HAART.
Unlike most other oral manifestations of HIV, studies from the USA and the United King‐
dom(UK) described an increase in the prevalence of oral warts with HAART (Patton et al.,
2000; Greenwood et al., 2002), which may reach statistical significance (Greenspan et al.,
2001). Others looking at a different population (Mexicans) reported similar detection rates of
oral warts, papillomas, condylomas and focal epithelial hyperplasia in HIV-positive subjects
on HAART compared with those not on therapy (Ramírez-Amador et al., 2003).
Other lesions that are showing a trend of rising prevalence include HIV-related salivary
gland disease (Patton et al., 2000). However, this was not supported by other studies (Ramír‐
ez-Amador et al., 2003). Studies from industrialized world report a decreased frequency of
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HIV-related oral manifestations of 10–50% following the introduction of HAART (Hodgson
et al., 2006).
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patients. With the advent of HAART, most studies reported a decrease in the prevalence of
Oral Candidiasis. In a study on 93 patients, 7% of patients on protease inhibitors (PI) had
Oral Candidiasis, compared with 36% in non-PI-treated patients (Cauda et al., 1999).
Schmidt-Westhausen et al (2000) detected Oral Candidiasis in 10/103 (9.7%) of their study
subjects who had been on HAART for 4 weeks and in none after 6 months’ therapy (n = 61).
Tappuni and Fleming (2000) reported that the prevalence of Oral Candidiasis was about
50% less in patients on therapy (n = 89) compared with drug-naïve patients (n = 195). Con‐
versely, Patton et al (2000) found no significant difference in the prevalence of Oral Candi‐
diasis with the use of Protease Inhibitors (n = 507). In the same study, the prevalence of oral
hairy leukoplakia (OHL) was found to decrease with therapy (Patton et al., 2000), in agree‐
ment with reports from other studies (Tappuni and Fleming, 2001).
The prevalence of HIV-associated periodontal diseases was reported to decrease significantly
in an American cohort, from 4.8% to 1.7% with HAART (Patton et al., 2000), in concordance with
findings in other studies (Ceballos-Salobrena et al., 2000; Tappuni and Fleming, 2001).
Kaposi’s Sarcoma (KS) is one of the oral manifestations that is strongly associated with HIV,
although its prevalence is quite low in this group (Ceballos-Salobrena et al., 2000), Studies
from the USA (Patton et al., 2000) and Mexico (Ramírez-Amador et al., 2003) found no sig‐
nificant change in the occurrence of Kaposi Sarcoma with HAART.
Unlike most other oral manifestations of HIV, studies from the USA and the United King‐
dom(UK) described an increase in the prevalence of oral warts with HAART (Patton et al.,
2000; Greenwood et al., 2002), which may reach statistical significance (Greenspan et al.,
2001). Others looking at a different population (Mexicans) reported similar detection rates of
oral warts, papillomas, condylomas and focal epithelial hyperplasia in HIV-positive subjects
on HAART compared with those not on therapy (Ramírez-Amador et al., 2003).
Other lesions that are showing a trend of rising prevalence include HIV-related salivary
gland disease (Patton et al., 2000). However, this was not supported by other studies (Ramír‐
ez-Amador et al., 2003). Studies from industrialized world report a decreased frequency of
Current Perspectives in HIV Infection234
HIV-related oral manifestations of 10–50% following the introduction of HAART (Hodgson
et al., 2006).
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1. Introduction
Human Immune deficiency Virus (HIV) infection has assumed pandemic proportion since
after its identification as the causative agent of Acquired Immunodeficiency Syndrome
(AIDS).The spectrum of HIV infection and AIDS is quite wide and variable. HIV infected
patients have an increased risk of developing endocrine abnormalities [1]. The endocrine
glands are affected in a variety of ways such as functional derangement, direct effects of
HIV infection and the resultant immune suppression, effects of opportunistic infections both
acute and chronic, invasion by neoplasms and the effects of the various medications used to
treat HIV or any of the opportunistic infections associated with it (Table 1). While endocrine
dysfunction has not been a prominent clinical feature of AIDS, all endocrine glands may be
affected by the opportunistic infections and malignancies; as a result of antiretroviral treat‐
ment or indeed as a result of the direct invasion of the glands by the virus (Table 2). The
introduction of anti-retroviral (ARV) drugs has significantly reduced both morbidity and
mortality attributable to HIV infection [2]. The prolonged administration of these drugs
however, has led to new challenges for both physicians and patients [3- 8].
Apart from the effects of acute and chronic illnesses, the relentless progression of immune
dysfunction in AIDS affects endocrine function through the activation of several cytokines,
chemokines and antibody formation. The use of protease inhibitors (PIs) and nonnucleoside
reverse transcriptase inhibitors (NNRTIs) is associated with multiple abnormalities in glu‐
cose and lipid metabolism such as insulin resistance, increased triglycerides and increased
levels of low-density lipoprotein cholesterol. These metabolic disturbances might be due to a
combination of factors, including the direct effect of medications, restoration to health; HIV
disease as well as individual genetic predisposition. Of the available antiretroviral medica‐
tions, indinavir had been associated with causing the most insulin resistance and ritonavir
with causing the most hypertriglyceridemia.
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b. Interference with Endocrine function
• Acute illness
• Chronic illness
• Cytokines (tumour necrosis factor, interleukin-1, interferon)
• Antibodies
c. Effects of medications
• ARV’s




Table 1. Mechanisms of Endocrine dysfunction in patients with HIV [1]
a. Endocrinopathies as a result of direct effects of the virus.
• HIV adrenalities and impaired adrenal reserve
• Hypercorticolism




• AIDS wasting syndrome
b. Endocrinopathies as a resultof structural destruction of gland.s
• Cytomegalovirus (CMV) adrenalitis
• Pneumocystis thyroiditis
• Mycobacterial infection, cryptococcosis, toxoplasmosis(pituitary, thyroid, adrenals)
• Haemorrhages and abscesses causing insufficiency of glands (pituitary, thyroid and adrenals)
Table 2. Common Endocrine abnormalities in HIV infected patients [1].
2. The pituitary
Involvement of the pituitary gland is common in advanced HIV infection, at autopsy; varying
degrees of infarction and necrosis are the most common findings occurring in nearly 10% of
cases [1]. Also common are opportunistic Infections by CMV, Pneumocystis carinii, Toxoplas‐
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mosis and mycobacteria among others [9]. Furthermore, the pituitary may also be affected by
neoplasms such as cerebral lymphoma with peripheral involvement of the gland.
Despite the foregoing, evaluation of anterior pituitary reserve in HIV infected patients by
TSH or gonadotropin stimulation has demonstrated a normal response in nearly all patients.
Suggesting that panhypopituitarism is rare in these patients.
GH deficiency does not appear to be common [1]. Posterior pituitary function may be al‐
tered in HIV patients with Hyponatremia occurring in up to 50% of inpatients and about
20% of outpatients with AIDS; two-thirds of these patients are clinically euvolemic with se‐
rum arginine vasopressin levels that are inappropriately high for the serum osmolality, con‐
sistent with the syndrome of inappropriate antidiuretic hormone secretion [10 - 12]. The
presence of Pneumocystis carinii pneumonia and/ or treatment with trimethoprim appears
to be the most significant risk factors for this complication. Furthermore, central diabetes in‐
sipidus has been reported in AIDS patients with herpetic meningoencephalitis.
3. Thyroid dysfunction
Although thyroid function tests are often abnormal in HIV patients, the prevalence of overt
thyroid disorder is not significantly different from that of the general population [13]. Most
asymptomatic patients with HIV infection have normal thyroid function. Some, however, ex‐
hibit increased serum total thyroxine (T4) and triiodothyronine (T3) concentrations. These in‐
creases are as a result of increases in serum thyroxine-binding globulin, the cause of which is
unknown [14]. However, with progression of HIV infection and as the patients become more
ill, serum T4 and T3 concentrations decline, as is obtained in most if not all chronically ill pa‐
tients; serum thyrotropin concentrations however remain normal or slightly depressed. These
changes are as a result of reduction in serum binding proteins, decreased extrathyroidal con‐
version of T4 to T3, and decreased secretion of thyrotropin [13], [14]. Cytokines may be in‐
volved in some of these; especially the reduction in the peripheral conversion of T4 to T3 [15].
An increasing number of patients taking anti-HIV drugs are presenting with thyroid disor‐
ders as a result of improved immune function (immune reconstitution syndrome). Graves’
disease is the commonest among immune reconstitution syndromes; others include Hashi‐
moto’s thyroiditis and hypothyroidism. Autoimmune Thyroid Disease (AITD) occurs in 3%
of women and 0.2% of men [13- 17]. Goddard proposed a staging of autoimmune manifesta‐
tions related to HIV/AIDS (table 3) [18].
The prevalence of immune reconstitution Autoimmune Thyroid Disease (AITD) (Graves’
disease, Hashimoto thyroiditis, and hypothyroidism) is about 3% for women and 0.2% for
men. Patients with lower CD4 counts at baseline with greater increments in the CD4 counts
following HAART are more likely to develop AITD.
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Stage I Acute HIV infection, the immune system is intact and autoimmune diseases may develop.
Stage II The quiescent period without overt manifestations of AIDS associated with a declining
CD4 count indicative of some immunosuppression. Autoimmune diseases are not found.
Stage III Immunosuppression with low CD4 count and the development of AIDS. CD8 T cells
predominate and diseases such as psoriasis and diffuse immune lymphocytic syndrome
(similar to Sjogren’s syndrome) may present or even be the initial manifestation of AIDS.
No autoimmune diseases are found.
Stage IV Restoration of immune competence following HAART. In this setting, there is a
resurgence of autoimmune disorders.
Table 3. Stages of autoimmune manifestations in HIV/AIDS.
Thyroid dysfunction in HIV-positive individuals can result from gland destruction by op‐
portunistic pathogens such as Pneumocystis jirovecii which has been reported to cause a
painful low uptake thyroiditis like picture with hyperthyroidism followed by hypothyroid‐
ism. Other opportunistic pathogens that could affect the thyroid gland in HIV infected indi‐
viduals include Cryptococcus neoformans, Aspergillosis and cytomegaloviurs [19 - 23]. The
gland may also be invaded by Kaposi Sracoma with resultant hypothyroidism [24].
Overt Hypothyroidism should be treated with levothyroxine keeping in mind that drug in‐
teractions between levothyroxine and protease inhibitors have been reported, perhaps
through the shared metabolic pathway of glucuronidation. In subclinical hypothyroidism
however, the TSH level should be determined again within three months as the levels nor‐
malize within a year in up to 30% of affected patients. In cases of overt hyperthyroidism, it
is paramount to establish whether it is as a result of Graves’ disease, or thyroiditis and the
appropriate therapy instituted.
4. Adrenal dysfunction
Biochemical evidence of adrenal insufficiency is relatively common in hospitalized AIDS pa‐
tients occurring in almost a fifth of such patients however, only about 4% are clinically
symptomatic patients [25]. Adrenal dysfunction may be suspected in HIV-infected patients
with advanced stage of AIDS. High index of suspicion is required; subtle impairment of
adrenal function is manifested as fatigue, hyponatremia or rarely with clinical symptoms of
adrenal insufficiency. At autopsy, the adrenal gland shows evidence of both inflammation
and necrosis1, [26 - 28]. Adrenal secretion of aldosterone and adrenal androgens may also be
impaired. In fact, there appears to be a shift from adrenal androgen and aldosterone produc‐
tion toward glucocorticoid production. However, the secretion of aldosterone in response to
assumption of the upright posture and the administration of angiotensin II is normal. The
mechanisms by which HIV might affect adrenal secretion appear to be dependent on effects
of cytokines and other immunomodulatory substances on the hypothalamo-pituitary-adre‐
nal axis [29 - 32]. The potential sites of immune modulation of this is shown in this figure 1.
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Interleukin-1 is a likely candidate as either a direct or an indirect adrenal stimulator. Its pro‐
duction by macrophages is stimulated by tumor necrosis factor, and the production by mac‐
rophages of both interleukin-1 and tumor necrosis factor is stimulated by HIV infection [33].
Interleukin-1 may affect the hypothalamus, pituitary, or adrenal glands in a variety of ways
[29]. Interleukin-1 stimulates the release of corticotropin-releasing hormone from the hypo‐
thalamus into the portal circulation leading to the increases in corticotropin and consequent‐
ly cortisol secretion. Furthermore, Interleukin-1 has been shown to directly stimulate
cultured pituitary cells to release corticotropin. Cultured adrenocortical cells secrete more
cortisol when cocultured with mononuclear cells most likely as a result of a response to the
production of interleukin-1 by mononuclear cells [30 - 32]. Interferon, another product of
HIV-infected monocytes and macrophages, is also an immunomodulator of the hypothala‐
mo-pituitary-adrenal axis [34].
Figure 1. Effects of cytokines on the Hypothalamo-pituitary-adrenal axis.
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Both interleukin-1 and interferon thus have effects that could stimulate adrenal function.
Conversely, adrenal function could be inhibited in patients with HIV infection as a result of
polyclonal B-cell activation and the production of anti—adrenal-cell antibodies. The specific
cellular or hormonal antigenic determinants and the pathogenetic importance of these anti‐
bodies are unclear. In addition to these mechanisms of adrenal dysfunction in patients with
HIV infection, drugs which impair adrenal function directly such as Ketoconazole which in‐
hibits adrenal steroidogenesis, Rifampicin, phenytoin, and opiates which accelerate the deg‐
radation of cortisol and therefore lower serum cortisol concentrations are frequently
prescribed in HIV infected patients. Although the resulting need for increased cortisol secre‐
tion is easily met in normal subjects, it may not be so in patients with HIV infection.
5. Glucocorticoids
The adrenal corticosteroids ( Cortisol and Aldosterone), exert profound influences on many
physiologic functions by virtue of their diverse roles in growth, development and mainte‐
nance of homeostasis [35]. The actions of these corticosteroids are mediated by intracellular
receptor proteins, the glucocorticoid (GR) and mineralocorticoid (MR) receptors respective‐
ly. These receptors act as hormone-activated transcription factors which regulate the expres‐
sion of the glucocorticoid and mineralocorticoid target genes respectively. The GR is
ubiquitous and is found in virtually all human tissues and organs [1, 35].
Glucocorticoids are essential to maintain the integrity of central nervous system and cardio‐
vascular function,as well as the maintenance of metabolic and immune function.
Tissue hypersensitivity to glucocorticoids was recently hypothesized in patients with Hu‐
man Immunodeficiency Virus type-1 infection via the accessory proteins Vpr and Tat which
enhance GR transactivation [36]. Since HIV-1 long terminal repeat (LTR) and glucocorticoid-
responsive promoters use the same set of co-activators, these proteins may stimulate HIV-1-
LTR and glucocorticoid-inducible genes concurrently. The former may directly stimulate
viral proliferation, while the latter may indirectly enhance viral propagation by suppressing
the host immune system through glucocorticoid mediated mechanisms.
6. Glucocorticoid hypersensitivity in AIDS
AIDS patients have several manifestations compatible with tissue hypersensitivity to gluco‐
corticoids [37]. Some of the manifestations include reduction of innate and cellular immuni‐
ty mediated through T helper 1 cells with resultant reduction in the secretion of interleukin
(IL)-2, IL-12 and interferon and increased secretion of IL-4. These changes are similar to
what obtains when exogenous glucocorticoids are administered as well as in hypercortisole‐
mic patients with endogenous Cushing’s syndrome. Furthermore, hippocampal atrophy
similar to what is observed in individuals who exhibit hypercortisolism is seen in HIV in‐
fected patients especially in pediatric AIDS patients. Other features seen in HIV/AIDS pa‐
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tients that are similar to features of hypercortisolism include muscle wasting and myopathy,
dyslipidemia and visceral obesity and insulin resistance. From the foregoing, it seems possi‐
ble that some unknown factor(s) modulate tissue sensitivity to glucocorticoids in HIV infect‐
ed patients.
The observed glucocorticoid hypersensitivity in HIV infected patients seem to preferentially
affect the brain, fat cells, the liver, the musculoskeletal system and the immune system. It is
noteworthy that the hypothalamo-pituitary-adrenal axis is not affected suggesting that ap‐
propriate negative feedback sensitivity to glucocorticoids is preserved.
There is evidence to suggest that glucocorticoid hypersensitivity in HIV/AIDS is mediated
through one of the HIV-1 accessory proteins the virion-associated protein (Vpr). This is a 96
amino acid protein with multiple functions. This protein is known to act as a transcriptional
activator of several viral promoters and as an enhancer of HIV-1 long terminal repeat pro‐
moter activated by Tat as well as enhances the replication of HIV-1 virus in lymphocyte-
and monocyte-derived cell lines. Furthermore, the protein also increases the translocation of
the HIV-1 pre-integration complex into the nucleus promoting efficient infection of non-di‐
viding macrophages.
The protein circulates in HIV-1-infected individuals and has the capacity to penetrate cell
membranes. This suggests that its effects have the potential to involve all cells including
those not infected by HIV-1. It is indeed this protein that has been shown by Kino et al [36]to
increase the tissue sensitivity to glucocorticoids by functioning as a coactivator of the GR on
its responsive promoters. By inducing hypersensitivity to glucocorticoids, these proteins
contribute to the proliferation of the virus indirectly by suppressing the host immune sys‐
tem. Extensive further clinical and basic investigations are crucial to examine the clinical im‐
portance of glucocorticoid hypersensitivity and to develop novel effective therapeutic
approaches in AIDS.
Although the involvement of the adrenal gland is common in HIV patients, routine screen‐
ing is not however recommended as adrenal insufficiency is a relatively rare complication of
HIV infection. Its presence should however be considered, however, in those with dissemi‐
nated cytomegalovirus infection or tuberculosis. It should also be suspected, in patients with
otherwise unexplained symptoms and signs compatible with adrenal insufficiency, such as
anorexia, nausea, weight loss, and fatigue, and especially in patients with more specific
manifestations of adrenal insufficiency, such as postural hypotension, hyponatremia, or hy‐
perkalemia. It is also reasonable to be concerned about adrenal reserve in patients who are
about to undergo major stress, such as surgery. The simplest test is to measure the serum
cortisol concentration in the morning, when it is highest in normal subjects. A concentration
of 10 µg per deciliter (280 nmol per liter) or less suggests the presence of adrenal insufficien‐
cy. However, higher cortisol concentrations do not rule out the possibility of diminished
adrenal reserve. If the basal serum cortisol concentration is low or the suspicion of adrenal
insufficiency persists, provocative testing with corticotropin is indicated. Such testing in‐
volves measuring the serum cortisol concentration before and 30 and 60 minutes after the
intravenous or intramuscular administration of 0.25 mg of cosyntropin. The cortisol concen‐
tration should increase by at least 7 µg per deciliter (196 nmol per liter) at 30 minutes and 11
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µg per deciliter (308 nmol per liter) at 60 minutes. Alternatively, a normal response is a con‐
centration twice the basal value at 60 minutes. Whether one considers the extent of a change
in the cortisol concentration or the multiple of the basal value, the peak stimulated value
should be 18 µg per deciliter (504 nmol per liter) or more for the response to be considered
normal [48, 49]. Glucocorticoid therapy should be given only in cases of documented adre‐
nal insufficiency or when there is a medical emergency in which the possibility of adrenal
crisis cannot be excluded.
7. Gonadal dysfunction in male
Male gonadal dysfunction is common among AIDS patients. With more than two-thirds of
male patients with advanced HIV disease exhibit of loss of libido and up to one-third of
them having erective dysfunction [38, 39]. The prevalence and severity of male gonadal dys‐
function is directly proportional to disease severity. In advanced disease stages, biochemical
hypogonadism is found in up to half of male AIDS patients. With the advent of HAART, the
prevalence of male gonal dysfunction has reduced to about 20% among those receiving
HAART [40]. Gonadal dysfunction in HIV/AIDS is usually attributable to secondary causes
such as the effect of under nutrition, infection-inflammation and several drugs on gonado‐
tropin production. Other secondary causes include the role of cytokines produced in re‐
sponse to systemic illness may impair the secretion of gonadotropin-releasing hormone or
gonadotropin [41]. Low levels of interleukin-1 enhance testicular steroidogenesis in vitro,
whereas higher doses inhibit the binding of gonadotropin to Leydig cells and steroidogene‐
sis by these cells. Ketoconazole used in the treatment of fungal infections in HIV/AIDS pa‐
tients inhibits gonadal as well as adrenal steroid production and could therefore also
contribute to the observed gonadal dysfunction.
Furthermore, hyperprolactinaemia and gynecomastia have been reported among HIV-in‐
fected patients [42]. Prolactin has for long been known to be an immunostimulatory hor‐
mone and is also known to be elevated in other immunostimulatory states such as systemic
lupus erythematosis (SLE). Similarly, prolactin receptors are found in T and B lymphocytes
as well as monocytes [43], while lymphocytes are known to produce a prolactin like protein.
The men with low serum testosterone concentrations may have inappropriately normal se‐
rum gonadotropin concentrations, suggesting involvement of the pituitary gland or hypo‐
thalamus however, there is neither CT scans nor autopsy data provide evidence of pituitary
or hypothalamic disease.
As sex hormone binding capacity increases in up to a third of HIV patients, the use of free
testosterone assay is recommended for diagnosis. [38] Physiologic testosterone replacement
that does not suppress endogenous gonadal function results in increased lean body mass,
improved quality of life and reduction in depression. Standard therapy for hypogonadism
has been intramuscular testosterone (enanthate or ciprionate esters) every 1–3 weeks to pro‐
vide 100 mg per week. Alternate transdermal or oral routes for androgen administration are
also available. Prostate-specific antigen level should be monitored in elderly patients receiv‐
ing testosterone.
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8. Gonadal dysfunction in female
Ovarian dysfunction among female AIDS patients is less common. Amenorrhoea is seen in
about a quarter of women during stress of illness; while failure of ovulation is seen among
half of the female patients with low CD4 counts [44]. Early menopause has been seen in up
to 8% of HIV-infected female patients. Androgen deficiency has been reported especially in
women with significant weight loss. The reasons for the above observations are not clear,
but could be as a result of intra-adrenal shunting toward cortisol production from androgen
synthesis. Human chorionic gonadotropin levels suggest intact ovarian androgen produc‐
tion. Delivery of low doses of testosterone using transdermal patches improves functional
capacity without hirsuitism or virilisation but does not increase lean body mass [38].
9. Glucose homeostasis in HIV/AIDS
Normal glucose metabolism is largely dependent on normal insulin secretion, insulin sensi‐
tivity and to a lesser extent on the influences of other hormones and cytokines. Before the
advent of highly active anti-retroviral therapy (HAART), HIV infection on its own was
thought to be protective against the development of diabetes mellitus1, this may be due to
the following observations in clinically stable, symptomatic HIV-infected patients. These in‐
dividuals have been shown to have higher rates of insulin clearance and increased sensitivi‐
ty of peripheral tissues to insulin as well as an increase in noninsulin-mediated glucose
uptake. The increase in glucose uptake is predominantly accounted for by an increase in
non-oxidative glucose disposal.
Pancreatic abnormalities are common in AIDS patients as a result of opportunistic infections
and malignancies1. However, the majority of these lesions are not extensive enough to cause
clinically significant pancreatic dysfunction. Clinically significant pancreatic dysfunction is
usually as a result of therapeutic interventions; noteworthy in this regard is Pentamidine
[45], which is used in the management of Pneumocystis carinii and may cause pancreatic β-
cell toxicity with resultant hypoglycaemia in the acute phase and some of these patients may
later develop diabetes mellitus.
With the advent of HAART however, a new dysmetabolic syndrome with substantially in‐
creased risk for cardiovascular events emerged [46]. This syndrome has variable expressibil‐
ity; and includes insulin resistance, visceral adiposity, peripheral lipodystrophy,
dyslipidaemia and glucose intolerance. Several studies have demonstrated an increased risk
of diabetes among HIV infected individual on HAART especially when protease inhibitors
(PIs) are included in the regimen. Among HIV infected minority patients in the USA for ex‐
ample, the prevalence of diabetes after three years of PI therapy was 12%, compared to none
among those not receiving PI’s4. However, although PI’s are the most frequent agents associ‐
ated with metabolic complication, there are evidences to suggest that virtually all classes of
agents used in ART has the potential to cause metabolic derangements. Although the mech‐
anism by which ART drugs induce these metabolic changes are not fully clear; it has been
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usually as a result of therapeutic interventions; noteworthy in this regard is Pentamidine
[45], which is used in the management of Pneumocystis carinii and may cause pancreatic β-
cell toxicity with resultant hypoglycaemia in the acute phase and some of these patients may
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With the advent of HAART however, a new dysmetabolic syndrome with substantially in‐
creased risk for cardiovascular events emerged [46]. This syndrome has variable expressibil‐
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dyslipidaemia and glucose intolerance. Several studies have demonstrated an increased risk
of diabetes among HIV infected individual on HAART especially when protease inhibitors
(PIs) are included in the regimen. Among HIV infected minority patients in the USA for ex‐
ample, the prevalence of diabetes after three years of PI therapy was 12%, compared to none
among those not receiving PI’s4. However, although PI’s are the most frequent agents associ‐
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shown that indinavir, a PI dramatically inhibits glucose uptake in a dose dependent manner
in adipocytes by selectively inhibiting the Glut-4 transporter function [47]. Furthermore,
there is evidence at least in laboratory studies to show that indinavir down regulates the
peroxisome proliferator–activated receptor -γ (PPAγ) receptor in adipocytes [48]. Obviously
some genetic predisposition could explain why not all patients on PI’s develop diabetes, or
any of the other metabolic complications.
10. Bone mineral dysfunction
Both osteoporosis and osteopenia are common among AIDS patients. Reduced bone mineral
density is seen in almost three quarter of HIV-infected patients compared to about 30% in
HIV-negative individuals of similar age [49]. Reduced vertebral bone density is associated
with visceral adiposity among HIV-infected patients. Similarly, reduced bone density also
occurs in HIV-infected children receiving HAART with maximum reduction seen among
those with lipodystrophy. Several factors are thought to be responsible for the observed ef‐
fects on the skeleton. The effects of low GH and IGF1, hypogonadism and excess visceral
adiposity are possible factors as they have been found to correlate significantly with verte‐
bral bone density [50 - 52]. Protease Inhibitors are also known to induce relative vitamin D
deficiency and may also act as an additive factor.
11. Calcium and vitamin D balance
Hypocalcemia is common in HIV infected patients occurring in more than 5% of them [53].
It appears the level of calcium has an inverse relationship with the stage of the disease and
its severity. Factors responsible for hypocalcaemia in these patients include vitamin D defi‐
ciency and reduced parathyroid hormone (PTH ) level. The cause of the relatively reduced
PTH is not known but may be as a result of the effects of cytokines; and presence of hypo‐
magnesemia which is relatively common among HIV infected patients especially those with
chronic diarhoea. On the other hand, the cause of Vitamin D deficiency is multifactorial in
the setting of HIV/AIDS and may include malabsorption, decreased hydroxylation as a re‐
sult of the effects of protease inhibitors. Furthermore, several therapeutic agents such as fo‐
scarnet, pentamidine, and ketoconazole, may affect calcium homeostasis [53].
Hypercalcemia is uncommon in AIDS. When present it is likely to be due to infectious, ma‐
lignant, or granulomatous processes [54 - 55]. Patients with lymphoma who have hypercal‐
cemia typically have increased serum 1,25-dihydroxyvitamin D concentrations, because the
tumors contain vitamin D 1-hydroxylase and therefore convert 25-hydroxyvitamin D to
1,25-dihydroxyvitamin D. Cultured lymphoma cells infected with HIV have the same syn‐
thetic activity. Human T-cell lymphotropic virus Type I (HTLV-I), a retrovirus linked to T-
cell leukemia and lymphoma may be associated with hypercalcemia. Increased bone
resorption in this syndrome may be due to lymphokines such as interleukin-2 or to parathy‐
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roid hormone-related protein. A HTLV-I gene product, tax,has been implicated in the activa‐
tion of the parathyroid hormone-related protein gene. Serum concentrations of parathyroid
hormone and 1,25-dihydroxyvitamin D are not elevated in HTLV-I—related hypercalcemia.
12. AID wasting syndrome
Wasting is an age-old terminal event of AIDS, even with the advent of HAART, wasting re‐
mains common affecting more than one-third of patients [57]. Unfortunately, weight loss is a
significant predictor of mortality in HIV infection. Those with a body mass index (BMI) of
less than 18.4 kg/M2 are at 2.2-fold increased risk of mortality, while those with a BMI less
than 16 kg/M2 are at 4.4-fold increased risk of mortality [58].
Currently, AIDS wasting syndrome is defined as body weight less than 90% of ideal weight
or weight loss of more than 10% of body weight over 3 months. The condition is character‐
ised by a disproportionate loss of lean body mass with a relative sparing of body fat as the
disease progresses this is associated with muscle wasting, weakness, increased resting ener‐
gy expenditure and hypertriglyceridemia. The exact mechanisms involved in the aetiology
of this condition are not clear. However, the roles of Cytokine related increased energy ex‐
penditure and decreased appetite, diarrhoea, malabsorption and hypogonadism are likely
mechanisms behind such wasting [59, 60].
Management of this condition include optimal antiretroviral therapy and adequate nutri‐
tion. Testosterone (intramuscular/transdermal) has been successfully used to increase lean
body mass in men with this syndrome, whereas it has also been shown to be safe and well
tolerated in women. A number of agents like anabolic steroids (oxandrolone, nandrolone),
megesrtol acetate, thalidomide, human chorionic gonadotropin, pentoxyfiline, amino acid
mixtures and omega 3 fatty acids have been tried in this setting with variable efficacy but
potential side effects. Only testosterone administration has proved useful to increase lean
body mass, especially in conjunction with progressive resistance training. Administration of
supraphysiologic doses of growth hormone is currently reserved for severe wasting refrac‐
tory to other treatments.
13. HIV lipodystrophy syndrome
HIV lipodystrophy syndrome is associated with metabolic derangements, changes in body
composition and abnormal fat distribution. It has been most widely recognized since the era
of HAART but can also be seen in antiretroviral-naïve patients [61]. It is characterized by
phenotypic changes similar to those observed in Cushing’s syndrome, such as like truncal
obesity, buffalo hump, peripheral fat loss, atrophy of facial fat and breast enlargement in
women. Considering some physical similarities to Cushing's syndrome, it has been termed
as “a pseudo-Cushing's syndrome” though no other specific stigmata of Cushing's syn‐
drome (proximal muscle weakness, bruising and facial plethora) nor biochemical parame‐
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shown that indinavir, a PI dramatically inhibits glucose uptake in a dose dependent manner
in adipocytes by selectively inhibiting the Glut-4 transporter function [47]. Furthermore,
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any of the other metabolic complications.
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HIV-negative individuals of similar age [49]. Reduced vertebral bone density is associated
with visceral adiposity among HIV-infected patients. Similarly, reduced bone density also
occurs in HIV-infected children receiving HAART with maximum reduction seen among
those with lipodystrophy. Several factors are thought to be responsible for the observed ef‐
fects on the skeleton. The effects of low GH and IGF1, hypogonadism and excess visceral
adiposity are possible factors as they have been found to correlate significantly with verte‐
bral bone density [50 - 52]. Protease Inhibitors are also known to induce relative vitamin D
deficiency and may also act as an additive factor.
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sult of the effects of protease inhibitors. Furthermore, several therapeutic agents such as fo‐
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than 16 kg/M2 are at 4.4-fold increased risk of mortality [58].
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or weight loss of more than 10% of body weight over 3 months. The condition is character‐
ised by a disproportionate loss of lean body mass with a relative sparing of body fat as the
disease progresses this is associated with muscle wasting, weakness, increased resting ener‐
gy expenditure and hypertriglyceridemia. The exact mechanisms involved in the aetiology
of this condition are not clear. However, the roles of Cytokine related increased energy ex‐
penditure and decreased appetite, diarrhoea, malabsorption and hypogonadism are likely
mechanisms behind such wasting [59, 60].
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tion. Testosterone (intramuscular/transdermal) has been successfully used to increase lean
body mass in men with this syndrome, whereas it has also been shown to be safe and well
tolerated in women. A number of agents like anabolic steroids (oxandrolone, nandrolone),
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mixtures and omega 3 fatty acids have been tried in this setting with variable efficacy but
potential side effects. Only testosterone administration has proved useful to increase lean
body mass, especially in conjunction with progressive resistance training. Administration of
supraphysiologic doses of growth hormone is currently reserved for severe wasting refrac‐
tory to other treatments.
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composition and abnormal fat distribution. It has been most widely recognized since the era
of HAART but can also be seen in antiretroviral-naïve patients [61]. It is characterized by
phenotypic changes similar to those observed in Cushing’s syndrome, such as like truncal
obesity, buffalo hump, peripheral fat loss, atrophy of facial fat and breast enlargement in
women. Considering some physical similarities to Cushing's syndrome, it has been termed
as “a pseudo-Cushing's syndrome” though no other specific stigmata of Cushing's syn‐
drome (proximal muscle weakness, bruising and facial plethora) nor biochemical parame‐
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ters are associated with this syndrome. Normal cortisol level with its normal diurnal
variation and adequate suppressibility to dexamethasone are also seen in HIV lipodystro‐
phy syndrome. However, it is very often associated with insulin resistance, hyperglycemia,
and hypertriglyceridemia. In particular, dyslipidemia and diabetes mellitus are increasingly
common among patients receiving HAART. management consist of exercise and lifestyle
modification, switching to less-toxic NRTIs or PIs, fenofibrates to decrease serum triglycer‐
ide level, and use of insulin sensitizers like metformin to reduce visceral fat and thiazolidi‐
nediones to improve subcutaneous fat loss. Testosterone and anabolic steroids have no
effect in reducing visceral fat in this syndrome.
14. Conclusion
Although HIV endocrinopathy is common, overt glandular failure is a rare clinical entity.
HIV infection, acting by a number of mechanisms, may be responsible for subtle clinical and
not-so-subtle biochemical abnormalities. Drug-induced endocrine toxicity is important
cause of endocrinopathy in HIV infected patients.
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1. Introduction
Human lipodystrophies are a heterogeneous group of diseases characterized by generalized
or partial fat loss. If localized, they are often associated with fat hypertrophy in other depots,
varying according to the type of lipodystrophy. Lipodystrophies can be genetic, which is
usually uncommon, or acquired. Genetic lipodystrophy is generally related to severe meta‐
bolic alterations including insulin resistance (IR) and its associated complications, such as
glucose intolerance and diabetes, dyslipidemia, hepatic steatosis, polycystic ovaries, acan‐
thosis nigricans and early cardiovascular (CV) complications [1, 2]. The autosomal recessive
congenital generalized lipodystrophy (CGL) and autosomal dominant familiar partial lipo‐
dystrophy (FPL) are the two most common types of genetic lipodystrophy [2]. Lipodystro‐
phies have been reported in the medical literature for more than 100 years [2, 3]. However,
only 13 years ago, new lipodystrophy syndromes were recognized, being associated with vi‐
ral infection, specifically with the human immunodeficiency virus, in patients treated with
combined antiretroviral therapy (cART) [4]. This has become the most frequent form of lipo‐
dystrophy [2]. Some first-generation antiretroviral drugs used in HIV patients are strongly
related with peripheral lipoatrophy and metabolic alterations [1].
Human lipodystrophies leads to severe metabolic alterations resulting in premature CV com‐
plications. On the other hand, high adiposity, such as seen in obesity, also increases metabolic
alterations and leads to increased CV risk. So, it seems that the two extremes, the absence or the
excess of fat mass, are associated with the same metabolic and CV complications. The conse‐
quences of increased fat depots are markedly dependent upon their localization. Adipose tis‐
sue in the lower part of the body is able to expand and can therefore accumulate excessive
energy from diet, store triglycerides, and it appears to be protective at the metabolic level [5].
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By contrast, accumulation of fat in the upper part of the body is deleterious. Therefore, de‐
creased peripheral subcutaneous adipose tissue (SAT), and even more increased visceral adi‐
pose tissue (VAT), are strongly associated with metabolic alterations and IR [1].
With regards to the HIV-associated lipodystrophy, the available data suggest that this con‐
dition is caused by a complex interaction involving side effects of cART, disease related in‐
flammation, and individual characteristics [6]. At present, HIV-infected patients are exposed
to an increased metabolic risk like the general population, resulting from ageing, increased
weight and fat gain, high fat and energy food and marked sedentariness. Moreover, a num‐
ber of additional factors could worsen their metabolic profile, such as the ongoing HIV in‐
fection, the presence of lipodystrophy and the continuous use of antiretroviral drugs [7].
HIV-associated lipodystrophy is also associated with premature aging [8]resembling meta‐
bolic laminopathies and progeria [1]. Premature aging of HIV-infected patients affects bone,
brain, vascular wall, muscles, kidney and liver, and results of the combined effects of long-
term HIV-1 infection, depleted immune responses, the toxicity of some antiretrovirals and
lipodystrophy. Cellular senescence seems to result from prelamin-A accumulation induced
by some antiretroviral drugs, mitochondrial dysfunction and oxidative stress. In addition,
increased cytokine release in lipodystrophy further contributes to premature aging and
therefore, to early CV and hepatic disease risks [9].
We focus on adipocytes dysregulation in genetic and acquired lipodystrophy, with empha‐
sis on the most common form, HIV-lipodystrophy, fromthe etiology to its complications.
2. Adipose tissue biology –Three different adipose tissue compartments
Adipocytes are a dynamic and highly regulated population of cells. Adipose tissue is char‐
acterized by a marked cellular heterogeneity among its cellular components: adipocytes,
preadipocytes, fibroblasts, macrophages, lymphocytes, endothelial cells and multipotent
stem cells, able to differentiate into several cell types. Adipose tissue can release regulatory
factors (adipokines, cytokines, or chemokines) or metabolites (FFAs) capable of influencing
other surrounding cells, thus establishing active cross-talk among cells within adipose tis‐
sue. [9]. Overall, fat tissue consists of approximately one third mature adipocytes. The re‐
maining two thirds are a combination of small blood vessels, nerve tissue, fibroblasts and
preadipocytes in various stages of development. Preadipocytes have the ability to prolifer‐
ate and differentiate into mature adipocytes, conferring a constant functional plasticity on
adipose tissue [10]. Preadipocytes mature in two steps: differentiation and then hypertro‐
phy. During the early maturation stage, an increased number of mitochondria are required
[11, 12], resulting in small adipocytes, which are highly sensitive to insulin and that secrete
high levels of adiponectin [12]. By contrast, older adipocytes increase in size (hypertrophy),
their functional activities are lost and they become resistant to insulin. These adipocytes also
exhibit decreased numbers of mitochondria with impaired mitochondrial reactive oxygen
species (ROS) generated by the respiratory chain, which could have dual effects on adipo‐
cyte differentiation. New adipocytes form constantly to replace lost adipocytes, to the extent
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that 50 % of adipocytes in the human subcutaneous fat mass are replaced approximately ev‐
ery eight years. Preadipocytes are recruited to become lipid-filled mature adipocytes at the
same rate that adipocytes die, and in this way the fat mass is in constant flux, and adipocyte
number is kept constant. Cellular death of fat cells in white adipose tissue occurs primarily
by necrosis-like cell death, which involves macrophage recruitment and a subsequent in‐
flammatory response. This has been implicated in the metabolic complications of obesity. In‐
creased visceral fat mass leads to IR and a low-grade inflammation status in which many
adipokines and other adipocyte and macrophage factors are involved [13].
Adipose tissue is not homogeneous but rather a tissue with specific regional compartments
with varying roles and metabolic functions [14]. Individually considered, adipose tissue
compartments have stronger associations with physiological and pathological processes
than does total adipose tissue mass [15-17]. The upper-body adipose tissue, including viscer‐
al fat, is involved in fat storage after meals and the release of free fatty acids (FFA) between
meals to feed the liver, muscles and other organs, therefore sparing glucose for the brain.
Visceral fat has a more lipolytic profile than subcutaneous fat. Peripheral lower-body fat, in
the femoro-gluteal region, is mainly used for its storage capacity, thereby buffering excess
fat [7]. The femoro-gluteal fat depot is relatively insensitive to lipolytic stimuli and highly
sensitive to anti-lipolytic stimuli, and may play a protective role by acting as a “sink” for
circulating FFA [18]. This uptake of FFA prevents ectopic fat storage in the liver, skeletal
muscle, and pancreas, which causes IR and beta-cell dysfunction [19]. The excessive lipolytic
capacity of visceral fat (and probably subcutaneous upper-body depots as well) results in a
condition referred as lipotoxicity (see section below on lipotoxicity) [7]. The reasons for the
lower degree of expansibility of visceral adipocytes remain unknown. Visceral adipose tis‐
sue (VAT) differs histologically from subcutaneous adipose tissue (SAT): it has smaller adi‐
pocytes and a larger supply of nerves and vessels; VAT has many of the characteristics of
brown adipose tissue turned into white adipose tissue [20].
3. Lipohypertrophy and lipoatrophy
Adipose tissue can be subject of different influences and undergo different transformations.
SAT has a lower mitochondria content and this contributes to adipocyte apoptosis and
therefore, to more lipoatrophy. VAT, with a higher number of resident macrophages [21]
and more 11βhydroxysteroid dehydrogenase activity than SAT [22], is predisposed to hy‐
pertrophy. Hypertrophied VAT from HIV-infected patients demonstrates mitochondrial
dysfunction but not impairment of adipogenic gene expression in comparison with SAT
[23]. cART can differentially alter fat development depending on the environment and phys‐
iology of the different compartments. In the case of lipoatrophy, because peripheral subcuta‐
neous adipocytes cannot store triglycerides, non-lipoatrophic fat depots such as VAT,
probably buffers the increase in FFA, which worsens lipohypertrophy [8].
Subcutaneous adipocytes seem to be more susceptible to the deleterious effects of protease
inhibitors (PIs) than visceral adipocytes [24]. Accordingly, studies performed on control hu‐
man SAT explants reveal that some PIs increase FFA, interleukin – 6 (IL-6) and TNF-α pro‐
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iology of the different compartments. In the case of lipoatrophy, because peripheral subcuta‐
neous adipocytes cannot store triglycerides, non-lipoatrophic fat depots such as VAT,
probably buffers the increase in FFA, which worsens lipohypertrophy [8].
Subcutaneous adipocytes seem to be more susceptible to the deleterious effects of protease
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duction through the activation of the proinflammatory nuclear factor – kB (NFkB) pathway.
This PI-induced deleterious paracrine loop, between adipocytes and macrophages, similar
to the observed in obesity, is not seen in VAT. These data indicate that SAT is more sensitive
to the adverse effects of some PIs than VAT [8].
4. Adipogenesis
Individuals can differ remarkably in body fat distribution and the known differences in FFA
uptake of adipose tissue compartments play a role in this difference. Premenopausal female
SAT takes up more FFAs than male [25] and upper-body SAT takes up FFAs more avidly
than femoral fat in men, but not in women. Gene expression, mRNA transcription of FA
transporters and consequently facilitated FA transport was greater in the upper body in men
and in the femoro-gluteal region in women. This novel FFA disposal pathway may also play
a role in the development or maintenance of body fat distribution. On the other hand, direct
FFA uptake in subcutaneous fat differs from fatty acid uptake from a meal in two respects:
1) direct FFA uptake is more efficient in women than in men and 2) in men there is no pref‐
erential direct FFA uptake in upper-body subcutaneous fat compared with femoral fat in
women. These gender-based differences are consistent with this process as a mechanism to
develop or maintain variations of body fat distribution between men and women, both lean
and obese.The greater direct FFA uptake in abdominal over femoral fat in men could be due
to the greater facilitation of inward fatty acid transport. Contrary to what is generally be‐
lieved, upper-body subcutaneous fat releases ~70 % of systemic FFAs in lean men and wom‐
en, whereas the leg contributes only ~20%; fatty acid uptake from a meal follows a similar
pattern [26]. In non-obese men, the direct uptake/storage of FFAs in upper-body and leg fat
mirrors this regional difference in FFA release, whereas in lean women, direct FFA uptake
was similar in upper-body and femoral adipose tissue. This imbalance between release and
direct reuptake in women could redistribute fatty acids toward leg fat. In obese women, the
total FFA reuptake in leg fat was also significantly greater than in upper-body fat. It may be
that some populations of fat cells, such as the smaller adipocytes, take up but do not actively
release FFAs, whereas larger fat cells briskly release FFAs and do not take up FFAs under
post-absorptive circumstances. In summary, there is a mechanism for adipocyte fatty acid
uptake and storage that has yet to be understood, but which is independent of lipoprotein
lipase and it’s not thought to exist in the post-absorptive state [25].
Macrophage infiltration of the human adipose organ is a well-documented phenomenon
that induces a low-grade chronic inflammation that is associated with IR. This reaction ap‐
pears to be related mainly to macrophage-produced cytokines (TNF-α and IL-6] capable of
interfering with the normal activity of insulin receptors. The greater amount of macrophages
and macrophage-secreted cytokines found in visceral fat is in line with the greater morbidity
associated with these depots. Subcutaneous and visceral adipocytes have cell-autonomous
properties due to inherently different progenitor cells that exhibit a different gene expres‐
sion pattern. Subcutaneous white adipose tissue responds better to the anti-lipolytic effects
of insulin, secretes more adiponectin and less inflammatory cytokines, and is differentially
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affected by molecules involved in signal transduction as well as drugs, compared with vis‐
ceral white adipose tissue [13].
Lipoatrophic adipose tissue is known to be characterized by smaller adipocytes, greater cell
size variation, disruption of cell membranes, and signs of apoptosis as determined by immu‐
nohistochemistry staining, when compared with non-lipodystrophic adipose tissue. There is
a marked difference in gene expression between dorsocervical and abdominal SAT, irrespec‐
tive of the lipodystrophy status, that lies in the expression of homeobox genes involved in
organogenesis and regionalization. Disparate expression of such fundamental regulators of
transcription might ultimately contribute to different patterns of differentiation and affect
the susceptibility of the adipose tissue depot to cART-induced toxicity, perhaps making the
abdominal subcutaneous and femoro-gluteal depot more vulnerable to atrophy [27].
Morphologic alterations in lipoatrophy-prone areas of SAT have been confirmed at the level
of gene expression [9]. Most studies report that these lipoatrophic areas show an abnormally
low expression of the major adipogenic transcription factors peroxisome proliferator-activat‐
ed receptor -γ (PPARγ), sterol-regulatory element binding protein-1 (SREBP-1), and
CCAAT/enhancer-binding protein-α (C/EBPα) [28-30]. Consequently, the expression of adi‐
pogenic differentiation-related genes is also decreased. For example, there is a reduction in
the expression of genes for lipoprotein lipase and for the insulin-sensitive glucose transport‐
er GLUT 4 [28, 29], resulting in impaired fatty acid and glucose uptake, respectively, and
thus leading to a deficit in the lipid-accretion capacity of SAT. Another major alteration de‐
tected, which is probably related to the impaired adipogenic gene expression, is reduced ex‐
pression of the adipokine genes adiponectin and leptin [28, 29]. In addition to impaired
expression of adipogenetic–related genes, adipose tissue from patients with lipodystrophy,
mainly those receiving NRTIs [31, 32] also show a reduction in mitochondrial DNA
(mtDNA) levels. This decrease is associated with complex alterations in mitochondrial func‐
tion, such as reduced expression of mtDNA-encoded transcripts and compensatory up-reg‐
ulation of dysfunctional mitochondrial mass, that likely reduce the endogenous oxidative
capacity of adipose tissue [33]. Moreover, increased oxidative stress and apoptosis have also
been reported in lipoatrophic SAT [34]. Lipoatrophy is also accompanied by a state of chron‐
ic low-level inflammation [35]. High levels of expression of the inflammatory markers, TNF-
α, IL- 6; IL-8 and IL-18 have been reported in SAT from HIV-1-infected lipoatrophic patients
[28, 30, 35-37]. Expression of TNFα and IL-6 mRNA in SAT of lipodystrophic patients corre‐
lates positively with tissue apoptosis and negatively with adipogenic marker expression,
which is consistent with a role for pro-inflammatory cytokines in adipocyte viability and
differentiation [30]. Unlike SAT, VAT did not exhibit impaired expression of adipogenic
marker genes. However, it did show some similar changes in inflammatory markers, such as
induction of TNF-α, whereas others differed from that of SAT, such as, for instance, lack of
monocyte chemoattractant protein -1 (MCP-1] induction. In contrast, mitochondrial dys‐
function in VAT was found to be similar to that in SAT. Therefore, mtDNA depletion and
signs of altered mitochondrial function are common to atrophic (subcutaneous) and hyper‐
trophic (visceral, dorsocervical) depots in HIV-1 lipodystrophy, indicating that mitochondri‐
al impairment cannot explain in a simple manner the final outcome for adipose depots,
either in terms of lipoatrophy or lipohypertrophy [23]. Taken together, these observations
indicate that different responses occurring in subcutaneous and visceral fat depots in lipo‐
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dystrophic patients are likely to be related to intrinsic differences in fat physiology and/or
capacity to react to the same insult. One adipose depot (visceral) enlarges in size and ap‐
proaches its fat storage capacity threshold (as in obesity) merely because another adipose
depot (subcutaneous) cannot [38]. A direct role for HIV-1 infection has been proposed by an‐
alyzing SAT from untreated HIV-1-infected patients (“naïve”) as compared to healthy con‐
trols. Early histological studies did not indicate clear mitochondrial or inflammatory-related
disturbances [39], but subsequent gene expression studies have shown a significant decrease
in the expression of the adipocyte differentiation controller PPARγ and some impairment in
the expression of genes encoding mitochondrial proteins and proteins specifically related to
adipocyte metabolism, including adiponectin and 11β-steroid dehydrogenase type-1, the en‐
zyme responsible for glucocorticoid activation [9, 29]. Some signs of inflammatory response
have also been reported [29]. All these alterations are further enhanced in SAT oflipody‐
strophic patients. Therefore, it appears that HIV-1 infection initiates a first wave of altera‐
tions in adipose tissue that is amplified by cART and ultimately results in lipoatrophy [9].
5. Congenital generalized lipodystrophies
Generalized lipodystrophies are rare disorders that may be congenital or acquired. The ge‐
netic lipodystrophies have been reported in about 1000 patients [2]. The congenital general‐
ized lipodystrophy (CGL) Berardinelli-Seip syndrome (BSCL), is an autosomal recessive
disorder initially reported by Berardinelli [3] and Seip [40] with frequent parental consan‐
guinity [41-44]. It has been proposed that Berardinelli-Seip syndrome could be a Portuguese
disease, later spread by the Portuguese across the world [45].
Patients with CGL are recognized at birth or soon thereafter due to a near-total lack of body
fat and prominent muscularity that causes a severe and striking phenotype (Figure 2A and
2B). Diabetes develops during infancy or most often during the teenage years. Hepatosple‐
nomegaly, umbilical prominence or hernia, acanthosis nigricans, voracious appetite and ac‐
celerated growth can occur. Female patients develop hirsutism, may have clitoromegaly,
oligomenorrhea and polycystic ovaries. Other uncommon manifestations include hypertro‐
phic cardiomyopathy, mild mental retardation, and focal lytic lesions in the appendicular
bones after puberty [41, 42]. Diabetes and its complications, hyperlipidemia and recurrent
attacks of acute pancreatitis, hepatic steatosis and occasionally cirrhosis are the causes of
morbidity and mortality [2].
At least 4 molecularly distinct forms of congenital lipodystrophy have been defined, with
the mutations of the enzyme acyltransferase 1-acylglycerol-3-phosphate O- acyltransferase 2
(AGPAT2) or (BSCL1- locus 1) and Berardinelli-Seip (BSCL2 - locus 2) being both responsi‐
ble for 95 % of gene mutations. AGPAT2 has been mapped in chromosomes 9q34. AGPATs
are critical enzymes involved in the biosynthesis of triglycerides and phospholipids from
glycerol-3-phosphate. They catalyze acylation of fatty acids at the sn-2 position of glycerol
moiety and convert lysophosphatidic acid to phosphatidic acid [2, 46]. AGPAT2 is highly ex‐
pressed in the adipose tissue, and its deficiency may cause lipodystrophy by limiting trigly‐
ceride or phospholipid biosynthesis [47].
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Figure 1. A: Two sisters with Berardinelli-Seip syndrome B: Women with Berardinelli-Seip syndrome
Type 2 CGL is due to BSCL2 gene mutations. This gene is located in chromosome11q13 and
encodes a protein called seipin [48]. Seipin appears to play a role in lipid droplet formation
and may also be involved in adipocyte differentiation [49-51].
Patients with BSCL2 mutations have the most severe variety of CGL and are born without
any body fat [2]. Two other genes were identified for CGL: caveolin 1 (CAV1) [52] and poly‐
merase I and transcript release factor (PTRF) [53]. Caveolin 1 is the main component of cav‐
eolae, specialized microdomains seen in abundance on adipocyte membranes [54]. It binds
fatty acids and translocates them to lipid droplets. PTRF (also known as cavin) is involved in
biogenesis of caveolae and regulates expression of caveolins 1 and 3 [53].
6. Mortality in generalized lipodystrophies
Patients with generalized lipodystrophies are predisposed to develop acute pancreatitis, cir‐
rhosis, endstage diabetic renal disease requiring transplantation, and blindness due to diabet‐
ic retinopathy. Many patients with FPL die of coronary heart disease or cardiomyopathy and
rhythm disturbances [55-57]. Sudden death has been reported during childhood in CGL, type
4, likely due to arrhythmias [58]. Patients with HIV-lipodystrophy are predisposed to develop‐
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ing coronary heart disease [59]. Patients with congenital Berardinelli-Seip lipodystrophy fre‐
quently develop hypertrophic cardiomyopathy that can lead to death from cardiac failure [41].
In individuals with BSCL, ventricular dysfunction and hypertrophic cardiomyopathy are of‐
ten observed. In cardiac biopsies performed in eight individuals with BSCL, the presence of
subendocardial fibrosis and an abnormal architecture in the left ventricular lumen was ob‐
served [60, 61]. Hypertrophic cardiomyopathy in BSCL patients has been correlated with high
plasmatic insulin levels, which activate the type 1 insulin-like growth receptors, present in
large quantities in the myocardial tissue, that stimulate cell growth [62, 63]. In addition, the
presence of IR and hypertriglyceridemia in individuals with BSCL may predispose them to
premature  atherosclerosis.  Individuals  who have  mutations  on chromosome 11  (BSCL2)
seemed to present more severe symptoms than those who had mutations in BSCL1, with a high
incidence of premature deaths. Cardiomyopathy was three times more frequent in those with
BSCL2 mutations than in individuals with alterations in BSCL1 [42].
7. Mandibuloacral Dysplasia (MAD)-associated lipodystrophy
MAD is characterized by skeletal abnormalities such as mandibular and clavicular hypoplasia
and acroosteolysis [64], progeroid manifestations, partial or generalized lipodystrophy and
metabolic complications, among other clinical features [65, 66]. Patients with MAD harbor mu‐
tations in lamin A/C (LMNA) or zinc metalloproteinase (ZMPSTE24) [67, 68]. ZMPSTE24 is in‐
volved in post-translational proteolytic processing of prelamin A to mature laminA [2].
8. Autoinflammatory syndromes
A syndrome of joint contractures, muscle atrophy, microcytic anemia, and panniculitis-in‐
duced (JMP) lipodystrophy was reported by Garg in three patients, belonging to two pedi‐
grees, who were from Portugal and Mexico [69]. Three other patients have been reported from
Japan [70, 71]. Mutations in PSMB8 may trigger an autoinflammatory response resulting in in‐
filtration of adipose tissue with lymphocytes and other immune cells and adipocytes [2]. The
other autoinflammatory syndrome is the chronic atypical neutrophilic dermatosis with lipo‐
dystrophy and elevated temperature (CANDLE) syndrome. The mode of inheritance seems to
be autosomal recessive, but the molecular basis remains unknown [2, 72, 73].
9. Familial Partial Lipodystrophy(FPL)
FPL is characterized by the onset of fat loss from the limbs and other regions of the body, usu‐
ally during childhood, adolescence or adulthood. Many regions of the body, such as the face,
neck, and intra-abdominal region are spared, and patients accumulate excess body fat in the
non-lipodystrophic regions [74-76]. Metabolic complications, acanthosis nigricans, oligoame‐
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norrhea, hirsutism, polycystic ovarian syndrome, mild to moderate myopathy, cardiomyop‐
athy, and conduction system abnormalities indicative of multisystem dystrophy can occur [2,
55, 56, 77]. The identification of the first gene for FPL, Dunnigan variety, i.e. LMNA, on chro‐
mosome 1q21-22 [2, 78-81], an integral component of nuclear lamin, was made in 1998. There‐
after, four other genes were identified: PPARγ [82-84], a key transcription factor involved in
adipocyte differentiation;  v-AKT murine thymoma oncogene homolog 2 (AKT2) [85],  in‐
volved in downstream insulin signaling; and cell death-inducing DNA fragmentation factor a-
like  effector  c  (CIDEC) [86]  and perilipin 1  (PLIN1)  [87],  both involved in lipid droplet
formation [2, 88]. Adipocyte loss is due to premature cell death resulting from disruption of the
nuclear envelope [87, 89]. Defective adipocyte differentiation seems to be the cause of the lipo‐
dystrophy of PPARγ and AKT2 mutations. Fibrosis of adipose tissue with small adipocytes is
responsible for the lipodystrophy of PLIN1 mutations [2, 87].
There are other rare genetic syndromes whose molecular basis remains unknown, namely
atypical progeroid syndrome [90], Hutchinson-Gilford progeria syndrome [91], SHORT-as‐
sociated lipodystrophy [92], and Wiedemann-Rautenstrauch syndrome [93].
Patients with FPL syndromes display mixed lipodystrophy with subcutaneous lipoatrophy
and central fat accumulation. Those with FPLD2 also have an increased amount of fat in the
cervico-facial area compared to patients without these mutations. Therefore, a single protein
mutation leads to two opposing fat localization phenotypes [8]. Importantly, mutations in
LMNA are also responsible for metabolic laminopathies resembling the metabolic syndrome
(MS) and Hutchinson-Gilford progeria, a severe syndrome of premature aging [94]. Prelamin
A is implicated in increased oxidative stress and in the occurrence of cellular senescence [8].
10. Acquired lipodystrophies
10.1. Acquired Generalized Lipodystrophy(AGL) – Lawrence syndrome
The onset of subcutaneous fat loss in patients with AGL usually occurs during childhood
[95]. The pattern and extent of fat loss is quite variable and most patients have generalized
loss of fat, but a few of them have areas such as intra-abdominal and bone marrow fat
spared. AGL patients are highly likely to develop severe hepatic steatosis and fibrosis, dia‐
betes, and hypertriglyceridemia [2]. The pathogenesis of fat loss remains unknown. Panni‐
culitis may precede loss of fat. Lipodystrophy can be associated with autoimmune diseases
such as juvenile dermatomyositis [95]. Chronic hepatitis with autoimmune features and low
serum complement 4 levels, suggesting involvement of the classical complement pathway in
the pathogenesis of fat loss, has been reported [96].
10.2. Acquired partial lipodystrophy–Barraquer-Simons syndrome
Fat loss occurs gradually in a symmetric fashion, first affecting the face and then spreading
downward. Most patients lose fat from the face, neck, upper extremities, and trunk, and
subcutaneous fat from the lower abdomen and legs is spared. Many patients accumulate ex‐
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cess subcutaneous fat in the hips and legs. Metabolic complications are rare. Misra et al sug‐
gest that the fat loss involves autoimmune-mediated destruction of adipocytes because the
patients have low serum levels of complement 3 and complement 3-nephritic factor, which
blocks degradation of the enzyme C3 convertase [95]. It is possible that the C3-nephritic fac‐
tor induces lysis of adipocytes expressing factor D [97].
10.3. Localized lipodystrophy
Localized lipodystrophies present focal loss of subcutaneous fat, usually causing one or
more dimples, and in general occurs due to subcutaneous injection of various drugs (Figure
4), panniculitis, pressure, and other mechanisms [98].
Figure 2. Patient with lipohypertrophy related to subcutaneous administration of pegvisomant.
10.4. Lipodystrophy associated with HIV-infection
The impressive progress resulting from the discovery of drugs able to control HIV infection
on a long-term basis, has offered most patients a prolonged lifespan, possibly as long as that
observed in non-infected subjects [7]. Suppression of viral replication has become a treat‐
ment goal that can be reached with the use ofcART. After the introduction of protease inhib‐
itors (PIs) in 1996, as a component of highly active antiretroviral therapy, the morbidity and
mortality associated with HIV has dramatically been reduced [99]. However, patients devel‐
op a syndrome of fat redistribution with peripheral fat loss (face, upper limbs and femoro-
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gluteal) and visceral fat accumulation, generally associated with metabolic abnormalities [4,
100-103] and increased risk of CV diseases [104, 105], similar to what occurs in congenital
lipodystrophies [4, 59]. Lipohypertrophy usually represents a central visceral fat accumula‐
tion in the abdomen and trunk, but can also be found in breasts (in women), dorsocervical
region (“buffalo hump”), double chin, lipomas, and within the muscle and liver [59, 106].
Lipoatrophy and lipohypertrophy are frequently associated (mixed form), but they also can
occur independently of each other [59]. This HIV-associated lipodystrophy has been pro‐
posed to be a age-related fat redistribution condition that could amplify age-related co-mor‐
bidities and lead to their earlier occurrence [8]. Also, hyperlactenemia and bone
demineralization can occur [107, 108].
Owing to a lack of a consensus on the definition of lipodystrophy and lipodystrophy syn‐
drome in HIV-infected patients, its exact prevalence is not known [6]. In the early 2000s, about
half of HIV-infected patients undergoing cART were diagnosed as lipodystrophic (20-80%)
[109]. Abnormalities in peripheral and central fat masses are clinically evident in 20-35 % of pa‐
tients after approximately 12-24 months of cART [59, 107, 110, 111]. With the new anti-retrovi‐
ral agents, the probability of developing lipoatrophy has decreased in western countries as the
pattern of cART prescription has significantly changed [112]. In the study of Nguyen, lipodys‐
trophy has become less frequent since 2003 [112]. Two widely used thymidine analogs from
the first class of ART, stavudine and zidovudine, are responsible for lipoatrophy and now they
have been replaced by a new generation of potent NRTIs. Although metabolic toxicity of boost‐
ed PIs is far less than of first-generation protease inhibitors (PIs), they are still considered re‐
sponsible for increased CV risk. The new classes of ART, fusion inhibitors (F20), integrase
inhibitors (raltegravir) or entry inhibitors (anti-CCR5, maraviroc) have not yet been shown to
alter metabolic parameters or fat distribution [8, 112-117].
HIV-infected patients can have 4 different phenotypes of body fat composition: no lipodys‐
trophy, isolated peripheral lipoatrophy, isolated central fat accumulation and a mixed form
of lipodystrophy (or redistribution syndrome) [100]. About 50% of patients with HIV-associ‐
ated lipodystrophy display mixed forms, with the loss of limb fat and marked expansion of
VAT [113]. The high frequency of this association suggests that these two opposite pheno‐
types could be, at least in part, causally related [8]. Also, HIV patients may have a picture
similar to partial lipodystrophy patients with peripheral fat atrophy and hypertrophied cen‐
tral fat depots. Thus, there are similarities between HIV lipodystrophy and genetic forms.
11. HIV-lipodystrophy and related factors
There is a possible role of the virus contribution for lipodystrophy i.e. the HIV or hepatitis in‐
fection affects fat tissue before any ART. Monocytes are relatively resistant to HIV infection,
but differentiated macrophages are highly susceptible and tissue macrophages have been
found to harbor HIV-1 [118]. Infected macrophages release pro-inflammatory cytokines. Sys‐
temic inflammation associated with HIV infection might promote monocyte migration across
the vascular endothelium, leading to an increased number of activated macrophages in fat
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[118]. Several studies reported that the severity of HIV infection is associated with an in‐
creased prevalence of lipodystrophy [59, 119], probably as a consequence of persistent HIV-in‐
fected macrophages in adipose tissue, which could enhance local inflammation.
ART-naïve HIV-positive patients have increased TNF-α expression compared with uninfect‐
ed controls [29], which is consistent with increased inflammation. TNF-α alters adipocyte
function and differentiation, in part through the inhibition of PPARγ expression [120]. In‐
fected macrophages might also release viral proteins (such as Vpr and Nef) that can impact
on adjacent adipocytes and lead to decreased PPARγ activity and inhibition of adipogenesis
[121, 122]. Although lipodystrophy is uncommon in ART-naïve patients [113], the HIV infec‐
tion of macrophages could itself result in low-grade fat inflammation and lead to the release
of viral proteins that affect neighboring adipocytes and decrease their differentiation.
The development of lipodystrophy and metabolic toxicities is partially related to the indi‐
vidual drugs included in cART regimens, associated with other risk factors [123] such as
gender and pre-HIV-infection body composition, disease-specific factors such as the nadir
levels of CD4+ lymphocytes and the duration of HIV infection [110, 123, 124]. The most sig‐
nificant risk factors associated with lipoatrophy are exposure to and duration of nucleoside
thymidine analogues (most commonly stavudine), age, severity of disease markers (CD4
lymphocyte count and plasma HIV viral load), therapy duration, and belonging to the Cau‐
casian race. On the other hand, the most common statistically significant risk factors for lipo‐
hypertrophy are therapy duration, PI administration, markers of disease severity, and age.
We cannot forget that along the years, patients have done multiple regimes and combina‐
tions of antiretroviral drugs, which makes it difficult to identify different risks with different
drugs, and studies therefore report conflicting results [6].
Figure 3. FFA uptake by gender (SAT - abdominal subcutaneous adipose tissue; VAT – visceral adipose tissue; FFA –
free fat acids)
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12. Protease inhibitors
PIs affect multiple metabolic pathways and are associated with lipohypertrophy, lipoatrophy,
atherogenic dyslipidemia and IR, [125, 126]. Studies in-vitro reported that PIs are able to alter a
number of adipocyte functions, including differentiation, expression of transcriptase factors
involved in adipogenesis, cell survival, cytokine production, mitochondrial function and IR
[127]. PIs may cause lipodystrophy by inhibiting ZMPSTE24, resulting in accumulation of tox‐
ic farnesylated prelamin A [128], increased oxidative stress and altered adipokine and cyto‐
kine production [89, 127, 129]. The adverse effect of PIs could also result from the induction of
endoplasmic reticulum stress or the inhibition of the proteasome [130, 131].
Different PIs might affect key intranuclear genes, causing reduction in levels of RNA encod‐
ing SREBP-1, which changes the expression of PPAR γ [28]. The levels reduction of intranu‐
clear SREBP-1 leads to a decreased adipocyte differentiation and an altered release of
adipocytokines [132]. PIs can inhibit lipogenesis and stimulate lipolysis [28, 132-135], and
may induce IR by inhibiting glucose transporter 4 expression (GLUT4) [136].
13. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
NRTIs are analogs that inhibit the viral reverse transcriptase enzyme. The thymidine NRTIs
(zidovudine, stavudine and didanosine) cause mitochondrial toxicity by mitochondrial DNA
polymerase inhibition and by causing DNA mitochondrial mutations [31, 137, 138]. These dis‐
turbances result in apoptosis of peripheral adipocytes and lead to lipoatrophy [31]. NRTIs are
also associated with fat hypertrophy in visceral depots [113, 139, 140]. Nucleoside analogues
may inhibit adipogenesis and adipocyte differentiation, promote lipolysis, and exert synergis‐
tic toxic effects when associated to PIs [31, 141-143]. Moreover, NRTIs promote lipolysis and
the subsequent efflux of non-esterified fatty acids from adipose tissue [142, 144].
14. Mitochondrial toxicity and fat redistribution
In western countries, long-term HIV-infected patients present several age-related comorbid‐
ities earlier than the general population [145], and display signs of premature aging [8]. New
hypotheses were recently suggested about the pathophysiology of fat redistribution, pro‐
posing that mitochondrial toxicity was involved in lipoatrophy and in fat hypertrophy. HIV-
associated lipodystrophy could be an age-related fat redistribution that could amplify age-
related comorbidities and their earlier occurrence [8]. Mitochondria play an important role
in adipocyte differentiation and function. At physiological low levels, ROS could act as sec‐
ondary messengers to activate adipogenesis and lipogenesis, resulting in increased adipo‐
cyte number and size. In hepatic cells, oxidative stress activates the transcription factor
SREBP1c, which is highly expressed in adipocytes and increases lipogenesis and lipid accu‐
mulation [146]. At higher levels, ROS could inhibit differentiation [8].
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Figure 4. Acquired partial lipodystrophy - Barraquer-Simons syndrome
Excessive VAT releases increased visceral adipocyte-FFAs, adipokines and cytokines. In‐
deed, activated macrophages, which have an M1 proinflammatory phenotype, invade ex‐
panded adipose tissue; upon invasion, their production of proinflammatory cytokines and
chemokines increases. This could lead to the decreased secretion of adiponectin by adipo‐
cytes in response to TNF-α [36]. Increased abdominal fat lipolysis increases ectopic fat depo‐
sition within tissues (liver, skeletal muscle and heart). Subsequently, these derivatives
overwhelm mitochondrial oxidative capacity and activate stress kinases, leading to IR. This
situation, known as lipotoxicity, associates ectopic depots of triglycerides in non-adipose tis‐
sues that buffer excess fatty acid derivatives [147]. Moreover, a paracrine loop is present be‐
tween adipocytes and macrophages; macrophage-secreted cytokines (TNF-α and IL-6]
activate the NFkB pathway in adipocytes, resulting in increased IL-6 and FFA production.
Saturated FFA can, in turn, activate the Toll-like receptor-4 (TLR-4) on macrophages and
adipocytes, thereby increasing the proinflammatory loop. This paracrine loop has been re‐
ported in obesity as a result of macrophages infiltrating fat [148].
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15. Cortisol and fat redistribution
Patients with hypercortisolism also have an acquired form of lipodystrophy [1], character‐
ized by fat hypertrophy in the upper body with increased VAT and decreased limb fat. Cor‐
tisol can activate adipocyte differentiation and hypertrophy, mainly in visceral fat depots,
because of the higher expression of glucocorticoid receptors (GR-α) and the 11β-hydroxyste‐
roid dehydrogenase type 1 (11β-HSD-1) that transforms inactive cortisone into active corti‐
sol in adipocytes from central depots [22]. In addition, cortisol induces IR and increases
lipolysis in adipocytes [22]. It has been hypothesized that glucocorticoid activation is in‐
volved in cART-linked central fat hypertrophy [8]. Higher ratios of urinary cortisol:cortisone
metabolites and higher subcutaneous 11β-HSD-1 expression are observed in patients with
severe lipodystrophy compared with those without [149]. In cART-naïve patients, 11β-
HSD-1 expression increases in both abdominal and thigh SAT after 12 months of ART, but
only in patients with lipohypertrophy or without lipoatrophy [150]. Because TNF-α expres‐
sion in fat is related to that of 11β-HSD-1 [149], inflammation is linked to glucocorticoid acti‐
vation [8]. TNF-α activates 11-β-hydroxysteroid dehydrogenase (HSD)-type 1, and this
enzyme’s activity is higher in visceral fat compared with subcutaneous fat. Visceral fat is
able to locally produce cortisol, which could act inside the adipocytes and increase lipid ac‐
cumulation [151]. Other hormones, such as growth hormone and testosterone, can modulate
the activity of 11β-HSD-1. It is interesting to note that HIV-infected patients with lipodystro‐
phy often present with a relative decrease in growth hormone [152] and testosterone levels.
Moreover, when patients with visceral fat hypertrophy are treated with growth hormone, a
reduced amount of visceral fat is reported, together with improved metabolic status [153].
16. Aging
In the general population, age is associated with central fat redistribution, mitochondrial im‐
pairment and increased levels of pro-inflammatory cytokines [154]. Aging adipocytes re‐
lease more pro-inflammatory cytokines than young ones [155]. Aging is physiologically
associated with fat redistribution, oxidative stress and low-grade inflammation. In the gen‐
eral population, the interaction between the proinflammatory state and genetic background
potentially triggers the onset of age-related inflammatory diseases such as atherosclerosis,
sarcopenia and frailty. Decreased immune response leading to immunosenescence is also
probably involved in early aging [8, 156]. Aging and some cARTs result in mitochondrial
dysfunction and oxidative stress, which lead to cellular senescence. Moreover, some PIs in‐
duce the accumulation of the pro-senescent protein prelaminA [8].
17. Genetic factors and HIV-lipodystrophy
A role for genetics is also probable in HIV-lipodystrophy. TNF-α gene promoter polymor‐
phism is associated with lipodystrophy, but this association has not been confirmed in larg‐
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er studies [157]. Interestingly, stavudine-induced lipoatrophy is linked to the HLA-
B100*4001 allele, which is located in close proximity to the TNF-α gene; this observation
further supports the theory that there is a role for inflammation in lipoatrophy [158]. Apo
C3-455 also plays a role in lipoatrophy, and two variants of the adipogenic β2 receptor
seems to be involved in fat accumulation, whereas PPARγ variants are not involved [159].
The toxicity of ART also depends on a patient’s metabolism, in part genetically determined.
18. Role of inflammation
Even if infectivity of adipocytes by HIV has been contested, the ability of the virus to modify
adipocyte phenotype has been shown in some studies [160, 161]. Moreover, macrophages
and dendritic cells present in lipodystrophic adipose tissue could be infected, which could
modify their characteristics [7]. Macrophage infiltration is observed in adipose tissue from
patients with HIV-related lipodystrophy together with decreased adipokine and increased
pro-inflammatory cytokine production [162]. Some anti-retrovirals increase oxidative stress
and generation of reactive species, which results in decreased production of adiponectin and
leptin by adipocytes and increased production of pro-inflammatory cytokines [7].
Figure 5. Patient with mixed lipodystrophy (absence of subcutaneous peripheral fat in arms, legs and face and in‐
creased abdominal fat mass)
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19. Lipotoxicity
Lipotoxicity is a possible explanation for the development of metabolic syndrome (MS) and
diabetes in multiple pathological situations, from obesity to lipodystrophies of distinct ori‐
gin. According to the lipotoxicity theory, excess availability of fatty acids or a limited capaci‐
ty to metabolize them in organs and tissues elicits most of the alterations that are
characteristic of MS, especially IR. The toxicity of fatty acids toward β-cells may lead to al‐
tered insulin production. Actually, high FA levels can induce a reduction in GLUT2 on β cell
surfaces and induce a decrease in insulin secretion [19]. Increased availability and, ultimate‐
ly, increased accumulation of fat into skeletal muscle tends to promote IR; and fatty acid lev‐
els in liver that exceed the capacity of this organ to oxidize or export them, lead to the
increased accumulation of fat that is often associated with MS. All of these events could re‐
sult from alterations in fat metabolism or excess intake of fat-enriched nutrients, but they
could also arise as a result of intrinsic alterations in the capacity of adipose tissue to store
and thereby buffer the excessive accumulation of fatty acids in other tissues and organs
[163]. One hypothesis consistent with the appearance of MS in ART-associated lipodystro‐
phy syndrome is lipotoxicity resulting from limitations in the capacity of subcutaneous fat
to store the appropriate amounts of fat and the subsequent diversion of fatty acids to ectopic
sites [164]. Several arguments in support of lipotoxicity as a major contributor to MS in dis‐
tinct human pathologies come from the paradoxically common metabolic alterations found
in the obesity and in lipodystrophies of genetic origin. According to the lipotoxicity theory,
the fat stored in adipose tissue is biologically inert and the observed metabolic alterations
are primarily caused by the increased exposure of cells to non-esterified fatty acid. Thus, in
obese patients, it is not the amount of fat stored in adipose tissue that elicits metabolic dys‐
functions, but rather the balance between the availability of those fatty acids to tissues and
organs and the capacity of the organs to eliminate them through triglyceride storage in adi‐
pose tissue, or oxidation [165]. A complementary concept is the idea that there is a threshold
for adipose tissue expansibility; once it’s reached, as it occurs in obese individuals, appropri‐
ate storage of fatty acids inside adipocytes in their inert and esterified form is impaired, de‐
termining the extent of lipotoxicity [164]. Either a total or partial lack of adipose tissue
storage capacity causes an increase in circulating lipid levels and is associated with ectopic
lipid accumulation in non-fat tissues such as liver, skeletal muscle and pancreas. These alter‐
ations lead to non-alcoholic fatty liver diseases, hepatic and muscle IR and development of
type 2 diabetes. Adipokine deficiency further contributes to metabolic alterations (e.g. hy‐
perphagia) owing to an associated leptin deficiency, which also contributes to positive ener‐
gy balance and potential lipotoxicity through increased fat intake [94].
20. Insulin resistance
IR occurs in about one-third of patients on certain PI-based regimens, although the thymi‐
dine NRTIs have also been associated [166]. Asymptomatic type 2 diabetes mellitus is diag‐
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er studies [157]. Interestingly, stavudine-induced lipoatrophy is linked to the HLA-
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seems to be involved in fat accumulation, whereas PPARγ variants are not involved [159].
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18. Role of inflammation
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leptin by adipocytes and increased production of pro-inflammatory cytokines [7].
Figure 5. Patient with mixed lipodystrophy (absence of subcutaneous peripheral fat in arms, legs and face and in‐
creased abdominal fat mass)
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19. Lipotoxicity
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nosed in 5-10 % of patients [126]. The new-generation PIs appear to have a milder IR effect
and the prevalence of diabetes is lower than described in the early 2000s. Its prevalence,
however, remains higher than in the general population at the same age. In particular, pa‐
tients with severe lipodystrophy are more prone to develop IR [7]. The pathogenesis of glu‐
cose metabolism disorders is still unclear and, although a direct effect of potent
antiretroviral combinations is certainly involved, it is likely that multiple factors play a role,
including genetic predisposition, cytokine and hormonal alterations, changes in the immune
system, non-antiretroviral drug-induced toxic effects, opportunistic diseases, and perhaps
the HIV infection itself [167]. Risk factors for the development of IR in HIV-positive popula‐
tion include duration of ART, PI treatment, concurrent fat redistribution syndrome, dyslipi‐
demia, increasing age, hepatitis C virus co-infection, as well as pharmacological treatment
with pentamidine or megestrol acetate [100, 167-169].
PIs (including indinavir, amprenavir, nelfinavir, and ritonavir) have been shown to induce
IR in vitro by reducing glucose transport mediated by the glucose transporter 4, a receptor
involved in glucose uptake [136]. The deleterious impact of some PIs on adipocytes through
the inhibition of GLUT4 transporters was directly demonstrated in healthy controls, after
given these molecules for a few weeks [169-171]. Several PIs can interfere with nuclear tran‐
scription factors, leading to decreased adiponectin levels, which also leads to IR [123]. Some
PIs might also cause mitochondrial toxicity [172]. Additionally, the increase in FFA levels as‐
sociated with PIs, as well as with fat redistribution, might also have a role in the develop‐
ment of IR (see lipotoxicity) [173].
21. Dyslipidemia
A number of HIV-infected patients present dyslipidemia, increased cholesterol, low-density
lipoprotein (LDL)-cholesterol and triglycerides together with decreased HDL. This profile
has been associated with the presence of a MS, resulting from an increased visceral fat
amount with IR [7].
In patients receiving cART, the prevalence of hyperlipidemia ranges from 28 to 80% in dif‐
ferent studies [167, 174], and it includes hypertriglyceridemia in the majority of cases [123].
Dyslipidemia is frequently, but not always, associated with fat redistribution syndrome: al‐
though lipid and glucose metabolism alterations are more common in patients with body-fat
abnormalities, they are also observed in those without these morphological changes [167].
Several pathogenetic mechanisms have been proposed to explain cART-associated hyperli‐
pidemia, which seems to result from a complex and multifactorial pathologic process: possi‐
bly HIV infection itself, leading in some cases to permanent low grade inflammation with
abnormal levels of some pro-inflammatory cytokines; lipodystrophy itself, as in the genetic
forms, with decreased lower-body fat depots and increased visceral fat; and antiretroviral
molecules (PIs, NNRTIs and some NRTIs) [7].
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Figure 6. Genetic and adquiredlipodystrophies (CGL – congenital generalized lipodystrophy; BSS – Berardinelli-Seip
syndrome; cART- combined antiretroviral therapy; NRTI – nucleoside and nucleotide reverse transcriptase inhibitors; PI
- protease inhibitors; FPL- familiar partial lipodystrophy; MADL- mandibuloacral dysplasia associated lipodystrophy;
adapted from Agarwal&Garg. Ann Rev Genomics Human Genet 2006; 7: 175-199]
Various mechanisms involved in ART-related dyslipidemia have been described: reduction
in the catabolism of VLDL, increased VLDL production, impaired catabolism of FFA, in‐
creased liver triglyceride synthesis, increased secretion of apolipoprotein B-containing lipo‐
proteins, reduced expression of LDL receptors, reduced degradation of SREBP, and
reduction in FXR (farnesoid X receptor) [175]. The first hypothesized mechanism is based
upon the structural similarity between the catalytic region of HIV-1 protease and two hu‐
man proteins involved in lipid metabolism: the cytoplasmic retinoic acid-binding protein
type 1 (CRABP-1) and the low-density lipoprotein-receptor-related protein (LRP). PIs proba‐
bly bind to CRABP-1 and erroneously inhibit the formation of cis-9-retinoic acid, leading to
increased apoptosis of peripheral adipocytes, decreased lipid storage and increased lipid re‐
lease into the bloodstream. Similarly, PIs may inhibit the normal functioning of LRP and in‐
terfere with fatty acid storage in the adipocytes [167, 176]. Furthermore, data from in vitro
and in vivo studies suggest that PIs may prevent proteasomal degradation of nascent apoli‐
poprotein B, a key protein component of circulating triglycerides, leading to increased pro‐
duction of VLDL particles. An upregulation of metabolic pathways leading to an excessive
production of VLDL can also be caused by the PI-induced intra-hepatocyte accumulation of
nuclear transcription factors involved in the metabolism of apolipoprotein B, such as SRBPs.
In addition, the levels of lipoprotein particles containing apolipoprotein C-III and apolipo‐
protein E are increased in PI-treated patients [176-179].
22. Metabolic syndrome
In the general population, MS is described as an association of increased upper-body fat,
particularly in the visceral area, with IR responsible for and revealed by metabolic altera‐
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Several pathogenetic mechanisms have been proposed to explain cART-associated hyperli‐
pidemia, which seems to result from a complex and multifactorial pathologic process: possi‐
bly HIV infection itself, leading in some cases to permanent low grade inflammation with
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tions, including increased LDL, decreased HDL, increased triglycerides, increased glycemia
or diabetes and increased blood pressure [180-182]. All these parameters constitute a con‐
stellation of major CV risk factors [180]. This situation also includes low-grade inflammation
and a prothrombotic state [7].
The pathophysiology of MS is complex – genetic factors, aging and weight gain associated
with sedentariness and food habits constitute major risk factors. Also, decreased mitochon‐
drial function related to aging [183] and an age-related redistribution of fat towards the cen‐
tral, visceral areas are involved, leading to IR and metabolic abnormalities [7].
The components of the HIV lipodystrophy syndrome(s) bear a striking resemblance to those
of MS [123]. Both can present hyperinsulinemia, glucose intolerance, central or abdominal
obesity, hypertension, atherogenic lipid profile, hyperuricemia, prothromboticand proin‐
flammatory states [123].
Liver lesions of nonalcoholic steatohepatitis (or NASH) are a complication of MS, with a
possible evolution towards severe liver complications such as cirrhosis. HIV-infected pa‐
tients, with IR in the context of a severe lipodystrophy, present an increased risk of liver le‐
sions [184]. Moreover, as HCV infection has been associated with steatosis and hepatic IR
resulting from viral or metabolic effects, HCV co-infection could aggravate the metabolic
and liver status of HIV-infected patients [185]. HIV-infected patients with MS are more like‐
ly to have higher values of carotid intima-media thickness (cIMT) and detectable coronary
artery calcium score [186].
23. Clinical sequelae associated with HIV and HIV-lipodystrophy
Different studies suggest that the CV risk is increased among HIV-infected patients on cART
and the responsible mechanisms are complex: in addition to the direct effect of the virus on
the vasculature, the toxicity of antiretroviral drugs and the set of metabolic alterations ag‐
gregated in the MS are involved [187]. Whether the increased CV risk is due to HIV infection
itself, to ART, or to a synergistic interaction between these factors, remains to be established
[167]. HIV infection itself may increase CV risk. The HIV surface glycoprotein gp120 can
stimulate endothelial cell production of tissue factor, an early step in the development of
atherosclerosis [188]. Both HIV infection and ART promote atherosclerosis and its clinical
manifestations through inflammatory mechanisms involving endothelial cells, either direct‐
ly or indirectly, and also by inducing lipid alterations [189, 190].
Furthermore, some data suggest that endothelial dysfunction, impaired fibrinolysis, and ex‐
cess inflammation are more common in HIV-positive patients than in general population,
which may contribute to an increased CV risk [191]. At the same time, cIMT and coronary
calcification assessments suggest increased incidence of atherosclerotic disease and prema‐
ture occurrence of arterial atherosclerotic lesions among HIV-infected individuals [192]. Sur‐
rogate markers of atherosclerosis, including abnormal cIMT [193, 194], altered endothelial
reactivity [195], abnormal coronary calcium scores [196], higher than expected C-reactive
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protein levels and abnormal proinflammatory and prothrombotic indices [197], all suggest a
state of increased atherosclerotic risk [123].






























Figure 7. The relationship between HIV infection, lipodystrophy, ART, insulin resistance, adipokines, metabolic altera‐
tions, metabolic syndrome and cardiovascular disease risk
Endothelial cells have been shown to be variably permissive for HIV infection. The HIV virus
itself is able to penetrate coronary artery and brain microvascular endothelial cell membranes
and to initiate inflammatory and biochemical intracellular reactions [198, 199]. The activation
of endothelium induced by either HIV infection itself or by a leukocyte-mediated inflammato‐
ry cascade triggered by the same virus leads to an increased expression of endothelial cellular
adhesion molecules, such as intercellular adhesion molecule 1 (ICAM-1), vascular adhesion
molecule 1 (VCAM-1], E-selectin, P-selectin, thrombomodulin, tissue plasminogen activator
(tPA), and PAI-1. A significant association between increasing serum concentrations of adhe‐
sion molecules and risk of future myocardial infarction has been shown in apparently healthy
men and women, and these molecules are now considered as soluble biomarkers of endothe‐
lial inflammation and early atherosclerosis [200, 201]. Increased serum levels of ICAM-1,
VCAM-1, E-selectin, and thrombomodulin were demonstrated in patients with advanced HIV
infection and opportunistic diseases. A correlation between ICAM-1 concentrations and the
progression of disease as well as the reduction of CD4 lymphocyte count was also reported. If
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circulating adhesion molecules indicate vascular endothelium injury, it seems clear that endo‐
thelium injury is associated with the progression and severity of HIV disease [202]. cART
should reduce the endothelial damage by controlling HIV infection, but it would also contrib‐
ute to stimulating endothelial activation by deranging both lipid and glucose metabolism
[167]. Some PIs, as ritonavir and indinavir are able to directly cause endothelial dysfunction,
with mitochondrial DNA damage and cell death, independently of lipid profile [203]. cART
may promote atherosclerosis both by direct effects on endothelial cells and by indirect effects
associated with metabolic disturbances [167].
Elevated serum levels of PAI-1, tPA, and CRP, as well as reduced serum levels of adiponec‐
tin could be considered biochemical markers of endothelial dysfunction, metabolic altera‐
tions, and CV risk in HIV-infected patients [192]. Some authors suggested that the
pathogenetic mechanism responsible for carotid lesions associated with HIV infection may
be more similar to an inflammatory process than to the classical atherogenesis [204, 205].
Some retrospective and prospective studies have shown that the incidence of myocardial in‐
farction in HIV-positive subjects treated with ART tends to be higher than in the general
population, particularly in those receiving a PI-based treatment [206]. However, reports
from large observational studies demonstrate that there is still considerable controversy re‐
garding the association of cART, particularly PI-based combinations, with increased inci‐
dence of coronary heart disease risk [167].
Moreover, prospective studies involving large cohorts of HIV-infected patients have docu‐
mented an increased incidence of myocardial infarction and cerebrovascular diseases in as‐
sociation with a prolonged exposure to cART. However, the absolute risk of CV events
remains low, and should be balanced against the remarkable benefits ofcART in terms of im‐
provement in immune function and related morbidity and mortality [167].
In other words, incidence of CV disease in successfully cART-treated HIV-infected patients
is low. However, the risk of CV disease is increased compared with that of uninfected peo‐
ple. This fact is due in great part to a higher prevalence of underlying traditional CV risk
factors that are mostly host dependent. HIV may additionally contribute through immune
activation, inflammation, and immunodeficiency. In a more modest way than HIV infection,
the type of ART may also contribute, mainly through the impact on metabolic and body fat
parameters, and possibly through other factors that are currently unclear. From the CV per‐
spective, the benefits of ART outweigh any potential risk [207, 208].
24. Conclusions
Human lipodystrophies are a heterogeneous group of diseases with generalized or partial
fat loss. They include rare genetic conditions or more frequent acquired forms, and may be
old, or more recent, such as HIV-related lipodystrophy. Almost all lipodystrophies are asso‐
ciated with metabolic alterations including IR, diabetes, dyslipidemia and early CV disease.
In this new context of increased aging of HIV-infected patients, increased metabolic and CV
complications are to be expected due to high incidences of smoking status, over-nutrition
Current Perspectives in HIV Infection282
and reduced exercise, lipodystrophy, dyslipidemia, altered glucose tolerance with IR and
low-grade infection with the ongoing drug-induced inflammation. It is important to be
aware of these alterations and to apply risk-modification strategies to reduce CV risk in the
HIV-infected patients.
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is low. However, the risk of CV disease is increased compared with that of uninfected peo‐
ple. This fact is due in great part to a higher prevalence of underlying traditional CV risk
factors that are mostly host dependent. HIV may additionally contribute through immune
activation, inflammation, and immunodeficiency. In a more modest way than HIV infection,
the type of ART may also contribute, mainly through the impact on metabolic and body fat
parameters, and possibly through other factors that are currently unclear. From the CV per‐
spective, the benefits of ART outweigh any potential risk [207, 208].
24. Conclusions
Human lipodystrophies are a heterogeneous group of diseases with generalized or partial
fat loss. They include rare genetic conditions or more frequent acquired forms, and may be
old, or more recent, such as HIV-related lipodystrophy. Almost all lipodystrophies are asso‐
ciated with metabolic alterations including IR, diabetes, dyslipidemia and early CV disease.
In this new context of increased aging of HIV-infected patients, increased metabolic and CV
complications are to be expected due to high incidences of smoking status, over-nutrition
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and reduced exercise, lipodystrophy, dyslipidemia, altered glucose tolerance with IR and
low-grade infection with the ongoing drug-induced inflammation. It is important to be
aware of these alterations and to apply risk-modification strategies to reduce CV risk in the
HIV-infected patients.
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1. Introduction
In The Eight Millennium Development Goals, the World Health Organization proposed to
attempt at reverting the world negative HIV/AIDS epidemics through disease prevention
and treatment for the year 2015. Attaining virtual elimination of Vertical Transmission (Pre‐
vention of mother-to-child transmission, PMTCT) worldwide is one of such aims [1].
The current chapter will address topics related to epidemiologic, pathophysiological, diag‐
nostic and therapeutic aspects of vertical transmission of the Human Immunodeficiency Vi‐
rus (HIV). Such information will enable the reader to understand how the health strategies
aiming at preventing transmission to the fetus have turned into a paradigm of Perinatal
Medicine, since the implementation of a series of biomedical interventions has proven to be
successful to prevent transmission of HIV from an infected pregnant mother to her child.
2. Epidemiology
World Epidemiological Status
Prevalence of Vertical Transmission (VT) in the different regions of the world varies with
geographic location and, specifically, with the economic resources invested by the different
countries to support various strategies applied to health care policies that aim at the preven‐
tion and treatment of infected mothers. Proof of thereof is the fact that in countries with gov‐
ernment programs in which the economic support is sufficient to implement the planned
strategies for VT prevention, the prevalence of perinatal infection is under 2% [2,3].
HIV epidemics are showing a trend towards stabilization worldwide. Thus, in 2009 approxi‐
mately 2.6 million persons became newly infected by the virus, representing 19% fewer than
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the newly infected in 1999 and more than a fifth less (21%) of the estimates in 1997. In fact, in
33 countries the incidence of infection has fallen by 25%. This includes 22 countries of the
Sub-Saharan African region, the zone with the highest number of new cases worldwide
(Ethiopia, Nigeria, South Africa, Zambia and Zimbabwe). In Eastern, Central and Western
Europe, Central and Northern Asia the incidence of HIV infection has remained stable for
the past five years. However in some high income countries infection rates have increased
due to sex practices between homosexuals. Central Asia and Eastern Europe continue with
high transmission rates among drug addicts and their sexual partners [4].
Regarding vertical transmission, an estimate of 370,000 children became infected with HIV
during perinatal and lactation periods in 2009. Such figure is quite lower than the estimated
500,000 newly infected children in 2001. The latter has been possible thanks to Vertical
Transmission (VT) prevention healthcare strategies that have been planned and implement‐
ed. Accordingly, the WHO and the UNAIDS proposed to virtually eliminate such transmis‐
sion route by 2015. To accomplish such goal, besides the efforts already implemented, they
stated the importance of controlling the infection among youngsters. It is estimated that
more than half of seropositive persons are girls and women [1,4].
In the Sub-Saharan African region, there are 8 times more infected women than men among
persons aged between 15 and 24. Most of women are infected during unsafe heterosexual
sexual activity. Such situation is the main responsible for the fact that such countries are as‐
sembling 90% of the children infected worldwide. Despite of the latter, the incidence of sub‐
jects with a carrier status among children under 15 years of age has declined in 32% in South
Africa, the country in which AIDS is the main cause of maternal death and that accounts for
35% of deaths in children under 5 years of age. Accordingly, worldwide data show that only
15% of women in whom the carrier status had been detected during their perinatal period
stayed subsequently on lifelong antiretroviral therapy [4].
It is estimated that approximately 4.9 million people in Asia were seropositive during 2009.
Such figure is similar to those reported in the previous years, thus reflecting that the epi‐
demics has stabilized. In such continent, the number of infected children under the age of 15
has increased marginally, from 140,000 in 2005 to 160,000 in 2009 and AIDS-related deaths
have dropped in 15% since 2004 [4].
In Western Europe, epidemiology indicators regarding maternal carrier status have evolved
favorably. The estimated prevalence of infection among pregnant women in the United
Kingdom is 0.2% and HIV screening coverage in gestating women is 90%. The latter has re‐
sulted in a sustained decline of VT from 12% in 1999 to 2% in 2007 [4,5].
In North America the carrier status has reached stability and VT has evidenced a dramatic
decrease. In Canada, infection of the newborn has decreased from 5.2% in 1997 to 2.7% in
2012, and when the seropositive mother was administered HAART, such figure reached
0.4% [4,6].
In Central and South America the number of affected children under 15 years of age is still
low, with approximately 4000 new cases during 2009, in spite of the fact that the coverage of
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VT prevention programs is only marginally superior to that reported in countries with low
or moderate income [4].
According to reports from 2006, the estimated number of seropositive subjects in Latin
America is 1.7 millions, with 140,000 new cases and 65,000 deaths. Two thirds of the infected
individuals live in four countries: Argentina, Brazil, Colombia and Mexico. The main agent
responsible for the infection is HIV-1. The most commonly isolated genotype is type B, fol‐
lowed by types F and A [2].
In the American countries that compose the Southern Cone, HIV/AIDS epidemiological sur‐
veillance is carried out through mandatory notification (passive mechanism) and in some,
through active surveillance by means of sentinel centers [2].
Most of such Latin American countries have implemented, since the second half of the 90s,
an Antenatal Prevention of Mother To Child Transmission (APMTCT) program, consisting
of the early voluntary diagnosis of HIV infection in the gestating population, universal ac‐
cess to antiretroviral therapy (ART) for the mother-child binomial, the C-section surgery and
suppression of lactation, a program that aims at eliminating vertical transmission as a route
of infection [2,3].
The main route of transmission in Latin America is represented by sex between men. There
has been a significant increase in transmission through heterosexual intercourse since 1990.
With the exception of Argentina, where initially transmission was mainly represented by
needle sharing during drug injection, with a current dramatic drop, estimates of new cases
of transmission through such route in 2005 do not exceed 5%. On the other hand, there is
concern in the area, regarding the relationship between HIV and drug addition, since it has
been demonstrated that illicit drug abuse, regardless of the route of administration, favors
risk behaviors [2].
In view of the above stated, it is possible to conclude that the features of the epidemics in the
Southern Cone have varied, showing a trend to impoverishment, feminization, and shift to‐
wards homosexual and scholar populations. Moreover, the fact of the most affected age
group is between 20 and 39 years is of great importance, since it demonstrates that the most‐
ly affected population is that representing the childbearing age, a situation that has a direct
impact on VT risk. The latter warrants the importance of implementing human sexuality ed‐
ucation to all levels of the population, providing the necessary information and recognizing
the right of women to be informed to enable them to take the appropriate measures to pro‐
tect themselves and prevent HIV infection. [2-4].
The rate of HIV seropositive pregnant women fluctuates in the different countries of the Re‐
gion, between 3 and 7/1000. It is estimated that more than 2 million HIV (+) women get
pregnant and 90% of them belong to developing countries, thus between 370,000 and
500,000 infected children are born annually, that die mostly because of the disease [4]. Preg‐
nancy would play a protective role for maternal mortality among HIV (+) women. Such ef‐
fect would be related to the low pregnancy rates achieved among women at advanced
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VT prevention programs is only marginally superior to that reported in countries with low
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py (HAART). Moreover, the latter has increased the probability of achieving pregnancy,
thus decreasing the rate of stillbirths and gestation-related diseases [7].
Since the beginning of the pandemics, the importance of VT as transmission route has been
clear. However, not even the most optimistic would have thought that PMTCT would turn
into an example of effective biomedical intervention to prevent HIV transmission. It is im‐
portant to point that most of Latin American countries have healthcare programs aiming at
decreasing VT (PMTCT) that are based on the early prenatal voluntary screening for infec‐
tion, the offering of antiretroviral therapies (ARVT), the C-section [8], substitution of breast‐
feeding [9] and multidisciplinary management during pregnancy. Regarding antenatal
carrier status diagnosis, it is important to note that there are studies that reveal that between
25 and 55% of the total number of pregnant women who accept the test do not schedule a
subsequent visit to know the results, thus they do not receive therapy. The latter suggests
that fast intrapartum tests should be implemented on pregnant women unaware of their se‐
rologic condition. This is supported by a recent study carried out in Peru. The study con‐
cluded that the use of fast result tests (oral or blood) is a strategy advisable to decrease VT
risk, in populations where PMTCT coverage does not reach the expected goals [10].
Pharmacological measures that have been implemented to decrease VT in the Southern re‐
gion of America, were based on the ACTG 076 protocol [11] involving therapeutic antiretro‐
viral management aiming at obtaining low or undetectable maternal viral loads, without toxic
and/or teratogenic fetal effects. Such protocol consisted on the administration of Zidovudine
to the mother during pregnancy and delivery, as well as to the newborn until the 6th week of
life, together with indication of an elective C-section operation and contraindication of breast‐
feeding. Such scheme managed to decrease VT in the region, from 29% to 5.6% during 2001.
[2] Subsequently, due to the emergence of new evidence supporting that triple-drug therapy
was even more effective than monotherapy for VT prevention, a protocol was designed using
a combination of reverse transcriptase and protease inhibitors. Such schemes were named
together HAART. Thanks to such therapy, VT has dropped to figures close to 1% [2].
Because of the implementation and coverage of healthcare government programs in coun‐
tries of the region, only few pregnant women have viral loads higher than 1000 copies/ml in
the proximity of delivery. The latter is responsible for the VT drop estimated as 1%. [2] A
recent study assessed the risk of VT in pregnant women who were administered PMTCT
and concluded that the VT risk was 0.097 (95% IC; 0.030-0.163). This reflects a reduction of
transmission risk related to such route in almost 40% regarding VT before the implementa‐
tion of such program [12].
Chile, where an early detection program and timely treatment are currently being carried
out, is probably one of the countries in the region having reached the best VT rates. This is a
result of healthcare strategies aiming an adequate and permanently updated diagnosis of
the behavior of the epidemics in the country. The proportion of female HIV carriers has in‐
creased as compared to that of males, due to the fact that the main transmission route is sex
(93.6%). Such figure together with the impact of viral transmission both through homosexu‐
al as well as bisexual intercourse (46.1%), positions the monogamous heterosexual woman
as the highest risk population (51.1%). Moreover, there is a sustained increase of cases trans‐
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mitted through sex between men and women as compared to those transmitted through ho‐
mosexual intercourse. This has shifted the epidemics towards heterosexual population
groups, with a higher impact among female populations [2,3].
To summarize, HIV VT in the region is responsible for a low percentage of people reported
with HIV/AIDS, but is accountable for most of the children affected by the infection in the
Southern Cone. An important reduction of transmission by means of such exposition route,
reaching levels very close to the proposed goals, has been evidenced. Such decline might
probably be explained by the wide coverage and effectiveness of the measures propounded
by the health authorities to tackle the issue [2,3].
3. Virology and Natural History of the Infection
The Human Immunodeficiency Virus (HIV) is a lentivirus that belongs to the Retroviridae
family. Two types of HIV have been identified: HIV-1, the most common, results in acquired
immunodeficiency syndrome and death, and HIV-2, affecting mainly inhabitants or visitors
from Western Africa, is transmitted less effectively and results in a more indolent disease
with subsequent AIDS and death. They share less than 50% sequence homology. Through
phylogenetic analysis, HIV-1 strains can be divided into two large groups: The M (Major)
group in turn divided into 10 subtypes (from A to J) and the O (Outlier) group. The eventual
importance of HIV-1 typification lies in developing antibody screening techniques, diagnos‐
ing the infection in the newborn, and in the quantification of plasma viral RNA for follow
up of infected patients [13, 14,15].
This monostranded RNA virus incorporates its genetic material into the host cell DNA, in‐
fecting cells that express CD4 antigen on their surface, such as helper T cells, macrophages,
central nervous system cells and even placental cells [13,16,17].
Once the infection has occurred, the patient may present a primoinfection characterized by
mononucleosis–like non-specific symptoms, where antibody production is triggered. Subse‐
quently the patient undergoes a silent carrier phase. The latter used to last between 9 and 11
years before the emergence of antiretroviral therapy. As the immune system is being pro‐
gressively involved, the host becomes more susceptible to suffer opportunistic infections,
cancers and dementia / encephalopathy, which are complications that enable labeling such
stage as AIDS stage. In further consensus, the following findings were added: CD4 count
under 200/mm3, uterine cervix cancer, lung tuberculosis and recurrent pneumonia [13,16,17].
4. Viral Replication Mechanism
The genome of HIV-1 is relatively small, and composed of genes coding for structural, regu‐
latory and accessory proteins. The viral particle joins the cells of the susceptible host, among
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high affinity bond is generated between the gp 120 of the viral surface and the CD4 receptor
molecule on the host cell. Cell membranes fuse together and the virus enters the cell, uncov‐
ering its RNA. It is propounded that after infection, it is the downregulation of CD4 expres‐
sion on the infected cell surface that prevents a superinfection, enables an efficacious
replication of the virus, and decreases the possibility of early cell death or apoptosis. During
an early stage, the viral reverse transcriptase is activated together with other factors, and
complete double stranded DNA copies are formed from the viral RNA. Such DNA copy is
transported to the cell nucleus and binds to the host cell DNA through the viral integrase,
generating the so-called provirus. The provirus may remain latent during a period of time.
The host factors that influence the latency period duration are unknown. In activated cells,
proviral transcription generates genomic RNA for its incorporation into new virions and
messenger RNA that will be translated into structural proteins and several regulator and ac‐
cessory proteins that facilitate viral replication, assembling and release [13,16,17].
The adult immune system has several components that are critical for HIV infection, such as
B and T cells, antigen-presenting cells, major histocompatibility antigens (types I and II),
natural killer cells, cytokines and complement. Before an infection or antigenic stimulation,
B cells are always “naïve”. Following their stimulation, they generate two HIV specific sub‐
groups that actively secrete antibodies against the virus. Likewise, there are “innocent” and
other T cells with specific memory as a result of a prior exposure to the virus. In the great
majority of the infected people HIV invasion disrupts normal immune reactions and induces
a chronic progressive, polymorphic dysfunction that, at a given time, makes the individual
susceptible to opportunistic infections, cancers, neurological disorders and premature death.
The initial HIV infection in adults is frequently followed 2 to 6 weeks later by an acute viral
syndrome that manifests with fever, pharyngitis, myalgia, tender lymphadenopathies, non-
specific rash and lasts from 7 to 14 days. There is an acute drop of circulating lymphocyte
counts, with a fairly rapid normalization of figures. However, CD4+ T cell counts do not
fully regain baseline values. During such period viral replication and dissemination to
lymph nodes and mononuclear / macrophagic cells occur speedily [13,16,17].
The circulating viral load is high in the initial absence of an effective antibody response.
Typically, IgM appear one or two months after HIV exposure, followed by IgG (specifically
anti-gp 120/41) and the development of an anti-p24 response that fades out in more ad‐
vanced stages of the infection. Shortly afterwards, anti-gp120 and gp41 antibodies emerge,
and persist for a lifetime. As anti–HIV antibody titers increase, the circulating viral load de‐
creases and the infected subjects initiate an asymptomatic phase that commonly lasts from 3
to 11 years. During such asymptomatic phase viral replication is extremely intense, as well
as is the destruction and replacement of CD4+ T cells. It should be taken into consideration
that before causing a gradual CD4+ T cell depletion, HIV infection causes a CD4+ T cell dys‐
function. Chemoprophylaxis, antibody-related cell-mediated cytotoxicity, intracellular anti‐
microbial activity and disorders of cytokine production also occur due to monocyte and
macrophage dysfunction caused by the HIV infection [13,16,17].
During pregnancy, the mother undergoes a modulation of her immune response character‐
ized by a TH2 response (humoral type) more prominent than TH1-type (cellular) response
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that renders her more susceptible to certain infections. Based on the latter, it has been postu‐
lated that pregnancy might influence the course of the infection. Such hypothesis has been
thoroughly discussed, and currently the conclusion is that gestation does not have adverse
effects on survival or on the expression of the disease. Such conclusion is supported by the
fact that the absolute CD4 count and the viral load remain stable during pregnancy in un‐
treated pregnant women [7,13,16 -18].
Almost all clinical disorders described in HIV-infected adults may appear in infants, howev‐
er their rates of onset might be different in both life periods. The evolution of disease among
infants infected during the perinatal stage is faster than in adults. This has raised questions
such as if the developing immune system in fetuses and newborns represents a better
ground for viral replication or is less efficient for infection control. Immaturity of the im‐
mune system of fetuses, newborns and infants causes two pathophysiological differences
between adults and children: B cells are seldom susceptible to HIV infection and their circu‐
lating values remain normal; however such cells show abnormalities in infected children as
compared to infected adults. As the infant has been exposed to few external antigens (and
thus has a limited immune memory), the resulting immune dysfunction is more severe than
in adults. Because of the poor development of T and B cell memory, children infected in per‐
inatal stages are more vulnerable to antibody-mediated pyogenic infections than infected
adults [13,16,17].
Almost as soon as the infected cells die, they are replaced, until the degree of the immune
dysfunction is such as to make the immune control of the virus inefficient. Thus, the clinical
conditions defining AIDS are progressively met.
5. HIV behavior in women
The main HIV transmission risk factor for females worldwide is sexual intercourse. More
than 90% of HIV-AIDS-infected women have acquired the infection through heterosexual
transmission. In most of the cases, such women had sexual intercourse only with their stable
spouse, thus attesting for their vulnerability to transmission, which is directly related to
their sexual partner’s behavior (bisexuality, drug addictions, promiscuity) [3].
The reasons explaining why women are more susceptible to be infected by HIV than men
are varied. Thus, healthcare staff must be aware of such factors and therefore generate a
sympathetic and empathic environment to achieve a good physician-patient relationship.
Among such reasons, the following should be considered:
- Sexual transmission of the virus is several times more common from men to women than
vice versa. Women with thinned vaginal mucosa or lacking the physiological defense mech‐
anisms (pubertal and postmenopausal women) are at higher risk.
- Asymptomatic sexually transmitted vaginosis is commonly underdiagnosed and results in




high affinity bond is generated between the gp 120 of the viral surface and the CD4 receptor
molecule on the host cell. Cell membranes fuse together and the virus enters the cell, uncov‐
ering its RNA. It is propounded that after infection, it is the downregulation of CD4 expres‐
sion on the infected cell surface that prevents a superinfection, enables an efficacious
replication of the virus, and decreases the possibility of early cell death or apoptosis. During
an early stage, the viral reverse transcriptase is activated together with other factors, and
complete double stranded DNA copies are formed from the viral RNA. Such DNA copy is
transported to the cell nucleus and binds to the host cell DNA through the viral integrase,
generating the so-called provirus. The provirus may remain latent during a period of time.
The host factors that influence the latency period duration are unknown. In activated cells,
proviral transcription generates genomic RNA for its incorporation into new virions and
messenger RNA that will be translated into structural proteins and several regulator and ac‐
cessory proteins that facilitate viral replication, assembling and release [13,16,17].
The adult immune system has several components that are critical for HIV infection, such as
B and T cells, antigen-presenting cells, major histocompatibility antigens (types I and II),
natural killer cells, cytokines and complement. Before an infection or antigenic stimulation,
B cells are always “naïve”. Following their stimulation, they generate two HIV specific sub‐
groups that actively secrete antibodies against the virus. Likewise, there are “innocent” and
other T cells with specific memory as a result of a prior exposure to the virus. In the great
majority of the infected people HIV invasion disrupts normal immune reactions and induces
a chronic progressive, polymorphic dysfunction that, at a given time, makes the individual
susceptible to opportunistic infections, cancers, neurological disorders and premature death.
The initial HIV infection in adults is frequently followed 2 to 6 weeks later by an acute viral
syndrome that manifests with fever, pharyngitis, myalgia, tender lymphadenopathies, non-
specific rash and lasts from 7 to 14 days. There is an acute drop of circulating lymphocyte
counts, with a fairly rapid normalization of figures. However, CD4+ T cell counts do not
fully regain baseline values. During such period viral replication and dissemination to
lymph nodes and mononuclear / macrophagic cells occur speedily [13,16,17].
The circulating viral load is high in the initial absence of an effective antibody response.
Typically, IgM appear one or two months after HIV exposure, followed by IgG (specifically
anti-gp 120/41) and the development of an anti-p24 response that fades out in more ad‐
vanced stages of the infection. Shortly afterwards, anti-gp120 and gp41 antibodies emerge,
and persist for a lifetime. As anti–HIV antibody titers increase, the circulating viral load de‐
creases and the infected subjects initiate an asymptomatic phase that commonly lasts from 3
to 11 years. During such asymptomatic phase viral replication is extremely intense, as well
as is the destruction and replacement of CD4+ T cells. It should be taken into consideration
that before causing a gradual CD4+ T cell depletion, HIV infection causes a CD4+ T cell dys‐
function. Chemoprophylaxis, antibody-related cell-mediated cytotoxicity, intracellular anti‐
microbial activity and disorders of cytokine production also occur due to monocyte and
macrophage dysfunction caused by the HIV infection [13,16,17].
During pregnancy, the mother undergoes a modulation of her immune response character‐
ized by a TH2 response (humoral type) more prominent than TH1-type (cellular) response
Current Perspectives in HIV Infection306
that renders her more susceptible to certain infections. Based on the latter, it has been postu‐
lated that pregnancy might influence the course of the infection. Such hypothesis has been
thoroughly discussed, and currently the conclusion is that gestation does not have adverse
effects on survival or on the expression of the disease. Such conclusion is supported by the
fact that the absolute CD4 count and the viral load remain stable during pregnancy in un‐
treated pregnant women [7,13,16 -18].
Almost all clinical disorders described in HIV-infected adults may appear in infants, howev‐
er their rates of onset might be different in both life periods. The evolution of disease among
infants infected during the perinatal stage is faster than in adults. This has raised questions
such as if the developing immune system in fetuses and newborns represents a better
ground for viral replication or is less efficient for infection control. Immaturity of the im‐
mune system of fetuses, newborns and infants causes two pathophysiological differences
between adults and children: B cells are seldom susceptible to HIV infection and their circu‐
lating values remain normal; however such cells show abnormalities in infected children as
compared to infected adults. As the infant has been exposed to few external antigens (and
thus has a limited immune memory), the resulting immune dysfunction is more severe than
in adults. Because of the poor development of T and B cell memory, children infected in per‐
inatal stages are more vulnerable to antibody-mediated pyogenic infections than infected
adults [13,16,17].
Almost as soon as the infected cells die, they are replaced, until the degree of the immune
dysfunction is such as to make the immune control of the virus inefficient. Thus, the clinical
conditions defining AIDS are progressively met.
5. HIV behavior in women
The main HIV transmission risk factor for females worldwide is sexual intercourse. More
than 90% of HIV-AIDS-infected women have acquired the infection through heterosexual
transmission. In most of the cases, such women had sexual intercourse only with their stable
spouse, thus attesting for their vulnerability to transmission, which is directly related to
their sexual partner’s behavior (bisexuality, drug addictions, promiscuity) [3].
The reasons explaining why women are more susceptible to be infected by HIV than men
are varied. Thus, healthcare staff must be aware of such factors and therefore generate a
sympathetic and empathic environment to achieve a good physician-patient relationship.
Among such reasons, the following should be considered:
- Sexual transmission of the virus is several times more common from men to women than
vice versa. Women with thinned vaginal mucosa or lacking the physiological defense mech‐
anisms (pubertal and postmenopausal women) are at higher risk.
- Asymptomatic sexually transmitted vaginosis is commonly underdiagnosed and results in




- Women depend economically, socially and emotionally on men and such situation makes
rejection of high-risk sexual intercourse difficult.
- Cultural norms encourage promiscuity among males, thus increasing transmission risk
among monogamous females.
- There is a lack of easy access to woman-controlled-preventive methods (female condoms).
Regarding the last point and aiming at identifying other prevention methods, recent studies
have demonstrated that the use of tenofovir gel might be a useful tool to prevent infection.
In fact, a South African study concluded that the pre and post-coital prophylactic use of
such microbicide among women aged between 18 and 40 reduced HIV infection in 39% and
HSV-2 infection in 51%. [19] On the other hand, circumcision in adults has proven to be ef‐
fective to prevent infection among seronegative males with an HIV+ partner. The latter has
led the UNAIDS and WHO to recommend such intervention in countries with high preva‐
lence [4]. Finally, there are also studies that propose the use of tenofovir prior to sexual in‐
tercourse in infected or high-risk couples. All these prophylactic measures should be
assessed with further adequately designed studies.
Probably due to such reasons and in light of the pooled data in developing and developed
countries, the proportion of HIV carrier women has increased as compared to that of men.
The cause is that the main transmission route is sex. The latter together with the impact of
viral transmission route in homo and heterosexual mode, have transformed heterosexual
monogamous women into the highest risk population. Moreover, there is a sustained in‐
crease of cases transmitted by sexual intercourse between men and women as compared to
those transmitted through homosexual intercourse. This has shifted the epidemics towards
population groups with a lower social-economic level and with a clear decrease of females
in higher school education levels [2, 3, 16,17].
Epidemiology studies suggest that the observed prevalence among women in childbearing
age is comparable to prevalence in pregnant women. On the other hand, pregnancy rates in
seropositive women that have not developed AIDS are comparable to those seen among un‐
infected women, while among women who developed the disease the probability of getting
pregnant is quite lower [13-15].
6. Management of seropositive pregnant woman for Vertical
Transmission Prevention
Most of women discover their carrier status or their disease during pregnancy or subse‐
quently after birth upon screening of their offspring. With regard to the need for screening
of all women during their pre and/or post-conception consultation, the American College of
Obstetricians and Gynecologists recommends carrying it out on a routine basis, which is a
conduct commonly adopted in many countries of the world. In fact, in most of these coun‐
tries, such screening is performed together with the mandatory pre-test counseling act, with
the informed consent and with the willfulness of individuals in the decision to undergo the
Current Perspectives in HIV Infection308
test. Therefore, screening requires the participation of staff trained in “counseling”, which
has reinforced the decision to undergo the test among women. This has shown to be of most
importance for the generation of awareness about the disease, adherence to therapy and the
incorporation of behaviors by the carrier to prevent transmission to her personal environ‐
ment [20-24]. Pre and post-conceptional counseling is understood as a “confidential dia‐
logue between a questioner and a counselor aiming at empowering women to face stress,
decision making regarding HIV/AIDS during pregnancy and discussion of the elements for
prevention of vertical transmission”. It is important to recommend the following topics to be
addressed upon counseling:
- Impact of HIV on pregnancy.
- Vertical Transmission risk and impact of prophylactic measures.
- Risks and benefits of antiretroviral therapy.
- Prognosis for children who become infected.
– Breastfeeding-related risks.
7. Diagnosis
The most popular methods worldwide are tests that screen for specific antibodies against
viral  antigens.  The  most  used  technique  for  screening  is  Enzyme  Linked  Immunosorb‐
ent  Assay  (ELISA).  The  most  used  technique  for  infection  confirmation  is  the  Western
blot technique [25].
The ELISA test uses antigens derived from the intact virus and binds them to microtitration
wells. The serum or plasma from the patient is added into the wells and if there are antibod‐
ies against HIV they bind to the antigen present. A chromogen substrate is also provided to
evidence the potentially bound enzyme and the intensity of the color generated is read on a
spectrophotometer. Color reading is proportional to the amount of the enzyme-antibody
complex that bound the HIV antigen present in the wells. Commercially available tests have
sensitivity and specificity rates between 98 and 100%. The disadvantage of such tests is they
detect antibodies and thus may yield false positive results if transmission occurred shortly
before the test. Such time lapse is known as window period, which may last between 3 and 6
months. For such reason, fourth generation ELISA is recommended. Such test is able to de‐
tect simultaneously Ag p24 and its respective antibodies, and therefore it can shorten the
window period to approximately 30 days, with 99.9% sensitivity and 99.5% specificity. De‐
spite the latter, it is important to point that the positive predictive value of this test during
pregnancy is approximately 50%, because it is applied to a low prevalence population, and
therefore a confirmation test is mandatory (Western blot) [16].
Additionally, in pregnant women with unknown serology status and attending consultation
for labor or medical situations where pregnancy termination is imminent, services should




- Women depend economically, socially and emotionally on men and such situation makes
rejection of high-risk sexual intercourse difficult.
- Cultural norms encourage promiscuity among males, thus increasing transmission risk
among monogamous females.
- There is a lack of easy access to woman-controlled-preventive methods (female condoms).
Regarding the last point and aiming at identifying other prevention methods, recent studies
have demonstrated that the use of tenofovir gel might be a useful tool to prevent infection.
In fact, a South African study concluded that the pre and post-coital prophylactic use of
such microbicide among women aged between 18 and 40 reduced HIV infection in 39% and
HSV-2 infection in 51%. [19] On the other hand, circumcision in adults has proven to be ef‐
fective to prevent infection among seronegative males with an HIV+ partner. The latter has
led the UNAIDS and WHO to recommend such intervention in countries with high preva‐
lence [4]. Finally, there are also studies that propose the use of tenofovir prior to sexual in‐
tercourse in infected or high-risk couples. All these prophylactic measures should be
assessed with further adequately designed studies.
Probably due to such reasons and in light of the pooled data in developing and developed
countries, the proportion of HIV carrier women has increased as compared to that of men.
The cause is that the main transmission route is sex. The latter together with the impact of
viral transmission route in homo and heterosexual mode, have transformed heterosexual
monogamous women into the highest risk population. Moreover, there is a sustained in‐
crease of cases transmitted by sexual intercourse between men and women as compared to
those transmitted through homosexual intercourse. This has shifted the epidemics towards
population groups with a lower social-economic level and with a clear decrease of females
in higher school education levels [2, 3, 16,17].
Epidemiology studies suggest that the observed prevalence among women in childbearing
age is comparable to prevalence in pregnant women. On the other hand, pregnancy rates in
seropositive women that have not developed AIDS are comparable to those seen among un‐
infected women, while among women who developed the disease the probability of getting
pregnant is quite lower [13-15].
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tive results on such tests should be able to generate the recommendation of preventive
measures during the peripartum period, with prior patient informed consent [5,10].
The confirmation Western blot technique is carried out with a nitrocellulose strip to which
HIV shell proteins are added. Patient serum is applied on the strips: any antibody against
such virus present in serum will bind to its specific antigen. This generates a series of dark
bands. By comparing the band position with a control, it is possible to determine if the pa‐
tient’s blood contains HIV-specific antibodies [16].
On occasions, individuals with recent infection or in the process of structuring a complete
antibody response yield undetermined responses. In such cases, the test should be repeated
within one to two months.
PCR tests are sensitive and useful to confirm the infection status. They are able to detect
very small amounts of virus and they do not rely on an antibody response to infection. PCR
is used in clinical practice to establish the infection status on infants born to infected moth‐
ers and potentially within the window period between infection and presence of detectable
specific antibodies. PCR and other amplification techniques have been improved to quantify
HIV RNA. There is considerable interest on perfecting reliable tests to detect the virus in or‐
al fluids or urine, since they are easy to collect without causing either disturbance to the pa‐
tient or risks to the collector. Moreover, they can be especially helpful in children and adults
in whom vein access can be difficult [16].
Assessment of HIV infection status is complex in children under the age of 6 months be‐
cause of gestation and early lactation immunology. The most commonly used tests in adults
are based on the detection of IgG antibodies against the virus. During pregnancy, maternal
IgG crosses easily the placenta towards fetal circulation, where it remains until 18 months
after birth. For such reason, assessment of the HIV infection status in infants requires testing
other than ELISA and Western blot. The options are virus cultures and PCR, as well as de‐
tection of IgA antibodies directed against HIV [14,16].
8. HIV and Pregnancy
According to epidemiological studies, pregnancy rates among seropositive women that
have not presented AIDS are comparable to rates in uninfected women. The probability of
becoming pregnant is quite lower among women who develop AIDS. Despite of certain con‐
tradictory evidence, latest studies seem to confirm that pregnancy does not affect the course
or the complications of the disease [26].
As for the role played by the viral load or the immune condition of the pregnant woman,
there is evidence supporting a close relationship between high viral loads and higher VT
risk. However there is not a viral load warranting a virus-free neonate. Mother-to-child
transmission is possible despite viral levels being undetectable in the mother. On the other
hand, maternal CD4 concentrations < 700 cells/mm relate to a higher VT risk [27].
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Nevertheless, opportunistic infections (Pneumocystis jirovecii, Herpes Zoster, etc.) and
prevalent diseases such as tuberculosis and malaria are those with more aggressive course
in seropositive pregnant women and increase significantly maternal and perinatal morbidity
and mortality. [28]
Vertical transmission is one of the mostly studied transmission routes, thus it is possible to
share some conclusions regarding the moment of transmission to the fetus or newborn and
the factors that increase VT risk [14,16].
Moment of transmission to the product of conception:
- During pregnancy: up to 35%.
- During delivery: up to 65%.
- During lactation: up to 14%.
Obstetric factors that favor VT:
- Premature Rupture of Membranes of more than 4 hours.
- Premature delivery.
- Low Birth Weight (under 2,500 g).
- Ovular infection.
- Direct contact of the fetus with cervical and vaginal secretions and/or blood in the birth
canal.
Fortunately, the gravid status does not seem to have an impact on the course or the natural
history of HIV infection, since although a decrease in CD4+ T cell counts has been described
during pregnancy, they return to baseline values after delivery [17]. In the absence of com‐
plications such as drug addictions or chronic medical diseases, the incidence of obstetric
pathology does not increase; spontaneous abortion, intrauterine growth restriction, preterm
delivery and stillbirth are within the expected prevalence range. However, the risk of infec‐
tious complications increases among pregnant women with a significant impairment of the
immune system (CD4 < 300/dl) [18].
A seropositive gestating woman should be clinically addressed based on a multidisciplinary
and thorough assessment of her initial health status. The latter should include a full physical
examination, especially observing those signs that guide diagnosis towards an opportunistic
infectious pathology and assessing the current immune status. Upon indicating the thera‐
peutic and/or prophylactic antiretroviral treatment, a risk versus benefit assessment should
be carried out to evaluate the effectiveness of the pharmacological scheme and the eventual
teratogenic and toxic effects on mother and fetus.
The following laboratory tests might be performed in addition to the routine tests that
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- Hepatitis B surface antigen Hepatitis B core antigen for Hepatitis B virus.
- Serology for the detection of Syphilis (RPR or VDRL).
- Serology for Hepatitis C.
- PPD (skin test for tuberculosis).
- Serology for certain parasitoses depending on their geographic prevalence (Toxoplasma
gondii, Chagas disease, Malaria, etc.).
- Serology for cytomegalovirus.
- Culture for gonococcus, Chlamydia, Mycoplasma and Ureaplasma.
Immunological parameters:
- CD4+ T cell counts
- Viral load assessment (PCR).
Sequential detection of the viral load and CD4 counts are used to predict the risk of a rapid
disease progression in the pregnant woman and the eventual VT in such patient group.
However, as an intent to identify a more cost-effective test than the latter, the role of HIV
typification through sequential study of specific bands offered by the Western blot techni‐
que has been studied recently. Such preliminary studies demonstrated that the absence of
anti pol antibodies was associated with an acute infection. Although it is true that the lack of
anti gag p39 antibodies was related to a rapid disease progression and a higher probability
of infection of the newborn, such absence was not as statistically significant to predict a
higher risk for VT. Therefore, such diagnostic tool needs still to be upheld by further studies
before it becomes indicated for clinical use. [29]
All antenatal diagnostic assessments may be carried out without contradictions, except for
those involving invasive techniques that imply an additional infection risk to the fetus (cho‐
rionic villus biopsy, amniocentesis, cordocentesis).
9. Antiretroviral therapy during pregnancy
The aim of antiretroviral therapy during pregnancy is to decrease the maternal viral load to
undetectable levels without causing deleterious or teratogenic effects on the product of con‐
ception, and on the other hand, to decrease the risk of vertical transmission. To attain such
goal, there are currently 14 antiretroviral drugs available (Table 1). Such drugs must be used
within schemes individually adapted for each patient. Drug selection should be based on
the prior treatment of the woman (if she were under any), the current status of the patient
and her motivation, the viral load, drug resistance, CD4+ T cell counts, and associated toxic
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and teratogenic effects (Table 2). The use of Zidovudine is recommended within the scheme.
Zidovudine has been the only drug to enter a protocol and that has demonstrated efficacy in
the protection of the fetus from vertical transmission. However, new studies have demon‐
strated the efficacy of other antiretroviral drugs in VT reduction.
Generic name FDA Classs
Abacavir                   C
Didanosine (ddI)                   B
Lamivudine (3TC)                   C
Lamivudine + Zidovudine (Convivir)                   C
Stavudine (d4T Zalcitabine)                   C
Zidovudine (ZDZ, AZT)                   C
Non-nucleosidic reverse transcriptase Inhibitors
Delavirdine                   C
Efavirenz *                   X
Nevirapine                   C
Protease inhibitors
Amprenavir *                   X
Indinavir                   C
Nelfinavir                   X
Ritonavir                   B
Saquinavir                   B
Table 1. ANTIRETROVIRAL AGENTS,Nucleosidic reverse transcriptase inhibitors
A: Controlled studies show no risk
B: No evidence of risks in humans
C: Risks cannot be ruled out. However, a potential benefit might justify its use.
D: Positive evidence of risk.
X: Contraindicated in pregnancy.
Table 2. FDA Drug Category Rankings (Drugs and pregnancy)
10. Management Protocol in the Prevention of Vertical Transmission
(ACTG 076)
The first formalized intent in prevention of VT was that assessed by a joint study carried out
in France and the United States, attempting at the evaluation of a management protocol
(Clinical Group Protocol 076-ACTG 076) [11], consisting of a study and follow up of HIV+
pregnant women that had a gestational age between weeks 14 and 34, without antiretroviral
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The group that was administered placebo was compared to the group receiving AZT (orally
during pregnancy, injectable during delivery and as syrup to the newborn for 6 weeks). Re‐
sults showed that transmission was 8.3% with AZT and 25% with placebo, which is equiva‐
lent to a reduction in 67% (p= 0,00006). (Table 3)
Prepartum:
AZT between weeks 14 and 34:
AZT 100 mg po 5 times per day or
AZT 200 mg po 3 times per day or
AZT 300 mg po 2 times per day
Intrapartum:
AZT 2 mg/kg intravenous during one
hour,Followed by continuous infusion of 1 mg/kg
until delivery
Postpartum:
AZT to the neonate from 8 to 12 hours
after birth in 2 mg/kg doses (syrup) every 6
hours during the first 6 weeks of life
Table 3. ACTG 076 PROTOCOL
11. High Activity Antiretroviral (ART) Therapy (HAART)
The first attempt at a successful pharmacological scheme to control VT was achieved by the
ACTG 076 protocol. Such protocol together with elective C-section and suppression of lacta‐
tion (biomedical measures) achieved a decrease in VT from 29% to 5.6% [11]. Although the
latter is true, new evidence demonstrated that the triple drug therapy was more effective
than monotherapy or bitherapy to prevent Vertical Transmission (VT). A protocol, that com‐
bined the biomedical preventive measures already mentioned and the indication of three an‐
tiretroviral drugs was designed. Such drugs included nucleosidic and non-nucleosidic
reverse transcriptase inhibitors (NRTI and NNRTI respectively) and Protease inhibitors (PI),
and together formed a series of schemes known as highly active antiretroviral therapy
(HAART). It is by virtue of the latter that VT has decreased to values close to 1.0 [2-6, 30-34].
It is a known fact that VT may occur among seropositive pregnant women during pregnan‐
cy (35%), delivery (65%) and lactation (14%-29%) and that there are factors that increase the
risk of fetal infection (Primoinfection, Sexually transmitted diseases and CD4+ T cell counts).
The most important of such factors is maternal viral load [27]. Loads under 1000 copies/ml
have significantly lower risks of VT, however there is no evidence pointing to the minimal
load that exempts from risk. The latter supports the need to use a highly active antiretroviral
therapy (HAART) with the highest effectiveness and safety to reach, hopefully, undetectable
viral load levels. With such purpose, and considering that most of transmissions to the new‐
born occur during the peripartum period, an attempt at reaching the lowest viral loads dur‐
Current Perspectives in HIV Infection314
ing the third trimester of gestation (weeks 34-36) should be made. However, due to the
potential toxic effects of therapeutic drugs, it is suggested their use is limited to the periods
of maximum effectiveness considering risks and benefits of such exposure to the mother-
child binomial. Anyway, AZT should be added to the therapeutic scheme if possible, even
in cases in which such drug was not used during the antepartum period, since it has proven
to be helpful to decrease vertical transmission even in abbreviated schemes (intrapartum
and postpartum) [4,5,34].
Based on the above-mentioned, HAART type ART should be indicated in the following sit‐
uations: [34]
1. In seropositive pregnant women without prior treatment from week 24
2. In pregnant women with viral loads higher than 100,000 copies/ml from 14 weeks
3. In case of seroconversion during pregnancy it should be indicated at once
Within the HAART concept, the selection of the NRTI combination to be used should follow
the efficacy of the latter in reducing VT, considering the potential teratogenic effects and the
eventual toxicity to the mother-child binomial. Based on the teratogenesis risk classification
of the FDA, NRTI are classed as B or C. The largest experience involves Zidovudine (AZT or
ZDV) that has demonstrated being quite a safe drug, with low resistance and high efficacy to
prevent VT. In addition, the association of ZDV and Lamivudine (ZDV/3TC) has demonstrat‐
ed to be more effective than ZDV as monotherapy in mother-to-child transmission preven‐
tion. Such combination does not imply higher toxicity or risk of teratogenesis [2-6, 30-34].
Regarding the search for the third drug, Lopinavir-Ritonavir has demonstrated efficacy and
safety in VT prevention. The association of Saquinavir reinforced with Ritonavir has gath‐
ered enough evidence to suggest that such combination is a good supplementary alternative
to render the pharmacological therapy more effective [26].
Although Nevirapine (NVP) has been widely indicated and has demonstrated being effec‐
tive in the prevention of mother-to-child transmission mostly in developing countries with
low economical resources, the use of such drug has been related to the development of viral
resistance both in mothers as in children who were infected despite the received prophylax‐
is. Moreover, mothers who were administered Nevirapine had a higher incidence of toxic
effects (hepatic, hypersensitivity) in particular pregnant women with CD4+ T cell counts
higher than 250 cells/ml. The above mentioned suggests that such indication should be con‐
sidered among patients never having received Nevirapine and with CD4+ T cell counts un‐
der 250 cells/ml. When such drug is used in the intrapartum period, it is advisable to
indicate ZDV y Lamivudine (3TC) for 7 days both to the mother as well as to the newborn,
to reduce the risk of viral resistance to Nevirapine and other NNTRI [30-34].
The following are among the drugs that should not be indicated during pregnancy: Efavir‐
enz, Nelfinavir and the association of d4T (Stavudine) and ddI (Didanosine). All share tera‐
togenicity and toxicity risk for the mother-child binomial [30-36].
In 2010 the World Health Organization stressed the importance of offering a lifelong antire‐
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ing the third trimester of gestation (weeks 34-36) should be made. However, due to the
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WHO proposed two prophylactic treatment schemes (A and B) for pregnant women who
did not meet the criterion of a certain CD4+ T cell count (<350/ mm3). A third option (B+) as
appeared recently, aiming at implementing the HAART for a lifetime to all seropositive
pregnant women regardless of their CD4+ T cell count (Table 4). This new option has the
following advantages: it simplifies drug supply, since it relates drugs to national antiretrovi‐
ral therapy programs, protects against VT, prevents transmission to seronegative partners
and prevents discontinuation of the follow up of therapies already implemented by the pa‐
tients. It finally suggests that such new option should be evaluated depending on the reality
of each country [31].
Woman Receives:
Treatment Prophylaxis Infant receives:
(for CD4 count
≤  350 cells/mm3 )
(for CD4 count
> 350 cells/ mm3)
Option Aa Triple ARVs starting as soon as
diagnosed, continued for life
Antepartum: AZT starting as early
as 14 weeks gestation
Intrapartum: at onset of labour,
single-dose NVP and first dose of
AZT/3TC
Postpartum: daily AZT/3TC
through 7 days postpartum
Daily NVP from birth until 1
week after cessation of all
breastfeeding; or, if not
breastfeeding or if mother is
on treatment, through age
4–6 weeks
Option Ba Same initial ARVs for bothb:
Triple ARVs starting as soon as
diagnosed, continued for life
Same initial ARVs for bothb:
Triple ARVs starting as early as 14
weeks gestation and continued
intrapartum and through
childbirth if not breastfeeding or
until 1 week after cessation of all
breastfeeding
Daily NVP or AZT from birth
through age 4–6 weeks
regardless of infant feeding
method
Option B+ Same for treatment and
prophylaxisb:
Regardless of CD4 count, triple
ARVs starting as soon as
diagnosed,c continued for life
Same for treatment and
prophylaxisb:
Regardless of CD4 count, triple
ARVs starting as soon as
diagnosed,c continued for life
Daily NVP or AZT from birth
through age 4–6 weeks
regardless of infant feeding
method
Table 4. Note: “Triple ARVs” refers to the use of one of the recommended 3-drug fully suppressive treatment options.
For the drug abbreviations in the table: AZT (azidothymidine, zidovudine [ZDV]); NVP (nevirapine); 3TC (lamivudine).a
Recommended in WHO 2010 PMTCT guidelines b True only for EFV-based first-line ART; NVP-based ART not
recommended for prophylaxis (CD4 >350) c Formal recommendations for Option B+ have not been made, but
presumably ART would start at diagnosis. Options for PMTCT programs
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11.1. Toxic and Side effects of ART
The eventual toxic effect of such medications on the mother-child binomial is among the as‐
pects that need to be assessed for the election of the pharmacological treatment. According
to study reports, approximately 80% of gestating women under treatment developed some
side effect such as anemia, nausea, vomiting, hepatic enzyme disorders or hyperglycemia
[26,35-37]. Because of this, it is important to know which are the side and toxic effects of the
drugs that are commonly used, in order to identify them and treat them accordingly.
11.2. Protease inhibitors and hyperglycemia
In non-pregnant women, the use of protease inhibitors has been related to the development
of different degrees of carbohydrate Intolerance. This should be considered when they are
used during pregnancy since they may trigger gestational diabetes [26,35-37].
11.3. Mitochondrial toxicity and nucleosidic reverse transcriptase inhibitors
Reverse transcriptase nucleoside inhibitors are recognized for their induction of mitochon‐
drial dysfunction due to their affinity for mitochondrial DNA-polymerase gamma. Such ef‐
fect is more intense for Stavudine (d4T), ddI (Didanosine) and less intense for ZDV
(Zidovudine), 3TC (Lamivudine), ABC (Abacavir) and TDF (Tenofir). Additionally, these
drugs are also related to lactic acidosis in cases with concomitant hepatic steatosis. Such as‐
sociation would be higher with the use of d4T (Stavudine) with an estimated rate of 0,8%
and 1,2% per year per treated patient. [26, 35-37]. Clinical manifestations of this condition
are varied and include polyneuritis, myopathies, cardiopathies, hepatic steatosis and lactic
acidosis. Not uncommonly patients develop a condition similar to the HELLP Syndrome
that should be considered when addressing differential diagnoses. Finally, there are reports
about uninfected children, born to seropositive mothers that received ZDV or ZDV/Lamivu‐
dine (ZDV/3TC) during pregnancy, who developed mitochondrial dysfunction –related
symptoms during the first months of life. Such finding was not confirmed with the protocol
assessment ACTG 076 [11].
Regarding the mode of delivery in seropositive pregnant women who did not receive ART
or had partial indication of ART, elective C-section at week 38 (a surgical procedure carried
out before the initiation of labor and without premature rupture of membranes) has demon‐
strated a decrease of VT risk in one half. [8,38]. Recent studies propose the option of vaginal
delivery to be used according to the obstetric conditions in seropositive women with viral
load under 1000 copies/ml and prior patient consent. Such indication is supported by the
fact that C-section benefits are indeed difficult to evaluate and moreover, data retrieved
from a large number of patients did not evidence a higher reduction of VT among patients
with viral loads < 1000 copies/ml that underwent C-section. Furthermore, C-section in‐
creased infectious morbidity between 7 and 10 fold [33].
When facing the vaginal delivery option, episiorrhaphy and forceps or spatulas should be
avoided. Invasive procedures such as amniocentesis, chorionic villus biopsy and invasive
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be avoided. The use of oxytocin has no contraindications, as opposed to ergot-derivatives
that might present an eventual synergic action in association to Protease Inhibitors that
would exaggerate vasoconstriction and ischemia, and therefore are contraindicated [39].
During delivery (C-section or vaginal delivery), the indication of intravenous administration
of ZDV to the mother should be the rule, since fetal plasma levels of such drug, reached by
transplacental route, ensure an adequate pre-exposition prophylaxis. Such indication togeth‐
er with the administration of ZDV suspension orally to the newborn during six weeks in‐
creases the preventive effect on infection transmission. This is regardless of the mother
being administered ZDV within the therapeutic scheme or even in the event of resistance to
ZDV. Finally, the use of Nevirapine (200 mg one time only dose) should only be indicated to
patients with late initiation of the prevention protocol, on patients with a viral load > 1000
copies/ml or in the case of diagnosis of maternal carrier status during labor [4,5,33,34].
There is evidence pointing that among patients that are not treated within an antiretroviral
management protocol, transmission to the newborn through breastfeeding ranges between
5% and 14% [9,40]. Free and cell-bound virus has been isolated from breast milk through
PCR techniques and viral culture. Such cells are more numerous in the colostrum and in
breast milk secreted during the immediate puerperium. The latter, in association with the
immature immune system of the newborn, make transmission through breastfeeding higher
during the first month of life. All the above-mentioned, warrant the recommendation to sup‐
press lactation in countries where infantile malnutrition and diarrheic syndrome - related
mortality are low [34].
12. Summary of Mother-to-child Prevention Management
1. Every pregnant woman should be offered the possibility of undergoing HIV testing not
later than upon the second pregnancy follow-up visit within the first trimester of gesta‐
tion, and depending on resources, also within the third trimester.
2. A quick HIV test for HIV diagnosis enabling immediate action to be taken should be
offered to women who arrive to delivery without having their test results available,
even if tests have been carried out. Counseling and consent are mandatory.
3. ART is recommended to prevent HIV vertical transmission in pregnant women without
prior therapy between gestation weeks 20 and 28. The use of ZDV in association with
Lamivudine is recommended.
4. Viral loads should be followed up 6 weeks after initiation of ART during gestation and
subsequently on a monthly basis until gestation weeks 34 and 36.
5. Elective C-section should be indicated at 39 weeks in HIV+ women without ART over
pregnancy, in women that do not have a viral load result upon weeks 34-36, in those
with a viral load > 1.000 copies/ ml or in women co-infected with Hepatitis C virus.
6. In the event a pregnant woman meets the conditions for a vaginal delivery, her con‐
sent should be obtained after being informed about the eventual associated risks. Epis‐
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iorrhaphy  and  all  procedures  involving  the  use  of  instruments  should  be  avoided
(forceps or spatulas).
7. Intrapartum intravenous ZDV should be used regardless of the delivery mode chosen.
8. ZDV suspension should be administered orally for 6 weeks starting from 8 to 12 hours
from birth, to all newborns to HIV+ mothers. The recommended ZDV dose for term
newborns is 2 mg/Kg/dose every 6 hours p.o. or 1.5 mg/Kg/dose every 6 hours intrave‐
nous. The same dose should be administered every 12 hours in preterm newborns of
less than 35 weeks gestational age.
9. If Nevirapine is administered intrapartum, ZDV/3TC must be associated for 7 days after
delivery to reduce the risk of developing NVP resistance.
10. Lactation should be suppressed with cabergoline or bromocriptin.
11. The newborn should be administered ZDV suspension, orally, for 6 weeks starting from
8 to 12 hours after birth. The recommended AZT dose for term newborns is 2 mg/ Kg/
dose every 6 hours orally or 1.5 mg/Kg/dose every 6 hours intravenous. The same dose
should be administered every 12 hours in preterm newborns of less than 35 weeks gestation.
12. Newborns to mothers who received NVP as part of mother-to-child transmission pre‐
vention should receive, besides ZDV, 2 doses of 2 mg/Kg of NVP oral solution. The first
dose should be administered the earliest as possible postpartum and the second should
be administered at 48 to 72 hours of life.
13. The newborns to mothers who did not receive the mother-to-child transmission preven‐
tion protocol, or who just received intrapartum prophylaxis, should be administered
the AZT scheme and 1 to 2 NVP doses.
13. Conclusion
A seropositive gestating woman should be clinically addressed based on a multidisciplinary
and thorough assessment of her initial health status. The latter should include a full physical
examination, especially observing those signs that guide diagnosis towards an opportunistic
infectious pathology and assessing the current immune status.Once the effectiveness of bio‐
medical healthcare provisions for the prevention of MTCT (mother-to-child-transmission) is
demonstrated, it is important to ensure collection of epidemiological history in order to ach‐
ieve an adequate report, key data to reassess the design and the effectiveness of preventive
programs. To achieve such aims, it is critical to maintain and improve diagnosis and pri‐
mary prevention of the infection among women in childbearing age. ON the other hand, it is
important to prevent high rates of unwanted pregnancies and abortions that are direct indi‐
cators of risk behaviors in such population group. Likewise, one should aim at achieving
100% screening during the first trimester, also at the possibility of repeating it during the
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during labor, for those pregnant women without having accessed an AMTCPP (Antenatal
Mother-to-Child Prevention Program).
Finally, MTCT prevention strategy has been based on the ongoing revision of the pooled
evidence, therefore it is of key importance to continue evaluating new conducts that enable
identification of other aspects: the eventual induction of antiviral resistance and toxicity on
the pregnant woman and the newborn and their potential impacts on further quality of life,
the use of micronutrients and their impact on MTCT decrease, assessment of the vaginal de‐
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1. Introduction
The human immunodeficiency Virus (HIV) pandemic is one of the most serious health crisis
faced by the world today. An estimated 34 million people were living with HIV/AIDS as at
2010 [1]. A disproportionate burden has been placed on women and children who continue
to experience high rates of new infection and HIV-related illness and death. Availability and
use of antiretroviral drugs has changed the landscape of HIV/AIDS bringing about a change
in the perception of HIV from an incurable deadly disease to a chronic manageable illness.
As effective HIV treatments become more widespread, HIV-infected individuals in sub Sa‐
haran Africa are living longer, healthier lives. Many HIV-affected couples (sero-discordant
and sero-concordant) are now considering long-term life projects including options for safer
reproduction or procreation. There has also been increase in advocacy to expand the capaci‐
ty for the health care system particularly in Africa to provide the sexual and reproductive
health services that HIV infected persons in Africa desperately need [2]. This decade has
witnessed greater commitment to sexual and reproductive health and HIV linkages particu‐
larly in the developed world. More recent opportunities include policy developments within
the Global Fund to Fight AIDS, Tuberculosis and Malaria to accept proposals that form link‐
ages with sexual and reproductive health within the overall frameworks of HIV, tuberculo‐
sis (TB) and malaria. There has also been a renewed commitment by the United States of
America to international sexual and reproductive health through support of the United Na‐
tions Population Fund and the repeal of the Mexico City Policy, also known as the “global
gag rule”, a United States government policy that hitherto prohibited non-governmental or‐
ganizations from receiving federal funding for performing or promoting abortion services in
other countries. A large body of evidence suggests that reproductive technologies can help
HIV-affected couples to safely conceive with minimal risk of HIV transmission to their part‐
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ner and baby. However, for most couples particularly in low income countries in sub Sahar‐
an Africa, such technologies are neither geographically nor economically accessible. In sub-
Saharan Africa where HIV is endemic, 63% of women have an unmet need for sexual and
reproductive health services, there is a high incidence of unintended pregnancies, a signifi‐
cant number of women do not know their HIV status, many women have limited access to
sexual and reproductive health information and services (family planning, management of
sexually transmitted diseases, HIV prevention and maternal health) to help them protect
themselves from the triad of unwanted pregnancy, HIV infection and HIV transmission to
their sexual partners and their children. With HIV now considered to be a chronic managea‐
ble disease, attention is shifting to offering and improving quality of life particularly by the
provision of reproductive health options/care to men and women living with HIV-1.
A healthcare workforce that is highly motivated and well informed on the evidence –based
practices in sexual and reproductive health options for persons living with HIV/AIDS is cru‐
cial to meeting the sexual and reproductive needs of PLWHA in Africa. A high morale and
productive workforce are the driving force for the success of any reproductive health pro‐
gramme. Unless these staffs are motivated and have high morale, they may become a stum‐
bling block to the success and scaling –up of sexual and reproductive health services [3].
There are several challenges associated with meeting the sexual and reproductive health
needs of persons living with HIV/AIDS in Africa; suboptimal antenatal care, absence of evi‐
dence-based and affordable assisted reproductive technologies, inadequate number of ap‐
propriately trained healthcare workers, suboptimal health infrastructure, lack of enabling
legislation and policies on sexual and reproductive health of HIV-infected persons, chal‐
lenge of stigmatization and discrimination, unprofessional negative attitudes towards
PLWHA desiring to procreate. The aim of this chapter is to highlight the reproductive health
concerns associated with living with HIV infection in sub Saharan Africa.
2. History of Africa
Africa is the world's second-largest and second-most-populous continent in the planet, af‐
ter Asia. With 1,032,532,874 billion people as at 2011 [4]. It accounts for about 14.72% of
the world's human population. At about 30.2 million km² (11.7 million sq miles) includ‐
ing adjacent islands, it covers 6% of the Earths’ total surface area and 20.4% of the total
land area [5]. It is made up of 54 member states. Western Sahara although a member of
the  African  union,  its  sovereignty  is  being  disputed  by  Morocco.  South  Sudan  has  be‐
come Africa newest nation having recently separated from North Sudan. The population
of Africa is estimated at greater than one billion people.  Africa account for a significant
14% of the world’s population. Africa contains the Nile River system which is the worlds
longest. It also prides itself as the continent with the world’s largest Sahara desert. Africa
is  surrounded  by  the  Mediterranean  Sea  (north)  and  the  Suez  Canal  and  the  Red  sea
(northwest),  the  Indian Ocean (east)  and the  Atlantic  Ocean (west).  Although endowed
with abundant natural resources,  Africa remains the world's poorest and most underde‐
veloped continent, the result of a variety of causes that may include the spread of deadly
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viruses and diseases (HIV/AIDS, malaria and tuberculosis), corruption in government that
have often committed serious human right abuses and violations, failed central planning,
high levels of illiteracy, lack of access to foreign capital, and frequent tribal and military
conflict  (ranging  from guerrilla  warfare  to  genocide).  According to  the  United  Nation’s
Human Development Report in 2003, the bottom 25 ranked nations (151st to 175th) were
all  African [6].Poverty,  illiteracy,  malnutrition  and inadequate  water  supply  and sanita‐
tion, as well as poor health, affect a large proportion of the people who reside in the Afri‐
can continent. About 80.5% of the Sub-Saharan Africa population lives on less than $2.50
per person per day in 2005 [7].  Africa faces several daunting challenges with regards to
access to basic health services like their counterparts in most developed countries of the
world. The healthcare system and infrastructure are suboptimal. This is often due to fun‐
damental limitations in funding, lack of adequate qualified health professional and equip‐
ment as well as deep rooted, institutionalized and chronic corruption among the political
class  and bureaucratic  compensation and corruption among civil  servants  [8].  Africa re‐
mains the world's most corrupt continent. Corruption is the abuse of entrusted power for
private gain, in public and private sectors [9]. This vice has contributed to a large extent
to the stunted development and impoverishment seen in many African states.  The Afri‐
can  union  estimates  that  corruption  among  the  political  class  is  costing  the  continent
more than $150 billion dollars per year.  These are funds that could be used to improve
the health infrastructure and quality of life of people of people in the continent but rather
are laundered out of developing countries to banks in the developed world thus perpe‐
trating poverty among African people. Industrialized countries have continued to encour‐
age  corruption  in  Africa  and  perpetuation  of  poverty  among  people  in  the  African
continent by providing crooked African leaders with a safe haven for their looted funds
rather than repatriating such funds back and ensuring that they are used to enhance the
infrastructural  development  of  the  continent.  Corruption  is  endemic  and  continues  to
thrive  in  the  African  continent  for  several  reasons;  institutional  weakness  and  criminal
collaboration between the executive and the legislative and judicial arms of government,
non-existence of the principle of rule of law, political god fatherism, institutional failure
and criminal collaboration between civil servants and politicians. Corruption is a canker‐
worm that continues to weaken societies, ruins lives, and impedes development in the Af‐
rican  continent  [10].  This  is  further  compounded  by  the  high  incidence  of  infectious
diseases (HIV, TB and Malaria).  Africa is plagued by poverty, malnutrition, poor sanita‐
tion, disease, high mortality rate, conflict, wars and crime. These challenges have a signif‐
icant  negative  effect  on  life  expectance  in  the  continent.  The  continent  has  the  world’s
shortest life expectancy. Citizens of Sub-Saharan African countries are much more likely
to die prematurely, than people in wealthier parts of the world. Children under- the age
of 5 years are more likely to die from malaria, respiratory tract infections, diarrhoea, peri‐
natal conditions, measles and HIV/AIDS while those who survive the first 5 years of life
are  likely  to  die  before  their  60th  birthday  from  HIV/AIDS,  tuberculosis,  and  maternal
mortality  (for  women as  a  result  of  pregnancy-related mortality).  According to  the CIA
World Fact  book 2009  [11],  the  life  expectancy at  birth  of  the  world  is  67.2  years  (65.0
years for males and 69.5 years for females). The United Nations World Population Pros‐
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concerns associated with living with HIV infection in sub Saharan Africa.
2. History of Africa
Africa is the world's second-largest and second-most-populous continent in the planet, af‐
ter Asia. With 1,032,532,874 billion people as at 2011 [4]. It accounts for about 14.72% of
the world's human population. At about 30.2 million km² (11.7 million sq miles) includ‐
ing adjacent islands, it covers 6% of the Earths’ total surface area and 20.4% of the total
land area [5]. It is made up of 54 member states. Western Sahara although a member of
the  African  union,  its  sovereignty  is  being  disputed  by  Morocco.  South  Sudan  has  be‐
come Africa newest nation having recently separated from North Sudan. The population
of Africa is estimated at greater than one billion people.  Africa account for a significant
14% of the world’s population. Africa contains the Nile River system which is the worlds
longest. It also prides itself as the continent with the world’s largest Sahara desert. Africa
is  surrounded  by  the  Mediterranean  Sea  (north)  and  the  Suez  Canal  and  the  Red  sea
(northwest),  the  Indian Ocean (east)  and the  Atlantic  Ocean (west).  Although endowed
with abundant natural resources,  Africa remains the world's poorest and most underde‐
veloped continent, the result of a variety of causes that may include the spread of deadly
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viruses and diseases (HIV/AIDS, malaria and tuberculosis), corruption in government that
have often committed serious human right abuses and violations, failed central planning,
high levels of illiteracy, lack of access to foreign capital, and frequent tribal and military
conflict  (ranging  from guerrilla  warfare  to  genocide).  According to  the  United  Nation’s
Human Development Report in 2003, the bottom 25 ranked nations (151st to 175th) were
all  African [6].Poverty,  illiteracy,  malnutrition  and inadequate  water  supply  and sanita‐
tion, as well as poor health, affect a large proportion of the people who reside in the Afri‐
can continent. About 80.5% of the Sub-Saharan Africa population lives on less than $2.50
per person per day in 2005 [7].  Africa faces several daunting challenges with regards to
access to basic health services like their counterparts in most developed countries of the
world. The healthcare system and infrastructure are suboptimal. This is often due to fun‐
damental limitations in funding, lack of adequate qualified health professional and equip‐
ment as well as deep rooted, institutionalized and chronic corruption among the political
class  and bureaucratic  compensation and corruption among civil  servants  [8].  Africa re‐
mains the world's most corrupt continent. Corruption is the abuse of entrusted power for
private gain, in public and private sectors [9]. This vice has contributed to a large extent
to the stunted development and impoverishment seen in many African states.  The Afri‐
can  union  estimates  that  corruption  among  the  political  class  is  costing  the  continent
more than $150 billion dollars per year.  These are funds that could be used to improve
the health infrastructure and quality of life of people of people in the continent but rather
are laundered out of developing countries to banks in the developed world thus perpe‐
trating poverty among African people. Industrialized countries have continued to encour‐
age  corruption  in  Africa  and  perpetuation  of  poverty  among  people  in  the  African
continent by providing crooked African leaders with a safe haven for their looted funds
rather than repatriating such funds back and ensuring that they are used to enhance the
infrastructural  development  of  the  continent.  Corruption  is  endemic  and  continues  to
thrive  in  the  African  continent  for  several  reasons;  institutional  weakness  and  criminal
collaboration between the executive and the legislative and judicial arms of government,
non-existence of the principle of rule of law, political god fatherism, institutional failure
and criminal collaboration between civil servants and politicians. Corruption is a canker‐
worm that continues to weaken societies, ruins lives, and impedes development in the Af‐
rican  continent  [10].  This  is  further  compounded  by  the  high  incidence  of  infectious
diseases (HIV, TB and Malaria).  Africa is plagued by poverty, malnutrition, poor sanita‐
tion, disease, high mortality rate, conflict, wars and crime. These challenges have a signif‐
icant  negative  effect  on  life  expectance  in  the  continent.  The  continent  has  the  world’s
shortest life expectancy. Citizens of Sub-Saharan African countries are much more likely
to die prematurely, than people in wealthier parts of the world. Children under- the age
of 5 years are more likely to die from malaria, respiratory tract infections, diarrhoea, peri‐
natal conditions, measles and HIV/AIDS while those who survive the first 5 years of life
are  likely  to  die  before  their  60th  birthday  from  HIV/AIDS,  tuberculosis,  and  maternal
mortality  (for  women as  a  result  of  pregnancy-related mortality).  According to  the CIA
World Fact  book 2009  [11],  the  life  expectancy at  birth  of  the  world  is  67.2  years  (65.0
years for males and 69.5 years for females). The United Nations World Population Pros‐
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pects 2006 Revision put the world’s life expectancy at birth at 66.57 years (64.52 years for
males and 68.76 years for females).Women on the average are found to live longer than
men with the exception of Zimbabwe, Afghanistan, Swaziland and Lesotho [12].Countries
in  Africa  particularly  those  with  a  high HIV/AIDS prevalence  have must  lower  life  ex‐
pectancies [11]. Provision of low technology, safer, affordable and readily available repro‐
ductive  health  options  particularly  for  PLWHA  in  Africa  is  a  crucial  but  often
unaddressed  component  of  HIV  prevention  programme.  The  aim  of  this  chapter  is  to
evaluate the sexual  and reproductive health challenges associated with HIV infection in
sub Saharan Africa.
Figure 1.
3. Challenge of suboptimal antenatal services in Africa
Organized preventive screening programmes for antenatal care were first introduced in
Western Europe in the twentieth century with the hope that routine antenatal care would
contribute to a reduction in maternal and infant mortality rates. Figures on maternal mortal‐
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ity in the developed world show that the risk of death as a result of pregnancy and child
birth is approximately 1 in 7000 compared to 1 in 23 for women living in many parts of Afri‐
ca where antenatal care is poor or non-existent [13]. Antenatal care is an opportunity to
reach the mothers and young girls in a safe non-stigmatising environment. The importance
of developing links between sexual and reproductive health and HIV services is widely rec‐
ognized. Four priority areas for linkages has been identified– learning about one’s HIV sta‐
tus, promoting safer sex, optimizing links between HIV and sexually transmitted infection
services and integrating HIV with maternal and infant health. These priorities could lead to
significant public health benefits and improve efficient use of resources particularly in re‐
source –constrained settings in Africa. There are many challenges and issues that affect re‐
productive health choices particularly for persons living with HIV in Africa. They include;
paucity of evidenced-based information regarding safe pregnancy and Prevention of Mother
To Child Transmission (PMTCT) of HIV, absence of universal access to Voluntary Counsel‐
ling and Testing (VCT) services, negative attitudes by society and un-informed healthcare
workers towards PLWHA desiring to have children, lack of universal access to condoms,
contraceptives medications and Highly Active Antiretroviral Therapy (HAART), sup-opti‐
mal levels of skilled sexual and reproductive health staffs, lack of service infrastructures and
absence of legislation on the reproductive health right of PLWHA. All these factors nega‐
tively affects and complicates the ability of PLWHA to make evidenced based reproductive
health choices particularly in many sub Saharan African settings.
Antenatal care creates an opportunity for women to access HIV testing and counselling. It is
the port of entry to accessing HIV prevention and care. In 2001, CDC modified the recom‐
mendations for pregnant women to emphasize HIV screening as a routine part of prenatal
care, simplification of the testing process so that pre-test counselling would not pose a barri‐
er, and flexibility of the consent process to allow multiple types of informed consent
[14].Many pregnant women particularly in Africa do not know their HIV serostatus. Many
particularly those in rural settings lack adequate information on the benefit of antenatal care
for themselves and their babies. High level of illiteracy, inequalities in access to healthcare
services, being pregnant at an early age, women dependence economically on men, limited
mobility, poverty, religious and cultural restrictions, being a member of a marginalized
community or population remains major barriers or stumbling blocks that militate against
access to effective antenatal particularly in resource-constrained settings in sub Saharan Af‐
rica [15]. Women all over the world will most likely accept VCT services if it is offered espe‐
cially in settings where there is universal access to HAART and evidenced-based effective
sexual and reproductive services rendered by staff who are appropriately trained to render
the best possible evidenced-based counselling about HIV and other STIs as well as afforda‐
ble and readily available reproductive health options with empathy rather than being judge‐
mental. Humiliating and stigmatising attitudes and breaches of confidentiality of antenatal
women can create a barrier that can potentially prevent women from accessing sexual and
reproductive health services even when they are available.
There are several ways to possibly enhance the uptake of VCT services in Africa. They in‐
clude approaches such as the “opt-out” approach, use of traditional voluntary counselling
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ca where antenatal care is poor or non-existent [13]. Antenatal care is an opportunity to
reach the mothers and young girls in a safe non-stigmatising environment. The importance
of developing links between sexual and reproductive health and HIV services is widely rec‐
ognized. Four priority areas for linkages has been identified– learning about one’s HIV sta‐
tus, promoting safer sex, optimizing links between HIV and sexually transmitted infection
services and integrating HIV with maternal and infant health. These priorities could lead to
significant public health benefits and improve efficient use of resources particularly in re‐
source –constrained settings in Africa. There are many challenges and issues that affect re‐
productive health choices particularly for persons living with HIV in Africa. They include;
paucity of evidenced-based information regarding safe pregnancy and Prevention of Mother
To Child Transmission (PMTCT) of HIV, absence of universal access to Voluntary Counsel‐
ling and Testing (VCT) services, negative attitudes by society and un-informed healthcare
workers towards PLWHA desiring to have children, lack of universal access to condoms,
contraceptives medications and Highly Active Antiretroviral Therapy (HAART), sup-opti‐
mal levels of skilled sexual and reproductive health staffs, lack of service infrastructures and
absence of legislation on the reproductive health right of PLWHA. All these factors nega‐
tively affects and complicates the ability of PLWHA to make evidenced based reproductive
health choices particularly in many sub Saharan African settings.
Antenatal care creates an opportunity for women to access HIV testing and counselling. It is
the port of entry to accessing HIV prevention and care. In 2001, CDC modified the recom‐
mendations for pregnant women to emphasize HIV screening as a routine part of prenatal
care, simplification of the testing process so that pre-test counselling would not pose a barri‐
er, and flexibility of the consent process to allow multiple types of informed consent
[14].Many pregnant women particularly in Africa do not know their HIV serostatus. Many
particularly those in rural settings lack adequate information on the benefit of antenatal care
for themselves and their babies. High level of illiteracy, inequalities in access to healthcare
services, being pregnant at an early age, women dependence economically on men, limited
mobility, poverty, religious and cultural restrictions, being a member of a marginalized
community or population remains major barriers or stumbling blocks that militate against
access to effective antenatal particularly in resource-constrained settings in sub Saharan Af‐
rica [15]. Women all over the world will most likely accept VCT services if it is offered espe‐
cially in settings where there is universal access to HAART and evidenced-based effective
sexual and reproductive services rendered by staff who are appropriately trained to render
the best possible evidenced-based counselling about HIV and other STIs as well as afforda‐
ble and readily available reproductive health options with empathy rather than being judge‐
mental. Humiliating and stigmatising attitudes and breaches of confidentiality of antenatal
women can create a barrier that can potentially prevent women from accessing sexual and
reproductive health services even when they are available.
There are several ways to possibly enhance the uptake of VCT services in Africa. They in‐
clude approaches such as the “opt-out” approach, use of traditional voluntary counselling
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and testing strategies as well as making antenatal visit as interactive and activity based.
These approaches are more likely to provide the much needed coverage [16]. There has been
argument as to whether the “opt-out” approach negates the principle of informed consent
[17] particularly in African settings where many antenatal women are reluctant to challenge
health care procedures. It is important however to note that “opt-out” approach does not in
any way compromise the principle of informed consent. This approach assumes that testing
is an intrinsic part of an effective and holistic antenatal care. The women are informed about
what test is required as well as the importance of testing to the mother and the developing
baby with an opportunity given to women to refuse testing if they so desire.
There is also the need to foster more male involvement in antenatal care in Africa. Evidence
has shown that involving men in the reproductive health care of their partners rather than
basing antenatal care exclusively on women can potentially enhance the pregnancy experi‐
ence, reduces incidence of gender-based violence, promote the likelihood of getting a joint
consent, facilitate HIV prevention, compliance to HAART in partner in which it is indicated
as well as enables a holistic uptake of sexual and reproductive health service for couples.
There are several challenges that militate against male-gender involvement in antenatal care
particularly in Africa; cultural and religious beliefs, obstacles of working fathers, prevalence
of polygamy and maintenance by men of multiple sex partners [18-19].
When HIV infection is diagnosed, health-care providers should strongly encourage patients
to disclose their HIV status to their spouses, current sex partners, and previous sex partners
and recommend that these partners be tested for HIV infection. Health departments can as‐
sist patients by notifying, counselling, and providing HIV testing for partners without dis‐
closing the patient's identity [20]. Policy allowing providers to inform patients who receive a
new diagnosis of HIV infection that they might be contacted by health department staff for a
voluntary interview to discuss notification of their partners may play a beneficial role and
facilitate uptake of sexual and reproductive health services in Africa. A disproportionate
burden has been placed on women and children who continue to experience high rate of
new HIV infection and HIV-related illness and death. Most children living with HIV acquire
the infection through Mother to Child Transmission (MTCT) which can occur during preg‐
nancy, during delivery or during breastfeeding.
3.1. A strong cultural and religious attachment to having children puts PLWHA under
pressure to procreate
Being HIV positive has been shown to modify but not remove the reproductive desires of
individuals. Diversity existed in reproductive intentions among PLWHA. Some HIV posi‐
tive individuals wished to avoid pregnancy. Fears of partner and infant infection and hav‐
ing a previously infected baby were important factors deterring some individuals from
considering having children. There is also strongly perceived community disapproval asso‐
ciated with HIV and reproduction. Strong desires to experience parenthood, mediated by
prevailing social and cultural norms that encouraged childbearing in society have also been
reported. Motherhood is seen as an important component of married women's identity and
important for women's social status in Africa. Family, husbands and societal expectations
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for childbearing have significant influences on the African woman's reproductive intentions
[21]. Availability and use of antiretroviral drugs has changed the landscape of HIV/AIDS
bringing about a change in the perception of HIV from an incurable deadly disease to a
chronic manageable illness. As effective HIV treatments become more widespread, HIV-in‐
fected individuals are living longer, healthier lives. Many HIV-affected couples (sero-dis‐
cordant and sero-concordant) are considering options for safer reproduction. A large body
of evidence suggests that reproductive technologies can help HIV-affected couples to safely
conceive with minimal risk of HIV transmission to their partner and baby. However, for
most couples particularly in low income countries in sub Saharan Africa, such technologies
are neither geographically nor economically accessible. With HIV now considered to be a
chronic manageable disease, attention is shifting to offering and improving quality of life
particularly by the provision of reproductive health options/care to men and women living
with HIV-1. Many HIV-infected men and women are now expressing their desire to father
or mother a child. Assisted reproductive technologies, including intrauterine insemination
(IUI), in vitro fertilisation (IVF) and intracytoplasmatic sperm injection (ICSI) in combination
with semen washing have been used to decrease the risk of HIV -1 transmission in HIV-1-
infected discordant couples with an HIV-1-infected man. Previous report indicates that in
HIV-positive men taking HAART, seminal viral load is decreased but not eliminated and
fertilization should be achieved through sperm washing to offer maximum protection for
the uninfected female. Pregnant HIV-positive women on antiretroviral medication have a
reduced risk of transmitting the virus, but should still be counselled about the possibility to
further limit the chances of infecting their infant through elective Caesarean section. HIV se‐
ro-discordant couples with strong desire for childbearing have a dilemma of risking HIV in‐
fection or infecting their spouse. Some risk transmission of HIV infection to reproduce. Over
two-thirds of 104 surveyed couple wanting to procreate reported unprotected sex with their
partner in the past 6 months. Most respondents, regardless of serostatus, said that viral load
testing and awareness of post-exposure prevention had no effect on their condom use. A
paucity of interventions targeting sero-discordant couples on contraceptive choices is at
odds with a strong cultural importance in Africa attached to having children. HIV discord‐
ance in Africa creates a serious dilemma for fertility decision-making in couples. Stigma, dis‐
crimination, and non-disclosure fuel HIV transmission between partners. A previous study
[22] in Nigeria a country in the Western part of Africa that investigated the reproductive
health concerns among persons living with HIV/AIDS in the Niger Delta of Nigeria has
shown that a significant number of PLWHA in Nigeria have conception dreams. The main
reasons for wanting to procreate included: ensuring lineage continuity and posterity
(52.3%), securing relationships (27.0%) and pressure from relatives to reproduce (20.7%).
Single subjects were more inclined to have children (76.3%) compared to married (51.5%),
widowed (18.2%) and separated/divorced (11.1%) (p=0.03). Of the 111 subjects that indicated
their desire to have children, women were more inclined to have children (64.5%) compared
to men (47.7%). The major concern among the 84 (43.1%) subjects not desiring more children
were the fear of infecting sero-discordant partner and baby (57.1%), fear of dying and leav‐
ing behind orphans (28.6%) and the fear that they may become too ill and unable to finan‐
cially support the child (14.3%). Persons with no formal education were more likely to have
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and testing strategies as well as making antenatal visit as interactive and activity based.
These approaches are more likely to provide the much needed coverage [16]. There has been
argument as to whether the “opt-out” approach negates the principle of informed consent
[17] particularly in African settings where many antenatal women are reluctant to challenge
health care procedures. It is important however to note that “opt-out” approach does not in
any way compromise the principle of informed consent. This approach assumes that testing
is an intrinsic part of an effective and holistic antenatal care. The women are informed about
what test is required as well as the importance of testing to the mother and the developing
baby with an opportunity given to women to refuse testing if they so desire.
There is also the need to foster more male involvement in antenatal care in Africa. Evidence
has shown that involving men in the reproductive health care of their partners rather than
basing antenatal care exclusively on women can potentially enhance the pregnancy experi‐
ence, reduces incidence of gender-based violence, promote the likelihood of getting a joint
consent, facilitate HIV prevention, compliance to HAART in partner in which it is indicated
as well as enables a holistic uptake of sexual and reproductive health service for couples.
There are several challenges that militate against male-gender involvement in antenatal care
particularly in Africa; cultural and religious beliefs, obstacles of working fathers, prevalence
of polygamy and maintenance by men of multiple sex partners [18-19].
When HIV infection is diagnosed, health-care providers should strongly encourage patients
to disclose their HIV status to their spouses, current sex partners, and previous sex partners
and recommend that these partners be tested for HIV infection. Health departments can as‐
sist patients by notifying, counselling, and providing HIV testing for partners without dis‐
closing the patient's identity [20]. Policy allowing providers to inform patients who receive a
new diagnosis of HIV infection that they might be contacted by health department staff for a
voluntary interview to discuss notification of their partners may play a beneficial role and
facilitate uptake of sexual and reproductive health services in Africa. A disproportionate
burden has been placed on women and children who continue to experience high rate of
new HIV infection and HIV-related illness and death. Most children living with HIV acquire
the infection through Mother to Child Transmission (MTCT) which can occur during preg‐
nancy, during delivery or during breastfeeding.
3.1. A strong cultural and religious attachment to having children puts PLWHA under
pressure to procreate
Being HIV positive has been shown to modify but not remove the reproductive desires of
individuals. Diversity existed in reproductive intentions among PLWHA. Some HIV posi‐
tive individuals wished to avoid pregnancy. Fears of partner and infant infection and hav‐
ing a previously infected baby were important factors deterring some individuals from
considering having children. There is also strongly perceived community disapproval asso‐
ciated with HIV and reproduction. Strong desires to experience parenthood, mediated by
prevailing social and cultural norms that encouraged childbearing in society have also been
reported. Motherhood is seen as an important component of married women's identity and
important for women's social status in Africa. Family, husbands and societal expectations
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for childbearing have significant influences on the African woman's reproductive intentions
[21]. Availability and use of antiretroviral drugs has changed the landscape of HIV/AIDS
bringing about a change in the perception of HIV from an incurable deadly disease to a
chronic manageable illness. As effective HIV treatments become more widespread, HIV-in‐
fected individuals are living longer, healthier lives. Many HIV-affected couples (sero-dis‐
cordant and sero-concordant) are considering options for safer reproduction. A large body
of evidence suggests that reproductive technologies can help HIV-affected couples to safely
conceive with minimal risk of HIV transmission to their partner and baby. However, for
most couples particularly in low income countries in sub Saharan Africa, such technologies
are neither geographically nor economically accessible. With HIV now considered to be a
chronic manageable disease, attention is shifting to offering and improving quality of life
particularly by the provision of reproductive health options/care to men and women living
with HIV-1. Many HIV-infected men and women are now expressing their desire to father
or mother a child. Assisted reproductive technologies, including intrauterine insemination
(IUI), in vitro fertilisation (IVF) and intracytoplasmatic sperm injection (ICSI) in combination
with semen washing have been used to decrease the risk of HIV -1 transmission in HIV-1-
infected discordant couples with an HIV-1-infected man. Previous report indicates that in
HIV-positive men taking HAART, seminal viral load is decreased but not eliminated and
fertilization should be achieved through sperm washing to offer maximum protection for
the uninfected female. Pregnant HIV-positive women on antiretroviral medication have a
reduced risk of transmitting the virus, but should still be counselled about the possibility to
further limit the chances of infecting their infant through elective Caesarean section. HIV se‐
ro-discordant couples with strong desire for childbearing have a dilemma of risking HIV in‐
fection or infecting their spouse. Some risk transmission of HIV infection to reproduce. Over
two-thirds of 104 surveyed couple wanting to procreate reported unprotected sex with their
partner in the past 6 months. Most respondents, regardless of serostatus, said that viral load
testing and awareness of post-exposure prevention had no effect on their condom use. A
paucity of interventions targeting sero-discordant couples on contraceptive choices is at
odds with a strong cultural importance in Africa attached to having children. HIV discord‐
ance in Africa creates a serious dilemma for fertility decision-making in couples. Stigma, dis‐
crimination, and non-disclosure fuel HIV transmission between partners. A previous study
[22] in Nigeria a country in the Western part of Africa that investigated the reproductive
health concerns among persons living with HIV/AIDS in the Niger Delta of Nigeria has
shown that a significant number of PLWHA in Nigeria have conception dreams. The main
reasons for wanting to procreate included: ensuring lineage continuity and posterity
(52.3%), securing relationships (27.0%) and pressure from relatives to reproduce (20.7%).
Single subjects were more inclined to have children (76.3%) compared to married (51.5%),
widowed (18.2%) and separated/divorced (11.1%) (p=0.03). Of the 111 subjects that indicated
their desire to have children, women were more inclined to have children (64.5%) compared
to men (47.7%). The major concern among the 84 (43.1%) subjects not desiring more children
were the fear of infecting sero-discordant partner and baby (57.1%), fear of dying and leav‐
ing behind orphans (28.6%) and the fear that they may become too ill and unable to finan‐
cially support the child (14.3%). Persons with no formal education were more likely to have
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children irrespective of their positive HIV status (66.7%) compared to persons educated to
tertiary education level (37.0%) (p=0.01). Out of the 111 subjects that desired to have more
children, only 58% had gone for reproductive health counselling with HIV counsellors. Rea‐
sons for not seeking advice were anticipated negative reactions and discrimination from the
counsellors. A significant number of subjects were only aware of some reproductive health
options available to reduce risk of infecting their partners and or baby such as artificial vagi‐
nal insemination, intrauterine insemination, caesarean section, avoidance of breast feeding
and offering prenatal pre-exposure prophylaxis to the foetus. They were unaware of other
options such as sperm washing, IVF and ICSI. Of the 43.1% not anticipating more children,
36.9% were anticipating adoption.
A significant number of PLWHA in Africa desire to have children irrespective of the HIV
positive status. Women are more inclined to have children compared to men. Persons with
no formal education are more inclined to have children irrespective of their positive HIV
status compared to persons educated to tertiary education level. The main reasons for want‐
ing a child included: ensuring lineage continuity and posterity, securing relationships and
pressure from relatives to reproduce. There may be several reasons for this association, in‐
cluding the fact that better educated people generally having greater access to information
particularly the mode of transmission of HIV than those who have less formal education,
and are more likely to make informed decisions and act on information given. In addition,
better educated people generally have better jobs and greater access to money and other re‐
sources which can help them lead healthier lives. Also single persons living with HIV are
more likely to want to have children compared to married, separated and widowed subjects.
Regardless of interpersonal and public health concerns, studies in both resource-rich and re‐
source-limited settings suggest that HIV-infected men and women desire children [23 – 25].
In addition, in resource limited settings, couples often desire larger families. The reasons for
this are debated but likely include among others, the strong cultural attachment to having
children, stigmatization associated with childlessness, role of children with inheritance, the
importance of children in agricultural economies, the importance of childbearing on the sta‐
tus of women, the role of children as caretakers of the elderly, and high rates of infant mor‐
tality [26]. Previous report indicated that forty percent of HIV infected women desired more
children and women with fewer children were more likely to become pregnant [27].
PLWHA are often not wanting to procreate because of the fear of infecting sero-discordant
partner and baby, fear of dying and living behind orphans and the fear that they may be‐
come too ill and unable to financially support the child.Previous report indicates that the
major challenges faced by HIV-infected subjects not desiring to procreate included: risk of
HIV transmission to partner and child and failure of health systems to offer safe methods of
reproduction [28]. Identifying the determinants of the decision to have children among sero-
discordant couples will help in setting reproductive intervention priorities in resource-poor
countries. The gender of the positive partner affects the factors associated with a desire for
children. Interventions targeting sero-discordant couples should explore contraceptive
choices, the cultural importance of children, and partner communication [29].
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Given the importance of procreation in African settings and the lack of low –technology and af‐
fordable assisted reproduction services, HIV-infected couples are faced with a serious dilem‐
ma about making an informed decision to procreate. Many PLWHA in Africa who have a desire
to have children do not seek reproductive health counselling from HIV counsellors. Reasons for
not seeking counselling were anticipated negative reactions and stigmatization from the coun‐
sellors resulting from their negative attitude towards unprotected sexual activity and child
bearing by HIV-infected couples. HIV-infected individuals and their partners are requiring ed‐
ucation and counselling regarding HIV disease and reproduction and HIV counsellors particu‐
larly in Africa do not seem to have access to evidenced -based information that the HIV-
infected population desperately need to enable them make informed reproductive health
decisions. Previous report suggest that there is need to draw up a protocol for reproductive
counselling of HIV infected that have a desire for conception [30]. HIV counsellors need to come
to terms with the fact that simply encouraging HIV- infected couples to abstain from procrea‐
tion may no longer be a realistic strategy, particularly in sub Saharan Africa where there is strong
cultural attachment to having children. In the absence of counselling that recognizes the desire
and importance of having children, couples may knowingly take on the risks of transmission in
order to have children. Sharing our evidenced- based best practices about HIV transmission and
reproductive health options while recognizing patient goals may help couples minimize risk
and reduce the harm of unprotected sex. However, the great risks taken by HIV –infected per‐
sons desiring to procreate could be minimized through counselling and close monitoring by re‐
productive health care provider.
Reproductive health knowledge among HIV-infected subjects desiring to procreate in Africa
is poor. Most PLWHA in Africa are unaware of reproductive health options such as sperm
washing, in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) available to
reduce risk of infecting their partners and or baby. A significant number of men taking
HAART have lower seminal concentration of HIV, and sexual transmission may be reduced.
However, a certain percentage of aviraemic men retain viral presence in semen, and unpro‐
tected intercourse to achieve fertilization must be discouraged as it carries the risk of sexual
transmission of the virus. HIV-discordant couples should be informed that sperm washing
can remove HIV from semen, allowing conception without the risk of infection for the sero‐
negative female and eventually the child. In HIV-positive women, perinatal transmission of
HIV can be curtailed to less than 2% by using HAART to decrease maternal viral load and
offering prenatal pre-exposure prophylaxis of the foetus, and elective Caesarean section.
Each intervention carries specific risks and benefits. The contribution of each preventive arm
in achieving foetal protection can only be crudely measured and optimal obstetric manage‐
ment must involve discussion with the pregnant woman of the pros and cons of each strat‐
egy. HIV-affected couples who want to have children is presented with at least three distinct
and daunting clinical challenges. The first is dealing with stigma arising from many health
care providers’ negative attitude towards sexual activity and child bearing by HIV infected
couples [31] and stigmatization from immediate family members and society [32]. The sec‐
ond is maintaining the mother’s health before, during and after pregnancy. The third is pre‐
venting vertical transmission from mother to child as well as preventing HIV transmission
to the partner in sero-discordant relationship. Several approaches have been suggested to re‐
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children irrespective of their positive HIV status (66.7%) compared to persons educated to
tertiary education level (37.0%) (p=0.01). Out of the 111 subjects that desired to have more
children, only 58% had gone for reproductive health counselling with HIV counsellors. Rea‐
sons for not seeking advice were anticipated negative reactions and discrimination from the
counsellors. A significant number of subjects were only aware of some reproductive health
options available to reduce risk of infecting their partners and or baby such as artificial vagi‐
nal insemination, intrauterine insemination, caesarean section, avoidance of breast feeding
and offering prenatal pre-exposure prophylaxis to the foetus. They were unaware of other
options such as sperm washing, IVF and ICSI. Of the 43.1% not anticipating more children,
36.9% were anticipating adoption.
A significant number of PLWHA in Africa desire to have children irrespective of the HIV
positive status. Women are more inclined to have children compared to men. Persons with
no formal education are more inclined to have children irrespective of their positive HIV
status compared to persons educated to tertiary education level. The main reasons for want‐
ing a child included: ensuring lineage continuity and posterity, securing relationships and
pressure from relatives to reproduce. There may be several reasons for this association, in‐
cluding the fact that better educated people generally having greater access to information
particularly the mode of transmission of HIV than those who have less formal education,
and are more likely to make informed decisions and act on information given. In addition,
better educated people generally have better jobs and greater access to money and other re‐
sources which can help them lead healthier lives. Also single persons living with HIV are
more likely to want to have children compared to married, separated and widowed subjects.
Regardless of interpersonal and public health concerns, studies in both resource-rich and re‐
source-limited settings suggest that HIV-infected men and women desire children [23 – 25].
In addition, in resource limited settings, couples often desire larger families. The reasons for
this are debated but likely include among others, the strong cultural attachment to having
children, stigmatization associated with childlessness, role of children with inheritance, the
importance of children in agricultural economies, the importance of childbearing on the sta‐
tus of women, the role of children as caretakers of the elderly, and high rates of infant mor‐
tality [26]. Previous report indicated that forty percent of HIV infected women desired more
children and women with fewer children were more likely to become pregnant [27].
PLWHA are often not wanting to procreate because of the fear of infecting sero-discordant
partner and baby, fear of dying and living behind orphans and the fear that they may be‐
come too ill and unable to financially support the child.Previous report indicates that the
major challenges faced by HIV-infected subjects not desiring to procreate included: risk of
HIV transmission to partner and child and failure of health systems to offer safe methods of
reproduction [28]. Identifying the determinants of the decision to have children among sero-
discordant couples will help in setting reproductive intervention priorities in resource-poor
countries. The gender of the positive partner affects the factors associated with a desire for
children. Interventions targeting sero-discordant couples should explore contraceptive
choices, the cultural importance of children, and partner communication [29].
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Given the importance of procreation in African settings and the lack of low –technology and af‐
fordable assisted reproduction services, HIV-infected couples are faced with a serious dilem‐
ma about making an informed decision to procreate. Many PLWHA in Africa who have a desire
to have children do not seek reproductive health counselling from HIV counsellors. Reasons for
not seeking counselling were anticipated negative reactions and stigmatization from the coun‐
sellors resulting from their negative attitude towards unprotected sexual activity and child
bearing by HIV-infected couples. HIV-infected individuals and their partners are requiring ed‐
ucation and counselling regarding HIV disease and reproduction and HIV counsellors particu‐
larly in Africa do not seem to have access to evidenced -based information that the HIV-
infected population desperately need to enable them make informed reproductive health
decisions. Previous report suggest that there is need to draw up a protocol for reproductive
counselling of HIV infected that have a desire for conception [30]. HIV counsellors need to come
to terms with the fact that simply encouraging HIV- infected couples to abstain from procrea‐
tion may no longer be a realistic strategy, particularly in sub Saharan Africa where there is strong
cultural attachment to having children. In the absence of counselling that recognizes the desire
and importance of having children, couples may knowingly take on the risks of transmission in
order to have children. Sharing our evidenced- based best practices about HIV transmission and
reproductive health options while recognizing patient goals may help couples minimize risk
and reduce the harm of unprotected sex. However, the great risks taken by HIV –infected per‐
sons desiring to procreate could be minimized through counselling and close monitoring by re‐
productive health care provider.
Reproductive health knowledge among HIV-infected subjects desiring to procreate in Africa
is poor. Most PLWHA in Africa are unaware of reproductive health options such as sperm
washing, in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) available to
reduce risk of infecting their partners and or baby. A significant number of men taking
HAART have lower seminal concentration of HIV, and sexual transmission may be reduced.
However, a certain percentage of aviraemic men retain viral presence in semen, and unpro‐
tected intercourse to achieve fertilization must be discouraged as it carries the risk of sexual
transmission of the virus. HIV-discordant couples should be informed that sperm washing
can remove HIV from semen, allowing conception without the risk of infection for the sero‐
negative female and eventually the child. In HIV-positive women, perinatal transmission of
HIV can be curtailed to less than 2% by using HAART to decrease maternal viral load and
offering prenatal pre-exposure prophylaxis of the foetus, and elective Caesarean section.
Each intervention carries specific risks and benefits. The contribution of each preventive arm
in achieving foetal protection can only be crudely measured and optimal obstetric manage‐
ment must involve discussion with the pregnant woman of the pros and cons of each strat‐
egy. HIV-affected couples who want to have children is presented with at least three distinct
and daunting clinical challenges. The first is dealing with stigma arising from many health
care providers’ negative attitude towards sexual activity and child bearing by HIV infected
couples [31] and stigmatization from immediate family members and society [32]. The sec‐
ond is maintaining the mother’s health before, during and after pregnancy. The third is pre‐
venting vertical transmission from mother to child as well as preventing HIV transmission
to the partner in sero-discordant relationship. Several approaches have been suggested to re‐
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duce risk of horizontal transmission for HIV-affected couples who want to conceive chil‐
dren. These approaches includes the use of ; male sperm washing, IUI, ICSI, screening and
pre-treatment for Sexually Transmitted Infections (STI’s), Delay in procreation until viral
load is controlled, limited, timed unprotected sexual encounters, female artificial insemina‐
tion, self-insemination and circumcision. Experience among couples in whom the male was
(HIV) seropositive who underwent assisted reproductive technologies (ART) in order to at‐
tain family goals while minimizing the risk of HIV transmission indicated that all female re‐
cipients tested seronegative for HIV at 3 and 6 months post-embryo transfer. All delivered
babies (n = 8) tested seronegative for HIV at birth and 3 months postpartum and that ART
should be considered for HIV serodiscordant couples who desire to have children in order
to minimize the risk of viral infection [33]. Several people play a role in reproductive health
decision making of PLWHA; the relatives who used traditional norms to encourage procrea‐
tion; the health workers who violates the autonomy and human rights of HIV-infected by
using their medical knowledge to dissuade clients from childbearing by preaching mandato‐
ry contraception [34] and the health care system that do not recognize and meet the sexual
and reproductive health needs of their clients [35]. Health care providers in Africa must real‐
ize that it is their responsibility to offer information to enable HIV-infected persons arrive at
their own informed decisions on their reproductive and sexual health needs regardless of
the health professional’s opinion. Similarly, there may be need to offer additional training to
enable counsellors’ particularly in sub Saharan Africa offer evidenced- based sexual and re‐
productive health information to their clients. Reproductive health policies in this HIV/AIDS
era are lacking in most African settings. It is recommended that sero-discordant couples
who desire to have children should undergo assisted fertility treatment such as sperm wash‐
ing, intra uterine insemination and in-vitro fertilization to avoid HIV transmission to their
partners [36]. However cost implication is a major issue affecting the feasibility of offering
assisted fertility treatment such as sperm washing, intra uterine insemination and in-vitro
fertilization particularly among low socioeconomic people. There is a major challenge with
the development of evidenced- based, cost- effective and best-practice guidelines in most
settings in Africa to optimize the sexual and reproductive health service rendered to persons
living with HIV/AIDS. In resource-limited settings, couples should be counselled on ovula‐
tion cycles and may engage in timed unprotected sex only during the fertile period of the
woman’s monthly cycle to facilitate conception while reducing number of exposures. If the
man is HIV-negative with a positive partner, partners can be taught artificial insemination,
timed to the woman’s fertile period. For couples in which both partners are positive, there
may be need for a careful and informed natural conception when their viral loads have fall‐
en to below the level of detection.
4. Lack of integration between sexual and reproductive, family planning
and existing HIV /AIDS services
There is increasing concern that Sub-Saharan Africa is the region where more women are
infected by HIV than men. About 60 per cent of people living with HIV infections in Afri‐
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ca are women. Among young men and women aged 15 to 24 years, for every one man, four
women are infected with HIV. There were 12-13 infected women to 10 infected men in 2001
[37]. Biological, cultural and socio-economic factors contribute to women’s greater vulnera‐
bility to HIV/AIDS. Women are 4 times more at risk of becoming infected with HIV dur‐
ing  unprotected  vaginal  intercourse  than  men.  The  vagina’s  greater  area  of  susceptible
tissue and micro trauma that occurs during sexual intercourse makes women more physio‐
logically more vulnerable [38]. Semen has higher viral load than vaginal fluids and the se‐
men stays longer in the female genital  tract  after sexual intercourse which increases the
chances of  HIV transmission.  The synergy between HIV and sexually transmitted infec‐
tion (STIs) is another biological factor that makes women more vulnerable to HIV. This is
especially significant among African women. Most STI cases in women often go untreat‐
ed, symptoms are often latent, women diagnosed with STIs are often stigmatised and ma‐
jority have no access to medical treatments [39]. Socio-economic factors including women’s
lack of access to education, personal income, and economic dependence on men perpetu‐
ate  women’s  lower  status.  Moreover  widespread  poverty  often  drives  these  vulnerable
women into commercial sex work. Furthermore men control over condom use- the main
tool for reducing the risk of sexual transmission of HIV puts women at risk of HIV. Cultur‐
al practices inherent in Africa such as forced marriage, polygamy, female genital mutila‐
tion and older men’s preferences for sex with younger women, Sexual violence coercion at
home and in the work place during job hiring, promotion and to avoid dismissal are com‐
mon practices, use of women as bait by companies to secure contracts, sexual abuse of or‐
phans and domestic workers further complicates female gender vulnerability to HIV [40].
Moreover, women are more subjected to HIV stigma and discrimination. In Africa, the HIV
virus that causes AIDS is transmitted through two major routes. The first, which accounts
for 80 per cent of the cases, is through unprotected sex between men and women. This is
followed by HIV transmission from mother to child during pregnancy, labour and breast‐
feeding, which is responsible for about 20 per cent of the cases. There are several biologi‐
cal, social and cultural reasons why women and girls in Africa are more vulnerable to HIV
infection. Gender inequalities that exist in African society, women have less access to infor‐
mation than men, they are less likely to make informed decisions and act on information
given, they have less access to education, and better jobs, money and other resources which
can help them lead healthier lives. During vaginal sex, which is commonly practiced in Af‐
rica, the chance of HIV transmission from a man to a woman is two to three times greater
than transmission from a woman to a man. This is due to the biological make up of the fe‐
male genital tract. The female genital tract has a larger area of exposed tissue. Young girls
are especially vulnerable when they have sex with older men because because the genital
tract of young girls are immature, prone to tear and invasion by HIV.
There has never been a better time than this to target and integrate sexual and reproductive
health, family planning and HIV/AIDS services particularly in Africa. Most sceptics errone‐
ously often consider reproductive health to be a euphemism for abortion services. It is wor‐
thy to note that reproductive health covers a broad range of women’s health issues
including detecting and treating sexually transmitted infections and supporting HIV-infect‐
ed women’s desire to have children safely. Integration of HIV and reproductive health has
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duce risk of horizontal transmission for HIV-affected couples who want to conceive chil‐
dren. These approaches includes the use of ; male sperm washing, IUI, ICSI, screening and
pre-treatment for Sexually Transmitted Infections (STI’s), Delay in procreation until viral
load is controlled, limited, timed unprotected sexual encounters, female artificial insemina‐
tion, self-insemination and circumcision. Experience among couples in whom the male was
(HIV) seropositive who underwent assisted reproductive technologies (ART) in order to at‐
tain family goals while minimizing the risk of HIV transmission indicated that all female re‐
cipients tested seronegative for HIV at 3 and 6 months post-embryo transfer. All delivered
babies (n = 8) tested seronegative for HIV at birth and 3 months postpartum and that ART
should be considered for HIV serodiscordant couples who desire to have children in order
to minimize the risk of viral infection [33]. Several people play a role in reproductive health
decision making of PLWHA; the relatives who used traditional norms to encourage procrea‐
tion; the health workers who violates the autonomy and human rights of HIV-infected by
using their medical knowledge to dissuade clients from childbearing by preaching mandato‐
ry contraception [34] and the health care system that do not recognize and meet the sexual
and reproductive health needs of their clients [35]. Health care providers in Africa must real‐
ize that it is their responsibility to offer information to enable HIV-infected persons arrive at
their own informed decisions on their reproductive and sexual health needs regardless of
the health professional’s opinion. Similarly, there may be need to offer additional training to
enable counsellors’ particularly in sub Saharan Africa offer evidenced- based sexual and re‐
productive health information to their clients. Reproductive health policies in this HIV/AIDS
era are lacking in most African settings. It is recommended that sero-discordant couples
who desire to have children should undergo assisted fertility treatment such as sperm wash‐
ing, intra uterine insemination and in-vitro fertilization to avoid HIV transmission to their
partners [36]. However cost implication is a major issue affecting the feasibility of offering
assisted fertility treatment such as sperm washing, intra uterine insemination and in-vitro
fertilization particularly among low socioeconomic people. There is a major challenge with
the development of evidenced- based, cost- effective and best-practice guidelines in most
settings in Africa to optimize the sexual and reproductive health service rendered to persons
living with HIV/AIDS. In resource-limited settings, couples should be counselled on ovula‐
tion cycles and may engage in timed unprotected sex only during the fertile period of the
woman’s monthly cycle to facilitate conception while reducing number of exposures. If the
man is HIV-negative with a positive partner, partners can be taught artificial insemination,
timed to the woman’s fertile period. For couples in which both partners are positive, there
may be need for a careful and informed natural conception when their viral loads have fall‐
en to below the level of detection.
4. Lack of integration between sexual and reproductive, family planning
and existing HIV /AIDS services
There is increasing concern that Sub-Saharan Africa is the region where more women are
infected by HIV than men. About 60 per cent of people living with HIV infections in Afri‐
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ca are women. Among young men and women aged 15 to 24 years, for every one man, four
women are infected with HIV. There were 12-13 infected women to 10 infected men in 2001
[37]. Biological, cultural and socio-economic factors contribute to women’s greater vulnera‐
bility to HIV/AIDS. Women are 4 times more at risk of becoming infected with HIV dur‐
ing  unprotected  vaginal  intercourse  than  men.  The  vagina’s  greater  area  of  susceptible
tissue and micro trauma that occurs during sexual intercourse makes women more physio‐
logically more vulnerable [38]. Semen has higher viral load than vaginal fluids and the se‐
men stays longer in the female genital  tract  after sexual intercourse which increases the
chances of  HIV transmission.  The synergy between HIV and sexually transmitted infec‐
tion (STIs) is another biological factor that makes women more vulnerable to HIV. This is
especially significant among African women. Most STI cases in women often go untreat‐
ed, symptoms are often latent, women diagnosed with STIs are often stigmatised and ma‐
jority have no access to medical treatments [39]. Socio-economic factors including women’s
lack of access to education, personal income, and economic dependence on men perpetu‐
ate  women’s  lower  status.  Moreover  widespread  poverty  often  drives  these  vulnerable
women into commercial sex work. Furthermore men control over condom use- the main
tool for reducing the risk of sexual transmission of HIV puts women at risk of HIV. Cultur‐
al practices inherent in Africa such as forced marriage, polygamy, female genital mutila‐
tion and older men’s preferences for sex with younger women, Sexual violence coercion at
home and in the work place during job hiring, promotion and to avoid dismissal are com‐
mon practices, use of women as bait by companies to secure contracts, sexual abuse of or‐
phans and domestic workers further complicates female gender vulnerability to HIV [40].
Moreover, women are more subjected to HIV stigma and discrimination. In Africa, the HIV
virus that causes AIDS is transmitted through two major routes. The first, which accounts
for 80 per cent of the cases, is through unprotected sex between men and women. This is
followed by HIV transmission from mother to child during pregnancy, labour and breast‐
feeding, which is responsible for about 20 per cent of the cases. There are several biologi‐
cal, social and cultural reasons why women and girls in Africa are more vulnerable to HIV
infection. Gender inequalities that exist in African society, women have less access to infor‐
mation than men, they are less likely to make informed decisions and act on information
given, they have less access to education, and better jobs, money and other resources which
can help them lead healthier lives. During vaginal sex, which is commonly practiced in Af‐
rica, the chance of HIV transmission from a man to a woman is two to three times greater
than transmission from a woman to a man. This is due to the biological make up of the fe‐
male genital tract. The female genital tract has a larger area of exposed tissue. Young girls
are especially vulnerable when they have sex with older men because because the genital
tract of young girls are immature, prone to tear and invasion by HIV.
There has never been a better time than this to target and integrate sexual and reproductive
health, family planning and HIV/AIDS services particularly in Africa. Most sceptics errone‐
ously often consider reproductive health to be a euphemism for abortion services. It is wor‐
thy to note that reproductive health covers a broad range of women’s health issues
including detecting and treating sexually transmitted infections and supporting HIV-infect‐
ed women’s desire to have children safely. Integration of HIV and reproductive health has
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the potential to produce important HIV-related outcomes. Recent international consensus
statements have urged the strengthening of these linkages [41]. In order to reduce HIV-in‐
fected births, infant and child mortality, the number of children orphaned by AIDS and ma‐
ternal mortality, adding family planning and reproductive health to PMTCT, VCT and ARV
programmes makes a logical and a programmatic sense.
5. HIV–infected need information and services on safe procreation and
the health system is unable to provide evidenced-based answers
Data from most settings in Africa increasingly demonstrate that some HIV-infected women par‐
ticularly those on ARVs as they begin to feel better and function more normally due to the ef‐
fect of treatment on reduction on viral load, would like to become pregnant [42]. It is a growing
expectation that the health system should have the ability to counsel HIV-positive women on the
risk and benefits of child bearing and to respect the reproductive intentions, choices and rights
including access to contraception and other reproductive health services. Previous report [22]
indicates that reproductive health knowledge among HIV-infected subjects desiring to procre‐
ate was poor. Subjects were unaware of reproductive health options such as sperm washing, in
vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) available to reduce risk of
infecting their partners and or baby. A significant number of men taking HAART have lower
seminal concentration of HIV, and sexual transmission may be reduced. However, a certain per‐
centage of aviraemic men retain viral presence in semen, and unprotected intercourse to ach‐
ieve fertilization must be discouraged as it carries the risk of sexual transmission of the virus.
HIV-discordant couples should be informed that sperm washing can remove HIV from semen,
allowing conception without the risk of infection for the seronegative female and eventually the
child. In HIV-positive women, perinatal transmission of HIV can be curtailed to less than 2% by
using HAART to decrease maternal viral load and offering prenatal pre-exposure prophylaxis
of the foetus, and elective Caesarean section. Each intervention carries specific risks and bene‐
fits. The contribution of each preventive arm in achieving foetal protection can only be crudely
measured and optimal obstetric management must involve discussion with the pregnant wom‐
an of the pros and cons of each strategy. Several approaches have been suggested to reduce risk
of horizontal transmission for HIV-affected couples who want to conceive children. These ap‐
proaches includes the use of ; male sperm washing, IUI, ICSI, screening and pre-treatment for
Sexually Transmitted Infections (STI’s), delay in procreation until viral load is controlled, limit‐
ed, timed unprotected sexual encounters, female artificial insemination, self-insemination and
circumcision. Accurate and accessible information to make informed choices and safe, pleasur‐
able sexual relationships possible is best delivered through peer education and health profes‐
sionals trained on empathetic approaches to sensitive issues [43].  Interventions based on
positive prevention, which combine protection of personal health with avoiding HIV/STI trans‐
mission to partners, are recommended.
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6. Non-protection of the reproductive rights of PLWHA in Africa
It is increasing clear particularly that a significant majority of PLWHA in Africa are of reproduc‐
tive age, that conception and reproductive options for this population are important issues for
health care delivery and research and that HIV-seropositive individuals deserve full reproduc‐
tive rights like every other person [44]. International reproductive guidelines shifted a decade
ago from recommending avoidance of pregnancy to recognizing conception and parenting as
realistic options and rights for people with HIV infection and their partners [45]. Mindful of this
indisputable fact, US Centers for Disease Control and Prevention (CDC) has encouraged infor‐
mation and support for HIV-affected couples who want to explore their reproductive options
[14]. There are many persons who plays a role in reproductive health decision making of per‐
sons living with HIV/AIDS: The relatives who used traditional norms to encourage procrea‐
tion; the health workers who violates the autonomy and human rights of HIV-infected by using
their medical knowledge to dissuade clients from childbearing by preaching mandatory con‐
traception [34] and health care system that does not recognize and meet the sexual and repro‐
ductive health needs of their clients [35].Health care providers in Africa must realize that it is
their responsibility to offer information to enable HIV-infected persons arrive at their own in‐
formed decisions on their reproductive and sexual health needs regardless of the health profes‐
sional’s opinion. Similarly, there may need to offer additional training to enable counsellors’
offer evidenced- based sexual and reproductive health information to their clients. Reproduc‐
tive health policies in this HIV/AIDS era are lacking in most African settings. It is recommend‐
ed that sero-discordant couples who desire to have children should undergo assisted fertility
treatment such as sperm washing, intra uterine insemination and in-vitro fertilization to avoid
HIV transmission to their partners [36, 46]. However cost implication is a major issue affecting
the feasibility of offering assisted fertility treatment such as sperm washing, intra uterine in‐
semination and in-vitro fertilization particularly among low socioeconomic people. There is a
major challenge with the development of evidenced- based, cost effective and best-practice
guidelines locally in most African setting to help optimize the sexual and reproductive health
service rendered to persons living with HIV/AIDS particularly in the Africa. Like it is in other
developed countries in the world. HIV-infected couples wanting to procreate in Africa should
be counselled on ovulation cycles, timed sex only during the fertile period of the woman’s
monthly cycle to facilitate conception while reducing number of exposures. If the man is HIV-
negative with a positive partner, partners can be taught artificial insemination, timed to the
woman’s fertile period. For couples in which both partners are positive, there may be need for a
careful and informed natural conception when their viral loads have fallen to below the level of
detection. There is the need to support the sexual and reproductive rights of HIV-infected indi‐
viduals. Additional training needs to be offered to HIV counsellors on evidence- based best and
affordable practices regarding reproductive health issues among persons living with HIV. Pol‐
icies that support the availability and accessibility to relevant reproductive and sexual health
services including contraception and procreation needs to be developed. Public enlightenment
programmes on HIV is needed to reduce the stigmatization that HIV-infected persons face from
family members and their communities. Developing and testing safer conception methods that
reduce HIV transmission to HIV-seronegative partners in serodiscordant couples and reduce
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the potential to produce important HIV-related outcomes. Recent international consensus
statements have urged the strengthening of these linkages [41]. In order to reduce HIV-in‐
fected births, infant and child mortality, the number of children orphaned by AIDS and ma‐
ternal mortality, adding family planning and reproductive health to PMTCT, VCT and ARV
programmes makes a logical and a programmatic sense.
5. HIV–infected need information and services on safe procreation and
the health system is unable to provide evidenced-based answers
Data from most settings in Africa increasingly demonstrate that some HIV-infected women par‐
ticularly those on ARVs as they begin to feel better and function more normally due to the ef‐
fect of treatment on reduction on viral load, would like to become pregnant [42]. It is a growing
expectation that the health system should have the ability to counsel HIV-positive women on the
risk and benefits of child bearing and to respect the reproductive intentions, choices and rights
including access to contraception and other reproductive health services. Previous report [22]
indicates that reproductive health knowledge among HIV-infected subjects desiring to procre‐
ate was poor. Subjects were unaware of reproductive health options such as sperm washing, in
vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) available to reduce risk of
infecting their partners and or baby. A significant number of men taking HAART have lower
seminal concentration of HIV, and sexual transmission may be reduced. However, a certain per‐
centage of aviraemic men retain viral presence in semen, and unprotected intercourse to ach‐
ieve fertilization must be discouraged as it carries the risk of sexual transmission of the virus.
HIV-discordant couples should be informed that sperm washing can remove HIV from semen,
allowing conception without the risk of infection for the seronegative female and eventually the
child. In HIV-positive women, perinatal transmission of HIV can be curtailed to less than 2% by
using HAART to decrease maternal viral load and offering prenatal pre-exposure prophylaxis
of the foetus, and elective Caesarean section. Each intervention carries specific risks and bene‐
fits. The contribution of each preventive arm in achieving foetal protection can only be crudely
measured and optimal obstetric management must involve discussion with the pregnant wom‐
an of the pros and cons of each strategy. Several approaches have been suggested to reduce risk
of horizontal transmission for HIV-affected couples who want to conceive children. These ap‐
proaches includes the use of ; male sperm washing, IUI, ICSI, screening and pre-treatment for
Sexually Transmitted Infections (STI’s), delay in procreation until viral load is controlled, limit‐
ed, timed unprotected sexual encounters, female artificial insemination, self-insemination and
circumcision. Accurate and accessible information to make informed choices and safe, pleasur‐
able sexual relationships possible is best delivered through peer education and health profes‐
sionals trained on empathetic approaches to sensitive issues [43].  Interventions based on
positive prevention, which combine protection of personal health with avoiding HIV/STI trans‐
mission to partners, are recommended.
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It is increasing clear particularly that a significant majority of PLWHA in Africa are of reproduc‐
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health care delivery and research and that HIV-seropositive individuals deserve full reproduc‐
tive rights like every other person [44]. International reproductive guidelines shifted a decade
ago from recommending avoidance of pregnancy to recognizing conception and parenting as
realistic options and rights for people with HIV infection and their partners [45]. Mindful of this
indisputable fact, US Centers for Disease Control and Prevention (CDC) has encouraged infor‐
mation and support for HIV-affected couples who want to explore their reproductive options
[14]. There are many persons who plays a role in reproductive health decision making of per‐
sons living with HIV/AIDS: The relatives who used traditional norms to encourage procrea‐
tion; the health workers who violates the autonomy and human rights of HIV-infected by using
their medical knowledge to dissuade clients from childbearing by preaching mandatory con‐
traception [34] and health care system that does not recognize and meet the sexual and repro‐
ductive health needs of their clients [35].Health care providers in Africa must realize that it is
their responsibility to offer information to enable HIV-infected persons arrive at their own in‐
formed decisions on their reproductive and sexual health needs regardless of the health profes‐
sional’s opinion. Similarly, there may need to offer additional training to enable counsellors’
offer evidenced- based sexual and reproductive health information to their clients. Reproduc‐
tive health policies in this HIV/AIDS era are lacking in most African settings. It is recommend‐
ed that sero-discordant couples who desire to have children should undergo assisted fertility
treatment such as sperm washing, intra uterine insemination and in-vitro fertilization to avoid
HIV transmission to their partners [36, 46]. However cost implication is a major issue affecting
the feasibility of offering assisted fertility treatment such as sperm washing, intra uterine in‐
semination and in-vitro fertilization particularly among low socioeconomic people. There is a
major challenge with the development of evidenced- based, cost effective and best-practice
guidelines locally in most African setting to help optimize the sexual and reproductive health
service rendered to persons living with HIV/AIDS particularly in the Africa. Like it is in other
developed countries in the world. HIV-infected couples wanting to procreate in Africa should
be counselled on ovulation cycles, timed sex only during the fertile period of the woman’s
monthly cycle to facilitate conception while reducing number of exposures. If the man is HIV-
negative with a positive partner, partners can be taught artificial insemination, timed to the
woman’s fertile period. For couples in which both partners are positive, there may be need for a
careful and informed natural conception when their viral loads have fallen to below the level of
detection. There is the need to support the sexual and reproductive rights of HIV-infected indi‐
viduals. Additional training needs to be offered to HIV counsellors on evidence- based best and
affordable practices regarding reproductive health issues among persons living with HIV. Pol‐
icies that support the availability and accessibility to relevant reproductive and sexual health
services including contraception and procreation needs to be developed. Public enlightenment
programmes on HIV is needed to reduce the stigmatization that HIV-infected persons face from
family members and their communities. Developing and testing safer conception methods that
reduce HIV transmission to HIV-seronegative partners in serodiscordant couples and reduce
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superinfection in HIV-seroconcordant couples is a crucial component of HIV prevention pro‐
gramme that needs to be urgently addressed in Africa [47].
7. Challenge of HIV-related stigma and discrimination
HIV-related stigma and discrimination remains an enormous barrier to the fight against
AIDS. Fear of discrimination often prevents people from getting tested, seeking treatment
and admitting their HIV status publicly. Since laws and policies alone cannot reverse the
stigma that surrounds HIV infection, AIDS education in Africa needs to be scaled-up to
combat the ignorance that causes people to discriminate. The fear and prejudice that lies at
the core of HIV and AIDS discrimination needs to be tackled at both community and nation‐
al levels. There is strong ethical imperative to support the sexual and reproductive health
needs of HIV-infected individuals allowing them to make informed decisions about their re‐
productive health. Increasingly, fertility clinics in developed countries are offering their
services to HIV-serodiscordant couples where the woman is seropositive and in HIV-sero‐
concordant relationships. Reproductive health care workers in Africa can learn from the evi‐
denced- based best practices in the developed world to ensure that like their counterparts in
most developed countries, HIV infected persons particularly in Africa can access the best
quality reproductive and sexual health service. Recent advances in HIV clinical care and as‐
sisted reproduction technique (ART) procedures directed at reducing the risk of viral trans‐
mission during gamete transfer particularly where good healthcare is available has
significantly reduced the risk of transmission of HIV among discordant couples to 1-2%.
Promotion of risk reduction counselling, screening for sexually transmitted diseases and
lower genital tract disease, assessment of options for birth control, and pre-conception coun‐
selling should be integral components of gynaecologic health care for HIV-infected women.
Since the beginning of the human immunodeficiency virus (HIV) epidemic, stigma and dis‐
crimination (SAD) have been identified as the major obstacles to effective responses to HIV
[48]. HIV-affected couples who desire sexual and reproductive health services are faced
with at least three distinct and daunting challenges. The first is dealing with stigma arising
from many health care providers’ negative attitude towards sexual activity and child bear‐
ing by HIV infected couples [49] and stigmatization from immediate family members and
society [32]. The second is maintaining the mother’s health before, during and after preg‐
nancy. The third is preventing vertical transmission from mother to child as well as prevent‐
ing HIV transmission to the partner in sero-discordant relationship. HIV/AIDS-related SAD
has been extensively documented among health care providers. There have been many re‐
ports from health care settings of HIV testing without consent, breaches of confidentiality,
labelling, gossip, verbal harassment, differential treatment, and even denial of treatment.
HIV-infected-individuals who feel stigmatized by health care providers face problems ac‐
cessing HIV testing and other sexual and reproductive health care services [50]. The fear of
stigma impedes prevention efforts, including discussions of safer sex and the prevention of
mother-to-child transmission [51].
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Sexually transmitted infection including HIV have always been imbued with stigma and
discrimination particularly in Africa particularly due to their negative association with be‐
haviour considered by society as deviant or immoral [52]. Stigma generally refers to nega‐
tively perceived defining characteristics either tangible or intangible. It is an attribute used
to set the infected person or group from the normalized social order. It has a way of devalu‐
ing a person [53]. Similarly; societies have historically reacted with fear to disfiguring, debil‐
itating, and fatal diseases and have translated this aversion into discriminatory actions
against the infected [54]. The HIV/AIDS pandemic has presented the world with a condition
that combines these characteristics – and it has frequently been met with stigma and dis‐
crimination, a reaction dubbed “the second epidemic” [55]. HIV infection affects women and
men’s view of parenthood. It has a negative impact on their ability to have children, related
not only to psychosocial aspects such as stigma and discrimination and decreased sexual ac‐
tivity, but also to the clinical impact of HIV infection and sexually transmitted infections
(STIs) on fertility [56-57]. Learning more about stigma is important given the growing asser‐
tions that testing is a 'critical gateway' to HIV prevention and treatment. As access to HIV
testing and treatment improves, providers increasingly need to understand and address
how stigma acts as a barrier to services. There is need to develop programs to address the
negative service provider attitudes towards HIV-positive women, especially those wanting
children. Stigma and discrimination is a population and health system level barrier that dis‐
courages HIV-infected women and men from seeking reproductive health counselling and
other sexual and reproductive health counselling.
HIV-related stigmatization, discrimination and denial continue to characterize the pandemic
in Africa and present a major challenge to the effectiveness of prevention, sexual and repro‐
ductive care and treatment programmes. Much of the societal and individual reaction to‐
wards people with HIV/AIDS is stigma and discrimination oriented. Stigmatization and
discrimination occurs in a variety of forms. It ranges from societal level responses such as
coercive government policies and laws, to apathy and denial of the HIV epidemic. At the
individual level, the internalization of these societal responses may result in an individual's
self-exclusion from information, treatment and care. Stigmatization and discrimination are
often explored through socio-cultural understandings of illness and disease transmission
and its manifestations at societal and individual level. Contexts of discrimination include
employment, health care systems, and travel and migration restrictions. Although there are
widespread reports of HIV-related discrimination throughout the world there has also been
significant progress towards reducing these practices. In addition to what is being done
there is still much that we need to understand about the forms and contexts of stigmatiza‐
tion and discrimination if we are to succeed in our efforts to control the HIV epidemic par‐
ticularly in Africa [58]. Stigma and discrimination in Africa can be challenged. One way to
reduce their impact is at the legislative level, it is also vital to focus on community-based
interventions. These projects target stigmatization manifested in a wide range of community
contexts, including: family and immediate community, workplace, health services, religion
and the media.
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superinfection in HIV-seroconcordant couples is a crucial component of HIV prevention pro‐
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and admitting their HIV status publicly. Since laws and policies alone cannot reverse the
stigma that surrounds HIV infection, AIDS education in Africa needs to be scaled-up to
combat the ignorance that causes people to discriminate. The fear and prejudice that lies at
the core of HIV and AIDS discrimination needs to be tackled at both community and nation‐
al levels. There is strong ethical imperative to support the sexual and reproductive health
needs of HIV-infected individuals allowing them to make informed decisions about their re‐
productive health. Increasingly, fertility clinics in developed countries are offering their
services to HIV-serodiscordant couples where the woman is seropositive and in HIV-sero‐
concordant relationships. Reproductive health care workers in Africa can learn from the evi‐
denced- based best practices in the developed world to ensure that like their counterparts in
most developed countries, HIV infected persons particularly in Africa can access the best
quality reproductive and sexual health service. Recent advances in HIV clinical care and as‐
sisted reproduction technique (ART) procedures directed at reducing the risk of viral trans‐
mission during gamete transfer particularly where good healthcare is available has
significantly reduced the risk of transmission of HIV among discordant couples to 1-2%.
Promotion of risk reduction counselling, screening for sexually transmitted diseases and
lower genital tract disease, assessment of options for birth control, and pre-conception coun‐
selling should be integral components of gynaecologic health care for HIV-infected women.
Since the beginning of the human immunodeficiency virus (HIV) epidemic, stigma and dis‐
crimination (SAD) have been identified as the major obstacles to effective responses to HIV
[48]. HIV-affected couples who desire sexual and reproductive health services are faced
with at least three distinct and daunting challenges. The first is dealing with stigma arising
from many health care providers’ negative attitude towards sexual activity and child bear‐
ing by HIV infected couples [49] and stigmatization from immediate family members and
society [32]. The second is maintaining the mother’s health before, during and after preg‐
nancy. The third is preventing vertical transmission from mother to child as well as prevent‐
ing HIV transmission to the partner in sero-discordant relationship. HIV/AIDS-related SAD
has been extensively documented among health care providers. There have been many re‐
ports from health care settings of HIV testing without consent, breaches of confidentiality,
labelling, gossip, verbal harassment, differential treatment, and even denial of treatment.
HIV-infected-individuals who feel stigmatized by health care providers face problems ac‐
cessing HIV testing and other sexual and reproductive health care services [50]. The fear of
stigma impedes prevention efforts, including discussions of safer sex and the prevention of
mother-to-child transmission [51].
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tively perceived defining characteristics either tangible or intangible. It is an attribute used
to set the infected person or group from the normalized social order. It has a way of devalu‐
ing a person [53]. Similarly; societies have historically reacted with fear to disfiguring, debil‐
itating, and fatal diseases and have translated this aversion into discriminatory actions
against the infected [54]. The HIV/AIDS pandemic has presented the world with a condition
that combines these characteristics – and it has frequently been met with stigma and dis‐
crimination, a reaction dubbed “the second epidemic” [55]. HIV infection affects women and
men’s view of parenthood. It has a negative impact on their ability to have children, related
not only to psychosocial aspects such as stigma and discrimination and decreased sexual ac‐
tivity, but also to the clinical impact of HIV infection and sexually transmitted infections
(STIs) on fertility [56-57]. Learning more about stigma is important given the growing asser‐
tions that testing is a 'critical gateway' to HIV prevention and treatment. As access to HIV
testing and treatment improves, providers increasingly need to understand and address
how stigma acts as a barrier to services. There is need to develop programs to address the
negative service provider attitudes towards HIV-positive women, especially those wanting
children. Stigma and discrimination is a population and health system level barrier that dis‐
courages HIV-infected women and men from seeking reproductive health counselling and
other sexual and reproductive health counselling.
HIV-related stigmatization, discrimination and denial continue to characterize the pandemic
in Africa and present a major challenge to the effectiveness of prevention, sexual and repro‐
ductive care and treatment programmes. Much of the societal and individual reaction to‐
wards people with HIV/AIDS is stigma and discrimination oriented. Stigmatization and
discrimination occurs in a variety of forms. It ranges from societal level responses such as
coercive government policies and laws, to apathy and denial of the HIV epidemic. At the
individual level, the internalization of these societal responses may result in an individual's
self-exclusion from information, treatment and care. Stigmatization and discrimination are
often explored through socio-cultural understandings of illness and disease transmission
and its manifestations at societal and individual level. Contexts of discrimination include
employment, health care systems, and travel and migration restrictions. Although there are
widespread reports of HIV-related discrimination throughout the world there has also been
significant progress towards reducing these practices. In addition to what is being done
there is still much that we need to understand about the forms and contexts of stigmatiza‐
tion and discrimination if we are to succeed in our efforts to control the HIV epidemic par‐
ticularly in Africa [58]. Stigma and discrimination in Africa can be challenged. One way to
reduce their impact is at the legislative level, it is also vital to focus on community-based
interventions. These projects target stigmatization manifested in a wide range of community
contexts, including: family and immediate community, workplace, health services, religion
and the media.
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8. Need for the development and implementation of affordable, readily
available, low technology and safer conception services
Many HIV-infected men and women are now expressing their desire to have children. Al‐
though no conception methods are 100% risk -free of HIV infection other than those that
use fresh sperm from an HIV negative donor or adoption. The strong desire among Afri‐
cans to have their own biological children makes these options untenable for many PLWHA.
However there is several risk reduction method for safer conception in which the HIV in‐
fected partner is on antiretroviral therapy to achieve a significant reduction of viral load
and increase in CD4 count. Assisted reproductive technologies, including intrauterine in‐
semination (IUI), in vitro fertilisation (IVF) and intracytoplasmatic sperm injection (ICSI) in
combination with semen washing have been used to decrease the risk of HIV -1 transmis‐
sion in HIV-1-infected discordant couples with an HIV-1-infected man particularly in devel‐
oped countries. Previous report indicates that in HIV-positive men taking HAART, seminal
viral load is decreased to undetectable limits but not eliminated and fertilization should be
achieved through sperm washing to offer maximum protection for the uninfected female.
Pregnant HIV-positive women on antiretroviral medication have a reduced risk of transmit‐
ting the virus, but should still be counselled about the possibility to further limit the chan‐
ces of infecting their infant through elective Caesarean section. HIV sero-discordant couples
with strong desire for childbearing have a dilemma of risking HIV infection or infecting
their spouse. Some risk transmission of HIV infection to reproduce. Majority of HIV –infect‐
ed couples wanting to procreate are having unprotected sex with their partners. Most per‐
sons living with HIV infection need information on viral load testing, awareness of post-
exposure  prevention  and  condom  use.  A  paucity  of  interventions  targeting  HIV  sero-
discordant couples on contraceptive choices is at odds with a strong cultural importance in
Africa attached to having children. HIV discordance creates a serious dilemma for fertility
decision-making in couples. However, majority of these risk reduction method for safer con‐
ception are either unavailable regionally in Africa or unaffordable. Other low-technology
and readily  available  and affordable  option  that  could  be  used in  Africa  and other  re‐
source- constrained settings include; timed unprotected sexual intercourse for HIV concord‐
ant couples, vaginal insemination of fresh semen into the vagina via a disposable pipette or
syringe, for HIV positive men with sero negative partners, the use of antiretroviral drugs
by the HIV-infected male partner to lower HIV viral load in seminal plasma to undetecta‐
ble levels, use of pre-exposure prophylaxis (PrEP) by the HIV sero-negative female part‐
ner prior to and following timed unprotected sex at the female partners ovulation period.
It is vital that couples practice safer sex practices after conception and throughout the preg‐
nancy. Previous report [59] has shown that HIV horizontal seroconversion occurred in cou‐
ples  who  reported  unsafe  sex  practices  during  pregnancy  after  conception.  American
researchers and clinicians have advocated the possibilities of using PrEP for safer concep‐
tion [60]. A Recent study has indicated the potential role of PrEP in the prevention of het‐
erosexual HIV transmission [61]. Similarly, the Pre-exposure Prophylaxis Initiative (IPrEx)
trial using tenofovir/ emtricitabine has shown that PrEP is safe and capable of producing a
reduction in HIV infection risk in HIV-seronegative men who have sex with men [62]. Al‐
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so the CAPRISA 004 trial showed that the use of 1% tenofovir topical gel reduced the rate
of HIV acquisition by 39% in heterosexual seronegative women [63]. The use of PrEP is rap‐
idly growing as an important component of safer conception programs for HIV-serodiscord‐
ant couples [47, 64]. In the face of the high HIV prevalence in most African setting, it is
expedient that low –technology, safer conception methods that is feasible, affordable and
are acceptable is implemented.
8.1. Sperm washing with intrauterine insemination
Several studies have reported on the efficacy of sperm washing in combination with IUI in
terms of pregnancy rates, live birth rates, and HIV transmission incidence [65- 67]. However,
evaluation of the efficacy of this safer conception strategy is limited by methodological is‐
sues, including small sample sizes, lack of standardized protocols, and non-rigorous study
designs. For example, most studies reported only on retrospective data and very few used
control groups. Sperm washing and insemination lower transmission risk for HIV-negative
women who want to have children with HIV-positive men. Data from the European experi‐
ence which included a 14 years of follow up for 1,036 sero-discordant couples with an HIV-
positive male resulted in 580 pregnancies and no HIV sero conversions [68].
Intracytoplasmic sperm injection (ICSI).ICSI is a high-technology in vitro fertilization pro‐
cedure in which a single sperm is injected into an egg. It is a popular assisted reproduction
technique used as a safe conception technique in HIV seropositive men and their partners.
Previous reports have shown that ICSI is particularly useful and effective in the prevention
of HIV among serodiscordant couples in which the man is HIV-seropositive [46, 69]. How‐
ever there are a number of challenges associated with its utility particularly in Africa. These
include high cost, increased risk of multiple pregnancies and the risk of use of an HIV-in‐
fected gamete [68]. It is crucial to introduce harm-reduction methods and safer conception
methods for people with HIV infection in settings where assisted reproductive technologies
are unavailable and unaffordable. However, these strategies are not feasible on a wide‐
spread basis in resource-constrained settings. Sperm washing and ICSI is not feasible in
most resource-constrained settings. Its high cost, the invasive nature of the procedure, the
high number of cancelled cycles, increased risk of multiple pregnancies and potential dan‐
ger of using an HIV-infected gamete all militate against the use of ICSI. The most practicable
method in most settings in Africa is vaginal insemination with an uninfected male partner’s
sperm during the fertile time of the woman’s menstrual cycle. Several studies in Africa have
evaluated the outcome of natural concention in HIV sero-discordant couples. Ryder and col‐
leagues [70] studied 178 married HIV sero-discordant couples in the Democratic Republic of
Congo between 1987 to 1990. Couples engaged in unprotected sex during the moment ovu‐
lation period and resulted in the birth of 24 children and one sero -conversion. Similarly a
cross sectional study [71] involving 55 HIV-positive Nigeria women on antiretroviral thera‐
py married to HIV-sero-negative men indicated that younger women compared to older
women were more likely to pursue natural conception options than assisted reproduction.
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8. Need for the development and implementation of affordable, readily
available, low technology and safer conception services
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cans to have their own biological children makes these options untenable for many PLWHA.
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semination (IUI), in vitro fertilisation (IVF) and intracytoplasmatic sperm injection (ICSI) in
combination with semen washing have been used to decrease the risk of HIV -1 transmis‐
sion in HIV-1-infected discordant couples with an HIV-1-infected man particularly in devel‐
oped countries. Previous report indicates that in HIV-positive men taking HAART, seminal
viral load is decreased to undetectable limits but not eliminated and fertilization should be
achieved through sperm washing to offer maximum protection for the uninfected female.
Pregnant HIV-positive women on antiretroviral medication have a reduced risk of transmit‐
ting the virus, but should still be counselled about the possibility to further limit the chan‐
ces of infecting their infant through elective Caesarean section. HIV sero-discordant couples
with strong desire for childbearing have a dilemma of risking HIV infection or infecting
their spouse. Some risk transmission of HIV infection to reproduce. Majority of HIV –infect‐
ed couples wanting to procreate are having unprotected sex with their partners. Most per‐
sons living with HIV infection need information on viral load testing, awareness of post-
exposure  prevention  and  condom  use.  A  paucity  of  interventions  targeting  HIV  sero-
discordant couples on contraceptive choices is at odds with a strong cultural importance in
Africa attached to having children. HIV discordance creates a serious dilemma for fertility
decision-making in couples. However, majority of these risk reduction method for safer con‐
ception are either unavailable regionally in Africa or unaffordable. Other low-technology
and readily  available  and affordable  option  that  could  be  used in  Africa  and other  re‐
source- constrained settings include; timed unprotected sexual intercourse for HIV concord‐
ant couples, vaginal insemination of fresh semen into the vagina via a disposable pipette or
syringe, for HIV positive men with sero negative partners, the use of antiretroviral drugs
by the HIV-infected male partner to lower HIV viral load in seminal plasma to undetecta‐
ble levels, use of pre-exposure prophylaxis (PrEP) by the HIV sero-negative female part‐
ner prior to and following timed unprotected sex at the female partners ovulation period.
It is vital that couples practice safer sex practices after conception and throughout the preg‐
nancy. Previous report [59] has shown that HIV horizontal seroconversion occurred in cou‐
ples  who  reported  unsafe  sex  practices  during  pregnancy  after  conception.  American
researchers and clinicians have advocated the possibilities of using PrEP for safer concep‐
tion [60]. A Recent study has indicated the potential role of PrEP in the prevention of het‐
erosexual HIV transmission [61]. Similarly, the Pre-exposure Prophylaxis Initiative (IPrEx)
trial using tenofovir/ emtricitabine has shown that PrEP is safe and capable of producing a
reduction in HIV infection risk in HIV-seronegative men who have sex with men [62]. Al‐
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idly growing as an important component of safer conception programs for HIV-serodiscord‐
ant couples [47, 64]. In the face of the high HIV prevalence in most African setting, it is
expedient that low –technology, safer conception methods that is feasible, affordable and
are acceptable is implemented.
8.1. Sperm washing with intrauterine insemination
Several studies have reported on the efficacy of sperm washing in combination with IUI in
terms of pregnancy rates, live birth rates, and HIV transmission incidence [65- 67]. However,
evaluation of the efficacy of this safer conception strategy is limited by methodological is‐
sues, including small sample sizes, lack of standardized protocols, and non-rigorous study
designs. For example, most studies reported only on retrospective data and very few used
control groups. Sperm washing and insemination lower transmission risk for HIV-negative
women who want to have children with HIV-positive men. Data from the European experi‐
ence which included a 14 years of follow up for 1,036 sero-discordant couples with an HIV-
positive male resulted in 580 pregnancies and no HIV sero conversions [68].
Intracytoplasmic sperm injection (ICSI).ICSI is a high-technology in vitro fertilization pro‐
cedure in which a single sperm is injected into an egg. It is a popular assisted reproduction
technique used as a safe conception technique in HIV seropositive men and their partners.
Previous reports have shown that ICSI is particularly useful and effective in the prevention
of HIV among serodiscordant couples in which the man is HIV-seropositive [46, 69]. How‐
ever there are a number of challenges associated with its utility particularly in Africa. These
include high cost, increased risk of multiple pregnancies and the risk of use of an HIV-in‐
fected gamete [68]. It is crucial to introduce harm-reduction methods and safer conception
methods for people with HIV infection in settings where assisted reproductive technologies
are unavailable and unaffordable. However, these strategies are not feasible on a wide‐
spread basis in resource-constrained settings. Sperm washing and ICSI is not feasible in
most resource-constrained settings. Its high cost, the invasive nature of the procedure, the
high number of cancelled cycles, increased risk of multiple pregnancies and potential dan‐
ger of using an HIV-infected gamete all militate against the use of ICSI. The most practicable
method in most settings in Africa is vaginal insemination with an uninfected male partner’s
sperm during the fertile time of the woman’s menstrual cycle. Several studies in Africa have
evaluated the outcome of natural concention in HIV sero-discordant couples. Ryder and col‐
leagues [70] studied 178 married HIV sero-discordant couples in the Democratic Republic of
Congo between 1987 to 1990. Couples engaged in unprotected sex during the moment ovu‐
lation period and resulted in the birth of 24 children and one sero -conversion. Similarly a
cross sectional study [71] involving 55 HIV-positive Nigeria women on antiretroviral thera‐
py married to HIV-sero-negative men indicated that younger women compared to older
women were more likely to pursue natural conception options than assisted reproduction.
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9. Factors to consider before implementation of safer conception in sub
Saharan Africa
National medical societies such as the American Society of Reproductive Medicine and the
American College of Obstetricians /Gynaecologist has re-affirmed that it is unethical to re‐
fuse to provide safer conception services to PLWHA [72].The protection of the sexual and
reproductive health of all people including PLWHA has been recognized as a fundamental
human right. PLWHA particularly in Africa have the right to choose to have children and to
access non-judgemental, non-stigmatised and non-discriminatory evidenced-based quality
sexual and reproductive services. There are however factors that need to be considered in
implementing safer conception intervention; the feasibility, availability and affordability of
the intervention, the need for antiretroviral therapy to ensure a low viral load, high CD4
count, absence of AIDS defining symptoms and STIs, the need for couple anticipating con‐
ception to be in a stable relationship [73], consideration of fertility problems in HIV-infected
population, concomitant low success rate with assisted reproductive technologies in
PLWHA, low pregnancy rate and high fetal death rates among HIV-infected women [74].
10. Conclusion
Sustained and increased investment in sexual and reproductive health services in Africa
promises tremendous benefits to women, families and societies. In addition to improved
health, sexual and reproductive health services contribute to economic growth, societal and
gender equity, and democratic governance. Evidence has shown that a significant number of
HIV-infected persons in Africa desire to have children irrespective of their positive sero sta‐
tus. There is the need to support the sexual and reproductive rights of HIV-infected individ‐
uals. Additional training needs to be offered to HIV counsellors on evidenced- based best
and affordable practices regarding reproductive health issues among persons living with
HIV. There is the urgent need to develop policies that support the availability and accessibil‐
ity to relevant reproductive and sexual health services including contraception and procrea‐
tion. There is also the need for public enlightenment programmes on HIV to reduce the
stigmatization that HIV-infected persons in sub Saharan Africa face from family members
and their communities. Implementation of explicit policies recognizing reproductive rights
and choice of HIV-infected in Africa as well as support for health counselling and service
interventions that advance safer and healthier reproductive options for HIV positive indi‐
viduals is advocated. Intrauterine insemination (IUI) and Intracytoplasmic sperm injection
ICSI does not seem a cost-effective option in Africa and other resource-constrained settings.
However vaginal insemination with the sperm of an HIV-seronegative male partner is high‐
ly feasible and has been found to be reasonably acceptable to both men and women and re‐
duces the risk of transmission of HIV from infected women to their uninfected partners.
This may be a practicable, affordable, low- technology, safer conception option that may
need to be implemented in Africa and other resource-limited settings. There is increasing
advocacy that timed, limited, unprotected sex for HIV-seroconcordant couples, and timed,
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unprotected sex accompanied by periconceptionPrEP for the HIV seronegative female part‐
ner in serodisconcordant relationship could form part of a harm-reduction strategy to re‐
duce exposure to HIV when planning conception in resource-limited settings. There is the
need to increase the awareness, understanding, and acceptability of readily available, af‐
fordable, evidenced-based, low-technology and safer conception strategies among PLWHA
in Africa. Evidenced based –best practices needs to be implemented in Africa to avoid HIV
transmission enabling HIV-affected couples to embark on safer childbearing and to prevent
the risk of mother-to-child HIV transmission as well as infection of the uninfected partners
particularly in sero-discordance relationships. Countries in Africa must now come to terms
that failure of the health system to engage HIV-seropositive women and men in fertility
management and denying safer conception services to PLWHA who want to conceive a
child is unethical and a deprivation of their fundamental reproductive right.
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9. Factors to consider before implementation of safer conception in sub
Saharan Africa
National medical societies such as the American Society of Reproductive Medicine and the
American College of Obstetricians /Gynaecologist has re-affirmed that it is unethical to re‐
fuse to provide safer conception services to PLWHA [72].The protection of the sexual and
reproductive health of all people including PLWHA has been recognized as a fundamental
human right. PLWHA particularly in Africa have the right to choose to have children and to
access non-judgemental, non-stigmatised and non-discriminatory evidenced-based quality
sexual and reproductive services. There are however factors that need to be considered in
implementing safer conception intervention; the feasibility, availability and affordability of
the intervention, the need for antiretroviral therapy to ensure a low viral load, high CD4
count, absence of AIDS defining symptoms and STIs, the need for couple anticipating con‐
ception to be in a stable relationship [73], consideration of fertility problems in HIV-infected
population, concomitant low success rate with assisted reproductive technologies in
PLWHA, low pregnancy rate and high fetal death rates among HIV-infected women [74].
10. Conclusion
Sustained and increased investment in sexual and reproductive health services in Africa
promises tremendous benefits to women, families and societies. In addition to improved
health, sexual and reproductive health services contribute to economic growth, societal and
gender equity, and democratic governance. Evidence has shown that a significant number of
HIV-infected persons in Africa desire to have children irrespective of their positive sero sta‐
tus. There is the need to support the sexual and reproductive rights of HIV-infected individ‐
uals. Additional training needs to be offered to HIV counsellors on evidenced- based best
and affordable practices regarding reproductive health issues among persons living with
HIV. There is the urgent need to develop policies that support the availability and accessibil‐
ity to relevant reproductive and sexual health services including contraception and procrea‐
tion. There is also the need for public enlightenment programmes on HIV to reduce the
stigmatization that HIV-infected persons in sub Saharan Africa face from family members
and their communities. Implementation of explicit policies recognizing reproductive rights
and choice of HIV-infected in Africa as well as support for health counselling and service
interventions that advance safer and healthier reproductive options for HIV positive indi‐
viduals is advocated. Intrauterine insemination (IUI) and Intracytoplasmic sperm injection
ICSI does not seem a cost-effective option in Africa and other resource-constrained settings.
However vaginal insemination with the sperm of an HIV-seronegative male partner is high‐
ly feasible and has been found to be reasonably acceptable to both men and women and re‐
duces the risk of transmission of HIV from infected women to their uninfected partners.
This may be a practicable, affordable, low- technology, safer conception option that may
need to be implemented in Africa and other resource-limited settings. There is increasing
advocacy that timed, limited, unprotected sex for HIV-seroconcordant couples, and timed,
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unprotected sex accompanied by periconceptionPrEP for the HIV seronegative female part‐
ner in serodisconcordant relationship could form part of a harm-reduction strategy to re‐
duce exposure to HIV when planning conception in resource-limited settings. There is the
need to increase the awareness, understanding, and acceptability of readily available, af‐
fordable, evidenced-based, low-technology and safer conception strategies among PLWHA
in Africa. Evidenced based –best practices needs to be implemented in Africa to avoid HIV
transmission enabling HIV-affected couples to embark on safer childbearing and to prevent
the risk of mother-to-child HIV transmission as well as infection of the uninfected partners
particularly in sero-discordance relationships. Countries in Africa must now come to terms
that failure of the health system to engage HIV-seropositive women and men in fertility
management and denying safer conception services to PLWHA who want to conceive a
child is unethical and a deprivation of their fundamental reproductive right.
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1. Introduction
The prognosis of patients infected with human immunodeficiency virus (HIV) type 1 has
dramatically improved since the advent of the highly active antiretroviral therapy
(HAART), which have enabled sustained suppression of HIV replication and recovery of
CD4+ T cells count [1-3]. However, many patients in resource-poor settings still start
HAART at a late stage of HIV infection when they already have advanced immunodeficien‐
cy [4,5]. Immune reconstitution in HIV infected patients is characterized by replenishment
of immune cells depleted directly or indirectly by HIV infection, by regeneration of primary
and secondary lymphoid organs, by restoration of pathogen-specific T, B and NK cells and
by a regulation of the reconstituted immune system [2]. It is unclear whether complete im‐
mune reconstitution ever occurs but individuals with human immunodeficiency virus infec‐
tion starting antiretroviral therapy when they are very immunodeficient are susceptible to
immune reconstitution disorders. This phenomenon is known as a multitude of names in‐
cluding “immune reconstitution inflammatory syndrome (IRIS)”, “immune reconstitution or
restoration disease” (IRD) or immune reconstitution syndrome” and includes various forms
of a clinical deterioration as a consequence of a rapid and dysregulated restoration of anti‐
gen specific immune responses causing an exuberant inflammatory reaction and a cytokines
storm [1-3]. This was first noted following the introduction of zidovudine monotherapy in
the early 1990s, when localized forms of Mycobacterium avium intracellulare (MAI) infection
where observed in association with the recovery rather than failure of cellular immune re‐
sponse [6]. Later, in 1992, French MA et al showed that the disease associated with Mycobac‐
terium avium complex (MAC) infection occurred after nucleoside analogue therapy and
correlated with restoration of delayed hypersensitivity (DTH) responses to mycobacterial
antigens [7].
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2. Definition and epidemiology
IRIS is a well established entity still lacking of a consistent definition due to a wide variety
of pathogens and disease processes involved. It has been associated with herpetic, mycobac‐
terial and cryptococcal infections, Kaposi’s sarcoma, non – Hodgkin lymphoma and pro‐
gressive multifocal leukoencephalopathy. Non AIDS defining pathologies such as
sarcoidosis, Graves disease and rheumatic disease can also occur [1-3]. General case defini‐
tions have been proposed by Shelburne et al (2009), French MA et al (2004) and by Robertson J
et al (2006) [8,9,10] but diagnostic criteria for IRIS have not been standardized except for TB-
IRIS [3, 11]. This syndrome can be elicited by infectious and non infectious antigens and
may arise in two different settings, depending on whether HAART was started in a patient
treated for an ongoing opportunistic infection or in a clinically stable patient with or without
requiring primary prophylaxis [2]. “Unsmasking IRIS” is an immune response against an in‐
fection that was subclinical before the initiation of HAART whereas “paradoxical IRIS” indi‐
cates a condition in which the opportunistic infection is present and treated at the time of
initiation of HAART and worsens on therapy. Unmasking IRIS usually presents within the
first three months of therapy and viable pathogens may be isolated from samples obtained
from affected body sites, particularly when there is tissue necrosis. Paradoxical IRIS is com‐
mon during the first three months of HAART but may present later and frequently immune
response is against non viable pathogens. It occurs in 8-43% of patients with treated tubercu‐
losis and in 4-66% of patients with treated cryptococcal infection becoming an important
concern in poor resources countries [1-3]. Paradoxical IRIS is also exemplified by immune
recovery, which occurs in eyes previously affected by cytomegalovirus (CMV) retinitis. Par‐
ticularly in paradoxical IRIS, clinicians need to exclude alternative explanations for deterio‐
ration, such as failure to treat the opportunistic infection or failure of HAART because of
poor adherence or drug resistance [3].
Some authors suggested using terms of “simultaneous IRIS” for patients who develop IRIS
and a newly diagnosed opportunistic infection (OI) at the same time and “delayed IRIS” for
those with an OI in which IRIS manifests sometimes thereafter [12].
However, although several case definitions for IRIS have been proposed, certain minimum
criteria should be fulfilled in order to diagnose it. First of all, there must be the temporal as‐
sociation between initiation of HAART and subsequent development of symptoms of an in‐
flammatory localized or systemic process, characterized by worsening of clinical or
laboratory parameters despite “favorable” evolution of the HIV surrogate markers [1,2]. A
rise in blood CD4 + T cells is commonly seen in IRIS but it is not an essential element for the
diagnosis and is only a supportive criterion in both of the general case definitions for IRIS
[9,10]. Philips P et al found that about 10% of patients with Mycobacterium avium complex
immune restoration disease haven’t an increased CD4+ T cells count [13]. Neverthless, a lack
of rise in blood CD4 + T cells doesn’t indicate that there has been no restoration of functional
T lymphocyte response. On the other hand, IRIS has been described at higher CD4 + T cells
count, suggesting that functional status of cells has a role in the pathogenesis of IRIS too.
Therefore a falling plasma viral load is a more important indicator than CD4 T cells count
recovery [14].
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The immune restoration outcomes range from minimal morbidity to fatal progression [15].
The immune restoration shows a biphasic pattern and is demonstrated by a decrease in plas‐
ma HIV RNA levels by more than 1 log10 copies/ml and an increase in CD4 + T cells count
from baseline [1,2,16]. Initial recovery of the immune system consists in an increase in mem‐
ory T cells followed by an increase in thymic production of naïve T cells [1,2,16-20]. In addi‐
tion there is the recovery of reduced or damaged secondary lymphoid organs such as the
gut and the mesentheric associated lymphoid tissue, which are often lost due to chronic
HIV- mediated inflammation [21]. The initial and rapid rise of CD4 + T memory cells re‐
leased from compartments into circulation can be detrimental and a mild OI can appear as
an overwhelming infection because memory T cells respond to their antigens more readily
than naïve T cells [2,22].
CD8 + T cells also increase during the first two months of HAART and then tend to return to
baseline [18].
Differentiation between an opportunistic infection with normal presentation and a disorder
with a presentation compatible with unmasking IRIS is particularly difficult and the differ‐
ences between intended HAART – associated immune reconstitution and undesired mani‐
festations of IRIS is probably a continuum [3].The damage may indicate a failure of the
immune system to properly regulate the potency of the immune response [23].
The differential diagnosis includes failure of the antimicrobial therapy in patient with active
infection, manifestations of a new opportunistic infection, unmasking of an ongoing, previ‐
ously undiagnosed infection or manifestation of a diagnosed, ongoing infection in a previ‐
ously unrecognized site of involvement [1-3,16]. Drug toxicity must be ruled out. For
example, hepatitis flares in patients coinfected with hepatitis B virus or hepatitis C virus
may be the result of IRIS in the liver or of HAART- associated hepatotoxicity [2, 24].In occur‐
ring IRIS, inflammation is atypical in presentation or more exaggerated than in immunodefi‐
ciency disease being characterized by pain, suppuration and necrosis and examination of
affected tissue or body fluids samples reveals evidence of an immune response with scarcity
of pathogens, infiltrating lymphocytes and granulomatous reaction [1-3].
IRIS may be estimated to occur in 10% to 50 % of patients starting HAART with similar per‐
centages occurring in children and the incidence varies with the AIDS-defining illness [1-3].
Differences reported in the incidence of IRIS between opportunistic infections seem to be re‐
lated to CD4+ T cells count at baseline [3]. IRIS is common in patients starting HAART with
a low CD4 + T cells count and a CMV retinitis or cryptococcal meningitis whereas Kaposi’s
sarcoma and TB-IRIS have also been described at an high count of CD4 + T cells count [3,25].
Moreover, the variation reported in frequency is due to differences in case definitions and,
above all, to differences in study populations with heterogeneous risk profiles and underly‐
ing burden of opportunistic infections [1,2]. In a recent meta-analysis and systematic review
including 54 cohort studies and 13.103 patients starting HAART of whom 1699 develope
IRIS, the lowest to highest incidence of IRIS by previously diagnosed opportunistic illness
resulted 6,4% in patients with Kaposi’s sarcoma (based on two studies), 12,2% in patients
with Herpes Zoster (based on one study), 15,7% in patients with tuberculosis (based on 16
studies), 16,7% in patients with progressive multifocal leukoencephalopathy (based on two
studies), 19,5% in patients with cryptococcal meningitis (based on six studies) and 37,7% in
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patients with cytomegalovirus retinitis (based on ten studies). In the same review IRIS de‐
veloped in 16,1% of unselected patients starting HAART and the incidence of IRIS associat‐
ed with tuberculosis and cryptococcal meningitis seemed to be lower in cohorts from low
and middle income countries probably due to limited diagnostic capacity in these settings.
The strength of this affirmation is supported by the evidence of an high incidence of IRIS
associated uveitis in all settings: inflammatory reactions, even if moderate, are more likely to
be recognized in the eye than in other organs [3].
Risk factors for IRIS are difficult to establish because of the cohorts differ with regards to the
study populations and the type of IRIS examined. Anyway, several risk factors for IRIS has
been identified and, first of all, the presence of an opportunistic infection at the time of ini‐
tiation of HAART, specially for TB and cryptococcal diseases [1,2]. Müller M et colleagues re‐
ported an analysis stratified by median CD4+ T cells count at the beginning of HAART
showing the different incidence of IRIS [Tab. 1, 3]. Male sex and younger age have been
identified as significant predictors too [15,26].
Initiation of HAART soon after treatment for an opportunistic infection is considered a risk
factor too [1-3,15].
A shorter interval between the treatment of an opportunistic infection and the initiation of
HAART is associated with a higher risk of IRIS in these patients [1-3,15].
3. Pathogenesis
The immunopathological process is still poorly understood but is strictly related with the
provoking pathogen and with host. In fact, some people develop IRIS and others, with simi‐
lar clinical status and risk factors, do not. It remains unclear if the disease mechanisms asso‐
ciated with IRIS are the same for each OI or if there are microbial-driven specific immune
responses that result in different pathologies for each pathogen [12]. Several studies using a
simian immunodeficiency virus model indicate differential expression of viral peptides by
distinct MHC alleles, which could influence the aggressiveness of the immune response di‐
rected toward SIV [27].
Essentially any pathogen that can cause an opportunistic infection in patients with impaired
cellular immune responses can provoke IRIS. It also appears that HIV infection itself can
cause IRIS [28]. Two patients were reported with HIV encephalitis after effective HAART.
Neuropathological features consisted in massive CD8+/CD4- lymphocytes brain infiltration
and in a diffuse microglial hyperplasia [28].
The antigenic stimulus in infectious conditions are either intact viable organism or dead or‐
ganism and their residual antigens whereas autoimmunity to innate antigens are involved
in the non-infectious causes of the syndrome [1-3].
If the pathogen is viral, i.e. CMV or JC, CD8 + - T lymphocytes predominate in inflammatory
cells infiltrates whereas if the pathogen is tuberculous or non tuberculous mycobacteria, a
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protozoan as Leishmania species or a fungus as Cryptococcus neoformans granulomatous
CD4 + - T helper cells type 1 inflammation predominates [1-3].
Price P et al suggested a genetic predisposition and certain genes have been associated with
an increased susceptibility to development of IRIS in presence of mycobacteria and herpes‐
viruses. The TNF α-308*2 carried in linkage disequilibrium with HLA-A2,-B44,-DR4 and
without BAT1 (intron 10)*2 is more common in patients with herpesvirus-associated IRIS
and is not present in any patients who has experienced mycobacterial IRIS. Therefore TNF α
polymorphisms should be considered in the context of the adjacent MHC alleles. The ab‐
sence of C allele of IL6-174 together with TNF α - 308*1 confers an increased relative risk for
mycobacterial IRIS probably due to a limited TNF-mediated bactericidal activity and to a
lower TNFα production in monocytes [29]. The CMV retinitis IRD patients have over 4 years
on HAART progressively increased plasma levels of bioavailable IL-6 and of soluble CD30,
a type 2 (T2) immune response marker and 92% of them result homozygous for
IL12B-3’UTR* 1 suggesting a dysregulation of the T1/T2 balance [30,31]. Th1 cells are charac‐
terized by the production of interferon γ and elicit proinflammatory responses. Th2 cells
produce antiinflammatory and immunosuppressive cytokines (i.e. interleukin 10). [31,32 ].
These considerations suggest that IRIS could be sustained form several immunopathological
mechanisms and that further studies need to better establish the role of cytokines in the dif‐
ferent forms of IRIS [31].
In addition to the reconstitution of immune cell numbers and function, redistribution of
lymphocytes, defects in regulatory function, changes in Th cell profile are also involved [23].
Mycobacterial IRIS usually presents with suppuration of lympho nodes or other organ af‐
fected because of an activation of Th 17 lymphocytes inducing inflammation mediated by
neutrophils [33]. Production of cytokines inducing cellular proliferation is the main mecha‐
nism of IRIS-Kaposi [34]. An unbalanced immune reconstitution of effector and regulatory T
cells in patients receiving HAART has been noted. In particular, two types of T cells seem to
take part to the development of the disease: the proinflammatory Th 17 lymphocytse and
the T regulatory cells. The latter are implied in preventing collateral damage from exuberant
inflammatory responses and may be defective in number and function during IRIS
[1,2,23,31]. A role has been hypotized for NK cells by killer immunoglobulin-like receptors
activity. Macrophages are inappropriately activated in IRIS-TB [1].
Actually serological markers for IRIS diagnosis are lacking. Inflammatory markers, cyto‐
kines and chemokines are shown to be elevated in IRIS, specially IL 6. Paradoxical TB-IRIS
has been associated with elevation of interleukin(IL) -4, IL -6, IL-7, IFN (interferon) γ and
tumor necrosis factor alpha (TNF-α) and cryptococcal meningitis with increased pre-
HAART levels of C reactive protein (CRP), IL-4 e IL-17 and lower levels of vascular endo‐
thelial growth factor (VEGF), granulocytes colony-stimulating factor (G-CSF) and TNF-α
during clinical events [1,31,35].
To sum up, IRIS has been associated with certain human leucocyte antigen (HLA) profiles
and regulatory cytokine genes polymorphisms but further research is needed to evaluate
their potential role in identifying patients at risk, developing better therapeutics and moni‐
toring response to therapy.
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The antigenic stimulus in infectious conditions are either intact viable organism or dead or‐
ganism and their residual antigens whereas autoimmunity to innate antigens are involved
in the non-infectious causes of the syndrome [1-3].
If the pathogen is viral, i.e. CMV or JC, CD8 + - T lymphocytes predominate in inflammatory
cells infiltrates whereas if the pathogen is tuberculous or non tuberculous mycobacteria, a
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protozoan as Leishmania species or a fungus as Cryptococcus neoformans granulomatous
CD4 + - T helper cells type 1 inflammation predominates [1-3].
Price P et al suggested a genetic predisposition and certain genes have been associated with
an increased susceptibility to development of IRIS in presence of mycobacteria and herpes‐
viruses. The TNF α-308*2 carried in linkage disequilibrium with HLA-A2,-B44,-DR4 and
without BAT1 (intron 10)*2 is more common in patients with herpesvirus-associated IRIS
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tumor necrosis factor alpha (TNF-α) and cryptococcal meningitis with increased pre-
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To sum up, IRIS has been associated with certain human leucocyte antigen (HLA) profiles
and regulatory cytokine genes polymorphisms but further research is needed to evaluate
their potential role in identifying patients at risk, developing better therapeutics and moni‐
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Lots of clinical manifestation have been described in occurring IRIS.
Several pathogens have been associated with IRIS, including JC virus, herpes viruses, BK vi‐
rus, Parvovirus B19, human T lymphotropic virus type 2, Epstein Barr virus, HHV 8, Cyto‐
megalovirus, Cryptococcus neoformans, Toxoplasma gondii. Mycobacterium tuberculosis,
Mycobacterium leprae and Mycobacterium avium complex (MAC) contribute too [1-3,15].
The antigens driving IRIS often belong to opportunistic pathogens but sometimes IRIS can
be a result of HIV- specific responses [1-3,15].
TB-IRIS manifestations include worsening respiratory symptoms, fever, lymphonode en‐
largement and suppuration, appearance of new infiltrates and mediastinal lymphoadenop‐
athy on chest radiograph, visceral or cutaneous abscesses, pleural and pericardial effusion
and rarely intracranial tubercoloma, acute renal failure, meningitis and cognitive impair‐
ment. Moreover abdominal TB-IRIS can present with non-specific abdominal pain and ob‐
structive jaundice. Differential diagnosis from drug-resistant tuberculosis is difficult
[15,36-39]. MAC remains the most reported atypical mycobacterium and the most common
manifestation in MAC-IRIS is fever with suppurative painful lymphadenitis followed by
pulmonary disease but involvement of joints, spine, skin and soft tissue has also been re‐
ported. In contrast to disseminated MAC disease of advanced AIDS, MAC-IRIS usually
presents as localized disease [40]. Mycobacterial IRIS has to be distinguished from sarcoido‐
sis that can also occur in the context of IRIS [1]. Measurement of a delayed-type hypersensi‐
tivity response to tuberculin by a skin test may help to differentiate immune reconstitution-
associated sarcoidosis from mycobacterial IRIS, because a response is absent in patients with
sarcoidosis but is often present in patients with mycobacterial IRIS [1,2,7, 41,42].
Patients with Pneumocystis jirovecii IRIS manifest recurrence of fever, worsening hypoxia
and fresh pulmonary infiltrates on chest radiograph. In addition to the general risk factors,
PaO2 < 70 mmHg and a recent completion of steroid therapy for Pneumocystis jirovecii
pneumonia promote IRIS [1, 43,44].
CNS-IRIS occurs at much lower frequencies with about 0,9-1,5% of patients developing
some CNS-IRIS after initiating HAART [45-47]. The heightened immune response in a rela‐
tively closed space leads to raised intracranial pressure, with potentially irreversible dam‐
age. Diagnosis of CNS-IRIS is difficult because CNS is a region of limited access and
requires pathological confirmation and invasive procedures. A worsening of clinical neuro‐
logical status can be accompanied by new neuroradiological findings or by deterioration of
previous findings with T cell infiltrates into the CNS. Depending on the severity of CNS-
IRIS it may be classified as asymptomatic, symptomatic and catastrophic. Asymptomatic
CNS-IRIS consists in radiological changes only, such as increased enhancement. Sympto‐
matic CNS-IRIS is characterized by clinical deterioration in neurological function with new
changes on MRI scan of brain. In the catastrophic CNS-IRIS severe neurological deficits oc‐
cur such as coma and imminent signs of cerebral herniation [12, 45-48]. JC virus is the causa‐
tive agent of PML and one of the most devastating of the OIs associated with IRIS leading to
a 42% mortality. Of the approximate 5% of HIV + patients who develop PML up to 19% are
PML-IRIS patients. Differential diagnosis between PML and PML-IRIS can be done by MRI:
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the presence of contrast enhancement suggest an inflammatory response and is indicative of
PML-IRIS. The response to steroids confirms the diagnosis. The prognosis of delayed PML-
IRIS is worse than the form that begins simultaneously [49,50].
A stroke occurring after initiation of HAART can be due to a vasculitis in the context of a
VZV-IRIS [51]. Genital ulceration related to Herpes Simplex virus and genital warts related
to human papillomavirus are frequently observed [1]. Most commonly CMV is associated
with CMV-IRIS retinitis, vitreitis and uveitis with loss of visual acuity and floaters [1, 52].
CMV ventriculitis without retinal damage has been described [53].
Cryptococcus neoformans is frequently involved in IRIS development. It can provoke a CNS
associated IRIS and a non-CNS IRIS: the first results in an aseptic recurrence of meningitis or
rarely in a cryptococcoma; the second is more common and is a lymphoadenitis or a media‐
stinitis or rarely a cavitary pneumonia. In a patient with cryptococcal meningitis rapidly
worsening because of headache, nausea and vomiting after HAART initiation IRIS has to be
considered above all in presence of sterile inflammation of the CSF, residual cryptococcal
antigens and absence of viable yeast on culture. Patients with Cryptococcus neoformans as‐
sociated IRIS has usually higher opening pressure, white cell count and glucose levels than
patients with Cryptococcus neoformans infection only. Neuroimaging is usually not useful
in cryptococcal meningitis diagnosis but in occurring IRIS evidence of meningeal or choroid
plexus enhancement or linear perivascular enhancement in the sulci at CT scan is frequent
and represent a sign of inflammation [54-57]. Patients with cryptococcal meningitis particu‐
larly with IRIS are likely to develop a communicating idrocephalus due to blockage of CSF
absorption at the arachnoid villi by cryptococcal antigens and by the inflammatory cells.
This is a serious condition that may require drainage by repeated lumbar punctures [48].
There is only a case report of immune reconstitution syndrome occurring in a patient with
Candida meningitis in the literature and a case report of visual loss and detection of EBV in
CSF by PCR after initiation of HAART [12, 58]. In few cases Toxoplasma gondi is the re‐
sponsible agent of CNS-IRIS [59].
Some patients may develop a severe progressive encephalitis after initiation of HAART with
seizures, altered mental status, coma and death. HIV may be detectable in CSF even when
results undetectable in blood. MRI can show diffuse multifocal white matter changes with
associated cerebral edema [12,28].
Given the known associations of Kaposi’s sarcoma with human herpesvirus 8 and non
Hodgkin lymphoma with Epstein Barr virus it is not surprising to observe these cancers oc‐
curring or worsening in the context of IRIS [12,60-63]. Both clinical sudden progression of
established lesions and new Kaposi sarcoma have been described after HAART initiation
[12, 60-62]. HIV-infected patients starting HAART may present manifestations of autoim‐
mune disease like most frequently sarcoidosis and Graves disease but also systemic lupus
erythematosus, rheumatoid arthritis, Reiter’s syndrome, polymyositis and Guillain-Barrè
syndrome [1-3, 64-70]. At last, high levels of CNS inflammation have been demonstrated in
the hippocampus of patients successfully treated with HAART and IRIS could contribute to
pathogenetic mechanism leading to a cognitive impairment [12].
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5. Treatment and prevention
Till now, on the grounds of available data, it appears prudent that HAART should be initiat‐
ed before the onset of severe immunodeficiency. A detailed evaluation should be done for
identification of opportunistic infections before HAART initiation. Patients with high risk
features for the development of IRIS should be identified and OIs should be optimally treat‐
ed if present [1-3, 71-73]. In the context of opportunistic infections, the benefit of reducing
the likelihood of IRIS by deferring HAART must be balanced with the risk of delaying
HAART, above all if patients are severely immunodeficient. The ACTG 5164 is a random‐
ized trial comparing immediate versus deferred antiretroviral therapy initiation in patients
presenting with acute OIs. Significant reduction in clinical progression or death among pa‐
tients who received antiretroviral therapy within 14 days of presenting with acute OI versus
those who deferred antiretroviral therapy until after OI had been treated was found and the
incidence of immune reconstitution events resulted similar between groups [73].
To date, literature is lacking about the optimal time of HAART initiation following a treat‐
ment of opportunistic infections with exception of tuberculosis/HIV coinfection. Regarding
this concern the most recent WHO and DHHS guidelines recommend the initiation of
HAART between 2 and 8 weeks after starting treatment against tuberculosis for patients
with a CD4 count < 200/µl [71,72].
Actually management of patients with IRIS was founded upon clinical observations and ex‐
pert opinions only. In general non steroidal anti-inflammatory drugs should be reserved for
milder manifestations and steroids for cases with severe inflammation. Interruption of
HAART is rarely necessary but could be considered in life threatening situations or when
pathogens involved are not controllable by specific antimicrobial therapy, as JC virus [15].
Stopping HAART may improve symptoms but there is no guarantee that the condition will
not recur once HAART is resumed [74]. In a randomized controlled trial, Meintjes G et al
reported the utility of prednisolone (1.5 mg/kg per day for two weeks followed by 0.75
mg/kg per day for further two weeks) in the treatment of paradoxical tuberculosis-IRIS with
worsening chest radiograph, enlarging lymph node, serous effusion and cold abscess, CNS
manifestations, tracheal compression due to lymphadenopathy and acute respiratory dis‐
tress syndrome (ARDS). For atypical mycobacterial – IRIS treatment is similar to TB-IRIS.
Surgical excision of profoundly enlarged nodes or debridement of necrotic areas is anecdo‐
tally reported [75,76]. Cryptococcal meningoencephalitis IRIS requires prompt control of
raised intracranial pressure and hydrocephalus by serial lumbar punctures. Corticosteroids
are indicated for cerebral oedema and ARDS in pulmonary cryptococcosis [48,77-78]. The
development of PCP-IRIS after discontinuation of steroid therapy suggest a role for the rein‐
troduction of steroids in these patients [44]. In cases of ocular CMV-IRIS systemic or perioc‐
ular steroid injections have been used bur a clear benefit has not been demonstrated. The
role of corticosteroids in PML-IRIS is not clear and a long term treatment may be necessary
until T memory cells and a more directed immune response against JC virus predominates
[50,79]. Unfortunately increased risk of progression of herpes zoster and Kaposi’s sarcoma
and reactivation of latent infections have also been reported with corticosteroids.
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6. Conclusions
The majority of patients with IRIS have a self-limiting disease course but associated morbid‐
ity places a considerable burden on the health care system. Morbidity and mortality rates
vary according to the pathogen and organ involved. Mortality is usually uncommon with
the exception of the setting of opportunistic infections involving the CNS [1]. Lethality rang‐
es from about 3% in patients with tuberculosis to more than 20% in patients with cryptococ‐
cal meningitis, with an higher early mortality in resource-limited settings due to probable
underdiagnoses [3]. The occurrence of IRIS and its contribution to mortality in a given set‐
ting is affected by the relative importance of different infections, the degree of access to fa‐
cilities for diagnosis of such illnesses and the extent of screening for and treatment of
opportunistic infections before starting HAART [80].Research efforts should be focused on
increasing knowledge about IRIS so that diagnostic tests and prevention and treatment
strategies could be improved.
CD4 < 50 μl CD4 > 50 μl
IRIS-TB 20,7% 17,7%
IRIS-cryptococcal meningitis 28,3% 2%
IRIS- CMV retinitis 37,7% No studies
Table 1. Development of IRIS in analysis stratified by median CD4+ cells count at the start of HAART [3]
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1. Introduction
The epidemiology of HIV infection and viral hepatitis among injection drug users (IDUs) is
changing in western countries; reductions in the epidemic of blood-borne infections, such as
HIV infection, and viral hepatitis among drug users are probably related to the generaliza‐
tion of harm-reduction interventions and to the treatment of both HIV/AIDS and substance
abuse. Opioid substitution therapy for the treatment of patients with heroin dependence,
needle exchange programmes, access to Highly Active Antiretroviral Therapy (HAART)
and supervised injecting facilities, among other preventive interventions, have contributed
to reduce the impact of the HIV epidemic among drug users.
Surveillance of HIV infection in Spain is available in 15 out of the country’s 17 autonomous
regions. According to the National AIDS Programme, 2,264 new HIV infections were diag‐
nosed in 2009, which represents 79 cases per million of the population [1].
As previously reported [2], the beginning of the HIV epidemic in Spain was largely driven
by IDUs and the initial decrease in the rates of infection were reported more than a decade
ago [3]. In 2009, 77% of new HIV infections were reported as sexually transmitted and IDUs
represented less than 8% of cases [1].
The HIV epidemic among IDUs continues to develop differently across different parts of Eu‐
rope. In the European Union, the reported rates of newly diagnosed cases of HIV infection
in IDUs are mostly stable or in decline [4]. Data on newly reported cases of HIV infection in
IDUs for 2009 suggest that rates of infection are still declining in Europe, following a peak in
2002, which was due to outbreaks in eastern countries. Reductions in the rates of HIV infec‐
tion in IDUs are partially the result of better preventive interventions and access to care
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[5,6], however, Spain is one of the western European countries reporting high rates of newly
diagnosed HIV infection among IDUs between 2004 and 2009 (Figure 1)[4].
Figure 1. Newly diagnosed HIV infections among IDUs from Europe and central Asia in 2009. Source: Annual Report
2011, European Monitoring Centre for Drugs and Drug Addiction(4).
Several studies have shown that IDUs are at increased risk of sexually transmitted HIV in‐
fection [7,8] and other authors have shown higher rates of HIV infection among recent and
younger IDUs [9,10].
Non-injecting drug users (non-IDUs) are not exposed to blood-borne infections, but remain
at risk of sexually transmitted diseases including HIV. Some studies have found a relation‐
ship between non-IDU and the increased risk of HIV and other sexually transmitted diseas‐
es [11,12]. Moreover, there have been reports on the causal relationship between alcohol
drinking and the risk of HIV infection [13-15].
1.1. Hepatitis B and C
About 80% of individuals exposed to hepatitis C virus (HCV) infection and 5% of adults ex‐
posed to hepatitis B virus (HBV) infection develop chronic liver disease. Cirrhosis and hepa‐
tocellular carcinoma are the most important sequelae of these infections [16].
It is well known that HCV infection is highly prevalent among drug users and that many
IDUs contract the infection early in the course of injecting drugs; this implies that there may
be only a small time window for initiating preventive interventions to reduce transmission
of HCV infection.
About 10 million IDUs (range 6.0-15.2 million) worldwide were anti-HCV positive in 2010
and 1.2 million IDUs (range 0.3-2.7 million) were HBV infected (HBsAg positive). Geograph‐
ical differences exist in the distribution of blood-borne infections among drug users and
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eastern Europe, east Asia and southeast Asia have the largest populations of IDUs infected
with viral hepatitis [4,17].
Two major risk factors for HBV infection include the IDU his/herself and unprotected sex
[18-21]. Studies among drug users from the United States have shown that 70% of cases are
infected within five years of initiating drug use [22] and that 38%-89% of IDUs from Europe
and North America have markers of HBV infection in cross-sectional studies [23].
In 2004, 16% of acute viral hepatitis reported to the Center for Disease Control in the United
States had recent use of injected drugs as a risk factor [24].
In any case, the epidemiology of hepatitis B virus infection in drug users and other subpo‐
pulations at risk may vary according to the extent of preventive immunization; in Spain, the
first selective hepatitis B vaccination programme began in 1984 [25].
In this study among IDUs and non-IDUs seeking treatment of substance abuse in Barcelona,
Spain, we aimed to analyse trends in the epidemiology of HIV, HCV and HBV infections.
2. Patients and methods
2.1. Setting and study population
Prospective study in a cohort of patients admitted to substance abuse treatment pro‐
grammes in three teaching hospitals between January 1997 and December 2006. The treat‐
ment units are located in Barcelona (Hospital del Mar), Badalona (Hospital Universitari
Germans Trias i Pujol) and L’Hospitalet de Llobregat (Hospital Universitari de Bellvitge).
Patients admitted to treatment were referred from primary care centres and the principal
criterion for admission was the severity of addiction. Patients were required to be older than
18 years and the main objective of admission was to control signs and symptoms of with‐
drawal. Upon admission, we collected socio-demographic characteristics, the history of sub‐
stance abuse (main drug, age at first drug use, route of administration, history of opioid
substitution treatment) and blood samples to test for HIV infection, HCV infection and HBV
(HBcAb) infection, as previously reported [26,27].
The blood samples were tested by Enzyme ImmunoAssay (EIA) for antibodies to HIV infec‐
tion and the results were confirmed by Western blot.
At discharge, patients were referred to their primary care providers. Pharmacological treat‐
ment was recommended in the majority of cases and all patients were advised to continue
with medical visits at the outpatient clinics.
For the purposes of this study, patients who were admitted more than once between 1997
and 2006 were analysed only with regard to the first admission. Similarly, data from two
hospitals were controlled so that no duplicate patients existed.
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[5,6], however, Spain is one of the western European countries reporting high rates of newly
diagnosed HIV infection among IDUs between 2004 and 2009 (Figure 1)[4].
Figure 1. Newly diagnosed HIV infections among IDUs from Europe and central Asia in 2009. Source: Annual Report
2011, European Monitoring Centre for Drugs and Drug Addiction(4).
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All the participants gave their consent for the determination of HIV and hepatitis serology.
The methods utilized to perform this study complied with ethical standards for medical re‐
search and with principles of good clinical practice.
2.2. Statistical analysis
Bivariate analyses were performed on the characteristics of patients according to the route of
drug administration: 1) non-IDU patients were defined as those individuals without a histo‐
ry of injection drug use; 2) IDU patients were defined as those with current or past use of
intravenous drug use. The bivariate analyses included the χ2 Pearson test for categorical var‐
iables and Student’s t test for continuous variables.
Prevalent cases correspond to patients that tested HIV, HCV or HBV-positive at admission.
Incident cases were defined as those HIV-seronegative patients at admission that subse‐
quently became HIV-positive during follow-up.
We carried out a direct measurement of HIV incidence based on the follow-up of the initial‐
ly HIV-seronegative patients. However, due to the relatively low percentage (44%) of pa‐
tients that underwent new HIV tests, we used a sensitivity analysis in a scenario based on
the absence of new infections among those not re-tested for HIV infection during follow-up.
Sensitivity analysis is useful in predicting the outcome of a decision if a situation turns out
to be different compared to that which was previously assumed. By creating a given set of
scenarios, the method can determine how changes in one variable will impact on the results.
All incidence rates were calculated in person-years with the number of HIV infections (inci‐
dent cases) in the numerator and the sum of follow-up times in the denominator.
Joinpoint regression models were fitted to analyse changes in trends of HIV and viral hepa‐
titis over time. These models evaluate changes that are produced on a logarithmic scale with
a binomial distribution for the prevalence of infection and a Poisson distribution for the inci‐
dence of infection.
Descriptive analyses of the data were performed with STATA, version 8.0 (Stata Corp., Col‐
lege Station, TX, USA). For the Joinpoint regression models, we used the US National Can‐
cer Institute’s Joinpoint Regression Program software [28].
P values less than 0.05 (p<0.05) were considered statistically significant.
3. Results
3.1. Characteristics of the study population
Between January 1997 and December 2006 there were 3,318 admissions corresponding to
2,488 patients, of which 2,432 were eligible. Median age at admission was 34 years (IQR: 29 -
40 years) and 78.7% were men. A total of 925 (38%) patients were non-IDUs and 1,507 (62%)
were current or past IDUs.
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The baseline characteristics of the patients according to the antecedent of IDU/non-IDU are
presented in Table 1. The majority of non-IDUs cases were patients with alcohol use disorders.
The main drug of abuse in IDUs patients was opiates (57.8%) and the median duration of
drug abuse was 12 years (IQR:5 – 17 years); 28.9% of them were receiving methadone at ad‐
mission. Non-IDU patients were significantly older (37 years, IQR 30 – 45 years) than in IDU
(32 years, IQR 28 – 37 years) (p<0.05). The non-IDU were admitted mostly (65.1%) during
the 2002 – 2006 period, whereas IDUs were admitted mostly (63%) during the 1997 – 2001
period (p<0.05). As expected, the prevalence of HCV infection was significantly higher in
IDUs (86.6%) than in non-IDUs (9.7%) (p< 0.05). In this sense, the prevalence of hepatitis B
virus infection (HBcAb-positive) was significantly higher in IDUs (56.8%) than in non-IDUs
(17.7%) (p<0.05) (Table 1).
Non-IDU IDU
p-valueN=925 N=1507
N (%) n (%)
Male 726 (78.5) 1188 (78.8) 0.840
Age median [IQR] 37 [30-45] 32 [28-37] <0.05








Duration of drug abuse, years
(n=1888) median [IQR] 10 [5-18] 12 [5-17] 0.079
HIV positive 26 (2.8) 636 (42.2) <0.05
HCV positive (n=2394) 88 (9.7) 1284 (86.6) <0.05
HBcAb positive (n=1890) 136 (17.7) 636 (56.8) <0.05










Antecedent of imprisonment (n=2291) 168 (19.4) 716 (50.2) <0.05
Methadone* (n=1499) 46 (7.7) 261 (28.9) <0.05
* Available in two hospitals
Table 1. Characteristics of IDU and non-IDU patients admitted to substance abuse treatment programmes in the
Barcelona area, Spain, 1997-2006.
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Table 1. Characteristics of IDU and non-IDU patients admitted to substance abuse treatment programmes in the
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Table 2 shows the prevalence and incidence of HIV infection in non-IDUs according to the
year of admission. Regarding HIV prevalence, 2.8% (95% CI: 1.8-4.1) of patients were HIV-
positive at admission with the highest prevalence of infection observed in 1999 (8.3%).
Among the 899 non-IDU, HIV-negative patients, 364 (40.5%) were followed-up for a median
of 2.3 years (IQR: 0.9 – 4.1 years; 1060 p-y); only five patients acquired HIV infection during
follow-up (incidence rate 0.47 x 100 p-y; 95% CI: 0.2-1.1).
The prevalence of HIV in IDUs was 42.2% (636/1507). The highest prevalence was observed
in 1997 (45.1%) and the lowest in 2006 (32.1%).
Among the 871 IDUs, HIV-negative patients, 47.1% were followed for a median of 2.7 years
(IQR: 1.2 - 5.2 years, 1415.5 p-y) and 36 acquired HIV infection (incidence rate 2.54 x 100 p-y
(95% CI: 1.8-3.5); the highest rate of infection was observed in 1999 (3.7 x 100p-y). Patients
followed-up were similar to those not followed regarding the proportion of male/female, the
main drug of abuse and the prevalence of HCV infection and HBV (HBcAb) infection.









n (%) 95% CI n (%) x100 p-y 95% CI
1997 0 (0.0) -- 51 24 (47.1) 13.7 0 0.00 --
1998 2 (3.3) (0.4-11.3) 59 30 (50.8) 37.8 1 2.65 (0.4-18.8)
1999 5 (8.3) (2.8-18.4) 55 25 (45.5) 52.1 0 0.00 --
2000 2 (2.7) (0.3-9.4) 72 24 (33.3) 71.1 0 0.00 --
2001 1 (1.3) (0.03-7.0) 76 34 (44.7) 93.9 0 0.00 --
2002 4 (3.9) (1.1-9.6) 99 44 (44.4) 112.8 0 0.00 --
2003 2 (1.7) (0.2-6.0) 116 50 (43.1) 138.3 1 0.72 (0.1-5.1)
2004 3 (2.5) (0.5-7.0) 119 50 (42.0) 170.1 1 0.59 (0.1-4.2)
2005 3 (2.5) (0.5-7.0) 118 35 (29.7) 184.9 1 0.54 (0.1-3.8)
2006 4 (2.9) (0.8-7.2) 134 48 (35.8) 185.3 1 0.54 (0.1-3.8)
1997-2006 26 (2.8) (1.8-4.1) 899 364 (40.5) 1060 5 0.47 (0.2-1.1)
Table 2. HIV serial prevalence and HIV serial incidence among non-IDUs by year of admission to substance abuse
treatment programmes in the Barcelona area, Spain, 1997-2006.
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Table 3 shows the prevalence and incidence of HIV infection in IDUs according to the year
of admission, ultimately showing values slightly lower than the rates registered since 1999.
Trends of HIV prevalence in non-IDUs is shown in the upper part of Figure 2 (Graphic A).
Overall, changes in HIV prevalence were not statistically significant, in spite of the model
indicating a decrease in prevalence over time (p=0.24).
In terms of HIV incidence (Figure 2, Graphic B), the model shows statistically significant dif‐
ferences over time (p=0.004).
The trend of HIV prevalence in IDUs showed a significant (p=0.01) decline between 1997
and 2006 (Figure 3, Graphic A). With respect to HIV incidence among IDUs, no changes
in the trends of infection rate were detected after adjusting the regression model (p=0.944)
(Figure 3, Graphic B).









n (%) 95% CI n (%) x100 p-y 95% CI
1997 124 (45.1) (39.1-51.2) 151 84 (55.6) 45.3 1 2.21 (0.3-15.7)
1998 84 (43.5) (36.4-50.8) 109 63 (57.8) 102.4 2 1.95 (0.5-7.8)
1999 83 (44.4) (37.1-51.8) 104 52 (50.0) 133.3 5 3.75 (1.6-9.0)
2000 71 (41.8) (34.3-59.6) 99 47 (47.5) 153.5 3 1.95 (0.6-6.1)
2001 53 (42.7) (33.9-51.9) 71 29 (40.8) 163.3 4 2.45 (0.9-6.5)
2002 59 (38.6) (30.8-46.8) 94 35 (37.2) 168.9 3 1.77 (0.6-5.5)
2003 50 (42.7) (33.6-52.2) 67 31 (46.3) 174.0 6 3.45 (1.5-7.7)
2004 53 (42.7) (33.9-51.9) 71 31 (43.7) 175.6 5 2.85 (1.2-6.8)
2005 34 (39.5) (29.1-50.7) 52 21 (40.4) 160.4 4 2.49 (0.9-6.6)
2006 25 (32.1) (21.9-43.6) 53 17 (32.1) 138.8 3 2.16 (0.7-6.7)
1997-2006 636 (42.2) (39.7-44.7) 871 410 (47.1) 1415.5 36 2.54 (1.8-3.5)
Table 3. HIV serial prevalence and HIV serial incidence in IDUs by year of admission to substance abuse treatment
programmes in the Barcelona area, Spain, 1997-2006.
In sensitivity analysis, the rate of HIV infection among non-IDUs was 0.19x100 p-y (95% CI:
0.07-0.45) and 1.08 x100p-y (95% CI: 0.5-1.5) among IDUs.
In sensitivity analysis, trends of HIV incidence for non-IDU patients remained unchanged
with respect to the direct method. However, HIV incidence for IDUs significantly decreased
over time in the best scenario (no new infections among those lost to follow-up, p=0.04).
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Table 3 shows the prevalence and incidence of HIV infection in IDUs according to the year
of admission, ultimately showing values slightly lower than the rates registered since 1999.
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The prevalence of HCV infection and HBV (HBcAb) infection in non-IDUs was 9.7%, and
17.7%, respectively. The prevalence of HCV in the years analysed oscillated between 6.8%
and 15.6%, but differences were not statistically significant (p=0.589) (Figure 4, Graphic A).
As expected, the prevalence of HCV infection in IDUs was high (86.6%) and changes over
the years analysed were negligible (p=0.240) (Figure 5, Graphic A).
The prevalence of HBV (HBcAb) infection in non-IDUs oscillated between 8.3% and 22.9%,
and changes over time were not statistically significant (p=0.696) (Figure 4, Graphic B). HBV
(HBcAb) infection was observed in 56.8% of IDUs, which oscillated between 48.8% and
64.3% in the years analysed. Analysis of the trend did not show statistically significant dif‐
ferences during the period analysed (p=0.218) (Figure 5, Graphic B).
Graphic B 
Graphic A 
Figure 2. Trends in HIV prevalence (Graphic A) and HIV incidence (Graphic B) in non-IDU patients admitted to sub‐
stance abuse treatment programmes in the Barcelona area, Spain, 1997- 2006.
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Figure 3. Trends in HIV prevalence (Graphic A) and HIV incidence (Graphic B) in IDUs admitted to substance abuse
treatment programmes in the Barcelona area, Spain, 1997- 2006.
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As expected, the prevalence of HCV infection in IDUs was high (86.6%) and changes over
the years analysed were negligible (p=0.240) (Figure 5, Graphic A).
The prevalence of HBV (HBcAb) infection in non-IDUs oscillated between 8.3% and 22.9%,
and changes over time were not statistically significant (p=0.696) (Figure 4, Graphic B). HBV
(HBcAb) infection was observed in 56.8% of IDUs, which oscillated between 48.8% and
64.3% in the years analysed. Analysis of the trend did not show statistically significant dif‐
ferences during the period analysed (p=0.218) (Figure 5, Graphic B).
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Figure 2. Trends in HIV prevalence (Graphic A) and HIV incidence (Graphic B) in non-IDU patients admitted to sub‐
stance abuse treatment programmes in the Barcelona area, Spain, 1997- 2006.
Current Perspectives in HIV Infection374
Graphic B 
Graphic A 
Figure 3. Trends in HIV prevalence (Graphic A) and HIV incidence (Graphic B) in IDUs admitted to substance abuse
treatment programmes in the Barcelona area, Spain, 1997- 2006.





Figure 4. Prevalence of HCV infection (Graphic A) and HBV infection (Graphic B) in non-IDUs admitted to treatment
programmes in the Barcelona area, Spain, 1997- 2006.
Current Perspectives in HIV Infection376
Graphic B 
Graphic A 
Figure 5. Prevalence of HCV infection (Graphic A) and HBV infection (Graphic B) in IDUs admitted to treatment pro‐
grammes in the Barcelona area, Spain, 1997- 2006.





Figure 4. Prevalence of HCV infection (Graphic A) and HBV infection (Graphic B) in non-IDUs admitted to treatment
programmes in the Barcelona area, Spain, 1997- 2006.
Current Perspectives in HIV Infection376
Graphic B 
Graphic A 
Figure 5. Prevalence of HCV infection (Graphic A) and HBV infection (Graphic B) in IDUs admitted to treatment pro‐
grammes in the Barcelona area, Spain, 1997- 2006.




Results from this cohort of patients seeking substance abuse treatment indicate that drug
users, irrespective of the main route of drug administration, are at increased risk of HIV in‐
fection and viral hepatitis. In fact, the prevalence of HIV infection and HCV infection in non-
IDU patients is 2.8% and 9.7%, respectively. Several studies analysing risky sexual
behaviour of drug and alcohol abusers suggest an association between cocaine, ampheta‐
mines or alcohol abuse and the sexual transmission of HIV [19-24], which could explain the
relatively high prevalence of HIV infection among non-IDU patients from this study [29-34].
Despite the relatively high prevalence of HIV infection, there was a trend in the decline of
HIV incidence among the non-IDUs. To some extent, the incidence of HIV infection was low
(0.47 per 100 p-y) and the results shown here indicate that non-IDUs have a fivefold lower
risk of HIV than the IDUs, as shown in a previous study [35].
The observed decline in the prevalence of HIV infection among IDUs is likely the result of
some preventive interventions introduced in Spain at the beginning of 1990s. Harm-reduc‐
tion interventions to reduce the impact of the HIV epidemic associated with heroin depend‐
ence included the access to opioid substitution therapy with methadone and the needle
exchange programmes, among other interventions. Our findings indicate that HIV infection
among IDUs from metropolitan Barcelona has stabilized and that rates of new infections are
moderate with respect to reports from other cities [36-38]. In addition, our results agree with
those reported nationally, indicating that sexual transmission now represents 80% of new
HIV infections in Spain [39]. Further, our results show that the proportion of IDUs being ad‐
mitted for substance abuse treatment is declining, suggesting a decrease in the number of
IDUs in Spain [40].
Data from European countries show tendencies toward a low rate of HIV infection in drug
users. For example, Poland, Finland and Germany have considerably reduced the rates of
infection to two cases per million inhabitants in 2007 [41]. In this study, we determined an
overall rate of infection of 2.54 per 100 p-y between 1997 and 2006, which is similar to that
observed in other studies [6].
In contrast, the decline in the prevalence of HIV infection is not accompanied by a decline in
HCV prevalence [42,43]. This observation suggests that IDUs still maintain non-sterile injec‐
tion practices. The HIV and hepatitis C virus are transmitted primarily by large or repeated
direct percutaneous exposures to contaminated blood. In Spain, IDU is a factor in 28% of all
contemporary AIDS cases and it accounts for more than 60% of new hepatitis C infections in
Europe and the USA [1,44].
It is well known that the majority of IDUs become infected with hepatitis C during their first
year of injecting and that because of its infectivity HCV spreads more rapidly than HIV
[45,46,47].
In this study, the prevalence of HBV is high. A recent systematic review suggests that
worldwide around 1.2 million IDUs are chronic carriers of HBV infection and that the pat‐
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tern of infection shows clear geographical differences [17]. In fact, rates of HBcAb-positive
varied widely between countries from 4.2% in Slovenia to 85.0% in Mexico [17].
Because of the high rate of both HCV and HBV infection, the probability of coinfection in
IDUs is high. In this sense, vaccination against HBV must be prioritized for all susceptible
drug users.
There are several limitations to this study that need to be mentioned. First of all, a propor‐
tion of patients, HIV-seronegative, were not re-tested for HIV infection during follow-up de‐
spite the fact that many of them were regularly visited in their primary care centres; in this
sense, assessment of risk behaviour and awareness of drug use disorders by health care pro‐
fessionals are key components for developing preventive interventions. Second, in this
study assessment of HBV infection was limited to one marker of infection; in other words,
more accurate estimation of chronic carriers of HBV infection, susceptibility to infection or
immunization due to HBV vaccination was not available. For the HCV pattern of infection
we only analysed antibodies against HCV and RNA-HCV was not available; it is well
known that a minority (10-15%) of the individuals infected with HCV clear the virus during
the natural history of the disease. Third, in this study we did not analyse the impact of sexu‐
al transmission of HIV and viral hepatitis on the results shown here. In this sense, drug-ad‐
dicted women have been reported to have a higher risk of HIV infection than drug-addicted
men [48].
In contrast, the strength of this cross-sectional and longitudinal study is based on data col‐
lected at three centres that provide clinical care and treatment for the majority of severe
drug addicts in Barcelona and its metropolitan area. Having data from the three hospitals
adds external validity to the results and may reflect changes in the epidemiology of HIV and
viral hepatitis in young adults seeking treatment for substance abuse in an urban area.
In summary, since 1997 we observed a significant decline in the prevalence of HIV infection
in IDUs, however, background prevalence of HIV and viral hepatitis is still high thus sug‐
gesting that prevention efforts and treatment of substance abuse are necessary to further re‐
duce transmission of blood-borne infections in this population.
Nomenclature
HIV= Human Immunodeficiency Virus.
IDU= Injecting Drug User.
AIDS= Acquired Immunodeficiency Syndrome.
HAART= Highly Active Antiretroviral Therapy.
HCV= Hepatitis C virus.
HBV= Hepatitis B virus.
HBsAg= Surface Antigen of Hepatitis B Virus.




Results from this cohort of patients seeking substance abuse treatment indicate that drug
users, irrespective of the main route of drug administration, are at increased risk of HIV in‐
fection and viral hepatitis. In fact, the prevalence of HIV infection and HCV infection in non-
IDU patients is 2.8% and 9.7%, respectively. Several studies analysing risky sexual
behaviour of drug and alcohol abusers suggest an association between cocaine, ampheta‐
mines or alcohol abuse and the sexual transmission of HIV [19-24], which could explain the
relatively high prevalence of HIV infection among non-IDU patients from this study [29-34].
Despite the relatively high prevalence of HIV infection, there was a trend in the decline of
HIV incidence among the non-IDUs. To some extent, the incidence of HIV infection was low
(0.47 per 100 p-y) and the results shown here indicate that non-IDUs have a fivefold lower
risk of HIV than the IDUs, as shown in a previous study [35].
The observed decline in the prevalence of HIV infection among IDUs is likely the result of
some preventive interventions introduced in Spain at the beginning of 1990s. Harm-reduc‐
tion interventions to reduce the impact of the HIV epidemic associated with heroin depend‐
ence included the access to opioid substitution therapy with methadone and the needle
exchange programmes, among other interventions. Our findings indicate that HIV infection
among IDUs from metropolitan Barcelona has stabilized and that rates of new infections are
moderate with respect to reports from other cities [36-38]. In addition, our results agree with
those reported nationally, indicating that sexual transmission now represents 80% of new
HIV infections in Spain [39]. Further, our results show that the proportion of IDUs being ad‐
mitted for substance abuse treatment is declining, suggesting a decrease in the number of
IDUs in Spain [40].
Data from European countries show tendencies toward a low rate of HIV infection in drug
users. For example, Poland, Finland and Germany have considerably reduced the rates of
infection to two cases per million inhabitants in 2007 [41]. In this study, we determined an
overall rate of infection of 2.54 per 100 p-y between 1997 and 2006, which is similar to that
observed in other studies [6].
In contrast, the decline in the prevalence of HIV infection is not accompanied by a decline in
HCV prevalence [42,43]. This observation suggests that IDUs still maintain non-sterile injec‐
tion practices. The HIV and hepatitis C virus are transmitted primarily by large or repeated
direct percutaneous exposures to contaminated blood. In Spain, IDU is a factor in 28% of all
contemporary AIDS cases and it accounts for more than 60% of new hepatitis C infections in
Europe and the USA [1,44].
It is well known that the majority of IDUs become infected with hepatitis C during their first
year of injecting and that because of its infectivity HCV spreads more rapidly than HIV
[45,46,47].
In this study, the prevalence of HBV is high. A recent systematic review suggests that
worldwide around 1.2 million IDUs are chronic carriers of HBV infection and that the pat‐
Current Perspectives in HIV Infection378
tern of infection shows clear geographical differences [17]. In fact, rates of HBcAb-positive
varied widely between countries from 4.2% in Slovenia to 85.0% in Mexico [17].
Because of the high rate of both HCV and HBV infection, the probability of coinfection in
IDUs is high. In this sense, vaccination against HBV must be prioritized for all susceptible
drug users.
There are several limitations to this study that need to be mentioned. First of all, a propor‐
tion of patients, HIV-seronegative, were not re-tested for HIV infection during follow-up de‐
spite the fact that many of them were regularly visited in their primary care centres; in this
sense, assessment of risk behaviour and awareness of drug use disorders by health care pro‐
fessionals are key components for developing preventive interventions. Second, in this
study assessment of HBV infection was limited to one marker of infection; in other words,
more accurate estimation of chronic carriers of HBV infection, susceptibility to infection or
immunization due to HBV vaccination was not available. For the HCV pattern of infection
we only analysed antibodies against HCV and RNA-HCV was not available; it is well
known that a minority (10-15%) of the individuals infected with HCV clear the virus during
the natural history of the disease. Third, in this study we did not analyse the impact of sexu‐
al transmission of HIV and viral hepatitis on the results shown here. In this sense, drug-ad‐
dicted women have been reported to have a higher risk of HIV infection than drug-addicted
men [48].
In contrast, the strength of this cross-sectional and longitudinal study is based on data col‐
lected at three centres that provide clinical care and treatment for the majority of severe
drug addicts in Barcelona and its metropolitan area. Having data from the three hospitals
adds external validity to the results and may reflect changes in the epidemiology of HIV and
viral hepatitis in young adults seeking treatment for substance abuse in an urban area.
In summary, since 1997 we observed a significant decline in the prevalence of HIV infection
in IDUs, however, background prevalence of HIV and viral hepatitis is still high thus sug‐
gesting that prevention efforts and treatment of substance abuse are necessary to further re‐
duce transmission of blood-borne infections in this population.
Nomenclature
HIV= Human Immunodeficiency Virus.
IDU= Injecting Drug User.
AIDS= Acquired Immunodeficiency Syndrome.
HAART= Highly Active Antiretroviral Therapy.
HCV= Hepatitis C virus.
HBV= Hepatitis B virus.
HBsAg= Surface Antigen of Hepatitis B Virus.
HIV Infection and Viral Hepatitis in Drug Abusers
http://dx.doi.org/10.5772/53074
379






This work was partially funded by grants from the Ministry of Science and Innovation,
Spain (grants RD06/001, RD06/006 and PI07/0342), Ministry of Health (grant EC11-042) and
Ministry of Education (grant 2010-0945).
Author details
Arantza Sanvisens1, Ferran Bolao2, Gabriel Vallecillo3, Marta Torrens4, Daniel Fuster5,8,
Santiago Pérez-Hoyos6, Jordi Tor5, Inmaculada Rivas7 and Robert Muga1*
*Address all correspondence to: rmuga.germanstrias@gencat.cat
1 Department of Internal Medicine and AIDS Vaccine Research Project – HIVACAT. Hospi‐
tal Universitari Germans Trias i Pujol, Badalona, Universitat Autònoma Barcelona, Spain
2 Department of Internal Medicine. Hospital Universitari de Bellvitge, L’Hospitalet de Llo‐
bregat, Universitat de Barcelona, Spain
3 Department of Internal Medicine and Institute of Neuropsychiatry & Addictions. Parc de
Salut Mar, Barcelona, Universitat Autònoma Barcelona, Spain
4 Institute of Neuropsychiatry & Addictions. Parc de Salut Mar, Barcelona, Universitat Au‐
tònoma Barcelona, Spain
5 Department of Internal Medicine. Hospital Universitari Germans Trias i Pujol, Badalona,
Universitat Autònoma Barcelona, Spain
6 Department of Preventive Medicine and Public Health. Vall d’Hebrón Institut de Recerca.
Universitat Autònoma Barcelona, Spain
7 Municipal Centre for Substance Abuse Treatment (Centro Delta). IMSP Badalona, Spain
8 Section of General Internal Medicine. Boston Medical Center, Boston University School of
Medicine; Boston (MA), U.S.A.
Current Perspectives in HIV Infection380
References
[1] Vigilancia epidemiológica del VIH en España. Nuevos diagnósticos de VIH en Espa‐
ña. Periodo 2003-2009. Ministerio de Sanidad, Política Social e Igualdad, Ministerio
de Ciencia e Innovación; 2010.
[2] Hernandez-Aguado I, Avino MJ, Perez-Hoyos S, Gonzalez-Aracil J, Ruiz-Perez I,
Torrella A, et al. Human immunodeficiency virus (HIV) infection in parenteral drug
users: evolution of the epidemic over 10 years. Valencian Epidemiology and Preven‐
tion of HIV Disease Study Group. Int J Epidemiol 1999;28(2):335-340.
[3] Castilla J, Lorenzo JM, Izquierdo A, Lezaun ME, Lopez I, Moreno-Iribas C, et al.
Characteristics and trends of newly diagnosed HIV-infections, 2000-2004. Gac Sanit
2006;20(6):442-448.
[4] European Monitoring Centre for Drugs and Drug Addiction. Annual report 2011:
The state of the drug problems in Europe. EMCDDA, Lisbon, November 2011. http://
www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCD‐
DA_AR2011_EN.pdf (accessed 30 July 2012)
[5] Muga R, Sanvisens A, Bolao F, Tor J, Santesmases J, Pujol R, et al. Significant reduc‐
tions of HIV prevalence but not of hepatitis C virus infections in injection drug users
from metropolitan Barcelona: 1987-2001. Drug Alcohol Depend 2006;82 Suppl
1:S29-33.
[6] Hurtado I, Alastrue I, Ferreros I, del Amo J, Santos C, Tasa T, et al. Trends in HIV
testing, serial HIV prevalence and HIV incidence among people attending a Center
for AIDS Prevention from 1988 to 2003. Sex Transm Infect 2007;83(1):23-28. DOI:
10.1136/sti.2005.019299.
[7] Celentano DD, Latimore AD, Mehta SH. Variations in sexual risks in drug users:
emerging themes in a behavioral context. Curr HIV/AIDS Rep 2008;5(4):212-218.
[8] Nelson KE, Galai N, Safaeian M, Strathdee SA, Celentano DD, Vlahov D. Temporal
trends in the incidence of human immunodeficiency virus infection and risk behav‐
ior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol
2002;156(7):641-653.
[9] Chitwood DD, Comerford M, Sanchez J. Prevalence and risk factors for HIV among
sniffers, short-term injectors, and long-term injectors of heroin. J Psychoactive Drugs
2003;35(4):445-453.
[10] Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, et al. The future face
of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection
among young injection drug users. J Acquir Immune Defic Syndr 2004;36(2):743-749.
[11] Jenness SM, Neaigus A, Hagan H, Murrill CS, Wendel T. Heterosexual HIV and sex‐
ual partnerships between injection drug users and noninjection drug users. AIDS Pa‐
tient Care STDS 2010;24(3):175-181. DOI:10.1089/apc.2009.0227.
HIV Infection and Viral Hepatitis in Drug Abusers
http://dx.doi.org/10.5772/53074
381






This work was partially funded by grants from the Ministry of Science and Innovation,
Spain (grants RD06/001, RD06/006 and PI07/0342), Ministry of Health (grant EC11-042) and
Ministry of Education (grant 2010-0945).
Author details
Arantza Sanvisens1, Ferran Bolao2, Gabriel Vallecillo3, Marta Torrens4, Daniel Fuster5,8,
Santiago Pérez-Hoyos6, Jordi Tor5, Inmaculada Rivas7 and Robert Muga1*
*Address all correspondence to: rmuga.germanstrias@gencat.cat
1 Department of Internal Medicine and AIDS Vaccine Research Project – HIVACAT. Hospi‐
tal Universitari Germans Trias i Pujol, Badalona, Universitat Autònoma Barcelona, Spain
2 Department of Internal Medicine. Hospital Universitari de Bellvitge, L’Hospitalet de Llo‐
bregat, Universitat de Barcelona, Spain
3 Department of Internal Medicine and Institute of Neuropsychiatry & Addictions. Parc de
Salut Mar, Barcelona, Universitat Autònoma Barcelona, Spain
4 Institute of Neuropsychiatry & Addictions. Parc de Salut Mar, Barcelona, Universitat Au‐
tònoma Barcelona, Spain
5 Department of Internal Medicine. Hospital Universitari Germans Trias i Pujol, Badalona,
Universitat Autònoma Barcelona, Spain
6 Department of Preventive Medicine and Public Health. Vall d’Hebrón Institut de Recerca.
Universitat Autònoma Barcelona, Spain
7 Municipal Centre for Substance Abuse Treatment (Centro Delta). IMSP Badalona, Spain
8 Section of General Internal Medicine. Boston Medical Center, Boston University School of
Medicine; Boston (MA), U.S.A.
Current Perspectives in HIV Infection380
References
[1] Vigilancia epidemiológica del VIH en España. Nuevos diagnósticos de VIH en Espa‐
ña. Periodo 2003-2009. Ministerio de Sanidad, Política Social e Igualdad, Ministerio
de Ciencia e Innovación; 2010.
[2] Hernandez-Aguado I, Avino MJ, Perez-Hoyos S, Gonzalez-Aracil J, Ruiz-Perez I,
Torrella A, et al. Human immunodeficiency virus (HIV) infection in parenteral drug
users: evolution of the epidemic over 10 years. Valencian Epidemiology and Preven‐
tion of HIV Disease Study Group. Int J Epidemiol 1999;28(2):335-340.
[3] Castilla J, Lorenzo JM, Izquierdo A, Lezaun ME, Lopez I, Moreno-Iribas C, et al.
Characteristics and trends of newly diagnosed HIV-infections, 2000-2004. Gac Sanit
2006;20(6):442-448.
[4] European Monitoring Centre for Drugs and Drug Addiction. Annual report 2011:
The state of the drug problems in Europe. EMCDDA, Lisbon, November 2011. http://
www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCD‐
DA_AR2011_EN.pdf (accessed 30 July 2012)
[5] Muga R, Sanvisens A, Bolao F, Tor J, Santesmases J, Pujol R, et al. Significant reduc‐
tions of HIV prevalence but not of hepatitis C virus infections in injection drug users
from metropolitan Barcelona: 1987-2001. Drug Alcohol Depend 2006;82 Suppl
1:S29-33.
[6] Hurtado I, Alastrue I, Ferreros I, del Amo J, Santos C, Tasa T, et al. Trends in HIV
testing, serial HIV prevalence and HIV incidence among people attending a Center
for AIDS Prevention from 1988 to 2003. Sex Transm Infect 2007;83(1):23-28. DOI:
10.1136/sti.2005.019299.
[7] Celentano DD, Latimore AD, Mehta SH. Variations in sexual risks in drug users:
emerging themes in a behavioral context. Curr HIV/AIDS Rep 2008;5(4):212-218.
[8] Nelson KE, Galai N, Safaeian M, Strathdee SA, Celentano DD, Vlahov D. Temporal
trends in the incidence of human immunodeficiency virus infection and risk behav‐
ior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol
2002;156(7):641-653.
[9] Chitwood DD, Comerford M, Sanchez J. Prevalence and risk factors for HIV among
sniffers, short-term injectors, and long-term injectors of heroin. J Psychoactive Drugs
2003;35(4):445-453.
[10] Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, et al. The future face
of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection
among young injection drug users. J Acquir Immune Defic Syndr 2004;36(2):743-749.
[11] Jenness SM, Neaigus A, Hagan H, Murrill CS, Wendel T. Heterosexual HIV and sex‐
ual partnerships between injection drug users and noninjection drug users. AIDS Pa‐
tient Care STDS 2010;24(3):175-181. DOI:10.1089/apc.2009.0227.
HIV Infection and Viral Hepatitis in Drug Abusers
http://dx.doi.org/10.5772/53074
381
[12] Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among
injection and non-injection drug users. J Urban Health 2003;80(4 Suppl 3):iii7-14.
[13] Howe CJ, Cole SR, Ostrow DG, Mehta SH, Kirk GD. A prospective study of alcohol
consumption and HIV acquisition among injection drug users. AIDS 2011;25(2):
221-228. DOI:10.1097/QAD.0b013e328340fee2.
[14] Zakhari S, Li TK. Determinants of alcohol use and abuse: Impact of quantity and fre‐
quency patterns on liver disease. Hepatology 2007;46(6):2032-2039. DOI:10.1002/hep.
22010.
[15] Shuper PA, Neuman M, Kanteres F, Baliunas D, Joharchi N, Rehm J. Causal consid‐
erations on alcohol and HIV/AIDS--a systematic review. Alcohol Alcohol 2010;45(2):
159-166. DOI:10.1093/alcalc/agp091.
[16] Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview.
Clin Liver Dis 2010;14(1):1-21, vii. DOI:10.1016/j.cld.2009.11.009.
[17] Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global
epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of sys‐
tematic reviews. Lancet 2011;378(9791):571-583. DOI:10.1016/S0140-6736(11)61097-0.
[18] Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehen‐
sive immunization strategy to eliminate transmission of hepatitis B virus infection in
the United States: recommendations of the Advisory Committee on Immunization
Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep
2006;55(RR-16):1-33; quiz CE1-4.
[19] Kuo I, Sherman SG, Thomas DL, Strathdee SA. Hepatitis B virus infection and vacci‐
nation among young injection and non-injection drug users: missed opportunities to
prevent infection. Drug Alcohol Depend 2004;73(1):69-78.
[20] Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23(1):
39-46. DOI:10.1055/s-2003-37583.
[21] Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Inci‐
dence and risk factors for acute hepatitis B in the United States, 1982-1998: implica‐
tions for vaccination programs. J Infect Dis 2002;185(6):713-719. DOI:10.1086/339192.
[22] Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-
term injection drug users: the prevalence of the hepatitis C, hepatitis B, human im‐
munodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86(5):
655-661.
[23] Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology
of hepatitis B virus in a population of injecting drug users. Association with drug in‐
jection patterns. Am J Epidemiol 1995;142(3):331-341.
[24] Burt RD, Hagan H, Garfein RS, Sabin K, Weinbaum C, Thiede H. Trends in hepatitis
B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk be‐
Current Perspectives in HIV Infection382
haviors, and preventive measures among Seattle injection drug users aged 18-30
years, 1994-2004. J Urban Health 2007;84(3):436-454. DOI:10.1007/s11524-007-9178-2.
[25] Salleras L, Bruguera M, Taberner JL, Dominguez A, Batalla J, Buti M, et al. Effective‐
ness of the mass antihepatitis B program in preadolescents in Catalonia. Med Clin
(Barc) 2003;121 Suppl 1:79-82.
[26] Muga R, Roca J, Egea JM, Tor J, Sirera G, Rey-Joly C, et al. Mortality of HIV-positive
and HIV-negative heroin abusers as a function of duration of injecting drug use. J
Acquir Immune Defic Syndr 2000;23(4):332-338.
[27] Rivas I, Martinez E, Sanvisens A, Bolao F, Tor J, Torrens M, et al. Hepatitis B virus
serum profiles in injection drug users and rates of immunization over time in Barce‐
lona: 1987-2006. Drug Alcohol Depend 2010;110(3):234-9. DOI:10.1016/j.drugalcdep.
2010.03.005.
[28] US National Cancer Institute Software. Jointpoint Regression Program. 2010;3.4.3.
[29] Wang B, Li X, Stanton B, Zhang L, Fang X. Alcohol Use, Unprotected Sex, and Sexu‐
ally Transmitted Infections Among Female Sex Workers in China. Sex Transm Dis
2010;37(10):629-36. DOI:10.1097/OLQ.0b013e3181e2118a.
[30] Baliunas D, Rehm J, Irving H, Shuper P. Alcohol consumption and risk of incident
human immunodeficiency virus infection: a meta-analysis. Int J Public Health
2010;55(3):159-166. DOI:10.1007/s00038-009-0095-x.
[31] Booth RE, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviors: differen‐
tial risks among injection drug users, crack smokers, and injection drug users who
smoke crack. Drug Alcohol Depend 2000;58(3):219-226.
[32] de Azevedo RC, Botega NJ, Guimaraes LA. Crack users, sexual behavior and risk of
HIV infection. Rev Bras Psiquiatr 2007;29(1):26-30.
[33] Colfax G, Santos GM, Chu P, Vittinghoff E, Pluddemann A, Kumar S, et al. Ampheta‐
mine-group substances and HIV. Lancet 2010;376(9739):458-474. DOI:10.1016/
S0140-6736(10)60753-2.
[34] Van Tieu H, Koblin BA. HIV, alcohol, and noninjection drug use. Curr Opin HIV
AIDS 2009;4(4):314-318. DOI:10.1097/COH.0b013e32832aa902.
[35] Kellogg TA, McFarland W, Perlman JL, Weinstock H, Bock S, Katz MH, et al. HIV
incidence among repeat HIV testers at a county hospital, San Francisco, California,
USA. J Acquir Immune Defic Syndr 2001;28(1):59-64.
[36] Kozlov AP, Shaboltas AV, Toussova OV, Verevochkin SV, Masse BR, Perdue T, et al.
HIV incidence and factors associated with HIV acquisition among injection drug
users in St Petersburg, Russia. AIDS 2006;20(6):901-906. DOI:10.1097/01.aids.
0000218555.36661.9c.
HIV Infection and Viral Hepatitis in Drug Abusers
http://dx.doi.org/10.5772/53074
383
[12] Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among
injection and non-injection drug users. J Urban Health 2003;80(4 Suppl 3):iii7-14.
[13] Howe CJ, Cole SR, Ostrow DG, Mehta SH, Kirk GD. A prospective study of alcohol
consumption and HIV acquisition among injection drug users. AIDS 2011;25(2):
221-228. DOI:10.1097/QAD.0b013e328340fee2.
[14] Zakhari S, Li TK. Determinants of alcohol use and abuse: Impact of quantity and fre‐
quency patterns on liver disease. Hepatology 2007;46(6):2032-2039. DOI:10.1002/hep.
22010.
[15] Shuper PA, Neuman M, Kanteres F, Baliunas D, Joharchi N, Rehm J. Causal consid‐
erations on alcohol and HIV/AIDS--a systematic review. Alcohol Alcohol 2010;45(2):
159-166. DOI:10.1093/alcalc/agp091.
[16] Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview.
Clin Liver Dis 2010;14(1):1-21, vii. DOI:10.1016/j.cld.2009.11.009.
[17] Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global
epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of sys‐
tematic reviews. Lancet 2011;378(9791):571-583. DOI:10.1016/S0140-6736(11)61097-0.
[18] Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehen‐
sive immunization strategy to eliminate transmission of hepatitis B virus infection in
the United States: recommendations of the Advisory Committee on Immunization
Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep
2006;55(RR-16):1-33; quiz CE1-4.
[19] Kuo I, Sherman SG, Thomas DL, Strathdee SA. Hepatitis B virus infection and vacci‐
nation among young injection and non-injection drug users: missed opportunities to
prevent infection. Drug Alcohol Depend 2004;73(1):69-78.
[20] Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23(1):
39-46. DOI:10.1055/s-2003-37583.
[21] Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Inci‐
dence and risk factors for acute hepatitis B in the United States, 1982-1998: implica‐
tions for vaccination programs. J Infect Dis 2002;185(6):713-719. DOI:10.1086/339192.
[22] Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-
term injection drug users: the prevalence of the hepatitis C, hepatitis B, human im‐
munodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86(5):
655-661.
[23] Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology
of hepatitis B virus in a population of injecting drug users. Association with drug in‐
jection patterns. Am J Epidemiol 1995;142(3):331-341.
[24] Burt RD, Hagan H, Garfein RS, Sabin K, Weinbaum C, Thiede H. Trends in hepatitis
B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk be‐
Current Perspectives in HIV Infection382
haviors, and preventive measures among Seattle injection drug users aged 18-30
years, 1994-2004. J Urban Health 2007;84(3):436-454. DOI:10.1007/s11524-007-9178-2.
[25] Salleras L, Bruguera M, Taberner JL, Dominguez A, Batalla J, Buti M, et al. Effective‐
ness of the mass antihepatitis B program in preadolescents in Catalonia. Med Clin
(Barc) 2003;121 Suppl 1:79-82.
[26] Muga R, Roca J, Egea JM, Tor J, Sirera G, Rey-Joly C, et al. Mortality of HIV-positive
and HIV-negative heroin abusers as a function of duration of injecting drug use. J
Acquir Immune Defic Syndr 2000;23(4):332-338.
[27] Rivas I, Martinez E, Sanvisens A, Bolao F, Tor J, Torrens M, et al. Hepatitis B virus
serum profiles in injection drug users and rates of immunization over time in Barce‐
lona: 1987-2006. Drug Alcohol Depend 2010;110(3):234-9. DOI:10.1016/j.drugalcdep.
2010.03.005.
[28] US National Cancer Institute Software. Jointpoint Regression Program. 2010;3.4.3.
[29] Wang B, Li X, Stanton B, Zhang L, Fang X. Alcohol Use, Unprotected Sex, and Sexu‐
ally Transmitted Infections Among Female Sex Workers in China. Sex Transm Dis
2010;37(10):629-36. DOI:10.1097/OLQ.0b013e3181e2118a.
[30] Baliunas D, Rehm J, Irving H, Shuper P. Alcohol consumption and risk of incident
human immunodeficiency virus infection: a meta-analysis. Int J Public Health
2010;55(3):159-166. DOI:10.1007/s00038-009-0095-x.
[31] Booth RE, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviors: differen‐
tial risks among injection drug users, crack smokers, and injection drug users who
smoke crack. Drug Alcohol Depend 2000;58(3):219-226.
[32] de Azevedo RC, Botega NJ, Guimaraes LA. Crack users, sexual behavior and risk of
HIV infection. Rev Bras Psiquiatr 2007;29(1):26-30.
[33] Colfax G, Santos GM, Chu P, Vittinghoff E, Pluddemann A, Kumar S, et al. Ampheta‐
mine-group substances and HIV. Lancet 2010;376(9739):458-474. DOI:10.1016/
S0140-6736(10)60753-2.
[34] Van Tieu H, Koblin BA. HIV, alcohol, and noninjection drug use. Curr Opin HIV
AIDS 2009;4(4):314-318. DOI:10.1097/COH.0b013e32832aa902.
[35] Kellogg TA, McFarland W, Perlman JL, Weinstock H, Bock S, Katz MH, et al. HIV
incidence among repeat HIV testers at a county hospital, San Francisco, California,
USA. J Acquir Immune Defic Syndr 2001;28(1):59-64.
[36] Kozlov AP, Shaboltas AV, Toussova OV, Verevochkin SV, Masse BR, Perdue T, et al.
HIV incidence and factors associated with HIV acquisition among injection drug
users in St Petersburg, Russia. AIDS 2006;20(6):901-906. DOI:10.1097/01.aids.
0000218555.36661.9c.
HIV Infection and Viral Hepatitis in Drug Abusers
http://dx.doi.org/10.5772/53074
383
[37] Duan S, Xiang LF, Yang YC, Ye RH, Jia MH, Luo HB, et al. Incidence and risk factors
on HIV infection among injection drug users in Dehong prefecture area of Yunnan
province. Zhonghua Liu Xing Bing Xue Za Zhi 2009;30(12):1226-1229.
[38] Hurtado Navarro I, Alastrue I, Del Amo J, Santos C, Ferreros I, Tasa T, et al. Differen‐
ces between women and men in serial HIV prevalence and incidence trends. Eur J
Epidemiol 2008;23(6):435-440. DOI:10.1007/s10654-008-9246-2.
[39] Valoración de los nuevos diagnósticos de VIH en España a partir de los sistemas de
notificación de casos de las CCAA. Periodo 2003-2008. Ministerio de Sanidad y Políti‐
ca Social, Ministerio de Ciencia e Innovación;2009. http://www.isciii.es/htdocs/pdf/
nuevos_diagnosticos_ccaa.pdf. (accessed 30 july 2012)
[40] Sanchez-Niubo A, Domingo-Salvany A, Melis GG, Brugal MT, Scalia-Tomba G. Two
methods to analyze trends in the incidence of heroin and cocaine use in Barcelona
[Spain]. Gac Sanit 2007;21(5):397-403.
[41] European Monitoring centre for Drugs and Drug Addiction. Drug-related infectious
diseases and drug-related deaths. http://www.emcdda.europa.eu/situation/diseases-
and-deaths/1 (accessed 30 july 2012).
[42] Somaini B, Wang J, Perozo M, Kuhn F, Meili D, Grob P, et al. A continuing concern:
HIV and hepatitis testing and prevalence among drug users in substitution pro‐
grammes in Zurich, Switzerland. AIDS Care 2000;12(4):449-460. DOI:
10.1080/09540120050123855.
[43] van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C
virus among injecting drug users in a prevention setting: retrospective cohort study.
BMJ 1998;317(7156):433-437.
[44] Centers for Disease Control and Prevention (CDC). HIV Infection Among Injection-
Drug Users --- 34 States, 2004--2007. MMWR 2009;58:1291-1295.
[45] Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infec‐
tion: prevalence, risk factors, and prevention opportunities among young injection
drug users in Chicago, 1997-1999. J Infect Dis 2000;182(6):1588-1594. DOI:
10.1086/317607.
[46] Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term
injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodefi‐
ciency, and human T-lymphotropic viruses. Am J Public Health 1996;86(5):655-661.
[47] Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Si‐
nai J Med 2000;67(5-6):423-428.
[48] Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender dif‐
ferences in sexual and injection risk behavior among active young injection drug
users in San Francisco (the UFO Study). J Urban Health 2003;80(1):137-146. DOI:
10.1093/jurban/jtg137.
Current Perspectives in HIV Infection384
Chapter 17
Prevention of Sexually Transmitted HIV Infection
Jose G. Castro and Maria L. Alcaide
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54168
1. Introduction
Bio-medical prevention of sexually transmitted HIV infection is an evolving area in the field
of HIV. In recent years, multiple studies have demonstrated the efficacy of diverse biomedical
interventions to prevent the sexual acquisition of HIV infection in specific populations. The
major developments in the field of prevention of sexual transmission of HIV include male
circumcision, HIV viral suppression of HIV infected individuals (Treatment of positives), use
of antiretrovirals before exposure to HIV (Pre-exposure prophylaxis), and use of microbicides.
Some of these highly controlled studies demonstrated high levels of protection ranging from
55 to more than 90% when a single intervention has been studied. However, in real world
situations, it is foreseeable that individuals will have the opportunity and option to choose,
and ideally to combine, appropriate interventions according to their background, attitudes,
preferences and availability of methods.
Male circumcision: Male circumcision effectively decreases rates of heterosexual transmission
of HIV: There is now ample scientific evidence that male circumcision reduces the risk of
acquiring HIV through heterosexual intercourse in males by approximately 51 to 60%, thus
exceeding the 30 percent risk reduction set as a target for an AIDS vaccine. This level of
protection is similar to the 67.5% relative reduction in the risk of maternal-infant transmission
of HIV with the use of zidovudine in HIV infected pregnant women; currently one of the most
successful strategies to prevent HIV infection in a selected population, newborns. The evidence
of the effectiveness of male circumcision in decreasing the risk of HIV infection in males is so
compelling that in March 2007, the World Health Organization and the Joint United Nations
Programme on HIV/AIDS held a technical consultation on male circumcision and produced a
document that stated that male circumcision should be recognized as an efficacious interven‐
tion for the prevention of heterosexually acquired HIV infection in men. Male circumcision
(MC) has been proven to be a potent HIV prevention strategy, reducing risk of HIV acquisition
in heterosexual men by 50-60%. One of the most successful interventions to prevent the
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Bio-medical prevention of sexually transmitted HIV infection is an evolving area in the field
of HIV. In recent years, multiple studies have demonstrated the efficacy of diverse biomedical
interventions to prevent the sexual acquisition of HIV infection in specific populations. The
major developments in the field of prevention of sexual transmission of HIV include male
circumcision, HIV viral suppression of HIV infected individuals (Treatment of positives), use
of antiretrovirals before exposure to HIV (Pre-exposure prophylaxis), and use of microbicides.
Some of these highly controlled studies demonstrated high levels of protection ranging from
55 to more than 90% when a single intervention has been studied. However, in real world
situations, it is foreseeable that individuals will have the opportunity and option to choose,
and ideally to combine, appropriate interventions according to their background, attitudes,
preferences and availability of methods.
Male circumcision: Male circumcision effectively decreases rates of heterosexual transmission
of HIV: There is now ample scientific evidence that male circumcision reduces the risk of
acquiring HIV through heterosexual intercourse in males by approximately 51 to 60%, thus
exceeding the 30 percent risk reduction set as a target for an AIDS vaccine. This level of
protection is similar to the 67.5% relative reduction in the risk of maternal-infant transmission
of HIV with the use of zidovudine in HIV infected pregnant women; currently one of the most
successful strategies to prevent HIV infection in a selected population, newborns. The evidence
of the effectiveness of male circumcision in decreasing the risk of HIV infection in males is so
compelling that in March 2007, the World Health Organization and the Joint United Nations
Programme on HIV/AIDS held a technical consultation on male circumcision and produced a
document that stated that male circumcision should be recognized as an efficacious interven‐
tion for the prevention of heterosexually acquired HIV infection in men. Male circumcision
(MC) has been proven to be a potent HIV prevention strategy, reducing risk of HIV acquisition
in heterosexual men by 50-60%. One of the most successful interventions to prevent the
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acquisition of HIV infection in heterosexual men is circumcision, which has reduced HIV risk
by 50-60% among heterosexual men in sub-Saharan Africa. The uptake of male circumcision
in traditionally non-circumcision communities have been varied and influenced by different
factor. In the US males from racial and ethnic minorities are less likely to be circumcised and
also more likely to become infected with HIV so a recently published analyses showed that
newborn circumcision resulted in lower expected HIV-related treatment costs and a slight
increase in quality-adjusted life years.
Treatment of Positives: Since the early years of the epidemic, it was demonstrated that the use
of antiretrovirals in infected pregnant women decreased the likelihood of HIV infection in the
new born. Additional studies demonstrated that the key factor in the transmission of the
infection from the mother to the newborn was the maternal HIV viral load; and then the
suppression of HIV by the administration of antiretrovirals became the standard of care in the
management of HIV infected pregnant women. This practice led to the almost eradication of
congenital HIV infection in communities with access to medications. Circumstantial evidence
suggested that the same principle could be applied to the sexual transmission of HIV as in
general there is correlation between the HIV viral load in blood and genital secretions. In 2011
a breakthrough study proved that treatment of HIV positive decreased the likelihood of sexual
transmission in more than 96% in discordant heterosexual couples.
Pre-exposure prophylaxis (PrEP) in MSM and heterosexual men and women: PrEP involves
the use of antiretroviral medications before potential HIV exposure to prevent infection. In
recent years several studies suggested the possible efficacy of the use of TDF/FTC as PrEP; but
in the last six months, several controlled studies have provided definitive proof of its efficacy
in certain populations: iPrEx was a study that randomized 2499 HIV-negative MSM or
transgender women who have sex with men to take oral daily tenofovir and emtricitabine
(FTC/TDF) or placebo. Overall, 100 subjects became infected during the study (36 in the FTC/
TDF group and 64 in the placebo group), indicating a 44% reduction in the HIV incidence. The
Partners PrEP Study was a phase III, randomized, double blind, placebo-controlled, three arm
trial of oral daily (FTC/TDF) PrEP for the prevention of HIV acquisition by HIV seronegative
partner in HIV serodiscordant partnerships. The independent DSMB recommended that the
results of the study be publically reported, nearly 2 years earlier than expected, and the placebo
arm discontinued, because clear demonstration of HIV protection due to PrEP. The TDF2A
was a double-blind, randomized, trial of daily oral FTC/TDF or placebo for prevention of HIV
acquisition in young (18-39) women and men in Bostwana. A total of 1219 individuals were
randomized, about 30% of the study population did not complete follow up. Adherence to
PrEP overall was estimated to be approximately 84%. Overall 9 HIV infections occurred among
those assigned to FTC/TDF compared to 24 among those assigned to placebo, translating to
an efficacy for HIV protection of 63%. All these studies shown that PrEP is a viable biomedical
intervention that can be use for the prevention of sexually transmitted HIV infection in both
heterosexual and male who have sex with men populations but is highly dependent of the
adherence to the medications. There are few promising agents that could be use over extended
periods of time decreasing the need for daily medication.
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Microbicides: Given the theoretical advantages of a microbicide (controlled by women, no
need for male cooperation) the search for an effective product was elusive until investigators
from CAPRISA 004 study reported at the World AIDS conference in 2010 in Vienna, that 1%
tenofovir gel used with coitus reduced HIV risk by 39% among 889 South African women.
Sub-analyses of the data showed that protection was more pronounced (54%) in women with
higher adherence to the gel. Several studies are under way with other products and with
alternative delivery systems that will alleviate the need for strict adherence to its use before
and after sex.
2. Bio-medical interventions to prevent hiv sexually transmitted infection
2.1. Male circumcision
Male circumcision is the surgical procedure that consists in the removal of some or all the
foreskin of the penis [1]. The word “circumcision” comes from the Latin circum (meaning
“around”) and caedere (meaning “to cut”) [2]. The foreskin is a continuation of the skin from
the shaft of the penis, which covers the glans penis and the urethral meatus. The foreskin is
attached to the glans by the frenulum, a highly vascularized tissue of the penis. Male circum‐
cision is one of the oldest surgical procedures known, traditionally undertaken as a mark of
cultural identity or religious importance [3]. Rates of male circumcision are different around
the word and related to cultural and religious beliefs [4]. Historically, male circumcision has
been associated with religious practice and ethnic identity. Circumcision was practiced among
ancient Semitic peoples including Egyptians and Jews, with the earliest records depicting the
practice coming from Egyptian tomb artwork (from the Sixth Dynasty, 2345-2181 B.C.) and
wall paintings dating from around 2300 BC [3]. Muslims are the largest religious group to
practice male circumcision. As an Abrahamic faith, Muslims practice circumcision, as a
confirmation of their relationship with God, and the practice is also known as tahera, meaning
purification [3]. With the global spread of Islam from the 7th century AD, circumcision was
widely adopted among previously non-circumcising peoples. In some regions, male circum‐
cision was already a cultural tradition prior to the arrival of Islam (for example among the
Poro in West Africa, and in Timor in SE Asia). [5-7] Circumcision has also been practice for
non-religious reasons for many thousand of years in sub-Saharan Africa, and in many ethnic
groups around the world, including aboriginal Australasians, the Aztecs and Mayans in the
Americas, inhabitants of the Philippines and eastern Indonesia and various pacific Islands,
including Fiji and the Polynesian islands [3]. In the majority of these cultures, circumcision is
an integral part of a rite of passage to manhood, although originally it may have been a test of
bravery and endurance. Male circumcision traditionally has been done for medical and non
medical reasons (including religious or cultural reasons). When it is practiced for non-medical
reasons it is typically performed in the neonatal period or just before the adolescence. The
practice of circumcision, in particular of neonatal circumcision remains highly controversial
despite recent evidence of the medical benefits, including decreased risk of heterosexual
acquisition of HIV infection by men, decreased risk of acquisition of several sexually trans‐
mitted infections, decreased risk of urinary tract infection and recent evidence of decreased
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infection from the mother to the newborn was the maternal HIV viral load; and then the
suppression of HIV by the administration of antiretrovirals became the standard of care in the
management of HIV infected pregnant women. This practice led to the almost eradication of
congenital HIV infection in communities with access to medications. Circumstantial evidence
suggested that the same principle could be applied to the sexual transmission of HIV as in
general there is correlation between the HIV viral load in blood and genital secretions. In 2011
a breakthrough study proved that treatment of HIV positive decreased the likelihood of sexual
transmission in more than 96% in discordant heterosexual couples.
Pre-exposure prophylaxis (PrEP) in MSM and heterosexual men and women: PrEP involves
the use of antiretroviral medications before potential HIV exposure to prevent infection. In
recent years several studies suggested the possible efficacy of the use of TDF/FTC as PrEP; but
in the last six months, several controlled studies have provided definitive proof of its efficacy
in certain populations: iPrEx was a study that randomized 2499 HIV-negative MSM or
transgender women who have sex with men to take oral daily tenofovir and emtricitabine
(FTC/TDF) or placebo. Overall, 100 subjects became infected during the study (36 in the FTC/
TDF group and 64 in the placebo group), indicating a 44% reduction in the HIV incidence. The
Partners PrEP Study was a phase III, randomized, double blind, placebo-controlled, three arm
trial of oral daily (FTC/TDF) PrEP for the prevention of HIV acquisition by HIV seronegative
partner in HIV serodiscordant partnerships. The independent DSMB recommended that the
results of the study be publically reported, nearly 2 years earlier than expected, and the placebo
arm discontinued, because clear demonstration of HIV protection due to PrEP. The TDF2A
was a double-blind, randomized, trial of daily oral FTC/TDF or placebo for prevention of HIV
acquisition in young (18-39) women and men in Bostwana. A total of 1219 individuals were
randomized, about 30% of the study population did not complete follow up. Adherence to
PrEP overall was estimated to be approximately 84%. Overall 9 HIV infections occurred among
those assigned to FTC/TDF compared to 24 among those assigned to placebo, translating to
an efficacy for HIV protection of 63%. All these studies shown that PrEP is a viable biomedical
intervention that can be use for the prevention of sexually transmitted HIV infection in both
heterosexual and male who have sex with men populations but is highly dependent of the
adherence to the medications. There are few promising agents that could be use over extended
periods of time decreasing the need for daily medication.
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confirmation of their relationship with God, and the practice is also known as tahera, meaning
purification [3]. With the global spread of Islam from the 7th century AD, circumcision was
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risk of prostate cancer [8-10]. There are no reliable data of the rate of circumcision in many
areas of the world in particular in regions where is not commonly practiced; but in general it
is believed that rates of circumcision are very low in Latin-America including the Caribbean
region, China, India and Europe [2], Fig 1.
Global map of male circumcision prevalence at country level, as of December 2006.
Figure 1. Worldwide prevalence of Male Circumcision.
2.1.1. Studies addressing MC in the field of HIV prevention
2.1.1.1. Cohort studies
The first paper suggesting a protective effect of MC against HIV infection was published in
1986 [11]. Since then, many observational studies have been published, some of which have
observed that most men living in East and southern Africa, the regions with the highest
prevalence of HIV are not circumcised [12-14]. More than 30 cross-sectional studies found the
prevalence of HIV to be significantly higher in uncircumcised men than in those who are
circumcised [15] and 14 prospective studies all showed a protective effect, ranging from 48%
to 88% [16-18]. A systematic review and meta analyses of studies from sub-Saharan Africa
reported an adjusted relative risk of 042 (95% CI 0.34-0.54) in all circumcised men, with a
stronger adjusted relative risk of 0.29 (0.20 – 0.41) in circumcised men who were at higher risk
of acquiring HIV [19].
2.1.1.2. Randomized studies
Given the compelling observational data of the potential protective role of male circumcision
in the acquisition of heterosexually transmitted HIV infection and the growing crisis of HIV
infection in sub-Saharan Africa; it was clear that only randomized studies could provide
unequivocally evidence of this protection. Under the sponsorship of the National Institutes of
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Health (NIH) and the ARNS (French National Research Agency), three independent but
similar randomized control trials were launched in three different communities in South Africa
in 2002-2003 to address this question. The studies were performed in South Africa, Kenya, and
Uganda, within peri-urban, urban, and rural communities respectively [20-22]. The study
conducted in South Africa (Orange farm, bordering Johannesburg) included 3,128 men 18 to
24 years old. Eligible men were randomly allocated to undergo immediate or delayed (offered
at the end of the follow up period) circumcision. Men were assessed at 3, 12 and 24 months for
HIV acquisition, sexually transmitted infections, and changes in sexual behaviors. Interim
analysis in 2004 revealed a 0.4 relative risk of HIV acquisition (95% CI, 0.24%-0.68%.; P < 0.001)
among the circumcised compared to uncircumcised participants. This finding corresponds to
a protective effect of circumcision of 60%, which is a level of protection similar many used
vaccines. Given these striking results, the safety and monitoring board discontinued the trial
early, and circumcision was offered to the control arm. The Orange Farm study results
prompted ethical concerns about continuation of the two remaining studies. The World Health
Organization (WHO) recommended continuation but mandated a previously unplanned,
earlier interim evaluation. At the interim evaluation, the studies in Kenya and Uganda
provided evidence of protection against HIV infection of 50% to 60%, remarkably similar to
the results from the Orange Farm trial. These two trials were discontinued prematurely on
December 12, 2006. Together, the three studies demonstrated a 50% to 60% reduction in HIV
acquisition by medicalized circumcision. [20-22] In total, 10,908 uncircumcised, HIV-negative
adult men were randomly assigned to intervention or control arms, and followed for up to 2
years. Overall retention rates were high (86-92% at the end of follow up, when men in the
control arm were offered circumcision). Recent findings support the long-term benefit
conveyed by MC, with the Kisumu, Kenya cohort maintaining/modestly increasing the earlier
level of protection (60% to 64%) at 54 month follow up [23]. These studies, among others,
provide “unequivocal evidence that circumcision plays a causal role in reducing the risk of
HIV infection among men” [24].
On the basis of the findings from the three clinical trials, a WHO and UNAIDS consultation in
March 2007, recommended that circumcision should be recognized as an effective intervention
for HIV prevention of heterosexual HIV acquisition in men [24]. WHO and UNAIDS also
recommended that male circumcision should be offered HIV-negative men in addition, but
not as a substitute, to other HIV risk-reduction strategies. The public-health effect of male
circumcision will be largest in generalized epidemics. As such, WHO and UNAIDS recom‐
mend that countries with hyperendemic and generalized epidemics and low prevalence of
male circumcision expand access to safe male circumcision services within the context of
ensuring universal access to comprehensive HIV prevention, treatment, care, and support. [25]
2.2. Acceptability of MC as a tool for HIV prevention
The public health benefit of MC as a tool for HIV prevention, will depend of many factors. One
of the most important is the acceptability and uptake of circumcision in traditionally non-
circumcising societies. It can be expected that the benefit can spread beyond circumcised men
because if sufficient number of males are circumcised, circumcision in the long range will also
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risk of prostate cancer [8-10]. There are no reliable data of the rate of circumcision in many
areas of the world in particular in regions where is not commonly practiced; but in general it
is believed that rates of circumcision are very low in Latin-America including the Caribbean
region, China, India and Europe [2], Fig 1.
Global map of male circumcision prevalence at country level, as of December 2006.
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protect women; effect similar to herd immunity [26]. In addition to the proportion of males
who will become circumcised, the age at circumcision will be also a determinant of how rapidly
the intervention results in reduction of HIV prevalence in the population. For example, if boys
and young men before sexual debut are targeted, the measurable impact it is not likely to be
realized for over 10 years; if older boys and men up to 30 years are prioritized a more rapid
effect can be expected. On the other hand, circumcision of neonates, in whom the procedure
is simpler and less risky, the impact of the strategy on HIV incidence would not be expected
for at least 20 years. [25] Because acceptance of male circumcision by men and by parents of
males in traditionally non-circumcising communities will be crucial to the success of a MC
intervention for reducing HIV prevalence a significant number of studies have been conducted
in different non-circumcising communities with high or increasing rates of HIV infection
across the globe [26-29]. Across most of these studies, the most common barriers to the
acceptability of male circumcision include the following factors: pain (apprehension about
pain during and after the procedure has been reported to be the major barrier to MC accept‐
ability; culture and religion have also factors that have been consistently brought up in the
discussions about acceptability of MC in diverse groups; cost of the procedure has been named
as a significant barrier to MC acceptability and safety (potential for complications and adverse
effects). Other potential barriers named in some but not in all studies include: lack of access to
health care, required time away from work, the concern about loss of penile sensitivity,
reduction in penis size, decreased ability to satisfy women, excessive sexual desire, increased
promiscuity and the perception of circumcision as old-fashioned [28-29]. On the other hand,
the most consistently named facilitators of MC include the following factors: hygiene, which
has universally been recognized as a major benefit of MC; protection from sexually transmitted
diseases and HIV (linked through hygiene) and improved sexual pleasure.
In summary, the protective effect of adult male circumcision on HIV acquisition has been
reported in a review of epidemiological studies and demonstrated by three randomized
controlled trials conducted in Southern and Eastern Africa, which found that the risk of HIV
acquisition among circumcised men was reduced by about 60%. Based on this evidence, in
2007 WHO/UNAIDS recommended adult male circumcision as an important, additional
intervention which should be delivered as part of a comprehensive HIV prevention package
in communities with generalized HIV epidemics and low male circumcision rates. Since then,
a number of initiatives have taken place in different countries to role out adult male circum‐
cision services as an additional scientifically proven biomedical strategy to prevent HIV
acquisition.
3. Treatment of positives
The idea to use antiretrovirals to prevent the acquisition and transmission of the Human
Immunodeficiency virus was tested early in the 90’s after animal models of retroviral infection
demonstrated that zidovudine could prevent or alter the course of maternally transmitted HIV
infection [30 – 33]. The results of this initial US Pediatric AIDS Clinical Trials Group Protocol
(PACTG) 076 clinical trial were announced in 1994, which showed that giving pregnant women
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infected with HIV oral zidovudine from 14 weeks, intravenously at labor and delivery, and
followed by six weeks of zidovudine prophylaxis to their newborns, could reduce transmission
by 67.5% (95 percent confidence interval, 40.7 to 82.1 percent) [30]. Since this pivotal study
proved the concept that antiretrovirals could be use to prevent HIV infection, significant
progress has been accomplished in the prevention of mother to child transmission, to the point
that current transmission rates are estimated at less than 2 percent with the use of triple
antiretroviral drugs during pregnancy. [34, 35], Figure 2. Despite these major advances in the
prevention of mother to child transmission of HIV-1, it was not until several years later that
these ideas were extrapolated to the prevention of sexual transmission of HIV-1. A central idea
was that the quantity of HIV-1 in plasma was a primary determinant of the risk of HIV-1
transmission [36]. By then it was already clear that antiretroviral therapy could reduce plasma
HIV-1 to undetectable concentrations within 6 months of initiation in most patients [37, 38]
and seminal and cervicovaginal HIV-1 concentrations could also be reduced to undetectable
levels in most people on ART [39 – 41]. A meta-analyses of data from five studies reported
only five cases of HIV-1 transmission from patients receiving antiretroviral therapy to sexual
partners during 1098 person-years of follow up, which is consistent with an infection rate of
0.19 – 1.09 per 100 person-years [42]. Additional evidence was obtained from a pos-hoc analysis
of the Partners in Prevention HSV/HIV Transmission study of acyclovir HSV-2 suppressive
therapy versus placebo [43]. In this analysis of almost 3,400 HIV-1 serodiscordant heterosexual
couples from seven African countries, ART use by the infected person was accompanied by a
92% reduction in the risk of HIV-1 transmission to their partner. Several other observational
and some ecological studies added to the evidence and set the need for a randomized study
to test the hypothesis if index individuals taking ART are less likely to transmit HIV infection
than individuals not on ART. In 2007 the HIV Prevention Trials Network (HPTN) started to
enroll participants in a multi-continent, randomized, controlled trial, called HPTN 052, to
compare early versus delayed antiretroviral therapy for patients with HIV-1 infection who had
CD4 counts between 350 and 550 cells per cubic millimeter and who were in a stable hetero‐
sexual relationship with a partner who was not infected [44]. A total of 1763 HIV-1 serodis‐
cordant couples were enrolled (886 couples were randomly assigned to the early therapy group
and 877 to the delayed-therapy group). The study was slated to end in 2015, but an interim
data review on April 26 2011, by an independent data and safety monitoring board (DSMB)
found that of the total 28 cases of HIV infection among the previously uninfected partners,
only one case occurred among those couples where the HIV-infected partner began immediate
antiretroviral therapy. The DSMB, therefore, called for immediate public release of the study's
findings on the basis of data collection through February 21, 2011. At that time, 90% of couples
remained enrolled in the study, with a median follow up of 1.7 years. This study demonstrated
the power of early antiretroviral treatment (ART) for almost completely preventing onward
sexual HIV transmission in the clinical trial setting. This study offered proof of the concept
that reduction of viral load through treatment could prevent HIV transmission, a concept that
has served as the foundation for multiple modeling studies on treatment-as-prevention and
one which was already held to be true by many. The data are incontrovertible, and although
they resolve the question of whether this approach can prevent HIV transmission, they also
lead to a more fully informed discussion of how ART might actually be used to prevent
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and young men before sexual debut are targeted, the measurable impact it is not likely to be
realized for over 10 years; if older boys and men up to 30 years are prioritized a more rapid
effect can be expected. On the other hand, circumcision of neonates, in whom the procedure
is simpler and less risky, the impact of the strategy on HIV incidence would not be expected
for at least 20 years. [25] Because acceptance of male circumcision by men and by parents of
males in traditionally non-circumcising communities will be crucial to the success of a MC
intervention for reducing HIV prevalence a significant number of studies have been conducted
in different non-circumcising communities with high or increasing rates of HIV infection
across the globe [26-29]. Across most of these studies, the most common barriers to the
acceptability of male circumcision include the following factors: pain (apprehension about
pain during and after the procedure has been reported to be the major barrier to MC accept‐
ability; culture and religion have also factors that have been consistently brought up in the
discussions about acceptability of MC in diverse groups; cost of the procedure has been named
as a significant barrier to MC acceptability and safety (potential for complications and adverse
effects). Other potential barriers named in some but not in all studies include: lack of access to
health care, required time away from work, the concern about loss of penile sensitivity,
reduction in penis size, decreased ability to satisfy women, excessive sexual desire, increased
promiscuity and the perception of circumcision as old-fashioned [28-29]. On the other hand,
the most consistently named facilitators of MC include the following factors: hygiene, which
has universally been recognized as a major benefit of MC; protection from sexually transmitted
diseases and HIV (linked through hygiene) and improved sexual pleasure.
In summary, the protective effect of adult male circumcision on HIV acquisition has been
reported in a review of epidemiological studies and demonstrated by three randomized
controlled trials conducted in Southern and Eastern Africa, which found that the risk of HIV
acquisition among circumcised men was reduced by about 60%. Based on this evidence, in
2007 WHO/UNAIDS recommended adult male circumcision as an important, additional
intervention which should be delivered as part of a comprehensive HIV prevention package
in communities with generalized HIV epidemics and low male circumcision rates. Since then,
a number of initiatives have taken place in different countries to role out adult male circum‐
cision services as an additional scientifically proven biomedical strategy to prevent HIV
acquisition.
3. Treatment of positives
The idea to use antiretrovirals to prevent the acquisition and transmission of the Human
Immunodeficiency virus was tested early in the 90’s after animal models of retroviral infection
demonstrated that zidovudine could prevent or alter the course of maternally transmitted HIV
infection [30 – 33]. The results of this initial US Pediatric AIDS Clinical Trials Group Protocol
(PACTG) 076 clinical trial were announced in 1994, which showed that giving pregnant women
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infected with HIV oral zidovudine from 14 weeks, intravenously at labor and delivery, and
followed by six weeks of zidovudine prophylaxis to their newborns, could reduce transmission
by 67.5% (95 percent confidence interval, 40.7 to 82.1 percent) [30]. Since this pivotal study
proved the concept that antiretrovirals could be use to prevent HIV infection, significant
progress has been accomplished in the prevention of mother to child transmission, to the point
that current transmission rates are estimated at less than 2 percent with the use of triple
antiretroviral drugs during pregnancy. [34, 35], Figure 2. Despite these major advances in the
prevention of mother to child transmission of HIV-1, it was not until several years later that
these ideas were extrapolated to the prevention of sexual transmission of HIV-1. A central idea
was that the quantity of HIV-1 in plasma was a primary determinant of the risk of HIV-1
transmission [36]. By then it was already clear that antiretroviral therapy could reduce plasma
HIV-1 to undetectable concentrations within 6 months of initiation in most patients [37, 38]
and seminal and cervicovaginal HIV-1 concentrations could also be reduced to undetectable
levels in most people on ART [39 – 41]. A meta-analyses of data from five studies reported
only five cases of HIV-1 transmission from patients receiving antiretroviral therapy to sexual
partners during 1098 person-years of follow up, which is consistent with an infection rate of
0.19 – 1.09 per 100 person-years [42]. Additional evidence was obtained from a pos-hoc analysis
of the Partners in Prevention HSV/HIV Transmission study of acyclovir HSV-2 suppressive
therapy versus placebo [43]. In this analysis of almost 3,400 HIV-1 serodiscordant heterosexual
couples from seven African countries, ART use by the infected person was accompanied by a
92% reduction in the risk of HIV-1 transmission to their partner. Several other observational
and some ecological studies added to the evidence and set the need for a randomized study
to test the hypothesis if index individuals taking ART are less likely to transmit HIV infection
than individuals not on ART. In 2007 the HIV Prevention Trials Network (HPTN) started to
enroll participants in a multi-continent, randomized, controlled trial, called HPTN 052, to
compare early versus delayed antiretroviral therapy for patients with HIV-1 infection who had
CD4 counts between 350 and 550 cells per cubic millimeter and who were in a stable hetero‐
sexual relationship with a partner who was not infected [44]. A total of 1763 HIV-1 serodis‐
cordant couples were enrolled (886 couples were randomly assigned to the early therapy group
and 877 to the delayed-therapy group). The study was slated to end in 2015, but an interim
data review on April 26 2011, by an independent data and safety monitoring board (DSMB)
found that of the total 28 cases of HIV infection among the previously uninfected partners,
only one case occurred among those couples where the HIV-infected partner began immediate
antiretroviral therapy. The DSMB, therefore, called for immediate public release of the study's
findings on the basis of data collection through February 21, 2011. At that time, 90% of couples
remained enrolled in the study, with a median follow up of 1.7 years. This study demonstrated
the power of early antiretroviral treatment (ART) for almost completely preventing onward
sexual HIV transmission in the clinical trial setting. This study offered proof of the concept
that reduction of viral load through treatment could prevent HIV transmission, a concept that
has served as the foundation for multiple modeling studies on treatment-as-prevention and
one which was already held to be true by many. The data are incontrovertible, and although
they resolve the question of whether this approach can prevent HIV transmission, they also
lead to a more fully informed discussion of how ART might actually be used to prevent
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transmission in communities. The magnitude of protection against HIV infection demonstrat‐
ed in HPTN 052 has made the successful strategy of the clinical trial a key component of public
health policies recently discussed by federal officials and others saying that achieving an end
to the HIV/AIDS pandemic is now feasible with additional research and implementation
efforts. Given the profound implications of HPTN 052's for the future response to the AIDS
epidemic, the journal Science choose this study as its Breakthrough of the Year [45].
In summary, in 2011 it was scientifically demonstrated that treating individuals with HIV
infection will prevent the transmission of HIV infection. However, the use of this strategy to
the population level it is still not ready to fully achieve its potential because there are resource
constraints and logistical hurdles, that limit its implementation.
Figure 2. AIDS Diagnoses among perinatally infected persons, 1985-2010. United States and 6 U.S. dependent areas.
This slide from the CDC presents trends from 1985 through 2010 in the estimated numbers of
AIDS diagnoses among persons who were perinatally infected in the U.S. The blue line shows
the annual numbers of perinatally infected children who were diagnosed with AIDS when
they were less than 13 years of age; the pink line shows the annual numbers of persons who
were infected with HIV perinatally and were diagnosed with AIDS at the age of 13 or older.
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This graphic provides evidence of the impact at the population of an effective bio-medical
intervention to prevent HIV infection.
4. Pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) involves the use of antiretroviral medications by HIV
negative individuals before exposure to the HIV virus, to prevent HIV acquisition. The
principle behind the use of antiretrovirals (ART) to prevent sexually acquisition of HIV lies on
the success of HIV prevention in mother to Child transmission (PMTCT) and accidental
exposure in healthcare workers. Early in the HIV epidemics, two large prevention trials (HIV
Prevention Network Trial, HPTN 076 and HIVNET 012) showed that providing ART to infants
born to HIV positive mothers significantly decreased the rates of HIV infection in newborns
[30,46]. This is one of the greatest accomplishments in the field of HIV prevention, has been
incorporated to PMTCT guidelines, and provided a starting ground for PrEP [30,46, 47]. In the
area of health care related exposure to HIV, primarily needle sticks, the use of ART by the
negative individual during the weeks after exposure reduces HIV acquisition by 80% [48, 49].
Following the human studies assessing PMTCT and prevention in the healthcare setting,
animal studies to address PrEP demostrated that the administration of ART to macaque
monkeys exposed to HIV prevented HIV infection [50,51]. All this data provided basis for
designing clinical trials to test PrEP in humans.
In recent years, tremendous advances in the field of PrEP in individuals at risk for HIV
acquisition have led to landmark large randomized controlled studies using oral or topical
agents. Results of the initial major studies addressing PrEP were somehow controversial, but
recent data provides evidence that PrEP is an effective and safe alternative to prevent HIV
infection.
A major benefit of PrEP is its use by the individual at risk without involvement of sexual
partners. Men who have sex with men (MSM) and women are especially vulnerable to HIV
infection due to cultural, social and biological factors. Stigma associated with homosexuality,
gender disparities, inability for women to negotiate condom use and fidelity, as well as
frangibility of vaginal and rectal mucosa, predispose these populations to HIV infection and
make them ideal candidates for such preventive method. PrEP is therefore emerging as a new
powerful prevention method of especial importance in those populations at higher risk.
To date, most studies regarding PrEP have focused on two main modes of delivery: oral agents
or topical microbidides. The two delivery modes will be presented separate in this chapter.
Other forms of delivery such as subcutaneous or vaginal implants are under investigation and
will be briefly mentioned.
While some studies addressing PrEP yielded important and relevant results, other studies are
still undergoing and some are in the early stages of development. PrEP is therefore an evolving
area in the field of HIV prevention and emerging data is likely to change the way we prevent
sexually acquired HIV infection in the near future.
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4. Pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) involves the use of antiretroviral medications by HIV
negative individuals before exposure to the HIV virus, to prevent HIV acquisition. The
principle behind the use of antiretrovirals (ART) to prevent sexually acquisition of HIV lies on
the success of HIV prevention in mother to Child transmission (PMTCT) and accidental
exposure in healthcare workers. Early in the HIV epidemics, two large prevention trials (HIV
Prevention Network Trial, HPTN 076 and HIVNET 012) showed that providing ART to infants
born to HIV positive mothers significantly decreased the rates of HIV infection in newborns
[30,46]. This is one of the greatest accomplishments in the field of HIV prevention, has been
incorporated to PMTCT guidelines, and provided a starting ground for PrEP [30,46, 47]. In the
area of health care related exposure to HIV, primarily needle sticks, the use of ART by the
negative individual during the weeks after exposure reduces HIV acquisition by 80% [48, 49].
Following the human studies assessing PMTCT and prevention in the healthcare setting,
animal studies to address PrEP demostrated that the administration of ART to macaque
monkeys exposed to HIV prevented HIV infection [50,51]. All this data provided basis for
designing clinical trials to test PrEP in humans.
In recent years, tremendous advances in the field of PrEP in individuals at risk for HIV
acquisition have led to landmark large randomized controlled studies using oral or topical
agents. Results of the initial major studies addressing PrEP were somehow controversial, but
recent data provides evidence that PrEP is an effective and safe alternative to prevent HIV
infection.
A major benefit of PrEP is its use by the individual at risk without involvement of sexual
partners. Men who have sex with men (MSM) and women are especially vulnerable to HIV
infection due to cultural, social and biological factors. Stigma associated with homosexuality,
gender disparities, inability for women to negotiate condom use and fidelity, as well as
frangibility of vaginal and rectal mucosa, predispose these populations to HIV infection and
make them ideal candidates for such preventive method. PrEP is therefore emerging as a new
powerful prevention method of especial importance in those populations at higher risk.
To date, most studies regarding PrEP have focused on two main modes of delivery: oral agents
or topical microbidides. The two delivery modes will be presented separate in this chapter.
Other forms of delivery such as subcutaneous or vaginal implants are under investigation and
will be briefly mentioned.
While some studies addressing PrEP yielded important and relevant results, other studies are
still undergoing and some are in the early stages of development. PrEP is therefore an evolving
area in the field of HIV prevention and emerging data is likely to change the way we prevent
sexually acquired HIV infection in the near future.
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Table 1 summarizes the results of clinical trials on oral and topical agents addressing PrEP.
Study name Sponsor Country Participants Design Results





















































5,000 women TDF vs placebo
FTC vs placebo
TDF gel vs placebo








South Africa 1,341 women TDF gel vs placebo 39% reduction
Table 1. Summary of randomized controlled studies addressing the use of PrEP to prevent sexually transmitted HIV
infection.
4.1. PrEP using oral agents to prevent HIV infection in MSM and heterosexual men and
women
The oral agents evaluated or under evaluation for PrEP include anti HIV drugs currently
approved for treatment of HIV infection. Such drugs are tenofovir (TDF) and a combination
of emtricitabine/tenofovir FTC/ TDF.
Tenofovir is a nucleoside analog approved in combination with other ART for the treatment
of HIV infection. As a nucleoside analog, the mechanism of action of TDF is to blocking HIV
reverse transcriptase, which prevents HIV virus from replicating. In HIV infected individuals,
as a result, TDF lowers HIV viral load in the blood. Tenofovir is a drug that achieves good
drug levels in plasma as well as in female lower genital tract mucosa and rectal mucosa [52].
TDF is used orally and once a day, and is normally well tolerated, but as most drugs, could
have potential side effects. The most common side effects of TDF are gastrointestinal (nausea
and vomiting), rash or headaches, and occur in about 10% of the patients. The most serious
risk factors of TDF are acute liver and kidney toxicity. Chronic risk factors of TDF, relevant to
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the chronic use of TDF for PrEP, include decline in kidney function and decrease in bone
density [52].
Emtricitabine/tenofovir is a combination of nucleoside analogs approved for treatment of HIV.
FTC/TDF is formulated as single day pill and is taken in combination with other agents for the
treatment of HIV infection. Orally administered emtricitabine achieves good levels in plasma,
lower female genital tract, and especially in the rectum making this combination a promise for
PrEP [52]. The combination of FTC/TDF can cause those side effects listed above as well as
those associated with FTC. Emtricitabine common side effects include nausea, vomiting,
headaches, rash, abdominal pain, dizziness or abnormal dreams and occur in about 10% of the
cases. Emtricitabine can also be associated with fatal lactic acidosis, liver or kidney toxicity.
4.1.1. Studies addressing oral PrEP
Five studies have evaluated the use of oral agents to prevent HIV infection and will be
described in this section. One study included only MSM (iPrEX), 2 included men and women
(TDF2, PIP), and 2 included exclusively women (FEM-PrEP and VOICE). Two of these studies
have validated the use of PrEP for HIV prevention, two have been prematurely stopped due
to futility, and others are undergoing. Important to say is that all of these studies have
addressed the use of PrEP in combination with intensive safer sex practices counseling.
4.1.1.1. iPREX (pre exposure prophylaxis initiative)
iPREX was a randomized controlled study to evaluate the efficacy in reduction of new HIV
infections using a daily tablet of fixed dose of FTC/TDF when compared to placebo. iPREX
was funded by the National Institute of Allergy and Infectious Diseases and by the Bill and
Melinda Gates Foundation. The study included 2499 young high-risk MSM in South America,
Thailand and the US. The preliminary results of this study were released in 2010 and the study
was the landmark for the use of oral PrEP. Results suggested for the first time that oral ART
in combination with safe sex and condom use counseling could be used to reduce new HIV
infections in MSM. The use of oral FTC/TDF was associated with a 42% reduction in HIV
acquisition over 3 years (CI: 6%-60%). The study also analyzed the results according to self-
reported adherence and reveal the importance of adhere to the prescribed drug. The incidence
of new HIV cases was reduced to 68% when adherence was high (more than 90% of pills taken),
to 50% if adherence was between 50% and 90%, and to 32% if adherence was low (less than
50%). In order to clarify if detectable drug levels were associated with protection against HIV
infection a case control design was used to compare rates of infection in individuals with
detectable blood levels with those without detectable levels. A relative risk reduction of 92%
(CI: 40%-99%) in individuals with detectable study drug levels was found. This finding
provided evidence that protection was directly related with drug levels, an indirect measure‐
ment of adherence. In addition, this study showed that FTC/TDF had a good safety profile
with minimal gastrointestinal side effects. A minimal decrease in bone density in individuals
taking the drug was also observed. Among the individuals that seroconvert, most of them were
in the process of HIV seroconversion at enrollment and some developed a virus with resistant
mutations. This finding reinforced the importance of excluding HIV infection when using FTC/
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Table 1 summarizes the results of clinical trials on oral and topical agents addressing PrEP.
Study name Sponsor Country Participants Design Results





















































5,000 women TDF vs placebo
FTC vs placebo
TDF gel vs placebo








South Africa 1,341 women TDF gel vs placebo 39% reduction
Table 1. Summary of randomized controlled studies addressing the use of PrEP to prevent sexually transmitted HIV
infection.
4.1. PrEP using oral agents to prevent HIV infection in MSM and heterosexual men and
women
The oral agents evaluated or under evaluation for PrEP include anti HIV drugs currently
approved for treatment of HIV infection. Such drugs are tenofovir (TDF) and a combination
of emtricitabine/tenofovir FTC/ TDF.
Tenofovir is a nucleoside analog approved in combination with other ART for the treatment
of HIV infection. As a nucleoside analog, the mechanism of action of TDF is to blocking HIV
reverse transcriptase, which prevents HIV virus from replicating. In HIV infected individuals,
as a result, TDF lowers HIV viral load in the blood. Tenofovir is a drug that achieves good
drug levels in plasma as well as in female lower genital tract mucosa and rectal mucosa [52].
TDF is used orally and once a day, and is normally well tolerated, but as most drugs, could
have potential side effects. The most common side effects of TDF are gastrointestinal (nausea
and vomiting), rash or headaches, and occur in about 10% of the patients. The most serious
risk factors of TDF are acute liver and kidney toxicity. Chronic risk factors of TDF, relevant to
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the chronic use of TDF for PrEP, include decline in kidney function and decrease in bone
density [52].
Emtricitabine/tenofovir is a combination of nucleoside analogs approved for treatment of HIV.
FTC/TDF is formulated as single day pill and is taken in combination with other agents for the
treatment of HIV infection. Orally administered emtricitabine achieves good levels in plasma,
lower female genital tract, and especially in the rectum making this combination a promise for
PrEP [52]. The combination of FTC/TDF can cause those side effects listed above as well as
those associated with FTC. Emtricitabine common side effects include nausea, vomiting,
headaches, rash, abdominal pain, dizziness or abnormal dreams and occur in about 10% of the
cases. Emtricitabine can also be associated with fatal lactic acidosis, liver or kidney toxicity.
4.1.1. Studies addressing oral PrEP
Five studies have evaluated the use of oral agents to prevent HIV infection and will be
described in this section. One study included only MSM (iPrEX), 2 included men and women
(TDF2, PIP), and 2 included exclusively women (FEM-PrEP and VOICE). Two of these studies
have validated the use of PrEP for HIV prevention, two have been prematurely stopped due
to futility, and others are undergoing. Important to say is that all of these studies have
addressed the use of PrEP in combination with intensive safer sex practices counseling.
4.1.1.1. iPREX (pre exposure prophylaxis initiative)
iPREX was a randomized controlled study to evaluate the efficacy in reduction of new HIV
infections using a daily tablet of fixed dose of FTC/TDF when compared to placebo. iPREX
was funded by the National Institute of Allergy and Infectious Diseases and by the Bill and
Melinda Gates Foundation. The study included 2499 young high-risk MSM in South America,
Thailand and the US. The preliminary results of this study were released in 2010 and the study
was the landmark for the use of oral PrEP. Results suggested for the first time that oral ART
in combination with safe sex and condom use counseling could be used to reduce new HIV
infections in MSM. The use of oral FTC/TDF was associated with a 42% reduction in HIV
acquisition over 3 years (CI: 6%-60%). The study also analyzed the results according to self-
reported adherence and reveal the importance of adhere to the prescribed drug. The incidence
of new HIV cases was reduced to 68% when adherence was high (more than 90% of pills taken),
to 50% if adherence was between 50% and 90%, and to 32% if adherence was low (less than
50%). In order to clarify if detectable drug levels were associated with protection against HIV
infection a case control design was used to compare rates of infection in individuals with
detectable blood levels with those without detectable levels. A relative risk reduction of 92%
(CI: 40%-99%) in individuals with detectable study drug levels was found. This finding
provided evidence that protection was directly related with drug levels, an indirect measure‐
ment of adherence. In addition, this study showed that FTC/TDF had a good safety profile
with minimal gastrointestinal side effects. A minimal decrease in bone density in individuals
taking the drug was also observed. Among the individuals that seroconvert, most of them were
in the process of HIV seroconversion at enrollment and some developed a virus with resistant
mutations. This finding reinforced the importance of excluding HIV infection when using FTC/
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TDF for PrEP. The study results were published in the New England Journal of Medicine in
2010 [53]
4.1.1.2. TDF2
TDF2 was a randomized controlled study to evaluate the efficacy to reduce new HIV infection
of a daily fixed dose of an oral combination pill of TDF/FTC when compared to placebo. This
study was funded by the Centers for Disease Control and Prevention (CDC) and the division
of AIDS at the National Institutes of Health. The study was conducted in Bostwana and
included 1219 males and females, unmarried adults. This study had high rates of loss of follow
up (30%) and due to low retention, enrollment was prematurely stopped and study closed.
Enrolled participants were followed as planned and the last participant was followed until
2011. The results offered 62% (CI: 21%-83%) protection against HIV infection overall. This
study also evaluated drug levels in individuals receiving the drug and revealed that plasma
concentration were lower among the participants who seroconverted to HIV. Reported
adherence was high and similar in the two groups (above 80%), although detectable drug levels
in the drug arm suggested that adherence was lower that reported. Risky sexual behaviors
were similar and did not change in the two groups during the study. Among the participants
receiving the study drugs, there was and increase number of gastrointestinal side effects
(nausea and vomiting) and dizziness as well as a significant decline in bone density. One
participant was enrolled with unrecognized acute HIV infection and developed a resistant
virus [54].
4.1.1.3. Partners PrEP (partners in prevention)
Partners in Prevention study is the largest trial evaluating PrEP in heterosexual discordant
couples. It is an ongoing study with 3 study arms: daily TDF, daily TDF/FTC, and placebo.
This study is supported by the Bill and Melinda Gates Foundation. The study enrolled 4758
serodiscordant couples in which the HIV infected partner was not eligible for ART according
to country guidelines. This study in being conducted in sub Saharan Africa (Bostwana, Kenya,
Rwanda, South Africa, Tanzania, Uganda and Zambia). Extensive counseling in safe sex and
condom use was additionally provided to enrolled participants. TDF conferred a 67% (CI:
44%-81%) and FTC/TDF a 75% (CI: 55%-87%) reduction in new HIV infections. The difference
in rates of HIV seroconversion among the two treatment groups was not statistically different.
In July 2011 the DSMB recommended that the placebo group discontinued since the prede‐
termined criteria for stopping had already been made and a benefit in the treatment arms was
achieved [55]. The study results followed iPREX in supporting the use of PrEP in high risk
individuals.
4.1.1.4. FEM-PrEP
The  FEM-PrEP  study  was  a  randomized  controlled  trial  that  included  women  in  sub
Saharan  Africa  (Kenya,  South  Africa  and  Tanzania).  This  study  was  supported  by  US
Agency  for  International  Development.  Women were  randomized to  receive  either  oral
daily FTC/TDF or placebo. This study evaluated 2120 women and was the first one designed
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to  address the effectiveness and safety of  PrEP by gender.  Incidence of  new HIV infec‐
tions was 4.7% person-years in the treatment group and 5% person-years in the placebo
group and this different was not statistically significant. This study was the first large study
discontinued  based  on  recommendations  from  the  Data  Safety  Monitoring  Board  after
interim results  were unable to demonstrate efficacy of  PrEP.  In April  of  2011 the study
was stopped. As in prior studies, gastrointestinal side effects occurred more commonly in
the  treatment  arm (nausea,  vomiting and elevation of  ALT)  as  well  as  renal  laboratory
abnormalities. Despite extensive counseling on adherence, less than 40% of the women in
the treatment arm enrolled in the study had detectable drug levels raising once again the
importance of adherence to the prescribed regimen, perhaps lower in women [56].
4.1.1.5. VOICE (vaginal and oral interventions to control the epidemic)
VOICE is the largest clinical trial being conducted evaluating efficacy of PrEP in women. The
study is sponsored by the Microbicide Trials Network and the National Institutes of Health.
It enrolled over 5000 women in South Africa, Uganda, Zambia and Zimbabwe. Women were
randomized to 3 arms: daily oral TDF, daily oral TDF/FTC, or topical TDF. Results of this trial
resulted in the discontinuation of the oral TDF arm in September 2011 and the topical TDF arm
in November 2011 because of inability to demonstrate efficacy. The topical arm of the study
will be discussed under the microbicide section below and results of the TDF/FTC arm are
expected to be reported in 2013 [57].
4.1.1.6. Bangkok TDF trial
The Bangkok tenofovir study is an ongoing trial evaluating the efficacy of oral TDF in male
injection drug users receiving direct observation therapy. Enrollment for this study is complete
but no results are available at the time of this publication.
Studies addressing oral PrEP have yielded conflicting results and although the use of oral PrEP
appears to be beneficial in high risk MSM, the use in women still is under debate. Partners
PrEP, TDF2 and iPrEx provided a proof of concepts for the use of oral antiretrovirals for HIV
prevention. However, the results from VOICE and Fem-PrEP and other ongoing studies will
provide further information on the efficacy and safety of oral PrEP, especially in women.
Efficacy of PrEP seems to be directly related to adherence, and detectable blood levels is a
better marker of protection than self-reported adherence or pill count. Although in most
studies, adherence measured by self reporting or by pill count was high, detectable blood drug
levels were found only in 50% of participants in the treatment arm of iPREX [53].
The highest levels of adherence were reported in Partner PrEP, where serodiscordant couples
were enrolled and received extensive counseling. Tenofovir was detected in over 80% of
participants in the treatment group and PrEP reduced by 70% new HIV infections. The results
of Partner PrEP suggest that partner involvement is important, especially when addressing
HIV prevention in women [58,59].
In regards to decrease efficacy of PrEP in women the question of availability of drug at the
exposure site has been raised. However, high drug levels are found in cervicovaginal lavages,
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TDF for PrEP. The study results were published in the New England Journal of Medicine in
2010 [53]
4.1.1.2. TDF2
TDF2 was a randomized controlled study to evaluate the efficacy to reduce new HIV infection
of a daily fixed dose of an oral combination pill of TDF/FTC when compared to placebo. This
study was funded by the Centers for Disease Control and Prevention (CDC) and the division
of AIDS at the National Institutes of Health. The study was conducted in Bostwana and
included 1219 males and females, unmarried adults. This study had high rates of loss of follow
up (30%) and due to low retention, enrollment was prematurely stopped and study closed.
Enrolled participants were followed as planned and the last participant was followed until
2011. The results offered 62% (CI: 21%-83%) protection against HIV infection overall. This
study also evaluated drug levels in individuals receiving the drug and revealed that plasma
concentration were lower among the participants who seroconverted to HIV. Reported
adherence was high and similar in the two groups (above 80%), although detectable drug levels
in the drug arm suggested that adherence was lower that reported. Risky sexual behaviors
were similar and did not change in the two groups during the study. Among the participants
receiving the study drugs, there was and increase number of gastrointestinal side effects
(nausea and vomiting) and dizziness as well as a significant decline in bone density. One
participant was enrolled with unrecognized acute HIV infection and developed a resistant
virus [54].
4.1.1.3. Partners PrEP (partners in prevention)
Partners in Prevention study is the largest trial evaluating PrEP in heterosexual discordant
couples. It is an ongoing study with 3 study arms: daily TDF, daily TDF/FTC, and placebo.
This study is supported by the Bill and Melinda Gates Foundation. The study enrolled 4758
serodiscordant couples in which the HIV infected partner was not eligible for ART according
to country guidelines. This study in being conducted in sub Saharan Africa (Bostwana, Kenya,
Rwanda, South Africa, Tanzania, Uganda and Zambia). Extensive counseling in safe sex and
condom use was additionally provided to enrolled participants. TDF conferred a 67% (CI:
44%-81%) and FTC/TDF a 75% (CI: 55%-87%) reduction in new HIV infections. The difference
in rates of HIV seroconversion among the two treatment groups was not statistically different.
In July 2011 the DSMB recommended that the placebo group discontinued since the prede‐
termined criteria for stopping had already been made and a benefit in the treatment arms was
achieved [55]. The study results followed iPREX in supporting the use of PrEP in high risk
individuals.
4.1.1.4. FEM-PrEP
The  FEM-PrEP  study  was  a  randomized  controlled  trial  that  included  women  in  sub
Saharan  Africa  (Kenya,  South  Africa  and  Tanzania).  This  study  was  supported  by  US
Agency  for  International  Development.  Women were  randomized to  receive  either  oral
daily FTC/TDF or placebo. This study evaluated 2120 women and was the first one designed
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to  address the effectiveness and safety of  PrEP by gender.  Incidence of  new HIV infec‐
tions was 4.7% person-years in the treatment group and 5% person-years in the placebo
group and this different was not statistically significant. This study was the first large study
discontinued  based  on  recommendations  from  the  Data  Safety  Monitoring  Board  after
interim results  were unable to demonstrate efficacy of  PrEP.  In April  of  2011 the study
was stopped. As in prior studies, gastrointestinal side effects occurred more commonly in
the  treatment  arm (nausea,  vomiting and elevation of  ALT)  as  well  as  renal  laboratory
abnormalities. Despite extensive counseling on adherence, less than 40% of the women in
the treatment arm enrolled in the study had detectable drug levels raising once again the
importance of adherence to the prescribed regimen, perhaps lower in women [56].
4.1.1.5. VOICE (vaginal and oral interventions to control the epidemic)
VOICE is the largest clinical trial being conducted evaluating efficacy of PrEP in women. The
study is sponsored by the Microbicide Trials Network and the National Institutes of Health.
It enrolled over 5000 women in South Africa, Uganda, Zambia and Zimbabwe. Women were
randomized to 3 arms: daily oral TDF, daily oral TDF/FTC, or topical TDF. Results of this trial
resulted in the discontinuation of the oral TDF arm in September 2011 and the topical TDF arm
in November 2011 because of inability to demonstrate efficacy. The topical arm of the study
will be discussed under the microbicide section below and results of the TDF/FTC arm are
expected to be reported in 2013 [57].
4.1.1.6. Bangkok TDF trial
The Bangkok tenofovir study is an ongoing trial evaluating the efficacy of oral TDF in male
injection drug users receiving direct observation therapy. Enrollment for this study is complete
but no results are available at the time of this publication.
Studies addressing oral PrEP have yielded conflicting results and although the use of oral PrEP
appears to be beneficial in high risk MSM, the use in women still is under debate. Partners
PrEP, TDF2 and iPrEx provided a proof of concepts for the use of oral antiretrovirals for HIV
prevention. However, the results from VOICE and Fem-PrEP and other ongoing studies will
provide further information on the efficacy and safety of oral PrEP, especially in women.
Efficacy of PrEP seems to be directly related to adherence, and detectable blood levels is a
better marker of protection than self-reported adherence or pill count. Although in most
studies, adherence measured by self reporting or by pill count was high, detectable blood drug
levels were found only in 50% of participants in the treatment arm of iPREX [53].
The highest levels of adherence were reported in Partner PrEP, where serodiscordant couples
were enrolled and received extensive counseling. Tenofovir was detected in over 80% of
participants in the treatment group and PrEP reduced by 70% new HIV infections. The results
of Partner PrEP suggest that partner involvement is important, especially when addressing
HIV prevention in women [58,59].
In regards to decrease efficacy of PrEP in women the question of availability of drug at the
exposure site has been raised. However, high drug levels are found in cervicovaginal lavages,
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and even higher than in plasma or rectal mucosa, what would dispute this hypothesis [52,60].
Another possibility is a decrease of drug levels in women receiving hormonal contraceptives
and it is under evaluation by the study team.
Nevertheless, the possibility of low efficacy of oral PrEP in women suggest that microbicides
or other delivery methods may be a better option in this population.
Following the positive results of daily ART use for HIV prevention, especially in MSM, newer
studies are undergoing to evaluate the use of intermittent PrEP. These intermittent regimens
could be more feasible in certain setting such as in non stable relationships. A large study in
Kenia (ADAPT, Alternative Dosing to Augment PrEP Pill-Taking) is evaluating the safety and
adherence to daily oral TDF/FTC versus intermittent TDF/FTC (Monday, Friday and within 2
hours after sex) or placebo. Another study (HPTN 067) is a study including MSM and heter‐
osexual women aiming to identify dosing regiments in people at high risk for HIV infection.
Preliminary data demonstrated that although adherence may be decreased in intermittent
dosing, it may still be appropriate for PrEP.
4.1.2. Potential problems associated with oral PrEP
In July 2012, and based on the results of the mentioned trials, especially iPREX and Partners
PrEP, the United States Food and Drug administration (US FDA) approved the use of daily
TDF/FTC or Truvada® for prevention of sexually acquired HIV in individuals at risk for HIV
infection. However, even if approval was granted, serious concerns have been raised by experts
in the field of HIV prevention. The issues that need to be addressed before recommending
PrEP as a generalized HIV prevention strategy are: development of drug resistance viruses,
long term side effects, increase in sexual risk behaviors, cost, and incorporating PrEP as part
of primary care prevention.
4.1.2.1. Development of drug resistant viruses
Development of drug resistance was identified in some of the participants who seroconvert in
the mentioned studies but in most cases, occurred in individuals that enrolled with a new non
identified HIV infection. Addressing this potential problem is difficult, since individuals at
risk may have an early infection missed by routine antibody testing and routine viral load may
not be easily available in high risk settings.
4.1.2.2. Long term side toxicity
As both TDF and FTC have potential serious long term side effects, it is important to determine
if long use of FTC/TDF in HIV negative individuals will increase the risk of kidney failure or
osteoporosis. In order to evaluate long term side effects, long term follow up is necessary to
address if decline in renal function or bone density are clinically significant. However, as in
HIV positive individuals using those agents, side effects may take many years to develop.
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4.1.2.3. Increased of high risk sexual behavior
In regards to increase of risky sexual risk behaviors, both iPREX and Partners PrEP revealed
that all participants increased condom use, decrease number in sexual partners, unprotect‐
ed anal intercourse,  and reduced rates for syphilis.  This was likely due to the extensive
counseling that both drug and placebo groups received and sustainability of sexual risk
behavior needs to be further examined.
4.1.2.4. Cost
The cost of providing PrEP to individuals at risk is of course under great debate due to both
economical and ethical issues. ART are expensive medications and not available for all HIV
infected patients in need for their own health. PrEP is an expensive approach and cost
effectiveness will need to be justified prior to generalization to the population at risk. A cost-
effectiveness analysis of PrEP for HIV prevention in MSM published in 2012 in Annals of
Internal Medicine revealed that although PrEP could have an important impact in the HIV
epidemics, it will be an extremely expensive approach [63]. In a modeling analysis, Juusola
recently showed that providing PrEp to all high-risk MSM for 20 years will cost $75 billion in
health care related cost, a non-insignificant amount [61]. An ethical concern is whether
providing them to those HIV uninfected individuals will interfere with the treatment of HIV
infected patient in need for treatment, especially in poor resource settings.
4.1.3. Feasibility of generalizing the use of oral PrEP to the population at risk.
The use of PrEP includes identification of high risk individuals, extensive risk counseling,
provision of a drug and follow up risk assessments, HIV and laboratory tests. If PrEp is
incorporated as part of primary care prevention activities, the primary care physician will need
to become familiar with drugs normally prescribed for highly specialized physicians and will
need to be aware of new research data and changes in the recommendations as they become
available [63].
As summary, oral PrEP has demonstrated efficacy in certain populations at risk for HIV
infection, especially in MSM. Studies assessing acceptability, long term efficacy, toxicity, risk
of HIV resistance, cost and use in women are needed before including oral PrEP as part of HIV
prevention tools in the population at risk.
4.2. Microbicides to prevent HIV infection in women and MSM
Women are more vulnerable than men to acquire HIV during sex due to biological factors as
well as difficulties in negotiating barrier methods and fidelity. Women can rarely negotiate
condom use or faithfulness with their sexual partners and could greatly benefit of controlling
their own risk of HIV infection without involvement of male partners. Studies addressing oral
PrEP suggested lower efficacy of oral agents in women, which make microbicides an attractive
alternative for HIV prevention in women at risk.
Microbicides are topical products applied to the rectum or the vagina to prevent HIV infection
in HIV negative individuals. Research on microbicides has included primarily women but
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and even higher than in plasma or rectal mucosa, what would dispute this hypothesis [52,60].
Another possibility is a decrease of drug levels in women receiving hormonal contraceptives
and it is under evaluation by the study team.
Nevertheless, the possibility of low efficacy of oral PrEP in women suggest that microbicides
or other delivery methods may be a better option in this population.
Following the positive results of daily ART use for HIV prevention, especially in MSM, newer
studies are undergoing to evaluate the use of intermittent PrEP. These intermittent regimens
could be more feasible in certain setting such as in non stable relationships. A large study in
Kenia (ADAPT, Alternative Dosing to Augment PrEP Pill-Taking) is evaluating the safety and
adherence to daily oral TDF/FTC versus intermittent TDF/FTC (Monday, Friday and within 2
hours after sex) or placebo. Another study (HPTN 067) is a study including MSM and heter‐
osexual women aiming to identify dosing regiments in people at high risk for HIV infection.
Preliminary data demonstrated that although adherence may be decreased in intermittent
dosing, it may still be appropriate for PrEP.
4.1.2. Potential problems associated with oral PrEP
In July 2012, and based on the results of the mentioned trials, especially iPREX and Partners
PrEP, the United States Food and Drug administration (US FDA) approved the use of daily
TDF/FTC or Truvada® for prevention of sexually acquired HIV in individuals at risk for HIV
infection. However, even if approval was granted, serious concerns have been raised by experts
in the field of HIV prevention. The issues that need to be addressed before recommending
PrEP as a generalized HIV prevention strategy are: development of drug resistance viruses,
long term side effects, increase in sexual risk behaviors, cost, and incorporating PrEP as part
of primary care prevention.
4.1.2.1. Development of drug resistant viruses
Development of drug resistance was identified in some of the participants who seroconvert in
the mentioned studies but in most cases, occurred in individuals that enrolled with a new non
identified HIV infection. Addressing this potential problem is difficult, since individuals at
risk may have an early infection missed by routine antibody testing and routine viral load may
not be easily available in high risk settings.
4.1.2.2. Long term side toxicity
As both TDF and FTC have potential serious long term side effects, it is important to determine
if long use of FTC/TDF in HIV negative individuals will increase the risk of kidney failure or
osteoporosis. In order to evaluate long term side effects, long term follow up is necessary to
address if decline in renal function or bone density are clinically significant. However, as in
HIV positive individuals using those agents, side effects may take many years to develop.
Current Perspectives in HIV Infection398
4.1.2.3. Increased of high risk sexual behavior
In regards to increase of risky sexual risk behaviors, both iPREX and Partners PrEP revealed
that all participants increased condom use, decrease number in sexual partners, unprotect‐
ed anal intercourse,  and reduced rates for syphilis.  This was likely due to the extensive
counseling that both drug and placebo groups received and sustainability of sexual risk
behavior needs to be further examined.
4.1.2.4. Cost
The cost of providing PrEP to individuals at risk is of course under great debate due to both
economical and ethical issues. ART are expensive medications and not available for all HIV
infected patients in need for their own health. PrEP is an expensive approach and cost
effectiveness will need to be justified prior to generalization to the population at risk. A cost-
effectiveness analysis of PrEP for HIV prevention in MSM published in 2012 in Annals of
Internal Medicine revealed that although PrEP could have an important impact in the HIV
epidemics, it will be an extremely expensive approach [63]. In a modeling analysis, Juusola
recently showed that providing PrEp to all high-risk MSM for 20 years will cost $75 billion in
health care related cost, a non-insignificant amount [61]. An ethical concern is whether
providing them to those HIV uninfected individuals will interfere with the treatment of HIV
infected patient in need for treatment, especially in poor resource settings.
4.1.3. Feasibility of generalizing the use of oral PrEP to the population at risk.
The use of PrEP includes identification of high risk individuals, extensive risk counseling,
provision of a drug and follow up risk assessments, HIV and laboratory tests. If PrEp is
incorporated as part of primary care prevention activities, the primary care physician will need
to become familiar with drugs normally prescribed for highly specialized physicians and will
need to be aware of new research data and changes in the recommendations as they become
available [63].
As summary, oral PrEP has demonstrated efficacy in certain populations at risk for HIV
infection, especially in MSM. Studies assessing acceptability, long term efficacy, toxicity, risk
of HIV resistance, cost and use in women are needed before including oral PrEP as part of HIV
prevention tools in the population at risk.
4.2. Microbicides to prevent HIV infection in women and MSM
Women are more vulnerable than men to acquire HIV during sex due to biological factors as
well as difficulties in negotiating barrier methods and fidelity. Women can rarely negotiate
condom use or faithfulness with their sexual partners and could greatly benefit of controlling
their own risk of HIV infection without involvement of male partners. Studies addressing oral
PrEP suggested lower efficacy of oral agents in women, which make microbicides an attractive
alternative for HIV prevention in women at risk.
Microbicides are topical products applied to the rectum or the vagina to prevent HIV infection
in HIV negative individuals. Research on microbicides has included primarily women but
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studies addressing several rectal formulations in MSM are currently undergoing. Unfortu‐
nately, results on microbicide research have been conflicting and further research is needed.
Topical vaginally applied TDF showed promising results in the CAPRISA trial. However, other
agents have not been efficacious and research in this area is ongoing.
In order for a microbicide to be successful it must fulfill the following characteristics: be
biologically active, safe, and acceptable by the individual at risk. The principals mechanisms
of action evaluated in microbide development are: buffer agents, surfactants, blockers and
antiretrovirals.
4.2.1. Buffers
Buffers are supplements to the natural immune defenses of the vagina. Buffers maintain the
vaginal pH favoring the persistence of the naturally protective vaginal lactobacilli. Alterations
of the vaginal pH due to exposure to semen or vaginal infections such as bacterial vaginosis
damage the vaginal microbiota and facilitate HIV infection. Buffergel ®, a buffer designed to
maintain vaginal pH was tested in animals and in a phase III effectiveness trial; but unfortu‐
nately, did not prevent new HIV infections [63].
4.2.2. Surfactants
Surfactants act by inactivating infectious agents. Noxynol-9, a wide available microbicide with
known activity against several infectious agents has been tested in multiple forms (film, sponge
and gel) and was not effective in preventing new HIV infections [64]. SAVVY® (C31G) was a
surfactant in a gel form tested in Ghana and Nigeria between 2004-2006 and not found to be
effective [65]. Surfactants are no longer being considered as potential agents for microbicide
use.
4.2.3. Blockers
Blockers inhibit the fusion of the HIV virus to the cell membrane. Four compounds in this
category have been tested to date: PRO2000®, Carrguard®, cellulose sulfate and dextrin 2-
sulfate and have not demonstrated activity in clinical trials [66].
4.2.4. Drugs with anti HIV activity
Antiretroviral agents act by inhibiting the HIV replication cycle in the vaginal mucosa have
been tested in two major clinical trials (CAPRISA and VOICE). Other agents acting as co-
receptor blockers binding to chemokine co-receptors such as VVR5 or CxCR4 are also under
investigation.
4.2.4.1. CAPRISA
The landmark study suggesting that the potential of microbicides as HIV prevention tools
is  CAPRISA,  a  two-arm randomized double  blind placebo controlled trial  conducted in
South Africa between 2007 and 2010. The study evaluated the efficacy in HIV reduction of
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a coitally (before and after sex) related application of TDF vaginal gel when compared to
placebo. 1341 women were enrolled. The incidence of HIV infections in the tenofovir arm
was 5.6 (CI: 4.0-7.7) per 100 women-years and 9.1 (CI: 6.9-11.7) in the placebo arm. (IRR:
0.61;  CI:0.4-0.94,p=0.017).  Tenofovir  gel  reduced  HIV acquisition  by  an  estimate  of  39%
overall  and by 54% in women with high adherence to  the gel.  This  study did not  find
major side effects associated with the use of TDF and no TDF resistant virus were found
in women who seroconverted. The results of this study were released in the Internation‐
al AIDS conference in Vienna in 2010 and provided a potential armamentum for women
unable to negotiate fidelity and condom use.  Caprisa also provided a reduction in HSV
acquisition [67].
4.2.4.2. VOICE
VOICE as described in the oral PrEP section included one arm evaluating daily use of vaginal
TDF gel. The gel arm enrolled approximately 1000 women. In September of 2011 this arm was
discontinued as a recommendation from the DSMB due to no efficacy. No safety issues were
identified [68]. In order to clarify if the differences between CAPRISA (39% reduction on new
HIV infections) was found and VOICE (no effect of TDF gel), a new study will replicate
CAPRISA (FACTS 001) and its results will help to clarify if TDF gel is useful and can be
incorporated to the field of HIV prevention.
4.2.5. Agents under development
4.2.5.1. Vaginal rings
The use of vaginal rings for prevention of HIV acquisition is under evaluation in several
studies. Vaginal rings with antivirals could potentially be used in combination with contra‐
ceptives, and will release antiviral agent long term and independent of sexual intercourse.
Dapivirine (TMC120) vaginal ring is currently evaluated under phase III studies as ASPIRE –
A Study to Prevent Infection with a Ring for Extended study [69]. A combination of Dapivirine
and Maraviroc is currently undergoing a phase 1 safety and pharmacokinetic study [70]. Other
vaginal rings with maraviroc alone or in combination with tenofovir are also being developed.
4.2.5.2. Long acting injectables
The use of a long acting injectable agent that will provide protection for 3-9 months is a
potential method that will increase adherence. Rilpivirine is under development for this
purpose [71].
PrEP using oral or topical agents is a promising strategy in the field of HIV prevention.
However, as single intervention may not be successful in controlling the HIV epidemics
and the results obtained in controlled clinical trials are unlikely to persist overtime. The
CDC recently published interim guidance for clinicians considering the use of PrEP for the
prevention of HIV infection in heterosexually active adults [72]. This report addresses the
remaining gap in knowledge regarding PrEP but provides a comprehensive evaluation of
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the  available  data  and  guidance  to  health  care  providers  regarding  the  use  of  PrEP.
However, HIV prevention guidelines are under development and 30 years of the history
of  HIV  have  shown  the  scientific  community  that  a  single  intervention  is  unlikely  to
succeed.
In summary, the science of HIV prevention has seen significant progress in recent years. After
decades of frustration and lagging behind the spectacular progress brought up in the control
of HIV disease by the use of antiretrovirals, the field of biomedical prevention of HIV has been
revolutionized and energized by the scientific evidence produced in the last few years that
supports the use of the four strategies discussed above: adult male circumcision, treatment of
HIV infected people, pre-exposure prophylaxis and microbicides (Figure 3). However,
although the foundations for successful HIV prevention programs are being laid out, there are
still significant challenges ahead that will need to be solved before all these strategies can be
fully scaled up, combined and delivered to the at risk individuals and communities. The field
is also confident that the still elusive vaccine to prevent HIV infection can be unveiled in a not
distant future.
Figure 3 lists currently proven biomedical interventions that prevent sexually transmitted HIV
infection by gender.
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1. Introduction
Although sharing identical transmission routes as well as structural and genomic properties,
human immunodeficiency viruses 1 and 2 (HIV-1 and HIV-2, respectively) show different
pathogenic abilities in human host. Despite both HIV-1 and HIV-2 lead to immunological
failure and Acquired Immunodeficiency Syndrome (AIDS), a slower rate of disease progres‐
sion with a longer asymptomatic period and lower levels of viremia in general characterize
HIV-2 infection (Table 1). Comparative studies measuring the progression rates of both HIV-1
and HIV-2 infections provided clear evidence that the majority of HIV-2 infected individuals
fit in a definition of long-term non-progressors [1-3].
HIV-1 HIV-2
Geographic distribution Worldwide Restricted to West African countries and to
countries sharing economical-social links with them
Viral load Usually moderate to high Usually undetectable
Transmission By sexual route is usually inefficient, requiring
multiple exposures




Usually less than 10 years Usually decades
Treatment Plenty of data regarding viral susceptibility to
all anti-retroviral drugs. Resistance-conferring
mutations well established and defined
Naturally resistant to non-nucleoside analogous
targeting reverse transcriptase. Scarce and
sometimes conflicting results regarding
susceptibility to other anti-retroviral drugs
Table 1. Comparison between epidemiologic and clinical data of HIV-1 and HIV-2 infections
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unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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All these findings support the notion that in HIV-2 infected individuals several factors (e.g.
virologic and immunologic) should account for a best fitted response that ultimately leads to
a better control of HIV-2 infection compared to HIV-1. Deciphering these factors should
provide crucial information about the mechanisms underlying the delayed disease progression
and may help explain how a retroviruses infection could be coped for such a long time without
causing disease. This knowledge is important to clarify AIDS pathogenesis and to identify the
correlates of protection crucial to develop an efficient HIV vaccine.
Despite the potential importance of HIV-2 as a model to address those issues, it has been mostly
neglected and very few data exists regarding HIV-2 interaction with target cells. In this chapter
I will focus on these interactions, particularly those concerning early events. Distinguishing
features between HIV-1 and HIV-2 will be highlighted and their implications in viral fitness
and pathogenic differences between the two viruses will be discussed.
2. Origin of HIV-2
HIV-2, as HIV-1, belongs to Family Retroviridae, Subfamily Orthoretrovirinae, Genus Lentivi‐
rus [4]. It was first isolated from a symptomatic patient from Guinea-Bissau [5] and subse‐
quently associated with immunological failure and clinical manifestations typically observed
in AIDS patients infected with HIV-1 [6].
HIV-1 and HIV-2 were introduced into human population as a consequence of multiple cross-
species transmissions from simian immunodeficiency virus (SIV)-infected non-human
primates. The genetic relatedness between HIV-1, HIV-2 and SIV strains, and the coincidence
of natural habitats of specific simian species and geographic regions where HIV-1 and HIV-2
had probably emerged, allowed the identification of SIVcpz (infecting the chimpanzee
subspecies Pan troglodytes troglodytes) and SIVsm (infecting sooty mangabey subspecies
Cercocebus atys) as viral ancestors of HIV-1 and HIV-2, respectively [7-9]. Through a combina‐
tion of phylogenetic and molecular clock analysis it was estimated that the date of the most
recent common ancestor of HIV-1 group M was 1930 ± 15, and that of "HIV-2 group A was
1940 ± 16 [8, 10]. These cross-species transmission events was then fuelled-up by social, sexual
and iatrogenic factors during colonial period in Africa [11], converting a restricted zoonotic
disease into an epidemic (HIV-2) and pandemic (HIV-1) infections.
3. Genomic organization of HIV-2
The genomic information of HIV-2 is  comprised in two identical  copies of  9.2 kb single
strand RNA. HIV-2 genome encodes nine open reading frames (i.e.  gag,  pol,  vif,  vpr,  tat,
rev, vpx, env  and nef),  flanked by two long terminal repeats (5’LTR and 3’LTR). Soon af‐
ter entry into target cell the genomic RNA is converted to a double-stranded DNA mole‐
cule,  a  reaction  catalized  by  reverse  transcriptase  (RT)  enzyme,  that  occurs  in  a
cytoplasmic  complex,  named  reverse  transcriptase  complex  (RTC).  The  RTC  transforms
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to the preintegration complex (PIC) composed by several cellular and viral  components,
e.g. viral DNA, RT, integrase (IN), matrix (MA) and Vpr proteins (reviewed in [12]). This
PIC allows the  reverse  transcribed viral  DNA to  enter  the  nucleus  through the  nuclear
pore and to be integrated into the genome of target cell.
After integration, the HIV-2 proviral DNA is transcribed into several mRNAs by cellular RNA
polymerase II, a process initiated through the binding of cellular activation factors to the viral
LTR, culminating in the synthesis of viral proteins and in the production of new progeny
virions. The function of each HIV-2 protein has been inferred from HIV-1 counterparts and
reviewed in [13].
Compared to HIV-1, HIV-2 lacks the vpu gene while has the vpx gene. The Vpu protein has
been associated with two main functions in HIV-1 replication: induces a rapid degradation of
CD4 molecules (see below the role of CD4 as viral receptor) in endoplasmic reticulum through
the ubiquitin-proteasome system [14]; and enhancing the budding and release of viral particles
[15] by counteracting the activity of Tetherin/BST2, a cellular factor that restricts the egress of
enveloped viruses (e.g. HIV, Ebola virus), thereby reducing viral production and cell-free virus
propagation [16, 17]. In HIV-2, this latter role in viral replication seems to be assumed by the
membrane-anchored subunit and the extracellular domain of transmembrane (TM) envelope
glycoprotein [18, 19].
Vpx is a protein only present in HIV-2 and SIVsm lineage. Sequence analysis suggests that the
vpx gene is a duplication of vpr gene but despite amino acid sequence similarities between both
proteins, their functions are clearly distinct. While Vpr is mainly involved in cell cycle arrest
in G2/M phase [20], the Vpx protein has been recently linked to the enhancement of HIV-1
infection of dendritic cells and an essential factor in innate response to HIV infection [21]. The
obvious importance of Vpx in the pathogenesis of human lentiviral infection will be further
discussed in subchapters 4 and 5.
4. HIV-2 as a limited spreading virus
As in all zoonosis, the emergence of HIV-1 and HIV-2, as successful new human pathogens,
involved not only a close contact with animal reservoirs but also the capability of the cross-
species viruses to: encounter and efficiently infect human host cells, and to be able to be
effectively transmitted within the human population.
Although HIV-1 and HIV-2 shared common transmission routes, they show a clear distinct
epidemiology. While HIV-1, particularly group M, has spread literally worldwide, HIV-2
infection reveal a much more confined geographic distribution: West Africa and countries that
maintained social-economic links to this region (e.g. Portugal, France and their former
colonies). Since both viruses had begun to spread nearly at the same time, somewhere between
1950 and 1970, this limited expansion of HIV-2 indicates a less efficient human transmission.
Heterosexual spread of HIV-2 is remarkably lower than in HIV-1: it seems that HIV-2 is five
to nine times less efficiently transmitted than HIV-1 by sexual route [22]. Likewise, mother-to-
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ter entry into target cell the genomic RNA is converted to a double-stranded DNA mole‐
cule,  a  reaction  catalized  by  reverse  transcriptase  (RT)  enzyme,  that  occurs  in  a
cytoplasmic  complex,  named  reverse  transcriptase  complex  (RTC).  The  RTC  transforms
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to the preintegration complex (PIC) composed by several cellular and viral  components,
e.g. viral DNA, RT, integrase (IN), matrix (MA) and Vpr proteins (reviewed in [12]). This
PIC allows the  reverse  transcribed viral  DNA to  enter  the  nucleus  through the  nuclear
pore and to be integrated into the genome of target cell.
After integration, the HIV-2 proviral DNA is transcribed into several mRNAs by cellular RNA
polymerase II, a process initiated through the binding of cellular activation factors to the viral
LTR, culminating in the synthesis of viral proteins and in the production of new progeny
virions. The function of each HIV-2 protein has been inferred from HIV-1 counterparts and
reviewed in [13].
Compared to HIV-1, HIV-2 lacks the vpu gene while has the vpx gene. The Vpu protein has
been associated with two main functions in HIV-1 replication: induces a rapid degradation of
CD4 molecules (see below the role of CD4 as viral receptor) in endoplasmic reticulum through
the ubiquitin-proteasome system [14]; and enhancing the budding and release of viral particles
[15] by counteracting the activity of Tetherin/BST2, a cellular factor that restricts the egress of
enveloped viruses (e.g. HIV, Ebola virus), thereby reducing viral production and cell-free virus
propagation [16, 17]. In HIV-2, this latter role in viral replication seems to be assumed by the
membrane-anchored subunit and the extracellular domain of transmembrane (TM) envelope
glycoprotein [18, 19].
Vpx is a protein only present in HIV-2 and SIVsm lineage. Sequence analysis suggests that the
vpx gene is a duplication of vpr gene but despite amino acid sequence similarities between both
proteins, their functions are clearly distinct. While Vpr is mainly involved in cell cycle arrest
in G2/M phase [20], the Vpx protein has been recently linked to the enhancement of HIV-1
infection of dendritic cells and an essential factor in innate response to HIV infection [21]. The
obvious importance of Vpx in the pathogenesis of human lentiviral infection will be further
discussed in subchapters 4 and 5.
4. HIV-2 as a limited spreading virus
As in all zoonosis, the emergence of HIV-1 and HIV-2, as successful new human pathogens,
involved not only a close contact with animal reservoirs but also the capability of the cross-
species viruses to: encounter and efficiently infect human host cells, and to be able to be
effectively transmitted within the human population.
Although HIV-1 and HIV-2 shared common transmission routes, they show a clear distinct
epidemiology. While HIV-1, particularly group M, has spread literally worldwide, HIV-2
infection reveal a much more confined geographic distribution: West Africa and countries that
maintained social-economic links to this region (e.g. Portugal, France and their former
colonies). Since both viruses had begun to spread nearly at the same time, somewhere between
1950 and 1970, this limited expansion of HIV-2 indicates a less efficient human transmission.
Heterosexual spread of HIV-2 is remarkably lower than in HIV-1: it seems that HIV-2 is five
to nine times less efficiently transmitted than HIV-1 by sexual route [22]. Likewise, mother-to-
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child transmission rate of HIV-2 is 0-4%, while in HIV-1 this transmission occurs in 15-40% of
untreated pregnancies [23].
This poor capability to infect new hosts could lead HIV-2 to a dead end. Viral ecology imposes
two ideal conditions: maintain the host alive as long as possible while being efficiently
transmitted within host population. HIV-2 only fulfils the first condition leading to a decline
in HIV-2 prevalence even in regions (i.e. West Africa) where, in the early stages of AIDS
epidemic, a clear predominance of HIV-2 infections existed compared to HIV-1 [24].
4.1. Viral load and transmission
Many different factors account for a successful transmission of HIV by sexual route. One of
the most critical is the amount of infectious viral particles present in the transmitting body
fluid (e.g. blood, semen or cervicovaginal secretion). Higher concentrations are more likely
associated with transmission events. Apparently, in HIV-1, the cutoff of 1500 copies of viral
RNA per ml of plasma is required for efficient transmission [25].
Not surprisingly, plasma and semen viral loads are significantly lower in patients infected
with HIV-2 compared to those infected with HIV-1 [26, 27], providing a likely explanation for
the reduced transmission rate and spread within human population. This lower viral load is
observed throughout the infection and persists until late in the course of the disease, but is
remarkably important during asymptomatic stage. During this stage, which in HIV-2 could
last for several decades, an undetectable viremia is a hallmark of almost every HIV-2 patients.
However, a similar proviral burden is detected in both HIV-1 and HIV-2-infected individuals
[28, 29]. This apparent paradox suggests that the lower plasma viral load observed in HIV-2
infection may be due to lower levels of infectious virus production, or a better host-driven
suppression of viral replication, or both.
4.2. The mucosal barrier
Besides viral load, numerous barriers decrease the efficiency of mucosal transmission. The
foundations of this important notion emanates from studies of couples discordant for HIV-1
infection, which demonstrated that heterosexual transmission is very inefficient requiring
multiple exposures for a successful transmission [30, 31]. A detailed understanding of the
events surrounding transmission should provide important clues how HIV establishes a new
infection and what additional vulnerabilities HIV-2 has, at this stage, that can help explain its
lower spread.
Although HIV-1 and HIV-2 (as well as SIV) are commonly referred as “lentivirus” based on
the long incubation period and slow onset of disease, it is now clear from data using rhesus
macaque model infected with SIV, that initial virus-host interactions, crucial to establishing
systemic infection, take place in a rapid succession of related events, soon after mucosal
transmission (recently reviewed in [32]). In sexual transmission, the most common form of
HIV transmission, these events involve the interactions with cells present in cervical/vaginal
mucosa epithelial surfaces. To establish infection, HIV present in semen must go through
mucus that covers female genital epithelia and penetrate through the epithelial layer to access
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susceptible cells such as T lymphocytes, macrophages, Langerhans cells and dendritic cells.
Mucus, particularly abundant in upper female genital tract, provides the first barrier to HIV
infection. Mucus protective role of underlying epithelial cells is provided by the presence of
soluble factors (e.g. chemokines produced by epithelial cells) that decrease viral infectivity and
by mechanical trapping of virions in the dense protein mesh that constitutes the cervical mucus
[33]. By slowing viral diffusion, mucus reduces the probability of infectious virus reach the
surface of underlying cells.
Virions that successfully crossed the mucus encounters the epithelial cells layer that line the
different compartments of the female genital tract. These different compartments show
remarkable differences in the structure of epithelial layer. The mucosa from the lower female
genital tract (i.e. exocervix and vagina) consists of stratified squamous epithelium, several
layers thick. In contrast, in the upper reproductive compartment (i.e. endocervix and endo‐
metrium) the mucosal lining is composed of a single layer of columnar epithelium over the
basement membrane and is characterized by the presence of tight junctions between cells.
As expected by their different composition, the lower female genital epithelium is much more
robust and provides a more effective physical barrier than the fragile single columnar layer of
upper genital epithelium. Furthermore, the junction between the exocervix and the endocervix,
where the structure of the epithelium abruptly changes from stratified to single layer (called
the transitional or transformational zone), is characterized by an intense immunologic activity
and thus enriched with abundant lymphocytes and antigen presenting cells (e.g. dendritic cells
and macrophages), particularly during inflammatory processes [34]. The physical vulnerabil‐
ity and the presence of abundant target cells in transitional zone, make this region highly
susceptible to HIV entry and infection [35].
Even the thicker vaginal epithelial barrier could quickly expose susceptible cells in the
submucosa to HIV. In fact, the stratified squamous epithelium changes markedly through the
menstrual cycle, in response to progesterone [36], leading to a thinning of this physical barrier.
Additionally, breaches could occur because of microulcerations and breaks in the epithelium
due to sexual intercourse, inflammatory processes, sexually transmitted infections, and other
genital infections, increasing the likelihood of establishing an HIV infection [37-39].
Additionally, the mere exposure of genital mucosa to semen induces local alterations that
could potentiate the transmission of HIV-1 and (probably) HIV-2. These include the neutrali‐
zation of the acidic pH of the cervicovaginal secretions, the regulation of inflammatory
cytokines in genital tract epithelial cells, and the promotion of leukocyte infiltration and the
attraction of Langerhans cells in cervical and vaginal mucosae [40, 41]. Semen could also
directly promote HIV infection of epithelial target cells through the formation of amyloid fibrils
that capture HIV particles and enhances virus-cell attachment and fusion [42]. This amyloi‐
dogenic activity of human semen seems to be related with fragments of prostatic acidic
phosphatase [42]. Apparently this enhancement is semen donor-dependent but independent
of HIV strain or cell type used [43].
In contrast to female genital tract, HIV transmission through male genital tract is poorly
understood. Despite the presence of CD4+ T lymphocytes, Langerhans cells, dendritic cells
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child transmission rate of HIV-2 is 0-4%, while in HIV-1 this transmission occurs in 15-40% of
untreated pregnancies [23].
This poor capability to infect new hosts could lead HIV-2 to a dead end. Viral ecology imposes
two ideal conditions: maintain the host alive as long as possible while being efficiently
transmitted within host population. HIV-2 only fulfils the first condition leading to a decline
in HIV-2 prevalence even in regions (i.e. West Africa) where, in the early stages of AIDS
epidemic, a clear predominance of HIV-2 infections existed compared to HIV-1 [24].
4.1. Viral load and transmission
Many different factors account for a successful transmission of HIV by sexual route. One of
the most critical is the amount of infectious viral particles present in the transmitting body
fluid (e.g. blood, semen or cervicovaginal secretion). Higher concentrations are more likely
associated with transmission events. Apparently, in HIV-1, the cutoff of 1500 copies of viral
RNA per ml of plasma is required for efficient transmission [25].
Not surprisingly, plasma and semen viral loads are significantly lower in patients infected
with HIV-2 compared to those infected with HIV-1 [26, 27], providing a likely explanation for
the reduced transmission rate and spread within human population. This lower viral load is
observed throughout the infection and persists until late in the course of the disease, but is
remarkably important during asymptomatic stage. During this stage, which in HIV-2 could
last for several decades, an undetectable viremia is a hallmark of almost every HIV-2 patients.
However, a similar proviral burden is detected in both HIV-1 and HIV-2-infected individuals
[28, 29]. This apparent paradox suggests that the lower plasma viral load observed in HIV-2
infection may be due to lower levels of infectious virus production, or a better host-driven
suppression of viral replication, or both.
4.2. The mucosal barrier
Besides viral load, numerous barriers decrease the efficiency of mucosal transmission. The
foundations of this important notion emanates from studies of couples discordant for HIV-1
infection, which demonstrated that heterosexual transmission is very inefficient requiring
multiple exposures for a successful transmission [30, 31]. A detailed understanding of the
events surrounding transmission should provide important clues how HIV establishes a new
infection and what additional vulnerabilities HIV-2 has, at this stage, that can help explain its
lower spread.
Although HIV-1 and HIV-2 (as well as SIV) are commonly referred as “lentivirus” based on
the long incubation period and slow onset of disease, it is now clear from data using rhesus
macaque model infected with SIV, that initial virus-host interactions, crucial to establishing
systemic infection, take place in a rapid succession of related events, soon after mucosal
transmission (recently reviewed in [32]). In sexual transmission, the most common form of
HIV transmission, these events involve the interactions with cells present in cervical/vaginal
mucosa epithelial surfaces. To establish infection, HIV present in semen must go through
mucus that covers female genital epithelia and penetrate through the epithelial layer to access
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susceptible cells such as T lymphocytes, macrophages, Langerhans cells and dendritic cells.
Mucus, particularly abundant in upper female genital tract, provides the first barrier to HIV
infection. Mucus protective role of underlying epithelial cells is provided by the presence of
soluble factors (e.g. chemokines produced by epithelial cells) that decrease viral infectivity and
by mechanical trapping of virions in the dense protein mesh that constitutes the cervical mucus
[33]. By slowing viral diffusion, mucus reduces the probability of infectious virus reach the
surface of underlying cells.
Virions that successfully crossed the mucus encounters the epithelial cells layer that line the
different compartments of the female genital tract. These different compartments show
remarkable differences in the structure of epithelial layer. The mucosa from the lower female
genital tract (i.e. exocervix and vagina) consists of stratified squamous epithelium, several
layers thick. In contrast, in the upper reproductive compartment (i.e. endocervix and endo‐
metrium) the mucosal lining is composed of a single layer of columnar epithelium over the
basement membrane and is characterized by the presence of tight junctions between cells.
As expected by their different composition, the lower female genital epithelium is much more
robust and provides a more effective physical barrier than the fragile single columnar layer of
upper genital epithelium. Furthermore, the junction between the exocervix and the endocervix,
where the structure of the epithelium abruptly changes from stratified to single layer (called
the transitional or transformational zone), is characterized by an intense immunologic activity
and thus enriched with abundant lymphocytes and antigen presenting cells (e.g. dendritic cells
and macrophages), particularly during inflammatory processes [34]. The physical vulnerabil‐
ity and the presence of abundant target cells in transitional zone, make this region highly
susceptible to HIV entry and infection [35].
Even the thicker vaginal epithelial barrier could quickly expose susceptible cells in the
submucosa to HIV. In fact, the stratified squamous epithelium changes markedly through the
menstrual cycle, in response to progesterone [36], leading to a thinning of this physical barrier.
Additionally, breaches could occur because of microulcerations and breaks in the epithelium
due to sexual intercourse, inflammatory processes, sexually transmitted infections, and other
genital infections, increasing the likelihood of establishing an HIV infection [37-39].
Additionally, the mere exposure of genital mucosa to semen induces local alterations that
could potentiate the transmission of HIV-1 and (probably) HIV-2. These include the neutrali‐
zation of the acidic pH of the cervicovaginal secretions, the regulation of inflammatory
cytokines in genital tract epithelial cells, and the promotion of leukocyte infiltration and the
attraction of Langerhans cells in cervical and vaginal mucosae [40, 41]. Semen could also
directly promote HIV infection of epithelial target cells through the formation of amyloid fibrils
that capture HIV particles and enhances virus-cell attachment and fusion [42]. This amyloi‐
dogenic activity of human semen seems to be related with fragments of prostatic acidic
phosphatase [42]. Apparently this enhancement is semen donor-dependent but independent
of HIV strain or cell type used [43].
In contrast to female genital tract, HIV transmission through male genital tract is poorly
understood. Despite the presence of CD4+ T lymphocytes, Langerhans cells, dendritic cells
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and macrophages in the foreskin and glans of the penis [44, 45], the mechanisms underlying
the transmission across these mucosae are not completed elucidated. Foreskin seems to play
a crucial role in female-to-male transmission of HIV-1, since several randomized controlled
clinical trials have shown that circumcision reduce this route of transmission by approximately
60% [46]. One plausible mechanism for greater susceptibility to HIV-1 infection in uncircum‐
cised men could be the increased risk for sexually transmitted infections and consequent
inflammation of the foreskin (reviewed in [47]). This predisposition to local infection and
inflammatory reactions will lead to the recruitment of activated target cells that facilitates the
early events of HIV transmission and provides a local environment suitable for productive
HIV systemic infection.
The vaginal flora could in some circumstances also favour female-to-male HIV transmission.
The predominance of potential pathogenic bacteria instead of normal Lactobacillus species,
observed during bacterial vaginosis, seems to be related not only with increased risk of HIV-1
acquisition by women (as referred above) but also with higher concentrations of HIV-1 in
cervicovaginal secretions, due to a bacterial-driven augmentation of HIV-1 replication and
shedding [48-50]. Thus, women with bacterial vaginosis are more infectious and the proba‐
bility of female-to-male HIV-1 transmission during sexual intercourse is greater than in women
with normal vaginal flora [51].
4.3. Crossing the intact mucosal barrier
Although infection of mucosal epithelial cells could happen, HIV must gain access to permis‐
sive host cells present in underlying submucosa tissue (e.g. dendritic cells macrophages and
CD4+ T-lymphocytes) to facilitate virus production and dissemination. The mechanisms for
crossing intact stratified squamous epithelium of the vagina or the simple columnar epithelium
of the cervix could be one (or more) of the following: (i) transcytosis by a vesicular pathway
[52] – an apparently rare but possible event [53]; (ii) capture or infection of dendritic cells
resident in the stratified squamous epithelium of the vaginal mucosa and in the underlying
tissues of the vagina and cervix [54]; and (iii) direct infection of intraepithelial lymphocytes in
the endocervical mucosa [55].
Regardless the pathway used by cell-free HIV virions to penetrate the epithelial cell barrier,
they ultimately lead to viral exposure of dendritic cells, macrophages and CD4+ T-lymphocytes
present in underlying submucosal tissues, allowing the initiation of infection. Dendritic cells
can capture HIV virions through C-type lectin receptors (CLRs) present at cell membrane (e.g.
DC-SIGN, DCIR), and internalize the captured virus without being infected. This internalized
virus, as well as those bound to dendritic cell membrane, remains full infectious and able to
be transmitted to surrounding CD4+ T-lymphocytes through a structure analogous to the
immunological synapse, named “virological synapse”. This tight adhesive junction between
an HIV-exposed dendritic cell and an uninfected CD4+ T-lymphocyte allows the virus to be
efficiently transferred from one cell to the other, in a process named trans-infection (for a review
in HIV interactions with dendritic cells see [56]). Besides trans-infection through virological
synapse, dendritic cells could also transfer HIV to CD4+ T lymphocytes by cell-free exosomes.
These endosomal multivesicular bodies (MVB), containing endocytosed HIV particles, could
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be released to extracellular milieu and fuse with target-cell membranes allowing the transfer
of HIV to them [57].
Alternatively, HIV can directly infect the dendritic cell subset, present in submucosal tissues
(cis-infection), using the natural expression of the main HIV cellular receptors (i.e. CD4 and
CCR5; see bellow) at dendritic cell surface [56, 58, 59]. Despite the susceptibility of dendritic
cells, conferred by the presence of these major receptors, HIV replication in dendritic cells is
in general less productive, compared with CD4+ T lymphocytes [60]. The reasons for the
decreased viral production in dendritic cells include: (i) lower expression levels of HIV
receptors; (ii) degradation of internalized virions, soon after infection; and (iii) presence of
intracellular restriction factors that inhibited post-entry events of replication cycle.
Interestingly, although HIV can infect dendritic cells, extensive viral replication only takes
place after dendritic cells come into contact with CD4+ T lymphocytes in lymphoid tissue [61].
The dendritic cell-T lymphocyte interaction provides activation signaling to the latter, allowing
HIV to be presented to a population of highly activated and susceptible T-lymphocytes. This
further indicates that the infection of dendritic cells by HIV-1 is a double-edged sword:
dendritic cells must deliver appropriate signals to T lymphocytes in order to induce an HIV-
specific immune response; however, this interaction imposes a close contact between dendritic
cells and T lymphocytes (immunological synapse) leaving the latter susceptible to infection by
the HIV-1 carried by dendritic cells.
In conclusion, dendritic cell-mediated virus transfer occurs in two distinct phases: in the first
phase (trans-infection), dendritic cell capture and internalize virus within endosomal com‐
partments which are relocated at the dendritic cell/CD4+ T-lymphocyte contact zone (virolog‐
ical synapse); alternatively, a fraction of the endocytosed particles may be targeted for
exocytosis, associated with exosomes [62]. Both processes occur without dendritic cell
productive infection. In the second phase, the direct infection of dendritic cell (cis-infection)
contributes to the spread of newly synthesized progeny virus to CD4+ T-lymphocytes [63]. In
this regard, several studies have provided important data defining entry-enhancement factors
on dendritic cells, such as DC-SIGN, and other C-type lectins receptors (mannose receptor,
langerin, syndecan-3, and dendritic cell immunoreceptor - DCIR) [63]. The role of C-type lectin
receptors seems to be crucial in both trans- and cis-infection modes. For example, HIV-1 bound
to DC-SIGN is rapidly taken up within endolysosomal vacuoles and protected from degrada‐
tion while remaining infectious for 1–3 days [64]. Interestingly, suppression of DC-SIGN
expression has been shown to impair the viral synapse formation, and to inhibit trans-infection
of HIV-1 to CD4+ T-lymphocytes [65].
All the data reviewed until now was obtained almost exclusively using HIV-1 model (and in
some instances SIV). As referred earlier in this chapter, HIV-2 is a lentivirus that shows a
decreased capacity to spread between humans, and probably with additional vulnerabilities
during transmission, compared with HIV-1. Besides the lower viral load both in plasma and
semen referred previously, little is know about HIV-2 interaction with mucosal cells and how
the described physical barriers counteract effective HIV-2 transmission to a new host. For
example, very few data exists about HIV-2 interaction with DC-SIGN or the way HIV-2 uses
trans-infection mechanisms to spread to T-lymphocytes. Apparently the T-cell line adapted
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and macrophages in the foreskin and glans of the penis [44, 45], the mechanisms underlying
the transmission across these mucosae are not completed elucidated. Foreskin seems to play
a crucial role in female-to-male transmission of HIV-1, since several randomized controlled
clinical trials have shown that circumcision reduce this route of transmission by approximately
60% [46]. One plausible mechanism for greater susceptibility to HIV-1 infection in uncircum‐
cised men could be the increased risk for sexually transmitted infections and consequent
inflammation of the foreskin (reviewed in [47]). This predisposition to local infection and
inflammatory reactions will lead to the recruitment of activated target cells that facilitates the
early events of HIV transmission and provides a local environment suitable for productive
HIV systemic infection.
The vaginal flora could in some circumstances also favour female-to-male HIV transmission.
The predominance of potential pathogenic bacteria instead of normal Lactobacillus species,
observed during bacterial vaginosis, seems to be related not only with increased risk of HIV-1
acquisition by women (as referred above) but also with higher concentrations of HIV-1 in
cervicovaginal secretions, due to a bacterial-driven augmentation of HIV-1 replication and
shedding [48-50]. Thus, women with bacterial vaginosis are more infectious and the proba‐
bility of female-to-male HIV-1 transmission during sexual intercourse is greater than in women
with normal vaginal flora [51].
4.3. Crossing the intact mucosal barrier
Although infection of mucosal epithelial cells could happen, HIV must gain access to permis‐
sive host cells present in underlying submucosa tissue (e.g. dendritic cells macrophages and
CD4+ T-lymphocytes) to facilitate virus production and dissemination. The mechanisms for
crossing intact stratified squamous epithelium of the vagina or the simple columnar epithelium
of the cervix could be one (or more) of the following: (i) transcytosis by a vesicular pathway
[52] – an apparently rare but possible event [53]; (ii) capture or infection of dendritic cells
resident in the stratified squamous epithelium of the vaginal mucosa and in the underlying
tissues of the vagina and cervix [54]; and (iii) direct infection of intraepithelial lymphocytes in
the endocervical mucosa [55].
Regardless the pathway used by cell-free HIV virions to penetrate the epithelial cell barrier,
they ultimately lead to viral exposure of dendritic cells, macrophages and CD4+ T-lymphocytes
present in underlying submucosal tissues, allowing the initiation of infection. Dendritic cells
can capture HIV virions through C-type lectin receptors (CLRs) present at cell membrane (e.g.
DC-SIGN, DCIR), and internalize the captured virus without being infected. This internalized
virus, as well as those bound to dendritic cell membrane, remains full infectious and able to
be transmitted to surrounding CD4+ T-lymphocytes through a structure analogous to the
immunological synapse, named “virological synapse”. This tight adhesive junction between
an HIV-exposed dendritic cell and an uninfected CD4+ T-lymphocyte allows the virus to be
efficiently transferred from one cell to the other, in a process named trans-infection (for a review
in HIV interactions with dendritic cells see [56]). Besides trans-infection through virological
synapse, dendritic cells could also transfer HIV to CD4+ T lymphocytes by cell-free exosomes.
These endosomal multivesicular bodies (MVB), containing endocytosed HIV particles, could
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be released to extracellular milieu and fuse with target-cell membranes allowing the transfer
of HIV to them [57].
Alternatively, HIV can directly infect the dendritic cell subset, present in submucosal tissues
(cis-infection), using the natural expression of the main HIV cellular receptors (i.e. CD4 and
CCR5; see bellow) at dendritic cell surface [56, 58, 59]. Despite the susceptibility of dendritic
cells, conferred by the presence of these major receptors, HIV replication in dendritic cells is
in general less productive, compared with CD4+ T lymphocytes [60]. The reasons for the
decreased viral production in dendritic cells include: (i) lower expression levels of HIV
receptors; (ii) degradation of internalized virions, soon after infection; and (iii) presence of
intracellular restriction factors that inhibited post-entry events of replication cycle.
Interestingly, although HIV can infect dendritic cells, extensive viral replication only takes
place after dendritic cells come into contact with CD4+ T lymphocytes in lymphoid tissue [61].
The dendritic cell-T lymphocyte interaction provides activation signaling to the latter, allowing
HIV to be presented to a population of highly activated and susceptible T-lymphocytes. This
further indicates that the infection of dendritic cells by HIV-1 is a double-edged sword:
dendritic cells must deliver appropriate signals to T lymphocytes in order to induce an HIV-
specific immune response; however, this interaction imposes a close contact between dendritic
cells and T lymphocytes (immunological synapse) leaving the latter susceptible to infection by
the HIV-1 carried by dendritic cells.
In conclusion, dendritic cell-mediated virus transfer occurs in two distinct phases: in the first
phase (trans-infection), dendritic cell capture and internalize virus within endosomal com‐
partments which are relocated at the dendritic cell/CD4+ T-lymphocyte contact zone (virolog‐
ical synapse); alternatively, a fraction of the endocytosed particles may be targeted for
exocytosis, associated with exosomes [62]. Both processes occur without dendritic cell
productive infection. In the second phase, the direct infection of dendritic cell (cis-infection)
contributes to the spread of newly synthesized progeny virus to CD4+ T-lymphocytes [63]. In
this regard, several studies have provided important data defining entry-enhancement factors
on dendritic cells, such as DC-SIGN, and other C-type lectins receptors (mannose receptor,
langerin, syndecan-3, and dendritic cell immunoreceptor - DCIR) [63]. The role of C-type lectin
receptors seems to be crucial in both trans- and cis-infection modes. For example, HIV-1 bound
to DC-SIGN is rapidly taken up within endolysosomal vacuoles and protected from degrada‐
tion while remaining infectious for 1–3 days [64]. Interestingly, suppression of DC-SIGN
expression has been shown to impair the viral synapse formation, and to inhibit trans-infection
of HIV-1 to CD4+ T-lymphocytes [65].
All the data reviewed until now was obtained almost exclusively using HIV-1 model (and in
some instances SIV). As referred earlier in this chapter, HIV-2 is a lentivirus that shows a
decreased capacity to spread between humans, and probably with additional vulnerabilities
during transmission, compared with HIV-1. Besides the lower viral load both in plasma and
semen referred previously, little is know about HIV-2 interaction with mucosal cells and how
the described physical barriers counteract effective HIV-2 transmission to a new host. For
example, very few data exists about HIV-2 interaction with DC-SIGN or the way HIV-2 uses
trans-infection mechanisms to spread to T-lymphocytes. Apparently the T-cell line adapted
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strain HIV-2ROD is able to bind to DC-SIGN [66], however data from primary isolates (more
closely related to circulating viral variants) are still missing.
Early reports referred that dendritic cells derived from hematopoietic progenitor cells or from
peripheral blood monocytes are less susceptible to productive infection by HIV-2 compared
with HIV-1 [67, 68]. Paradoxically, recent data have disclosed a cellular protein (SAMHD1)
that inhibits HIV-1 replication in immature monocytes-derived dendritic cells, in dendritic
cells derived from PMA-differentiated THP-1 monocytic cell line [69] and in macrophages [70].
This restriction factor affects the efficiency of reverse transcription leading to a reduced amount
of viral cDNA [71]. SAMHD1 is counteracted by the HIV-2/SIV Vpx protein and its inhibitory
mechanism, in the absence of Vpx, helps to explain the different permissivity of these non-
dividing cells to lentiviral infection [21]. In this scenario, the non-permissiveness of dendritic
cells to HIV-1 infection favours viral dissemination by trans-infection pathway, enabling more
virions being delivered to CD4+ T-lymphocytes through virological synapse and eventually
enhancing the depletion of these latter cells [72]. More importantly, HIV-2 avoiding the effect
of SAMHD1 is more prone to trigger host innate immune responses through type I interferon,
mediated by viral DNA-exposed dendritic cells [73, 74]. Also, productive infection of dendritic
cells by HIV-2 may lead to a different spectrum of presented antigens that ultimately could
lead to a different adaptive immune response [74].
5. HIV-2 chronic infection in human host: a natural long-term non
progressive infection
The long-term non-progressive infection that characterizes the HIV-2 infection in humans is
determined by several host-virus interactions that, in contrast to HIV-1, enable the control and
the confinement of HIV-2 pathogenic potential.
As referred above, the different pathogenic outcome observed in HIV-2 infection compared to
HIV-1 seems to be dictated as early as the initial interactions with dendritic cells and macro‐
phages present at mucosae surfaces. The expression of Vpx by HIV-2, allowing the bypass of
SAMHD1 restriction and the consequent productive infection of dendritic cells and macro‐
phages (cis-infection), may result in reduced trans-infection to CD4+ T-lymphocytes, a more
appropriate innate and adaptive immune response and thus to a more limited infection.
Noteworthy,  and  despite  the  described  mechanisms  that  could  lead  to  a  hindrance  in
HIV-2 dissemination at early stages during acute infection, a similar proviral load is ob‐
served in HIV-2 and HIV-1 infected patients. These observations suggest that HIV-2, like
HIV-1,  is  able  to  disseminate  and  an  equal  number  of  target  cells  are  infected  during
acute  and  chronic  phase  or,  alternatively,  that  in  HIV-1  a  greater  number  of  infected
CD4+ T-cells  are destroyed in the course of  the disease,  leading to a similar  number of
cells containing integrated HIV-1 or HIV-2 genomes.
Typically, infection with HIV-1 is characterized by a gradual and irreversible depletion of
CD4+ T-lymphocytes, leading to severe immune dysfunction and the development of AIDS
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within a median time of 10 years. However, in contrast to the aforementioned typical pro‐
gression, virtually all HIV-2 and a small percentage [75] of HIV-1 infections (appropriately
referred as “long-term nonprogressors” or “elite controllers”) remain healthy for several
decades without any antiretroviral therapy, with undetectable plasma viral load and CD4+
cell counts above 500 cells/µL.
A longer asymptomatic phase and slower progression to AIDS are indeed hallmarks of the
natural course of HIV-2 infection [1-3]. A clear demonstration of both features was provided
by a prospective study conducted with untreated Senegalese sex workers, where 67% of HIV-1-
infected women remain AIDS-free 5 years after seroconversion, in contrast with 100% for
HIV-2-infected women [3]. The rate of developing CD4+ lymphocyte counts bellow 400 cells/
µl was also reduced in HIV-2 participants [3]. Thus, as a rule, HIV-2-infection has no effect on
survival in adults [2].
The mechanisms responsible for this less pathogenic course of HIV-2 infection are still poorly
understood but surely result from a combination of distinct factors involving the virus, the
infected cell and the equilibrium established between viral replication and host immunologic
response. This equilibrium is clearly much well preserved in HIV-2 than in HIV-1 infection
and it is paradoxical that the study of HIV-2 interaction with host cells remains poorly explored
and sometimes neglected. Interestingly, a recent report indicates that a pre-existing infection
by HIV-2 appears to inhibit the rate of HIV-1 disease progression [76], together with higher
CD4+ T-cell counts and lower viral diversity of HIV-1. This apparent protective effect of HIV-2
may be explained by several viral and immunological mechanisms, namely the higher
immunosupression of surface glycoprotein of HIV-2 compared to HIV-1 counterpart [77], or
the ability of HIV-2 Nef protein to promote the downmodulation of TCR-CD3 from the surface
of CD4+ T-cells [78] and thus the impairment of immunological synapse, established between
these lymphocytes and antigen presenting cells (i.e. dendritic cells and macrophages). Both
mechanisms have direct impact on immune activation and may help explain the better
outcome of HIV-2 infection alone or after superinfection with HIV-1.
5.1. HIV-2 entry into target cells — Early events
HIV replication cycle begins by a specific interaction between viral envelope glycoproteins
and cellular receptors allowing the binding of virion to target cell. Further sequential interac‐
tions eventually lead to viral envelope and cell membrane fusion. The cellular receptors
involved in these early events are the CD4 molecule [79, 80] and a member of seven-trans‐
membrane, G-protein-coupled, receptors' family (GPCRs), referred as coreceptor. According
to the proposed model, the specific binding of SU envelope glycoprotein to CD4 induces
structural changes in this glycoprotein that expose, create or stabilize the coreceptor-binding
regions, enabling the SU to engage the coreceptor molecule. This second binding event causes
further conformational changes in SU that allows the disclosure of an amino-terminal hydro‐
phobic region (fusion peptide) of the TM envelope glycoprotein subunit. The insertion of the
fusion peptide in the cell surface leads to the fusion of viral envelope with the cell membrane
and the release of viral nucleocapside into the cell cytoplasm (reviewed in [81, 82]). This fusion
process as long been assumed to occur at the cell surface through a direct fusion mechanism
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strain HIV-2ROD is able to bind to DC-SIGN [66], however data from primary isolates (more
closely related to circulating viral variants) are still missing.
Early reports referred that dendritic cells derived from hematopoietic progenitor cells or from
peripheral blood monocytes are less susceptible to productive infection by HIV-2 compared
with HIV-1 [67, 68]. Paradoxically, recent data have disclosed a cellular protein (SAMHD1)
that inhibits HIV-1 replication in immature monocytes-derived dendritic cells, in dendritic
cells derived from PMA-differentiated THP-1 monocytic cell line [69] and in macrophages [70].
This restriction factor affects the efficiency of reverse transcription leading to a reduced amount
of viral cDNA [71]. SAMHD1 is counteracted by the HIV-2/SIV Vpx protein and its inhibitory
mechanism, in the absence of Vpx, helps to explain the different permissivity of these non-
dividing cells to lentiviral infection [21]. In this scenario, the non-permissiveness of dendritic
cells to HIV-1 infection favours viral dissemination by trans-infection pathway, enabling more
virions being delivered to CD4+ T-lymphocytes through virological synapse and eventually
enhancing the depletion of these latter cells [72]. More importantly, HIV-2 avoiding the effect
of SAMHD1 is more prone to trigger host innate immune responses through type I interferon,
mediated by viral DNA-exposed dendritic cells [73, 74]. Also, productive infection of dendritic
cells by HIV-2 may lead to a different spectrum of presented antigens that ultimately could
lead to a different adaptive immune response [74].
5. HIV-2 chronic infection in human host: a natural long-term non
progressive infection
The long-term non-progressive infection that characterizes the HIV-2 infection in humans is
determined by several host-virus interactions that, in contrast to HIV-1, enable the control and
the confinement of HIV-2 pathogenic potential.
As referred above, the different pathogenic outcome observed in HIV-2 infection compared to
HIV-1 seems to be dictated as early as the initial interactions with dendritic cells and macro‐
phages present at mucosae surfaces. The expression of Vpx by HIV-2, allowing the bypass of
SAMHD1 restriction and the consequent productive infection of dendritic cells and macro‐
phages (cis-infection), may result in reduced trans-infection to CD4+ T-lymphocytes, a more
appropriate innate and adaptive immune response and thus to a more limited infection.
Noteworthy,  and  despite  the  described  mechanisms  that  could  lead  to  a  hindrance  in
HIV-2 dissemination at early stages during acute infection, a similar proviral load is ob‐
served in HIV-2 and HIV-1 infected patients. These observations suggest that HIV-2, like
HIV-1,  is  able  to  disseminate  and  an  equal  number  of  target  cells  are  infected  during
acute  and  chronic  phase  or,  alternatively,  that  in  HIV-1  a  greater  number  of  infected
CD4+ T-cells  are destroyed in the course of  the disease,  leading to a similar  number of
cells containing integrated HIV-1 or HIV-2 genomes.
Typically, infection with HIV-1 is characterized by a gradual and irreversible depletion of
CD4+ T-lymphocytes, leading to severe immune dysfunction and the development of AIDS
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within a median time of 10 years. However, in contrast to the aforementioned typical pro‐
gression, virtually all HIV-2 and a small percentage [75] of HIV-1 infections (appropriately
referred as “long-term nonprogressors” or “elite controllers”) remain healthy for several
decades without any antiretroviral therapy, with undetectable plasma viral load and CD4+
cell counts above 500 cells/µL.
A longer asymptomatic phase and slower progression to AIDS are indeed hallmarks of the
natural course of HIV-2 infection [1-3]. A clear demonstration of both features was provided
by a prospective study conducted with untreated Senegalese sex workers, where 67% of HIV-1-
infected women remain AIDS-free 5 years after seroconversion, in contrast with 100% for
HIV-2-infected women [3]. The rate of developing CD4+ lymphocyte counts bellow 400 cells/
µl was also reduced in HIV-2 participants [3]. Thus, as a rule, HIV-2-infection has no effect on
survival in adults [2].
The mechanisms responsible for this less pathogenic course of HIV-2 infection are still poorly
understood but surely result from a combination of distinct factors involving the virus, the
infected cell and the equilibrium established between viral replication and host immunologic
response. This equilibrium is clearly much well preserved in HIV-2 than in HIV-1 infection
and it is paradoxical that the study of HIV-2 interaction with host cells remains poorly explored
and sometimes neglected. Interestingly, a recent report indicates that a pre-existing infection
by HIV-2 appears to inhibit the rate of HIV-1 disease progression [76], together with higher
CD4+ T-cell counts and lower viral diversity of HIV-1. This apparent protective effect of HIV-2
may be explained by several viral and immunological mechanisms, namely the higher
immunosupression of surface glycoprotein of HIV-2 compared to HIV-1 counterpart [77], or
the ability of HIV-2 Nef protein to promote the downmodulation of TCR-CD3 from the surface
of CD4+ T-cells [78] and thus the impairment of immunological synapse, established between
these lymphocytes and antigen presenting cells (i.e. dendritic cells and macrophages). Both
mechanisms have direct impact on immune activation and may help explain the better
outcome of HIV-2 infection alone or after superinfection with HIV-1.
5.1. HIV-2 entry into target cells — Early events
HIV replication cycle begins by a specific interaction between viral envelope glycoproteins
and cellular receptors allowing the binding of virion to target cell. Further sequential interac‐
tions eventually lead to viral envelope and cell membrane fusion. The cellular receptors
involved in these early events are the CD4 molecule [79, 80] and a member of seven-trans‐
membrane, G-protein-coupled, receptors' family (GPCRs), referred as coreceptor. According
to the proposed model, the specific binding of SU envelope glycoprotein to CD4 induces
structural changes in this glycoprotein that expose, create or stabilize the coreceptor-binding
regions, enabling the SU to engage the coreceptor molecule. This second binding event causes
further conformational changes in SU that allows the disclosure of an amino-terminal hydro‐
phobic region (fusion peptide) of the TM envelope glycoprotein subunit. The insertion of the
fusion peptide in the cell surface leads to the fusion of viral envelope with the cell membrane
and the release of viral nucleocapside into the cell cytoplasm (reviewed in [81, 82]). This fusion
process as long been assumed to occur at the cell surface through a direct fusion mechanism
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independent of the pH [83]. However, more recent data describe HIV-1 entry and fusion occurs
following endocytosis [84, 85].
After the initial identification of CXCR4 and CCR5 in 1996 [86, 87], several other GPCRs have
been described as being able to act as coreceptors for HIV-1, HIV-2 and SIV: CCR1, CCR2b,
CCR3, CCR4, CCR5, CCR8, CCR9, CCR10, CXCR2, CXCR4, CXCR5, CXCR6, CX3CR1, XCR1,
FPRL1, GPR1, GPR15, APJ, ChemR23, CXCR7/ RDC1, D6, BLTR and US28 [88-92]. Despite this
extensive array of potential HIV entry coreceptors, only CCR5 and CXCR4 have been consid‐
ered important for HIV-1 infection in vivo [93, 94]. This notion stems from studies reporting:
(i) the apparent selection of CCR5-using (R5) variants during mucosal transmission; (ii) the
predominance of R5 population during asymptomatic stage of infection; and (iii) the arise and
eventual predominance of CXCR4-using (X4) variants in late stages of HIV-1 infection.
However, several exceptions to this simplistic R5/X4 dichotomy have been reported [89, 91,
95-104], revealing that some HIV-1 and HIV-2 isolates can exploit other coreceptors in vitro,
raising the possibility that these alternate molecules can in vivo contribute to HIV infection of
natural target cells, at least under certain circumstances.
Genetic studies of HIV-1 variants present soon after sexual transmission have shown that only
R5, and occasionally dual tropic R5X4, are transmitted regardless the diversity of viral
population present in initial inoculum. During chronic infection HIV genetic diversity
increases due to viral replication based on an error-prone reverse transcriptase. The resulting
viral population (or quasiespecies) provides the substrate for natural selection exerted by host
immune response and local environment, leading to continuous viral adaptation and persis‐
tence within HIV infected patient. However, during mucosal transmission this diversity is
severely reduced suggesting a “bottleneck” or “gatekeeper” effect (reviewed in [105]),
probably as a result of the biology of mucosal transmission and the kind of cells encountered
by HIV (discussed above).
The analysis by single-genome amplification, together with full-length cloning of transmitted/
founder variants, has provided remarkable data on HIV transmission and viral evolution
during acute infection. Based on this data, the selection of transmitted/founder viruses
encompasses three main signatures: usage of CCR5, high replication rate in CD4+ T-lympho‐
cytes and lack of macrophage tropism (reviewed in [106]). The deficient replication in mono‐
cyte-derived macrophages observed in HIV-1 transmitted viruses, although requiring
confirmation using tissue macrophages, is consistent with data obtained in nonhuman
primates infected with SIV, indicating that CD4+ T-lymphocytes are the predominant cellular
substrate for viral replication soon after transmission.
However, a recent and unprecedented observation, regarding HIV coreceptor usage and
transmission, revealed that a transmitted/founder HIV-1 was unable to efficiently use either
CCR5 or CXCR4 to infect CD4+ cell lines or peripheral blood mononuclear cells [95]. Alternate
GPCRs (GPR15, APJ, and FPRL-1) were efficiently used, further emphasizing the notion that
“rare” coreceptors could be used in vivo in some circumstances or in some cell populations by
HIV-1 and HIV-2 alike. Additionally, Chalmet et al. [107] have recently provided important
data showing that the transmitted viruses could be X4 or R5X4. Considering the established
concept, stating that during mucosal transmission the R5 variants present in initial inoculum
Current Perspectives in HIV Infection420
population of transmitted viruses are favored, these two reports support the idea that non-R5
viruses could indeed be transmitted. This warrants reconsidering the dogma of exclusive R5
variants transmission and should lead us to the following question: is there actually any
biological filter at mucosae environment (including physical or chemical barriers, epithelial
cells and immune cells present at mucosal surface or in the submucosal layer) that suppresses
the invasion and/or dissemination of non-R5 variants; and why in these cases (and other cases?)
they were not selected? In other words, are there sufficient and conclusive data to discard the
hypothesis of random transmission in favor of a gatekeeper or bottleneck theory [108]? Perhaps
the preferential transmission of R5 variants are solely a consequence of their higher proportion
in body fluids involved in transmission, either in acute or during most of chronic infection.
Further studies are warranted in order to elucidate if X4 or R5X4 variants (and other biotypes,
including CCR8-using viruses) are less transmissible.
In HIV-2 no data exists regarding transmitted/founder viruses, or the characteristics or the
viral evolution during primary infection. The mechanisms described for HIV-1 and SIV should
also be present in HIV-2 infection. However, the identification of HIV-2 isolates unable to infect
target cells using the CCR5 or CXCR4 coreceptors [96, 109] obtained from individuals at
asymptomatic stage of infection and immunologically competent [96], raises the possibility
that, at least in some patients, CCR5 usage is acquired in vivo as a result of HIV-2 evolution
from an initial population of CCR5- and CXCR4-independent viruses.
5.2. Molecular determinants of coreceptor usage
Identification of the biochemical processes required for HIV fusion and the engagement of
chemokine receptors as critical step for HIV entry, has also unveiled several important aspects
on envelope glycoproteins structure crucial to the fusion process. HIV-1 and HIV-2 SU
glycoprotein contain five conserved regions (C1 to C5), separated by an equal number of
variable regions (V1 to V5). The variable regions are limited by cysteine residues forming
flexible loops on the outer domain of SU glycoprotein [110-112]. HIV coreceptor usage seems
to be largely determined by variable regions of the SU subunit. In HIV-1, the most studied
model, the third variable (V3) region has been referred as the major determinant of coreceptor
engagement [113-117]. Higher positive net charge (above +5) in V3 region of HIV-1 has been
associated with CXCR4 usage (or usage of both CXCR4 and CCR5) [118, 119]. Structural models
of SU bound to CD4 and chemokine receptor have provided further information about the
functional roles played by several regions of SU, revealing that the V1V2 region is also involved
in coreceptor binding, by a direct cooperation with the V3 region [120-124].
In HIV-2, structural and functional studies of the envelope glycoproteins regions are much
more scarce and in some aspects contradictory. The genetic characterization of HIV-2 SU has
revealed a limited variability, probably as a result of the lower replication rate within the
infected individual. Noteworthy, in contrast to HIV-1, the V3 region of HIV-2 SU glycoprotein
appears to be highly conserved. Conversely, the V1V2 region is much more prone to genetic
variation [125], suggesting that either this region is more exposed and under a stronger
selective pressure, or that the lack of V3 loop variation is related to some functional constraints
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independent of the pH [83]. However, more recent data describe HIV-1 entry and fusion occurs
following endocytosis [84, 85].
After the initial identification of CXCR4 and CCR5 in 1996 [86, 87], several other GPCRs have
been described as being able to act as coreceptors for HIV-1, HIV-2 and SIV: CCR1, CCR2b,
CCR3, CCR4, CCR5, CCR8, CCR9, CCR10, CXCR2, CXCR4, CXCR5, CXCR6, CX3CR1, XCR1,
FPRL1, GPR1, GPR15, APJ, ChemR23, CXCR7/ RDC1, D6, BLTR and US28 [88-92]. Despite this
extensive array of potential HIV entry coreceptors, only CCR5 and CXCR4 have been consid‐
ered important for HIV-1 infection in vivo [93, 94]. This notion stems from studies reporting:
(i) the apparent selection of CCR5-using (R5) variants during mucosal transmission; (ii) the
predominance of R5 population during asymptomatic stage of infection; and (iii) the arise and
eventual predominance of CXCR4-using (X4) variants in late stages of HIV-1 infection.
However, several exceptions to this simplistic R5/X4 dichotomy have been reported [89, 91,
95-104], revealing that some HIV-1 and HIV-2 isolates can exploit other coreceptors in vitro,
raising the possibility that these alternate molecules can in vivo contribute to HIV infection of
natural target cells, at least under certain circumstances.
Genetic studies of HIV-1 variants present soon after sexual transmission have shown that only
R5, and occasionally dual tropic R5X4, are transmitted regardless the diversity of viral
population present in initial inoculum. During chronic infection HIV genetic diversity
increases due to viral replication based on an error-prone reverse transcriptase. The resulting
viral population (or quasiespecies) provides the substrate for natural selection exerted by host
immune response and local environment, leading to continuous viral adaptation and persis‐
tence within HIV infected patient. However, during mucosal transmission this diversity is
severely reduced suggesting a “bottleneck” or “gatekeeper” effect (reviewed in [105]),
probably as a result of the biology of mucosal transmission and the kind of cells encountered
by HIV (discussed above).
The analysis by single-genome amplification, together with full-length cloning of transmitted/
founder variants, has provided remarkable data on HIV transmission and viral evolution
during acute infection. Based on this data, the selection of transmitted/founder viruses
encompasses three main signatures: usage of CCR5, high replication rate in CD4+ T-lympho‐
cytes and lack of macrophage tropism (reviewed in [106]). The deficient replication in mono‐
cyte-derived macrophages observed in HIV-1 transmitted viruses, although requiring
confirmation using tissue macrophages, is consistent with data obtained in nonhuman
primates infected with SIV, indicating that CD4+ T-lymphocytes are the predominant cellular
substrate for viral replication soon after transmission.
However, a recent and unprecedented observation, regarding HIV coreceptor usage and
transmission, revealed that a transmitted/founder HIV-1 was unable to efficiently use either
CCR5 or CXCR4 to infect CD4+ cell lines or peripheral blood mononuclear cells [95]. Alternate
GPCRs (GPR15, APJ, and FPRL-1) were efficiently used, further emphasizing the notion that
“rare” coreceptors could be used in vivo in some circumstances or in some cell populations by
HIV-1 and HIV-2 alike. Additionally, Chalmet et al. [107] have recently provided important
data showing that the transmitted viruses could be X4 or R5X4. Considering the established
concept, stating that during mucosal transmission the R5 variants present in initial inoculum
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population of transmitted viruses are favored, these two reports support the idea that non-R5
viruses could indeed be transmitted. This warrants reconsidering the dogma of exclusive R5
variants transmission and should lead us to the following question: is there actually any
biological filter at mucosae environment (including physical or chemical barriers, epithelial
cells and immune cells present at mucosal surface or in the submucosal layer) that suppresses
the invasion and/or dissemination of non-R5 variants; and why in these cases (and other cases?)
they were not selected? In other words, are there sufficient and conclusive data to discard the
hypothesis of random transmission in favor of a gatekeeper or bottleneck theory [108]? Perhaps
the preferential transmission of R5 variants are solely a consequence of their higher proportion
in body fluids involved in transmission, either in acute or during most of chronic infection.
Further studies are warranted in order to elucidate if X4 or R5X4 variants (and other biotypes,
including CCR8-using viruses) are less transmissible.
In HIV-2 no data exists regarding transmitted/founder viruses, or the characteristics or the
viral evolution during primary infection. The mechanisms described for HIV-1 and SIV should
also be present in HIV-2 infection. However, the identification of HIV-2 isolates unable to infect
target cells using the CCR5 or CXCR4 coreceptors [96, 109] obtained from individuals at
asymptomatic stage of infection and immunologically competent [96], raises the possibility
that, at least in some patients, CCR5 usage is acquired in vivo as a result of HIV-2 evolution
from an initial population of CCR5- and CXCR4-independent viruses.
5.2. Molecular determinants of coreceptor usage
Identification of the biochemical processes required for HIV fusion and the engagement of
chemokine receptors as critical step for HIV entry, has also unveiled several important aspects
on envelope glycoproteins structure crucial to the fusion process. HIV-1 and HIV-2 SU
glycoprotein contain five conserved regions (C1 to C5), separated by an equal number of
variable regions (V1 to V5). The variable regions are limited by cysteine residues forming
flexible loops on the outer domain of SU glycoprotein [110-112]. HIV coreceptor usage seems
to be largely determined by variable regions of the SU subunit. In HIV-1, the most studied
model, the third variable (V3) region has been referred as the major determinant of coreceptor
engagement [113-117]. Higher positive net charge (above +5) in V3 region of HIV-1 has been
associated with CXCR4 usage (or usage of both CXCR4 and CCR5) [118, 119]. Structural models
of SU bound to CD4 and chemokine receptor have provided further information about the
functional roles played by several regions of SU, revealing that the V1V2 region is also involved
in coreceptor binding, by a direct cooperation with the V3 region [120-124].
In HIV-2, structural and functional studies of the envelope glycoproteins regions are much
more scarce and in some aspects contradictory. The genetic characterization of HIV-2 SU has
revealed a limited variability, probably as a result of the lower replication rate within the
infected individual. Noteworthy, in contrast to HIV-1, the V3 region of HIV-2 SU glycoprotein
appears to be highly conserved. Conversely, the V1V2 region is much more prone to genetic
variation [125], suggesting that either this region is more exposed and under a stronger
selective pressure, or that the lack of V3 loop variation is related to some functional constraints
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that impairs its evolution. Accordingly, the role of HIV-2 V3 region as a target for neutralizing
antibodies has been controversial [126-132].
Similar to neutralization data, molecular determinants of coreceptor usage by HIV-2 is also
controversial. Some studies had claimed an association between V3 loop sequence and CCR5
or CXCR4 usage [133-137], while others had found no genetic signature underlying coreceptors
usage [138-140]. Particularly, the C-terminal region of the V3 loop, a global net charge above
+6 and the presence of mutations in amino acids 18 and 19, appear to dictate the ability to use
CXCR4 alone or in addition to CCR5 [134, 137]. However, those studies have some limitations
due to the low number of X4 or R5X4 strains and because they restricted the coreceptors usage
to the dichotomy R5 vs. X4, without considering the concomitant or alternative use of other
coreceptors. We have shown in the molecular characterization of the env gene of two CCR5/
CXCR4-independent isolates that, although this phenotype is determined by the SU glyco‐
protein [125], no genetic signature could be clearly found in the V3 region of those strains [125].
Noteworthy and considering that the ability to use a certain coreceptor is solely determined
by the V3 loop, the absence of a significant variability in this region is hardly concealed with
the broad and “exotic” coreceptor usage observed in HIV-2. Obviously, different regions
beside V3 cooperate during envelope glycoproteins interaction with cellular receptors, playing
a role in coreceptor choice by a particular virus. One of the strongest candidates is the V1V2
region, where an outstanding genetic variability was observed [140], including length
variation and loss of potential glycosilation sites. Moreover, some unique sequence signatures
were also founded in the central ectodomain and in the second heptad repeat (HR2) of the TM
glycoprotein [140]. All these mutations may affect the conformation of the envelope glyco‐
proteins complex, leading to a more open structure. This will affect not only the dynamics of
HIV-2 interaction with cellular receptors, but also the way neutralizing epitopes are exposed
and recognized by host immune response, leading to decreased viral fitness, lower replication
rate and increased susceptibility to neutralization.
5.3. Evolution of coreceptor usage during HIV-2 chronic infection
Earlier studies addressing the correlation between HIV infection stages (i.e. acute/primary
infection, asymptomatic stage and AIDS) and in vitro biological characteristics of HIV, gave
rise to three distinct classifications according to: (i) the efficiency of replication (rapid/high,
slow/low); (ii) the capacity to induce syncytia formation in T-cells (syncytium-inducing/non
syncytium-inducing; SI/NSI); and (iii) the ability to replicate in primary macrophages vs. T-
cell lines (M-tropic/T-tropic). From these earlier studies it was also clear that, during the course
of infection, selection might occur for variants more cytopathic (i.e. able to induce syncytia),
with faster replication kinetics (rapid/high) and with tropism for T-cell lines (T-tropic).
Identification of the biochemical processes required for HIV fusion and the engagement of
chemokine receptors, clarified the determinants of HIV tropism. Consistent with the proposed
model, HIV cell tropism is largely determined by the expression patterns of the appropriate
coreceptor molecule at the target-cell membrane. T-tropic viruses (in general with rapid/high
and SI phenotype) required the presence of CXCR4 coreceptor (X4 strains) while M-tropic
(associated generally with slow/low and NSI phenotype) use CCR5 as coreceptor (R5 strains).
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The evolution that was observed in viral phenotype has now an explanation based on the
coreceptors used: isolates obtained during asymptomatic stage are R5 (formerly NSI, M-tropic
and slow/low) while in later stages of infection, coincident with immunodeficiency and
opportunistic infections, the predominant variants are X4 (formerly SI, T-tropic and rapid/
high). This shift from predominance of R5 variants to X4, during disease progression, occurs
in about 40% of the patients and could be seen as an additional consequence of an already
deteriorated immune response, which contributes to an accelerated depletion of T-lympho‐
cytes and disease progression.
In HIV-2, the usage of cell receptors seems to be much more complex and the correlation
between disease stage and receptors usage is apparently less clear-cut than in HIV-1. The key
notions about cell receptors engagement by HIV-2 are: (i) non-usage of CCR5 or CXCR4 as
coreceptors; (ii) a broader coreceptor usage compared to HIV-1; and (iii) the CD4-independent
infection of target cells.
5.3.1. Non-usage of CCR5 or CXCR4 as coreceptors
Although CCR5 or CXCR4 usage seems to be an absolute requirement for HIV to fuse its
envelope with target-cell membrane, we and others have identified HIV-2 variants that in
vitro do not use those chemokine receptors (or use it inefficiently) as cofactors for viral entry.
These reports indicate that other coreceptors could replace CCR5 and CXCR4 as key players
in HIV infection, not just “in addition to” but also “instead of” these coreceptors, clearly
suggesting that they have an important role in HIV-2 infection and pathogenesis. Furthermore,
we demonstrated that these variants have lower replicative capacity in vitro [96, 125], an
observation later confirmed by others [141].
The main inference made from studies addressing coreceptors usage by HIV is that the
acquisition of CCR5 usage is crucial for HIV pathogenesis. And why CCR5 usage is so
important and provides a clear selective advantage in vivo? One of the reasons is because CCR5
usage confers HIV the ability to infect stimulated, full-permissive cells, leading to the produc‐
tion of a significantly more infectious viral population. While CXCR4 is expressed in both
resting and stimulated T-lymphocytes [142], CCR5 expression is higher in memory CD4+ T-
cells (CD45RO+) than in naïve (non-activated) CD4+ T-lymphocyte subset (CD45RA+) [143,
144]. Remarkably, the former are highly permissive to HIV replication, while productive
infection of CD45RA+ lymphocytes requires cellular activation soon after viral entry; other‐
wise, an abortive infection is observed [145].
In addition, the persistence of R5 viruses throughout the asymptomatic stage and in some cases
even in individuals with clinical symptoms, suggests that they may escape immune surveil‐
lance mechanisms (e.g. neutralization by specific antibodies) or that they could infect long-
lived cell reservoirs, such as macrophages and dendritic cells, thus providing long-lasting R5
viruses production.
Interestingly, the described CCR5/CXCR4-independent HIV-2 variants were obtained during
asymptomatic stage of infection [96, 109]. As referred, HIV-1 and HIV-2 infections are
strikingly different during this period: a longer asymptomatic period with higher CD4+ T-cell
HIV-2 Interaction with Target Cell Receptors, or Why HIV-2 is Less Pathogenic Than HIV-1
http://dx.doi.org/10.5772/53201
423
that impairs its evolution. Accordingly, the role of HIV-2 V3 region as a target for neutralizing
antibodies has been controversial [126-132].
Similar to neutralization data, molecular determinants of coreceptor usage by HIV-2 is also
controversial. Some studies had claimed an association between V3 loop sequence and CCR5
or CXCR4 usage [133-137], while others had found no genetic signature underlying coreceptors
usage [138-140]. Particularly, the C-terminal region of the V3 loop, a global net charge above
+6 and the presence of mutations in amino acids 18 and 19, appear to dictate the ability to use
CXCR4 alone or in addition to CCR5 [134, 137]. However, those studies have some limitations
due to the low number of X4 or R5X4 strains and because they restricted the coreceptors usage
to the dichotomy R5 vs. X4, without considering the concomitant or alternative use of other
coreceptors. We have shown in the molecular characterization of the env gene of two CCR5/
CXCR4-independent isolates that, although this phenotype is determined by the SU glyco‐
protein [125], no genetic signature could be clearly found in the V3 region of those strains [125].
Noteworthy and considering that the ability to use a certain coreceptor is solely determined
by the V3 loop, the absence of a significant variability in this region is hardly concealed with
the broad and “exotic” coreceptor usage observed in HIV-2. Obviously, different regions
beside V3 cooperate during envelope glycoproteins interaction with cellular receptors, playing
a role in coreceptor choice by a particular virus. One of the strongest candidates is the V1V2
region, where an outstanding genetic variability was observed [140], including length
variation and loss of potential glycosilation sites. Moreover, some unique sequence signatures
were also founded in the central ectodomain and in the second heptad repeat (HR2) of the TM
glycoprotein [140]. All these mutations may affect the conformation of the envelope glyco‐
proteins complex, leading to a more open structure. This will affect not only the dynamics of
HIV-2 interaction with cellular receptors, but also the way neutralizing epitopes are exposed
and recognized by host immune response, leading to decreased viral fitness, lower replication
rate and increased susceptibility to neutralization.
5.3. Evolution of coreceptor usage during HIV-2 chronic infection
Earlier studies addressing the correlation between HIV infection stages (i.e. acute/primary
infection, asymptomatic stage and AIDS) and in vitro biological characteristics of HIV, gave
rise to three distinct classifications according to: (i) the efficiency of replication (rapid/high,
slow/low); (ii) the capacity to induce syncytia formation in T-cells (syncytium-inducing/non
syncytium-inducing; SI/NSI); and (iii) the ability to replicate in primary macrophages vs. T-
cell lines (M-tropic/T-tropic). From these earlier studies it was also clear that, during the course
of infection, selection might occur for variants more cytopathic (i.e. able to induce syncytia),
with faster replication kinetics (rapid/high) and with tropism for T-cell lines (T-tropic).
Identification of the biochemical processes required for HIV fusion and the engagement of
chemokine receptors, clarified the determinants of HIV tropism. Consistent with the proposed
model, HIV cell tropism is largely determined by the expression patterns of the appropriate
coreceptor molecule at the target-cell membrane. T-tropic viruses (in general with rapid/high
and SI phenotype) required the presence of CXCR4 coreceptor (X4 strains) while M-tropic
(associated generally with slow/low and NSI phenotype) use CCR5 as coreceptor (R5 strains).
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The evolution that was observed in viral phenotype has now an explanation based on the
coreceptors used: isolates obtained during asymptomatic stage are R5 (formerly NSI, M-tropic
and slow/low) while in later stages of infection, coincident with immunodeficiency and
opportunistic infections, the predominant variants are X4 (formerly SI, T-tropic and rapid/
high). This shift from predominance of R5 variants to X4, during disease progression, occurs
in about 40% of the patients and could be seen as an additional consequence of an already
deteriorated immune response, which contributes to an accelerated depletion of T-lympho‐
cytes and disease progression.
In HIV-2, the usage of cell receptors seems to be much more complex and the correlation
between disease stage and receptors usage is apparently less clear-cut than in HIV-1. The key
notions about cell receptors engagement by HIV-2 are: (i) non-usage of CCR5 or CXCR4 as
coreceptors; (ii) a broader coreceptor usage compared to HIV-1; and (iii) the CD4-independent
infection of target cells.
5.3.1. Non-usage of CCR5 or CXCR4 as coreceptors
Although CCR5 or CXCR4 usage seems to be an absolute requirement for HIV to fuse its
envelope with target-cell membrane, we and others have identified HIV-2 variants that in
vitro do not use those chemokine receptors (or use it inefficiently) as cofactors for viral entry.
These reports indicate that other coreceptors could replace CCR5 and CXCR4 as key players
in HIV infection, not just “in addition to” but also “instead of” these coreceptors, clearly
suggesting that they have an important role in HIV-2 infection and pathogenesis. Furthermore,
we demonstrated that these variants have lower replicative capacity in vitro [96, 125], an
observation later confirmed by others [141].
The main inference made from studies addressing coreceptors usage by HIV is that the
acquisition of CCR5 usage is crucial for HIV pathogenesis. And why CCR5 usage is so
important and provides a clear selective advantage in vivo? One of the reasons is because CCR5
usage confers HIV the ability to infect stimulated, full-permissive cells, leading to the produc‐
tion of a significantly more infectious viral population. While CXCR4 is expressed in both
resting and stimulated T-lymphocytes [142], CCR5 expression is higher in memory CD4+ T-
cells (CD45RO+) than in naïve (non-activated) CD4+ T-lymphocyte subset (CD45RA+) [143,
144]. Remarkably, the former are highly permissive to HIV replication, while productive
infection of CD45RA+ lymphocytes requires cellular activation soon after viral entry; other‐
wise, an abortive infection is observed [145].
In addition, the persistence of R5 viruses throughout the asymptomatic stage and in some cases
even in individuals with clinical symptoms, suggests that they may escape immune surveil‐
lance mechanisms (e.g. neutralization by specific antibodies) or that they could infect long-
lived cell reservoirs, such as macrophages and dendritic cells, thus providing long-lasting R5
viruses production.
Interestingly, the described CCR5/CXCR4-independent HIV-2 variants were obtained during
asymptomatic stage of infection [96, 109]. As referred, HIV-1 and HIV-2 infections are
strikingly different during this period: a longer asymptomatic period with higher CD4+ T-cell
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counts and undetectable viremia is observed in HIV-2. The host and viral factors that contrib‐
utes for this high level of control remain poorly understood, but we hypothesized that one of
the viral factors that could be involved is the existence of a less fitted viral population, during
a variable period of the asymptomatic stage. This population has lower replicative capacity
and, at least in some cases, they do not efficiently use CCR5 and/or CXCR4 coreceptors.
5.3.2. Broad coreceptor usage
A hallmark of earlier studies addressing the coreceptors usage by HIV-2 primary isolates was
that HIV-2 entry into target cells could be mediated by an array of different GPCRs in vitro
(reviewed in [146, 147]). In contrast, HIV-1 isolates with coreceptor usage biotype other than
R5 and/or X4 have been rarely described. Furthermore, HIV-2 isolates can exploit these
alternative coreceptors as efficiently as they use CCR5 or CXCR4, even those rarely used by
HIV-1. However, it should be noted that most of the viruses used in these studies were obtained
from patients in advanced disease stages, were more pathogenic variants could be present,
presumably leading to a bias in the viral population that was preferentially isolated.
The ability to use a larger set of coreceptors should constitute an advantage for HIV-2, since it
contributes to a potentially broader cell tropism, with the inherent ability to infect different
cell types in different compartments [98, 135, 148]. Yet, as referred in R5-to-X4 evolution (see
above) this could lead to the infection of non-activated cells, and thus to abortive cycles.
Moreover, the engagement of alternative GPCRs, although being sufficient to mediate HIV-2
entry, could be inadequate to trigger appropriate intracellular signaling required for produc‐
tive infection. Several studies have shown a direct correlation between the capacity of envelope
glycoproteins to elicit appropriate signaling and the ability to perform a productive infection
in several cell types (reviewed in [149]). Such signalling events affect multiple intracellular
pathways (in a process mimicking chemokine signaling through binding to their receptors)
and include: actin depolymerization, cytoskeleton rearrangement, migration of cells and
activation of kinases and transcription factors associated with cell activation (Table 2).
Although the relevance of coreceptor signaling in HIV pathogenesis has not been clearly
defined, it seems that HIV takes advantage of the chemokine signaling network to create an
intracellular environment suitable to accomplish a productive infection [149].
Another factor that may account for the apparent paradox of HIV-2 broad coreceptor usage
and low virus production in vivo, could be the relative concentration of appropriate viral
receptors and their co-localization in plasma membrane of specific cell types [150-153].
Moreover, their expression levels could change during activation/differentiation of T lym‐
phocytes and macrophages, as referred for CD4, CCR5 and CXCR4 [144, 154, 155]. Thus, the
availability of target cells expressing CD4 and the appropriate coreceptor in vivo could be a
limiting factor for HIV-2 infection and spread.
Recently we have studied the contribution of CCR8 as an effective coreceptor for HIV-1 and
HIV-2 primary isolates [89]. A major and interesting finding arise from this report: a minor
coreceptor such as CCR8 was used much more frequently by HIV-1 than by HIV-2 primary
isolates, regardless the clinical stage, the plasma viral load or the CD4+ T-cell counts of patients.
The rationale for revisiting CCR8 as coreceptor was based on our earlier findings, revealing
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the existence of HIV-2 unable to use CCR5 or CXCR4 as coreceptors to infect primary CD4+
lymphocytes or CD4-expressing cell lines [96, 125]. CCR8, formerly known as TER1, ChemR1
and CKR-L1, is the receptor for the chemokine CCL1/I-309 [156, 157]. It is expressed in a wide
range of cells; some of them are primary targets for HIV infection in vivo, e.g. monocytes,
thymocytes and peripheral blood CD4+ T-lymphocytes [157-159]. Its tissue distribution and
the significant proportion of HIV-1 isolates able to use CCR8, deserves a deeper discussion. If
in HIV-2, due to the well-known promiscuous usage of chemokine receptors as coreceptors,
the usage of this GPCR was expected, in HIV-1, this was completely unpredicted. As I pointed
before, identification of viruses able to use other coreceptors besides CCR5 and CXCR4 seems
to be an abnormality in HIV-1. Yet, the findings presented in the cited report [89] together with
previous data [91, 100, 103, 160], indicating the efficient use of CCR8 as coreceptor by distinct
HIV-1 isolates, either in indicator cell lines or in primary cells, highlight the potential relevance
of this molecule for viral transmission and pathogenesis, including HIV-1.
Chemokine interaction with CXCR4* or CCR5**
receptors
HIV interaction*** with CCR5 or CXCR4 coreceptors
































* Ligand: SDF-1α; ** Ligands: MIP-1α, MIP-1β, and RANTES; *** by the surface envelope glycoprotein
Table 2. Major chemokine receptor signalling pathways triggered after binding of chemokines or HIV envelope
surface glycoprotein (for more details see [149])
It is widely recognized that during later stages of HIV-1 infection, a significant proportion of
viral variants that constitute the quasispecies within an infected individual, evolve in order to
efficiently use CXCR4 (and probably other chemokine receptors) in addition to, or instead of,
CCR5-using variants, which predominate during early stages of infection [161]. These X4
variants are characterized by increased replicative capacity, a more cytopathic phenotype and
the ability to infect a broader range of cells [162]. Accordingly, the emergence of X4 variants
is associated with accelerated disease progression and increased CD4+ T-lymphocytes
depletion [161]. The infection of naive T-cells by X4 strains is likely to occur early in T-
lymphocyte ontogeny and may thus contribute to the described enhancement of T-cells
depletion by X4 strains. Studies of thymocyte development demonstrated that CXCR4 is highly
expressed on immature T-cell progenitors resident to thymic cortex. As a result, infection of
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counts and undetectable viremia is observed in HIV-2. The host and viral factors that contrib‐
utes for this high level of control remain poorly understood, but we hypothesized that one of
the viral factors that could be involved is the existence of a less fitted viral population, during
a variable period of the asymptomatic stage. This population has lower replicative capacity
and, at least in some cases, they do not efficiently use CCR5 and/or CXCR4 coreceptors.
5.3.2. Broad coreceptor usage
A hallmark of earlier studies addressing the coreceptors usage by HIV-2 primary isolates was
that HIV-2 entry into target cells could be mediated by an array of different GPCRs in vitro
(reviewed in [146, 147]). In contrast, HIV-1 isolates with coreceptor usage biotype other than
R5 and/or X4 have been rarely described. Furthermore, HIV-2 isolates can exploit these
alternative coreceptors as efficiently as they use CCR5 or CXCR4, even those rarely used by
HIV-1. However, it should be noted that most of the viruses used in these studies were obtained
from patients in advanced disease stages, were more pathogenic variants could be present,
presumably leading to a bias in the viral population that was preferentially isolated.
The ability to use a larger set of coreceptors should constitute an advantage for HIV-2, since it
contributes to a potentially broader cell tropism, with the inherent ability to infect different
cell types in different compartments [98, 135, 148]. Yet, as referred in R5-to-X4 evolution (see
above) this could lead to the infection of non-activated cells, and thus to abortive cycles.
Moreover, the engagement of alternative GPCRs, although being sufficient to mediate HIV-2
entry, could be inadequate to trigger appropriate intracellular signaling required for produc‐
tive infection. Several studies have shown a direct correlation between the capacity of envelope
glycoproteins to elicit appropriate signaling and the ability to perform a productive infection
in several cell types (reviewed in [149]). Such signalling events affect multiple intracellular
pathways (in a process mimicking chemokine signaling through binding to their receptors)
and include: actin depolymerization, cytoskeleton rearrangement, migration of cells and
activation of kinases and transcription factors associated with cell activation (Table 2).
Although the relevance of coreceptor signaling in HIV pathogenesis has not been clearly
defined, it seems that HIV takes advantage of the chemokine signaling network to create an
intracellular environment suitable to accomplish a productive infection [149].
Another factor that may account for the apparent paradox of HIV-2 broad coreceptor usage
and low virus production in vivo, could be the relative concentration of appropriate viral
receptors and their co-localization in plasma membrane of specific cell types [150-153].
Moreover, their expression levels could change during activation/differentiation of T lym‐
phocytes and macrophages, as referred for CD4, CCR5 and CXCR4 [144, 154, 155]. Thus, the
availability of target cells expressing CD4 and the appropriate coreceptor in vivo could be a
limiting factor for HIV-2 infection and spread.
Recently we have studied the contribution of CCR8 as an effective coreceptor for HIV-1 and
HIV-2 primary isolates [89]. A major and interesting finding arise from this report: a minor
coreceptor such as CCR8 was used much more frequently by HIV-1 than by HIV-2 primary
isolates, regardless the clinical stage, the plasma viral load or the CD4+ T-cell counts of patients.
The rationale for revisiting CCR8 as coreceptor was based on our earlier findings, revealing
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the existence of HIV-2 unable to use CCR5 or CXCR4 as coreceptors to infect primary CD4+
lymphocytes or CD4-expressing cell lines [96, 125]. CCR8, formerly known as TER1, ChemR1
and CKR-L1, is the receptor for the chemokine CCL1/I-309 [156, 157]. It is expressed in a wide
range of cells; some of them are primary targets for HIV infection in vivo, e.g. monocytes,
thymocytes and peripheral blood CD4+ T-lymphocytes [157-159]. Its tissue distribution and
the significant proportion of HIV-1 isolates able to use CCR8, deserves a deeper discussion. If
in HIV-2, due to the well-known promiscuous usage of chemokine receptors as coreceptors,
the usage of this GPCR was expected, in HIV-1, this was completely unpredicted. As I pointed
before, identification of viruses able to use other coreceptors besides CCR5 and CXCR4 seems
to be an abnormality in HIV-1. Yet, the findings presented in the cited report [89] together with
previous data [91, 100, 103, 160], indicating the efficient use of CCR8 as coreceptor by distinct
HIV-1 isolates, either in indicator cell lines or in primary cells, highlight the potential relevance
of this molecule for viral transmission and pathogenesis, including HIV-1.
Chemokine interaction with CXCR4* or CCR5**
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HIV interaction*** with CCR5 or CXCR4 coreceptors
































* Ligand: SDF-1α; ** Ligands: MIP-1α, MIP-1β, and RANTES; *** by the surface envelope glycoprotein
Table 2. Major chemokine receptor signalling pathways triggered after binding of chemokines or HIV envelope
surface glycoprotein (for more details see [149])
It is widely recognized that during later stages of HIV-1 infection, a significant proportion of
viral variants that constitute the quasispecies within an infected individual, evolve in order to
efficiently use CXCR4 (and probably other chemokine receptors) in addition to, or instead of,
CCR5-using variants, which predominate during early stages of infection [161]. These X4
variants are characterized by increased replicative capacity, a more cytopathic phenotype and
the ability to infect a broader range of cells [162]. Accordingly, the emergence of X4 variants
is associated with accelerated disease progression and increased CD4+ T-lymphocytes
depletion [161]. The infection of naive T-cells by X4 strains is likely to occur early in T-
lymphocyte ontogeny and may thus contribute to the described enhancement of T-cells
depletion by X4 strains. Studies of thymocyte development demonstrated that CXCR4 is highly
expressed on immature T-cell progenitors resident to thymic cortex. As a result, infection of
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immature thymocytes by X4 strains may disrupt thymopoiesis leading to an impairment of T-
cell development and to an accelerated T-cell depletion [163-165].
However, in HIV-2 the correlation between disease progression and coreceptor usage was not
consistently observed and a clear pattern of R5-to-X4 evolution, along with disease progres‐
sion, has been difficult to establish. Even so, R5 viruses are mainly observed in asymptomatic
or early symptomatic patients, and strains showing a restricted CXCR4 usage are only
observed in late symptomatic individuals [96, 166-168]. In a study comparing CCR5, CXCR4
and CCR8 usage by HIV-1 and HIV-2, an interesting observation was withdrawn pointing to
a more frequent usage of CXCR4 by HIV-1 than by HIV-2 primary isolates [89]. Conversely,
CCR5 use was significantly more common in HIV-2 isolates than in HIV-1. According to the
described enhancement of T-cell depletion by X4 variants, the predominance of a non-X4 viral
population, mostly observed in HIV-2 cohort, may contribute to better preserve CD4+
lymphocyte repertoire and immune system functionality and help explain the slower disease
progression, generally observed in HIV-2 infected patients compared with HIV-1.
5.3.3. CD4-independent infection
Despite the potential advantage of broader cell tropism associated with lower CD4 depend‐
ency, CD4-independent HIV-1 variants, although readily derived in vitro [169-172], have been
rarely described in vivo [173-175]. In contrast, several primary HIV-2 and SIV isolates have
been shown to enter cells in a CD4-independent way [81, 148, 168, 176-179].
The ability to entry cells through direct interaction with the coreceptor molecule, bypassing
the requirement of prior CD4 engagement, may enable viruses to infect a broader range of cells
CD4 negative/coreceptor positive, or cells where CD4 expression is lower and thus limiting.
This notion is consistent with studies showing that neutopathogenic HIV-1 variants show
reduced CD4 dependence and the ability to infect CD4-negative cells. Viruses with a CD4-
independent phenotype could infect cells in different tissue compartments within an infected
individual, besides haematopoietic CD4+ cells, such as the brain, testes, lymphoid tissue,
kidneys or lungs, further suggesting that CD4-independence could constitute an advantage
and might play an important role in some particular tissue settings [148, 173-175, 180, 181].
Interestingly, the CD4-independent phenotype not only appears to be a potential advantage
but it can be easily acquired as a consequence of very few amino acids changes in viral envelope
glycoproteins [169-172, 182, 183]. Therefore, a central question may arise: why CD4-independ‐
ent HIV-1 variants are so rare, or why the occurrence of such variants in HIV-2 is not associated
with an increased pathogenic outcome?
The infrequent detection of CD4-independent HIV-1 isolates should reflect the selective
advantage of CD4 interaction prior to coreceptor engagement. One of the reasons could be the
high affinity of CD4-SU envelope glycoprotein binding, stabilizing virion attachment to target
cell. However, many other surface molecules have been described to interact with HIV-1
(reviewed in [184]) and thus capable of mediate a stabilizing interaction with virions. Another
possible explanation for CD4 dependency could be the shielding of coreceptor binding sites
from neutralizing antibodies [170, 182, 185-189]. Considering the proposed mechanism for HIV
fusion, the CD4-independent infection imposes that the coreceptor-binding site is already
Current Perspectives in HIV Infection426
formed or exposed allowing the virus to circumvent the need for prior CD4 interaction. The
conformation of envelope glycoproteins allowing the direct interaction with coreceptor (as
well as the interaction with different coreceptors) might elicit neutralizing antibodies targeting
these critical regions, favoring the host immunological control in HIV-2 infection. Consistent
with this notion, sera from HIV-2 infected individuals have higher and broader neutralizing
capacity compared to those of HIV-1 [126, 190].
Studies conducted with HIV-2 CD4-independent strains clearly demonstrated a less fitted
interaction and a reduced replication rate in vitro. This suggests that the coreceptor-binding
site is only partially formed (or exposed) affecting the stability/affinity of the complex formed
between coreceptor and the envelope glycoproteins. In turn, this may also indicate that prior
CD4 interaction is important to assure the infection of more permissive cells, enabling a more
productive infection. The intracellular factors that dictate this “friendly” environment for viral
replication in CD4+ cells remain unknown but may be related to some unidentified restriction
factors that could be present in CD4 negative cells. Conversely, the interaction with CD4 may
induce cell-signaling events that could account for optimal viral replication conditions, as I
discussed earlier about coreceptor engagement by envelope glycoproteins.
6. Concluding remarks
Two lentiviruses infect humans with different outcomes. HIV-1 and HIV-2, both a result of
cross-species transmission, have similar genomic and structural characteristics, and yet they
distinctively affect human host. While HIV-1 infection leads to severe immune dysfunction
and the development of AIDS within a median time of 10 years, HIV-2 usually takes decades
to accomplish that.
Through this chapter, I have provided several data that help to explain this different patho‐
genic potential of HIV-1 and HIV-2 (see Table 3 for a brief summary). I have focused on those
viral characteristics that determines different virus-host interactions and outcomes:
• Lower viral load in body fluids directly involved in HIV-2 transmission.
• Avoidance of SAMHD1 degradation of viral cDNA during infection of dendritic cells,
leading to sensing and stronger innate immune response by HIV-2.
• Inability to use CCR5 or CXCR4 that severely affects viral fitness during asymptomatic
phase of infection.
• A less common acquisition of CXCR4 usage during the course of infection and the conse‐
quent maintenance of a predominant less cytopathic R5 population, which may help to
better preserve CD4+ lymphocyte repertoire and immune system functionality in HIV-2
infected individuals.
• Usage of alternate coreceptors that ultimately could lead to inappropriate cell signalling
and/or infection of cell populations unable to fully support the HIV-2 replication cycle.
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immature thymocytes by X4 strains may disrupt thymopoiesis leading to an impairment of T-
cell development and to an accelerated T-cell depletion [163-165].
However, in HIV-2 the correlation between disease progression and coreceptor usage was not
consistently observed and a clear pattern of R5-to-X4 evolution, along with disease progres‐
sion, has been difficult to establish. Even so, R5 viruses are mainly observed in asymptomatic
or early symptomatic patients, and strains showing a restricted CXCR4 usage are only
observed in late symptomatic individuals [96, 166-168]. In a study comparing CCR5, CXCR4
and CCR8 usage by HIV-1 and HIV-2, an interesting observation was withdrawn pointing to
a more frequent usage of CXCR4 by HIV-1 than by HIV-2 primary isolates [89]. Conversely,
CCR5 use was significantly more common in HIV-2 isolates than in HIV-1. According to the
described enhancement of T-cell depletion by X4 variants, the predominance of a non-X4 viral
population, mostly observed in HIV-2 cohort, may contribute to better preserve CD4+
lymphocyte repertoire and immune system functionality and help explain the slower disease
progression, generally observed in HIV-2 infected patients compared with HIV-1.
5.3.3. CD4-independent infection
Despite the potential advantage of broader cell tropism associated with lower CD4 depend‐
ency, CD4-independent HIV-1 variants, although readily derived in vitro [169-172], have been
rarely described in vivo [173-175]. In contrast, several primary HIV-2 and SIV isolates have
been shown to enter cells in a CD4-independent way [81, 148, 168, 176-179].
The ability to entry cells through direct interaction with the coreceptor molecule, bypassing
the requirement of prior CD4 engagement, may enable viruses to infect a broader range of cells
CD4 negative/coreceptor positive, or cells where CD4 expression is lower and thus limiting.
This notion is consistent with studies showing that neutopathogenic HIV-1 variants show
reduced CD4 dependence and the ability to infect CD4-negative cells. Viruses with a CD4-
independent phenotype could infect cells in different tissue compartments within an infected
individual, besides haematopoietic CD4+ cells, such as the brain, testes, lymphoid tissue,
kidneys or lungs, further suggesting that CD4-independence could constitute an advantage
and might play an important role in some particular tissue settings [148, 173-175, 180, 181].
Interestingly, the CD4-independent phenotype not only appears to be a potential advantage
but it can be easily acquired as a consequence of very few amino acids changes in viral envelope
glycoproteins [169-172, 182, 183]. Therefore, a central question may arise: why CD4-independ‐
ent HIV-1 variants are so rare, or why the occurrence of such variants in HIV-2 is not associated
with an increased pathogenic outcome?
The infrequent detection of CD4-independent HIV-1 isolates should reflect the selective
advantage of CD4 interaction prior to coreceptor engagement. One of the reasons could be the
high affinity of CD4-SU envelope glycoprotein binding, stabilizing virion attachment to target
cell. However, many other surface molecules have been described to interact with HIV-1
(reviewed in [184]) and thus capable of mediate a stabilizing interaction with virions. Another
possible explanation for CD4 dependency could be the shielding of coreceptor binding sites
from neutralizing antibodies [170, 182, 185-189]. Considering the proposed mechanism for HIV
fusion, the CD4-independent infection imposes that the coreceptor-binding site is already
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formed or exposed allowing the virus to circumvent the need for prior CD4 interaction. The
conformation of envelope glycoproteins allowing the direct interaction with coreceptor (as
well as the interaction with different coreceptors) might elicit neutralizing antibodies targeting
these critical regions, favoring the host immunological control in HIV-2 infection. Consistent
with this notion, sera from HIV-2 infected individuals have higher and broader neutralizing
capacity compared to those of HIV-1 [126, 190].
Studies conducted with HIV-2 CD4-independent strains clearly demonstrated a less fitted
interaction and a reduced replication rate in vitro. This suggests that the coreceptor-binding
site is only partially formed (or exposed) affecting the stability/affinity of the complex formed
between coreceptor and the envelope glycoproteins. In turn, this may also indicate that prior
CD4 interaction is important to assure the infection of more permissive cells, enabling a more
productive infection. The intracellular factors that dictate this “friendly” environment for viral
replication in CD4+ cells remain unknown but may be related to some unidentified restriction
factors that could be present in CD4 negative cells. Conversely, the interaction with CD4 may
induce cell-signaling events that could account for optimal viral replication conditions, as I
discussed earlier about coreceptor engagement by envelope glycoproteins.
6. Concluding remarks
Two lentiviruses infect humans with different outcomes. HIV-1 and HIV-2, both a result of
cross-species transmission, have similar genomic and structural characteristics, and yet they
distinctively affect human host. While HIV-1 infection leads to severe immune dysfunction
and the development of AIDS within a median time of 10 years, HIV-2 usually takes decades
to accomplish that.
Through this chapter, I have provided several data that help to explain this different patho‐
genic potential of HIV-1 and HIV-2 (see Table 3 for a brief summary). I have focused on those
viral characteristics that determines different virus-host interactions and outcomes:
• Lower viral load in body fluids directly involved in HIV-2 transmission.
• Avoidance of SAMHD1 degradation of viral cDNA during infection of dendritic cells,
leading to sensing and stronger innate immune response by HIV-2.
• Inability to use CCR5 or CXCR4 that severely affects viral fitness during asymptomatic
phase of infection.
• A less common acquisition of CXCR4 usage during the course of infection and the conse‐
quent maintenance of a predominant less cytopathic R5 population, which may help to
better preserve CD4+ lymphocyte repertoire and immune system functionality in HIV-2
infected individuals.
• Usage of alternate coreceptors that ultimately could lead to inappropriate cell signalling
and/or infection of cell populations unable to fully support the HIV-2 replication cycle.
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• CD4-independent infection of target cells, providing the potential to infect cells in different
compartments but also exposing critical regions of coreceptor binding site to host neutral‐
izing immune response.
• A more relaxed envelope glycoproteins structure that could modulate HIV-2 interaction
with cellular receptors, helping explaining the exotic coreceptor usage and CD4-independ‐
ency but also a less fitted interaction with those receptors and thus to an inappropriate cell
signalling.
Much more data is needed to fully comprehend the way human host is able to cope with HIV-2
but not with HIV-1 infection. Further studies addressing HIV-2-cell interactions are warranted
as they could reveal undisclosed mechanisms and pathways that may help to clarify the
underlying causes for the different pathogenic potential observed between HIV-2 and HIV-1,




Conflicting results. Susceptible to antiviral
activity of cellular factor SAMHD1
Conflicting results. Resistant to antiviral




Less efficiently triggered due to several
factors, namely to the restricted infection
of dendritic cells
More robust than in HIV-1 namely
because infection of dendritic cells could
trigger IFN-I mediated response
Coreceptor usage Generally described has only being able to
efficiently use CCR5 and CXCR4
Generally described has being able to








Mostly the V3 region of SU envelope
glycoprotein
Conflicting data. Probably V1/V2 region
and, to a lesser extend, V3 region
Neutralization capacity
of serum antibodies
Reduced Higher and broader
Table 3. Differences between HIV-1 and HIV-2 regarding virus-host interaction (see text for further details)
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• CD4-independent infection of target cells, providing the potential to infect cells in different
compartments but also exposing critical regions of coreceptor binding site to host neutral‐
izing immune response.
• A more relaxed envelope glycoproteins structure that could modulate HIV-2 interaction
with cellular receptors, helping explaining the exotic coreceptor usage and CD4-independ‐
ency but also a less fitted interaction with those receptors and thus to an inappropriate cell
signalling.
Much more data is needed to fully comprehend the way human host is able to cope with HIV-2
but not with HIV-1 infection. Further studies addressing HIV-2-cell interactions are warranted
as they could reveal undisclosed mechanisms and pathways that may help to clarify the
underlying causes for the different pathogenic potential observed between HIV-2 and HIV-1,




Conflicting results. Susceptible to antiviral
activity of cellular factor SAMHD1
Conflicting results. Resistant to antiviral




Less efficiently triggered due to several
factors, namely to the restricted infection
of dendritic cells
More robust than in HIV-1 namely
because infection of dendritic cells could
trigger IFN-I mediated response
Coreceptor usage Generally described has only being able to
efficiently use CCR5 and CXCR4
Generally described has being able to








Mostly the V3 region of SU envelope
glycoprotein
Conflicting data. Probably V1/V2 region
and, to a lesser extend, V3 region
Neutralization capacity
of serum antibodies
Reduced Higher and broader
Table 3. Differences between HIV-1 and HIV-2 regarding virus-host interaction (see text for further details)
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1. Introduction
Since the emergence of the acquired immune deficiency syndrome (AIDS), there has been a
great deal of interest in identifying cofactors that accelerate progression of the disease elicit‐
ed by human immunodeficiency virus types 1 or 2 (HIV-1, HIV-2). Beside inherent factors
and environmental agents, speculations led to the conclusion that infectious diseases fre‐
quently occur in HIV infected persons, might augment HIV replication, and consequently
facilitate AIDS progression. HIV infection is followed by a long disease-free period, during
which a low number of CD4+ immune cells contains transcriptionally silent provirus. Acti‐
vation of CD4+ cells by external factors, including heterologous viruses, terminates latency
forcing towards a productive HIV infection. Transactivation of the HIV long terminal repeat
(LTR) by cellular, nuclear transcriptional factors (e.g. NF-κB, Sp1) induced by mitogens, cy‐
tokines, chemokines, simultaneous virus infections is followed by gene expression including
the synthesis of the HIV transactivator protein (TAT), which binds to the transactivating re‐
sponse (TAR) element of the genome, ultimately leading to large scale production of HIV
and death of infected cells through apoptosis [1,2]. In vitro studies showed that products of
immediate early (IE) or early (E) genes of several DNA viruses such as human herpesviruses
(HHV) -1, 2, 3, 4, 5, 6A, 8, adenoviruses, as well as hepatitis B virus (HBV) X gene, human T
lymphotropic virus type I (HTLV-I) tax gene upregulated production of these transcriptional
factors and activate HIV-1 or HIV-2 in the same cells. Simultaneous infection in a single cell
is relatively rare event in vivo; therefore such type of biological effects in nature could be
minimal. On the contrary, cross-talk between immune cells carrying different viruses via cy‐
tokines, chemokines is more common. Heterologous viruses infect many types of cells,
which are not targets of HIV, but release several immunomodulatory mediators, usually in
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an abnormal pattern. High level of tumour necrosis factor (TNF)-α, interleukin (IL)-6, IL-10,
and low level of IL-2, IL-12 were frequently observed in the blood of AIDS patients, only to
mention the most important ones. Abundant pro-inflammatory cytokines bind to HIV carri‐
er cells and through consequently activated secondary messenger systems activate the same
transcriptional factors for HIV activation. This category of interaction has a more significant
impact on HIV infection. This phenomenon called as transcellular transactivation can last
lifetime, its intensity may vary depending on the host, the other transiently or chronically
coinfecting microbes, etc. [3]. These external confounding factors act in a pleiotropic man‐
ner, which is impossible to study in vitro. Animal studies are ideal to establish their role in
AIDS progression [4].
2. The feline AIDS model
Feline AIDS (FAIDS) induced by feline immunodeficiency virus (FIV) is the only natural
small animal model of human AIDS [4,5-8 ]. FIV shares many genetic, structural and biologi‐
cal characteristics with HIV. FIV also shows tropism for CD4+ immune cells, but its receptor
is the CD134 molecule with the CXCR4 coreceptor. FIV LTR accommodates multiple en‐
hancer or promoter protein-binding sites (e.g. NF-κB, AP-1). Although FIV lacks TAT and
the TAR element, its Orf-2 (also designated as Orf-A) acts as a transactivator gene to some
degree and is necessary for productive FIV replication [7,9]. The similarities in the clinical
course of infection between HIV and FIV are striking [6,8,10]. Male gender and adult age are
known risk factors for both HIV and FIV transmission [6,7,11,12]. Domestic cats infected
with FIV develop progressive immune dysfunction characterised by depletion of CD4+ T
cells, wasting, cachexia, gingivostomatitis, neuropathological disorders, opportunistic infec‐
tions, unusual malignancies such as B cell lymphomas, fibrosarcomas [13]. CD4+CD25+hi‐
FoxP3+ immunosuppressive regulatory T (Treg) cells have been implicated as a possible
cause of immune dysfunction during FIV and HIV-1 infection, as they are capable of modu‐
lating virus-specific and inflammatory immune responses. Influence of Treg cell suppres‐
sion during FIV and HIV pathogenesis is most prominent after Treg cells are activated in the
environment of established FIV infection [10]. It is important to remember that increased ac‐
tivity of Treg cells promotes immunosenescence in the normal elderly, and AIDS is regarded
as an extremely rapid ageing process [14]. Disease progression occurs over a similar time
scale to HIV-1 infection in humans [6]. FIV is distributed worldwide; it has several subtypes
similarly to HIV [12,15]. Species-specific strains of FIV circulate in many members of Felidae
family, including endangered big cats in which also induce AIDS-like illnesses [6,12]. Some
opportunistic infections in cats also occur worldwide such as feline leukaemia virus (FeLV),
feline herpesvirus type 1 (FHV-1), Toxoplasma gondii (TG), feline coronavirus (FCoV), Barto‐
nella henselae (BH), canine distemper virus (CDV), fungal pathogens or mycoplasmas. Their
incidence depends on geographical regions, cat subpopulations (pet, indoor, stray, feral,
free-roaming, etc.), gender and age [11,12,16-28]. Incidence of other opportunistic microbes
depends on endemic geographical areas and local vectors (e.g. haemoplasma or Leishmania
species, different helminths) [16,18,29-33]. Some of these microbes establish coinfection in a
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particular felid species that carries a specific strain of FIV. Typical examples have been re‐
ported recently. A highly virulent FeLV outbreak in FIVPco infected free ranging Florida pu‐
mas (Puma concolor coryi) threatened this endangered species [12]. In another outbreak in the
Serengeti, FIVPle B infected lions (Panthera leo) were twice as likely to survive CDV infection
compared to lions infected with FIVPle A or FIVPle C [34]. These cases clearly demonstrate
that specificities of both microbes might express increased risk for severe synergistic patho‐
genicity. Recent surveys on coinfections mentioned above were carried out for descriptive
epidemiological purposes. In the majority of studies, occurrence of heterologous microbes
were judged as opportunistic infections, but some of the investigators have come to the con‐
clusion that FIV and heterologous microbes might mutually aggravate immunosuppression
at the level of the organism [12,17]. Both FIV and FeLV independently might predispose ani‐
mals for toxoplasma infection [21]. In spite of similar clinical manifestations by FIV or FeLV,
they might specifically predispose the host for different heterologous microbial pathogens:
FIV predisposes to Leishmania [12,16], mycoplasma [25,27,33,35], fungal [26], FCoV [12] in‐
fections, while FeLVsensitises the organism to BH infection [36]. Others found that the rate
of toxoplasma [16,30,32] or FCV [24] infections occur independently of FIV status. These re‐
sult, even some of them are contradictory, clearly show that each retrovirus must have its
specific way to interact with other microbes at molecular or immunological level. It is con‐
ceivable that HIV and human microbes have similar ways for interactions. Both direct trans‐
activation of FIV in the simultaneously infected cells (Figure 1) or cross-talk between cells
infected by FIV, and other cells infected by heterologous microbes (Figure 2) can take place
in the body of cats.
Figure 1. Scheme of intracellular virus transactivation
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Figure 2. Scheme of transcellular transactivation
Comparison of human clinical observations on opportunistic infections in HIV infected pa‐
tients and in vitro transactivation studies unambiguously demonstrate that several viruses
can cause both opportunistic infection and transactivate HIV. The domestic cat is afflicted
with multiple microbes that also induce human diseases (e.g. TG, Leishmania, fungi, myco‐
bacteria). Furthermore, domestic cats harbour several feline virus species that are homolo‐
gous to human viruses: FIV, FeLV, FHV, FCV, FCoV, as well as feline sarcoma virus, feline
parvovirus, feline morbillivirus [12]. These feline microbe species provide a panoply of in‐
fectious disease models for many devastating human diseases including for studies on the
possible interaction between retroviruses and heterologous microbes among natural condi‐
tions of FAIDS at molecular, immunological, cellular level in any organ or the whole body of
infected cats by any available methodology.
3. Simultaneous infections: Both opportunists and transactivators
3.1. Feline herpesvirus
Simultaneous infection by retroviruses and heterogenous microbes and their association
with a variety of diseases have come into focus recently. The very sensitive methods to de‐
tect nucleic acids of microbes have promoted our understanding that microbial interaction
may result in the synergistic induction of more severe disease course. Retroviruses and her‐
pesviruses might be associated with a variety of diseases in animals. Coinfection of chickens
with Marek’s disease virus (Gammaherpesvirinae) and retrovirus (avian leukosis virus) in‐
crease the incidence of retrovirus associated tumours [37]. As several species of human her‐
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pesviruses have been implicated as cofactors for AIDS progression, possible interaction of
feline herpesvirus 1 (FHV-1, subfamily Betaherpesvirinae, a homologue of human cytomega‐
lovirus /CMV/), with FIV has been studied in vivo and in vitro. FHV-1 might spread in some
captive felids with higher frequency than in their free-ranging counterparts demonstrating
the importance of human intervention in natural epidemiology [11,29,38]. Single or simulta‐
neous infection by FHV-1 and TG or BH have been implicated as causative agents of feline
uveitis [20]. It is of note, that FHV-1 homologue human CMV induces very severe retinitis in
HIV infected humans [12], and human CMV was found one of the clinically most frequent
and strongest transactivator of HIV. On the contrary to human experience with HSV-1 and
adenoviruses [39], FHV-1 could not be implicated in the multifactorial aetiology of gingivitis
[24]. FHV-1 also infects T lymphocytes. FHV-1 is a significant pathogen limited to the family
Felidae, causing an upper respiratory disease in cats. Interaction of acute FHV-1 infection in
chronically, experimentally FIV infected specific pathogen-free (SPF) animals results in sev‐
eral immunological abnormalities. FIV infected cats produce less FHV-1 neutralising IgM
antibodies during the first 3 weeks of infection than non-FIV infected animals, whereas the
IgG antibody response remains unaffected. The ongoing IgG antibody response to FIV is not
affected by FHV-1 infection. Lymphocyte blastogenic response to concanavalin A (Con-A) is
depressed in FIV-infected and non-infected cats, but response to pokeweed mitogen (PWM)
takes longer to return to normal in FIV infected animals. Lymphocytes from FIV infected
cats have a greater and more sustained proliferative response to FHV-1 antigen than non-
infected cats [40]. Cats with pre-existing FIV infection have more severe signs of disease af‐
ter exposure to FHV-1 or TG, than FIV-free counterparts. Primary immune responses to all
heterologous pathogens are delayed or diminished in FIV infected compared with non-FIV-
infected animals. Repeated infections have no significant effect on the level of FIV-specific
antibodies or on the production of peripheral blood mononuclear cells (PBMC) containing
FIV proviral DNA. FIV infected cats exposed to cofactors have normal levels of IL-2R and
major histocompatibility complex (MHC)-II antigen expression on PBMCs, while only-FIV-
infected animals have upregulated IL-2R and down-regulated MHC-II expression [41]. By
transfection of a recombinant plasmid containing the FIV LTR linked to the chloramphenicol
acetyltransferase (CAT) gene, followed by infection of FHV-1 into Crandell feline kidney
(CrFK) or Felis catus whole fetus 4 (fcwf-4) cells enhancement of CAT activity was demon‐
strated. Both immunofluorescence and electron microscopy showed productive coinfection
of individual T lymphocytes [42]. A series of FIV LTR deletion mutants were constructed
and cotransfected with FHV-1 to identify the regions that are responsible for transactivation.
It was demonstrated that sequences between -124 and -79, and between -21 and -32 (relative
to the cap site) are essential of FIV replication in fcwf-4 cells and that the sequence between
-63 and -23 responds to transactivation of FIV LTR by FHV-1 [43]. FHV-1 infected-cell-pro‐
tein 4 (ICP4) was found to down-regulate FIV LTR directed gene expression via the C/EBP
site in the LTR, but after introduction of a site-specific mutation of this site, ICP4 significant‐
ly stimulated LTR. These results indicate that FHV-1 ICP4 possesses both abilities to transac‐
tivate or down-regulate FIV-directed gene expression. C/EBP and AP-1 regulatory
sequences are known to act as both positive and negative regulators [44]. Interestingly
enough, plasmids expressing ICP4 homologues of Alphaherpesviruses, namely pseudora‐
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bies virus (PRV) and equine herpesvirus type 1 (EHV-1) could significantly inhibit FIV LTR-
directed gene expression in CrFK and fcwf-4 cells. Moreover, the ICP4 homologues also
exhibited a marked suppressive effect on FIV replication in CrFK cells cotransfected with an
infectious clone of FIV [45]. These experiments drow attention to the role of other herpesvi‐
ruses, among them Roseoloviruses [46], which might exist in cats. Similarities and differen‐
ces between the human or feline AIDS could help elucidating their devastating role in
human and feline patients.
3.2. Feline adenovirus
Among other DNA viruses, adenovirus (AdV) also might enhance AIDS progression in cats.
So far, the only feline adenovirus (FeAdV) isolate (also the first one from the family Felidae)
was obtained from a fecal sample of a cat with AdV PCR positivity [47] and unknown FIV
serostatus [48]. Its hexon [49], fiber [50], and nucleotide sequences published so far suggest
that it might be related to human AdV type 1 (HAdV-1). Similar nucleotide sequences have
been shown in the feces of a small child suffering with gastroenteritis and her cat in Japan
[51], and in one nasopharyngeal aspirate sample of a 468 member cohort of children present‐
ing acute respiratory disease in Brazil [52]. This virus might be widespread all over the
world and one can speculate that it could transactivate both HIV and FIV, e.g. in pet owners.
Seroepidemiological studies show that approx. 10-20% of free roaming cats are seropositive
in Hungary and Europe [53,54]. In a series of consecutive transfer of FIV by intravenous in‐
oculation of experimental SPF casts, four were AdV seropositive, but their serostatus before
FIV inoculation remained unknown. One can speculate that accidental transfer of AdV
along with FIV occurred [55]. FeAdV would be ideal to compare its unique clinical and mo‐
lecular effects in the human and the cat both in vivo and in vitro similarly to studies on the
interaction of HHV-6 and SIV in humans and pig-tailed macaques [56,57]. As it was isolated
from cat feces, one could use FeAdV and FIV to model intestinal molecular interaction of
HAdVs and HIV.
3.3. Feline leukaemia virus
Another common interaction in nature is between FIV infection and FeLV. FeLV is of partic‐
ular significance because it can also induce immunodeficiency [58]. FeLV is a homologue of
human T lymphotropic virus (HTLV). It displays a prevalence of 1-8% worldwide
[16,24,33,38], but in some geographical areas much higher prevalence of FeLV antigen has
been detected (14.2% in Iran, [21], 24.5% in Thailand, [18], 26% in Portugal, [28]). In catteries
its prevalence could be much lower or up to zero [17,26,30,32]. Its prevalence has been de‐
creasing in most countries and is regarded as a less important deadly infectious agent in the
last 20 years compared to FIV [19]. In confined geographical regions or among captive ani‐
mals in different facilities, simultaneous decline in the seroprevalence of both FeLV and FIV
has also been observed [29,33]. Seroprevalence is higher in intact males than females, and
increases with age [17,18]. Transmission is usually by direct contact or saliva wounds. FeLV
infection among non-domestic cats of the Felidae family is rare, but FeLV has been shown to
cross species barriers, especially in case of prior or simultaneous microbial immunosuppres‐
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sion [12,28]. There are four naturally occurring exogenous FeLV strains: FeLV-A, -B, -C, and
–T. FeLV-A is the predominant subgroup circulating in feral cats. Its integrated proviral se‐
quences are transmitted vertically through the germ line. Recombination might occur be‐
tween FeLV-A and other subgroups. The outcome after exposure depends on several host
and environmental factors, but the clinical course is more aggressive than seen with FIV. In
approximately one third of exposed cats, viraemia is persistent and eventually results in
clinical disorders such as immunosuppression, bone marrow suppression (mainly anaemia),
and neoplasm (mainly lymphoma) [12,19]. Like FIV, FeLV infection alone also renders the
animals more susceptible to infection, persistence and disease elicited by heterologous mi‐
crobes [19,28,33] such as TG [21] or BH [36]. Mortality among persistently FeLV infected cats
is high as 83% die within 3.5 years [references in 12]. About 10 to 15% of the cats that are
clinically ill with FIV infection are coinfected with FeLV worldwide [59,60]. Upon superin‐
fection with FIV, asymptomatic cats with persistent FeLV infection manifest a more acceler‐
ate and exacerbated FIV disease, anticipated death and show a higher FIV load in lymphoid
tissues than did naive cats under both natural and experimental conditions, while the blood
level of FeLV p27 antigen was not elevated. Interestingly, the synergy between FIV and
FeLV is bidirectional: doubly infected cats develop FeLV induced tumours more frequently
than did cats infected with either virus alone [61]. Dually infected cats remain more leuko‐
penic than cats infected with FIV or FeLV alone, and their CD4+/CD8+ T lymphocyte ratios
become rapidly inverted [62]. This interrelationship is similar to what has been described for
HIV and HTLV-I [63].
3.4. Simultaneous Listeria and FIV infection
Scarce data are available on the possible effect on FIV and FAIDS exerted by feline bacterial
infections. Listeria monocytogenes (LM) can infect both humans and cats, and its profound im‐
munomodulatory capabilities are well known. Beside HIV, both FIV and LM impair the in‐
nate immune response that fails to gain control of their replication prior to the adaptive
immune response. These effects might be additive or synergistic in simultaneously infected
individuals. In a series of recent experiments, chronically FIV infected and SPF control cats
were challenged with LM, then their whole blood and lymph nodes were collected 3 days
after challenge. The number and functions of natural killer (NK) cells (CD3-CD56+), NKT
cells (CD3+CD56+), CD4 (CD3+CD4+), CD8 (CD3+CD8+), regulatory T cells
(CD4+CD25+Fox3+) and Langerhans cells (CD1a) were evaluated. NK, NKT, CD4+ and
CD8+ T cells in the LM challenged lymph node of FIV-infected cats did not increase in num‐
ber, NK cells did not increase their proliferation, apoptosis was elevated, and perforin ex‐
pression was not upregulated when compared to SPF control animals. No difference in Treg
cell number was found. Delayed control and clearance of opportunistic LM was also ob‐
served. In the blood compartment of LM challenged cats, CD4+ T cell proliferation did not
differ in SPF-control and FIV positive cats, while CD8+ T cell proliferation increased in FIV-
positive animals. The number of Langerhans cells did not decrease in FIV and LM infected
animals, but their ability to produce NK-activating IL-15 and other mediators became im‐
paired. Although it is concluded that FIV-infected cats are more vulnerable to LM superin‐
fection [2], it is conceivable that precedent or ongoing Listeria infection diminishes the
Interaction of FIV with Heterologous Microbes in the Feline AIDS Model
http://dx.doi.org/10.5772/52767
453
bies virus (PRV) and equine herpesvirus type 1 (EHV-1) could significantly inhibit FIV LTR-
directed gene expression in CrFK and fcwf-4 cells. Moreover, the ICP4 homologues also
exhibited a marked suppressive effect on FIV replication in CrFK cells cotransfected with an
infectious clone of FIV [45]. These experiments drow attention to the role of other herpesvi‐
ruses, among them Roseoloviruses [46], which might exist in cats. Similarities and differen‐
ces between the human or feline AIDS could help elucidating their devastating role in
human and feline patients.
3.2. Feline adenovirus
Among other DNA viruses, adenovirus (AdV) also might enhance AIDS progression in cats.
So far, the only feline adenovirus (FeAdV) isolate (also the first one from the family Felidae)
was obtained from a fecal sample of a cat with AdV PCR positivity [47] and unknown FIV
serostatus [48]. Its hexon [49], fiber [50], and nucleotide sequences published so far suggest
that it might be related to human AdV type 1 (HAdV-1). Similar nucleotide sequences have
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sion [12,28]. There are four naturally occurring exogenous FeLV strains: FeLV-A, -B, -C, and
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(CD4+CD25+Fox3+) and Langerhans cells (CD1a) were evaluated. NK, NKT, CD4+ and
CD8+ T cells in the LM challenged lymph node of FIV-infected cats did not increase in num‐
ber, NK cells did not increase their proliferation, apoptosis was elevated, and perforin ex‐
pression was not upregulated when compared to SPF control animals. No difference in Treg
cell number was found. Delayed control and clearance of opportunistic LM was also ob‐
served. In the blood compartment of LM challenged cats, CD4+ T cell proliferation did not
differ in SPF-control and FIV positive cats, while CD8+ T cell proliferation increased in FIV-
positive animals. The number of Langerhans cells did not decrease in FIV and LM infected
animals, but their ability to produce NK-activating IL-15 and other mediators became im‐
paired. Although it is concluded that FIV-infected cats are more vulnerable to LM superin‐
fection [2], it is conceivable that precedent or ongoing Listeria infection diminishes the
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activity of NK cells, helps promote FIV replication and dissemination in the body of ani‐
mals. In HIV-infected patients, dysfunction of NK cells with low perforin expression, aner‐
gy, furthermore, abnormal antigen presentation and low level of IL-15, IL-12 levels are also
known [2]. In humans, infection by LM or other bacteria with immunosuppressive potential
might augment impaired immunosurveillance, consequently increase HIV load, and ulti‐
mately facilitate AIDS progression.
3.5. Feline haemotropic mycoplasmas (haemoplasmas)
Epidemiological surveys on simultaneous infections by FIV and feline haemophilic myco‐
plasmas suggest that opportunistic infections also promote FIV progression. Feline haemo‐
philic mycoplasmas (Mycoplasma haemofelis, Candidatus Mycoplasma haemominutus)
collectively called haemoplasmas can cause anaemia and severe clinical disease of affected
cats. Candidatus Mycoplasma haemominutus (CMH) is usually not associated with clinical dis‐
ease, but typically causes anaemia in cats carrying pre-existing FIV or FeLV infection
[29,64,65]. Chronic FIV infection appears to modify the acute phase response to feline hae‐
motropic mycoplasmas, which varies with the infecting haemoplasma species, namely CMH
and M. haemofelis (MH), respectively [64]. A recent study in a Canadian feral cat population
found that CMH positive cats were significantly more likely to be concurrently retrovirus
positive than were CMH negative animals [33]. Another recent study in Spain found that,
FIV seropositivity and male sex were significantly associated with MH, CMH and Ca. M. tu‐
ricensis infection [27]. It is of note, that mycoplasmas in HIV infected patients have been re‐
garded as AIDS promoting factors for a long time, and this phenomenon was proved in
vitro, either [66]. A meta-analysis of former studies unambiguously demonstrated that geni‐
tal infection by M. genitalium poses high risk for acquisition of HIV. Testing and treatment of
M. genitalium-positive individuals in high risk groups is recommended as a potential HIV
prevention strategy [67]. Bacterial vaginosis-associated microflora in the female genital tract
also predisposes for HIV infection. Among flora members, M. hominis was shown to activate
NF-κB and AP-1. Through mediation of a soluble HIV inducing factor (HIF), these transcrip‐
tional factors may subsequently increase genital tract viral load and potentially contribute to
HIV transmission [68]. MH infection along with BH infection has been verified by PCR in an
HIV infected person [69]. The 34 year old man owned several cats. Haemoplasma DNA is
present in saliva and feces of cats, which suggests that aggressive interactions among cats
and humans involving biting may lead to transmission of the organism. So far, haemotropic
mycoplasma infections have been reported in a patient with systemic lupus erythematosus
(SLE) and in an anaemic patient showing that some forms of immunosuppression are re‐
quired for acquisition of an unusual pathogen [70]. Increasing number of human patients
with compromised immune systems living near cats increases the possibility that haemo‐
plasma infections may emerge in this population [69]. Haemoplasma positive cats like my‐
coplasma positive humans ought to be regarded at increased risk for retrovirus infection.
Testing would also be appropriate prior to relocation of felids [29]. Feline mycoplasmas
could provide a unique model to clarify the exact role of mycoplasmas in AIDS progression.
Current Perspectives in HIV Infection454
3.6. Feline mycobacteria
Mycobacteria are important opportunistic infections in HIV infected patients worldwide. Es‐
pecially in Sub-Saharan Africa very aggressive forms of tuberculosis occur in the immuno‐
compromised population induced by several mycobacterium species. Mycobacteria severely
suppress activities of the cellular immune reactions but due to the difficulties in their culti‐
vation and the chronic nature of the disease, it is extremely difficult to study their mutual
effects on the immune system. Several mycobacterium species that infect the human and are
prevalent in HIV infected patients (e.g. M. bovis, M. avium, M. microti), induce disease in cats
[23]. This finding raises the idea that FAIDS would be an appropriate model to study inti‐
mate relationship between mycobacteria and feline retroviruses in vivo.
Repeated exposure of FIV positive cats to bacterial lipopolysaccharide endotoxin (LPS) re‐
sulted in lower plasma and brain viremia. In HIV infected humans and FIV infected cats,
macrophages produce elevated amount of specific chemokine CXCL10, which in turn dam‐
ages brain cells. LPS treatment of infected macrophages release IL-10 counteracting CXCL10
expression of brain cells. Suppressed CXCL10 level in the brain of FIV-positive cats and en‐
suing T cell infiltration is concomitant with reduction in neurovirulence [71]. This observa‐
tion is in correlation with earlier results, namely that LPS treatment of HHV-6A infected
lymphoid cells decrease expression of such soluble mediators that transactivate HIV-1 in
other lymphoid cultures [3].
3.7. Fungal and parasitic infections in FIV infected cats
Humans and cats can be infected by several common fungal pathogens, such as Cryptococ‐
cus [22], Malassezia, Microsporum [26] and others [28]. Dermatophyte fungi were isolated in
29.4% from stray cats in Portugal [28]. Microsporum gypseum and, occasionally, M. canis were
found in an equal ratio of FIV negative and positive cats (8 and 8.5%, respectively). In con‐
trast, Malassezia species were more frequently isolated from FIV infected cats than FIV-un‐
infected cats (84% vs. 28.6%) thus showing a closer biological relationship in the effect of FIV
and certain fungal species. The CD4:CD8 ratio for FIV infected cats with cutaneous overall
fungal infection was significantly lower than the CD4:CD8 ratio in the FIV infected cats but
without cutaneous fungal infection. It is obvious that worsening cellular immunity repre‐
sents a risk factor to cutaneous fungal colonisation in cats [26], but existence of a cutaneous
or systematic fungal infection due to insufficient activity of the cellular immunity acquired
by inherent or environmental effects might also make easier to acquire FIV infection. Dam‐
aged local immunity in the skin in case of wound FIV infection could be one of the most
frequent examples. Cats having human or human homologues of fungal species would be
ideal models to study such aspects.
Cats having access to the outdoor world, very easily acquire parasitic infections. Feral cats
can serve as a direct or indirect source of infectious diseases for pet cats. Contact with ani‐
mals of other species, conditions of breeding, food supply and age are considered significant
for infections. A recent study conducted in a Brazilian cat colony free from FIV, FeLV and
Neospora caninum infection, clearly showed these differences. Of cats from urban and rural
areas, 10.4% and 27.2% were seropositive for TG, respectively. Cats having access to streets
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positive than were CMH negative animals [33]. Another recent study in Spain found that,
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ricensis infection [27]. It is of note, that mycoplasmas in HIV infected patients have been re‐
garded as AIDS promoting factors for a long time, and this phenomenon was proved in
vitro, either [66]. A meta-analysis of former studies unambiguously demonstrated that geni‐
tal infection by M. genitalium poses high risk for acquisition of HIV. Testing and treatment of
M. genitalium-positive individuals in high risk groups is recommended as a potential HIV
prevention strategy [67]. Bacterial vaginosis-associated microflora in the female genital tract
also predisposes for HIV infection. Among flora members, M. hominis was shown to activate
NF-κB and AP-1. Through mediation of a soluble HIV inducing factor (HIF), these transcrip‐
tional factors may subsequently increase genital tract viral load and potentially contribute to
HIV transmission [68]. MH infection along with BH infection has been verified by PCR in an
HIV infected person [69]. The 34 year old man owned several cats. Haemoplasma DNA is
present in saliva and feces of cats, which suggests that aggressive interactions among cats
and humans involving biting may lead to transmission of the organism. So far, haemotropic
mycoplasma infections have been reported in a patient with systemic lupus erythematosus
(SLE) and in an anaemic patient showing that some forms of immunosuppression are re‐
quired for acquisition of an unusual pathogen [70]. Increasing number of human patients
with compromised immune systems living near cats increases the possibility that haemo‐
plasma infections may emerge in this population [69]. Haemoplasma positive cats like my‐
coplasma positive humans ought to be regarded at increased risk for retrovirus infection.
Testing would also be appropriate prior to relocation of felids [29]. Feline mycoplasmas
could provide a unique model to clarify the exact role of mycoplasmas in AIDS progression.
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lymphoid cells decrease expression of such soluble mediators that transactivate HIV-1 in
other lymphoid cultures [3].
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Humans and cats can be infected by several common fungal pathogens, such as Cryptococ‐
cus [22], Malassezia, Microsporum [26] and others [28]. Dermatophyte fungi were isolated in
29.4% from stray cats in Portugal [28]. Microsporum gypseum and, occasionally, M. canis were
found in an equal ratio of FIV negative and positive cats (8 and 8.5%, respectively). In con‐
trast, Malassezia species were more frequently isolated from FIV infected cats than FIV-un‐
infected cats (84% vs. 28.6%) thus showing a closer biological relationship in the effect of FIV
and certain fungal species. The CD4:CD8 ratio for FIV infected cats with cutaneous overall
fungal infection was significantly lower than the CD4:CD8 ratio in the FIV infected cats but
without cutaneous fungal infection. It is obvious that worsening cellular immunity repre‐
sents a risk factor to cutaneous fungal colonisation in cats [26], but existence of a cutaneous
or systematic fungal infection due to insufficient activity of the cellular immunity acquired
by inherent or environmental effects might also make easier to acquire FIV infection. Dam‐
aged local immunity in the skin in case of wound FIV infection could be one of the most
frequent examples. Cats having human or human homologues of fungal species would be
ideal models to study such aspects.
Cats having access to the outdoor world, very easily acquire parasitic infections. Feral cats
can serve as a direct or indirect source of infectious diseases for pet cats. Contact with ani‐
mals of other species, conditions of breeding, food supply and age are considered significant
for infections. A recent study conducted in a Brazilian cat colony free from FIV, FeLV and
Neospora caninum infection, clearly showed these differences. Of cats from urban and rural
areas, 10.4% and 27.2% were seropositive for TG, respectively. Cats having access to streets
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(17.1%), cats cohabiting with rats (19.6%), and cats feeding on homemade food and raw milk
(27.2%) were positive for this protozoon. In addition, 4.2% of cats were positive for Leishma‐
nia spp. [30]. In several countries, parasitic infections, especially intestinal parasites, of cats
are more frequent than infections with FIV or FeLV. In Italy, comparison of FIV, FeLV and
TG IgG seropositivity resulted in the same ratio: 6.6%, 3.8% and 30.5%, respectively [11]. Ep‐
idemiological studies in Portugal found 24.2% TG seropositivity, 31% carrier state of intesti‐
nal parasites (Toxocara cati, Isospora felis, Ankylostoma stenocephala, Toxascaris leonina) as
compared to FIV and FeLV infection (10.2% and 7.1%, respectively) in the same stray cat
population [28]. In a confined region of Canada, 29.8% of cats had TG antibodies, 1.3% ex‐
creted oocysts in their feces, while FIV and FeLV seropositivity was significantly lower
(5.2% and 3.1%, respectively [33]. In Thailand, although the ratio between retroviral and
parasitic infections were different (FIV, FeLV, heartworm (Dirofilaria immitis) and TG IgG
(20.1%, 24.5%, 4.6% and 10.1%, respectively) from the other data mentioned above, of the
348 cats sampled for all four pathogens, 3.1%, 2.8% and 0.28% were positive for TG antibod‐
ies and FIV antibodies, FeLV antigen or D. immitis antigen, respectively. Of the 35 TG sero‐
positive cats, 42.9% were coinfected with at least one of the other three pathogens [18]. Feral
cats from Cairo, Egypt exhibited an extremely high ratio of TG infestation as compared to
FIV, FeLV of heartworm seroprevalence: 95.5%, 33.9%, 4.6% and 3.4%, respectively. It is of
interest that 57.4% of TG positive cats had very high antibody titre (>1:640) [31]. Oocyst
shedding was found to be accompanied by high level antibodies: cats shedding TG had high
antibody level (>1:256). In the same cat cohort, Toxocara cati eggs were identified in 37%, Cys‐
toisospora felis oocysts in 14%, Taenia sp. segments in 15% of animals. Most of the fecal sam‐
ples showed evidence of at least one intestinal parasite, while many samples contained
evidence of multiple intestinal parasites. High prevalence of antibodies reflects latent infec‐
tions. However, it must be emphasized that cats with latent infection can pose a considera‐
ble zoonotic risk with respect to the shedding of intestinal parasites in their feces. Stress
conditions induce shedding. Intercurrent retroviral infections (FIV or FeLV or both) with
consequent declination in systemic and mucosal immunity are regarded as important stress
factors [33]. Result of the multivariate logistic regression analysis of another recent survey
on simultaneous virus and parasite seropositivity (FIV, FeLV and TG was 19.2%, 14.2% and
32.1%, respectively) in Iran showed that retroviral-associated immunosuppression is a risk
factor for activation of toxoplasmosis in cats [21]. Beside toxoplasmosis, Leishmania infec‐
tion is frequent in many countries. Cellular immunity of normal cats effectively controls
Leishmania infantum (syn. L. chagasi). However, feline immunosuppressive diseases such as
FIV and FeLV infection impair the normal response to infection and expose cats to reactiva‐
tion or new infections by other pathogens, among them Leishmania. Although no statistical
evidence of association between TG and Leishmania was found, but in cats coinfected with
FIV, a strong statistical association for the triple coinfection was found [16]. One can con‐
clude from these epidemiological surveys, that parasites cause not only opportunistic infec‐
tions in retrovirus infected cats, but activation of their latent infection by retroviruses
suggests existence of a closer relationship between phylogenetically distant two groups of
foreign agents at molecular or immunological level.
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Following infection of FIV carrier cats with a secondary pathogen, cytokine dysregulation is
more pronounced. TG increases both IFN-γ and IL-10, but fails to increase IL-2, IL-12, while
TG infected FIV negative cats show an increase in IFN-γ, IL-2 and IL-12 [72]. A similar dys‐
regulation has been reported in cats challenged with LM [73]. The increase in IL-10 to IL-12
ratio predicts the loss of cellular immunity in FIV infected cats [72,74]. These in vivo studies
are in good correlation with in vitro experiments. Latent infection in HIV or FIV infected
lymphocytes and macrophages can be reactivated and virus production can be increased by
chemical immune activators such as phorbol myristate acetate [75], concanavalin A [5],
granulocyte macrophage-colony stimulating factor [76]. Both HIV and FIV induce apoptosis
not only in the infected cells, but in the vicinity of infected cells as well. Programmed cell
death of infected cells is mediated mainly by TNF-α released from infected cells [77]. Cyto‐
kine dysregulation affects not only the FIV carrier animal, but damages the fetus by causing
a pro-inflammatory placental microenvironment at early pregnancy: increased expression of
IL-6, IL-12, decreased expression of IL-1β, SDF-1α. Similarly to AIDS patients, IL-6 expres‐
sion correlated with FIV load [78]. The exact role of cytokines and chemokines in the process
of simultaneous infections waits for clarification.
4. Diagnosis, treatment and prevention of simultaneous infections
Preventing exposure of healthy cats to FIV or FeLV infected cats by tests and removal or iso‐
lation is an important measure, and is not alternative to vaccination. The most common
method for diagnosis of FIV infection is screening for antibodies (typically against p24 and
p15) using an ELISA. Several commercial kits are available worldwide. Confirmatory testing
for cats with positive results is strongly recommended, Western-blot and immunofluores‐
cent antibody assays (IFA) are used. Infection from queens can be transmitted to kittens,
testing for newly acquired cats and kittens is strongly recommended. Vaccinated cats also
produce antibodies that cannot be distinguished, by any commercially available antibody
test [79], from antibodies due to natural infection, and queens might transmit these antibod‐
ies to the litter via colostrum. FIV vaccine induces fewer antibodies for non-structural pro‐
teins compared to natural infection. There are tests to discriminate this pattern, but these are
unsuitable for routine use. Polymerase chain reaction (PCR) has promoted by some com‐
mercial laboratories as a method to determine a cat’s true infection status. The test detects
FIV RNA or proviral DNA. A real-time PCR assay for FIV quantification of proviral DNA in
PBMC has high sensitivity and specificity. This and reverse transcriptase (RT)-PCR are
methods to quantitate viral load and dissemination in the body after activation of latent FIV
infection. Due to genetically heterologous nature of FIV, tests with concurrent determination
of subtype differentiation are recommended. Serological diagnosis of FeLV relies on detec‐
tion of the core antigen p27 in PBMC using an ELISA. IFA test is also used but discordant
results might occur. PCR is offered by a number of commercial laboratories, it can be per‐
formed on blood, saliva, bone marrow and tissues. Kittens can be tested for FeLV at any age,
as passively acquired maternal antibody does not interfere with testing for viral antigen.
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FIV, a strong statistical association for the triple coinfection was found [16]. One can con‐
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Following infection of FIV carrier cats with a secondary pathogen, cytokine dysregulation is
more pronounced. TG increases both IFN-γ and IL-10, but fails to increase IL-2, IL-12, while
TG infected FIV negative cats show an increase in IFN-γ, IL-2 and IL-12 [72]. A similar dys‐
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not only in the infected cells, but in the vicinity of infected cells as well. Programmed cell
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4. Diagnosis, treatment and prevention of simultaneous infections
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method for diagnosis of FIV infection is screening for antibodies (typically against p24 and
p15) using an ELISA. Several commercial kits are available worldwide. Confirmatory testing
for cats with positive results is strongly recommended, Western-blot and immunofluores‐
cent antibody assays (IFA) are used. Infection from queens can be transmitted to kittens,
testing for newly acquired cats and kittens is strongly recommended. Vaccinated cats also
produce antibodies that cannot be distinguished, by any commercially available antibody
test [79], from antibodies due to natural infection, and queens might transmit these antibod‐
ies to the litter via colostrum. FIV vaccine induces fewer antibodies for non-structural pro‐
teins compared to natural infection. There are tests to discriminate this pattern, but these are
unsuitable for routine use. Polymerase chain reaction (PCR) has promoted by some com‐
mercial laboratories as a method to determine a cat’s true infection status. The test detects
FIV RNA or proviral DNA. A real-time PCR assay for FIV quantification of proviral DNA in
PBMC has high sensitivity and specificity. This and reverse transcriptase (RT)-PCR are
methods to quantitate viral load and dissemination in the body after activation of latent FIV
infection. Due to genetically heterologous nature of FIV, tests with concurrent determination
of subtype differentiation are recommended. Serological diagnosis of FeLV relies on detec‐
tion of the core antigen p27 in PBMC using an ELISA. IFA test is also used but discordant
results might occur. PCR is offered by a number of commercial laboratories, it can be per‐
formed on blood, saliva, bone marrow and tissues. Kittens can be tested for FeLV at any age,
as passively acquired maternal antibody does not interfere with testing for viral antigen.
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Compliance of cat owners with FIV and FeLV testing is low, in spite of using combined test
kits, and professional recommendations by veterinarians (Table 1).
At risk of infection
cats access to outdoors





Cats entering new homes, shelters
Newly acquired cats and kittens about to be
vaccinated for FIV or FeLV
Cats used for blood or tissue donation
Table 1. Major recommendations for FIV and FeLV testing of cats
The owner must also consider the cost of immunisation, fecal parasite testing, de-worming,
or blood screening to reveal and eliminate concomitant infections [17]. Further commercially
available kits for serological screening, and/or antigen detection including FHV-1 and the
most pathogens are widely available for domestic and large cats. These kits used separately
depending on the clinical course of the animal can be combined in definitively. Well estab‐
lished, cheap but somewhat laborious and time consuming classical methods have been
used for direct detection of common bacteria, fungi and parasites (cultivation, biochemistry,
microscopy, etc.). For feline pathogens causing infection in humans, the same methods and
kits can be used as in human medicine. With technological advances quantitative real-time
or RT-PCR assays have been used subsequently their products are sequenced to determine
species or variants. Load of viruses in body fluids can be determined by quantitative molec‐
ular methods [5,7,24,36]. Simultaneous detection of nucleic acids of coinfecting microbes
would be ideal by using multiple PCR [20, 29]. Development of easily available panels is a
financial interest of biotechnology companies. Gene arrays capable of detecting even hun‐
dreds of microbes at nucleic acid level could also be marketed in near future.
Aims of detecting simultaneous infection in cats and large felids are very variable. As retro‐
viral infection might represent a considerable risk factor to several bacterial, fungal and par‐
asitic opportunistic infections and activating potential of their latency, demonstration of
retroviruses ought to be followed by screening for other pathogens [21]. Vice versa, cats liv‐
Current Perspectives in HIV Infection458
ing in endemic areas of certain parasites are significantly more likely to be co-infected with
FIV and/or FeLV, which may present confounding clinical signs and therefore cats in such
areas should be always carefully screened for coinfections [16]. Occasionally, knowing the
cat’s geographical location can be helpful, while the nature of the clinical presentation might
be less informative [23]. Informations concerning risk assessment of viral pathogens to other
animal populations are currently an important issue [28]. Screening for multiple infections is
appropriate prior to relocation of cats and other felids to prevent introduction of pathogens
in host colonies (households, catteries, zoos, national parks, etc.) [29]. As with HIV, careful
consideration should also be given to systematic testing and treatment of individuals in
high-risk populations, and this may prove to be a potential strategy to prevent FIV transmis‐
sion [67]. Preventive measures are important, because transmission of pathogens in cluster
conditions may occur between asymptomatic cats and immunocompromised animals
[25,32]. Furthermore, certain FIV or FeLV strains are able to emerge in new host species. Do‐
mestic cat strains of viruses can cross species barriers with potentially devastating conse‐
quences to fragile populations of large felids [12]. As seen with feline haemoplasma, it could
infect even the immunocompromised human cat owner [69] so; cat owners ought to be pro‐
tected from common zoonotic infections.
While testing and identification of infected cats is necessary for prevention and transmis‐
sion, vaccination is also an important tool. Various independent bodies, including the Inter‐
national Vaccination Guidelines Group (IVGG), the European Advisory Board on Cat
Diseases (ABCD), the World Small Animal Veterinary Association (WSAVA), or the Ameri‐
can Association of Feline Practitioners (AAFP) have developed and regularly issues recom‐
mendations for vaccination protocols for cats and kittens. The guidelines encompass the
types of antigens used, the types of vaccines available, the frequency of vaccination and the
anatomical site used for administration. These guidelines differ from each other and also
from the manufacturer’s datasheets or recommendations of national authorities. General as‐
pects and details of vaccination of cats are far beyond the scope of recent review; in this re‐
gard see a recent publication by Dean et al. 2012. Core vaccines are defined as those vaccines
which all cats, regardless of circumstances, should receive to protect animals from severe,
life threatening diseases which have global distribution. Only to emphasize those in context
with microbes with transactivating and opportunistic potential, FHV-1 vaccination of kittens
seems to be important. Vaccination against FCV, FPV also belongs to core vaccines. These
vaccinations are recommended to start as early as vaccination with FeLV, applying revacci‐
nations up to 16-20 weeks of age. Most practices routinely give the commonly used antigens
annually, although with the exception of the FHV, the FCV and FIV vaccination is recom‐
mended every 3 years [80]. Non-core vaccines are those that are required by only those ani‐
mals whose geographic location, local environment or lifestyle place them at risk of
contracting specific infections. This moment, both FIV and FeLV vaccines are regarded as
non-core. FIV vaccine development was initiated as a model for HIV vaccination. Vaccina‐
tion against HIV started with experiments to trigger a specific, potent and long-lasting im‐
munity in a surrogate animal model. Later, several novel approaches were tested in the
feline model. Although the quest for a truly effective AIDS vaccine is years away [81], vacci‐
nation against FIV became available [82]. This vaccine (Fel-O-Vax FIV®) is marketed in many
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annually, although with the exception of the FHV, the FCV and FIV vaccination is recom‐
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countries, but it might not protect cats against all field strains of subtypes A or B. Lifespan of
infected cats appears similar to that of uninfected cats, but exposure to other infectious dis‐
eases drastically reduces survival of FIV positive animals [17]. Historically, FeLV vaccina‐
tion has been used for decades, well before FIV vaccination. The combined use of testing
and vaccination programs is assumed to have decreased the prevalence of FeLV over the
last 20 years [17,19]. Administering the first vaccine to kittens is at 8-10 weeks of age, with
regular revaccinations usually every year. Several practitioners stopped revaccinating in‐
door and older cats, once they reached a certain age (≥ 6 years) assuming that they would
not have close contact with a persistently infected cat, or elder cats are less easily infected
with FeLV than younger animals. As persistently infected cats have been diagnosed at all
ages, due to the decreased susceptibility to FeLV infection, vaccinating at 2-3 years intervals
rather than annually seems to be acceptable. For free-roaming cats, annual FeLV vaccination
is recommended. To increase revaccination interval assuming the presence of high level an‐
tibodies is not feasible because quantitative assays to measure serum FeLV antibodies are
commercially available in few countries [80]. A marked difference in vaccination efficacy ex‐
ists, and suggests that only inactivated whole virus or canarypox-vectored recombinant vac‐
cines should be used. Cats with access to outdoors should be vaccinated, but should have at
least one negative FeLV ELISA test before vaccination. Several studies showed that the
mean survival time of FeLV positive cats are significantly shorter than that of FeLV-negative
cats including vaccinated ones (references in 17). Aspecific measures to prevent FIV and
FeLV transmission were set according to the biological characteristics of these viruses. Al‐
though retroviruses become inactivated within a few hours on dry surfaces, they may re‐
main viable in dried biological deposits for more than a week. Both viruses are inactivated
by common detergents and hospital disinfectants. Spreading via body fluids is best prevent‐
ed by single set of instruments in clinical practice. To prevent infections by other microbes,
including those with transactivation or opportunistic potential, hospitalised cats should not
be allowed to have direct contact with one another. It is important not to keep retrovirus-
infected cats in contagious disease ward as they are potentially immunosuppressed and car‐
ry or acquire other pathogens [17]. A recent survey in the UK showed that several
veterinarians are not aware of the guidelines, or they do not adhere to them. Similarly to
guidelines in human healthcare, other barriers included lack of agreement or lack of ability
to follow guidelines, lack of motivation to follow them, and lack to perceive benefits to pa‐
tients. The frequency, combination and selection of antigens routinely given to cats by veter‐
inarians remain unknown, as are the anatomical sites to inject cats. Therefore, the impact of
the published guidelines on practitioners working also remains unknown [80]. Further work
is required to elicit why following guidelines may reduce occurrence and severity of both
opportunistic infections and halt onset and slow progression of FAIDS by eliminating infec‐
tion by other microbes.
The FIV/cat model has provided a unique opportunity to test novel therapeutic interven‐
tions aimed at eradicating latent virus, but the use of antiretroviral drugs in FIV infected
cats and other felids has not gained grounds in the routine veterinary practice [7,8]. Several
conventional microbial coinfections are treated with routine medication.
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5. Conclusions
Descriptive epidemiological surveys on the simultaneous infection by feline retroviruses,
namely FIV and/or FeLV, and heterologous microbes clearly show that progression of
FAIDS is facilitated by certain viruses, bacteria and other parasites that also induce oppor‐
tunistic infections in a vicious circle. Scarce experimental data suggest that FIV transactivat‐
ing potential of heterologous microbes might increase FIV load, facilitate FAIDS course, and
help induce malignancies resulting in considerably impaired quality of life and shorter life
span of afflicted domestic cats. Simultaneous cross-species transmission of infection by par‐
ticular FIV and FeLV strains in endangered big cats may also occur. Emerging infections by
FIV transactivating and opportunistic feline microbes in immunocompromised humans
have already been described. Additive or synergistic impairing effects on the native immune
reactions, activation of negatively affecting Treg cells, depression of cytotoxic T cell activi‐
ties, and abnormal cytokine pattern exerted by heterologous microbes demonstrate striking
similarities between AIDS and FAIDS. Regular vaccination against transactivating microbes
(e.g. FeLV, FHV-1) and transactivated microbe (FIV) starting at early age prevents and dis‐
rupts deleterious microbial interactions. These result in a complete halt or a significant slow‐
down of acquired immunodeficiency states. Experience verified in the feline model enables
us to continue studying microbial interactions at molecular, cellular, immunological or clini‐
cal levels. Further experiments are warranted to better delineate the role of putative cofac‐
tors in FIV infection. Further studies should examine concurrent infections as contributing
factors in the development and progression of neoplasia in FIV-positive cats. Determination
of viral cooperative mechanisms that promote cancer during co-infection would be highly
relevant to both FIV- and HIV-related diseases.
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